
<html lang="en"     class="pb-page"  data-request-id="db26627c-d1a8-49b5-b9cd-b6a87667b1a7"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;article:article:10.1021/acs.jmedchem.9b02149;issue:issue:10.1021/jmcmar.2020.63.issue-4;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Preclinical Optimization of gp120 Entry Antagonists as anti-HIV-1 Agents with Improved Cytotoxicity and ADME Properties through Rational Design, Synthesis, and Antiviral Evaluation" /></meta><meta name="dc.Creator" content="Francesca  Curreli" /></meta><meta name="dc.Creator" content="Shahad  Ahmed" /></meta><meta name="dc.Creator" content="Sofia M.  Benedict Victor" /></meta><meta name="dc.Creator" content="Ildar R.  Iusupov" /></meta><meta name="dc.Creator" content="Dmitry S.  Belov" /></meta><meta name="dc.Creator" content="Pavel O.  Markov" /></meta><meta name="dc.Creator" content="Alexander V.  Kurkin" /></meta><meta name="dc.Creator" content="Andrea  Altieri" /></meta><meta name="dc.Creator" content="Asim K.  Debnath" /></meta><meta name="dc.Description" content="We previously reported a milestone in the optimization of NBD-11021, an HIV-1 gp120 antagonist, by developing a new and novel analogue, NBD-14189 (Ref1), which showed antiviral activity against HIV..." /></meta><meta name="Description" content="We previously reported a milestone in the optimization of NBD-11021, an HIV-1 gp120 antagonist, by developing a new and novel analogue, NBD-14189 (Ref1), which showed antiviral activity against HIV..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="February 7, 2020" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.9b02149" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2020 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b02149" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.9b02149" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b02149" /></link>
        
    
    

<title>Preclinical Optimization of gp120 Entry Antagonists as anti-HIV-1 Agents with Improved Cytotoxicity and ADME Properties through Rational Design, Synthesis, and Antiviral Evaluation | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.9b02149" /></meta><meta property="og:title" content="Preclinical Optimization of gp120 Entry Antagonists as anti-HIV-1 Agents with Improved Cytotoxicity and ADME Properties through Rational Design, Synthesis, and Antiviral Evaluation" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b02149/20200221/images/large/jm9b02149_0012.jpeg" /></meta><meta property="og:description" content="We previously reported a milestone in the optimization of NBD-11021, an HIV-1 gp120 antagonist, by developing a new and novel analogue, NBD-14189 (Ref1), which showed antiviral activity against HIV-1HXB2, with a half maximal inhibitory concentration of 89 nM. However, cytotoxicity remained high, and the absorption, distribution, metabolism, and excretion (ADME) data showed relatively poor aqueous solubility. To optimize these properties, we replaced the phenyl ring in the compound with a pyridine ring and synthesized a set of 48 novel compounds. One of the new analogues, NBD-14270 (8), showed a marked improvement in cytotoxicity, with 3-fold and 58-fold improvements in selectivity index value compared with that of Ref1 and NBD-11021, respectively. Furthermore, the in vitro ADME data clearly showed improvements in aqueous solubility and other properties compared with those for Ref1. The data for 8 indicated that the pyridine scaffold is a good bioisostere for phenyl, allowing the further optimization of this molecule." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.9b02149"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b02149">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.9b02149&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.9b02149&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.9b02149&amp;href=/doi/10.1021/acs.jmedchem.9b02149" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2020</span><span class="cit-fg-volume">, 63</span><span class="cit-fg-issue">, 4</span><span class="cit-fg-pageRange">, 1724-1749</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/63/4" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.9b02096" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.0c00033" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Preclinical Optimization of gp120 Entry Antagonists as anti-HIV-1 Agents with Improved Cytotoxicity and ADME Properties through Rational Design, Synthesis, and Antiviral Evaluation</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Francesca Curreli</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Francesca Curreli</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Laboratory of Molecular Modeling & Drug Design, Lindsley F. Kimball Research Institute, New York Blood Center, 310 E 67th Street, New York 10065, New York, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Francesca++Curreli">Francesca Curreli</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Shahad Ahmed</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Shahad Ahmed</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Laboratory of Molecular Modeling & Drug Design, Lindsley F. Kimball Research Institute, New York Blood Center, 310 E 67th Street, New York 10065, New York, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Shahad++Ahmed">Shahad Ahmed</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Sofia M. Benedict Victor</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Sofia M. Benedict Victor</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Laboratory of Molecular Modeling & Drug Design, Lindsley F. Kimball Research Institute, New York Blood Center, 310 E 67th Street, New York 10065, New York, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Sofia+M.++Benedict+Victor">Sofia M. Benedict Victor</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Ildar R. Iusupov</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ildar R. Iusupov</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">EDASA Scientific, Scientific Park, Moscow State University, Leninskie Gory Bld. 75, 77-101b,Moscow 119992, Russia</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ildar+R.++Iusupov">Ildar R. Iusupov</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Dmitry S. Belov</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Dmitry S. Belov</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">EDASA Scientific, Scientific Park, Moscow State University, Leninskie Gory Bld. 75, 77-101b,Moscow 119992, Russia</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Dmitry+S.++Belov">Dmitry S. Belov</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Pavel O. Markov</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Pavel O. Markov</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">EDASA Scientific, Scientific Park, Moscow State University, Leninskie Gory Bld. 75, 77-101b,Moscow 119992, Russia</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Pavel+O.++Markov">Pavel O. Markov</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Alexander V. Kurkin</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Alexander V. Kurkin</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">EDASA Scientific, Scientific Park, Moscow State University, Leninskie Gory Bld. 75, 77-101b,Moscow 119992, Russia</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Alexander+V.++Kurkin">Alexander V. Kurkin</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Andrea Altieri</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Andrea Altieri</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">EDASA Scientific, Scientific Park, Moscow State University, Leninskie Gory Bld. 75, 77-101b,Moscow 119992, Russia</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Andrea++Altieri">Andrea Altieri</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Asim K. Debnath</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Asim K. Debnath</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Laboratory of Molecular Modeling & Drug Design, Lindsley F. Kimball Research Institute, New York Blood Center, 310 E 67th Street, New York 10065, New York, United States</div></div><span class="conrtib-corresp"><strong>*</strong>Phone: 001-212-570-3373. Fax: 001-212-570-3168. Email: <a href="/cdn-cgi/l/email-protection#5b3a3f3e39353a2f331b352239387534293c"><span class="__cf_email__" data-cfemail="d1b0b5b4b3bfb0a5b991bfa8b3b2ffbea3b6">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Asim+K.++Debnath">Asim K. Debnath</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-2761-0506" title="Orcid link">http://orcid.org/0000-0003-2761-0506</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b02149&amp;href=/doi/10.1021%2Facs.jmedchem.9b02149" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2020</span></span><span class="cit-volume">, 63</span><span class="cit-issue">, 4</span><span class="cit-pageRange">, 1724–1749</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">February 7, 2020</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>23 December 2019</li><li><span class="item_label"><b>Published</b> online</span>7 February 2020</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 27 February 2020</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.9b02149" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b02149</a></div><div class="article_header-article-copyright"><strong>Copyright © 2020 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D1724%26pageCount%3D26%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DFrancesca%2BCurreli%252C%2BShahad%2BAhmed%252C%2BSofia%2BM.%2BBenedict%2BVictor%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D63%26issueNum%3D4%26contentID%3Dacs.jmedchem.9b02149%26title%3DPreclinical%2BOptimization%2Bof%2Bgp120%2BEntry%2BAntagonists%2Bas%2Banti-HIV-1%2BAgents%2Bwith%2BImproved%2BCytotoxicity%2Band%2BADME%2BProperties%2Bthrough%2BRational%2BDesign%252C%2BSynthesis%252C%2Band%2BAntiviral%2BEvaluation%26numPages%3D26%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D1749%26publicationDate%3DFebruary%2B2020">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.9b02149"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1148</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">5</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.9b02149" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Preclinical Optimization of gp120 Entry Antagonists as anti-HIV-1 Agents with Improved Cytotoxicity and ADME Properties through Rational Design, Synthesis, and Antiviral Evaluation&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Francesca&quot;,&quot;last_name&quot;:&quot;Curreli&quot;},{&quot;first_name&quot;:&quot;Shahad&quot;,&quot;last_name&quot;:&quot;Ahmed&quot;},{&quot;first_name&quot;:&quot;Sofia&quot;,&quot;last_name&quot;:&quot;M. Benedict Victor&quot;},{&quot;first_name&quot;:&quot;Ildar&quot;,&quot;last_name&quot;:&quot;R. Iusupov&quot;},{&quot;first_name&quot;:&quot;Dmitry&quot;,&quot;last_name&quot;:&quot;S. Belov&quot;},{&quot;first_name&quot;:&quot;Pavel&quot;,&quot;last_name&quot;:&quot;O. Markov&quot;},{&quot;first_name&quot;:&quot;Alexander&quot;,&quot;last_name&quot;:&quot;V. Kurkin&quot;},{&quot;first_name&quot;:&quot;Andrea&quot;,&quot;last_name&quot;:&quot;Altieri&quot;},{&quot;first_name&quot;:&quot;Asim&quot;,&quot;last_name&quot;:&quot;K. Debnath&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2020&quot;,&quot;month&quot;:&quot;02&quot;,&quot;day&quot;:&quot;07&quot;,&quot;issue&quot;:&quot;4&quot;,&quot;volume&quot;:&quot;63&quot;,&quot;pages&quot;:&quot;1724-1749&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.9b02149&quot;},&quot;abstract&quot;:&quot;We previously reported a milestone in the optimization of NBD-11021, an HIV-1 gp120 antagonist, by developing a new and novel analogue, NBD-14189 (Ref1), which showed antiviral activity against HIV-1HXB2, with a half maximal inhibitory concentration of 89 nM. However, cytotoxicity remained high, and the absorption, distribution, metabolism, and excretion (ADME) data showed relatively poor aqueous solubility. To optimize these properties, we replaced the phenyl ring in the compound with a pyridine ring and synthesized a set of 48 novel compounds. One of the new analogues, NBD-14270 (8), showed a marked improvement in cytotoxicity, with 3-fold and 58-fold improvements in selectivity index value compared with that of Ref1 and NBD-11021, respectively. Furthermore, the in vitro ADME data clearly showed improvements in aqueous solubility and other properties compared with those for Ref1. The data for 8 indicated that the pyridine scaffold is a good bioisostere for phenyl, allowing the further optimization of this m&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b02149&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b02149" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b02149&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b02149" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b02149&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b02149" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b02149&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b02149&amp;href=/doi/10.1021/acs.jmedchem.9b02149" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.9b02149" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.9b02149" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (3 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b02149&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.9b02149%26sid%3Dliteratum%253Aachs%26pmid%3D32031803%26genre%3Darticle%26aulast%3DCurreli%26date%3D2020%26atitle%3DPreclinical%2BOptimization%2Bof%2Bgp120%2BEntry%2BAntagonists%2Bas%2Banti-HIV-1%2BAgents%2Bwith%2BImproved%2BCytotoxicity%2Band%2BADME%2BProperties%2Bthrough%2BRational%2BDesign%252C%2BSynthesis%252C%2Band%2BAntiviral%2BEvaluation%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D63%26issue%3D4%26spage%3D1724%26epage%3D1749%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292035" title="Viruses">Viruses</a>,</li><li><a href="/action/doSearch?ConceptID=291171" title="Antagonists">Antagonists</a>,</li><li><a href="/action/doSearch?ConceptID=290703" title="Pyridines">Pyridines</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=290808" title="Toxicity">Toxicity</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/63/4" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/jmcmar.2020.63.issue-4/20200227/jmcmar.2020.63.issue-4.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b02149/20200221/images/medium/jm9b02149_0012.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b02149/20200221/images/large/jm9b02149_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02149&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">We previously reported a milestone in the optimization of NBD-11021, an HIV-1 gp120 antagonist, by developing a new and novel analogue, NBD-14189 (<b>Ref1</b>), which showed antiviral activity against HIV-1<sub>HXB2</sub>, with a half maximal inhibitory concentration of 89 nM. However, cytotoxicity remained high, and the absorption, distribution, metabolism, and excretion (ADME) data showed relatively poor aqueous solubility. To optimize these properties, we replaced the phenyl ring in the compound with a pyridine ring and synthesized a set of 48 novel compounds. One of the new analogues, NBD-14270 (<b>8</b>), showed a marked improvement in cytotoxicity, with 3-fold and 58-fold improvements in selectivity index value compared with that of <b>Ref1</b> and NBD-11021, respectively. Furthermore, the in vitro ADME data clearly showed improvements in aqueous solubility and other properties compared with those for <b>Ref1</b>. The data for <b>8</b> indicated that the pyridine scaffold is a good bioisostere for phenyl, allowing the further optimization of this molecule.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_52780" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_52780" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">According to the Joint United Nations Programme on HIVAIDS (UNAIDS) report, published in 2018, 37 million people are living with HIV, and almost 2 million new infections are diagnosed each year. Despite the availability of more than 30 Food and Drug Administration (FDA)-approved drugs for acquired immunodeficiency syndrome (AIDS) treatment, AIDS remains a major global public health concern, although combination antiretroviral therapies (cART) can help manage this devastating disease. However, no vaccine has yet been developed to manage the transmission of the human immunodeficiency virus (HIV), and despite many years of effort, no cure has been identified for HIV. Therefore, drug-based treatments remain the only option for those who have been infected with the virus. Furthermore, HIV patients must engage in lifelong therapy regimens. Unfortunately, because of the very high heterogeneity among HIV strains, drug-associated toxicities and difficulties with adherence often result in treatment failure. Long-term use of HIV treatment drugs may also lead to the emergence of drug-resistant HIV. As a result, treatment-experienced patients may exhaust their treatment options. Therefore, the development of novel drugs, with fewer side effects and high antiviral potencies against a large array of drug-resistant HIV-1, is urgently needed. To achieve this goal, the continued discovery of new classes of drugs that target novel HIV components is critical.</div><div class="NLM_p">HIV fusion and attachment (often collectively termed as “entry”) are the most critical steps necessary for HIV to initiate its life cycle in the host cell.<a onclick="showRef(event, 'ref1 ref2 ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref1 ref2 ref3 ref4">(1−4)</a> Despite the importance of these steps, only two FDA-approved drugs target the HIV-1 entry pathway: Fuzeone (Enfuvirtide), which targets HIV-1 glycoprotein 41 (gp41), and Maraviroc, which targets C–C chemokine receptor type 5 (CCR5) coreceptors. Thus far, no FDA-approved drugs target the HIV-1 envelope (Env) glycoprotein gp120. However, the potential of gp120 as a drug target was validated by reports describing several highly potent HIV-1 attachment inhibitors, from Bristol-Meyer Squibs (BMS),<a onclick="showRef(event, 'ref5 ref6 ref7 ref8 ref9 ref10 ref11 ref12 ref13'); return false;" href="javascript:void(0);" class="ref ref5 ref6 ref7 ref8 ref9 ref10 ref11 ref12 ref13">(5−13)</a> our group, and others.<a onclick="showRef(event, 'ref14 ref15 ref16 ref17 ref18'); return false;" href="javascript:void(0);" class="ref ref14 ref15 ref16 ref17 ref18">(14−18)</a> One of the BMS attachment inhibitors, known as Fostemsavir (BMS-663068), is currently in an advanced stage of clinical development and demonstrated success in a recent Phase III clinical trial (Bright Study). Until recently, the target site of this class of attachment inhibitors being developed by BMS was uncertain. In 2017, Pancera et al. reported first the X-ray crystal structures of these inhibitors, with a trimeric HIV-1 envelope.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> Interestingly, these crystal structures showed that the binding pocket for this class of inhibitors was distinct from the Phe43 cavity induced by the cluster of differentiation 4 (CD4), the cellular receptor that binds to gp120. In contrast, Madani et al. first suggested that NBD-556, which our group identified and reported in 2005,<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> binds to the highly conserved Phe43 cavity.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> In 2012, we solved the X-ray crystal structure of NBD-556 bound to gp120, confirming that NBD-556 binds to the Phe43 cavity.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> Unfortunately, NBD-556 was shown to be a CD4-agonist that could enhance HIV-1 infection in CD4-CCR5+ cells.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> This undesirable trait motivated us to use the insights gained from the crystal structure to modify the structure of NBD-556, to convert this compound into a gp120 entry antagonist. We were successful and reported the first gp120 entry antagonist, NBD-11021, in 2012.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> Subsequently, a series of X-ray structures, showing gp120 entry antagonists bound to monomeric gp120, have confirmed that these antagonists also bind to the Phe43 cavity.<a onclick="showRef(event, 'ref9 ref11 ref12 ref22'); return false;" href="javascript:void(0);" class="ref ref9 ref11 ref12 ref22">(9,11,12,22)</a></div><div class="NLM_p">Recently, we reported the successful design of our most advanced gp120 antagonist, NBD-14189 (<b>Ref1</b>, <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>), which was tested against a large panel of HIV-1 Env-pseudotyped viruses, representing a diverse set of clinical isolates and multiple HIV subtypes.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a><b>Ref1</b> showed remarkable antiviral potency (as low as 63 nM), indicating that this compound has broad-spectrum inhibitory activity against HIV-1.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> Furthermore, this inhibitor had absorption, distribution, metabolism, and excretion (ADME) properties comparable to BMS-626529, a prodrug of which, BMS-663068, is currently undergoing Phase III clinical trials.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> However, the in vitro ADME and cellular toxicity data confirmed that further improvements could be made to the cellular toxicity of <b>Ref1</b>, to improve the selectivity index (SI = CC<sub>50</sub>/IC<sub>50</sub>) (CC<sub>50</sub> = 50% cytotoxic concentration, IC<sub>50</sub> = half maximal inhibitory concentration) and to the ADME properties, especially, aqueous solubility. Toward that goal, we replaced the phenyl group in Region I (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>) with a pyridine moiety, a unique aromatic ring. The use of pyridine as a bioisostere of aromatic rings has been reported in the fields of medicinal chemistry and drug discovery to improve aqueous solubility, stability, and the ability to form H-bonds.<a onclick="showRef(event, 'ref23 ref24 ref25'); return false;" href="javascript:void(0);" class="ref ref23 ref24 ref25">(23−25)</a> Here, we report the detailed synthesis, structure–activity relationships (SARs), antiviral activities, and ADME properties of a large set of pyridine-based analogues, with considerable improvement over the most potent gp120 entry antagonists previously reported by our group. This study explored a new scaffold in Region I that resulted in many improved properties while still displaying potent antiviral activity.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b02149/20200221/images/medium/jm9b02149_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b02149/20200221/images/large/jm9b02149_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Chronology of improvement of anti-HIV-1 activity (IC<sub>50</sub> against HIV-1HXB2) and SI.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b02149/20200221/images/large/jm9b02149_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02149&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_01062" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_01062" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The syntheses of the novel inhibitors are described in <a class="ref internalNav" href="#sch1" aria-label="Schemes 1">Schemes 1</a><named-content content-type="anchor" rid="sch2" type="simple"></named-content><named-content content-type="anchor" rid="sch3" type="simple"></named-content><named-content content-type="anchor" rid="sch4" type="simple"></named-content><named-content content-type="anchor" rid="sch5" type="simple"></named-content><named-content content-type="anchor" rid="sch6" type="simple"></named-content>–<a class="ref internalNav" href="#sch7" aria-label="7">7</a>. First, we prepared a series of 5-arylpyrrole-2-carboxylic acids with pyridine pharmacophoric fragment or its bioisosteres—pyrimidine and pyridazine (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>). Acids <b>S4a–S4h</b> were prepared using the general scheme involving Suzuki coupling of pyridine/pyrimidine/pyridazine halogenides with N-Boc-2-pyrrole boronic acid, followed by Boc cleavage, acylation, and semihaloform reaction.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> Aryl bromides and aryl chlorides were commercially available. Acid <b>S8</b> was prepared using a general procedure A involving Suzuki coupling of 4-bromo-2-fluoropyridine and with N-Boc-2-pyrrole boronic acid, followed by Boc cleavage (MeOH-HCl) afforded the 2-methoxy-4-(1<i>H</i>-pyrrol-2-yl)pyridine <b>S6</b> in good yield (67%), which was then subjected first to an acylation and then to a semihaloform reaction.<a onclick="showRef(event, 'ref8 ref21 ref27 ref28 ref29'); return false;" href="javascript:void(0);" class="ref ref8 ref21 ref27 ref28 ref29">(8,21,27−29)</a></div><figure id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b02149/20200221/images/medium/jm9b02149_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b02149/20200221/images/large/jm9b02149_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Intermediate Acids</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b02149/20200221/images/large/jm9b02149_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02149&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b02149/20200221/images/medium/jm9b02149_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b02149/20200221/images/large/jm9b02149_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of 5-(2-Methoxypyridin-4-yl)-1<i>H</i>-pyrrole-2-carboxylic Acid</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b02149/20200221/images/large/jm9b02149_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02149&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="sch3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b02149/20200221/images/medium/jm9b02149_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b02149/20200221/images/large/jm9b02149_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of 5-(5-Substituted-2-yl)-3-methyl-1<i>H</i>-pyrrole-2-carboxylic Acid and Na Salt<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b02149/20200221/images/large/jm9b02149_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02149&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Asterisk (*) indicates acidification step performed only for <b>S16</b>.</p></p></figure><figure id="sch4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b02149/20200221/images/medium/jm9b02149_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b02149/20200221/images/large/jm9b02149_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of Allyl Allyl(2-amino-2-(4-(2-((<i>tert</i>-Butyldiphenylsilyl)oxy)-1-hydroxyethyl)thiazol-2-yl)ethyl)carbamate (<b>S23 fS</b> and <b>S23 fR</b>)<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b02149/20200221/images/large/jm9b02149_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02149&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Note all enantiomer compounds derived from the stereo-controlled addition of the allyl <i>N</i>-allyl-<i>N</i>-[(2<i>E</i>)-2-<i>tert</i>-butylsulfinyliminoethyl]carbamate with absolute configuration <i>S</i>, were specified with the <b>fS</b> descriptor, and all enantiomer compounds derived from the stereo-controlled addition of the allyl <i>N</i>-allyl-<i>N</i>-[(2<i>E</i>)-2-<i>tert</i>-butylsulfinyliminoethyl]carbamate with the absolute configuration <i>R</i> have been specified with the <b>fR</b> descriptor as per previous works.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a></p></p></figure><figure id="sch5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b02149/20200221/images/medium/jm9b02149_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b02149/20200221/images/large/jm9b02149_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of Allyl <i>N</i>-Allyl-<i>N</i>-[2-amino-2-[4-[2-[<i>tert</i>-butyl(diphenyl)silyl]oxy-1-hydroxy-ethyl]thiazol-2-yl]ethyl]carbamate (<b>S32 fR</b> and <b>S32 fS</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b02149/20200221/images/large/jm9b02149_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02149&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="sch6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b02149/20200221/images/medium/jm9b02149_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b02149/20200221/images/large/jm9b02149_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Synthesis of <i>tert</i>-Butyl (2-amino-2-(4-(((<i>tert</i>-butyldimethylsilyl)oxy)methyl)thiazol-2-yl)propyl)carbamate (<b>S37</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b02149/20200221/images/large/jm9b02149_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02149&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="sch7" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b02149/20200221/images/medium/jm9b02149_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b02149/20200221/images/large/jm9b02149_0009.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 7. Synthesis of HIV-1 Inhibitors 1-48 in Table 1</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b02149/20200221/images/large/jm9b02149_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02149&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">5-Aryl-3-methyl-1<i>H</i>-pyrrole-2-carboxylic acids were prepared using commercially available reagents (2-bromo-5-(trifluoromethyl)pyridine or 2-bromo-5-chloropyridine) and known compound N-Boc-β-iododehydroamino acid methyl esters <b>R4</b> as per the reported procedure<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>). This one-pot, two-step procedure occurs by a Sonogashira coupling followed by a 5-endo-dig-cyclization, which involves the nitrogen atom of the dehydroamino acid.</div><div class="NLM_p">The Suzuki approach could not be used with the methylpyrrole intermediates <b>S15</b> and <b>S16</b> due to chemical feasibility issues related to the synthesis of the methyl pyrrole boc-protected derivative needed as a substrate. Except for <b>S23</b>, <b>S32</b>, and <b>S37</b>, all the required intermediary protected secondary amines were prepared using an enantioselective pathway reported previously.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> Instead, <b>S23</b> and <b>S32</b>, due to the extended and different side chains, were prepared accordingly to <a class="ref internalNav" href="#sch4" aria-label="Schemes 4">Schemes 4</a> and <a class="ref internalNav" href="#sch5" aria-label="5">5</a>, respectively, but still exploiting the enantioselective step as per the <i>General Procedure E</i>. While the synthetic approach for <b>S37</b> is depicted in <a class="ref internalNav" href="#sch6" aria-label="Scheme 6">Scheme 6</a>, it was obtained as a racemate. Since the corresponding final compound <b>31</b> showed no improvement in anti-HIV-1 activity but, rather, a loss of activity, no attempts were wasted in the isolation of the corresponding enantiomers.</div><div class="NLM_p">The synthesis of all final 48 pyridine analogues (<b>1</b>–<b>48</b>, <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>) was performed as per <a class="ref internalNav" href="#sch7" aria-label="Scheme 7">Scheme 7</a>. The amines <b>S38</b>–<b>S40</b> were prepared using a method described in our earlier work. Similarly, amines <b>S41</b>–<b>S45</b> were synthesized, starting from the appropriate thiazole derivative and following the protocols as reported earlier.<a onclick="showRef(event, 'ref10 ref28'); return false;" href="javascript:void(0);" class="ref ref10 ref28">(10,28)</a></div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Anti-HIV-1 Activity (IC<sub>50</sub>) and Cytotoxicity (CC<sub>50</sub>) of gp120 Entry Antagonists in Single-Cycle (TZM-bl Cells) Assay</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b02149/20200221/images/medium/jm9b02149_0010.gif" alt="" id="GRAPHIC-d7e644-autogenerated" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center">μM<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">No. (enantiomer)</th><th class="colsep0 rowsep0" align="center">R<sub>1</sub></th><th class="colsep0 rowsep0" align="center">R<sub>2</sub></th><th class="colsep0 rowsep0" align="center">R<sub>3</sub></th><th class="colsep0 rowsep0" align="center">R<sub>4</sub></th><th class="colsep0 rowsep0" align="center">R<sub>5</sub></th><th class="colsep0 rowsep0" align="center">R<sub>6</sub></th><th class="colsep0 rowsep0" align="center">R<sub>7</sub></th><th class="colsep0 rowsep0" align="center">R<sub>8</sub></th><th class="colsep0 rowsep0" align="center">X</th><th class="colsep0 rowsep0" align="center">Y</th><th class="colsep0 rowsep0" align="center">Z</th><th class="colsep0 rowsep0" align="center">W</th><th class="colsep0 rowsep0" align="center">IC<sub>50</sub></th><th class="colsep0 rowsep0" align="center">CC<sub>50</sub></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Ref1 (S)</td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub>OH</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">CF<sub>3</sub></td><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">0.089 ± 0.001</td><td class="colsep0 rowsep0" align="left">21.9 ± 0.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Ref2 (R)</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub>OH</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">CF<sub>3</sub></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">0.27 ± 0.02</td><td class="colsep0 rowsep0" align="left">42.4 ± 1.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">1 (R)</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub>OH</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">0.85 ± 0.1</td><td class="colsep0 rowsep0" align="left">144 ± 7.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2 (S)</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub>OH</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">2.7 ± 0.7</td><td class="colsep0 rowsep0" align="left">142 ± 1.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">3 (R)</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub>OH</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">CH3</td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">1.2 ± 0.1</td><td class="colsep0 rowsep0" align="left">98.3 ± 4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">4 (S)</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub>OH</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">CH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">2.4 ± 0.2</td><td class="colsep0 rowsep0" align="left">95 ± 3.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">5 (R)</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub>OH</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">CF<sub>3</sub></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">0.96 ± 0.1</td><td class="colsep0 rowsep0" align="left">>122</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">6 (S)</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub>OH</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">CF<sub>3</sub></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">1.2 ± 0.3</td><td class="colsep0 rowsep0" align="left">>122</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">7 (R)</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub>OH</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">CH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">CF<sub>3</sub></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">0.36 ± 0.01</td><td class="colsep0 rowsep0" align="left">92.8 ± 2.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">8 (S)</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub>OH</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">CH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">CF<sub>3</sub></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">0.16 ± 0.004</td><td class="colsep0 rowsep0" align="left">109.3 ± 2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">9 (R)</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub>OH</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">CH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">CH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">CF<sub>3</sub></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">0.52 ± 0.09</td><td class="colsep0 rowsep0" align="left">74 ± 3.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">10 (S)</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub>OH</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">CH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">CH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">CF<sub>3</sub></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">0.5 ± 0.09</td><td class="colsep0 rowsep0" align="left">42.4 ± 4.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">11 (R)</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub>OH</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">CH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">CH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">CH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">CF<sub>3</sub></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">0.6 ± 0.2</td><td class="colsep0 rowsep0" align="left">35.3 ± 2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">12 (S)</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub>OH</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">CH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">CH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">CH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">CF<sub>3</sub></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">0.43 ± 0.05</td><td class="colsep0 rowsep0" align="left">37.5 ± 2.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">13 (R)</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">CHOHCH<sub>2</sub>OH</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">CH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">CF<sub>3</sub></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">2.1 ± 0.3</td><td class="colsep0 rowsep0" align="left">>113</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">14 (S)</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">CHOHCH<sub>2</sub>OH</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">CH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">CF<sub>3</sub></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">5.9 ± 0.6</td><td class="colsep0 rowsep0" align="left">>113</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">15 (R)</td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub>OH</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">5 ± 0.5</td><td class="colsep0 rowsep0" align="left">>132</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">16 (S)</td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub>OH</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">1.7 ± 0.3</td><td class="colsep0 rowsep0" align="left">>132</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">17 (R)</td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub>OH</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">>11</td><td class="colsep0 rowsep0" align="left">>138</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">18 (S)</td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub>OH</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">>11</td><td class="colsep0 rowsep0" align="left">>138</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">19 (R)</td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub>OH</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">CH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">9.6 ± 1.2</td><td class="colsep0 rowsep0" align="left">>140</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">20 (S)</td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub>OH</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">CH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">>11</td><td class="colsep0 rowsep0" align="left">>140</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">21 (R)</td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub>OH</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">CF<sub>3</sub></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">0.59 ± 0.07</td><td class="colsep0 rowsep0" align="left">94.3 ± 8.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">22 (S)</td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub>OH</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">CF<sub>3</sub></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">0.3 ± 0.04</td><td class="colsep0 rowsep0" align="left">77.9 ± 9.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">23 (R)</td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub>OH</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">CH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">CH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">CF<sub>3</sub></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">1.7 ± 0.04</td><td class="colsep0 rowsep0" align="left">61 ± 6.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">24 (S)</td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub>OH</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">CH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">CH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">CF<sub>3</sub></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">0.58 ± 0.05</td><td class="colsep0 rowsep0" align="left">59 ± 10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">25 (R)</td><td class="colsep0 rowsep0" align="left">(CH<sub>2</sub>)<sub>2</sub>OH</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">CF<sub>3</sub></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">1.7 ± 0.1</td><td class="colsep0 rowsep0" align="left">100 ± 7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">26 (S)</td><td class="colsep0 rowsep0" align="left">(CH<sub>2</sub>)<sub>2</sub>OH</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">CF<sub>3</sub></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">0.76 ± 0.04</td><td class="colsep0 rowsep0" align="left">91 ± 3.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">27 (R)</td><td class="colsep0 rowsep0" align="left">(CH<sub>2</sub>)<sub>3</sub>OH</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">CF<sub>3</sub></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">2.3 ± 0.3</td><td class="colsep0 rowsep0" align="left">>114</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">28 (S)</td><td class="colsep0 rowsep0" align="left">(CH<sub>2</sub>)<sub>3</sub>OH</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">CF<sub>3</sub></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">0.89 ± 0.12</td><td class="colsep0 rowsep0" align="left">81.2 ± 1.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">29 (R)</td><td class="colsep0 rowsep0" align="left">CHOHCH<sub>2</sub>OH</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">CF<sub>3</sub></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">5.2 ± 0.9</td><td class="colsep0 rowsep0" align="left">>113</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">30 (S)</td><td class="colsep0 rowsep0" align="left">CHOHCH<sub>2</sub>OH</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">CF<sub>3</sub></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">3.8 ± 0.2</td><td class="colsep0 rowsep0" align="left">>113</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">31-rac</td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub>OH</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">CH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">CH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">CF<sub>3</sub></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">2.6 ± 0.4</td><td class="colsep0 rowsep0" align="left">>68.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">32-rac</td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub>OH</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">CH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">CF<sub>3</sub></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">5.1 ± 0.4</td><td class="colsep0 rowsep0" align="left">>70.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">33 (R)</td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub>OH</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">CH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">CF<sub>3</sub></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">0.35 ± 0.02</td><td class="colsep0 rowsep0" align="left">85 ± 3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">34 (S)</td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub>OH</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">CH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">CF<sub>3</sub></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">1.1 ± 0.1</td><td class="colsep0 rowsep0" align="left">85 ± 4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">35 (R)</td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub>OH</td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub>OH</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">CF<sub>3</sub></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">1.8 ± 0.3</td><td class="colsep0 rowsep0" align="left">>113</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">36 (S)</td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub>OH</td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub>OH</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">CF<sub>3</sub></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">>13</td><td class="colsep0 rowsep0" align="left">>113</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">37 (R)</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">CF<sub>3</sub></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">2 ± 0.2</td><td class="colsep0 rowsep0" align="left">89.3 ± 1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">38 (S)</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">CF<sub>3</sub></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">1.2 ± 0.03</td><td class="colsep0 rowsep0" align="left">93.6 ± 1.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">39 (R)</td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub>OH</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">>11</td><td class="colsep0 rowsep0" align="left">>132</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">40 (S)</td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub>OH</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">>11</td><td class="colsep0 rowsep0" align="left">>132</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">41 (R)</td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub>OH</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">CF<sub>3</sub></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">12.7 ± 2.8</td><td class="colsep0 rowsep0" align="left">>122</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">42 (S)</td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub>OH</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">CF<sub>3</sub></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">11.9 ± 1.9</td><td class="colsep0 rowsep0" align="left">>122</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">43 (R)</td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub>OH</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">CF<sub>3</sub></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">>12</td><td class="colsep0 rowsep0" align="left">>73</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">44 (S)</td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub>OH</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">CF<sub>3</sub></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">>12</td><td class="colsep0 rowsep0" align="left">>73</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">45 (R)</td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub>OH</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">>15.8</td><td class="colsep0 rowsep0" align="left">>66</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">46 (S)</td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub>OH</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">>15.8</td><td class="colsep0 rowsep0" align="left">>66</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">47 (R)</td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub>OH</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">O CH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left">>11</td><td class="colsep0 rowsep0" align="left">>133</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">48 (S)</td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub>OH</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">O CH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left">>11</td><td class="colsep0 rowsep0" align="left">>133</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BMS-626529</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><1 nM</td><td class="colsep0 rowsep0" align="left">>100</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">The reported IC<sub>50</sub> and CC<sub>50</sub> values represent the means ± standard deviations (<i>n</i> = 3).</p></div></div></div><div class="NLM_p last">All the alloc protected intermediates were worked up as per the <i>general procedure H</i>,<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> and the corresponding alloc products (<b>1a</b>–<b>48a</b>) were used directly in the next step without characterization.</div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i12">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_82430" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_82430" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> Optimization Strategy</h3><div class="NLM_p last">In recent years, we have made significant progress converting NBD-556, the first-in-class CD4 agonist, into gp120 entry antagonists, such as NBD-11021, NBD-14010, and <b>Ref1</b>, while simultaneously dramatically improving the anti-HIV potencies of these new molecules (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>).<a onclick="showRef(event, 'ref9 ref10 ref21'); return false;" href="javascript:void(0);" class="ref ref9 ref10 ref21">(9,10,21)</a> Despite this success, we realized that our most potent inhibitor, <b>Ref1</b>, still requires further improvements in cytotoxicity and SI values. Furthermore, the in vitro ADME study indicated that <b>Ref1</b> requires improved solubility.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> Poor aqueous solubility can lead to slow drug absorption, which may result in the poor bioavailability of drugs. Therefore, we reasoned that improved aqueous solubility and reduced toxicity are urgently necessary for our best inhibitors. However, the X-ray crystal structures of CD4 bound to gp120 and those of Phe43 cavity-targeted inhibitors bound to gp120 have confirmed that the hydrophobic cavity where Phe43 binds is narrow;<a onclick="showRef(event, 'ref9 ref22'); return false;" href="javascript:void(0);" class="ref ref9 ref22">(9,22)</a> therefore, the structural manipulation of the phenyl ring in our best inhibitors required careful consideration. We used a pyridine scaffold as a bioisostere, replacing the phenyl ring, due to its aromatic characteristics and increased basicity compared with the phenyl ring, to improve aqueous solubility, minimize reactive metabolite formation, and mitigate toxicity liability.<a onclick="showRef(event, 'ref23 ref24 ref25'); return false;" href="javascript:void(0);" class="ref ref23 ref24 ref25">(23−25)</a> While this article was in preparation, Kobayakawa et al. reported successful improvements in aqueous solubility and cytotoxicity by replacing the phenyl ring of NBD-556 with a pyridine scaffold.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a></div></div><div id="sec3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> Anti-HIV-1 Screening and Structure–Activity Relationships (SARs)</h3><div class="NLM_p">Our previously reported data for <b>Ref1</b>, the best gp120 entry antagonist that we have identified, showed an anti-HIV-1 activity of 89 nM against HIV-1<sub>HXB2</sub>; however, <b>Ref1</b> showed high cytotoxicity, with an SI value of 246.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> Furthermore, although the SI value was considered to be reasonable, the cytotoxicity and ADME data indicated that further improvements in cytotoxicity and ADME properties, especially aqueous solubility, were necessary to develop this molecule into a preclinical candidate for further assessment. Until recently, our group and others have avoided altering the phenyl group in Region I (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>), because all of the X-ray crystal structures of this class of compounds bound to HIV-1 gp120 have confirmed that this hydrophobic ring was inserted deep inside the Phe43 cavity, which is surrounded by hydrophobic residues. Pyridine was used by BMS as a substitute for the phenyl ring in the inhibitor that prevents the attachment of HIV gp120 to CD4 host cells, which led to the development of the potent clinical candidate BMS-488043.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> BMS-488043 showed a better pharmacokinetic profile, including improved solubility, and better metabolic profiles than previously described inhibitors. To explore other alternative bioisosteres, we opted to utilize a pyridine scaffold for replacing the phenyl ring (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>).</div><div class="NLM_p">We made a concerted effort to synthesize pyridine analogues for some of our most active phenyl-containing inhibitors, produced 48 novel pyridine-based compounds, and determined comprehensive SARs for these compounds. In general, we observed that cytotoxicity improved considerably for these compounds compared with <b>Ref1</b> and a structurally similar analogue, NBD-14136<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> (<b>Ref2</b>, <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>), irrespective of the position of “N” within the pyridine ring. The introduction of CH<sub>2</sub>OH or higher congeners at position R<sub>1</sub> (<b>15</b>–<b>34</b>) improved cytotoxicity, but antiviral activity was dependent on other substituents in Regions I, II, and III. For example, the introduction of the CH<sub>3</sub> group at positions R<sub>4</sub> and R<sub>5</sub> in Region III generally retained antiviral potency, but the toxicities of these compounds were higher (<b>9</b>–<b>12</b>, <b>23</b>, and <b>24</b>). An electron-withdrawing substituent at position R<sub>7</sub> generally improved or maintained antiviral potency; however, antiviral activity reduced considerably when an electron-donating substituent, such as CH<sub>3</sub>, was introduced at position R<sub>7</sub> (<b>19</b> and <b>20</b>).</div><div class="NLM_p">Although fluorine is an electron-withdrawing substituent and is hydrophobic, its presence at R<sub>7</sub> reduced antiviral activity, most likely due to its small size. When the N atom in pyridine was at positions Y or W (see the structures in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>), the antiviral potencies of these compounds dropped dramatically. Similarly, the presence of a bulkier group at position R<sub>8</sub> also had detrimental effects on antiviral activity, most likely due to steric limitations in the narrow hydrophobic cavity.</div><div class="NLM_p">Interestingly, the presence of a CH<sub>3</sub> group at position R<sub>6</sub> improved antiviral activity, with no detrimental effects on toxicity. We also introduced a branched alcohol group (CHOHCH<sub>2</sub>OH) at position R<sub>1</sub>, which resulted in the loss of antiviral activity (<b>13</b>, <b>14</b> and <b>29</b>, <b>30</b>), although the cytotoxicity of these compounds remained low (higher CC<sub>50</sub> values). Similarly, we introduced longer alcohol groups, such as (CH<sub>2</sub>)<sub>2</sub>OH (<b>25</b>, <b>26</b>) and (CH<sub>2</sub>)<sub>3</sub>OH (<b>27</b>, <b>28</b>) at R<sub>1</sub>, and observed no substantial reductions in antiviral activity; however, cytotoxicity was somewhat higher for some of these compounds (<b>25</b>, <b>26</b>, and <b>28</b>).</div><div class="NLM_p">The most notable improvements we observed were for NBD-14270 (<b>8</b>), with an IC<sub>50</sub> of 0.16 μM and a CC<sub>50</sub> of 109.3 μM. The IC<sub>50</sub> of <b>8</b> reduced by approximately twofold compared with that of <b>Ref1</b>, while the cytotoxicity (CC<sub>50</sub>) improved by approximately fivefold. However, the activity and cytotoxicity of <b>8</b> improved by 2-fold and 2.5-fold, respectively, compared with those for <b>Ref2</b>. The SI value for <b>Ref1</b> was 246, whereas the SI value for <b>8</b> reached 683, an almost threefold improvement. This remarkable improvement in the cytotoxicity and SI values prompted more in-depth assessments of the antiviral potency and ADME properties of this inhibitor.</div><div class="NLM_p last">Kobayakawa et al., in their recent report describing the replacement of the phenyl ring with pyridine, also showed measurable improvements in cytotoxicity for their pyridine analogues of NBD-556.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> However, the closest analogue of NBD-556 (5-chloro-2-substituted pyridine) showed an antiviral potency (IC<sub>50</sub>) reduction of approximately 358-fold, whereas the cytotoxicity (CC<sub>50</sub>) improved by approximately threefold. Besides, some other reported analogues, such as 2-chloro-4-substituted pyridine and 2-chloro-5-substituted pyridine, showed antiviral potency reductions of 13-fold and 23-fold, respectively, whereas the cytotoxicity improvements were also approximately threefold for these compounds.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a></div></div><div id="sec3_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> The New Generation of Inhibitors Showed Entry Antagonist Traits</h3><div class="NLM_p">Our first-generation NBD compound, NBD-556,<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> was reported to facilitate HIV infection into CD4-negative cells that expressed the coreceptor CCR5 by mimicking CD4 and inducing a conformational change in gp120, promoting CCR5 binding and enhancing HIV-1 entry.<a onclick="showRef(event, 'ref31 ref32'); return false;" href="javascript:void(0);" class="ref ref31 ref32">(31,32)</a> Subsequently, we verified that our new inhibitors did not possess this undesirable trait and behaved as entry antagonists.<a onclick="showRef(event, 'ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref9 ref10">(9,10)</a> In this study, we initially tested all 48 pyridine-containing molecules in a single-cycle assay against HIV-1<sub>HXB2</sub>. We selected <b>8</b>, which exhibited the best anti-HIV-1 activity and a higher SI value (SI = 683), and NBD-14235 (<b>33</b>), which has an SI of 243 and close structural similarity to <b>8</b>, to confirm that they are HIV-1 gp120 entry antagonists. CD4-negative and CCR5-positive Cf2TH–CCR5 cells were infected with the recombinant CD4-dependent HIV-1<sub>ADA</sub> virus, in the presence of escalating concentrations of these inhibitors. NBD-556 was used as a control. As shown in <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>, NBD-556 significantly enabled the infection of the Cf2Th-CCR5 cells, whereas <b>8</b> and <b>33</b> did not, indicating that these compounds maintained the HIV-1 entry antagonist property. Additionally, these compounds did not show toxicity at the doses used in this assay. We used these two molecules for further antiviral evaluation.</div><figure id="fig2" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b02149/20200221/images/medium/jm9b02149_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b02149/20200221/images/large/jm9b02149_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Infectivity of Cf2Th–CCR5 cells by CD4-dependent HIV-1<sub>ADA</sub>. Cf2Th–CCR5 cells were infected with CD4-dependent HIV-1<sub>ADA</sub> in the presence of <b>8</b> and <b>33</b>. NBD-556 was used as a control. The relative virus infectivity designates the ratio of the amount of infection detected in the presence of the compounds and the amount of infection detected in the absence of the compounds. Three independent experiments were performed in triplicate, and the graph is representative of one experiment. The toxicity of the compounds against these cells was evaluated to calculate the CC<sub>50</sub> values: for NBD-556 the CC<sub>50</sub> was greater than 60; for <b>8</b> and <b>33</b> it was greater than 47. All the values represent the mean ± standard deviation.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b02149/20200221/images/large/jm9b02149_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02149&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> Antiviral Activities of 8 and 33 against a Large and Diverse Panel of HIV-1 Env-pseudotyped Clinical Isolates</h3><div class="NLM_p">We previously reported systematic improvements in the anti-HIV-1 activities of our gp120 entry antagonists against a large panel of diverse HIV-1 Env-pseudotyped clinical isolates.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> Some of our best inhibitors against HIV-1<sub>HXB2</sub> showed broad-spectrum antiviral activities against these clinical isolates.<a onclick="showRef(event, 'ref9 ref10 ref21 ref27'); return false;" href="javascript:void(0);" class="ref ref9 ref10 ref21 ref27">(9,10,21,27)</a> We selected <b>8</b> and <b>33</b> to evaluate the anti-HIV-1 activity against a set of 50 HIV-1 clinical isolates belonging to diverse subtypes, including primary, transmitted, and early founder HIV-1 isolates and a selection of 12 recombinant HIV-1 clones. Except for two dual-tropic (CCR5/CXCR4) clinical isolates, all of the clones tested use the CCR5 coreceptor for entry. We compared the antiviral activity of the new generation of inhibitors with that of the previously described inhibitor <b>Ref2</b>,<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> which has structural similarity to <b>8</b>. <b>33</b> exhibited anti-HIV-1 activity similar to that of <b>Ref2</b>, as demonstrated by their overall mean IC<sub>50</sub> values and their antiviral activities against the different HIV subtypes (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). The overall mean IC<sub>50</sub> value for <b>Ref2</b> was 0.39 ± 0.02 μM (IC<sub>50</sub> values ranged from 0.19 to 0.79 μM), whereas the overall mean IC<sub>50</sub> value determined for <b>33</b> was 0.43 ± 0.02 μM (IC<sub>50</sub> values ranged from 0.13 to 0.99 μM). <b>Ref2</b> showed better antiviral activities against subtype D viruses (mean IC<sub>50</sub> value of 0.26 ± 0.03 μM), whereas <b>33</b> showed better antiviral activities against subtype C and D viruses (mean IC<sub>50</sub> values of 0.37 ± 0.03 and 0.35 ± 0.07 μM, respectively). In contrast, the respective SI values (CC<sub>50</sub>/IC<sub>50</sub>) determined for the panel of pseudoviruses were higher for <b>33</b> than for <b>Ref2</b>, with 1.5–2.1-fold improvements, depending on the viral subtype. Furthermore, this new generation of compounds exhibited a better cytotoxicity profile (<b>8</b>: CC<sub>50</sub> of 109.3 ± 2 μM and <b>33</b>: CC<sub>50</sub> of 85 ± 3 μM) than that for <b>Ref2</b> (CC<sub>50</sub> of 42.4 ± 1.0 μM). <b>8</b> showed better SI values than both <b>Ref2</b> and <b>33</b>, as well as better anti-HIV-1 activities and a better cytotoxicity profile. The overall mean IC<sub>50</sub> value for <b>8</b> was 0.18 ± 0.008 μM (IC<sub>50</sub> values ranged from 0.11 to 0.33 μM). Except for subtype A (mean IC<sub>50</sub> value of 0.22 ± 0.003 μM), <b>8</b> worked equally well against all of the subtypes tested (mean IC<sub>50</sub> value of 0.17–0.18 μM). The SI value calculated using the overall mean IC<sub>50</sub> value was 607.2, and depending on the viral subtype, the SI values varied from 497 to 643, representing 4.9–5.6-fold improvements compared with <b>Ref2</b>. Overall, <b>8</b> and <b>33</b> were active against all of the tested clinical isolates, regardless of the viral subtypes (A–D), indicating that these compounds have broad-spectrum inhibitory activity, unlike BMS-378806, an early stage attachment inhibitor, which despite its low nanomolar potency showed weaker activity against A, C, and D subtypes.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> Furthermore, <b>8</b> and <b>33</b>, similar to earlier reports for <b>Ref2</b>, were poorly active against the pseudovirus VSV-G, which was used here as a control, suggesting that the inhibitory activities of these compounds are specific to HIV-1. Additionally, <b>8</b> and <b>33</b> did not induce toxicity in the U87-CD4-CXCR4 cell line at the doses used for this assay.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Neutralization Activity of gp120 Entry Antagonists against a Panel of HIV-1 Env Pseudoviruses</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center">IC<sub>50</sub>,<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a> μM</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">subtype</th><th class="colsep0 rowsep0" align="center">NIH No.</th><th class="colsep0 rowsep0" align="center">ENVs</th><th class="colsep0 rowsep0" align="center"><b>Ref2</b></th><th class="colsep0 rowsep0" align="center"><b>33</b></th><th class="colsep0 rowsep0" align="center"><b>8</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>A</b></td><td class="colsep0 rowsep0" align="left">11887</td><td class="colsep0 rowsep0" align="left">Q259ENV.W6</td><td class="colsep0 rowsep0" align="left">0.46 ± 0.06<a class="ref internalNav" href="#t2fn3" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">0.4 ± 0.05</td><td class="colsep0 rowsep0" align="left">0.23 ± 0.03</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">11888</td><td class="colsep0 rowsep0" align="left">QB726.70M.ENV.C4</td><td class="colsep0 rowsep0" align="left">0.31 ± 0.07</td><td class="colsep0 rowsep0" align="left">0.63 ± 0.1</td><td class="colsep0 rowsep0" align="left">0.22 ± 0.01</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">11890</td><td class="colsep0 rowsep0" align="left">QF495.23M.ENV.A1</td><td class="colsep0 rowsep0" align="left">0.44 ± 0.05</td><td class="colsep0 rowsep0" align="left">0.47 ± 0.05</td><td class="colsep0 rowsep0" align="left">0.14 ± 0.003</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">11891</td><td class="colsep0 rowsep0" align="left">QF495.23M.ENV.A3</td><td class="colsep0 rowsep0" align="left">0.26 ± 0.04<a class="ref internalNav" href="#t2fn3" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">0.71 ± 0.17</td><td class="colsep0 rowsep0" align="left">0.33 ± 0.01</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">BG505-T332N</td><td class="colsep0 rowsep0" align="left">0.41 ± 0.03</td><td class="colsep0 rowsep0" align="left">0.27 ± 0.007</td><td class="colsep0 rowsep0" align="left">0.124 ± 0.005</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">KNH1144</td><td class="colsep0 rowsep0" align="left">0.62 ± 0.08</td><td class="colsep0 rowsep0" align="left">0.74 ± 0.06</td><td class="colsep0 rowsep0" align="left">0.26 ± 0.02</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>A/D</b></td><td class="colsep0 rowsep0" align="left">11901</td><td class="colsep0 rowsep0" align="left">QA790.204I.ENV.A4</td><td class="colsep0 rowsep0" align="left">0.29 ± 0.01</td><td class="colsep0 rowsep0" align="left">0.36 ± 0.03</td><td class="colsep0 rowsep0" align="left">0.14 ± 0.003</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">11904</td><td class="colsep0 rowsep0" align="left">QA790.204I.ENV.E2</td><td class="colsep0 rowsep0" align="left">0.41 ± 0.03</td><td class="colsep0 rowsep0" align="left">0.36 ± 0.02</td><td class="colsep0 rowsep0" align="left">0.16 ± 0.03</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>A2/D</b></td><td class="colsep0 rowsep0" align="left">11905</td><td class="colsep0 rowsep0" align="left">QG393.60M.ENV.A1</td><td class="colsep0 rowsep0" align="left">0.34 ± 0.02</td><td class="colsep0 rowsep0" align="left">0.42 ± 0.03</td><td class="colsep0 rowsep0" align="left">0.22 ± 0.002</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">11906</td><td class="colsep0 rowsep0" align="left">QG393.60M.ENV.B7</td><td class="colsep0 rowsep0" align="left">0.6 ± 0.005</td><td class="colsep0 rowsep0" align="left">0.5 ± 0.04</td><td class="colsep0 rowsep0" align="left">0.17 ± 0.03</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>A/G</b></td><td class="colsep0 rowsep0" align="left">11591</td><td class="colsep0 rowsep0" align="left">CRF02_AG Clone 211</td><td class="colsep0 rowsep0" align="left">0.58 ± 0.05</td><td class="colsep0 rowsep0" align="left">0.38 ± 0.04</td><td class="colsep0 rowsep0" align="left">0.23 ± 0.04</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">11594</td><td class="colsep0 rowsep0" align="left">CRF02_AG clone 250</td><td class="colsep0 rowsep0" align="left">0.41 ± 0.01</td><td class="colsep0 rowsep0" align="left">0.42 ± 0.01</td><td class="colsep0 rowsep0" align="left">0.21 ± 0.01</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">11595</td><td class="colsep0 rowsep0" align="left">CRF02_AG clone 251</td><td class="colsep0 rowsep0" align="left">0.36 ± 0.06</td><td class="colsep0 rowsep0" align="left">0.39 ± 0.03</td><td class="colsep0 rowsep0" align="left">0.12 ± 0.01</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">11598</td><td class="colsep0 rowsep0" align="left">CRF02_AG clone 255</td><td class="colsep0 rowsep0" align="left">0.33 ± 0.01</td><td class="colsep0 rowsep0" align="left">0.66 ± 0.03</td><td class="colsep0 rowsep0" align="left">0.22 ± 0.01</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">11599</td><td class="colsep0 rowsep0" align="left">CRF02_AG clone 257</td><td class="colsep0 rowsep0" align="left">0.39 ± 0.01</td><td class="colsep0 rowsep0" align="left">0.74 ± 0.1</td><td class="colsep0 rowsep0" align="left">0.16 ± 0.002</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">11600</td><td class="colsep0 rowsep0" align="left">CRF13_cpx clone 258</td><td class="colsep0 rowsep0" align="left">0.52 ± 0.07</td><td class="colsep0 rowsep0" align="left">0.52 ± 0.1</td><td class="colsep0 rowsep0" align="left">0.14 ± 0.003</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">11602</td><td class="colsep0 rowsep0" align="left">CRF02_AG clone 266</td><td class="colsep0 rowsep0" align="left">0.51 ± 0.06</td><td class="colsep0 rowsep0" align="left">0.75 ± 0.05</td><td class="colsep0 rowsep0" align="left">0.23 ± 0.01</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>AE</b></td><td class="colsep0 rowsep0" align="left">11603</td><td class="colsep0 rowsep0" align="left">CRF01_AE clone 269</td><td class="colsep0 rowsep0" align="left">0.52 ± 0.02</td><td class="colsep0 rowsep0" align="left">0.41 ± 0.2</td><td class="colsep0 rowsep0" align="left">0.138 ± 0.01</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>B</b></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">B41</td><td class="colsep0 rowsep0" align="left">0.36 ± 0.04</td><td class="colsep0 rowsep0" align="left">0.38 ± 0.05</td><td class="colsep0 rowsep0" align="left">0.136 ± 0.001</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">11018</td><td class="colsep0 rowsep0" align="left">QH0692, clone 42</td><td class="colsep0 rowsep0" align="left">0.27 ± 0.01<a class="ref internalNav" href="#t2fn3" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">0.99 ± 0.05</td><td class="colsep0 rowsep0" align="left">0.28 ± 0.02</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">11022</td><td class="colsep0 rowsep0" align="left">PVO, clone 4</td><td class="colsep0 rowsep0" align="left">0.41 ± 0.06</td><td class="colsep0 rowsep0" align="left">0.33 ± 0.04</td><td class="colsep0 rowsep0" align="left">0.11 ± 0.03</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">11023</td><td class="colsep0 rowsep0" align="left">TRO, clone 11</td><td class="colsep0 rowsep0" align="left">0.39 ± 0.02</td><td class="colsep0 rowsep0" align="left">0.45 ± 0.03</td><td class="colsep0 rowsep0" align="left">0.23 ± 0.005</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">11036</td><td class="colsep0 rowsep0" align="left">RHPA4259 clone 7</td><td class="colsep0 rowsep0" align="left">0.37 ± 0.07</td><td class="colsep0 rowsep0" align="left">0.24 ± 0.09</td><td class="colsep0 rowsep0" align="left">0.15 ± 0.01</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">11037</td><td class="colsep0 rowsep0" align="left">THRO4156 clone 18</td><td class="colsep0 rowsep0" align="left">0.32 ± 0.02</td><td class="colsep0 rowsep0" align="left">0.15 ± 0.03</td><td class="colsep0 rowsep0" align="left">0.16 ± 0.02</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">11038</td><td class="colsep0 rowsep0" align="left">CAAN5342 clone A2</td><td class="colsep0 rowsep0" align="left">0.22 ± 0.03</td><td class="colsep0 rowsep0" align="left">0.38 ± 0.07</td><td class="colsep0 rowsep0" align="left">0.13 ± 0.005</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">11058</td><td class="colsep0 rowsep0" align="left">SC422661.8</td><td class="colsep0 rowsep0" align="left">0.32 ± 0.08</td><td class="colsep0 rowsep0" align="left">0.16 ± 0.01</td><td class="colsep0 rowsep0" align="left">0.13 ± 0.01</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">11560</td><td class="colsep0 rowsep0" align="left">1006_11.C3.1601</td><td class="colsep0 rowsep0" align="left">0.58 ± 0.06</td><td class="colsep0 rowsep0" align="left">0.27 ± 0.01</td><td class="colsep0 rowsep0" align="left">0.139 ± 0.003</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">11561</td><td class="colsep0 rowsep0" align="left">1054.TC4.1499</td><td class="colsep0 rowsep0" align="left">0.25 ± 0.02</td><td class="colsep0 rowsep0" align="left">0.39 ± 0.02</td><td class="colsep0 rowsep0" align="left">0.23 ± 0.01</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">11562</td><td class="colsep0 rowsep0" align="left">1056.TA11.1826</td><td class="colsep0 rowsep0" align="left">0.58 ± 0.01</td><td class="colsep0 rowsep0" align="left">0.71 ± 0.1</td><td class="colsep0 rowsep0" align="left">0.13 ± 0.006</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">11563</td><td class="colsep0 rowsep0" align="left">1058 11.B11.1550<a class="ref internalNav" href="#t2fn2" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">0.29 ± 0.02</td><td class="colsep0 rowsep0" align="left">0.49 ± 0.06</td><td class="colsep0 rowsep0" align="left">0.28 ± 0.01</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">11572</td><td class="colsep0 rowsep0" align="left">9021_14.B2.4571</td><td class="colsep0 rowsep0" align="left">0.36 ± 0.08</td><td class="colsep0 rowsep0" align="left">0.57 ± 0.13</td><td class="colsep0 rowsep0" align="left">0.11 ± 0.03</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">11578</td><td class="colsep0 rowsep0" align="left">WEAUd15.410.5017<a class="ref internalNav" href="#t2fn2" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">0.76 ± 0.04</td><td class="colsep0 rowsep0" align="left">0.54 ± 0.04</td><td class="colsep0 rowsep0" align="left">0.22 ± 0.002</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>C</b></td><td class="colsep0 rowsep0" align="left">11307</td><td class="colsep0 rowsep0" align="left">Du172, clone 17</td><td class="colsep0 rowsep0" align="left">0.3 ± 0.03</td><td class="colsep0 rowsep0" align="left">0.27 ± 0.02</td><td class="colsep0 rowsep0" align="left">0.19 ± 0.002</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">11308</td><td class="colsep0 rowsep0" align="left">Du422, clone 1</td><td class="colsep0 rowsep0" align="left">0.63 ± 0.09</td><td class="colsep0 rowsep0" align="left">0.42 ± 0.01</td><td class="colsep0 rowsep0" align="left">0.23 ± 0.01</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">11309</td><td class="colsep0 rowsep0" align="left">ZM197M.PB7, SVPC6</td><td class="colsep0 rowsep0" align="left">0.27 ± 0.01</td><td class="colsep0 rowsep0" align="left">0.31 ± 0.03</td><td class="colsep0 rowsep0" align="left">0.13 ± 0.006</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">11310</td><td class="colsep0 rowsep0" align="left">ZM214M.PL15, SVPC7</td><td class="colsep0 rowsep0" align="left">0.24 ± 0.007</td><td class="colsep0 rowsep0" align="left">0.26 ± 0.005</td><td class="colsep0 rowsep0" align="left">0.13 ± 0.005</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">11312</td><td class="colsep0 rowsep0" align="left">ZM249M.PL1, SVPC10</td><td class="colsep0 rowsep0" align="left">0.55 ± 0.07</td><td class="colsep0 rowsep0" align="left">0.44 ± 0.1</td><td class="colsep0 rowsep0" align="left">0.18 ± 0.01</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">11313</td><td class="colsep0 rowsep0" align="left">ZM53M.PB12, SVPC11</td><td class="colsep0 rowsep0" align="left">0.54 ± 0.03</td><td class="colsep0 rowsep0" align="left">0.57 ± 0.3</td><td class="colsep0 rowsep0" align="left">0.28 ± 0.002</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">11314</td><td class="colsep0 rowsep0" align="left">ZM109F.PB4</td><td class="colsep0 rowsep0" align="left">0.29 ± 0.01</td><td class="colsep0 rowsep0" align="left">0.47 ± 0.01</td><td class="colsep0 rowsep0" align="left">0.28 ± 0.003</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">11317</td><td class="colsep0 rowsep0" align="left">CAP210.2.00.E8, SVPC17</td><td class="colsep0 rowsep0" align="left">0.47 ± 0.03</td><td class="colsep0 rowsep0" align="left">0.14 ± 0.05</td><td class="colsep0 rowsep0" align="left">0.115 ± 0.002</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">11502</td><td class="colsep0 rowsep0" align="left">HIV-16055-2, clone 3</td><td class="colsep0 rowsep0" align="left">0.29 ± 0.06</td><td class="colsep0 rowsep0" align="left">0.29 ± 0.09</td><td class="colsep0 rowsep0" align="left">0.12 ± 0.006</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">11504</td><td class="colsep0 rowsep0" align="left">HIV-16936-2, clone 21</td><td class="colsep0 rowsep0" align="left">0.47 ± 0.05</td><td class="colsep0 rowsep0" align="left">0.48 ± 0.1</td><td class="colsep0 rowsep0" align="left">0.21 ± 0.04</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">11506</td><td class="colsep0 rowsep0" align="left">HIV-25711-2, clone 4</td><td class="colsep0 rowsep0" align="left">0.26 ± 0.02</td><td class="colsep0 rowsep0" align="left">0.32 ± 0.03</td><td class="colsep0 rowsep0" align="left">0.17 ± 0.01</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">11507</td><td class="colsep0 rowsep0" align="left">HIV-225925-2, clone 22</td><td class="colsep0 rowsep0" align="left">0.24 ± 0.02</td><td class="colsep0 rowsep0" align="left">0.46 ± 0.04</td><td class="colsep0 rowsep0" align="left">0.17 ± 0.01</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">11908</td><td class="colsep0 rowsep0" align="left">QB099.391M.ENV.B1</td><td class="colsep0 rowsep0" align="left">0.42 ± 0.05</td><td class="colsep0 rowsep0" align="left">0.33 ± 0.05</td><td class="colsep0 rowsep0" align="left">0.118 ± 0.002</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>D</b></td><td class="colsep0 rowsep0" align="left">11911</td><td class="colsep0 rowsep0" align="left">QA013.70I.ENV.H1</td><td class="colsep0 rowsep0" align="left">0.32 ± 0.01</td><td class="colsep0 rowsep0" align="left">0.55 ± 0.04</td><td class="colsep0 rowsep0" align="left">0.25 ± 0.01</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">11912</td><td class="colsep0 rowsep0" align="left">QA013.70I.ENV.M12</td><td class="colsep0 rowsep0" align="left">0.22 ± 0.01</td><td class="colsep0 rowsep0" align="left">0.25 ± 0.02</td><td class="colsep0 rowsep0" align="left">0.16 ± 0.02</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">11916</td><td class="colsep0 rowsep0" align="left">QD435.100M.ENV.B5</td><td class="colsep0 rowsep0" align="left">0.3 ± 0.01</td><td class="colsep0 rowsep0" align="left">0.37 ± 0.03</td><td class="colsep0 rowsep0" align="left">0.13 ± 0.01</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">11918</td><td class="colsep0 rowsep0" align="left">QD435.100M.ENV.E1</td><td class="colsep0 rowsep0" align="left">0.19 ± 0.04</td><td class="colsep0 rowsep0" align="left">0.24 ± 0.01</td><td class="colsep0 rowsep0" align="left">0.136 ± 0.002</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>G</b></td><td class="colsep0 rowsep0" align="left">11596</td><td class="colsep0 rowsep0" align="left">CRF02_G clone 252</td><td class="colsep0 rowsep0" align="left">0.26 ± 0.03</td><td class="colsep0 rowsep0" align="left">0.13 ± 0.01</td><td class="colsep0 rowsep0" align="left">0.11 ± 0.01</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="3" align="left">mean ± SEM (μM): overall (<i>n</i> = 50) <b>SI</b></td><td class="colsep0 rowsep0" align="left">0.39 ± 0.02 <b>108.7</b></td><td class="colsep0 rowsep0" align="left">0.43 ± 0.02 <b>198.4</b></td><td class="colsep0 rowsep0" align="left">0.18 ± 0.008 <b>607.2</b></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="3" align="left">subtype A (<i>n</i> = 6) <b>SI</b></td><td class="colsep0 rowsep0" align="left">0.42 ± 0.05 <b>101</b></td><td class="colsep0 rowsep0" align="left">0.54 ± 0.08 <b>158</b></td><td class="colsep0 rowsep0" align="left">0.22 ± 0.003 <b>496.8</b></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="3" align="left">subtype A<sub>rec</sub> (<i>n</i> = 12) <b>SI</b></td><td class="colsep0 rowsep0" align="left">0.44 ± 0.03 <b>96.4</b></td><td class="colsep0 rowsep0" align="left">0.49 ± 0.04 <b>174.1</b></td><td class="colsep0 rowsep0" align="left">0.18 ± 0.01 <b>607.2</b></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="3" align="left">subtype B (<i>n</i> = 14) <b>SI</b></td><td class="colsep0 rowsep0" align="left">0.39 ± 0.04 <b>108.7</b></td><td class="colsep0 rowsep0" align="left">0.43 ± 0.06 <b>198.4</b></td><td class="colsep0 rowsep0" align="left">0.17 ± 0.02 <b>642.9</b></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="3" align="left">subtype C (<i>n</i> = 13) <b>SI</b></td><td class="colsep0 rowsep0" align="left">0.38 ± 0.04 <b>111.6</b></td><td class="colsep0 rowsep0" align="left">0.37 ± 0.03 <b>230.5</b></td><td class="colsep0 rowsep0" align="left">0.18 ± 0.02 <b>607.2</b></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="3" align="left">subtype D (<i>n</i> = 4) <b>SI</b></td><td class="colsep0 rowsep0" align="left">0.26 ± 0.03 <b>163.1</b></td><td class="colsep0 rowsep0" align="left">0.35 ± 0.07 <b>243.7</b></td><td class="colsep0 rowsep0" align="left">0.17 ± 0.03 <b>642.9</b></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">control</td><td class="colsep0 rowsep0" align="left">VSV-G<a class="ref internalNav" href="#t2fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left">IC<sub>50</sub></td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>20</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">CC<sub>50</sub></td><td class="colsep0 rowsep0" align="left">46.3 ± 10.6</td><td class="colsep0 rowsep0" align="left">>94</td><td class="colsep0 rowsep0" align="left">>94</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="3" align="left">IC<sub>50</sub> (color code)</td><td class="colsep0 rowsep0" align="left">≤0.2</td><td class="colsep0 rowsep0" align="left">>0.2 ≤ 0.5</td><td class="colsep0 rowsep0" align="left">>0.5</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">The reported IC<sub>50</sub> values represent the means ± standard deviations (<i>n</i> = 3).</p></div><div class="footnote" id="t2fn3"><sup><sup>b</sup></sup><p class="last">Data previously published.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a></p></div><div class="footnote" id="t2fn2"><sup><sup>c</sup></sup><p class="last">R5 × 4-tropic virus; all the rest are CCR5-tropic viruses.</p></div><div class="footnote" id="t2fn4"><sup><sup>d</sup></sup><p class="last">VSV-G was tested in U87-CD4-CCR5 cells.</p></div></div></div><div class="NLM_p">Moreover, we tested the anti-HIV-1 activity of <b>8</b> and <b>33</b> against an HIV-1 panel, comprised of paired infant and maternal clones belonging to subtypes A and D/A. These HIV clones were isolated from chronically infected mothers and their respective infected infants.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> Previous studies have shown that vertically transmitted HIV infant variants were more difficult to neutralize using combinations of broadly neutralizing antibodies (bNAbs) 2G12, biz, 2F5, and 4E10.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> In this study, we found that <b>Ref2</b>, <b>8</b>, and <b>33</b> equally neutralized both the infant and maternal HIV-1 variants (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>), as shown by their overall mean IC<sub>50</sub> values and the means for infant and maternal viruses. <b>8</b>, the most effective compound with an overall mean IC<sub>50</sub> value of 0.37 ± 0.07 μM, was slightly more efficient against the maternal clones (mean IC<sub>50</sub> value of 0.31 ± 0.04 μM) than against the infant clones (mean IC<sub>50</sub> value of 0.43 ± 0.07 μM). These findings suggest that the new gp120 entry antagonists can neutralize both infant and maternal HIV-1 variants.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Neutralization Activity of gp120 Entry Antagonists against an HIV-1 Panel of Paired Infant (B) and Maternal (M) Env Molecular Clones</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center">IC<sub>50</sub><a class="ref internalNav" href="#t3fn1" aria-label="a">a</a> (μM)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">subtype</th><th class="colsep0 rowsep0" align="center">NIH No.</th><th class="colsep0 rowsep0" align="center">ENV</th><th class="colsep0 rowsep0" align="center"><b>Ref2</b></th><th class="colsep0 rowsep0" align="center"><b>33</b></th><th class="colsep0 rowsep0" align="center"><b>8</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">A</td><td class="colsep0 rowsep0" align="left">11518-B</td><td class="colsep0 rowsep0" align="left">BG505.W6M.ENV.C2</td><td class="colsep0 rowsep0" align="left">0.92 ± 0.16</td><td class="colsep0 rowsep0" align="left">1.38 ± 0.2</td><td class="colsep0 rowsep0" align="left">0.57 ± 0.06</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">A</td><td class="colsep0 rowsep0" align="left">11528-M</td><td class="colsep0 rowsep0" align="left">MG505.W0M.ENV.A2</td><td class="colsep0 rowsep0" align="left">0.93 ± 0.07</td><td class="colsep0 rowsep0" align="left">1.6 ± 0.08</td><td class="colsep0 rowsep0" align="left">0.47 ± 0.08.</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">A</td><td class="colsep0 rowsep0" align="left">11519-B</td><td class="colsep0 rowsep0" align="left">B1206.W6P.ENV.A1A</td><td class="colsep0 rowsep0" align="left">0.75 ± 0.06</td><td class="colsep0 rowsep0" align="left">1.8 ± 0.07</td><td class="colsep0 rowsep0" align="left">0.53 ± 0.05</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">A</td><td class="colsep0 rowsep0" align="left">11531-M</td><td class="colsep0 rowsep0" align="left">MI206.W0M.ENV.D1</td><td class="colsep0 rowsep0" align="left">0.7 ± 0.02</td><td class="colsep0 rowsep0" align="left">1 ± 0.02</td><td class="colsep0 rowsep0" align="left">0.28 ± 0.01</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">A</td><td class="colsep0 rowsep0" align="left">11521-B</td><td class="colsep0 rowsep0" align="left">BJ613.W6M.ENV.E1</td><td class="colsep0 rowsep0" align="left">0.8 ± 0.07</td><td class="colsep0 rowsep0" align="left">0.94 ± 0.14</td><td class="colsep0 rowsep0" align="left">0.26 ± 0.01</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">A</td><td class="colsep0 rowsep0" align="left">11535-M</td><td class="colsep0 rowsep0" align="left">MJ613.W0M.ENV.A2</td><td class="colsep0 rowsep0" align="left">0.5 ± 0.05</td><td class="colsep0 rowsep0" align="left">0.63 ± 0.07</td><td class="colsep0 rowsep0" align="left">0.31 ± 0.07</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">D/A</td><td class="colsep0 rowsep0" align="left">11524-B</td><td class="colsep0 rowsep0" align="left">BL035.W6M.ENV.C1</td><td class="colsep0 rowsep0" align="left">0.52 ± 0.16</td><td class="colsep0 rowsep0" align="left">0.54 ± 0.04</td><td class="colsep0 rowsep0" align="left">0.42 ± 0.01</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">D/A</td><td class="colsep0 rowsep0" align="left">11538-M</td><td class="colsep0 rowsep0" align="left">ML035.W0M.ENV.G2</td><td class="colsep0 rowsep0" align="left">0.59 ± 0.08</td><td class="colsep0 rowsep0" align="left">0.86 ± 0.05</td><td class="colsep0 rowsep0" align="left">0.23 ± 0.01</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">A</td><td class="colsep0 rowsep0" align="left">11525-B</td><td class="colsep0 rowsep0" align="left">BL274.W6M.ENV.A3</td><td class="colsep0 rowsep0" align="left">0.63 ± 0.12</td><td class="colsep0 rowsep0" align="left">0.84 ± 0.09</td><td class="colsep0 rowsep0" align="left">0.37 ± 0.05</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">A</td><td class="colsep0 rowsep0" align="left">11540-M</td><td class="colsep0 rowsep0" align="left">ML274.W0M.ENV.B1</td><td class="colsep0 rowsep0" align="left">0.66 ± 0.1</td><td class="colsep0 rowsep0" align="left">0.88 ± 0.06</td><td class="colsep0 rowsep0" align="left">0.25 ± 0.03</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="3" align="left">mean ± SEM (μM): overall (<i>n</i> = 10)</td><td class="colsep0 rowsep0" align="left">0.7 ± 0.05</td><td class="colsep0 rowsep0" align="left">1.05 ± 0.13</td><td class="colsep0 rowsep0" align="left">0.37 ± 0.04</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="3" align="left">infant (B) (<i>n</i> = 5)</td><td class="colsep0 rowsep0" align="left">0.72 ± 0.07</td><td class="colsep0 rowsep0" align="left">1.1 ± 0.22</td><td class="colsep0 rowsep0" align="left">0.43 ± 0.07</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="3" align="left">mother (M) (<i>n</i> = 5)</td><td class="colsep0 rowsep0" align="left">0.68 ± 0.07</td><td class="colsep0 rowsep0" align="left">0.99 ± 0.16</td><td class="colsep0 rowsep0" align="left">0.31 ± 0.04</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">The reported IC<sub>50</sub> values represent the means ± standard deviations (<i>n</i> = 3).</p></div></div></div></div><div id="sec3_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> Inhibitory Activity of 8 and 33 against a Large Panel of FDA-Approved Drug-Resistant Viruses</h3><div class="NLM_p">To further evaluate the neutralizing activities of <b>8</b> and <b>33</b>, we assessed these compounds against a large set of drug-resistant viruses, including five Enfuvirtide (T-20)-resistant viruses, seven multidrug, non-nucleoside reverse transcriptase inhibitor (NNRTI)-resistant viruses, which carry mutations that confer resistance to both NNRTIs and nucleoside inhibitors (NRTIs), three Raltegravir-resistant viruses, and nine protease inhibitor (PI)-resistant viruses (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). As a reference, the activities of the gp120 entry antagonists were assessed against the reconstructed wild-type (WT) HIV-1<sub>NL4–3</sub> clone, from which the drug-resistant clones were obtained. For this assay, the WT HIV-1<sub>NL4–3</sub> control virus or the drug-resistant viruses were pretreated with the gp120 entry antagonists and then used to infect TZMb-l cells. We found that <b>8</b> and <b>33</b> both inhibited WT HIV-1<sub>NL4–3</sub>, with IC<sub>50</sub> values of 2.1 and 1.1 μM, respectively. Moreover, both compounds neutralized the T-20-resistant viruses, with IC<sub>50</sub> values similar to the IC<sub>50</sub> values determined for the control virus, WT HIV-1<sub>NL4–3</sub>. Similar results were observed for the NNRTI-resistant viruses, and in some cases, the drug-resistant viruses appeared to be more sensitive to the gp120 entry antagonists than the WT virus. The Raltegravir-resistant viruses and the PI-resistant viruses were also highly sensitive to <b>8</b> and <b>33</b>, as shown by their low IC<sub>50</sub> values. For <b>33</b>, the IC<sub>50</sub> values detected against these clones were 1.8–10.5-fold lower than the IC<sub>50</sub> value detected for WT HIV-1<sub>NL4–3</sub>, and for <b>8</b>, the IC<sub>50</sub> values were 1.8–11.7-fold lower than the IC<sub>50</sub> value detected for WT HIV-1<sub>NL4–3</sub>. In conclusion, we found that <b>8</b> and <b>33</b> were active against all of the tested drug-resistant viruses, indicating that these compounds could potentially be successfully used in combination with other antiviral agents.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Inhibitory Activity of <b>8</b> and <b>33</b> against a Large Panel of FDA Approved Drug-Resistant Viruses</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center">NIH catalog No.</th><th class="colsep0 rowsep0" align="center">major mutations<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center"><b>33</b> IC<sub>50</sub><a class="ref internalNav" href="#t4fn2" aria-label="b">b</a> (μM)</th><th class="colsep0 rowsep0" align="center">fold increase/sensitive</th><th class="colsep0 rowsep0" align="center"><b>8</b> IC<sub>50</sub><a class="ref internalNav" href="#t4fn2" aria-label="b">b</a> (μM)</th><th class="colsep0 rowsep0" align="center">fold increase/sensitive</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">NL4–3 WT (wild-type)</td><td class="colsep0 rowsep0" align="left">114</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">2.1 ± 0.1</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">1.1 ± 0.04</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ENTRY (Enfuvirtide)-resistant</td><td class="colsep0 rowsep0" align="left">9498</td><td class="colsep0 rowsep0" align="left">V38A, N42T</td><td class="colsep0 rowsep0" align="left">1.5 ± 0.2</td><td class="colsep0 rowsep0" align="left">sensitive</td><td class="colsep0 rowsep0" align="left">0.94 ± 0.1</td><td class="colsep0 rowsep0" align="left">sensitive</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">9490</td><td class="colsep0 rowsep0" align="left">V38A</td><td class="colsep0 rowsep0" align="left">1.9 ± 0.1</td><td class="colsep0 rowsep0" align="left">sensitive</td><td class="colsep0 rowsep0" align="left">0.94 ± 0.02</td><td class="colsep0 rowsep0" align="left">sensitive</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">9496</td><td class="colsep0 rowsep0" align="left">V38E, N42S</td><td class="colsep0 rowsep0" align="left">1.6 ± 0.2</td><td class="colsep0 rowsep0" align="left">sensitive</td><td class="colsep0 rowsep0" align="left">0.89 ± 0.1</td><td class="colsep0 rowsep0" align="left">sensitive</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">9491</td><td class="colsep0 rowsep0" align="left">N42T, N43K</td><td class="colsep0 rowsep0" align="left">2.5 ± 0.2</td><td class="colsep0 rowsep0" align="left">sensitive</td><td class="colsep0 rowsep0" align="left">0.47 ± 0.02</td><td class="colsep0 rowsep0" align="left">sensitive</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">9489</td><td class="colsep0 rowsep0" align="left">D36G</td><td class="colsep0 rowsep0" align="left">0.73 ± 0.1</td><td class="colsep0 rowsep0" align="left">sensitive</td><td class="colsep0 rowsep0" align="left">0.71 ± 0.01</td><td class="colsep0 rowsep0" align="left">sensitive</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">multidrug (NNRTI) resistant</td><td class="colsep0 rowsep0" align="left">12227</td><td class="colsep0 rowsep0" align="left">K101P, K103N</td><td class="colsep0 rowsep0" align="left">0.48 ± 0.01</td><td class="colsep0 rowsep0" align="left">sensitive</td><td class="colsep0 rowsep0" align="left">0.23 ± 0.01</td><td class="colsep0 rowsep0" align="left">sensitive</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">12229</td><td class="colsep0 rowsep0" align="left">L100I, K103N</td><td class="colsep0 rowsep0" align="left">2.9 ± 0.1</td><td class="colsep0 rowsep0" align="left">1.38</td><td class="colsep0 rowsep0" align="left">2.4 ± 0.2</td><td class="colsep0 rowsep0" align="left">2.18</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">12231</td><td class="colsep0 rowsep0" align="left">K103N, Y181C</td><td class="colsep0 rowsep0" align="left">0.42 ± 0.04</td><td class="colsep0 rowsep0" align="left">sensitive</td><td class="colsep0 rowsep0" align="left">0.26 ± 0.02</td><td class="colsep0 rowsep0" align="left">sensitive</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">12233</td><td class="colsep0 rowsep0" align="left">K101E, Y181 V</td><td class="colsep0 rowsep0" align="left">3.7 ± 0.3</td><td class="colsep0 rowsep0" align="left">1.76</td><td class="colsep0 rowsep0" align="left">2.4 ± 0.07</td><td class="colsep0 rowsep0" align="left">2.18</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">12237</td><td class="colsep0 rowsep0" align="left">Y181C, G190A</td><td class="colsep0 rowsep0" align="left">3.5 ± 0.5</td><td class="colsep0 rowsep0" align="left">1.66</td><td class="colsep0 rowsep0" align="left">2 ± 0.1</td><td class="colsep0 rowsep0" align="left">1.82</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">12241</td><td class="colsep0 rowsep0" align="left">K101E, G190S</td><td class="colsep0 rowsep0" align="left">1.7 ± 0.3</td><td class="colsep0 rowsep0" align="left">sensitive</td><td class="colsep0 rowsep0" align="left">0.47 ± 0.01</td><td class="colsep0 rowsep0" align="left">sensitive</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">12243</td><td class="colsep0 rowsep0" align="left">L100I, M230L</td><td class="colsep0 rowsep0" align="left">4.5 ± 0.05</td><td class="colsep0 rowsep0" align="left">2.14</td><td class="colsep0 rowsep0" align="left">2.3 ± 0.05</td><td class="colsep0 rowsep0" align="left">2.09</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">integrase (Raltegravir-resistant)</td><td class="colsep0 rowsep0" align="left">11847</td><td class="colsep0 rowsep0" align="left">G140S, Q148H</td><td class="colsep0 rowsep0" align="left">0.2 ± 0.04</td><td class="colsep0 rowsep0" align="left">sensitive</td><td class="colsep0 rowsep0" align="left">0.23 ± 0.005</td><td class="colsep0 rowsep0" align="left">sensitive</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">11850</td><td class="colsep0 rowsep0" align="left">E92Q, N155H</td><td class="colsep0 rowsep0" align="left">0.72 ± 0.22</td><td class="colsep0 rowsep0" align="left">sensitive</td><td class="colsep0 rowsep0" align="left">0.3 ± 0.03</td><td class="colsep0 rowsep0" align="left">sensitive</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">11851</td><td class="colsep0 rowsep0" align="left">N155H</td><td class="colsep0 rowsep0" align="left">0.26 ± 0.1</td><td class="colsep0 rowsep0" align="left">sensitive</td><td class="colsep0 rowsep0" align="left">0.094 ± 0.005</td><td class="colsep0 rowsep0" align="left">sensitive</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">multiple-PI-resistant</td><td class="colsep0 rowsep0" align="left">11800</td><td class="colsep0 rowsep0" align="left">11I, 32I, 33F, 46I, 47 V, 54M, 58E, 73S, 84 V, 89 V, 90M</td><td class="colsep0 rowsep0" align="left">0.28 ± 0.05</td><td class="colsep0 rowsep0" align="left">sensitive</td><td class="colsep0 rowsep0" align="left">0.16 ± 0.07</td><td class="colsep0 rowsep0" align="left">sensitive</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">11801</td><td class="colsep0 rowsep0" align="left">10F, 33F, 43T, 46L, 54 V, 82A, 84 V, 90M</td><td class="colsep0 rowsep0" align="left">0.31 ± 0.16</td><td class="colsep0 rowsep0" align="left">sensitive</td><td class="colsep0 rowsep0" align="left">0.19 ± 0.1</td><td class="colsep0 rowsep0" align="left">sensitive</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">11803</td><td class="colsep0 rowsep0" align="left">33F, 43T, 46I, 48 V, 50 V, 54S, 82A</td><td class="colsep0 rowsep0" align="left">1.2 ± 0.2</td><td class="colsep0 rowsep0" align="left">sensitive</td><td class="colsep0 rowsep0" align="left">0.61 ± 0.2</td><td class="colsep0 rowsep0" align="left">sensitive</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">11804</td><td class="colsep0 rowsep0" align="left">32I, 46I, 47 V, 84 V</td><td class="colsep0 rowsep0" align="left">0.51 ± 0.07</td><td class="colsep0 rowsep0" align="left">sensitive</td><td class="colsep0 rowsep0" align="left">0.26 ± 0.04</td><td class="colsep0 rowsep0" align="left">sensitive</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">11805</td><td class="colsep0 rowsep0" align="left">48 V, 53L, 54 V, 82A, 90M</td><td class="colsep0 rowsep0" align="left">1 ± 0.1</td><td class="colsep0 rowsep0" align="left">sensitive</td><td class="colsep0 rowsep0" align="left">0.27 ± 0.14</td><td class="colsep0 rowsep0" align="left">sensitive</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">11807</td><td class="colsep0 rowsep0" align="left">32I, 33F, 47A, 82A, 90M</td><td class="colsep0 rowsep0" align="left">0.58 ± 0.1</td><td class="colsep0 rowsep0" align="left">sensitive</td><td class="colsep0 rowsep0" align="left">0.12 ± 0.02</td><td class="colsep0 rowsep0" align="left">sensitive</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">11808</td><td class="colsep0 rowsep0" align="left">10F, 11I, 33F, 43T, 46L, 54 V, 73S, 82A, 84 V, 89 V, 90M</td><td class="colsep0 rowsep0" align="left">0.47 ± 0.1</td><td class="colsep0 rowsep0" align="left">sensitive</td><td class="colsep0 rowsep0" align="left">0.73 ± 0.1</td><td class="colsep0 rowsep0" align="left">sensitive</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">12465</td><td class="colsep0 rowsep0" align="left">46I, 54 V, 58E, 74P, 82L, 90M</td><td class="colsep0 rowsep0" align="left">1 ± 0.2</td><td class="colsep0 rowsep0" align="left">sensitive</td><td class="colsep0 rowsep0" align="left">0.42 ± 0.1</td><td class="colsep0 rowsep0" align="left">sensitive</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">12466</td><td class="colsep0 rowsep0" align="left">32I, 33F, 43T, 46I, 47 V, 54M, 73S, 82A, 89 V, 90M</td><td class="colsep0 rowsep0" align="left">0.47 ± 0.1</td><td class="colsep0 rowsep0" align="left">sensitive</td><td class="colsep0 rowsep0" align="left">0.24 ± 0.09</td><td class="colsep0 rowsep0" align="left">sensitive</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">Mutants were reported here as per the data obtained from <a href="https://www.aidsreagent.org/" class="extLink">https://www.aidsreagent.org/</a> and associated references indicated in the <a class="ref internalNav" href="#sec5" aria-label="Experimental Section">Experimental Section</a>.</p></div><div class="footnote" id="t4fn2"><sup><sup>b</sup></sup><p class="last">The reported IC<sub>50</sub> values represent the means ± standard deviations (<i>n</i> = 3).</p></div></div></div><div class="NLM_p last">However, we are currently conducting experiments to identify the possible generation of drug-resistant mutants in response to the use of the most potent gp120 entry antagonists examined in this study.</div></div><div id="sec3_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> gp120 Entry Antagonists Inhibited Cell-to-Cell HIV-1 Transmission</h3><div class="NLM_p">Another important feature described for the earlier generation of gp120 entry antagonists was their ability to inhibit cell-to-cell HIV-1 transmission,<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> which has been reported to be more efficient than HIV-1 cell-free infection.<a onclick="showRef(event, 'ref35 ref36'); return false;" href="javascript:void(0);" class="ref ref35 ref36">(35,36)</a> Multiple viral particles can be transmitted to noninfected cells simultaneously. Additionally, cell-to-cell HIV-1 transmission in vitro has been shown to be resistant to some potent bNAbs, including CD4 binding site (CD4bs) antibodies<a onclick="showRef(event, 'ref36 ref37 ref38'); return false;" href="javascript:void(0);" class="ref ref36 ref37 ref38">(36−38)</a> and NRTIs, but not to other antiretrovirals, including entry inhibitors, NNRTIs, and protease inhibitors.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a></div><div class="NLM_p">Here, we evaluated the activities of the new generation of gp120 entry antagonists, <b>8</b> and <b>33</b>, against cell-to-cell HIV-1 transmission and compared their activities to that of <b>Ref2</b>, which has previously been reported to inhibit cell-to-cell HIV-1 transmission.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> H9 cells, chronically infected with HIV-1<sub>IIIB</sub> (CXCR4-tropic), and MOLT-4 cells, chronically infected with HIV-1<sub>ADA</sub> (CCR5-tropic), were used as donor cells, and TZM-bl cells were used as acceptor cells. BMS-626529 was used as a control treatment drug. Our results (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>) indicated that both <b>8</b> and <b>33</b> have similar activities to that for the previous generation compound, <b>Ref2</b>, against cell-to-cell HIV transmission. All of the tested compounds, including BMS-626529, showed better activities against the CXCR4-tropic virus HIV-1<sub>IIIB</sub> than against the CCR5-tropic virus HIV-1<sub>ADA</sub>. In particular, the IC<sub>50</sub> values for the gp120 entry antagonists calculated against HIV-1<sub>IIIB</sub> in the CXCR4-tropic assay were onefold lower than the IC<sub>50</sub> values calculated against HIV-1<sub>ADA</sub> in the CCR5-tropic assay.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Inhibitory Activity against Cell-to-Cell HIV Transmission by the gp120 Entry Antagonists</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center">IC<sub>50</sub><a class="ref internalNav" href="#t5fn1" aria-label="a">a</a> (μM)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center">TZMb-l/H9-HIV-1<sub>IIIB</sub></th><th class="colsep0 rowsep0" align="center">TZMb-l/Molt-HIV-1<sub>ADA</sub></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>Ref2</b></td><td class="colsep0 rowsep0" align="left">0.46 ± 0.2</td><td class="colsep0 rowsep0" align="left">0.89 ± 0.14</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>33</b></td><td class="colsep0 rowsep0" align="left">0.45 ± 0.1</td><td class="colsep0 rowsep0" align="left">1.2 ± 0.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8</b></td><td class="colsep0 rowsep0" align="left">0.47 ± 0.1</td><td class="colsep0 rowsep0" align="left">0.92 ± 0.13</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BMS-626529</td><td class="colsep0 rowsep0" align="left">0.02 ± 0.005</td><td class="colsep0 rowsep0" align="left">∼0.2</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup><sup>a</sup></sup><p class="last">The reported IC<sub>50</sub> values represent the means ± standard deviation (SD), <i>n</i> = 3.</p></div></div></div></div><div id="sec3_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> In Vitro ADME Assessment</h3><div class="NLM_p">The in vitro assessment of ADME properties has played an important role, especially for the pharmaceutical industry, in reducing the drug attrition rate. In 1997, the major causes of failure for drugs that advanced to clinical trials were poor ADME properties.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> However, the judicious use of ADME assessments during the early stages of drug development has dramatically improved the failure rate of drugs during recent years.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> Drug failures during the later stages of drug development can be very costly. Therefore, the major goal of the pharmaceutical industry with regard to drug development programs is to “fail early, fail cheaply”.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> Therefore, we also adopted in vitro ADME assessments in our early optimization phase of developing these entry antagonists as future clinical candidates. We previously reported the ADME properties of our most active inhibitor, <b>Ref1</b>, which targets the Phe43 cavity of gp120, and compared our results with the data obtained for BMS-626529, a prodrug of which is showing promising results in Phase III clinical trials.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> The ADME properties of <b>Ref1</b> indicated room for further improvements.</div><div class="NLM_p">Since this is the first time we decided to use a pyridine scaffold as an aromatic ring in Region I and this bioisostere was used before in medicinal chemistry to improve physicochemical and ADME properties, it was also imperative for us to evaluate these properties by selecting one of our most active inhibitors, <b>8</b>, which has a better cytotoxicity profile and SI values than the other compounds examined in this study and compared with <b>Ref1</b> previously reported.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> The data presented in <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a> shows that <b>8</b> (a pyridine analogue) has approximately threefold improved solubility compared with <b>Ref1</b> (a phenyl analogue) and BMS-626529, which was expected and was the basis of the design strategy used in this study. Since these inhibitors are expected to be used orally, we performed the Caco-2 bidirectional permeability experiment [apical to basolateral (A-B) and basolateral to apical (B-A) across the Caco-2 cell monolayer], which can be used to measure the efflux ratio and predict the human intestinal permeability of orally administered drugs. The data shown in <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a> indicates that the apparent permeabilities of <b>8</b> and the clinical candidate, BMS-626529, are similar. However, the permeability of <b>Ref1</b> was poor compared with both of these inhibitors. We used digoxin, a P-gp substrate, as a positive control to identify whether active efflux was mediated by P-gp. It is apparent that the efflux of <b>8</b>, <b>Ref1</b>, and digoxin was mediated by P-gp. However, we were unable to directly compare the effects of P-gp inhibitors on permeability parameters, because different P-gp inhibitors were used in the current study (1 μM valsopodar) and the previous study (100 μM verapamil).<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> However, the data confirmed that all three compounds had efflux ratios greater than 2, suggesting the potential involvement of an efflux transporter, which can mediate the transport of these inhibitors from the basolateral side to the apical side. Interestingly, the efflux ratios for all three cases were reduced in the presence of a P-gp inhibitor. For <b>8</b>, BMS-626529, and digoxin (positive control) the efflux ratios were reduced to less than 2, indicating that these compounds could be P-gp substrates. However, for <b>Ref1</b>, the efflux ratio was not reduced to less than 2, indicating the possible involvement of other transporters, such as breast cancer-resistant protein (BCRP) or multidrug resistance-associated protein 2 (MRP2).</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. In Vitro ADME Profile of the Most Potent Inhibitor <b>8</b></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center">compound</th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">assay performed</th><th class="colsep0 rowsep0" align="center">in vitro ADMET</th><th class="colsep0 rowsep0" align="center"><b>8</b></th><th class="colsep0 rowsep0" align="center">Ref1<a class="ref internalNav" href="#t6fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">BMS-626529<a class="ref internalNav" href="#t6fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">positive control used in the study (digoxin)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">solubility (mg/mL)</td><td class="colsep0 rowsep0" align="left">phosphate buffer, pH7.4</td><td class="colsep0 rowsep0" align="left">0.734</td><td class="colsep0 rowsep0" align="left">0.042–0.214</td><td class="colsep0 rowsep0" align="left">0.047–0.237</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Caco-2 permeability (mean <i>P</i><sub>app</sub> × 10<sup>–6</sup> cm/sec)</td><td class="colsep0 rowsep0" align="left">A-to-B</td><td class="colsep0 rowsep0" align="left">6.51</td><td class="colsep0 rowsep0" align="left">0.602</td><td class="colsep0 rowsep0" align="left">9.27</td><td class="colsep0 rowsep0" align="left">0.483</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">B-to-A</td><td class="colsep0 rowsep0" align="left">20.3</td><td class="colsep0 rowsep0" align="left">17.7</td><td class="colsep0 rowsep0" align="left">32.0</td><td class="colsep0 rowsep0" align="left">10.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">efflux ratio</td><td class="colsep0 rowsep0" align="left">3.12</td><td class="colsep0 rowsep0" align="left">30.5</td><td class="colsep0 rowsep0" align="left">3.46</td><td class="colsep0 rowsep0" align="left">21.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">(+ 1 μM Valspodar)</td><td class="colsep0 rowsep0" align="left">A-to-B</td><td class="colsep0 rowsep0" align="left">14.0</td><td class="colsep0 rowsep0" align="left">0.777<a class="ref internalNav" href="#t6fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">13.5<a class="ref internalNav" href="#t6fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">2.00</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">B-to-A</td><td class="colsep0 rowsep0" align="left">10.5</td><td class="colsep0 rowsep0" align="left">10.9<a class="ref internalNav" href="#t6fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">22.7<a class="ref internalNav" href="#t6fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">2.06</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">efflux ratio</td><td class="colsep0 rowsep0" align="left">0.755</td><td class="colsep0 rowsep0" align="left">14.4<a class="ref internalNav" href="#t6fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">1.69<a class="ref internalNav" href="#t6fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">1.03</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">metabolic stability (human liver microsomes)</td><td class="colsep0 rowsep0" align="left">parent compound remaining at 120 min (% of 0 min)</td><td class="colsep0 rowsep0" align="left">93.5</td><td class="colsep0 rowsep0" align="left">88.5</td><td class="colsep0 rowsep0" align="left">71.5</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">Cl<sub>int</sub> (mL/min/mg protein)</td><td class="colsep0 rowsep0" align="left"><0.0116</td><td class="colsep0 rowsep0" align="left">0.0018</td><td class="colsep0 rowsep0" align="left">0.0052</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">Half-life (min)</td><td class="colsep0 rowsep0" align="left">>120</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">protein binding (human plasma)</td><td class="colsep0 rowsep0" align="left">% bound</td><td class="colsep0 rowsep0" align="left">99.2</td><td class="colsep0 rowsep0" align="left">99.0</td><td class="colsep0 rowsep0" align="left">86.9</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">cytochrome P450 inhibition, IC<sub>50</sub> (μM)</td><td class="colsep0 rowsep0" align="left">CYP1A2 (Phenacetin)</td><td class="colsep0 rowsep0" align="left">70.1</td><td class="colsep0 rowsep0" align="left">>25</td><td class="colsep0 rowsep0" align="left">>25</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">CYP2B6 (Bupropion)</td><td class="colsep0 rowsep0" align="left">85.4</td><td class="colsep0 rowsep0" align="left">>25</td><td class="colsep0 rowsep0" align="left">>25</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">CYP2C8 (Amodiaquine)</td><td class="colsep0 rowsep0" align="left">>100</td><td class="colsep0 rowsep0" align="left">>25<a class="ref internalNav" href="#t6fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">>25<a class="ref internalNav" href="#t6fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">CYP2C9 (Diclofenac)</td><td class="colsep0 rowsep0" align="left">>100</td><td class="colsep0 rowsep0" align="left">>25</td><td class="colsep0 rowsep0" align="left">>25</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">CYP2C19 (S-Mephenytoin)</td><td class="colsep0 rowsep0" align="left">>100</td><td class="colsep0 rowsep0" align="left">>25</td><td class="colsep0 rowsep0" align="left">>25</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">CYP2D6 (Bufuralol)</td><td class="colsep0 rowsep0" align="left">>100</td><td class="colsep0 rowsep0" align="left">>25</td><td class="colsep0 rowsep0" align="left">>25</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">CYP3A (Testosterone)</td><td class="colsep0 rowsep0" align="left">>62.2</td><td class="colsep0 rowsep0" align="left">>25</td><td class="colsep0 rowsep0" align="left">>25</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">CYP3A (Midazolam)</td><td class="colsep0 rowsep0" align="left">>100</td><td class="colsep0 rowsep0" align="left">>25</td><td class="colsep0 rowsep0" align="left">>25</td><td class="colsep0 rowsep0" align="left"> </td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup><sup>a</sup></sup><p class="last">The data were from ref <a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a>.</p></div><div class="footnote" id="t6fn2"><sup><sup>b</sup></sup><p class="last">100 μM verapamil was used as a P-gp inhibitor.</p></div><div class="footnote" id="t6fn3"><sup><sup>c</sup></sup><p class="last">Paclitaxel was used as a substrate.</p></div></div></div><div class="NLM_p">We also examined the metabolic stability of <b>8</b> in the human liver microsome, because the liver is the primary site of drug metabolism. The data in <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a> shows that <b>8</b> has the highest stability (93.5%) among the examined compounds, followed by <b>Ref1</b>, whereas BMS-626529 was metabolized to some degree (71.5%) in our earlier study. The clearance data (Cl<sub>int</sub>) indicated that all three compounds are low-clearance compounds, and <b>8</b> had a half-life longer than 120 min. We did not calculate half-life data in our earlier reported study. It is worthwhile to mention that compounds with high clearance values may not be considered favorable, because they may be cleared rapidly from the body, and the drugs may have a short duration of action may need multiple dosing. We also examined the protein-binding potential of these inhibitors in human plasma. The data indicated that both <b>8</b> and <b>Ref1</b> were highly bound (>99%), whereas BMS-626529 had a binding potential of 86.9%.</div><div class="NLM_p last">The oxidative biotransformation of many lipophilic drugs into hydrophilic counterparts is critical, facilitating the elimination of drugs from the body. The cytochrome P450 enzyme system plays a critical role in these oxidative biotransformation reactions associated with drug metabolism. More than 50 CYP450 enzymes have been identified, but CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP3A4, and CYP3A5 metabolize almost 80% of all drugs. Therefore, we decided to use this set of eight CYP450 enzymes to determine whether any of our potent inhibitors have inhibitory effects that may help predict potential drug–drug interactions when coadministered with other treatment agents. Earlier, we reported the inhibitory effects of <b>Ref1</b> and BMS-626529, which showed no inhibitory activities for doses as high as 25 μM. In this study, we escalated the tested doses to as high as 100 μM, and our most potent inhibitor, <b>8</b>, showed no inhibition at greater than 50 μM dose levels against CYP1A2, CYP2B6, and CYP3A. No inhibitory activities were observed against the other CYP450 enzymes at the 100 μM dose level.</div></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i25">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_47255" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_47255" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">Here, we reported a significant shift in the design of gp120 antagonists, based on our previously reported and optimized inhibitor, <b>Ref1</b>. The phenyl ring in this class of inhibitors has been accepted to represent the critical moiety for antiviral potency, because this ring is located deep inside the narrow hydrophobic cavity, according to X-ray crystallography data. In this study, we deployed pyridine, a bioisostere of phenyl, as a scaffold to replace the phenyl ring. We synthesized 48 novel compounds and determined a comprehensive SAR to identify the best possible gp120 entry antagonists that display improved cytotoxicity and ADME properties. We identified the two best inhibitors, <b>8</b> and <b>33</b>, as determined by antiviral activity against HIV-1<sub>HXB2</sub>. These inhibitors were confirmed to be gp120 entry antagonists and showed broad-spectrum activity against a large panel of HIV-1 Env-pseudotyped viruses, representing diverse subtypes. Although the antiviral potency of these two new inhibitors remained similar to that for <b>Ref1</b>, the cytotoxicity of <b>8</b> was substantially improved, with an overall SI value of 607 against 50 diverse clinical isolates. This improvement was quite substantial compared to the SI value for <b>33</b>, which was 198. The ADME data for <b>8</b> also showed a considerable improvement in aqueous solubility. All other ADME properties for <b>8</b> were comparable to those for the clinical candidate BMS-626529, a prodrug of which is currently being tested in Phase III clinical trials. Overall, the pyridine substitution of the phenyl ring has been the most effective alteration in our quest to identify a clinically relevant gp120 antagonist. This finding is expected to improve the antiviral potency, cytotoxicity, and ADME properties of this class of inhibitors for subsequent preclinical studies.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i26">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_40867" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_40867" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> Cells and Viruses</h3><div class="NLM_p">TZM-bl cells,<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> U87CD4+CXCR4+ cells,<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> HIV-1 IIIB, infected H9 cells,<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> and MOLT-4 CCR5+ cells<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> were obtained through the National Institutes of Health AIDS Reagent Program (NIH ARP). HEK 293T cells were purchased from ATCC. CD4-negative Cf2Th-CCR5+ cells and Env expression vector pSVIIIenv-ADA were kindly provided by Dr. J. G. Sodroski.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> HIV-1 Env molecular clone expression vector pHXB2-env (X4) DNA was also obtained through the NIH ARP.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> HIV-1 Env molecular clones of gp160 genes for HIV-1 Env pseudovirus production were obtained as follows: clones representing the standard panels A, A/D, A2/D, D, and C (QB099.391M.Env.B1) were obtained through the NIH ARP from Dr. J. Overbaugh.<a onclick="showRef(event, 'ref48 ref49'); return false;" href="javascript:void(0);" class="ref ref48 ref49">(48,49)</a> The HIV-1 Env molecular clones panel of subtype A/G, A/E, and G Env clones were obtained through the NIH ARP from Drs. D. Ellenberger, B. Li, M. Callahan, and S. Butera.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> The HIV-1 Env panel of standard reference subtype B Env clones was obtained through the NIH ARP from Drs. D. Montefiori, F. Gao, and M. Li (PVO, clone 4 (SVPB11) TRO, clone 11 (SVPB12), QH0692, clone 42 (SVPB6), SC422661, clone B (SVPB8)); from Drs. B. H. Hahn and J. F. Salazar-Gonzalez (pRHPA4259, clone 7 (SVPB14)); from Drs. B. H. Hahn and D. L. Kothe (pTHRO4156 clone 18 (SVPB15), pCAAN5342 clone A2 (SVPB19)).<a onclick="showRef(event, 'ref51 ref52'); return false;" href="javascript:void(0);" class="ref ref51 ref52">(51,52)</a> The subtype B clones pWEAUd15.410.5017, p1058_11.B11.1550, p1054.TC4.1499, p1006_11.C3.1601, p1056.TA11.1826, and p9021_14.B2.4571 were obtained through the NIH ARP from Drs. B. H. Hahn, B. F. Keele, and G. M. Shaw.<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> The subtype C HIV-1 reference panel of Env clones was also obtained through the NIH ARP from Drs. D. Montefiori, F. Gao, S. A. Karim, and G. Ramjee (Du172.17); from Drs. D. Montefiori, F. Gao, C. Williamson, and S. A. Karim (Du422.1), from Drs. B. H. Hahn, Y. Li and J. F. Salazar-Gonzalez (ZM197M.PB7; ZM214M.PL15, ZM249M.PL1); from Drs. E. Hunter and C. Derdeyn (ZM53M.PB12; ZM109F.PB4); from Drs. L. Morris, K. Mlisana, and D. Montefiori, (CAP210.2.00.E8).<a onclick="showRef(event, 'ref54 ref55 ref56'); return false;" href="javascript:void(0);" class="ref ref54 ref55 ref56">(54−56)</a> The HIV-1 subtype C panel of Indian gp160 Env clones HIV-16055–2 clone 3, HIV-16936-2 clone 21, HIV-25711-2 clone 4 and HIV-225925-2 clone 22 were obtained through the NIH ARP from Drs. R. Paranjape, S. Kulkarni, and D. Montefiori.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> The panel of paired infant and maternal HIV-1 Env molecular clones were obtained through the NIH ARP from Dr. J. Overbaugh.<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> The Env pseudotyped genes of BG505.T332N, KNH1144, and B41 were kindly provided by Dr. J. P. Moore of the Weil Cornell Medical College.</div><div class="NLM_p">The Env-deleted proviral backbone plasmids pNL4-3.Luc.R-.E-DNA (from Dr. N. Landau),<a onclick="showRef(event, 'ref58 ref59'); return false;" href="javascript:void(0);" class="ref ref58 ref59">(58,59)</a> the pSG3Δ<sup>env</sup> DNA (from Drs. J. C. Kappes and X. Wu),<a onclick="showRef(event, 'ref42 ref52'); return false;" href="javascript:void(0);" class="ref ref42 ref52">(42,52)</a> and the pNL4-3 (from Dr. Malcolm Martin)<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a> were obtained through the NIH ARP Division of AIDS, NIAID, NIH. The following molecular clones were also obtained through the NIH ARP, Division of AIDS, NIAID, NIH: the panel of Enfuvirtide (T-20) resistant viruses from Trimeris, Inc.;<a onclick="showRef(event, 'ref60 ref61'); return false;" href="javascript:void(0);" class="ref ref60 ref61">(60,61)</a> the panel multidrug resistant NNRTI infectious clones from Dr. R. Shafer;<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> the Raltegravir-resistant infectious molecular clones from Dr. R. Shafer and E. Reuman, M.S.,<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a> and the multidrug protease inhibitor-resistant infectious clones from Dr. R. Shafer.<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a></div><div class="NLM_p last">MLV gag-pol-expressing vector pVPack-GP, Env-expressing vector pVPack-VSV-G, and a pFB-Luc vector were obtained from Stratagene.</div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> Pseudovirus Preparation</h3><div class="NLM_p last">Pseudoviruses capable of single-cycle infection were prepared as previously described.<a onclick="showRef(event, 'ref27 ref31'); return false;" href="javascript:void(0);" class="ref ref27 ref31">(27,31)</a> Briefly, 5 × 10<sup>6</sup> HEK293T cells were transfected with an HIV-1 Env-deleted pro-viral backbone plasmid pSG3<sup>Δenv</sup> or pNL4-3.Luc.R-.E-DNA, and an HIV-1 Env-expression plasmid by using FuGENE6 (Promega). The control VSV-G pseudovirus was prepared by transfecting the HEK293T cells with a combination of the Env-expressing plasmid pVPack-VSV-G, the MLV gag-pol-expressing plasmid pVPack-GP, the pFB-Luc plasmid, and FuGENE6. Pseudovirus-containing supernatantswere collected 2 d after transfection, filtered, titered, and stored in aliquots at −80 °C.</div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> Measurement of Antiviral Activity</h3><div id="sec5_3_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> Single-Cycle Infection Assay in TZM-bl Cells</h4><div class="NLM_p last">The antiviral activity of the gp120 entry antagonists was evaluated in single-cycle infection assay by infecting TZM-bl cells with HIV-1 pseudotyped with the Env from the lab-adapted HIV-1<sub>HXB-2</sub> (CXCR4-tropic). Additionally, <b>Ref2</b>, <b>33</b>, and <b>8</b> were tested against a large group of HIV-1 pseudotyped with the Env from the panel of clinical isolates as previously described.<a onclick="showRef(event, 'ref27 ref31'); return false;" href="javascript:void(0);" class="ref ref27 ref31">(27,31)</a> Briefly, TZM-bl cells were plated at 1 × 10<sup>4</sup>/ well in a 96-well tissue culture plate and cultured overnight. On the following day, HIV-1 pseudovirus was pretreated with graded concentrations of the small molecules for 30 min and added to the cells. After 3 d of incubation, the cells were washed and lysed with 50 μL of lysis buffer (Promega). Twenty microliters of the lysates were transferred to a white plate and mixed with the luciferase assay reagent (Promega). The luciferase activity was measured immediately with a Tecan Spark reader, and the percent inhibition by the compounds and the half-maximal inhibitory concentration values were calculated using the GraphPad Prism software.</div></div><div id="sec5_3_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> Single-Cycle Infection Assay in U87-CD4-CXCR4 Cells</h4><div class="NLM_p last">The antiviral activity of <b>Ref2</b>, <b>33</b>, and <b>8</b> was tested against the control pseudovirus VSV-G in U87-CD4-CXCR4 cells. Briefly, U87-CD4-CXCR4 cells were plated in a 96-well tissue culture plate at 1 × 10<sup>4</sup>/well and cultured at 37 °C. The following day, aliquots of pseudovirus pretreated with graded concentrations of the small molecules for 30 min were added to the cells and incubated for 3 d. Cells were washed and lysed with 40 μL of lysis buffer. The lysates were then transferred to a white plate and mixed with the luciferase assay reagent. The luciferase activity was immediately measured to calculate the percent of inhibition and IC<sub>50</sub> values by using the GraphPad Prism software.</div></div></div><div id="sec5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> Assay in Cf2Th-CCR5 Cells</h3><div class="NLM_p last">CD4-negative Cf2Th-CCR5 cells were plated at 6 × 10<sup>3</sup> cells/well in a 96-well tissue culture plate and incubated at 37 °C. The cells were infected with the recombinant CD4-dependent pseudovirus HIV-1<sub>ADA</sub> as previously described.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> Briefly, aliquots of HIV-1<sub>ADA</sub> pseudovirus pretreated with graded concentrations of compounds for 30 min were added to the cells and cultured for 48 h. Cells were washed with phosphate-buffered solution (PBS) and lysed with 40 μL of cell lysis reagent. Lysates were transferred to a white 96-well plate and mixed with the luciferase assay reagent. The luciferase activity was immediately measured to obtain the relative infection compared to the untreated control. The relative virus infectivity indicates the ratio of the amount of infection detected in the presence of the compounds and the amount of infection detected in the absence of the compounds.</div></div><div id="sec5_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> Measurement of Antiviral Activity against Drug-Resistant Viruses in TZM-bl Cells</h3><div class="NLM_p last">The antiviral activity of the gp120 entry antagonists against a panel of drug-resistant viruses was evaluated by infecting TZM-bl cells. Briefly, TZM-bl cells were plated at 10<sup>4</sup>/well in a 96-well plate and cultured overnight. On the following day, HIV-1 drug-resistant viruses were pretreated with graded concentrations of the small molecules for 30 min and added to the cells. Following 48 h of incubation, the cells were washed and lysed. The cellular lysates were transferred to a white plate, and the luciferase activity was immediately measured with a Tecan Spark reader. The percent inhibition by the compounds and the IC<sub>50</sub> values were calculated using the GraphPad Prism software, as reported above.</div></div><div id="sec5_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> Cell-to-Cell HIV-1 Transmission</h3><div class="NLM_p last">The cell-to-cell HIV-1 transmission inhibition assay was performed as previously described,<a onclick="showRef(event, 'ref65 ref66'); return false;" href="javascript:void(0);" class="ref ref65 ref66">(65,66)</a> with a few modifications. Briefly, TZM-bl cells (used as acceptor cells) wereplated at 10<sup>4</sup>/well in a 96-well plate 24 h before the assay. As transmitting cells, we used H9 cells chronically infected with HIV-1<sub>IIIB</sub> at 2 × 10<sup>3</sup> cells/well for the CXCR4-tropic assay and MOLT-4/CCR5 cells chronically infected with HIV-1<sub>ADA</sub> at 2 × 10<sup>3</sup> cells/well for theCCR5-tropic assay. The transmitting cells were pretreated with 200 μg/mL mitomycin C (Sigma) for 1 h at 37 °C, washed with PBS, and incubated with the acceptor cells in the presence of escalating concentrations of compounds for 24 h. Therefore, the cells were washed and lysed. The lysates were mixed with the luciferase assay reagent. The luciferase activity was immediately measured to calculate the percent of inhibition and IC<sub>50</sub> values by using the GraphPad Prism software.</div></div><div id="sec5_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> Evaluation of Cytotoxicity</h3><div id="sec5_7_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> TZM-bl Cells and U87-CD4-CXCR4 Cells</h4><div class="NLM_p last">The cytotoxicity of the gp120 entry antagonists in TZM-bl and U87-CD4-CXCR4 cells was measured by using the colorimetric CellTiter 96 AQueous One Solution Cell Proliferation Assay (MTS) (Promega) following the manufacturer’s instructions. Briefly, the cells were plated at 1 × 10<sup>4</sup>/ well and cultured at 37 °C. Following overnight incubation, the cells were incubated with 100 μL of the compounds at graded concentrations and cultured for 3 d. The MTS reagent was added to the cells and incubated for 4 h at 37 °C. The absorbance was recorded at 490 nm. The percent of cytotoxicity and the the concentration for 50% cytotoxicity values were calculated as above.</div></div><div id="sec5_7_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> Cf2Th-CCR5 Cells</h4><div class="NLM_p last">The cytotoxicity of the small molecules in Cf2Th-CCR5 cells was also measured with the colorimetric CellTiter 96 AQueous One Solution Cell Proliferation Assay. Briefly, Cf2Th-CCR5 cells were plated in a 96-well plate and cultured at 37 °C overnight. Next, the cells were incubated with 100 μL of the compounds at graded concentrations and cultured for 48 h. The MTS reagent was added to the cells, and 4 h later, the absorbance was recorded at 490 nm. The percent of cytotoxicity and the CC<sub>50</sub> values were calculated as above.</div></div></div><div id="sec5_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38"> In Vitro ADME Study</h3><div class="NLM_p last">Details of the in vitro ADME study and data analyses can be found in the <a class="ref internalNav" href="#notes1" aria-label="Supplemental Information">Supplemental Information</a>.</div></div><div id="sec5_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39"> Chemistry</h3><div class="NLM_p">General. We used commercial reagents and solvents without further purification. We also performed all reactions in the air atmosphere unless otherwise stated. Reactions were monitored by thin-layer chromatography (TLC) performed on Merck TLC Silica gel plates (60 F254), using a UV light for visualization and basic aqueous potassium permanganate or iodine fumes as a developing agent. <sup>1</sup>H and <sup>13</sup>C NMR spectra were recorded on Bruker Avance 400 instrument with operating frequency of 400 and 100 MHz, respectively, and calibrated using residual undeuterated chloroform (δH = 7.28 ppm) and CDCl<sub>3</sub> (δC = 77.16 ppm) or undeuterated dimethyl sulfoxide (DMSO) (δH = 2.50 ppm) and DMSO-<i>d</i><sub>6</sub> (δC = 39.51 ppm) as internal references. The following abbreviations are used to set multiplicities: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, br = broad. The purity of the final compounds was checked by liquid chromatography-mass spectrometry (LCMS) in a Shimadzu LCMS-2010A using three types of detection systems such as EDAD, ELSD, and UV and was found to be at least 95%.</div><div id="sec5_9_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> General Procedure A: For Suzuki Coupling</h4><div class="NLM_p last">To a solution containing appropriate bromide (or chloride) (50 mmol, 1 equiv), (1-(<i>tert</i>-butoxycarbonyl)-1<i>H</i>-pyrrol-2-yl)boronic acid (50 mmol, 1 equiv) in tetrahydrofuran (THF)–H<sub>2</sub>O (1:1, 100 mL), Na<sub>2</sub>CO<sub>3</sub> (100 mmol, 2 equiv) and Pd(Ph<sub>3</sub>P)Cl<sub>2</sub> (1 mol %) were added under a nitrogen atmosphere. The mixture was stirred at reflux for 8–15 h (TLC-control). After it cooled to room temperature, water (50 mL) and CH<sub>2</sub>Cl<sub>2</sub> (50 mL) were added. The organic layer was separated; the aqueous layer was extracted with CH<sub>2</sub>Cl<sub>2</sub> (3 × 50 mL). The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. Purification by flash chromatography using the hexane (Hex)–ethyl acetate (EtOAc) mixture as eluent afforded the desired compound. Compounds <b>S1a–S1h</b> were obtained following the <b><i>general procedure A</i></b>. Compounds <b>S1g</b> and <b>S1h</b> were obtained from the corresponding chlorides.</div></div><div id="sec5_9_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> tert-Butyl 2-(5-meth ylpyridin-2-yl)-1H-pyrrole-1-carboxylate (S1a)</h4><div class="NLM_p">Eluent: Hex–EtOAc (from 10:1 to 5:1), <i>R</i><sub>f</sub> = 0.2 (5:1, Hex-EtOAc). Yield = 63%.</div><div id="sec5_9_2_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i42" class="anchor-spacer"></div><h5 class="article-section__title" id="_i42"> <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz)</h5><div class="NLM_p last">δ = 1.37 (s, 9 H), 2.34 (s, 3 H), 6.22 (t, <i>J</i> = 3.3 Hz, 1 H), 6.36 (dd, <i>J</i> = 3.2, 1.7 Hz, 1 H), 7.28 (d, <i>J</i> = 8.1 Hz, 1 H), 7.33 (dd, <i>J</i> = 3.2, 1.8 Hz, 1 H), 7.48 (dd, <i>J</i> = 7.9, 1.8 Hz, 1 H), 8.42–8.45 (m, 1 H).</div></div><div id="sec5_9_2_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i43" class="anchor-spacer"></div><h5 class="article-section__title" id="_i43"> <sup>13</sup>C NMR (CDCl<sub>3</sub>, 100 MHz)</h5><div class="NLM_p last">δ = 18.3, 27.6 (3C), 83.5, 110.5, 115.3, 123.2, 123.2, 131.3, 134.2, 136.3, 149.2, 149.3, 150.2.</div></div></div><div id="sec5_9_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> tert-Butyl 2-(5-chloropyridin-2-yl)-1H-pyrrole-1-carboxylate (S1b)</h4><div class="NLM_p">Eluent: Hex–EtOAc (from 20:1 to 10:1), <i>R</i><sub>f</sub> = 0.3 (10:1, Hex-EtOAc). Yield = 84%.</div><div id="sec5_9_3_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i45" class="anchor-spacer"></div><h5 class="article-section__title" id="_i45"> <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz)</h5><div class="NLM_p last">δ = 1.41 (s, 9 H), 6.25 (t, <i>J</i> = 3.3 Hz, 1 H), 6.43 (dd, <i>J</i> = 3.3, 1.7 Hz, 1 H), 7.34–7.38 (m, 2 H), 7.66 (dd, <i>J</i> = 8.4, 2.5 Hz, 1 H), 8.57 (d, <i>J</i> = 2.4 Hz, 1 H).</div></div><div id="sec5_9_3_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i46" class="anchor-spacer"></div><h5 class="article-section__title" id="_i46"> <sup>13</sup>C NMR (CDCl<sub>3</sub>, 100 MHz)</h5><div class="NLM_p last">δ = 27.8 (3C), 84.1, 110.8, 116.3, 124.0, 124.3, 130.2, 133.1, 135.6, 147.8, 149.2, 151.0.</div></div></div><div id="sec5_9_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> tert-Butyl 2-(5-fluoropyridin-2-yl)-1H-pyrrole-1-carboxylate (S1c)</h4><div class="NLM_p">Eluent: Hex-EtOAc (from 20:1 to 10:1), <i>R</i><sub>f</sub> = 0.3 (10:1, Hex-EtOAc). Yield = 68%.</div><div id="sec5_9_4_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i48" class="anchor-spacer"></div><h5 class="article-section__title" id="_i48"> <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz)</h5><div class="NLM_p last">δ = 1.39 (s, 9 H), 6.23 (t, <i>J</i> = 3.3 Hz, 1 H), 6.39 (dd, <i>J</i> = 3.3, 1.7 Hz, 1 H), 7.35 (dd, <i>J</i> = 3.2, 1.7 Hz, 1 H), 7.39 (d, <i>J</i> = 1.8 Hz, 1 H), 7.40–7.42 (m, 1 H), 8.47 (t, <i>J</i> = 1.7 Hz, 1 H).</div></div><div id="sec5_9_4_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i49" class="anchor-spacer"></div><h5 class="article-section__title" id="_i49"> <sup>13</sup>C NMR (CDCl<sub>3</sub>, 100 MHz)</h5><div class="NLM_p last">δ = 27.7 (3C), 83.9, 110.6, 115.8, 122.7 (d, <i>J</i> = 18.6 Hz), 123.6, 124.6 (d, <i>J</i> = 4.2 Hz), 133.1, 137.0 (d, <i>J</i> = 23.8 Hz), 149.2 (d, <i>J</i> = 1.5 Hz), 149.3, 158.4 (d, <i>J</i> = 256.0 Hz).</div></div></div><div id="sec5_9_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> tert-Butyl 2-(5-(trifluoromethyl)pyridin-2-yl)-1H-pyrrole-1-carboxylate (S1d)</h4><div class="NLM_p">Eluent: Hex-EtOAc (from 30:1 to 20:1), <i>R</i><sub>f</sub> = 0.3 (30:1, Hex-EtOAc). Yield = 65%.</div><div id="sec5_9_5_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i51" class="anchor-spacer"></div><h5 class="article-section__title" id="_i51"> <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz)</h5><div class="NLM_p last">δ = 1.42 (s, 9 H), 6.28 (t, <i>J</i> = 3.3 Hz, 1 H), 6.54 (dd, <i>J</i> = 3.4, 1.7 Hz, 1 H), 7.40 (dd, <i>J</i> = 3.2, 1.7 Hz, 1 H), 7.54 (d, <i>J</i> = 8.2 Hz, 1 H), 7.92 (dd, <i>J</i> = 8.3, 2.2 Hz, 1 H), 8.87 (s, 1 H).</div></div><div id="sec5_9_5_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i52" class="anchor-spacer"></div><h5 class="article-section__title" id="_i52"> <sup>13</sup>C NMR (CDCl<sub>3</sub>, 100 MHz)</h5><div class="NLM_p last">δ = 27.6 (3C), 84.3, 110.9, 117.3, 122.8, 123.8 (q, <i>J</i> = 272.0 Hz), 124.4 (q, <i>J</i> = 33.0 Hz), 124.8, 132.9 (q, <i>J</i> = 3.5 Hz), 133.0, 145.8 (q, <i>J</i> = 4.1 Hz), 149.1, 156.0 (q, <i>J</i> = 1.5 Hz).</div></div></div><div id="sec5_9_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> tert-Butyl 2-(6-chloropyridin-3-yl)-1H-pyrrole-1-carboxylate (S1e)</h4><div class="NLM_p">Eluent: Hex-EtOAc (from 20:1 to 10:1), <i>R</i><sub>f</sub> = 0.4 (10:1, Hex-EtOAc). Yield = 76%.</div><div id="sec5_9_6_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i54" class="anchor-spacer"></div><h5 class="article-section__title" id="_i54"> <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz)</h5><div class="NLM_p last">δ = 1.44 (s, 9 H), 6.25–6.29 (m, 2 H), 7.33 (d, <i>J</i> = 8.2 Hz, 1 H), 7.41 (t, <i>J</i> = 2.5 Hz, 1 H), 7.66 (dd, <i>J</i> = 8.2, 2.5 Hz, 1 H), 8.38 (d, <i>J</i> = 2.3 Hz, 1 H).</div></div><div id="sec5_9_6_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i55" class="anchor-spacer"></div><h5 class="article-section__title" id="_i55"> <sup>13</sup>C NMR (CDCl<sub>3</sub>, 100 MHz)</h5><div class="NLM_p last">δ = 27.8 (3C), 84.6, 111.1, 116.1, 123.1, 123.8, 129.3, 130.0, 139.4, 149.0, 149.5, 150.0.</div></div></div><div id="sec5_9_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56"> tert-Butyl 2-(6-(trifluoromethyl)pyridin-3-yl)-1H-pyrrole-1-carboxylate (S 1f)</h4><div class="NLM_p">Eluent: Hex-EtOAc (from 30:1 to 20:1), <i>R</i><sub>f</sub> = 0.5 (30:1, Hex-EtOAc). Yield = 84%.</div><div id="sec5_9_7_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i57" class="anchor-spacer"></div><h5 class="article-section__title" id="_i57"> <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz)</h5><div class="NLM_p last">δ = 1.43 (s, 9 H), 6.30 (t, <i>J</i> = 3.3 Hz, 1 H), 6.32–6.35 (m, 1 H), 7.45 (dd, <i>J</i> = 3.2, 1.8 Hz, 1 H), 7.68 (d, <i>J</i> = 8.1 Hz, 1 H), 7.86 (dd, <i>J</i> = 8.1, 1.8 Hz, 1 H), 8.72 (d, <i>J</i> = 1.7 Hz, 1 H).</div></div><div id="sec5_9_7_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i58" class="anchor-spacer"></div><h5 class="article-section__title" id="_i58"> <sup>13</sup>C NMR (CDCl<sub>3</sub>, 400 MHz)</h5><div class="NLM_p last">δ = 27.7 (3C), 84.8, 111.3, 116.8, 119.5 (q, <i>J</i> = 2.8 Hz), 121.8 (q, <i>J</i> = 273.9 Hz), 124.3, 130.0, 133.2, 137.3, 146.3 (q, <i>J</i> = 34.8 Hz), 148.9, 150.0.</div></div></div><div id="sec5_9_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i59" class="anchor-spacer"></div><h4 class="article-section__title" id="_i59"> tert-Butyl 2-(6-(trifluoromethyl)pyridazin-3-yl)-1H-pyrrole-1-carboxylate (S1g)</h4><div class="NLM_p">Eluent: Hex-EtOAc (from 20:1 to 5:1), <i>R</i><sub>f</sub> = 0.4 (5:1, Hex-EtOAc). Yield = 61%.</div><div id="sec5_9_8_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i60" class="anchor-spacer"></div><h5 class="article-section__title" id="_i60"> <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz)</h5><div class="NLM_p last">δ = 1.45 (s, 9 H), 6.35 (t, <i>J</i> = 3.4 Hz, 1 H), 6.73 (dd, <i>J</i> = 3.4, 1.6 Hz, 1 H), 7.48 (dd, <i>J</i> = 3.2, 1.7 Hz, 1 H), 7.75–7.79 (m, 2 H).</div></div><div id="sec5_9_8_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i61" class="anchor-spacer"></div><h5 class="article-section__title" id="_i61"> <sup>13</sup>C NMR (CDCl<sub>3</sub>, 400 MHz)</h5><div class="NLM_p last">δ = 27.8 (3C), 85.1, 111.6, 119.2, 121.7 (q, <i>J</i> = 274.2 Hz), 122.8 (q, <i>J</i> = 2.4 Hz), 125.8, 127.7, 129.9, 148.9, 149.5 (q, <i>J</i> = 35.0 Hz), 157.2.</div></div></div><div id="sec5_9_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i62" class="anchor-spacer"></div><h4 class="article-section__title" id="_i62"> tert-Butyl 2-(5-chloropyrimidin-2-yl)-1H-pyrrole-1-carboxylate (S1h)</h4><div class="NLM_p">Eluent: Hex-EtOAc (from 30:1 to 20:1), <i>R</i><sub>f</sub> = 0.5 (30:1, Hex-EtOAc). Yield = 58%.</div><div id="sec5_9_9_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i63" class="anchor-spacer"></div><h5 class="article-section__title" id="_i63"> <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz)</h5><div class="NLM_p last">δ = 1.44 (s, 9 H), 6.26 (t, <i>J</i> = 3.3 Hz, 1 H), 6.78 (dd, <i>J</i> = 3.4, 1.7 Hz, 1 H), 7.35 (dd, <i>J</i> = 3.1, 1.7 Hz, 1 H), 8.67 (s, 2 H).</div></div><div id="sec5_9_9_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i64" class="anchor-spacer"></div><h5 class="article-section__title" id="_i64"> <sup>13</sup>C NMR (CDCl<sub>3</sub>, 400 MHz)</h5><div class="NLM_p last">δ = 27.8 (3C), 84.3, 110.9, 118.8, 125.7, 128.4, 131.8, 149.2, 155.2 (2C), 158.8.</div></div></div><div id="sec5_9_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i65" class="anchor-spacer"></div><h4 class="article-section__title" id="_i65"> General Procedure B: for Boc-deprotection</h4><div class="NLM_p last">To a solution containing Boc-protected compound (30 mmol) in MeOH (15 mL, 2 M solution), 1 M HCl solution in MeOH (45 mL) was added in one portion. The mixture was stirred at reflux for 7–8 h. After this mixture cooled to room temperature, the solvent was evaporated. Then 10% aqueous K<sub>2</sub>CO<sub>3</sub> (50 mL) was added carefully (CO<sub>2</sub> evolution), and the mixture was extracted with CH<sub>2</sub>Cl<sub>2</sub> (3 × 50 mL). The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. Crude product was used in the next step without purification. Compounds <b>S2a–S2h</b> were obtained following the <b><i>general procedure B</i></b>.</div></div><div id="sec5_9_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i66" class="anchor-spacer"></div><h4 class="article-section__title" id="_i66"> 5-Methyl-2-(1H-pyrrol-2-yl)pyridine (S2a)</h4><div class="NLM_p">Yield = 94%.</div><div id="sec5_9_11_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i67" class="anchor-spacer"></div><h5 class="article-section__title" id="_i67"> <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz)</h5><div class="NLM_p last">δ = 2.33 (s, 3 H), 6.31–6.35 (m, 1 H), 6.72–6.75 (m, 1 H), 6.89–6.91 (m, 1 H), 7.48 (dd, <i>J</i> = 8.2, 1.9 Hz, 1 H), 7.53 (d, <i>J</i> = 8.1 Hz, 1 H), 8.27–8.38 (m, 1 H), 10.73 (br. s., 1 H).</div></div><div id="sec5_9_11_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i68" class="anchor-spacer"></div><h5 class="article-section__title" id="_i68"> <sup>13</sup>C NMR (CDCl<sub>3</sub>, 100 MHz)</h5><div class="NLM_p last">δ = 18.2, 106.8, 109.9, 118.1, 119.9, 129.9, 131.8, 137.4, 148.5, 148.9.</div></div></div><div id="sec5_9_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i69" class="anchor-spacer"></div><h4 class="article-section__title" id="_i69"> 5-Chloro-2-(1H-pyrrol-2-yl)pyridine (S2b)</h4><div class="NLM_p">Yield = 92%.</div><div id="sec5_9_12_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i70" class="anchor-spacer"></div><h5 class="article-section__title" id="_i70"> <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz)</h5><div class="NLM_p last">δ = 6.31–6.34 (m, 1 H), 6.71–6.74 (m, 1 H), 6.92 (td, <i>J</i> = 2.6, 1.4 Hz, 1 H), 7.50 (d, <i>J</i> = 8.6 Hz, 1 H), 7.60 (dd, <i>J</i> = 8.6, 2.4 Hz, 1 H), 8.42 (d, <i>J</i> = 2.2 Hz, 1 H), 9.90 (br. s., 1 H).</div></div><div id="sec5_9_12_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i71" class="anchor-spacer"></div><h5 class="article-section__title" id="_i71"> <sup>13</sup>C NMR (CDCl<sub>3</sub>, 100 MHz)</h5><div class="NLM_p last">δ = 107.9, 110.6, 118.9, 120.5, 128.3, 130.7, 136.4, 147.7, 148.9.</div></div></div><div id="sec5_9_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i72" class="anchor-spacer"></div><h4 class="article-section__title" id="_i72"> 5-Fluoro-2-(1H-pyrrol-2-yl)pyridine (S2c)</h4><div class="NLM_p">Yield = 93%.</div><div id="sec5_9_13_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i73" class="anchor-spacer"></div><h5 class="article-section__title" id="_i73"> <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz)</h5><div class="NLM_p last">δ = 6.33 (dd, <i>J</i> = 6.2, 2.7 Hz, 1 H), 6.66–6.71 (m, 1 H), 6.88–6.94 (m, 1 H), 7.38 (td, <i>J</i> = 8.5, 2.8 Hz, 1 H), 7.56 (dd, <i>J</i> = 8.8, 4.3 Hz, 1 H), 8.35 (d, <i>J</i> = 2.8 Hz, 1 H), 9.96 (br. s., 1 H).</div></div><div id="sec5_9_13_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i74" class="anchor-spacer"></div><h5 class="article-section__title" id="_i74"> <sup>13</sup>C NMR (CDCl<sub>3</sub>, 100 MHz)</h5><div class="NLM_p last">δ = 107.1, 110.3, 119.1 (d, <i>J</i> = 4.1 Hz), 120.2, 123.9 (d, <i>J</i> = 19.3 Hz), 130.9, 136.7 (d, <i>J</i> = 23.9 Hz), 147.4 (d, <i>J</i> = 3.2 Hz), 157.8 (d, <i>J</i> = 253.2 Hz).</div></div></div><div id="sec5_9_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i75" class="anchor-spacer"></div><h4 class="article-section__title" id="_i75"> 2-(1H-Pyrrol-2-yl)-5-(trifluoromethyl)pyridine (S 2d)</h4><div class="NLM_p">Eluent: Hex-EtOAc (from 20:1 to 10:1), <i>R</i><sub>f</sub> = 0.5 (10:1, Hex-EtOAc). Yield = 88%.</div><div id="sec5_9_14_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i76" class="anchor-spacer"></div><h5 class="article-section__title" id="_i76"> <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz)</h5><div class="NLM_p last">δ = 6.32–6.37 (m, 1 H), 6.80–6.86 (m, 1 H), 6.94–7.03 (m, 1 H), 7.61 (d, <i>J</i> = 8.4 Hz, 1 H), 7.83 (dd, <i>J</i> = 8.4, 2.1 Hz, 1 H), 8.71 (s, 1 H), 9.74 (br. s., 1 H).</div></div><div id="sec5_9_14_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i77" class="anchor-spacer"></div><h5 class="article-section__title" id="_i77"> <sup>13</sup>C NMR (CDCl<sub>3</sub>, 100 MHz)</h5><div class="NLM_p last">δ = 109.6, 111.0, 117.6, 121.6 122.9 (q, <i>J</i> = 33.0 Hz), 124.0 (q, <i>J</i> = 271.6 Hz), 130.5, 133.7 (q, <i>J</i> = 3.5 Hz), 146.1 (q, <i>J</i> = 4.4 Hz), 153.5 (q, <i>J</i> = 1.5 Hz).</div></div></div><div id="sec5_9_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i78" class="anchor-spacer"></div><h4 class="article-section__title" id="_i78"> 2-Chloro-5-(1H-pyrrol-2-yl)pyridine (S2e)</h4><div class="NLM_p">Yield = 93%.</div><div id="sec5_9_15_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i79" class="anchor-spacer"></div><h5 class="article-section__title" id="_i79"> <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz)</h5><div class="NLM_p last">δ = 6.33–6.37 (m, 1 H), 6.57–6.60 (m, 1 H), 6.94–6.98 (m, 1 H), 7.32 (d, <i>J</i> = 8.4 Hz, 1 H), 7.74 (dd, <i>J</i> = 8.3, 2.6 Hz, 1 H), 8.52 (d, <i>J</i> = 2.4 Hz, 1 H), 8.84 (br. s., 1 H).</div></div><div id="sec5_9_15_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i80" class="anchor-spacer"></div><h5 class="article-section__title" id="_i80"> <sup>13</sup>C NMR (CDCl<sub>3</sub>, 100 MHz)</h5><div class="NLM_p last">δ = 107.9, 110.6, 120.8, 124.5, 127.4, 128.2, 134.2, 144.6.</div></div></div><div id="sec5_9_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i81" class="anchor-spacer"></div><h4 class="article-section__title" id="_i81"> 5-(1H-Pyrrol-2-yl)-2-(trifluoromethyl)pyridine (S 2f)</h4><div class="NLM_p">Yield = 92%.</div><div id="sec5_9_16_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i82" class="anchor-spacer"></div><h5 class="article-section__title" id="_i82"> <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz)</h5><div class="NLM_p last">δ = 6.29–6.41 (m, 1 H), 6.64–6.74 (m, 1 H), 6.92–7.04 (m, 1 H), 7.63 (d, <i>J</i> = 8.2 Hz, 1 H), 7.89 (dd, <i>J</i> = 8.2, 1.8 Hz, 1 H), 8.82 (d, <i>J</i> = 1.8 Hz, 1 H), 9.32 (br. s., 1 H).</div></div><div id="sec5_9_16_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i83" class="anchor-spacer"></div><h5 class="article-section__title" id="_i83"> <sup>13</sup>C NMR (CDCl<sub>3</sub>, 400 MHz)</h5><div class="NLM_p last">δ = 109.2, 111.0, 120.9 (q, <i>J</i> = 2.9 Hz), 121.8, 121.8 (q, <i>J</i> = 273.7 Hz), 127.2, 131.5, 131.7, 144.7 (q, <i>J</i> = 35.1 Hz), 144.9.</div></div></div><div id="sec5_9_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i84" class="anchor-spacer"></div><h4 class="article-section__title" id="_i84"> 3-(1H-Pyrrol-2-yl)-6-(trifluoromethyl)pyridazine (S2g)</h4><div class="NLM_p">Yield = 95%.</div><div id="sec5_9_17_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i85" class="anchor-spacer"></div><h5 class="article-section__title" id="_i85"> <sup>1</sup>H NMR (DMSO-d<sub>6</sub>, 400 MHz)</h5><div class="NLM_p last">δ = 6.25–6.29 (m, 1 H), 7.07–7.14 (m, 2 H), 8.10 (d, <i>J</i> = 9.0 Hz, 1 H), 8.20 (d, <i>J</i> = 9.0 Hz, 1 H), 12.15 (br. s., 1 H).</div></div><div id="sec5_9_17_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i86" class="anchor-spacer"></div><h5 class="article-section__title" id="_i86"> <sup>13</sup>C NMR (DMSO-d<sub>6</sub>, 100 MHz)</h5><div class="NLM_p last">δ = 110.5, 112.7, 122.0 (q, <i>J</i> = 273.5 Hz), 122.9, 124.2, 124.8 (q, <i>J</i> = 2.2 Hz), 126.9, 147.3 (q, <i>J</i> = 33.7 Hz), 154.8.</div></div></div><div id="sec5_9_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i87" class="anchor-spacer"></div><h4 class="article-section__title" id="_i87"> 5-Chloro-2-(1H-pyrrol-2-yl)pyrimidine (S2h)</h4><div class="NLM_p">Yield = 90%.</div><div id="sec5_9_18_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i88" class="anchor-spacer"></div><h5 class="article-section__title" id="_i88"> <sup>1</sup>H NMR (DMSO-d<sub>6</sub>, 400 MHz)</h5><div class="NLM_p last">δ = 6.20 (s, 1 H), 6.93 (d, <i>J</i> = 1.8 Hz, 1 H), 6.97 (s, 1 H), 8.78 (s, 2 H), 11.77 (br. s., 1 H).</div></div><div id="sec5_9_18_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i89" class="anchor-spacer"></div><h5 class="article-section__title" id="_i89"> <sup>13</sup>C NMR (DMSO-d<sub>6</sub>, 100 MHz)</h5><div class="NLM_p last">δ = 110.1, 112.3, 123.2, 125.7, 129.4, 155.6 (2C), 157.1.</div></div></div><div id="sec5_9_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i90" class="anchor-spacer"></div><h4 class="article-section__title" id="_i90"> General Procedure C: For Acylation</h4><div class="NLM_p last">Crude pyrrole from the previous step (1 equiv) was dissolved in CH<sub>2</sub>Cl<sub>2</sub> (0.5 M solution), and pyridine (1.2 equiv) was added, followed by dropwise addition of trifluoroacetic anhydride (TFAA) (1.2 equiv). After completion of the addition, the mixture was stirred for 1 h, and the solvent was evaporated. The product was triturated in aqueous, and the precipitate was filtered, washed with water twice, and dried on a filter. Compounds <b>S3a–S3h</b> were obtained following the<b><i>general procedure C</i></b>.</div></div><div id="sec5_9_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i91" class="anchor-spacer"></div><h4 class="article-section__title" id="_i91"> 2,2,2-Trifluoro-1-(5-(5-methylpyridin-2-yl)-1H-pyrrol-2-yl)ethanone (S3a)</h4><div class="NLM_p">Yield = 89%.</div><div id="sec5_9_20_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i92" class="anchor-spacer"></div><h5 class="article-section__title" id="_i92"> <sup>1</sup>H NMR (DMSO-d<sub>6</sub>, 400 MHz)</h5><div class="NLM_p last">δ = 2.34 (s, 3 H), 7.05 (d, <i>J</i> = 4.2 Hz, 1 H), 7.28 (dd, <i>J</i> = 3.9, 1.9 Hz, 1 H), 7.75 (dd, <i>J</i> = 8.0, 1.4 Hz, 1 H), 8.09 (d, <i>J</i> = 8.1 Hz, 1 H), 8.49–8.52 (m, 1 H), 12.87 (br. s., 1 H).</div></div><div id="sec5_9_20_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i93" class="anchor-spacer"></div><h5 class="article-section__title" id="_i93"> <sup>13</sup>C NMR (DMSO-d<sub>6</sub>, 100 MHz)</h5><div class="NLM_p last">δ = 17.8, 111.8, 117.0 (q, <i>J</i> = 290.3 Hz), 120.6, 122.9 (q, <i>J</i> = 3.5 Hz), 126.1, 133.4, 137.8, 142.6, 145.3, 149.8, 168.1 (q, <i>J</i> = 35.0 Hz).</div></div></div><div id="sec5_9_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i94" class="anchor-spacer"></div><h4 class="article-section__title" id="_i94"> 1-(5-(5-Chloropyridin-2-yl)-1H-pyrrol-2-yl)-2,2,2-trifluoroethanone (S3b)</h4><div class="NLM_p">Yield = 94%.</div><div id="sec5_9_21_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i95" class="anchor-spacer"></div><h5 class="article-section__title" id="_i95"> <sup>1</sup>H NMR (DMSO-d<sub>6</sub>, 400 MHz)</h5><div class="NLM_p last">δ =7.09 (dd, 1 H), 7.29 (dt, <i>J</i> = 4.1, 2.0 Hz, 1 H), 8.07 (dd, <i>J</i> = 8.6, 2.5 Hz, 1 H), 8.23 (d, <i>J</i> = 8.6 Hz, 1 H), 8.69 (d, <i>J</i> = 2.4 Hz, 1 H), 13.04 (br. s., 1 H).</div></div><div id="sec5_9_21_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i96" class="anchor-spacer"></div><h5 class="article-section__title" id="_i96"> <sup>13</sup>C NMR (DMSO-d<sub>6</sub>, 100 MHz)</h5><div class="NLM_p last">δ = 112.5, 117.0 (q, <i>J</i> = 290.25 Hz), 122.0, 122.7 (q, <i>J</i> = 3.5 Hz), 126.6, 130.7, 137.0, 141.5, 146.7, 148.3, 168.5 (q, <i>J</i> = 35.0 Hz).</div></div></div><div id="sec5_9_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i97" class="anchor-spacer"></div><h4 class="article-section__title" id="_i97"> 2,2,2-Trifluoro-1-(5-(5-fluoropyridin-2-yl)-1H-pyrrol-2-yl)ethanone (S3c)</h4><div class="NLM_p">Yield = 91%.</div><div id="sec5_9_22_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i98" class="anchor-spacer"></div><h5 class="article-section__title" id="_i98"> <sup>1</sup>H NMR (DMSO-d<sub>6</sub>, 400 MHz)</h5><div class="NLM_p last">δ =7.04 (dd, <i>J</i> = 4.1, 2.3 Hz, 1 H), 7.28 (dt, <i>J</i> = 4.1, 2.0 Hz, 1 H), 7.87 (td, <i>J</i> = 8.8, 2.9 Hz, 1 H), 8.27 (dd, <i>J</i> = 8.9, 4.4 Hz, 1 H), 8.65 (d, <i>J</i> = 2.8 Hz, 1 H), 12.96 (br. s., 1 H).</div></div><div id="sec5_9_22_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i99" class="anchor-spacer"></div><h5 class="article-section__title" id="_i99"> <sup>13</sup>C NMR (DMSO-d<sub>6</sub>, 100 MHz)</h5><div class="NLM_p last">δ = 112.0, 117.0 (q, <i>J</i> = 289.9 Hz), 122.4 (d, <i>J</i> = 4.8 Hz), 122.7 (q, <i>J</i> = 3.5 Hz), 124.1 (d, <i>J</i> = 19.0 Hz), 126.4, 138.0 (d, <i>J</i> = 24.5 Hz), 141.8, 144.9 (d, <i>J</i> = 3.9 Hz), 158.7 (d, <i>J</i> = 256.2 Hz), 168.3 (q, <i>J</i> = 35.0 Hz).</div></div></div><div id="sec5_9_23" class="NLM_sec NLM_sec_level_3"><div id="ac_i100" class="anchor-spacer"></div><h4 class="article-section__title" id="_i100"> 2,2,2-Trifluoro-1-(5-(5-(trifluoromethyl)pyridin-2-yl)-1H-pyrrol-2-yl)ethanone (S 3d)</h4><div class="NLM_p">Yield = 92%.</div><div id="sec5_9_23_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i101" class="anchor-spacer"></div><h5 class="article-section__title" id="_i101"> <sup>1</sup>H NMR (DMSO-d<sub>6</sub>, 400 MHz)</h5><div class="NLM_p last">δ = 7.19 (dd, <i>J</i> = 4.0, 2.2 Hz, 1 H), 7.27–7.32 (m, 1 H), 8.33 (dd, <i>J</i> = 8.4, 1.7 Hz, 1 H), 8.40 (d, <i>J</i> = 8.3 Hz, 1 H), 8.99 (s, 1 H), 13.19 (br. s., 1 H).</div></div><div id="sec5_9_23_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i102" class="anchor-spacer"></div><h5 class="article-section__title" id="_i102"> <sup>13</sup>C NMR (DMSO-d<sub>6</sub>, 100 MHz)</h5><div class="NLM_p last">δ = 113.7, 117.2 (q, <i>J</i> = 289.8 Hz), 120.9, 122.7 (q, <i>J</i> = 1.5 Hz), 124.0 (q, <i>J</i> = 271.5 Hz), 124.5 (q, <i>J</i> = 32.2 Hz), 127.5, 135.1, 141.2, 146.7, 152.0, 169.1 (q, <i>J</i> = 34.4 Hz).</div></div></div><div id="sec5_9_24" class="NLM_sec NLM_sec_level_3"><div id="ac_i103" class="anchor-spacer"></div><h4 class="article-section__title" id="_i103"> 1-(5-(6-Chloropyridin-3-yl)-1H-pyrrol-2-yl)-2,2,2-trifluoroethanone (S3e)</h4><div class="NLM_p">Yield = 87%.</div><div id="sec5_9_24_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i104" class="anchor-spacer"></div><h5 class="article-section__title" id="_i104"> <sup>1</sup>H NMR (DMSO-d<sub>6</sub>, 400 MHz)</h5><div class="NLM_p last">δ = 7.08 (dd, <i>J</i> = 4.2, 2.4 Hz, 1 H), 7.33 (dt, <i>J</i> = 4.1, 2.0 Hz, 1 H), 7.64 (d, <i>J</i> = 8.4 Hz, 1 H), 8.43 (dd, <i>J</i> = 8.4, 2.6 Hz, 1 H), 9.02 (d, <i>J</i> = 2.4 Hz, 1 H), 13.14 (br. s., 1 H).</div></div><div id="sec5_9_24_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i105" class="anchor-spacer"></div><h5 class="article-section__title" id="_i105"> <sup>13</sup>C NMR (DMSO-d<sub>6</sub>, 100 MHz)</h5><div class="NLM_p last">δ = 111.9, 117.1 (q, <i>J</i> = 289.9 Hz), 123.2 (q, <i>J</i> = 3.3 Hz), 124.5, 125.5, 126.8, 137.0, 139.1, 147.6, 150.2, 168.3 (q, <i>J</i> = 35.0 Hz).</div></div></div><div id="sec5_9_25" class="NLM_sec NLM_sec_level_3"><div id="ac_i106" class="anchor-spacer"></div><h4 class="article-section__title" id="_i106"> 2,2,2-Trifluoro-1-(5-(6-(trifluoromethyl)pyridin-3-yl)-1H-pyrrol-2-yl)ethanone (S 3f)</h4><div class="NLM_p">Yield = 93%.</div><div id="sec5_9_25_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i107" class="anchor-spacer"></div><h5 class="article-section__title" id="_i107"> <sup>1</sup>H NMR (DMSO-d<sub>6</sub>, 400 MHz)</h5><div class="NLM_p last">δ = 7.14 (d, <i>J</i> = 4.3 Hz, 1 H), 7.26–7.33 (m, 1 H), 7.96 (d, <i>J</i> = 8.3 Hz, 1 H), 8.61 (dd, <i>J</i> = 8.2, 1.8 Hz, 1 H), 9.32 (d, <i>J</i> = 1.7 Hz, 1 H), 13.24 (br. s., 1 H).</div></div><div id="sec5_9_25_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i108" class="anchor-spacer"></div><h5 class="article-section__title" id="_i108"> <sup>13</sup>C NMR (DMSO-d<sub>6</sub>, 100 MHz)</h5><div class="NLM_p last">δ = 112.6, 116.9 (q, <i>J</i> = 289.8 Hz), 120.8 (q, <i>J</i> = 2.2 Hz), 121.6 (q, <i>J</i> = 273.7 Hz), 122.9 (q, <i>J</i> = 3.7 Hz), 127.2, 129.1, 135.1, 138.4, 145.7 (q, <i>J</i> = 34.4 Hz), 147.7, 168.5 (q, <i>J</i> = 35.1 Hz).</div></div></div><div id="sec5_9_26" class="NLM_sec NLM_sec_level_3"><div id="ac_i109" class="anchor-spacer"></div><h4 class="article-section__title" id="_i109"> 2,2,2-Trifluoro-1-(5-(6-(trifluoromethyl)pyridazin-3-yl)-1H-pyrrol-2-yl)ethanone (S3g)</h4><div class="NLM_p">Yield = 85%.</div><div id="sec5_9_26_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i110" class="anchor-spacer"></div><h5 class="article-section__title" id="_i110"> <sup>1</sup>H NMR (DMSO-d<sub>6</sub>, 400 MHz)</h5><div class="NLM_p last">δ = 7.34–7.39 (m, 2 H), 8.39 (d, <i>J</i> = 9.0 Hz, 1 H), 8.70 (d, <i>J</i> = 9.0 Hz, 1 H), 13.50 (br. s., 1 H).</div></div><div id="sec5_9_26_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i111" class="anchor-spacer"></div><h5 class="article-section__title" id="_i111"> <sup>13</sup>C NMR (DMSO-d<sub>6</sub>, 100 MHz)</h5><div class="NLM_p last">δ = 114.1, 116.7 (q, <i>J</i> = 289.8 Hz), 121.6 (q, <i>J</i> = 274.0 Hz), 122.3 (q, <i>J</i> = 3.1 Hz), 125.4 (q, <i>J</i> = 2.0 Hz), 125.5, 128.0, 137.8, 149.2 (q, <i>J</i> = 34.1 Hz), 153.8, 169.1 (q, <i>J</i> = 35.4 Hz).</div></div></div><div id="sec5_9_27" class="NLM_sec NLM_sec_level_3"><div id="ac_i112" class="anchor-spacer"></div><h4 class="article-section__title" id="_i112"> 1-(5-(5-Chloropyrimidin-2-yl)-1H-pyrrol-2-yl)-2,2,2-trifluoroethanone (S3h)</h4><div class="NLM_p">Yield = 86%.</div><div id="sec5_9_27_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i113" class="anchor-spacer"></div><h5 class="article-section__title" id="_i113"> <sup>1</sup>H NMR (DMSO-d<sub>6</sub>, 400 MHz)</h5><div class="NLM_p last">δ = 7.10 (d, <i>J</i> = 3.9 Hz, 1 H), 7.24 (s, 1 H), 8.97 (s, 2 H), 13.07 (br. s., 1 H).</div></div><div id="sec5_9_27_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i114" class="anchor-spacer"></div><h5 class="article-section__title" id="_i114"> <sup>13</sup>C NMR (DMSO-d<sub>6</sub>, 100 MHz)</h5><div class="NLM_p last">δ = 114.2, 116.7 (q, <i>J</i> = 289.8 Hz), 122.2 (q, <i>J</i> = 2.9 Hz), 127.2, 129.2, 139.6, 155.3, 156.2 (2C), 168.7 (q, <i>J</i> = 35.1 Hz).</div></div></div><div id="sec5_9_28" class="NLM_sec NLM_sec_level_3"><div id="ac_i115" class="anchor-spacer"></div><h4 class="article-section__title" id="_i115"> General Procedure D: For Haloform Reaction</h4><div class="NLM_p last">Appropriate trifluoroethanone (1 equiv) was added to a solution of NaOH (5 equiv) in dioxane–H<sub>2</sub>O mixture (1:1, 0.5 M solution). The resulting reaction mixture was refluxed for 20 h and cooled to room temperature. A concentrated aqueous HCl solution (∼12 M, 5 equiv) was added dropwise. The resulting precipitate was filtered off, washed with H<sub>2</sub>O, and dried on a filter. Compounds <b>S4a–S4h</b> were obtained following <b><i>general procedure D</i></b>.</div></div><div id="sec5_9_29" class="NLM_sec NLM_sec_level_3"><div id="ac_i116" class="anchor-spacer"></div><h4 class="article-section__title" id="_i116"> 5-(5-Methylpyridin-2-yl)-1H-pyrrole-2-carboxylic Acid (S4a)</h4><div class="NLM_p">Yield = 82%.</div><div id="sec5_9_29_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i117" class="anchor-spacer"></div><h5 class="article-section__title" id="_i117"> <sup>1</sup>H NMR (DMSO-d<sub>6</sub>, 400 MHz)</h5><div class="NLM_p last">δ = 2.28 (s, 3 H), 6.77–6.84 (m, 2 H), 7.61 (dd, <i>J</i> = 8.1, 2.1 Hz, 1 H), 7.88 (d, <i>J</i> = 8.1 Hz, 1 H), 8.38 (d, <i>J</i> = 1.8 Hz, 1 H), 11.69 (br. s., 1 H).</div></div><div id="sec5_9_29_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i118" class="anchor-spacer"></div><h5 class="article-section__title" id="_i118"> <sup>13</sup>C NMR (DMSO-d<sub>6</sub>, 100 MHz)</h5><div class="NLM_p last">δ = 17.9, 109.2, 116.5, 119.1, 124.8, 131.6, 136.4, 137.6, 147.1, 149.7, 162.0.</div></div></div><div id="sec5_9_30" class="NLM_sec NLM_sec_level_3"><div id="ac_i119" class="anchor-spacer"></div><h4 class="article-section__title" id="_i119"> 5-(5-Chloropyridin-2-yl)-1H-pyrrole-2-carboxylic Acid (S4b)</h4><div class="NLM_p">Yield = 73%.</div><div id="sec5_9_30_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i120" class="anchor-spacer"></div><h5 class="article-section__title" id="_i120"> <sup>1</sup>H NMR (DMSO-d<sub>6</sub>, 400 MHz)</h5><div class="NLM_p last">δ = 6.78–6.93 (m, 2 H), 7.94 (dd, <i>J</i> = 8.6, 2.4 Hz, 1 H), 8.06 (d, <i>J</i> = 8.6 Hz, 1 H), 8.58 (d, <i>J</i> = 2.2 Hz, 1 H), 11.96 (br. s., 1 H), 12.57 (br. s., 1 H).</div></div><div id="sec5_9_30_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i121" class="anchor-spacer"></div><h5 class="article-section__title" id="_i121"> <sup>13</sup>C NMR (DMSO-d<sub>6</sub>, 100 MHz)</h5><div class="NLM_p last">δ = 110.3, 116.2, 120.3, 125.8, 128.8, 135.0, 136.8, 147.9, 148.2, 161.8.</div></div></div><div id="sec5_9_31" class="NLM_sec NLM_sec_level_3"><div id="ac_i122" class="anchor-spacer"></div><h4 class="article-section__title" id="_i122"> 5-(5-Fluoropyridin-2-yl)-1H-pyrrole-2-carboxylic Acid (S4c)</h4><div class="NLM_p">Yield = 85%.</div><div id="sec5_9_31_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i123" class="anchor-spacer"></div><h5 class="article-section__title" id="_i123"> <sup>1</sup>H NMR (DMSO-d<sub>6</sub>, 400 MHz)</h5><div class="NLM_p last">δ = 6.80–6.85 (m, 2 H), 7.74 (td, <i>J</i> = 8.8, 2.9 Hz, 1 H), 8.08 (dd, <i>J</i> = 8.8, 4.3 Hz, 1 H), 8.53 (d, <i>J</i> = 2.8 Hz, 1 H), 11.86 (br. s., 1 H), 12.52 (br. s., 1 H).</div></div><div id="sec5_9_31_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i124" class="anchor-spacer"></div><h5 class="article-section__title" id="_i124"> <sup>13</sup>C NMR (DMSO-d<sub>6</sub>, 100 MHz)</h5><div class="NLM_p last">δ = 109.7, 116.3, 120.6 (d, <i>J</i> = 4.4 Hz), 124.1 (d, <i>J</i> = 18.8 Hz), 125.1, 135.4, 137.4 (d, <i>J</i> = 24.0 Hz), 146.4 (d, <i>J</i> = 3.7 Hz), 158.0 (d, <i>J</i> = 253.4 Hz), 161.8.</div></div></div><div id="sec5_9_32" class="NLM_sec NLM_sec_level_3"><div id="ac_i125" class="anchor-spacer"></div><h4 class="article-section__title" id="_i125"> 5-(5-(Trifluoromethyl)pyridin-2-yl)-1H-pyrrole-2-carboxylic Acid S 4d)</h4><div class="NLM_p">Yield = 80%.</div><div id="sec5_9_32_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i126" class="anchor-spacer"></div><h5 class="article-section__title" id="_i126"> <sup>1</sup>H NMR (DMSO-d<sub>6</sub>, 400 MHz)</h5><div class="NLM_p last">δ = 6.76–6.95 (m, 1 H), 6.95–7.08 (m, 1 H), 8.12–8.31 (m, 2 H), 8.89 (s, 1 H), 12.18 (br. s., 1 H), 12.71 (br. s., 1 H).</div></div><div id="sec5_9_32_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i127" class="anchor-spacer"></div><h5 class="article-section__title" id="_i127"> <sup>13</sup>C NMR (DMSO-d<sub>6</sub>, 100 MHz)</h5><div class="NLM_p last">δ = 111.7, 116.3, 119.0, 122.7 (q, <i>J</i> = 32.2 Hz), 124.0 (q, <i>J</i> = 272.2 Hz), 126.7, 134.4 (q, <i>J</i> = 3.7 Hz), 134.8, 146.2 (q, <i>J</i> = 4.4 Hz), 153.1, 161.8.</div></div></div><div id="sec5_9_33" class="NLM_sec NLM_sec_level_3"><div id="ac_i128" class="anchor-spacer"></div><h4 class="article-section__title" id="_i128"> 5-(6-Chloropyridin-3-yl)-1H-pyrrole-2-carboxylic acid (S4e)</h4><div class="NLM_p">Yield = 91%.</div><div id="sec5_9_33_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i129" class="anchor-spacer"></div><h5 class="article-section__title" id="_i129"> <sup>1</sup>H NMR (DMSO-d<sub>6</sub>, 400 MHz)</h5><div class="NLM_p last">δ = 6.73–6.89 (m, 2 H), 7.52 (d, <i>J</i> = 8.4 Hz, 1 H), 8.29 (dd, <i>J</i> = 8.4, 2.6 Hz, 1 H), 8.90 (d, <i>J</i> = 2.4 Hz, 1 H), 12.26 (br. s., 1 H), 12.51 (br. s., 1 H).</div></div><div id="sec5_9_33_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i130" class="anchor-spacer"></div><h5 class="article-section__title" id="_i130"> <sup>13</sup>C NMR (DMSO-d<sub>6</sub>, 100 MHz)</h5><div class="NLM_p last">δ = 109.2, 116.4, 124.2, 125.5, 127.1, 132.0, 135.7, 146.3, 148.2, 161.8.</div></div></div><div id="sec5_9_34" class="NLM_sec NLM_sec_level_3"><div id="ac_i131" class="anchor-spacer"></div><h4 class="article-section__title" id="_i131"> 5-(6-(Trifluoromethyl)pyridin-3-yl)-1H-pyrrole-2-carboxylic Acid (S 4f)</h4><div class="NLM_p">Yield = 80%.</div><div id="sec5_9_34_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i132" class="anchor-spacer"></div><h5 class="article-section__title" id="_i132"> <sup>1</sup>H NMR (DMSO-d<sub>6</sub>, 400 MHz)</h5><div class="NLM_p last">δ = 6.84–6.87 (m, 1 H), 6.87–6.90 (m, 1 H), 7.85 (d, <i>J</i> = 8.3 Hz, 1 H), 8.45 (dd, <i>J</i> = 8.3, 1.5 Hz, 1 H), 9.20 (d, <i>J</i> = 1.2 Hz, 1 H), 12.40 (br. s., 1 H).</div></div><div id="sec5_9_34_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i133" class="anchor-spacer"></div><h5 class="article-section__title" id="_i133"> <sup>13</sup>C NMR (DMSO-d<sub>6</sub>, 100 MHz)</h5><div class="NLM_p last">δ = 110.5, 116.6, 120.9 (q, <i>J</i> = 2.9 Hz), 243.9 (q, <i>J</i> = 273.7 Hz), 126.5, 130.8, 131.8, 133.5, 144.2 (q, <i>J</i> = 33.7 Hz), 146.7, 161.9.</div></div></div><div id="sec5_9_35" class="NLM_sec NLM_sec_level_3"><div id="ac_i134" class="anchor-spacer"></div><h4 class="article-section__title" id="_i134"> 5-(6-(Trifluoromethyl)pyridazin-3-yl)-1H-pyrrole-2-carboxylic Acid (S4g)</h4><div class="NLM_p">Yield = 87%.</div><div id="sec5_9_35_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i135" class="anchor-spacer"></div><h5 class="article-section__title" id="_i135"> <sup>1</sup>H NMR (DMSO-d<sub>6</sub>, 400 MHz)</h5><div class="NLM_p last">δ = 6.91 (dd, <i>J</i> = 3.9, 2.3 Hz, 1 H), 7.20 (dd, <i>J</i> = 3.9, 2.4 Hz, 1 H), 8.27 (d, <i>J</i> = 9.0 Hz, 1 H), 8.57 (d, <i>J</i> = 9.0 Hz, 1 H), 12.55 (br. s., 1 H), 12.83 (br. s., 1 H).</div></div><div id="sec5_9_35_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i136" class="anchor-spacer"></div><h5 class="article-section__title" id="_i136"> <sup>13</sup>C NMR (DMSO-d<sub>6</sub>, 100 MHz)</h5><div class="NLM_p last">δ = 112.7, 116.4, 121.9 (q, <i>J</i> = 273.7 Hz), 123.9, 125.1 (q, <i>J</i> = 2.2 Hz), 127.9, 131.7, 148.2 (q, <i>J</i> = 33.7 Hz), 154.7, 161.6.</div></div></div><div id="sec5_9_36" class="NLM_sec NLM_sec_level_3"><div id="ac_i137" class="anchor-spacer"></div><h4 class="article-section__title" id="_i137"> 5-(5-Chloropyrimidin-2-yl)-1H-pyrrole-2-carboxylic Acid (S4h)</h4><div class="NLM_p">Yield = 75%.</div><div id="sec5_9_36_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i138" class="anchor-spacer"></div><h5 class="article-section__title" id="_i138"> <sup>1</sup>H NMR (DMSO-d<sub>6</sub>, 400 MHz)</h5><div class="NLM_p last">δ = 6.81 (d, <i>J</i> = 3.7 Hz, 1 H), 6.96 (d, <i>J</i> = 3.7 Hz, 1 H), 8.87 (s, 2 H), 11.63 (br. s., 1 H).</div></div><div id="sec5_9_36_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i139" class="anchor-spacer"></div><h5 class="article-section__title" id="_i139"> <sup>13</sup>C NMR (DMSO-d<sub>6</sub>, 100 MHz)</h5><div class="NLM_p last">δ = 112.7, 115.7, 127.4, 128.1, 132.9, 155.9 (2C), 156.2, 161.7.</div></div></div><div id="sec5_9_37" class="NLM_sec NLM_sec_level_3"><div id="ac_i140" class="anchor-spacer"></div><h4 class="article-section__title" id="_i140"> tert-Butyl 2-(2-fluoropyridin-4-yl)-1H-pyrrole-1-carboxylate (S5)</h4><div class="NLM_p">Compound <b>S5</b> was obtained following the <b><i>general procedure A</i></b>. Yield = 67%.</div><div id="sec5_9_37_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i141" class="anchor-spacer"></div><h5 class="article-section__title" id="_i141"> <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz)</h5><div class="NLM_p last">δ = 1.45 (s, 9 H), 6.24–6.27 (m, 1 H), 6.36 (dd, <i>J</i> = 3.3, 1.7 Hz, 1 H), 6.88–6.91 (m, 1 H), 7.14–7.17 (m, 1 H), 7.41 (dd, <i>J</i> = 3.2, 1.7 Hz, 1 H), 8.16 (d, <i>J</i> = 5.2 Hz, 1 H).</div></div><div id="sec5_9_37_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i142" class="anchor-spacer"></div><h5 class="article-section__title" id="_i142"> <sup>13</sup>C NMR (CDCl<sub>3</sub>, 100 MHz)</h5><div class="NLM_p last">δ = 27.7, 84.9, 109.0 (d, <i>J</i> = 38.3 Hz), 111.2, 117.0, 121.6 (d, <i>J</i> = 3.9 Hz), 124.8, 131.2 (d, <i>J</i> = 3.9 Hz), 146.6 (d, <i>J</i> = 15.5 Hz), 147.1 (d, <i>J</i> = 8.9 Hz), 148.8, 163.6 (d, <i>J</i> = 237.2 Hz).</div></div></div><div id="sec5_9_38" class="NLM_sec NLM_sec_level_3"><div id="ac_i143" class="anchor-spacer"></div><h4 class="article-section__title" id="_i143"> 2-Methoxy-4-(1H-pyrrol-2-yl)pyridine (S6)</h4><div class="NLM_p">Compound <b>S6</b> was obtained following the <b><i>general procedure B</i></b>. Yield 92%.</div><div id="sec5_9_38_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i144" class="anchor-spacer"></div><h5 class="article-section__title" id="_i144"> <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz)</h5><div class="NLM_p last">δ = 3.96 (s, 3 H), 6.31–6.36 (m, 1 H), 6.68–6.74 (m, 1 H), 6.78 (d, <i>J</i> = 1.2 Hz, 1 H), 6.93 (s, 1 H), 6.99 (dd, <i>J</i> = 5.5, 1.5 Hz, 1 H), 8.11 (d, <i>J</i> = 5.5 Hz, 1 H), 8.89 (br. s., 1 H).</div></div><div id="sec5_9_38_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i145" class="anchor-spacer"></div><h5 class="article-section__title" id="_i145"> <sup>13</sup>C NMR (CDCl<sub>3</sub>, 100 MHz)</h5><div class="NLM_p last">δ = 53.7, 103.8, 109.0, 110.7, 112.3, 121.0, 129.3, 142.4, 147.3, 165.1.</div></div></div><div id="sec5_9_39" class="NLM_sec NLM_sec_level_3"><div id="ac_i146" class="anchor-spacer"></div><h4 class="article-section__title" id="_i146"> 2,2,2-Trifluoro-1-(5-(2-methoxypyridin-4-yl)-1H-pyrrol-2-yl)ethanone (S7)</h4><div class="NLM_p">Compound <b>S7</b> was obtained following the <b><i>general procedure C</i></b>. Yield = 78%.</div><div id="sec5_9_39_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i147" class="anchor-spacer"></div><h5 class="article-section__title" id="_i147"> <sup>1</sup>H NMR (DMSO-d<sub>6</sub>, 400 MHz)</h5><div class="NLM_p last">δ = 3.88 (s, 3 H), 7.10 (dd, <i>J</i> = 4.2, 2.4 Hz, 1 H), 7.28 (dt, <i>J</i> = 4.0, 1.9 Hz, 1 H), 7.46 (s, 1 H), 7.54 (dd, <i>J</i> = 5.4, 1.4 Hz, 1 H), 8.21 (d, <i>J</i> = 5.4 Hz, 1 H), 13.12 (br. s., 1 H).</div></div><div id="sec5_9_39_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i148" class="anchor-spacer"></div><h5 class="article-section__title" id="_i148"> <sup>13</sup>C NMR (DMSO-d<sub>6</sub>, 100 MHz)</h5><div class="NLM_p last">δ = 53.4, 106.5, 112.4, 114.0, 116.9 (q, <i>J</i> = 290.1 Hz), 122.8 (q, <i>J</i> = 3.5 Hz), 126.8, 139.6, 140.2, 147.7, 164.5, 168.5 (q, <i>J</i> = 35.0 Hz).</div></div></div><div id="sec5_9_40" class="NLM_sec NLM_sec_level_3"><div id="ac_i149" class="anchor-spacer"></div><h4 class="article-section__title" id="_i149"> 5-(2-Methoxypyridin-4-yl)-1H-pyrrole-2-carboxylic acid (S8)</h4><div class="NLM_p">Compound <b>S8</b> was obtained following the <b><i>general procedure D</i></b>. Yield = 93%.</div><div id="sec5_9_40_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i150" class="anchor-spacer"></div><h5 class="article-section__title" id="_i150"> <sup>1</sup>H NMR (DMSO-d<sub>6</sub>, 400 MHz)</h5><div class="NLM_p last">δ = 3.86 (s, 3 H), 6.80–6.84 (m, 1 H), 6.84–6.88 (m, 1 H), 7.35 (s, 1 H), 7.43 (dd, <i>J</i> = 5.5, 1.4 Hz, 1 H), 8.11 (d, <i>J</i> = 5.5 Hz, 1 H), 12.26 (br. s., 1 H), 12.56 (br. s., 1 H).</div></div><div id="sec5_9_40_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i151" class="anchor-spacer"></div><h5 class="article-section__title" id="_i151"> <sup>13</sup>C NMR (DMSO-d<sub>6</sub>, 100 MHz)</h5><div class="NLM_p last">δ = 53.2, 104.9, 110.2, 113.2, 116.2, 125.9, 133.5, 141.3, 147.2, 161.7, 164.5.</div></div></div></div><div id="sec5_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i152" class="anchor-spacer"></div><h3 class="article-section__title" id="_i152"> Synthesis of Reagent Methyl 2-((tert-butoxycarbonyl)amino)-3-iodobut-2-enoate (R4)</h3><div id="sec5_10_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i153" class="anchor-spacer"></div><h4 class="article-section__title" id="_i153"> Methyl 2-((tert-butoxycarbonyl)amino)but-2-enoate (R3)</h4><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b02149/20200221/images/medium/jm9b02149_0013.gif" alt="" id="gr10" /></img><div class="NLM_p">4-Dimethylaminopyridine (DMAP) (3.64 g, 0.1 equiv) was added to a solution of the N-Boc acid methyl ester <b>R1</b> (69.59 g, 1 equiv) in dry acetonitrile (300 mL), followed by di-<i>tert</i>-butyl dicarbonate (65.0 g, 1.0 equiv) with rapid stirring at room temperature. The reaction was monitored by TLC (diethyl ether/<i>n</i>-hexane, 1:1), until all the reactants had been consumed. Tetramethylguanidine (TMG) (3.44 mL, 0.1 equiv) was then added, stirring was continued, and the reaction was followed by TLC. When all the reactants had been consumed, evaporation at reduced pressure gave a residue that was partitioned between CH<sub>2</sub>Cl<sub>2</sub> (300 mL) and 5% HCl (200 mL). The organic phase was thoroughly washed with NaHCO<sub>3</sub> and dried with Na<sub>2</sub>SO<sub>4</sub>. Removal of the solvent afforded the corresponding N-Boc-dehydroamino acid methyl ester. Mass (<i>M</i>) = 63.88 g.</div><div id="sec5_10_1_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i154" class="anchor-spacer"></div><h5 class="article-section__title" id="_i154"> <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz)</h5><div class="NLM_p last">δ = 1.48 (s, 9 H), 1.82 (d, <i>J</i> = 7.2 Hz, 3 H), 3.78 (s, 3 H), 6.00 (br. s, 1 H), 6.69 (q, <i>J</i> = 7.0 Hz, 1 H).</div></div></div><div id="sec5_10_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i155" class="anchor-spacer"></div><h4 class="article-section__title" id="_i155"> Methyl 2-((tert-butoxycarbonyl)amino)-3-iodobut-2-enoate (R4)</h4><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b02149/20200221/images/medium/jm9b02149_0014.gif" alt="" id="gr11" /></img><div class="NLM_p">A flask was charged with the dehydroamino acid derivative <b>R3</b> (63.88 g, 48.4 mmol), K<sub>2</sub>CO<sub>3</sub> (81.7 g, 2 equiv), and THF (400 mL). I<sub>2</sub> (90.9 g, 1.2 equiv) was added, and the reaction mixture was heated at reflux for ∼4 h. After the system had cooled to room temperature, the reaction mixture was quenched with a 10% solution of Na<sub>2</sub>SO<sub>3</sub> (100 mL). The mixture was extracted with CH<sub>2</sub>Cl<sub>2</sub> (3 × 100 mL). The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and evaporated. The residue was subjected to column chromatography (eluent hexanes/EtOAc, 10:1). <i>M</i> = 52.2 g.</div><div id="sec5_10_2_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i156" class="anchor-spacer"></div><h5 class="article-section__title" id="_i156"> <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz)</h5><div class="NLM_p last">δ = 1.47 (s, 9 H), 2.74 (s, 3 H), 3.83 (s, 3 H), 6.17 (br. s, 1 H).</div></div></div><div id="sec5_10_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i157" class="anchor-spacer"></div><h4 class="article-section__title" id="_i157"> 5-(Trifluoromethyl)-2-((trimethylsilyl)ethynyl)pyridine (S9)</h4><div class="NLM_p">In a pressurized vessel equipped with magnetic stirring bar containing solution of 2-bromo-5-(trifluoromethyl)pyridine (30 g; 133 mmol, 1 equiv) in Et<sub>3</sub>N (265 mL), TMS–acetylene (26.07 g, 36.8 mL, 265 mmol, 2 equiv), Pd(Ph<sub>3</sub>P)Cl<sub>2</sub> (0.93 g; 1 mol %), and CuI (0.51 g; 2 mol %) were added under argon atmosphere. It was heated to 50–60 °C, and the mixture was stirred at this temperature for 6–8 h (TLC-control). Water (500 mL) was added and extracted with hexane (3 × 150 mL). The combined extracts were washed with water and dried with anhydrous sodium sulfate. The solvent was removed by rotary evaporation, and the residue was purified using column chromatography (eluent: Hex–EtOAc, 30:1, <i>R</i><sub>f</sub> = 0.5 in hexane-EtOAc 30:1). <i>M</i> = 15.6 g. Yield = 48%.</div><div id="sec5_10_3_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i158" class="anchor-spacer"></div><h5 class="article-section__title" id="_i158"> <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz)</h5><div class="NLM_p last">δ = 0.28 (s, 9 H), 7.55 (d, <i>J</i> = 8.2 Hz, 1 H), 7.87 (dd, <i>J</i> = 8.2, 2.2 Hz, 1 H), 8.81 (s, 1 H).</div></div><div id="sec5_10_3_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i159" class="anchor-spacer"></div><h5 class="article-section__title" id="_i159"> <sup>13</sup>C NMR (CDCl<sub>3</sub>, 400 MHz)</h5><div class="NLM_p last">δ = −0.4 (3C), 98.2, 102.5, 123.3 (q, <i>J</i> = 272.2 Hz), 125.6 (q, <i>J</i> = 33.3 Hz), 126.9, 133.4 (q, <i>J</i> = 3.1 Hz), 146.5, 146.8 (q, <i>J</i> = 3.8 Hz).</div></div></div><div id="sec5_10_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i160" class="anchor-spacer"></div><h4 class="article-section__title" id="_i160"> 5-Chloro-2-((trimethylsilyl)ethynyl)pyridine (S10)</h4><div class="NLM_p">In a pressurized vessel equipped with magnetic stirring bar containing a solution of 2-bromo-5-chloropyridine (20 g; 104 mmol, 1 equiv) in Et<sub>3</sub>N (210 mL), TMS-acetylene (20.42 g, 28.8 mL, 208 mmol, 2 equiv), Pd(Ph<sub>3</sub>P)Cl<sub>2</sub> (0.73 g; 1 mol %), and CuI (0.4 g; 2 mol %) were added under argon atmosphere. It was heated to 50–60 °C, and the mixture was stirred at this temperature for 6–8 h (TLC-control). Water (500 mL) was added and extracted with hexane (3 × 150 mL). The combined extracts were washed with water and dried with anhydrous sodium sulfate. The solvent was removed by rotary evaporation, and the residue was purified using column chromatography (eluent: Hex-EtOAc, 30:1, <i>R</i><sub>f</sub> = 0.4 in hexane-EtOAc 30:1). <i>M</i> = 16.7 g. Yield = 74%.</div><div id="sec5_10_4_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i161" class="anchor-spacer"></div><h5 class="article-section__title" id="_i161"> <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz)</h5><div class="NLM_p last">δ = 0.27 (s, 9 H), 7.40 (d, <i>J</i> = 8.4 Hz, 1 H), 7.62 (dd, <i>J</i> = 8.4, 2.4 Hz, 1 H), 8.52 (d, <i>J</i> = 2.4 Hz, 1 H).</div></div><div id="sec5_10_4_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i162" class="anchor-spacer"></div><h5 class="article-section__title" id="_i162"> <sup>13</sup>C NMR (CDCl<sub>3</sub>, 100 MHz)</h5><div class="NLM_p last">δ = −0.3 (3c), 96.1, 102.6, 127.8, 131.5, 135.9, 141.0, 148.9.</div></div></div><div id="sec5_10_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i163" class="anchor-spacer"></div><h4 class="article-section__title" id="_i163"> 1-tert-Butyl 2-methyl 3-methyl-5-(5-(trifluoromethyl)pyridin-2-yl)-1H-pyrrole-1,2-dicarboxylate (S11)</h4><div class="NLM_p">To the solution of <b>S9</b> (9.81 g, 40 mmol, 1 equiv) in dimethylformamide (DMF) (200 mL), triethylamine trihydrofluoride (1.98 g, 2 mL, 12 mmol, 0.3 equiv) was added, and the mixture was stirred for 1 h under argon atmosphere. Then methyl (<i>E</i>)-2-(<i>tert</i>-butoxycarbonylamino)-3-iodo-but-2-enoate (13.75 g, 1 equiv), Pd(Ph<sub>3</sub>P)Cl<sub>2</sub> (1.42 g; 5 mol %), CuI (0.77 g; 10 mol %), and Cs<sub>2</sub>CO<sub>3</sub> (26.27 g; 80 mmol, 2 equiv) were added under argon atmosphere. It was heated to 70–80 °C, and the mixture was stirred at this temperature for 10–15 h (TLC-control). Water (300 mL) was added and extracted with Et<sub>2</sub>O (3 × 150 mL). Combined extracts were washed with water and brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. Purification by flash chromatography was done using hexane-EtOAc mixture (20:1) as eluent. <i>M</i> = 7.1 g, Yield 46%.</div><div id="sec5_10_5_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i164" class="anchor-spacer"></div><h5 class="article-section__title" id="_i164"> <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz)</h5><div class="NLM_p last">δ = 1.64 (s, 9 H), 2.34 (s, 3 H), 3.89 (s, 3 H), 6.52 (s, 1 H), 7.64 (d, <i>J</i> = 8.1 Hz, 1 H), 7.89 (d, <i>J</i> = 7.8 Hz, 1 H), 8.73 (br. s., 1 H).</div></div><div id="sec5_10_5_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i165" class="anchor-spacer"></div><h5 class="article-section__title" id="_i165"> <sup>13</sup>C NMR (CDCl<sub>3</sub>, 400 MHz)</h5><div class="NLM_p last">δ = 13.1, 27.4 (3C), 51.5, 85.1, 114.1, 120.5, 123.1, 123.6 (q, <i>J</i> = 272.2 Hz), 124.3 (q, <i>J</i> = 32.9 Hz),129.2, 133.2, 133.6 (q, <i>J</i> = 2.9 Hz), 145.1 (q, <i>J</i> = 4.4 Hz), 149.9, 152.5, 161.2.</div></div></div><div id="sec5_10_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i166" class="anchor-spacer"></div><h4 class="article-section__title" id="_i166"> 1-tert-Butyl 2-methyl 5-(5-chloropyridin-2-yl)-3-methyl-1H-pyrrole-1,2-dicarboxylate (S12)</h4><div class="NLM_p">To the solution of <b>S10</b> (13.1 g, 62 mmol, 1 equiv) in DMF (310 mL), triethylamine trihydrofluoride (3.01 g, 3.05 mL, 12 mmol, 0.3 equiv) was added, and mixture was stirred for 1 h under argon atmosphere. Then methyl (<i>E</i>)-2-(<i>tert</i>-butoxycarbonylamino)-3-iodo-but-2-enoate (21.31 g, 1 equiv), Pd(Ph<sub>3</sub>P)Cl<sub>2</sub> (1.32 g; 3 mol %), CuI (1.2 g; 10 mol %), and Cs<sub>2</sub>CO<sub>3</sub> (40.7 g; 125 mmol, 2 equiv) were added under argon atmosphere. It was heated to 70–80 °C, and the mixture was stirred at this temperature for 10–15 h (TLC-control). Water (300 mL) was added and extracted with Et<sub>2</sub>O (3 × 150 mL). Combined extracts were washed with water and brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. <i>M</i> = 8.95 g, Yield 41%.</div><div id="sec5_10_6_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i167" class="anchor-spacer"></div><h5 class="article-section__title" id="_i167"> <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz)</h5><div class="NLM_p last">δ = 1.61 (s, 9 H), 2.33 (s, 3 H), 3.87 (s, 3 H), 6.41 (s, 1 H), 7.49 (d, <i>J</i> = 8.5 Hz, 1 H), 7.65 (dd, <i>J</i> = 8.5, 2.4 Hz, 1 H), 8.45 (d, <i>J</i> = 2.1 Hz, 1 H).</div></div><div id="sec5_10_6_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i168" class="anchor-spacer"></div><h5 class="article-section__title" id="_i168"> <sup>13</sup>C NMR (CDCl<sub>3</sub>, 100 MHz)</h5><div class="NLM_p last">δ = 13.3, 27.5 (3C), 51.6, 85.1, 113.2, 122.0, 122.4, 129.5, 130.5, 133.9, 136.3, 147.3, 147.8, 150.1, 161.4.</div></div></div><div id="sec5_10_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i169" class="anchor-spacer"></div><h4 class="article-section__title" id="_i169"> Methyl 3-methyl-5-(5-(trifluoromethyl)pyridin-2-yl)-1H-pyrrole-2-carboxylate (S13)</h4><div class="NLM_p">To a solution of <b>S11</b> (5.87 g, 15 mmol, 1 equiv) in CH<sub>2</sub>Cl<sub>2</sub> (50 mL) trifluoroacetic acid (TFA) (11 g, 7.4 mL, 76 mmol, 5 equiv) was added in one portion, and the mixture was stirred overnight. Then solvent was evaporated; 10% aqueous K<sub>2</sub>CO<sub>3</sub> was added, and the mixture was extracted with CH<sub>2</sub>Cl<sub>2</sub> (3 × 100 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. Purification by flash chromatography was done using hexane-EtOAc mixture (10:1) as eluent. <i>M</i> = 3.96 g. Yield 91%.</div><div id="sec5_10_7_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i170" class="anchor-spacer"></div><h5 class="article-section__title" id="_i170"> <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz)</h5><div class="NLM_p last">δ = 2.40 (s, 3 H), 3.90 (s, 3 H), 6.62 (d, <i>J</i> = 2.8 Hz, 1 H), 7.61 (d, <i>J</i> = 8.3 Hz, 1 H), 7.87 (dd, <i>J</i> = 8.4, 2.1 Hz, 1 H), 8.76 (s, 1 H), 10.01 (br. s., 1 H).</div></div><div id="sec5_10_7_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i171" class="anchor-spacer"></div><h5 class="article-section__title" id="_i171"> <sup>13</sup>C NMR (CDCl<sub>3</sub>, 400 MHz)</h5><div class="NLM_p last">δ = 12.8, 51.4, 112.1, 118.4, 121.5, 123.7 (q, <i>J</i> = 272.2 Hz), 124.1 (q, <i>J</i> = 32.9 Hz), 129.6, 132.4, 133.8 (q, <i>J</i> = 3.7 Hz), 146.4 (q, <i>J</i> = 4.4 Hz), 152.1, 161.6.</div></div></div><div id="sec5_10_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i172" class="anchor-spacer"></div><h4 class="article-section__title" id="_i172"> Methyl 5-(5-chloropyridin-2-yl)-3-methyl-1H-pyrrole-2-carboxylate (S14)</h4><div class="NLM_p">To a solution of <b>S12</b> (8.25 g, 24 mmol, 1 equiv) in CH<sub>2</sub>Cl<sub>2</sub> (100 mL) TFA (13.4 g, 9.0 mL, 118 mmol, 5 equiv) was added in one portion, and the mixture was stirred overnight. Then solvent was evaporated; 10% aqueous K<sub>2</sub>CO<sub>3</sub> was added, and the mixture was extracted with CH<sub>2</sub>Cl<sub>2</sub> (3 × 100 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. Purification by flash chromatography was done using hexane-EtOAc mixture (10:1) as eluent. <i>M</i> = 5.76 g. Yield 98%.</div><div id="sec5_10_8_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i173" class="anchor-spacer"></div><h5 class="article-section__title" id="_i173"> <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz)</h5><div class="NLM_p last">δ = 2.38 (s, 3 H), 3.88 (s, 3 H), 6.50 (d, <i>J</i> = 2.6 Hz, 1 H), 7.46 (d, <i>J</i> = 8.4 Hz, 1 H), 7.62 (dd, <i>J</i> = 8.5, 2.4 Hz, 1 H), 8.45 (d, <i>J</i> = 2.2 Hz, 1 H), 9.89 (br. s., 1 H).</div></div><div id="sec5_10_8_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i174" class="anchor-spacer"></div><h5 class="article-section__title" id="_i174"> <sup>13</sup>C NMR (CDCl<sub>3</sub>, 100 MHz)</h5><div class="NLM_p last">δ = 12.9, 51.4, 110.9, 119.8, 120.7, 129.7, 129.9, 132.7, 136.5, 147.4, 148.2, 161.7.</div></div></div><div id="sec5_10_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i175" class="anchor-spacer"></div><h4 class="article-section__title" id="_i175"> Sodium 3-methyl-5-(5-(trifluoromethyl)pyridin-2-yl)-1H-pyrrole-2-carboxylate (S15)</h4><div class="NLM_p">To a solution of <b>S13</b> (3.96 g, 14 mmol, 1 equiv) in a mixture of dioxane–H<sub>2</sub>O (1:1, 30 mL), NaOH (0.61 g, 15 mmol, 1.1 equiv) was added in one portion, and the reaction mixture was stirred at reflux for 10–12 h (TLC-control). The mixture was evaporated to a volume of 10–20 mL, and the precipitate was filtered, washed with ether (2 × 50 mL), and dried under reduced pressure. <i>M</i> = 3.21 g. Yield 79%.</div><div id="sec5_10_9_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i176" class="anchor-spacer"></div><h5 class="article-section__title" id="_i176"> <sup>1</sup>H NMR (DMSO-d<sub>6</sub>, 400 MHz)</h5><div class="NLM_p last">δ = 2.28 (s, 3 H), 6.72 (s, 1 H), 7.92 (d, <i>J</i> = 8.6 Hz, 1 H), 8.01 (d, <i>J</i> = 8.6 Hz, 1 H), 8.75 (s, 1 H), 10.34 (br. s., 1 H).</div></div><div id="sec5_10_9_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i177" class="anchor-spacer"></div><h5 class="article-section__title" id="_i177"> <sup>13</sup>C NMR (DMSO-d<sub>6</sub>, 100 MHz)</h5><div class="NLM_p last">δ = 12.8, 113.1, 118.0, 121.0 (q, <i>J</i> = 32.2 Hz), 122.5, 124.2 (q, <i>J</i> = 271.5 Hz), 127.8, 131.3, 133.7 (q, <i>J</i> = 2.2 Hz), 145.8 (q, <i>J</i> = 3.7 Hz), 153.9, 167.1.</div></div></div><div id="sec5_10_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i178" class="anchor-spacer"></div><h4 class="article-section__title" id="_i178"> 5-(5-Chloropyridin-2-yl)-3-methyl-1H-pyrrole-2-carboxylic Acid (S16)</h4><div class="NLM_p">To a solution of <b>S14</b> (5.7 g, 22 mmol, 1 equiv) in a mixture of dioxane–H<sub>2</sub>O (1:1, 60 mL), NaOH (1.06 g, 25 mmol, 1.1 equiv) was added in one portion, and the reaction mixture was stirred at reflux for 10–12 h (TLC-control). Then sodium-salt solution was acidified by addition of an equivalent amount of HCl (12 M, 2.08 mL, 1.1 equiv), and the precipitate was filtered. <i>M</i> = 5.1 g. Yield 95%.</div><div id="sec5_10_10_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i179" class="anchor-spacer"></div><h5 class="article-section__title" id="_i179"> <sup>1</sup>H NMR (DMSO-d<sub>6</sub>, 400 MHz)</h5><div class="NLM_p last">δ = 2.29 (s, 3 H), 6.70 (s, 1 H), 7.89 (d, <i>J</i> = 8.3 Hz, 1 H), 7.98 (d, <i>J</i> = 8.4 Hz, 1 H), 8.53 (s, 1 H), 11.28 (br. s., 1 H).</div></div><div id="sec5_10_10_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i180" class="anchor-spacer"></div><h5 class="article-section__title" id="_i180"> <sup>13</sup>C NMR (DMSO-d<sub>6</sub>, 100 MHz)</h5><div class="NLM_p last">δ = 12.8, 112.2, 120.2, 123.1, 126.9, 128.5, 132.2, 136.7, 147.8, 148.2, 163.1.</div></div></div><div id="sec5_10_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i181" class="anchor-spacer"></div><h4 class="article-section__title" id="_i181"> Thiazole-5-carbaldehyde (S17)</h4><div class="NLM_p">A solution of DMSO (16.96 g, 15.4 mL, 217 mmol, 2.5 equiv) in CH<sub>2</sub>Cl<sub>2</sub> (100 mL) was added dropwise to a solution of oxalyl chloride (13.23 g, 8.94 mL, 104 mmol, 1.2 equiv) in CH<sub>2</sub>Cl<sub>2</sub> (100 mL) at −70 to −80 °C. The resulting solution was stirred for 10 min, and a solution of alcohol (10 g, 87 mmol, 1 equiv) in CH<sub>2</sub>Cl<sub>2</sub> (100 mL) was added dropwise at the same temperature. After 15 min, Et<sub>3</sub>N (35.15 g, 48.3 mL, 347 mmol, 4 equiv) was added dropwise, and 5 min later, the reaction mixture was allowed to warm to rt. The reaction mixture was quenched with water (300 mL), and the layers were separated. The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo (bath temperature not exceeding 45–50 °C). The purification by flash chromatography (hexanes/EtOAc, 3:1) afforded aldehyde as a slightly brown oil. <i>M</i> = 7.05 g. Yield = 72%.</div><div id="sec5_10_11_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i182" class="anchor-spacer"></div><h5 class="article-section__title" id="_i182"> <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz)</h5><div class="NLM_p last">δ = 8.48 (s, 1 H), 9.07 (s, 1 H), 10.04 (d, <i>J</i> = 1.0 Hz, 1 H).</div></div><div id="sec5_10_11_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i183" class="anchor-spacer"></div><h5 class="article-section__title" id="_i183"> <sup>13</sup>C NMR (CDCl<sub>3</sub>, 100 MHz)</h5><div class="NLM_p last">δ = 139.4, 151.6, 160.1, 182.3.</div></div></div><div id="sec5_10_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i184" class="anchor-spacer"></div><h4 class="article-section__title" id="_i184"> 5-Vinylthiazole (S18)</h4><div class="NLM_p">To the suspension of Ph<sub>3</sub>P<sup>+</sup>MeI<sup>–</sup> (25.74 g, 64 mmol, 1.1 equiv) in THF (70 mL), tBuOK (7.16 g, 64 mmol, 1.1 equiv) was added in one portion. The mixture was refluxed for 1 h and cooled to room temperature. Aldehyde <b>S17</b> (6.55 g, 58 mmol, 1 equiv) in THF (50 mL) was added dropwise under cooling with an aqueous bath. The solvent was evaporated (bath temperature not exceeding 35 °C), and the residue was triturated in ether and filtered. The filtrate was evaporated, and the crude product was purified by flash chromatography using hexane-EtOAc mixture (3:1) as eluent (<i>R</i><sub>f</sub> = 0.5in hexane-EtOAc 3:1). <i>M</i> = 4.79 g. Yield = 74%.</div><div id="sec5_10_12_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i185" class="anchor-spacer"></div><h5 class="article-section__title" id="_i185"> <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz)</h5><div class="NLM_p last">δ = 5.29 (d, <i>J</i> = 10.9 Hz, 1 H), 5.57 (d, <i>J</i> = 17.3 Hz, 1 H), 6.82 (dd, <i>J</i> = 17.3, 10.9 Hz, 1 H), 7.74 (s, 1 H), 8.63 (s, 1 H).</div></div><div id="sec5_10_12_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i186" class="anchor-spacer"></div><h5 class="article-section__title" id="_i186"> <sup>13</sup>C NMR (CDCl<sub>3</sub>, 100 MHz)</h5><div class="NLM_p last">δ = 117.2, 126.5, 138.0, 141.6, 151.7.</div></div></div><div id="sec5_10_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i187" class="anchor-spacer"></div><h4 class="article-section__title" id="_i187"> 1-(Thiazol-5-yl)ethane-1,2-diol (S19)</h4><div class="NLM_p">To a solution of alkene <b>S18</b> (4.7 g, 42 mmol, 1 equiv) in acetone-water (4:1, 50 mL), 4-methylmorpholine-4-oxide monohydrate (NMO monohydrate) (6.29 g, 47 mmol, 1.1 equiv) and potassium osmate(VI) dehydrate (0.16 g, 1 mol %) were added in one portion. The mixture was refluxed for 10–12 h (TLC-control) and cooled to room temperature. The solvent was evaporated, and crude product was purified by flash chromatography using pure EtOAc as eluent (<i>R</i><sub>f</sub> = 0.2 in EtOAc). <i>M</i> = 2.83 g. Yield = 46%.</div><div id="sec5_10_13_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i188" class="anchor-spacer"></div><h5 class="article-section__title" id="_i188"> <sup>1</sup>H NMR (DMSO-d<sub>6</sub>, 400 MHz)</h5><div class="NLM_p last">δ = 3.44–3.50 (m, 1 H), 3.51–3.58 (m, 1 H), 4.85 (q, <i>J</i> = 5.6 Hz, 1 H), 5.00 (t, <i>J</i> = 5.8 Hz, 1 H), 5.80 (d, <i>J</i> = 4.7 Hz, 1 H), 7.77 (s, 1 H), 8.96 (s, 1 H).</div></div><div id="sec5_10_13_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i189" class="anchor-spacer"></div><h5 class="article-section__title" id="_i189"> <sup>13</sup>C NMR (DMSO-d<sub>6</sub>, 100 MHz)</h5><div class="NLM_p last">δ = 66.9, 68.0, 139.5, 142.0, 153.1.</div></div></div><div id="sec5_10_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i190" class="anchor-spacer"></div><h4 class="article-section__title" id="_i190"> 5-(2,2,3,3,8,8,9,9-Octamethyl-4,7-dioxa-3,8-disiladecan-5-yl)thiazole (S20)</h4><div class="NLM_p">To a solution of alcohol, <b>S19</b> (2.83 g, 19 mmol, 1 equiv), and DMF (50 mL), imidazole (5.31 g, 78 mmol, 4 equiv) was added in one portion, followed by portionwise addition of <i>tert</i>-butyldimethylsilyl chloride (TBSCl) (8.81 g, 58 mmol, 3 equiv). The reaction mixture was stirred overnight at 50–60 °C, cooled to room temperature, diluted with water (100 mL), and extracted with EtoAc (3 × 50 mL). The combined organic phases were washed with water (50 mL) and brine (50 mL), dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and evaporated to give an oil, which was purified by flash chromatography using Hexane-EtOAc (10:1) as eluent (<i>R</i><sub>f</sub> = 0.3 in 10:1 hexane-EtOAc). <i>M</i> = 5.87 g. Yield = 80%.</div><div id="sec5_10_14_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i191" class="anchor-spacer"></div><h5 class="article-section__title" id="_i191"> <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz)</h5><div class="NLM_p last">δ = −0.02–0.03 (m, 9 H), 0.10 (s, 3 H), 0.87 (s, 9 H), 0.89 (s, 9 H), 3.58 (dd, <i>J</i> = 9.9, 6.3 Hz, 1 H), 3.75 (dd, <i>J</i> = 9.9, 5.9 Hz, 1 H), 5.01 (t, <i>J</i> = 6.1 Hz, 1 H), 7.76 (s, 1 H), 8.73 (s, 1 H).</div></div><div id="sec5_10_14_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i192" class="anchor-spacer"></div><h5 class="article-section__title" id="_i192"> <sup>13</sup>C NMR (CDCl<sub>3</sub>, 100 MHz)</h5><div class="NLM_p last">δ = −5.4, −5.4, −4.9, −4.7, 18.3, 18.5, 25.8 (3C), 26.0 (3C), 69.2, 70.4, 139.6, 141.7, 152.6.</div></div></div><div id="sec5_10_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i193" class="anchor-spacer"></div><h4 class="article-section__title" id="_i193"> General Procedure E: For 1,2-Addition</h4><div class="NLM_p last">The appropriate thiazole (1.3 equiv) was dissolved in THF (1M) and cooled to −78 °C. At this temperature, <i>n</i>-BuLi (2.5 M, 1.4 equiv) was added dropwise under a nitrogen atmosphere. The reaction mixture was stirred for 20 min at −78 °C, and the appropriate imine (1 equiv) was added dropwise as a solution in THF (1 M). The reaction mixture was slowly (∼1 h) warmed to 0 °C and poured into water (5 mL of water per 1 g of thiazole). The biphasic mixture was extracted with CH<sub>2</sub>Cl<sub>2</sub> (3 × 100 mL). The combined organic phases were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and evaporated to give a brown oil, which was purified by column chromatography. Eluent: hexanes/EtOAc (10:1, 5:1, 1:1, 0:1).</div></div><div id="sec5_10_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i194" class="anchor-spacer"></div><h4 class="article-section__title" id="_i194"> General Procedure F: For Amine Deprotection</h4><div class="NLM_p last">A 1 M HCl–MeOH solution was prepared by the dropwise addition of AcCl (1.5 equiv) to MeOH. The resulting solution was cooled to ambient temperature and added to a flask containing an appropriately protected compound (1 equiv). After dissolution, the reaction mixture was stirred for 1 h, evaporated, dissolved in CH<sub>2</sub>Cl<sub>2</sub>, and washed with 10% aqueous K<sub>2</sub>CO<sub>3</sub>. The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and evaporated, and the residue was loaded on silica. Eluting with CH<sub>2</sub>Cl<sub>2</sub>/MeOH (50:1) provided pure amine as a yellow oil.</div></div><div id="sec5_10_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i195" class="anchor-spacer"></div><h4 class="article-section__title" id="_i195"> General Procedure G: For TBDPS Protection</h4><div class="NLM_p last">Diol (1 equiv) was dissolved in CH<sub>2</sub>Cl<sub>2</sub> (10 mL per 1 g), and imidazole (1.2 equiv) was added in one portion, followed by a portionwise addition of <i>tert</i>-butyl(chloro)diphenylsilane (TBDPSCl) (1.1 equiv). The reaction mixture was stirred overnight, diluted with water (10 mL per 1 g), and extracted with CH<sub>2</sub>Cl<sub>2</sub> (3 × 50 mL). The combined organic phases were washed with brine and dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and evaporated to give an oil, which was purified by flash chromatography using a hexane-EtOAc mixture (1:1 and 0:1) as eluent.</div></div><div id="sec5_10_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i196" class="anchor-spacer"></div><h4 class="article-section__title" id="_i196"> Allyl Allyl(2-amino-2-(4-(2-((tert-butyldiphenylsilyl)oxy)-1-hydroxyethyl)thiazol-2-yl)ethyl)carbamate (S23-fS and S23-fR)</h4><div class="NLM_p">Compounds <b>S23-fS</b> and <b>S23-fR</b> were obtained following in succession the <b><i>general procedures E</i></b>, <b><i>F</i></b>, and <b><i>G</i></b> from <b>S20</b> (compounds <b>S21</b> and <b>S22</b> were considered pure enough and used directly in the next steps without any further purifications).</div><div id="sec5_10_18_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i197" class="anchor-spacer"></div><h5 class="article-section__title" id="_i197"> S23-fS</h5><div class="NLM_p last"><i>M</i> = 2.94 g. Yield (over three steps) = 30%.</div></div><div id="sec5_10_18_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i198" class="anchor-spacer"></div><h5 class="article-section__title" id="_i198"> S23-fR</h5><div class="NLM_p last"><i>M</i> = 1.81 g. Yield (over three steps) = 27%.</div></div><div id="sec5_10_18_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i199" class="anchor-spacer"></div><h5 class="article-section__title" id="_i199"> <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz)</h5><div class="NLM_p last">δ = 1.08 (s, 9 H), 2.43 (br. s., 3 H), 3.51–4.00 (m, 6 H), 4.40–4.54 (m, 1 H), 4.60 (d, <i>J</i> = 4.2 Hz, 2 H), 5.03 (dd, <i>J</i> = 7.1, 4.1 Hz, 1 H), 5.07–5.17 (m, 2 H), 5.20 (dd, <i>J</i> = 10.5, 1.3 Hz, 1 H), 5.29 (dd, <i>J</i> = 17.2, 1.4 Hz, 1 H), 5.67–5.83 (m, 1 H), 5.85–5.98 (m, 1 H), 7.36–7.49 (m, 6 H), 7.55 (s, 1 H), 7.61–7.68 (m, 4 H).</div></div></div><div id="sec5_10_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i200" class="anchor-spacer"></div><h4 class="article-section__title" id="_i200"> Methyl 2-(thiazol-4-yl)acetate (S24)</h4><div class="NLM_p">The compound (<b>S24</b>) was prepared by following a published procedure.<a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(67)</a></div><div id="sec5_10_19_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i201" class="anchor-spacer"></div><h5 class="article-section__title" id="_i201"> <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz)</h5><div class="NLM_p last">δ = 3.72 (s, 3 H), 3.89 (s, 2 H), 7.24 (d, <i>J</i> = 1.8 Hz, 1 H), 8.76 (d, <i>J</i> = 1.9 Hz, 1 H).</div></div><div id="sec5_10_19_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i202" class="anchor-spacer"></div><h5 class="article-section__title" id="_i202"> <sup>13</sup>C NMR (CDCl<sub>3</sub>, 100 MHz)</h5><div class="NLM_p last">δ = 36.6, 52.2, 116.1, 149.5, 152.8, 170.7.</div></div></div><div id="sec5_10_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i203" class="anchor-spacer"></div><h4 class="article-section__title" id="_i203"> 2-(Thiazol-4-yl)ethanol (S25)</h4><div class="NLM_p">A solution of ester <b>S24</b> (0.481 mol) in THF (480 mL) was added dropwise to a suspension of LiAlH<sub>4</sub> (0.500 mmol, 1.0 equiv) in THF (480 mL) at 0 °C. The reaction mixture was stirred for 60 min at 0 °C. It was then quenched by successive addition of EtOAc (100 mL), water (37 mL), 10% NaOH (37 mL) solution, and water (74 mL) (the temperature should not exceed 0 °C). The precipitate was filtered and washed several times with THF. The filtrate was evaporated to give <b>S25</b>, which was used without further purification.</div><div id="sec5_10_20_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i204" class="anchor-spacer"></div><h5 class="article-section__title" id="_i204"> <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz)</h5><div class="NLM_p last">δ = 3.03 (t, <i>J</i> = 5.9 Hz, 2 H), 3.43 (br. s., 1 H), 3.93 (t, <i>J</i> = 5.9 Hz, 2 H), 7.04–7.05 (m, 1 H), 8.74 (d, <i>J</i> = 2.0 Hz, 1 H).</div></div><div id="sec5_10_20_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i205" class="anchor-spacer"></div><h5 class="article-section__title" id="_i205"> <sup>13</sup>C NMR (CDCl<sub>3</sub>, 100 MHz)</h5><div class="NLM_p last">δ = 33.9, 61.5, 114.1, 152.8, 155.2.</div></div></div><div id="sec5_10_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i206" class="anchor-spacer"></div><h4 class="article-section__title" id="_i206"> 2-(Thiazol-4-yl)ethylmethanesulfonate (S26)</h4><div class="NLM_p">To a solution of corresponding alcohol <b>S25</b> (2.14 mmol) and triethylamine (0.36 mL, 2.59 mmol) in anhydrous dichloromethane (6 mL), kept to 0 °C, under an inert nitrogen atmosphere, was added mesyl chloride (2.31 mmol). The reaction was maintained at 0 °C during the first hour, followed by warming to room temperature, under vigorous stirring and nitrogen atmosphere for 3 h. Then, the solution was extracted with dichloromethane (3 × 30 mL), and the combined organic extracts were washed with a 10% aqueous HCl solution, washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and evaporated. The obtained residue was separated by chromatography on silica gel eluting with dichloromethane, followed by chloroform, to yield the desired O-mesylated derivative. Yield: 78%.</div><div id="sec5_10_21_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i207" class="anchor-spacer"></div><h5 class="article-section__title" id="_i207"> <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz)</h5><div class="NLM_p last">δ = 2.89 (s, 3 H), 3.24 (t, <i>J</i> = 6.5 Hz, 2 H), 4.56 (t, <i>J</i> = 6.5 Hz, 2 H), 7.13 (d, <i>J</i> = 1.3 Hz, 1 H), 8.76 (d, <i>J</i> = 1.8 Hz, 1 H).</div></div></div><div id="sec5_10_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i208" class="anchor-spacer"></div><h4 class="article-section__title" id="_i208"> 4-Vinylthiazole (S27)</h4><div class="NLM_p">To a mixture of <b>S26</b> (7.41 mmol) and triethylamine (TEA) (5 mL) in dichloromethane (DCM) (50 mL) was added 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) (5 mL) slowly at 0 °C. The mixture was stirred at rt overnight and then diluted with 50 mL of DCM, washed with 2 N HCl three times and with brine once. The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to dryness. The residue was purified by preparatory (prep) TLC to give <b>S27</b>. Yield: 58%.</div><div id="sec5_10_22_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i209" class="anchor-spacer"></div><h5 class="article-section__title" id="_i209"> <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz)</h5><div class="NLM_p last">δ = 5.39 (dd, <i>J</i> = 10.9, 1.5 Hz, 1 H), 6.09 (dd, <i>J</i> = 17.3, 1.5 Hz, 1 H), 6.77 (dd, <i>J</i> = 17.3, 10.9 Hz, 1 H), 7.14 (d, <i>J</i> = 1.8 Hz, 1 H), 8.76 (d, <i>J</i> = 1.8 Hz, 1 H).</div></div><div id="sec5_10_22_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i210" class="anchor-spacer"></div><h5 class="article-section__title" id="_i210"> <sup>13</sup>C NMR (CDCl<sub>3</sub>, 100 MHz)</h5><div class="NLM_p last">δ = 114.9, 116.9, 129.5, 152.9, 155.1.</div></div></div><div id="sec5_10_23" class="NLM_sec NLM_sec_level_3"><div id="ac_i211" class="anchor-spacer"></div><h4 class="article-section__title" id="_i211"> 1-(Thiazol-4-yl)ethane-1,2-diol (S28)</h4><div class="NLM_p">To a solution of alkene <b>S27</b> (42 mmol, 1 equiv) in acetone–water (4:1, 50 mL), NMO monohydrate (47 mmol, 1.1 equiv) and potassium osmate(VI) dehydrate (0.16 g, 1 mol %) were added in one portion. The mixture was refluxed for 10–12 h (TLC-control) and cooled to room temperature. The solvent was evaporated, and the crude product was purified by flash chromatography (eluent: EtOAc). Yield 70%.</div><div id="sec5_10_23_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i212" class="anchor-spacer"></div><h5 class="article-section__title" id="_i212"> <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz)</h5><div class="NLM_p last">δ = 3.77 (dd, <i>J</i> = 11.4, 7.2 Hz, 1 H), 3.91 (dd, <i>J</i> = 11.5, 3.4 Hz, 1 H), 4.72 (br. s., 1 H), 4.99 (dd, <i>J</i> = 6.9, 3.3 Hz, 1 H), 5.25 (br. s., 1 H), 7.32 (d, <i>J</i> = 1.9 Hz, 1 H), 8.71 (d, <i>J</i> = 2.0 Hz, 1 H).</div></div><div id="sec5_10_23_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i213" class="anchor-spacer"></div><h5 class="article-section__title" id="_i213"> <sup>13</sup>C NMR (CDCl<sub>3</sub>, 100 MHz)</h5><div class="NLM_p last">δ = 66.4, 71.3, 115.2, 153.6, 157.5.</div></div></div><div id="sec5_10_24" class="NLM_sec NLM_sec_level_3"><div id="ac_i214" class="anchor-spacer"></div><h4 class="article-section__title" id="_i214"> 4-(2,2,3,3,8,8,9,9-octamethyl-4,7-dioxa-3,8-disiladecan-5-yl)thiazole (S29)</h4><div class="NLM_p">To a solution of alcohol, <b>S28</b> (19 mmol, 1 equiv), and DMF (50 mL), imidazole (5.31 g, 78 mmol, 4 equiv) was added in one portion, followed by portionwise addition of TBSCl (8.81 g, 58 mmol, 3 equiv). The reaction mixture was stirred overnight at 50–60 °C, cooled to room temperature, diluted with water (100 mL), and extracted with EtOAc (3 × 50 mL). The combined organic phases were washed with water (50 mL), washed with brine (50 mL), dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and evaporated to give an oil, which was purified by flash chromatography using hexane-EtOAc (10:1) as eluent. Yield = 78%.</div><div id="sec5_10_24_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i215" class="anchor-spacer"></div><h5 class="article-section__title" id="_i215"> <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz)</h5><div class="NLM_p last">δ = −0.01–0.04 (m, 9 H), 0.11 (s, 3 H), 0.86 (s, 9 H), 0.90 (s, 9 H), 3.68 (dd, <i>J</i> = 10.2, 7.2 Hz, 1 H), 3.93 (dd, <i>J</i> = 10.2, 3.8 Hz, 1 H), 5.03 (dd, <i>J</i> = 7.0, 3.6 Hz, 1 H), 7.28 (d, <i>J</i> = 1.9 Hz, 1 H), 8.75 (d, <i>J</i> = 2.1 Hz, 1 H).</div></div><div id="sec5_10_24_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i216" class="anchor-spacer"></div><h5 class="article-section__title" id="_i216"> <sup>13</sup>C NMR (CDCl<sub>3</sub>, 100 MHz)</h5><div class="NLM_p last">δ = −5.3, −5.2, −4.8, −4.5, 18.4, 18.5, 26.0 (3C), 26.1 (3C), 68.5, 73.8, 114.8, 152.3, 159.3.</div></div></div><div id="sec5_10_25" class="NLM_sec NLM_sec_level_3"><div id="ac_i217" class="anchor-spacer"></div><h4 class="article-section__title" id="_i217"> Allyl N-Allyl-N-[2-[4-[1,2-bis[[tert-butyl(dimethyl)silyl]oxy]ethyl]thiazol-2-yl]-2-(tert-butylsulfinylamino)ethyl]carbamate (S30)</h4><div class="NLM_p last">Compounds <b>S30</b>-fR and <b>S30</b>-fS were obtained following the <i>general procedure E</i>.</div></div><div id="sec5_10_26" class="NLM_sec NLM_sec_level_3"><div id="ac_i218" class="anchor-spacer"></div><h4 class="article-section__title" id="_i218"> Allyl N-Allyl-N-[2-amino-2-[4-(1,2-dihydroxyethyl)thiazol-2-yl]ethyl]carbamate (S31)</h4><div class="NLM_p last">Compounds <b>S31</b>-fR and <b>S31</b>-fS were obtained following the <i>general procedure F</i>.</div></div><div id="sec5_10_27" class="NLM_sec NLM_sec_level_3"><div id="ac_i219" class="anchor-spacer"></div><h4 class="article-section__title" id="_i219"> Allyl N-Allyl-N-[2-amino-2-[4-[2-[tert-butyl(diphenyl)silyl]oxy-1-hydroxy-ethyl]thiazol-2-yl]ethyl]carbamate (S32)</h4><div class="NLM_p">Compounds <b>S32</b>-fR and <b>S32</b>-fS were obtained following the <i>general procedure G</i>.</div><div class="NLM_p last">The synthesis of compound <b>S33</b> was reported earlier.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a></div></div><div id="sec5_10_28" class="NLM_sec NLM_sec_level_3"><div id="ac_i220" class="anchor-spacer"></div><h4 class="article-section__title" id="_i220"> 1-(4-(((tert-Butyldimethylsilyl)oxy)methyl)thiazol-2-yl)ethanone (S34)</h4><div class="NLM_p">To a solution of thiazole <b>S33</b> (49.06 g, 214 mmol, 1 equiv) in THF (210 mL), BuLi (2.5 M in hexane, 85.55 mL, 1.2 equiv) was added dropwise at −78 °C under argon atmosphere. After the end of the addition, the mixture was stirred for 10 min, and then the solution of <i>N</i>-methoxy-<i>N</i>-methyl-acetamide (24.26 g, 235 mmol, 1.1 equiv) in THF (50 mL) was added dropwise. The resulting mixture was stirred overnight and poured into a saturated solution of NH<sub>4</sub>Cl (400 mL). The organic layer was separated, and the aqueous solution was extracted with CH<sub>2</sub>Cl<sub>2</sub> (2 × 100 mL). The combined organic layers were washed with brine (200 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. The crude product was purified by flash chromatography using hexane–EtOAc (10:1) as eluent. <i>M</i> = 44.39 g. Yield = 76%.</div><div id="sec5_10_28_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i221" class="anchor-spacer"></div><h5 class="article-section__title" id="_i221"> <sup>1</sup>H NMR</h5><div class="NLM_p last">(CDCl<sub>3</sub>, 400 MHz) δ = 0.12 (s, 6 H), 0.94 (s, 9 H), 2.67 (s, 3 H), 4.90 (d, <i>J</i> = 1.1 Hz, 2 H), 7.54 (t, <i>J</i> = 1.1 Hz, 1 H).</div></div><div id="sec5_10_28_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i222" class="anchor-spacer"></div><h5 class="article-section__title" id="_i222"> <sup>13</sup>C NMR</h5><div class="NLM_p last">(CDCl<sub>3</sub>, 100 MHz) δ = −5.3 (2C), 18.5, 26.0 (3C), 26.1, 62.2, 121.5, 159.7, 166.8, 191.8.</div></div></div><div id="sec5_10_29" class="NLM_sec NLM_sec_level_3"><div id="ac_i223" class="anchor-spacer"></div><h4 class="article-section__title" id="_i223"> 2-Amino-2-(4-(((tert-butyldimethylsilyl)oxy)methyl)thiazol-2-yl)propanenitrile (S35)</h4><div class="NLM_p">To the solution of <b>S34</b> (44.39 g, 164 mmol, 1 equiv) in MeOH–NH<sub>3</sub> (330 mL), NaCN (16.0 g, 327 mmol, 2 equiv) and NH<sub>4</sub>Cl (35.0 g, 654 mmol, 4 equiv) were added. The mixture was stirred for 4–5 d, and then water (600 mL) was added and extracted with DCM (3 × 200 mL). The combined organic layers were washed with brine (200 mL) and dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. The obtained crude product was purified by flash chromatography using a hexane–EtOAc mixture (3:1) as eluent. The compound was obtained in racemic form. <i>M</i> = 16.46 g. Yield = 34%.</div><div id="sec5_10_29_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i224" class="anchor-spacer"></div><h5 class="article-section__title" id="_i224"> <sup>1</sup>H NMR</h5><div class="NLM_p last">(CDCl<sub>3</sub>, 400 MHz) δ = 0.12 (s, 6 H), 0.95 (s, 9 H), 1.92 (s, 3 H), 2.42 (br. s., 2 H), 4.86 (d, <i>J</i> = 1.2 Hz, 2 H), 7.21 (t, <i>J</i> = 1.2 Hz, 1 H).</div></div><div id="sec5_10_29_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i225" class="anchor-spacer"></div><h5 class="article-section__title" id="_i225"> <sup>13</sup>C NMR</h5><div class="NLM_p last">(CDCl<sub>3</sub>, 100 MHz) δ = −5.3 (2C), 18.4, 26.0 (3C), 30.3, 52.6, 62.3, 114.8, 121.9, 158.2, 170.6.</div></div></div><div id="sec5_10_30" class="NLM_sec NLM_sec_level_3"><div id="ac_i226" class="anchor-spacer"></div><h4 class="article-section__title" id="_i226"> 2-(4-(((tert-Butyldimethylsilyl)oxy)methyl)thiazol-2-yl)propane-1,2-diamine (S36)</h4><div class="NLM_p">A solution of <b>S35</b> (16.46 g, 55 mmol, 1 equiv) in Et<sub>2</sub>O (55 mL) was added dropwise to a suspension of LiAlH<sub>4</sub> (6.31 g, 166 mmol, 3 equiv) in Et<sub>2</sub>O (55 mL) at −10 °C. The reaction mixture was stirred for 12 h at 0 °C. It was then quenched by successive addition of water (7 mL), 10% NaOH (7 mL) solution, and water (7 mL) (the temperature should not exceed 0 °C). The precipitate was filtered and washed several times with Et<sub>2</sub>O. The filtrate was evaporated to give diamine <b>S36</b>, which was purified by flash chromatography using pure EtOAc and CHCl<sub>3</sub>–MeOH saturated with NH<sub>3</sub> (10:1) as eluents). <i>M</i> = 9.13 g. Yield = 55%.</div><div id="sec5_10_30_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i227" class="anchor-spacer"></div><h5 class="article-section__title" id="_i227"> <sup>1</sup>H NMR</h5><div class="NLM_p last">(CDCl<sub>3</sub>, 400 MHz) δ = 0.09 (s, 6 H), 0.92 (s, 9 H), 1.46 (s, 3 H), 1.61 (br. s., 4 H), 2.76 (d, <i>J</i> = 12.8 Hz, 1 H), 3.15 (d, <i>J</i> = 12.8 Hz, 1 H), 4.81 (d, <i>J</i> = 1.2 Hz, 2 H), 7.06 (t, <i>J</i> = 1.2 Hz, 1 H).</div></div><div id="sec5_10_30_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i228" class="anchor-spacer"></div><h5 class="article-section__title" id="_i228"> <sup>13</sup>C NMR</h5><div class="NLM_p last">(CDCl<sub>3</sub>, 100 MHz) δ = −5.2 (2C), 18.5, 26.0 (3C), 28.1, 53.9, 58.1, 62.5, 113.5, 157.3, 179.8.</div></div></div><div id="sec5_10_31" class="NLM_sec NLM_sec_level_3"><div id="ac_i229" class="anchor-spacer"></div><h4 class="article-section__title" id="_i229"> tert-Butyl (2-amino-2-(4-(((tert-butyldimethylsilyl)oxy)methyl)thiazol-2-yl)propyl)carbamate (S37)</h4><div class="NLM_p">To a solution of diamine <b>S36</b> (9.13 g, 30 mmol, 1 equiv) in CH<sub>2</sub>Cl<sub>2</sub> (300 mL), a solution of Boc<sub>2</sub>O (6.93 g, 32 mmol, 1.05 equiv) in CH<sub>2</sub>Cl<sub>2</sub> (300 mL) was added dropwise at 0 °C. The mixture was stirred overnight, and then the solvent was evaporated. The crude product was used in the next step without purification. <i>M</i> = 12.1 g. Yield = 100%.</div><div id="sec5_10_31_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i230" class="anchor-spacer"></div><h5 class="article-section__title" id="_i230"> <sup>1</sup>H NMR</h5><div class="NLM_p last">(CDCl<sub>3</sub>, 400 MHz) δ = 0.11 (s, 6 H), 0.94 (s, 9 H), 1.42 (s, 9 H), 1.48 (s, 3 H), 1.85 (br. s., 2 H), 3.43–3.60 (m, 2 H), 4.80 (d, <i>J</i> = 1.2 Hz, 2 H), 5.07 (br. s., 1 H), 7.09 (t, <i>J</i> = 1.2 Hz, 1 H).</div></div><div id="sec5_10_31_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i231" class="anchor-spacer"></div><h5 class="article-section__title" id="_i231"> <sup>13</sup>C NMR</h5><div class="NLM_p last">(CDCl<sub>3</sub>, 100 MHz) δ = −5.2 (2C), 18.5, 26.0 (3C), 28.2, 28.5 (3C), 51.6, 57.5, 62.4, 79.6, 114.2, 156.6, 157.1, 179.1.</div></div></div><div id="sec5_10_32" class="NLM_sec NLM_sec_level_3"><div id="ac_i232" class="anchor-spacer"></div><h4 class="article-section__title" id="_i232"> General Procedure H: For Amide Coupling</h4><div class="NLM_p last"><i>N</i>,<i>N</i>-Diisopropylethylamine (DIPEA) (1 equiv) was added to an appropriate acid (1 equiv) followed by DMF (10 mL per 1 g of acid) and then <i>N</i>,<i>N</i>,<i>N</i>′,<i>N</i>′-tetramethyl-<i>O</i>-(1<i>H</i>-benzotriazol-1-yl)-uronium hexafluorophosphate (HBTU) (1 equiv). The resulting solution was stirred for 10 min and added to a solution of appropriate amine (1 equiv) in DMF (10 mL per 1 g of amine) in several portions. The reaction mixture was stirred overnight; DMF was evaporated, and the residue was dissolved in DCM (50 mL per 1 g of crude product) and successively washed with 5% aqueous NaOH and 10% tartaric acid solutions (25 mL per 1 g of crude product). The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, evaporated, and dry-loaded on silica. Eluting with hexanes/EtOAc (1:1, then pure EtOAc) gave the target compounds. The products were used in the next step without analysis.</div></div><div id="sec5_10_33" class="NLM_sec NLM_sec_level_3"><div id="ac_i233" class="anchor-spacer"></div><h4 class="article-section__title" id="_i233"> General Procedure I: for Deprotection</h4><div class="NLM_p last">To a solution containing protected compound (1 equiv) and <i>N</i>,<i>N</i>-dimethyl barbituric acid (NDMBA, 3 equiv) in MeOH (0.1 M solution), PPh<sub>3</sub> (10 mol %) was added under a nitrogen atmosphere followed by Pd(dba)<sub>2</sub> (5 mol %). The mixture was stirred for 1 d under reflux. After the mixture cooled, 50 mL of DCM was added, and the organic phase was shaken with 10% aqueous K<sub>2</sub>CO<sub>3</sub> (50 mL) to remove the unreacted NDMBA. The organic layer was separated, and the aqueous layer was extracted with DCM/EtOH (∼4:1, (2–4) × 50 mL). The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. Purification by flash chromatography (eluent: DCM/MeOH (saturated with NH<sub>3</sub> ≈ 7 M), 10:1) afforded amine as a slightly brown or yellowish solid.</div></div><div id="sec5_10_34" class="NLM_sec NLM_sec_level_3"><div id="ac_i234" class="anchor-spacer"></div><h4 class="article-section__title" id="_i234"> N-(2-Amino-1-(5-(hydroxymethyl)thiazol-2-yl)ethyl)-5-(5-chloropyridin-2-yl)-1H-pyrrole-2-carboxamide (1 and 2)</h4><div class="NLM_p">Compounds <b>1</b> and <b>2</b> were obtained following the <b><i>general procedures H</i></b> and <b><i>I</i></b> from amine <b>S39</b> and acid <b>S4b</b>. Compounds were purified using column chromatography on silica gel. The eluent was CHCl<sub>3</sub>–MeOH saturated with NH<sub>3</sub> (10:1 and 5:1).</div><div id="sec5_10_34_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i235" class="anchor-spacer"></div><h5 class="article-section__title" id="_i235"> 1</h5><div class="NLM_p last"><i>M</i> = 507 mg. Yield = 33% (over two steps). rt = 1.035 min. Purity = 100%. LC-MS: <i>m</i>/<i>z</i> [M + H]<sup>+</sup> = 378 Da.</div></div><div id="sec5_10_34_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i236" class="anchor-spacer"></div><h5 class="article-section__title" id="_i236"> 2</h5><div class="NLM_p last"><i>M</i> = 335 mg. Yield = 22% (over two steps). rt = 1.022 min. Purity = 100%. LC-MS: <i>m</i>/<i>z</i> [M + H]<sup>+</sup> = 378 Da.</div></div><div id="sec5_10_34_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i237" class="anchor-spacer"></div><h5 class="article-section__title" id="_i237"> <sup>1</sup>H NMR (DMSO-d<sub>6</sub>, 400 MHz)</h5><div class="NLM_p last">δ = 1.68 (br. s., 2 H), 2.97 (dd, <i>J</i> = 13.2, 7.9 Hz, 1 H), 3.11 (dd, <i>J</i> = 13.3, 5.3 Hz, 1 H), 4.59 (d, <i>J</i> = 4.2 Hz, 2 H), 5.12–5.20 (m, 1 H), 5.46 (t, <i>J</i> = 5.3 Hz, 1 H), 6.88–6.94 (m, 2 H), 7.54 (s, 1 H), 7.89–8.01 (m, 2 H), 8.52–8.64 (m, 1 H), 8.80 (d, <i>J</i> = 7.5 Hz, 1 H), 11.89 (br. s., 1 H).</div></div><div id="sec5_10_34_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i238" class="anchor-spacer"></div><h5 class="article-section__title" id="_i238"> <sup>13</sup>C NMR (DMSO-d<sub>6</sub>, 100 MHz)</h5><div class="NLM_p">δ = 45.8, 54.7, 55.8, 109.7, 114.3, 120.4, 128.4, 128.5, 133.4, 136.9, 139.1, 140.1, 147.6, 148.4, 160.0, 171.8.</div><div class="NLM_p last">High-resolution mass spectrometry (HRMS) electrospray ionization (ESI) calcd for C<sub>16</sub>H<sub>17</sub>ClN<sub>5</sub>O<sub>2</sub>S [M + H]<sup>+</sup> 378.0786, found 378.0787.</div></div></div><div id="sec5_10_35" class="NLM_sec NLM_sec_level_3"><div id="ac_i239" class="anchor-spacer"></div><h4 class="article-section__title" id="_i239"> N-(2-Amino-1-(5-(hydroxymethyl)thiazol-2-yl)ethyl)-5-(5-chloropyridin-2-yl)-3-methyl-1H-pyrrole-2-carboxamide (3 and 4)</h4><div class="NLM_p">Compounds <b>3</b> and <b>4</b> were obtained following the <b><i>general procedures H</i></b> and <b><i>I</i></b> from amine <b>S39</b> and acid <b>S16</b>. Compounds were purified using column chromatography on silica gel. The eluent was CHCl<sub>3</sub>–MeOH saturated with NH<sub>3</sub> (10:1 and 5:1).</div><div id="sec5_10_35_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i240" class="anchor-spacer"></div><h5 class="article-section__title" id="_i240"> 3</h5><div class="NLM_p last"><i>M</i> = 412 mg. Yield = 26% (over two steps). rt = 1.112 min. Purity = 100%. LC-MS: <i>m</i>/<i>z</i> [M + H]<sup>+</sup> = 392 Da.</div></div><div id="sec5_10_35_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i241" class="anchor-spacer"></div><h5 class="article-section__title" id="_i241"> 4</h5><div class="NLM_p last"><i>M</i> = 284 mg. Yield = 18% (over two steps). rt = 1.140 min. Purity = 100%. LC-MS: <i>m</i>/<i>z</i> [M + H]<sup>+</sup> = 392 Da.</div></div><div id="sec5_10_35_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i242" class="anchor-spacer"></div><h5 class="article-section__title" id="_i242"> <sup>1</sup>H NMR (DMSO-d<sub>6</sub>, 400 MHz)</h5><div class="NLM_p last">δ = 2.31 (s, 3 H), 3.00 (dd, <i>J</i> = 13.2, 8.1 Hz, 1 H), 3.13 (dd, <i>J</i> = 13.3, 5.1 Hz, 1 H), 4.60 (s, 2 H), 5.13–5.23 (m, 1 H), 5.49 (br. s., 1 H), 6.76 (s, 1 H), 7.55 (s, 1 H), 7.82–7.87 (m, 1 H), 7.92–7.96 (m, 1 H), 8.59 (d, <i>J</i> = 2.3 Hz, 1 H), 8.76 (d, <i>J</i> = 7.5 Hz, 1 H), 11.80 (br. s., 1 H).</div></div><div id="sec5_10_35_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i243" class="anchor-spacer"></div><h5 class="article-section__title" id="_i243"> <sup>13</sup>C NMR (DMSO-d<sub>6</sub>, 100 MHz)</h5><div class="NLM_p">δ = 13.1, 45.7, 54.2, 55.8, 111.9, 120.4, 123.5, 127.2, 128.4, 131.2, 136.9, 139.1, 140.1, 147.4, 148.3, 160.8, 172.0.</div><div class="NLM_p last">HRMS (ESI) calcd for C<sub>17</sub>H<sub>19</sub>ClN<sub>5</sub>O<sub>2</sub>S [M + H]<sup>+</sup> 392.0942, found 392.0942.</div></div></div><div id="sec5_10_36" class="NLM_sec NLM_sec_level_3"><div id="ac_i244" class="anchor-spacer"></div><h4 class="article-section__title" id="_i244"> N-(2-Amino-1-(5-(hydroxymethyl)thiazol-2-yl)ethyl)-5-(5-(trifluoromethyl)pyridin-2-yl)-1H-pyrrole-2-carboxamide (5 and 6)</h4><div class="NLM_p">Compounds <b>5</b> and <b>6</b> were obtained following the <b><i>general procedures H</i></b> and <b><i>I</i></b> from amine <b>S39</b> and acid <b>S4d</b>. Compounds were purified using column chromatography on silica gel. The eluent was CHCl<sub>3</sub>–MeOH saturated with NH<sub>3</sub> (10:1 and 5:1).</div><div id="sec5_10_36_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i245" class="anchor-spacer"></div><h5 class="article-section__title" id="_i245"> 5</h5><div class="NLM_p last"><i>M</i> = 262 mg. Yield = 38% (over two steps). rt = 1.260 min. Purity = 100%. LC-MS: <i>m</i>/<i>z</i> [M + H]<sup>+</sup> = 412 Da.</div></div><div id="sec5_10_36_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i246" class="anchor-spacer"></div><h5 class="article-section__title" id="_i246"> 6</h5><div class="NLM_p last"><i>M</i> = 162 mg. Yield = 24% (over two steps). rt = 1.265 min. Purity = 100%. LC-MS: <i>m</i>/<i>z</i> [M + H]<sup>+</sup> = 412 Da.</div></div><div id="sec5_10_36_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i247" class="anchor-spacer"></div><h5 class="article-section__title" id="_i247"> <sup>1</sup>H NMR (DMSO-d<sub>6</sub>, 400 MHz)</h5><div class="NLM_p last">δ = 3.02 (dd, <i>J</i> = 13.2, 7.8 Hz, 1 H), 3.15 (dd, <i>J</i> = 13.4, 5.4 Hz, 1 H), 4.62 (s, 2 H), 5.15–5.26 (m, 1 H), 5.51 (br. s., 1 H), 6.99 (d, <i>J</i> = 3.9 Hz, 1 H), 7.05 (d, <i>J</i> = 3.9 Hz, 1 H), 7.56 (s, 1 H), 8.12 (d, <i>J</i> = 8.4 Hz, 1 H), 8.19 (dd, <i>J</i> = 8.6, 2.1 Hz, 1 H), 8.81–8.97 (m, 2 H).</div></div><div id="sec5_10_36_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i248" class="anchor-spacer"></div><h5 class="article-section__title" id="_i248"> <sup>13</sup>C NMR (DMSO-d<sub>6</sub>, 100 MHz)</h5><div class="NLM_p">δ = 45.8, 54.7, 55.8, 111.2, 114.3, 118.9, 122.4 (q, <i>J</i> = 32.1 Hz), 124.0 (q, <i>J</i> = 271.5 Hz), 129.4, 133.1, 134.4 (q, <i>J</i> = 3.2 Hz), 139.1, 140.1, 146.0 (q, <i>J</i> = 4.0 Hz), 153.2, 159.9, 171.7.</div><div class="NLM_p last">HRMS (ESI) calcd for C<sub>17</sub>H<sub>17</sub>F<sub>3</sub>N<sub>5</sub>O<sub>2</sub>S [M + H]<sup>+</sup> 412.1050, found 412.1048.</div></div></div><div id="sec5_10_37" class="NLM_sec NLM_sec_level_3"><div id="ac_i249" class="anchor-spacer"></div><h4 class="article-section__title" id="_i249"> N-(2-Amino-1-(5-(hydroxymethyl)thiazol-2-yl)ethyl)-3-methyl-5-(5-(trifluoromethyl)pyridin-2-yl)-1H-pyrrole-2-carboxamide (7 and 8)</h4><div class="NLM_p">Compounds <b>8</b> and <b>7</b> were obtained following the <b><i>general procedures H</i></b> and <b><i>I</i></b> from amine <b>S39</b> and the sodium salt <b>S15</b>. Compounds were purified using column chromatography on silica gel. The eluent was CHCl<sub>3</sub>–MeOH saturated with NH<sub>3</sub> (10:1 and 5:1).</div><div id="sec5_10_37_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i250" class="anchor-spacer"></div><h5 class="article-section__title" id="_i250"> 8</h5><div class="NLM_p last"><i>M</i> = 358 mg. Yield = 40% (over two steps). rt = 1.202 min. Purity = 100%. LC-MS: <i>m</i>/<i>z</i> [M + H]<sup>+</sup> = 426 Da.</div></div><div id="sec5_10_37_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i251" class="anchor-spacer"></div><h5 class="article-section__title" id="_i251"> 7</h5><div class="NLM_p last"><i>M</i> = 253 mg. Yield = 28% (over two steps). rt = 1.208 min. Purity = 100%. LC-MS: <i>m</i>/<i>z</i> [M + H]<sup>+</sup> = 426 Da.</div></div><div id="sec5_10_37_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i252" class="anchor-spacer"></div><h5 class="article-section__title" id="_i252"> <sup>1</sup>H NMR (DMSO-d<sub>6</sub>, 400 MHz)</h5><div class="NLM_p last">δ = 1.93 (br. s., 2 H), 2.33 (s, 3 H), 3.00 (dd, <i>J</i> = 13.2, 8.0 Hz, 1 H), 3.12 (dd, <i>J</i> = 13.3, 5.1 Hz, 1 H), 4.61 (s, 2 H), 5.13–5.22 (m, 1 H), 5.50 (br. s., 1 H), 6.91 (s, 1 H), 7.56 (s, 1 H), 8.00 (d, <i>J</i> = 8.4 Hz, 1 H), 8.19 (dd, <i>J</i> = 8.5, 2.1 Hz, 1 H), 8.80 (d, <i>J</i> = 7.2 Hz, 1 H), 8.89 (s, 1 H), 12.00 (br. s., 1 H).</div></div><div id="sec5_10_37_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i253" class="anchor-spacer"></div><h5 class="article-section__title" id="_i253"> <sup>13</sup>C NMR (DMSO-d<sub>6</sub>, 100 MHz)</h5><div class="NLM_p">δ = 13.1, 45.7, 54.2, 55.8, 113.4, 119.0, 122.3 (q, <i>J</i> = 32.4 Hz), 124.0 (q, <i>J</i> = 271.8 Hz), 124.6, 127.3, 130.9, 134.4 (q, <i>J</i> = 3.3 Hz), 139.1, 140.1, 145.8 (q, <i>J</i> = 4.1 Hz), 153.1 (q, <i>J</i> = 1.1 Hz), 160.8, 171.8.</div><div class="NLM_p last">HRMS (ESI) calcd for C<sub>18</sub>H<sub>19</sub>F<sub>3</sub>N<sub>5</sub>O<sub>2</sub>S [M + H]<sup>+</sup> 426.1206, found 426.1216.</div></div></div><div id="sec5_10_38" class="NLM_sec NLM_sec_level_3"><div id="ac_i254" class="anchor-spacer"></div><h4 class="article-section__title" id="_i254"> N-(2-Amino-1-(5-(hydroxymethyl)thiazol-2-yl)-2-methylpropyl)-5-(5-(trifluoromethyl)pyridin-2-yl)-1H-pyrrole-2-carboxamide (9 and 10)</h4><div class="NLM_p">Compounds <b>9</b> and <b>10</b> were obtained following the <b><i>general procedures H</i></b> and <b><i>I</i></b> from amine <b>S45</b> and acid <b>S4d</b>. Compounds were purified using column chromatography on silica gel. The eluent was CHCl<sub>3</sub>–MeOH saturated with NH<sub>3</sub> (20:1 and 10:1).</div><div id="sec5_10_38_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i255" class="anchor-spacer"></div><h5 class="article-section__title" id="_i255"> 9</h5><div class="NLM_p last"><i>M</i> = 434 mg. Yield = 25% (over two steps). rt = 1.204 min. Purity = 100%. LC-MS: <i>m</i>/<i>z</i> [M + H]<sup>+</sup> = 440 Da.</div></div><div id="sec5_10_38_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i256" class="anchor-spacer"></div><h5 class="article-section__title" id="_i256"> 10</h5><div class="NLM_p last"><i>M</i> = 252 mg. Yield = 15% (over two steps). rt = 1.218 min. Purity = 96%. LC-MS: <i>m</i>/<i>z</i> [M + H]<sup>+</sup> = 440 Da.</div></div><div id="sec5_10_38_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i257" class="anchor-spacer"></div><h5 class="article-section__title" id="_i257"> <sup>1</sup>H NMR (DMSO-d<sub>6</sub>, 400 MHz)</h5><div class="NLM_p last">δ = 1.10 (s, 3 H), 1.14 (s, 3 H), 4.63 (s, 2 H), 5.29 (d, <i>J</i> = 4.9 Hz, 1 H), 5.51 (br. s., 1 H), 6.96 (d, <i>J</i> = 3.9 Hz, 1 H), 7.05 (d, <i>J</i> = 3.8 Hz, 1 H), 7.58 (s, 1 H), 8.11 (d, <i>J</i> = 8.4 Hz, 1 H), 8.20 (dd, <i>J</i> = 8.4, 2.2 Hz, 1 H), 8.64 (d, <i>J</i> = 7.2 Hz, 1 H), 8.88–8.92 (m, 1 H).</div></div><div id="sec5_10_38_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i258" class="anchor-spacer"></div><h5 class="article-section__title" id="_i258"> <sup>13</sup>C NMR (DMSO-d<sub>6</sub>, 100 MHz)</h5><div class="NLM_p">δ = 27.6, 28.3, 52.8, 55.8, 59.7, 111.2, 115.1, 119.1, 122.4 (q, <i>J</i> = 32.2 Hz), 124.0 (q, <i>J</i> = 272.1 Hz), 129.3, 133.2, 134.5 (q, <i>J</i> = 3.2 Hz), 138.7, 140.3, 145.9 (q, <i>J</i> = 4.1 Hz), 153.3, 159.4, 169.9.</div><div class="NLM_p last">HRMS (ESI) calcd for C<sub>19</sub>H<sub>21</sub>F<sub>3</sub>N<sub>5</sub>O<sub>2</sub>S [M + H]<sup>+</sup> 440.1363, found 440.1359.</div></div></div><div id="sec5_10_39" class="NLM_sec NLM_sec_level_3"><div id="ac_i259" class="anchor-spacer"></div><h4 class="article-section__title" id="_i259"> N-(2-Amino-1-(5-(hydroxymethyl)thiazol-2-yl)-2-methylpropyl)-3-methyl-5-(5-(trifluoro-methyl)pyridin-2-yl)-1H-pyrrole-2-carboxamide (11 and 12)</h4><div class="NLM_p">Compounds <b>11</b> and <b>12</b> were obtained following the <b><i>general procedures H</i></b> and <b><i>I</i></b> from amine <b>S45</b> and the sodium salt <b>S15</b>. Compounds were purified using column chromatography on silica gel. The eluent was CHCl<sub>3</sub>–MeOH saturated with NH<sub>3</sub> (20:1 and 10:1).</div><div id="sec5_10_39_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i260" class="anchor-spacer"></div><h5 class="article-section__title" id="_i260"> 11</h5><div class="NLM_p last"><i>M</i> = 609 mg. Yield = 32% (over two steps). rt = 1.268 min. Purity = 100%. LC-MS: <i>m</i>/<i>z</i> [M + H]<sup>+</sup> = 454 Da.</div></div><div id="sec5_10_39_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i261" class="anchor-spacer"></div><h5 class="article-section__title" id="_i261"> 12</h5><div class="NLM_p last"><i>M</i> = 674 mg. Yield = 33% (over two steps). rt = 1.306 min. Purity = 100%. LC-MS: <i>m</i>/<i>z</i> [M + H]<sup>+</sup> = 454 Da.</div></div><div id="sec5_10_39_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i262" class="anchor-spacer"></div><h5 class="article-section__title" id="_i262"> <sup>1</sup>H NMR (DMSO-d<sub>6</sub>, 400 MHz)</h5><div class="NLM_p last">δ = 1.09 (s, 3 H), 1.14 (s, 3 H), 2.32 (s, 3 H), 4.63 (d, <i>J</i> = 3.5 Hz, 2 H), 5.28 (s, 1 H), 5.45–5.56 (m, 1 H), 6.91 (s, 1 H), 7.58 (s, 1 H), 8.00 (d, <i>J</i> = 8.4 Hz, 1 H), 8.19 (dd, <i>J</i> = 8.6, 2.2 Hz, 1 H), 8.50 (br. s., 1 H), 8.86–8.92 (m, 1 H), 12.24 (br. s., 1 H).</div></div><div id="sec5_10_39_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i263" class="anchor-spacer"></div><h5 class="article-section__title" id="_i263"> <sup>13</sup>C NMR (DMSO-d<sub>6</sub>, 100 MHz)</h5><div class="NLM_p">δ = 13.4, 27.6, 28.1, 52.9, 55.8, 59.2, 113.6, 119.2, 122.3 (q, <i>J</i> = 32.3 Hz), 124.0 (q, <i>J</i> = 271.8 Hz) 124.5, 127.5, 131.0, 134.4 (q, <i>J</i> = 3.1 Hz), 138.7, 140.3, 145.8 (q, <i>J</i> = 4.1 Hz), 153.2, 160.4, 170.1.</div><div class="NLM_p last">HRMS (ESI) calcd for C<sub>20</sub>H<sub>23</sub>F<sub>3</sub>N<sub>5</sub>O<sub>2</sub>S [M + H]<sup>+</sup> 454.1519, found 454.1519.</div></div></div><div id="sec5_10_40" class="NLM_sec NLM_sec_level_3"><div id="ac_i264" class="anchor-spacer"></div><h4 class="article-section__title" id="_i264"> N-(2-Amino-1-(5-(1,2-dihydroxyethyl)thiazol-2-yl)ethyl)-5-(5-(trifluoromethyl)pyridin-2-yl)-1H-pyrrole-2-carboxamide (13 and 14)</h4><div class="NLM_p">Compounds <b>13</b> and were <b>14</b> obtained from amine <b>S23</b> and acid <b>S4d</b>, following in sequence the <b><i>general procedures H</i></b>, <b><i>I</i></b>, and the TBDPS cleavage as described below. Compounds were purified using column chromatography on silica gel. The eluent was CHCl<sub>3</sub>–MeOH saturated with NH<sub>3</sub> (10:1 and 5:1).</div><div class="NLM_p">TBDPS cleavage: To a solution of TBDPS-protected compound (1 equiv) in THF (0.1M), a solution of tetra-<i>n</i>-butylammonium fluoride (TBAF) trihydrate (1.1 equiv) in THF (0.1M) was added in one portion. The mixture was stirred for 1–2 h at room temperature (TLC-control) and concentrated. Purification was done by flash chromatography using CHCl<sub>3</sub>-MeOH saturated with NH<sub>3</sub> mixture (5:1 and 3:1) as eluent.</div><div class="NLM_p">Note that compounds <b>13</b> & <b>14</b> were obtained as a diastereisomeric mixture of two single compounds having the absolute configuration of the chiral carbon <b>a</b> as fR for <b>13</b> and fS for <b>14</b>.</div><div id="sec5_10_40_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i265" class="anchor-spacer"></div><h5 class="article-section__title" id="_i265"> 13</h5><div class="NLM_p last"><i>M</i> = 221 mg. Yield = 27% (over three steps). rt = 1.107 min. Purity = 97%. LC-MS: <i>m</i>/<i>z</i> [M + H]<sup>+</sup> = 442 Da.</div></div><div id="sec5_10_40_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i266" class="anchor-spacer"></div><h5 class="article-section__title" id="_i266"> 14</h5><div class="NLM_p last"><i>M</i> = 485 mg. Yield = 41% (over three steps). rt = 1.160 min. Purity = 100%. LC-MS: <i>m</i>/<i>z</i> [M + H]<sup>+</sup> = 442 Da.</div></div><div id="sec5_10_40_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i267" class="anchor-spacer"></div><h5 class="article-section__title" id="_i267"> <sup>1</sup>H NMR (DMSO-d<sub>6</sub>, 400 MHz)</h5><div class="NLM_p last">δ = 2.99 (dd, 1 H), 3.13 (dd, <i>J</i> = 13.2, 5.2 Hz, 1 H), 3.42 (ddd, <i>J</i> = 10.7, 5.7, 2.4 Hz, 1 H), 3.50 (dd, <i>J</i> = 10.8, 6.1 Hz, 1 H), 4.75 (t, <i>J</i> = 5.8 Hz, 1 H), 4.96 (br. s., 1 H), 5.14–5.24 (m, 1 H), 5.71 (br. s., 1 H), 6.98 (d, <i>J</i> = 3.9 Hz, 1 H), 7.05 (d, <i>J</i> = 3.9 Hz, 1 H), 7.57 (s, 1 H), 8.13 (d, <i>J</i> = 8.4 Hz, 1 H), 8.20 (dd, <i>J</i> = 8.6, 2.1 Hz, 1 H), 8.83–8.93 (m, 2 H).</div></div><div id="sec5_10_40_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i268" class="anchor-spacer"></div><h5 class="article-section__title" id="_i268"> <sup>13</sup>C NMR (DMSO-d<sub>6</sub>, 100 MHz)</h5><div class="NLM_p">δ = (45.8, 45.8), 54.6, 66.7, (68.1, 68.1), 111.3, 114.3, 119.0, 122.4 (q, <i>J</i> = 32.3 Hz), 124.0 (q, <i>J</i> = 271.8 Hz), 129.4, 133.2, 134.5 (q, <i>J</i> = 3.3 Hz), (138.6, 138.6), (141.4, 141.4), 146.0 (q, <i>J</i> = 4.1 Hz), (153.2, 153.2), 159.9, (171.0, 171.1).</div><div class="NLM_p last">HRMS (ESI) calcd for C<sub>18</sub>H<sub>19</sub>F<sub>3</sub>N<sub>5</sub>O<sub>3</sub>S [M + H]<sup>+</sup> 442.1155, found 442.1155.</div></div></div><div id="sec5_10_41" class="NLM_sec NLM_sec_level_3"><div id="ac_i269" class="anchor-spacer"></div><h4 class="article-section__title" id="_i269"> N-(2-Amino-1-(4-(hydroxymethyl)thiazol-2-yl)ethyl)-5-(5-chloropyridin-2-yl)-1H-pyrrole-2-carboxamide (15 and 16)</h4><div class="NLM_p">Compounds <b>15</b> and <b>16</b> were obtained following the <b><i>general procedures H</i></b> and <b><i>I</i></b> from amine <b>S38</b> and acid <b>S4b</b>. Compounds were purified using column chromatography on silica gel. The eluent was CHCl<sub>3</sub>-MeOH saturated with NH<sub>3</sub> (10:1 and 5:1).</div><div id="sec5_10_41_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i270" class="anchor-spacer"></div><h5 class="article-section__title" id="_i270"> 15</h5><div class="NLM_p last"><i>M</i> = 518 mg. Yield = 34% (over two steps). rt = 1.074 min. Purity = 100%. LC-MS: <i>m</i>/<i>z</i> [M + H]<sup>+</sup> = 378 Da.</div></div><div id="sec5_10_41_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i271" class="anchor-spacer"></div><h5 class="article-section__title" id="_i271"> 16</h5><div class="NLM_p last"><i>M</i> = 381 mg. Yield = 25% (over two steps). rt = 1.079 min. Purity = 100%. LC-MS: <i>m</i>/<i>z</i> [M + H]<sup>+</sup> = 378 Da.</div></div><div id="sec5_10_41_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i272" class="anchor-spacer"></div><h5 class="article-section__title" id="_i272"> <sup>1</sup>H NMR (DMSO-d<sub>6</sub>, 400 MHz)</h5><div class="NLM_p last">δ = 1.73 (br. s., 2 H), 2.99 (dd, <i>J</i> = 13.2, 7.8 Hz, 1 H), 3.12 (dd, <i>J</i> = 13.2, 5.3 Hz, 1 H), 4.54 (s, 2 H), 5.17–5.24 (m, 1 H), 5.30 (br. s., 1 H), 6.85–6.97 (m, 2 H), 7.29 (s, 1 H), 7.89–8.00 (m, 2 H), 8.59 (s, 1 H), 8.83 (d, <i>J</i> = 7.7 Hz, 1 H), 11.91 (br. s., 1 H).</div></div><div id="sec5_10_41_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i273" class="anchor-spacer"></div><h5 class="article-section__title" id="_i273"> <sup>13</sup>C NMR (DMSO-d<sub>6</sub>, 100 MHz)</h5><div class="NLM_p">δ = 45.8, 54.3, 59.8, 109.7, 114.2, 114.3, 120.4, 128.4, 128.6, 133.5, 136.9, 147.6, 148.4, 157.7, 160.0, 172.0.</div><div class="NLM_p last">HRMS (ESI) calcd for C<sub>16</sub>H<sub>17</sub>ClN<sub>5</sub>O<sub>2</sub>S [M + H]<sup>+</sup> 378.0786, found 378.0786.</div></div></div><div id="sec5_10_42" class="NLM_sec NLM_sec_level_3"><div id="ac_i274" class="anchor-spacer"></div><h4 class="article-section__title" id="_i274"> N-(2-Amino-1-(4-(hydroxymethyl)thiazol-2-yl)ethyl)-5-(5-fluoropyridin-2-yl)-1H-pyrrole-2-carboxamide (17 and 18)</h4><div class="NLM_p">Compounds <b>17</b> and <b>18</b> were obtained following the <b><i>general procedures H</i></b> and <b><i>I</i></b> from amine <b>S38</b> and acid <b>S4c</b>. Compounds were purified using column chromatography on silica gel. The eluent was CHCl<sub>3</sub>-MeOH saturated with NH<sub>3</sub> (10:1 and 5:1).</div><div id="sec5_10_42_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i275" class="anchor-spacer"></div><h5 class="article-section__title" id="_i275"> 17</h5><div class="NLM_p last"><i>M</i> = 420 mg. Yield = 31% (over two steps). rt = 0.987 min. Purity = 100%. LC-MS: <i>m</i>/<i>z</i> [M + H]<sup>+</sup> = 362 Da.</div></div><div id="sec5_10_42_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i276" class="anchor-spacer"></div><h5 class="article-section__title" id="_i276"> 18</h5><div class="NLM_p last"><i>M</i> = 325 mg. Yield = 24% (over two steps). rt = 1.001 min. Purity = 96%. LC-MS: <i>m</i>/<i>z</i> [M + H]<sup>+</sup> = 362 Da.</div></div><div id="sec5_10_42_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i277" class="anchor-spacer"></div><h5 class="article-section__title" id="_i277"> <sup>1</sup>H NMR (DMSO-d<sub>6</sub>, 400 MHz)</h5><div class="NLM_p last">δ = 1.78 (br. s., 2 H), 2.99 (dd, <i>J</i> = 13.2, 7.8 Hz, 1 H), 3.12 (dd, <i>J</i> = 13.2, 5.3 Hz, 1 H), 4.54 (d, <i>J</i> = 3.0 Hz, 2 H), 5.17–5.24 (m, 1 H), 5.30 (br. s., 1 H), 6.84 (d, <i>J</i> = 3.9 Hz, 1 H), 6.92 (d, <i>J</i> = 3.8 Hz, 1 H), 7.28 (s, 1 H), 7.77 (td, <i>J</i> = 8.8, 2.9 Hz, 1 H), 7.99 (dd, <i>J</i> = 8.9, 4.4 Hz, 1 H), 8.55 (d, <i>J</i> = 2.9 Hz, 1 H), 8.80 (d, <i>J</i> = 7.8 Hz, 1 H), 11.82 (br. s., 1 H).</div></div><div id="sec5_10_42_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i278" class="anchor-spacer"></div><h5 class="article-section__title" id="_i278"> <sup>13</sup>C NMR (DMSO-d<sub>6</sub>, 100 MHz)</h5><div class="NLM_p">δ = 45.9, 54.4, 59.8, 109.0, 114.1, 114.2, 120.6 (d, <i>J</i> = 4.6 Hz), 124.3 (d, <i>J</i> = 19.0 Hz), 128.0, 133.7, 137.0 (d, <i>J</i> = 24.0 Hz), 146.6 (d, <i>J</i> = 3.7 Hz), 157.7, 157.9 (d, <i>J</i> = 252.5 Hz), 160.1, 172.1.</div><div class="NLM_p last">HRMS (ESI) calcd for C<sub>16</sub>H<sub>17</sub>FN<sub>5</sub>O<sub>2</sub>S [M + H]<sup>+</sup> 362.1081, found 362.1080.</div></div></div><div id="sec5_10_43" class="NLM_sec NLM_sec_level_3"><div id="ac_i279" class="anchor-spacer"></div><h4 class="article-section__title" id="_i279"> N-(2-Amino-1-(4-(hydroxymethyl)thiazol-2-yl)ethyl)-5-(5-methylpyridin-2-yl)-1H-pyrrole-2-carboxamide (19 and 20)</h4><div class="NLM_p">Compounds <b>19</b> and <b>20</b> were obtained following the <b><i>general procedures H</i></b> and <b><i>I</i></b> from amine <b>S38</b> and acid <b>S4a</b>. Compounds were purified using column chromatography on silica gel. The eluent was CHCl<sub>3</sub>-MeOH saturated with NH<sub>3</sub> (10:1 and 5:1).</div><div id="sec5_10_43_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i280" class="anchor-spacer"></div><h5 class="article-section__title" id="_i280"> 19</h5><div class="NLM_p last"><i>M</i> = 357 mg. Yield = 35% (over two steps). rt = 0.829 min. Purity = 100%. LC-MS: <i>m</i>/<i>z</i> [M + H]<sup>+</sup> = 358 Da.</div></div><div id="sec5_10_43_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i281" class="anchor-spacer"></div><h5 class="article-section__title" id="_i281"> 20</h5><div class="NLM_p last"><i>M</i> = 254 mg. Yield = 25% (over two steps). rt = 0.773 min. Purity = 100%. LC-MS: <i>m</i>/<i>z</i> [M + H]<sup>+</sup> = 358 Da.</div></div><div id="sec5_10_43_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i282" class="anchor-spacer"></div><h5 class="article-section__title" id="_i282"> <sup>1</sup>H NMR (DMSO-d<sub>6</sub>, 400 MHz)</h5><div class="NLM_p last">δ = 1.71 (br. s., 2 H), 2.30 (s, 3 H), 2.99 (dd, <i>J</i> = 13.2, 7.8 Hz, 1 H), 3.12 (dd, <i>J</i> = 13.2, 5.3 Hz, 1 H), 4.54 (s, 2 H), 5.16–5.25 (m, 1 H), 5.32 (br. s., 1 H), 6.81 (d, <i>J</i> = 3.8 Hz, 1 H), 6.90 (d, <i>J</i> = 3.8 Hz, 1 H), 7.29 (s, 1 H), 7.63 (dd, <i>J</i> = 8.2, 2.0 Hz, 1 H), 7.79 (d, <i>J</i> = 8.1 Hz, 1 H), 8.41 (d, <i>J</i> = 1.7 Hz, 1 H), 8.82 (d, <i>J</i> = 7.8 Hz, 1 H), 11.78 (br. s., 1 H).</div></div><div id="sec5_10_43_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i283" class="anchor-spacer"></div><h5 class="article-section__title" id="_i283"> <sup>13</sup>C NMR (DMSO-d<sub>6</sub>, 100 MHz)</h5><div class="NLM_p">δ = 17.8, 46.0, 54.5, 59.8, 108.3, 114.0, 114.3, 118.7, 127.4, 131.0, 134.6, 137.4, 147.2, 149.2, 157.6, 160.0, 172.2.</div><div class="NLM_p last">HRMS (ESI) calcd for C<sub>17</sub>H<sub>20</sub>N<sub>5</sub>O<sub>2</sub>S [M + H]<sup>+</sup> 358.1332, found 358.1337.</div></div></div><div id="sec5_10_44" class="NLM_sec NLM_sec_level_3"><div id="ac_i284" class="anchor-spacer"></div><h4 class="article-section__title" id="_i284"> N-(2-Amino-1-(4-(hydroxymethyl)thiazol-2-yl)ethyl)-5-(5-(trifluoromethyl)pyridin-2-yl)-1H-pyrrole-2-carboxamide (21 and 22)</h4><div class="NLM_p">Compounds <b>21</b> and <b>22</b> were obtained following the <b><i>general procedures H</i></b> and <b><i>I</i></b> from amine <b>S38</b> and acid <b>S4d</b>. Compounds were purified using column chromatography on silica gel. The eluent was CHCl<sub>3</sub>-MeOH saturated with NH<sub>3</sub> (10:1 and 5:1).</div><div id="sec5_10_44_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i285" class="anchor-spacer"></div><h5 class="article-section__title" id="_i285"> 21</h5><div class="NLM_p last"><i>M</i> = 410 mg. Yield = 41% (over two steps). rt = 1.269 min. Purity = 100%. LC-MS: <i>m</i>/<i>z</i> [M + H]<sup>+</sup> = 412 Da.</div></div><div id="sec5_10_44_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i286" class="anchor-spacer"></div><h5 class="article-section__title" id="_i286"> 22</h5><div class="NLM_p last"><i>M</i> = 312 mg. Yield = 32% (over two steps). rt = 1.266 min. Purity = 100%. LC-MS: <i>m</i>/<i>z</i> [M + H]<sup>+</sup> = 412 Da.</div></div><div id="sec5_10_44_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i287" class="anchor-spacer"></div><h5 class="article-section__title" id="_i287"> <sup>1</sup>H NMR (DMSO-d<sub>6</sub>, 400 MHz)</h5><div class="NLM_p last">δ = 3.00 (dd, <i>J</i> = 13.2, 7.8 Hz, 1 H), 3.14 (dd, <i>J</i> = 13.2, 5.3 Hz, 1 H), 4.55 (s, 2 H), 5.18–5.26 (m, 1 H), 5.32 (br. s., 1 H), 6.98 (d, <i>J</i> = 3.8 Hz, 1 H), 7.05 (d, <i>J</i> = 3.9 Hz, 1 H), 7.29 (s, 1 H), 8.13 (d, <i>J</i> = 8.4 Hz, 1 H), 8.20 (dd, <i>J</i> = 8.6, 1.7 Hz, 1 H), 8.84–8.96 (m, 2 H).</div></div><div id="sec5_10_44_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i288" class="anchor-spacer"></div><h5 class="article-section__title" id="_i288"> <sup>13</sup>C NMR (DMSO-d<sub>6</sub>, 100 MHz)</h5><div class="NLM_p">δ = 45.9, 54.4, 59.8, 111.2, 114.1, 114.3, 118.9, 122.3 (q, <i>J</i> = 32.2 Hz), 124.0 (q, <i>J</i> = 272.2 Hz), 129.4, 133.1, 134.4 (q, <i>J</i> = 2.9 Hz), 146.0 (q, <i>J</i> = 3.7 Hz), 153.2, 157.7, 159.8, 171.8.</div><div class="NLM_p last">HRMS (ESI) calcd for C<sub>17</sub>H<sub>17</sub>F<sub>3</sub>N<sub>5</sub>O<sub>2</sub>S [M + H]<sup>+</sup> 412.1050, found 412.1056.</div></div></div><div id="sec5_10_45" class="NLM_sec NLM_sec_level_3"><div id="ac_i289" class="anchor-spacer"></div><h4 class="article-section__title" id="_i289"> N-(2-Amino-1-(4-(hydroxymethyl)thiazol-2-yl)-2-methylpropyl)-5-(5-(trifluoromethyl)pyridin-2-yl)-1H-pyrrole-2-carboxamide (23 and 24)</h4><div class="NLM_p">Compounds <b>23</b> and <b>24</b> were obtained following the <b><i>general procedures H</i></b> and <b><i>I</i></b> from amine <b>S44</b> and acid <b>S4d</b>. Compounds were purified using column chromatography on silica gel. The eluent was CHCl<sub>3</sub>-MeOH saturated with NH<sub>3</sub> (20:1 and 10:1).</div><div id="sec5_10_45_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i290" class="anchor-spacer"></div><h5 class="article-section__title" id="_i290"> 23</h5><div class="NLM_p last"><i>M</i> = 321 mg. Yield = 26% (over two steps). rt = 1.248 min. Purity = 100%. LC-MS: <i>m</i>/<i>z</i> [M + H]<sup>+</sup> = 440 Da.</div></div><div id="sec5_10_45_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i291" class="anchor-spacer"></div><h5 class="article-section__title" id="_i291"> 24</h5><div class="NLM_p last"><i>M</i> = 208 mg. Yield = 17% (over two steps). rt = 1.234 min. Purity = 100%. LC-MS: <i>m</i>/<i>z</i> [M + H]<sup>+</sup> = 440 Da.</div></div><div id="sec5_10_45_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i292" class="anchor-spacer"></div><h5 class="article-section__title" id="_i292"> <sup>1</sup>H NMR (DMSO-d<sub>6</sub>, 400 MHz)</h5><div class="NLM_p last">δ = 1.08 (s, 3 H), 1.13 (s, 3 H), 4.57 (s, 2 H), 5.10–5.50 (m, 2 H), 6.96 (d, <i>J</i> = 3.9 Hz, 1 H), 7.05 (d, <i>J</i> = 3.9 Hz, 1 H), 7.32 (s, 1 H), 8.09 (d, <i>J</i> = 8.4 Hz, 1 H), 8.18 (dd, <i>J</i> = 8.6, 2.1 Hz, 1 H), 8.65 (d, <i>J</i> = 7.2 Hz, 1 H), 8.87–8.91 (m, 1 H).</div></div><div id="sec5_10_45_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i293" class="anchor-spacer"></div><h5 class="article-section__title" id="_i293"> <sup>13</sup>C NMR (DMSO-d<sub>6</sub>, 100 MHz)</h5><div class="NLM_p">δ = 27.5, 28.3, 52.8, 59.4, 59.8, 111.2, 114.4, 115.1, 119.1, 122.4 (q, <i>J</i> = 32.2 Hz), 124.0 (q, <i>J</i> = 271.6 Hz), 129.3, 133.2, 134.5 (q, <i>J</i> = 3.2 Hz), 145.9 (q, <i>J</i> = 4.1 Hz), 153.3, 157.3, 159.4, 169.9.</div><div class="NLM_p last">HRMS (ESI) calcd for C<sub>19</sub>H<sub>21</sub>F<sub>3</sub>N<sub>5</sub>O<sub>2</sub>S [M + H]<sup>+</sup> 440.1363, found 440.1359.</div></div></div><div id="sec5_10_46" class="NLM_sec NLM_sec_level_3"><div id="ac_i294" class="anchor-spacer"></div><h4 class="article-section__title" id="_i294"> N-(2-Amino-1-(4-(2-hydroxyethyl)thiazol-2-yl)ethyl)-5-(5-(trifluoromethyl)pyridin-2-yl)-1H-pyrrole-2-carboxamide (25 and 26)</h4><div class="NLM_p">Compounds and <b>25</b> and <b>26</b> were obtained following the <b><i>general procedures H</i></b> and <b><i>I</i></b> from amine <b>S41</b> and acid <b>S4d</b>. Compounds were purified using column chromatography on silica gel. The eluent was CHCl<sub>3</sub>-MeOH saturated with NH<sub>3</sub> (10:1 and 5:1).</div><div id="sec5_10_46_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i295" class="anchor-spacer"></div><h5 class="article-section__title" id="_i295"> 25</h5><div class="NLM_p last"><i>M</i> = 490 mg. Yield = 43% (over two steps). rt = 1.198 min. Purity = 100%. LC-MS: <i>m</i>/<i>z</i> [M + H]<sup>+</sup> = 426 Da.</div></div><div id="sec5_10_46_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i296" class="anchor-spacer"></div><h5 class="article-section__title" id="_i296"> 26</h5><div class="NLM_p last"><i>M</i> = 368 mg. Yield = 32% (over two steps). rt = 1.153 min. Purity = 100%. LC-MS: <i>m</i>/<i>z</i> [M + H]<sup>+</sup> = 426 Da.</div></div><div id="sec5_10_46_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i297" class="anchor-spacer"></div><h5 class="article-section__title" id="_i297"> <sup>1</sup>H NMR (DMSO-d<sub>6</sub>, 400 MHz)</h5><div class="NLM_p last">δ = 2.85 (t, <i>J</i> = 6.9 Hz, 2 H), 3.01 (dd, <i>J</i> = 13.2, 7.8 Hz, 1 H), 3.15 (dd, <i>J</i> = 13.2, 5.1 Hz, 1 H), 3.71 (t, <i>J</i> = 6.8 Hz, 2 H), 4.69 (br. s., 1 H), 5.19–5.27 (m, 1 H), 6.99 (d, <i>J</i> = 3.8 Hz, 1 H), 7.05 (d, <i>J</i> = 3.8 Hz, 1 H), 7.18 (s, 1 H), 8.12 (d, <i>J</i> = 8.4 Hz, 1 H), 8.19 (dd, <i>J</i> = 8.4, 1.7 Hz, 1 H), 8.89 (s, 2 H).</div></div><div id="sec5_10_46_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i298" class="anchor-spacer"></div><h5 class="article-section__title" id="_i298"> <sup>13</sup>C NMR (DMSO-d<sub>6</sub>, 100 MHz)</h5><div class="NLM_p">δ = 34.9, 46.0, 54.6, 60.2, 111.2, 114.1, 114.3, 118.9, 122.3 (q, <i>J</i> = 32.4 Hz), 124.0 (q, <i>J</i> = 271.8 Hz), 129.4, 133.1, 134.4 (q, <i>J</i> = 3.3 Hz), 146.0 (q, <i>J</i> = 4.2 Hz), 153.2 (q, <i>J</i> = 1.1 Hz), 154.1, 159.9, 171.3.</div><div class="NLM_p last">HRMS (ESI) calcd for C<sub>18</sub>H<sub>19</sub>F<sub>3</sub>N<sub>5</sub>O<sub>2</sub>S [M + H]<sup>+</sup> 426.1206, found 426.1204.</div></div></div><div id="sec5_10_47" class="NLM_sec NLM_sec_level_3"><div id="ac_i299" class="anchor-spacer"></div><h4 class="article-section__title" id="_i299"> N-(2-Amino-1-(4-(3-hydroxypropyl)thiazol-2-yl)ethyl)-5-(5-(trifluoromethyl)pyridin-2-yl)-1H-pyrrole-2-carboxamide (27 and 28)</h4><div class="NLM_p">Compounds <b>27</b> and <b>28</b> were obtained following the <b><i>general proceduresH</i></b> and <b><i>I</i></b> from amine <b>S42</b> and acid <b>S4d</b>. Compounds were purified using column chromatography on silica gel. The eluent was CHCl<sub>3</sub>-MeOH saturated with NH<sub>3</sub> (10:1 and 5:1).</div><div id="sec5_10_47_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i300" class="anchor-spacer"></div><h5 class="article-section__title" id="_i300"> 27</h5><div class="NLM_p last"><i>M</i> = 483 mg. Yield = 34% (over two steps). rt = 1.226 min. Purity = 100%. LC-MS: <i>m</i>/<i>z</i> [M + H]<sup>+</sup> = 440 Da.</div></div><div id="sec5_10_47_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i301" class="anchor-spacer"></div><h5 class="article-section__title" id="_i301"> 28</h5><div class="NLM_p last"><i>M</i> = 727 mg. Yield = 39% (over two steps). rt = 1.220 min. Purity = 100%. LC-MS: <i>m</i>/<i>z</i> [M + H]<sup>+</sup> = 440 Da.</div></div><div id="sec5_10_47_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i302" class="anchor-spacer"></div><h5 class="article-section__title" id="_i302"> <sup>1</sup>H NMR (DMSO-d<sub>6</sub>, 400 MHz)</h5><div class="NLM_p last">δ = 1.73–1.83 (m, 2 H), 2.71 (t, <i>J</i> = 7.7 Hz, 2 H), 2.99 (dd, <i>J</i> = 13.2, 7.9 Hz, 1 H), 3.13 (dd, <i>J</i> = 13.2, 5.1 Hz, 1 H), 3.44 (t, <i>J</i> = 6.3 Hz, 2 H), 4.50 (br. s., 1 H), 5.17–5.24 (m, 1 H), 6.98 (d, <i>J</i> = 3.9 Hz, 1 H), 7.06 (d, <i>J</i> = 3.9 Hz, 1 H), 7.14 (s, 1 H), 8.13 (d, <i>J</i> = 8.5 Hz, 1 H), 8.21 (dd, <i>J</i> = 8.5, 2.1 Hz, 1 H), 8.84–8.94 (m, 2 H).</div></div><div id="sec5_10_47_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i303" class="anchor-spacer"></div><h5 class="article-section__title" id="_i303"> <sup>13</sup>C NMR (DMSO-d<sub>6</sub>, 100 MHz)</h5><div class="NLM_p">δ = 27.6, 32.1, 46.0, 54.6, 60.2, 111.2, 113.1, 114.3, 118.9, 122.3 (q, <i>J</i> = 32.4 Hz), 124.0 (q, <i>J</i> = 271.8 Hz), 129.4, 133.1, 134.4 (q, <i>J</i> = 3.1 Hz), 146.0 (q, <i>J</i> = 4.2 Hz), 153.2, 156.6, 159.9, 171.5.</div><div class="NLM_p last">HRMS (ESI) calcd for C<sub>19</sub>H<sub>21</sub>F<sub>3</sub>N<sub>5</sub>O<sub>2</sub>S [M + H]<sup>+</sup> 440.1363, found 440.1377.</div></div></div><div id="sec5_10_48" class="NLM_sec NLM_sec_level_3"><div id="ac_i304" class="anchor-spacer"></div><h4 class="article-section__title" id="_i304"> N-(2-Amino-1-(4-(1,2-dihydroxyethyl)thiazol-2-yl)ethyl)-5-(5-(trifluoromethyl)pyridin-2-yl)-1H-pyrrole-2-carboxamide (29 and 30)</h4><div class="NLM_p">Compounds <b>29</b> and <b>30</b> were obtained from amine <b>S32</b> and acid <b>S4d</b>, following in sequence the <b><i>general procedures H</i></b>, <b><i>I</i></b>, and the TBDPS cleavage (below). Compounds were purified using column chromatography on silica gel. The eluent was CHCl<sub>3</sub>-MeOH saturated with NH<sub>3</sub> (10:1 and 5:1).</div><div class="NLM_p">TBDPS cleavage: To a solution of TBDPS-protected compound (1 equiv) in THF (0.1M), a solution of TBAF trihydrate (1.1 equiv) in THF (0.1M) was added in one portion. The mixture was stirred for 1–2 h at room temperature (TLC-control) and concentrated. Purification was done by flash chromatography using CHCl<sub>3</sub>-MeOH saturated with NH<sub>3</sub> mixture (5:1 and 3:1) as eluent.</div><div class="NLM_p">Note that compounds <b>29</b> & <b>30</b> were obtained as diastereisomeric mixture of two single compounds having the absolute configuration of the chiral carbon <b>a</b> as fR for <b>29</b> and fS for <b>30</b>.</div><div id="sec5_10_48_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i305" class="anchor-spacer"></div><h5 class="article-section__title" id="_i305"> 29</h5><div class="NLM_p last"><i>M</i> = 358 mg. Yield = 29% (over two steps). rt = 1.143 min. Purity = 100%. LC-MS: <i>m</i>/<i>z</i> [M + H]<sup>+</sup> = 442 Da.</div></div><div id="sec5_10_48_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i306" class="anchor-spacer"></div><h5 class="article-section__title" id="_i306"> 30</h5><div class="NLM_p last"><i>M</i> = 238 mg. Yield = 19% (over two steps). rt = 1.124 min. Purity = 100%. LC-MS: <i>m</i>/<i>z</i> [M + H]<sup>+</sup> = 442 Da.</div></div><div id="sec5_10_48_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i307" class="anchor-spacer"></div><h5 class="article-section__title" id="_i307"> <sup>1</sup>H NMR (DMSO-d<sub>6</sub>, 400 MHz)</h5><div class="NLM_p last">δ = 3.00 (ddd, <i>J</i> = 13.2, 7.8, 2.1 Hz, 1 H), 3.10–3.18 (m, 1 H), 3.49 (ddd, <i>J</i> = 10.9, 7.1, 2.0 Hz, 1 H), 3.71 (dt, <i>J</i> = 10.9, 4.1 Hz, 1 H), 4.65 (dd, <i>J</i> = 6.8, 4.2 Hz, 1 H), 4.72 (br. s., 1 H), 5.16–5.26 (m, 1 H), 5.35 (br. s., 1 H), 6.98 (d, <i>J</i> = 3.9 Hz, 1 H), 7.05 (d, <i>J</i> = 3.9 Hz, 1 H), 7.29–7.32 (m, 1 H), 8.13 (d, <i>J</i> = 8.4 Hz, 1 H), 8.20 (dd, <i>J</i> = 8.6, 2.1 Hz, 1 H), 8.84–8.94 (m, 2 H).</div></div><div id="sec5_10_48_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i308" class="anchor-spacer"></div><h5 class="article-section__title" id="_i308"> <sup>13</sup>C NMR (DMSO-d<sub>6</sub>, 100 MHz)</h5><div class="NLM_p">δ = 45.7, 54.3, (65.8, 65.9), (71.3, 71.4), 111.3, 114.3, (114.5, 114.5), 118.9, 121.9 (q, <i>J</i> = 32.4 Hz), 124.0 (q, <i>J</i> = 271.8 Hz), 129.4, 133.2, 134.5 (q, <i>J</i> = 3.3 Hz), 146.0 (q, <i>J</i> = 4.2 Hz), 153.2 (q, <i>J</i> = 1.1 Hz), (158.4, 158.5), (159.9, 159.9), (171.5, 171.5).</div><div class="NLM_p last">HRMS (ESI) calcd for C<sub>18</sub>H<sub>19</sub>F<sub>3</sub>N<sub>5</sub>O<sub>3</sub>S [M + H]<sup>+</sup> 442.1155, found 442.1172.</div></div></div><div id="sec5_10_49" class="NLM_sec NLM_sec_level_3"><div id="ac_i309" class="anchor-spacer"></div><h4 class="article-section__title" id="_i309"> N-(1-Amino-2-(4-(hydroxymethyl)thiazol-2-yl)propan-2-yl)-3-methyl-5-(5-(trifluoromethyl)-pyridin-2-yl)-1H-pyrrole-2-carboxamide (31)</h4><div class="NLM_p">Compound <b>31</b> (racemate) was obtained following the <b><i>general procedures H</i></b> and <b><i>I</i></b> from amine <b>S37</b> and the sodium salt <b>S15</b>. The compound was purified using column chromatography on silica gel. The eluent was CHCl<sub>3</sub>-MeOH saturated with NH<sub>3</sub> (20:1 and 10:1).</div><div class="NLM_p"><i>M</i> = 190 mg. Yield = 12%. rt = 1.271 min. Purity = 100%. LC-MS: <i>m</i>/<i>z</i> [M + H]<sup>+</sup> = 440 Da.</div><div id="sec5_10_49_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i310" class="anchor-spacer"></div><h5 class="article-section__title" id="_i310"> <sup>1</sup>H NMR (DMSO-d<sub>6</sub>, 400 MHz)</h5><div class="NLM_p last">δ = 1.74 (s, 3 H), 2.25 (s, 3 H), 2.92 (d, <i>J</i> = 13.2 Hz, 1 H), 3.12 (d, <i>J</i> = 13.2 Hz, 1 H), 4.51 (d, <i>J</i> = 5.1 Hz, 2 H), 5.26 (t, <i>J</i> = 5.7 Hz, 1 H), 6.88 (s, 1 H), 7.21–7.23 (m, 1 H), 7.99 (d, <i>J</i> = 8.4 Hz, 1 H), 8.18 (dd, <i>J</i> = 8.6, 2.3 Hz, 1 H), 8.28 (s, 1 H), 8.86–8.89 (m, 1 H), 12.02 (br. s., 1 H).</div></div><div id="sec5_10_49_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i311" class="anchor-spacer"></div><h5 class="article-section__title" id="_i311"> <sup>13</sup>C NMR (DMSO-d<sub>6</sub>, 100 MHz)</h5><div class="NLM_p">δ = 13.1, 23.5, 51.8, 59.9, 60.5, 113.5, 113.8, 119.0, 122.2 (q, <i>J</i> = 32.3 Hz), 122.6, 125.4, 126.5, 130.6, 134.4 (q, <i>J</i> = 3.3 Hz), 145.8 (q, <i>J</i> = 4.1 Hz), 153.2 (q, <i>J</i> = 1.3 Hz), 156.8, 160.5, 176.6.</div><div class="NLM_p last">HRMS (ESI) calcd for C<sub>18</sub>H<sub>19</sub>F<sub>3</sub>N<sub>5</sub>O<sub>2</sub>S [M + H]<sup>+</sup> 440.1363, found 440.1373.</div></div></div><div id="sec5_10_50" class="NLM_sec NLM_sec_level_3"><div id="ac_i312" class="anchor-spacer"></div><h4 class="article-section__title" id="_i312"> N-(1-Amino-2-(4-(hydroxymethyl)thiazol-2-yl)propan-2-yl)-5-(5-(trifluoromethyl)pyridin-2-yl)-1H-pyrrole-2-carboxamide (32</h4><div class="NLM_p">Compound <b>32</b> (racemate) was obtained following the <b><i>general procedures H</i></b> and <b><i>I</i></b> from amine <b>S37</b> and acid <b>S4d</b>. The compound was purified using column chromatography on silica gel. The eluent was CHCl<sub>3</sub>/MeOH saturated with NH<sub>3</sub> (10:1 and 5:1).</div><div class="NLM_p"><i>M</i> = 332 mg. Yield = 38%. rt = 1.205 min. Purity = 98%. LC-MS: <i>m</i>/<i>z</i> [M + H]<sup>+</sup> = 426 Da.</div><div id="sec5_10_50_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i313" class="anchor-spacer"></div><h5 class="article-section__title" id="_i313"> <sup>1</sup>H NMR (DMSO-d<sub>6</sub>, 400 MHz)</h5><div class="NLM_p last">δ = 1.76 (s, 3 H), 2.94 (d, <i>J</i> = 13.3 Hz, 1 H), 3.14 (d, <i>J</i> = 13.3 Hz, 1 H), 4.52 (s, 2 H), 5.29 (br. s., 1 H), 6.90 (d, <i>J</i> = 3.9 Hz, 1 H), 7.04 (d, <i>J</i> = 3.9 Hz, 1 H), 7.23 (s, 1 H), 8.10 (d, <i>J</i> = 8.4 Hz, 1 H), 8.19 (dd, <i>J</i> = 8.6, 2.2 Hz, 1 H), 8.40 (s, 1 H), 8.85–8.92 (m, 1 H).</div></div><div id="sec5_10_50_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i314" class="anchor-spacer"></div><h5 class="article-section__title" id="_i314"> <sup>13</sup>C NMR (DMSO-d<sub>6</sub>, 100 MHz)</h5><div class="NLM_p">δ = 23.5, 51.7, 59.9, 60.6, 111.2, 113.8, 114.3, 118.9, 122.3 (q, <i>J</i> = 32.3 Hz), 124.0 (q, <i>J</i> = 271.8 Hz), 130.0, 132.9, 134.4 (q, <i>J</i> = 3.1 Hz), 145.9 (q, <i>J</i> = 4.2 Hz), 153.3, 156.9, 159.6, 176.4.</div><div class="NLM_p last">HRMS (ESI) calcd for C<sub>18</sub>H<sub>19</sub>F<sub>3</sub>N<sub>5</sub>O<sub>2</sub>S [M + H]<sup>+</sup> 426.1206, found 426.1217.</div></div></div><div id="sec5_10_51" class="NLM_sec NLM_sec_level_3"><div id="ac_i315" class="anchor-spacer"></div><h4 class="article-section__title" id="_i315"> N-(2-Amino-1-(4-(hydroxymethyl)thiazol-2-yl)ethyl)-3-methyl-5-(5-(trifluoromethyl)pyridin-2-yl)-1H-pyrrole-2-carboxamide (33 and 34)</h4><div class="NLM_p">Compounds <b>33</b> and <b>34</b> were obtained following the <b><i>general procedures H</i></b> and <b><i>I</i></b> from amine <b>S38</b> and sodium salt <b>S15</b>. Compounds were purified using column chromatography on silica gel. The eluent was CHCl<sub>3</sub>-MeOH saturated with NH<sub>3</sub> (10:1 and 5:1).</div><div id="sec5_10_51_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i316" class="anchor-spacer"></div><h5 class="article-section__title" id="_i316"> 33</h5><div class="NLM_p last"><i>M</i> = 248 mg. Yield = 33% (over two steps). rt = 1.333 min. Purity = 100%. LC-MS: <i>m</i>/<i>z</i> [M + H]<sup>+</sup> = 426 Da.</div></div><div id="sec5_10_51_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i317" class="anchor-spacer"></div><h5 class="article-section__title" id="_i317"> 34</h5><div class="NLM_p last"><i>M</i> = 162 mg. Yield = 22% (over two steps). rt = 1.328 min. Purity = 100%. LC-MS: <i>m</i>/<i>z</i> [M + H]<sup>+</sup> = 426 Da.</div></div><div id="sec5_10_51_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i318" class="anchor-spacer"></div><h5 class="article-section__title" id="_i318"> <sup>1</sup>H NMR (DMSO-d<sub>6</sub>, 400 MHz)</h5><div class="NLM_p last">δ = 2.33 (s, 3 H), 3.00 (dd, <i>J</i> = 13.2, 7.7 Hz, 1 H), 3.12 (dd, <i>J</i> = 13.3, 5.1 Hz, 1 H), 4.55 (s, 2 H), 5.18–5.26 (m, 1 H), 5.34 (br. s., 1 H), 6.90 (s, 1 H), 7.29 (s, 1 H), 7.98 (d, <i>J</i> = 8.6 Hz, 1 H), 8.17 (dd, <i>J</i> = 8.6, 2.2 Hz, 1 H), 8.81 (d, <i>J</i> = 6.8 Hz, 1 H), 8.86–8.90 (m, 1 H).</div></div><div id="sec5_10_51_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i319" class="anchor-spacer"></div><h5 class="article-section__title" id="_i319"> <sup>13</sup>C NMR (DMSO-d<sub>6</sub>, 100 MHz)</h5><div class="NLM_p">δ = 13.1, 46.1, 54.4, 59.8, 113.4, 114.0, 119.0, 122.3 (q, <i>J</i> = 32.2 Hz), 124.0 (q, <i>J</i> = 272.1 Hz), 124.6, 127.3, 130.9, 134.4 (q, <i>J</i> = 3.2 Hz), 145.8 (q, <i>J</i> = 4.1 Hz), 153.1, 157.7, 160.7, 172.2.</div><div class="NLM_p last">HRMS (ESI) calcd for C<sub>18</sub>H<sub>19</sub>F<sub>3</sub>N<sub>5</sub>O<sub>2</sub>S [M + H]<sup>+</sup> 426.1206, found 426.1213.</div></div></div><div id="sec5_10_52" class="NLM_sec NLM_sec_level_3"><div id="ac_i320" class="anchor-spacer"></div><h4 class="article-section__title" id="_i320"> N-(2-Amino-1-(4,5-bis(hydroxymethyl)thiazol-2-yl)ethyl)-5-(5-(trifluoromethyl)pyridin-2-yl)-1H-pyrrole-2-carboxamide (35 and 36)</h4><div class="NLM_p">Compounds <b>35</b> and <b>36</b> were obtained following the <b><i>general procedures H</i></b> and <b><i>I</i></b> from amine <b>S40</b> and acid <b>S4d</b>. Compounds were purified using column chromatography on silica gel. The eluent was CHCl<sub>3</sub>-MeOH saturated with NH<sub>3</sub> (15:1 and 3:1).</div><div id="sec5_10_52_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i321" class="anchor-spacer"></div><h5 class="article-section__title" id="_i321"> <b>35;</b> (fR)</h5><div class="NLM_p last"><i>M</i> = 468 mg. Yield = 38% (over two steps). rt = 1.221 min. Purity = 100%. LC-MS: <i>m</i>/<i>z</i> [M + H]<sup>+</sup> = 442 Da.</div></div><div id="sec5_10_52_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i322" class="anchor-spacer"></div><h5 class="article-section__title" id="_i322"> <b>36;</b> (fS)</h5><div class="NLM_p last"><i>M</i> = 290 mg. Yield = 24% (over two steps). rt = 1.225 min. Purity = 100%. LC-MS: <i>m</i>/<i>z</i> [M + H]<sup>+</sup> = 442 Da.</div></div><div id="sec5_10_52_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i323" class="anchor-spacer"></div><h5 class="article-section__title" id="_i323"> <sup>1</sup>H NMR (DMSO-d<sub>6</sub>, 400 MHz)</h5><div class="NLM_p last">δ = 2.99 (dd, <i>J</i> = 13.1, 7.9 Hz, 1 H), 3.07–3.15 (dd, <i>J</i> = 13.2, 5.3 Hz, 1 H), 4.46 (s, 2 H), 4.65 (s, 2 H), 5.08 (br. s., 1 H), 5.12–5.19 (m, 1 H), 5.45 (br. s., 1 H), 6.97 (d, <i>J</i> = 3.9 Hz, 1 H), 7.05 (d, <i>J</i> = 3.9 Hz, 1 H), 8.13 (d, <i>J</i> = 8.4 Hz, 1 H), 8.20 (dd, <i>J</i> = 8.6, 2.0 Hz, 1 H), 8.84–8.91 (m, 1 H).</div></div><div id="sec5_10_52_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i324" class="anchor-spacer"></div><h5 class="article-section__title" id="_i324"> <sup>13</sup>C NMR (DMSO-d<sub>6</sub>, 100 MHz)</h5><div class="NLM_p">δ = 45.5, 54.1, 55.1, 57.4, 111.2, 114.3, 118.9, 122.3 (q, <i>J</i> = 32.1 Hz), 124.0 (q, <i>J</i> = 271.5 Hz), 129.4, 133.1, 134.4 (q, <i>J</i> = 3.2 Hz), 136.3, 146.0 (q, <i>J</i> = 4.0 Hz), 150.8, 153.2, 159.8, 169.0.</div><div class="NLM_p last">HRMS (ESI) calcd for C<sub>18</sub>H<sub>19</sub>F<sub>3</sub>N<sub>5</sub>O<sub>3</sub>S [M + H]<sup>+</sup> 442.1155, found 442.1151.</div></div></div><div id="sec5_10_53" class="NLM_sec NLM_sec_level_3"><div id="ac_i325" class="anchor-spacer"></div><h4 class="article-section__title" id="_i325"> N-(2-Amino-1-(thiazol-2-yl)ethyl)-5-(5-(trifluoromethyl)pyridin-2-yl)-1H-pyrrole-2-carboxamide (37 and 38)</h4><div class="NLM_p">Compounds <b>37</b> and <b>38</b> were obtained following the <b><i>general procedures H</i></b> and <b><i>I</i></b> from amine <b>S43</b> and acid <b>S4d</b>. Compounds were purified using column chromatography on silica gel. The eluent was CHCl<sub>3</sub>-MeOH saturated with NH<sub>3</sub> (10:1 and 5:1).</div><div id="sec5_10_53_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i326" class="anchor-spacer"></div><h5 class="article-section__title" id="_i326"> 37; (fR)</h5><div class="NLM_p last"><i>M</i> = 220 mg. Yield = 30% (over two steps). rt = 1.230 min. Purity = 95%. LC-MS: <i>m</i>/<i>z</i> [M + H]<sup>+</sup> = 382 Da.</div></div><div id="sec5_10_53_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i327" class="anchor-spacer"></div><h5 class="article-section__title" id="_i327"> 38; (fS)</h5><div class="NLM_p last"><i>M</i> = 342 mg. Yield = 45% (over two steps). rt = 1.236 min. Purity = 96%. LC-MS: <i>m</i>/<i>z</i> [M + H]<sup>+</sup> = 382 Da.</div></div><div id="sec5_10_53_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i328" class="anchor-spacer"></div><h5 class="article-section__title" id="_i328"> <sup>1</sup>H NMR (DMSO-d<sub>6</sub>, 400 MHz)</h5><div class="NLM_p last">δ = 3.03 (dd, <i>J</i> = 13.2, 7.8 Hz, 1 H), 3.16 (dd, <i>J</i> = 13.2, 5.3 Hz, 1 H), 5.22–5.31 (m, 1 H), 6.98 (d, <i>J</i> = 3.8 Hz, 1 H), 7.06 (d, <i>J</i> = 3.8 Hz, 1 H), 7.61 (d, <i>J</i> = 3.2 Hz, 1 H), 7.77 (d, <i>J</i> = 3.2 Hz, 1 H), 8.13 (d, <i>J</i> = 8.5 Hz, 1 H), 8.20 (dd, <i>J</i> = 8.5, 2.0 Hz, 1 H), 8.80–9.01 (m, 2 H).</div></div><div id="sec5_10_53_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i329" class="anchor-spacer"></div><h5 class="article-section__title" id="_i329"> <sup>13</sup>C NMR (DMSO-d<sub>6</sub>, 100 MHz)</h5><div class="NLM_p">δ = 45.9, 54.5, 111.2, 114.2, 118.9, 119.6, 122.3 (q, <i>J</i> = 32.4 Hz), 124.0 (q, <i>J</i> = 271.8 Hz), 129.3, 133.1, 134.4 (q, <i>J</i> = 3.3 Hz), 142.4, 145.9 (q, <i>J</i> = 4.1 Hz), 153.2 (q, <i>J</i> = 1.3 Hz), 159.8, 172.1.</div><div class="NLM_p last">HRMS (ESI) calcd for C<sub>16</sub>H<sub>15</sub>F<sub>3</sub>N<sub>5</sub>OS [M + H]<sup>+</sup> 382.0944, found 382.0952.</div></div></div><div id="sec5_10_54" class="NLM_sec NLM_sec_level_3"><div id="ac_i330" class="anchor-spacer"></div><h4 class="article-section__title" id="_i330"> N-(2-Amino-1-(4-(hydroxymethyl)thiazol-2-yl)ethyl)-5-(6-chloropyridin-3-yl)-1H-pyrrole-2-carboxamide (39 and 40)</h4><div class="NLM_p">Compounds <b>39</b> and <b>40</b> were obtained following the <b><i>general procedures H</i></b> and <b><i>I</i></b> from amine <b>S38</b> and acid <b>S4e</b>. Compounds were purified using column chromatography on silica gel. The eluent was CHCl<sub>3</sub>-MeOH saturated with NH<sub>3</sub> (10:1 and 5:1).</div><div id="sec5_10_54_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i331" class="anchor-spacer"></div><h5 class="article-section__title" id="_i331"> 39; (fR)</h5><div class="NLM_p last"><i>M</i> = 375 mg. Yield = 24% (over two steps). rt = 1.044 min. Purity = 96%. LC-MS: <i>m</i>/<i>z</i> [M + H]<sup>+</sup> = 378 Da.</div></div><div id="sec5_10_54_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i332" class="anchor-spacer"></div><h5 class="article-section__title" id="_i332"> 40; (fS)</h5><div class="NLM_p last"><i>M</i> = 387 mg. Yield = 28% (over two steps). rt = 0.999 min. Purity = 100%. LC-MS: <i>m</i>/<i>z</i> [M + H]<sup>+</sup> = 378 Da.</div></div><div id="sec5_10_54_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i333" class="anchor-spacer"></div><h5 class="article-section__title" id="_i333"> <sup>1</sup>H NMR (DMSO-d<sub>6</sub>, 400 MHz)</h5><div class="NLM_p last">δ = 1.72 (br. s., 2 H), 2.99 (dd, <i>J</i> = 13.2, 7.9 Hz, 1 H), 3.13 (dd, <i>J</i> = 13.2, 5.3 Hz, 1 H), 4.52 (s, 2 H), 5.16–5.23 (m, 1 H), 5.28 (br. s., 1 H), 6.76 (d, <i>J</i> = 3.9 Hz, 1 H), 7.04 (d, <i>J</i> = 3.9 Hz, 1 H), 7.27 (s, 1 H), 7.51 (d, <i>J</i> = 8.5 Hz, 1 H), 8.25 (dd, <i>J</i> = 8.5, 2.6 Hz, 1 H), 8.61 (d, <i>J</i> = 8.1 Hz, 1 H), 8.86 (d, <i>J</i> = 2.4 Hz, 1 H), 12.07 (br. s., 1 H).</div></div><div id="sec5_10_54_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i334" class="anchor-spacer"></div><h5 class="article-section__title" id="_i334"> <sup>13</sup>C NMR (DMSO-d<sub>6</sub>, 100 MHz)</h5><div class="NLM_p">δ = 45.5, 54.2, 59.8, 108.7, 112.8, 114.1, 124.2, 127.3, 128.3, 130.6, 135.3, 146.0, 147.8, 157.6, 160.4, 172.2.</div><div class="NLM_p last">HRMS (ESI) calcd for C<sub>16</sub>H<sub>17</sub>ClN<sub>5</sub>O<sub>2</sub>S [M + H]<sup>+</sup> 378.0786, found 378.0786.</div></div></div><div id="sec5_10_55" class="NLM_sec NLM_sec_level_3"><div id="ac_i335" class="anchor-spacer"></div><h4 class="article-section__title" id="_i335"> N-(2-Amino-1-(4-(hydroxymethyl)thiazol-2-yl)ethyl)-5-(6-(trifluoromethyl)pyridin-3-yl)-1H-pyrrole-2-carboxamide (41 and 42)</h4><div class="NLM_p">Compounds <b>41</b> and <b>42</b> were obtained following the <b><i>general procedures H</i></b> and <b><i>I</i></b> from amine <b>S38</b> and acid <b>S4f</b>. Compounds were purified using column chromatography on silica gel. The eluent was CHCl<sub>3</sub>-MeOH saturated with NH<sub>3</sub> (10:1 and 5:1).</div><div id="sec5_10_55_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i336" class="anchor-spacer"></div><h5 class="article-section__title" id="_i336"> 41; (fR)</h5><div class="NLM_p last"><i>M</i> = 240 mg. Yield = 33% (over two steps). rt = 1.246 min. Purity = 100%. LC-MS: <i>m</i>/<i>z</i> [M + H]<sup>+</sup> = 412 Da.</div></div><div id="sec5_10_55_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i337" class="anchor-spacer"></div><h5 class="article-section__title" id="_i337"> 42; (fS)</h5><div class="NLM_p last"><i>M</i> = 290 mg. Yield = 40% (over two steps). rt = 1.262 min. Purity = 100%. LC-MS: <i>m</i>/<i>z</i> [M + H]<sup>+</sup> = 412 Da.</div></div><div id="sec5_10_55_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i338" class="anchor-spacer"></div><h5 class="article-section__title" id="_i338"> <sup>1</sup>H NMR (DMSO-d<sub>6</sub>, 400 MHz)</h5><div class="NLM_p last">δ = 3.03 (dd, <i>J</i> = 13.2, 7.8 Hz, 1 H), 3.16 (dd, <i>J</i> = 13.2, 5.4 Hz, 1 H), 4.55 (s, 2 H), 5.20–5.28 (m, 1 H), 5.36 (br. s., 1 H), 6.93 (d, <i>J</i> = 3.9 Hz, 1 H), 7.11 (d, <i>J</i> = 3.9 Hz, 1 H), 7.30 (s, 1 H), 7.88 (d, <i>J</i> = 8.3 Hz, 1 H), 8.47 (dd, <i>J</i> = 8.3, 1.7 Hz, 1 H), 8.71 (d, <i>J</i> = 7.8 Hz, 1 H), 9.22 (d, <i>J</i> = 1.6 Hz, 1 H).</div></div><div id="sec5_10_55_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i339" class="anchor-spacer"></div><h5 class="article-section__title" id="_i339"> <sup>13</sup>C NMR (DMSO-d<sub>6</sub>, 100 MHz)</h5><div class="NLM_p">δ = 45.6, 54.4, 59.8, 109.9, 113.0, 114.2, 120.8 (q, <i>J</i> = 2.6 Hz), 121.9 (q, <i>J</i> = 273.5 Hz), 129.2, 130.4, 130.9, 132.9, 143.7 (q, <i>J</i> = 33.9 Hz), 146.3, 157.7, 160.4, 172.1.</div><div class="NLM_p last">HRMS (ESI) calcd for C<sub>17</sub>H<sub>17</sub>F<sub>3</sub>N<sub>5</sub>O<sub>2</sub>S [M + H]<sup>+</sup> 412.1050, found 412.1054.</div></div></div><div id="sec5_10_56" class="NLM_sec NLM_sec_level_3"><div id="ac_i340" class="anchor-spacer"></div><h4 class="article-section__title" id="_i340"> N-(2-Amino-1-(4-(hydroxymethyl)thiazol-2-yl)ethyl)-5-(6-(trifluoromethyl)pyridazin-3-yl)-1H-pyrrole-2-carboxamide (43 and 44)</h4><div class="NLM_p">Compounds <b>43</b> and <b>44</b> were obtained following the <b><i>general procedures H</i></b> and <b><i>I</i></b> from amine <b>S38</b> and acid <b>S4g</b>. Compounds were purified using column chromatography on silica gel. The eluent was CHCl<sub>3</sub>-MeOH saturated with NH<sub>3</sub> (10:1 and 5:1).</div><div id="sec5_10_56_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i341" class="anchor-spacer"></div><h5 class="article-section__title" id="_i341"> 43; (fR)</h5><div class="NLM_p last"><i>M</i> = 322 mg. Yield = 42% (over two steps). rt = 1.095 min. Purity = 100%. LC-MS: <i>m</i>/<i>z</i> [M + H]<sup>+</sup> = 413 Da.</div></div><div id="sec5_10_56_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i342" class="anchor-spacer"></div><h5 class="article-section__title" id="_i342"> 44; (fS)</h5><div class="NLM_p last"><i>M</i> = 193 mg. Yield = 25% (over two steps). rt = 1.065 min. Purity = 100%. LC-MS: <i>m</i>/<i>z</i> [M + H]<sup>+</sup> = 413 Da.</div></div><div id="sec5_10_56_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i343" class="anchor-spacer"></div><h5 class="article-section__title" id="_i343"> <sup>1</sup>H NMR (DMSO-d<sub>6</sub>, 400 MHz)</h5><div class="NLM_p last">δ = 3.01 (dd, <i>J</i> = 13.1, 7.8 Hz, 1 H), 3.14 (dd, <i>J</i> = 13.2, 5.3 Hz, 1 H), 4.55 (s, 2 H), 5.20–5.28 (m, 1 H), 5.32 (br. s., 1 H), 7.03 (d, <i>J</i> = 3.9 Hz, 1 H), 7.22 (d, <i>J</i> = 3.9 Hz, 1 H), 7.30 (s, 1 H), 8.24 (d, <i>J</i> = 9.0 Hz, 1 H), 8.48 (d, <i>J</i> = 9.0 Hz, 1 H), 8.97 (d, <i>J</i> = 7.1 Hz, 1 H).</div></div><div id="sec5_10_56_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i344" class="anchor-spacer"></div><h5 class="article-section__title" id="_i344"> <sup>13</sup>C NMR (DMSO-d<sub>6</sub>, 100 MHz)</h5><div class="NLM_p">δ = 45.7, 54.3, 59.8, 112.7, 114.2, 114.4, 121.8 (q, <i>J</i> = 273.7 Hz), 124.0, 125.2 (q, <i>J</i> = 1.7 Hz), 130.1, 130.6, 148.1 (q, <i>J</i> = 33.9 Hz), 154.5, 157.7, 159.7, 171.6.</div><div class="NLM_p last">HRMS (ESI) calcd for C<sub>16</sub>H<sub>16</sub>F<sub>3</sub>N<sub>6</sub>O<sub>2</sub>S [M + H]<sup>+</sup> 413.1002, found 413.1000.</div></div></div><div id="sec5_10_57" class="NLM_sec NLM_sec_level_3"><div id="ac_i345" class="anchor-spacer"></div><h4 class="article-section__title" id="_i345"> N-(2-Amino-1-(4-(hydroxymethyl)thiazol-2-yl)ethyl)-5-(5-chloropyrimidin-2-yl)-1H-pyrrole-2-carboxamide (45 and 46)</h4><div class="NLM_p">Compounds <b>45</b> and <b>46</b> were obtained following the <b><i>general procedures H</i></b> and <b><i>I</i></b> from amine <b>S38</b> and acid <b>S4h</b>. Compounds were purified using column chromatography on silica gel. The eluent was CHCl<sub>3</sub>-MeOH saturated with NH<sub>3</sub> (10:1 and 5:1).</div><div id="sec5_10_57_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i346" class="anchor-spacer"></div><h5 class="article-section__title" id="_i346"> 45; (fR)</h5><div class="NLM_p last"><i>M</i> = 186 mg. Yield = 24% (over two steps). rt = 1.078 min. Purity = 100%. LC-MS: <i>m</i>/<i>z</i> [M + H]<sup>+</sup> = 379 Da.</div></div><div id="sec5_10_57_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i347" class="anchor-spacer"></div><h5 class="article-section__title" id="_i347"> 46; (fS)</h5><div class="NLM_p last"><i>M</i> = 124 mg. Yield = 16% (over two steps). rt = 1.099 min. Purity = 100%. LC-MS: <i>m</i>/<i>z</i> [M + H]<sup>+</sup> = 379 Da.</div></div><div id="sec5_10_57_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i348" class="anchor-spacer"></div><h5 class="article-section__title" id="_i348"> <sup>1</sup>H NMR (DMSO-d<sub>6</sub>, 400 MHz)</h5><div class="NLM_p last">δ = 2.99 (dd, <i>J</i> = 13.2, 7.8 Hz, 1 H), 3.12 (dd, <i>J</i> = 13.3, 5.3 Hz, 1 H), 4.55 (s, 2 H), 5.16–5.26 (m, 1 H), 5.31 (br. s., 1 H), 6.91 (d, <i>J</i> = 3.8 Hz, 1 H), 6.99 (d, <i>J</i> = 3.8 Hz, 1 H), 7.29 (s, 1 H), 8.90 (s, 2 H), 8.97 (d, <i>J</i> = 7.2 Hz, 1 H).</div></div><div id="sec5_10_57_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i349" class="anchor-spacer"></div><h5 class="article-section__title" id="_i349"> <sup>13</sup>C NMR (DMSO-d<sub>6</sub>, 100 MHz)</h5><div class="NLM_p">δ = 46.1, 54.5, 59.8, 112.5, 114.1, 114.9, 127.3, 129.7, 132.2, 155.9 (2C), 156.3, 157.7, 159.5, 171.8.</div><div class="NLM_p last">HRMS (ESI) calcd for C<sub>15</sub>H<sub>16</sub>ClN<sub>6</sub>O<sub>2</sub>S [M + H]<sup>+</sup> 379.0738, found 379.0745.</div></div></div><div id="sec5_10_58" class="NLM_sec NLM_sec_level_3"><div id="ac_i350" class="anchor-spacer"></div><h4 class="article-section__title" id="_i350"> N-(2-Amino-1-(4-(hydroxymethyl)thiazol-2-yl)ethyl)-5-(2-methoxypyridin-4-yl)-1H-pyrrole-2-carboxamide (47 and 48)</h4><div class="NLM_p">Compounds <b>47</b> and <b>48</b> were obtained following the <b><i>general procedures H</i></b> and <b><i>I</i></b> from amine <b>S38</b> and acid <b>S8</b>. Compounds were purified using column chromatography on silica gel. The eluent was CHCl<sub>3</sub>-MeOH saturated with NH<sub>3</sub> (20:1 and 10:1).</div><div id="sec5_10_58_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i351" class="anchor-spacer"></div><h5 class="article-section__title" id="_i351"> 47; (fR)</h5><div class="NLM_p last"><i>M</i> = 485 mg. Yield = 32% (over two steps). rt = 0.838 min. Purity = 100%. LC-MS: <i>m</i>/<i>z</i> [M + H]<sup>+</sup> = 374 Da.</div></div><div id="sec5_10_58_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i352" class="anchor-spacer"></div><h5 class="article-section__title" id="_i352"> 48; (fS)</h5><div class="NLM_p last"><i>M</i> = 423 mg. Yield = 28% (over two steps). rt = 0.839 min. Purity = 100%. LC-MS: <i>m</i>/<i>z</i> [M + H]<sup>+</sup> = 374 Da.</div></div><div id="sec5_10_58_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i353" class="anchor-spacer"></div><h5 class="article-section__title" id="_i353"> <sup>1</sup>H NMR (DMSO-d<sub>6</sub>, 400 MHz)</h5><div class="NLM_p last">δ = 1.74 (br. s., 2 H), 3.00 (dd, <i>J</i> = 13.1, 7.9 Hz, 1 H), 3.14 (dd, <i>J</i> = 13.2, 5.3 Hz, 1 H), 3.85 (s, 3 H), 4.54 (s, 2 H), 5.18–5.25 (m, 1 H), 5.30 (br. s., 1 H), 6.87 (d, <i>J</i> = 3.9 Hz, 1 H), 7.03 (d, <i>J</i> = 3.9 Hz, 1 H), 7.29 (t, <i>J</i> = 1.0 Hz, 1 H), 7.30 (d, <i>J</i> = 0.9 Hz, 1 H), 7.41 (dd, <i>J</i> = 5.5, 1.4 Hz, 1 H), 8.10 (d, <i>J</i> = 5.4 Hz, 1 H), 8.66 (d, <i>J</i> = 7.9 Hz, 1 H), 12.07 (br. s., 1 H).</div></div><div id="sec5_10_58_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i354" class="anchor-spacer"></div><h5 class="article-section__title" id="_i354"> <sup>13</sup>C NMR (DMSO-d<sub>6</sub>, 100 MHz)</h5><div class="NLM_p">δ = 45.7, 53.2, 54.5, 59.8, 104.5, 109.8, 112.9, 113.1, 114.1, 128.7, 132.1, 141.5, 147.2, 157.6, 160.4, 164.5, 172.2.</div><div class="NLM_p last">HRMS (ESI) calcd for C<sub>17</sub>H<sub>20</sub>N<sub>5</sub>O<sub>3</sub>S [M + H]<sup>+</sup> 374.1281, found 374.12.</div></div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i355"><a href="/doi/suppl/10.1021/acs.jmedchem.9b02149" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_58370" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_58370" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.9b02149?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b02149</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">ADME solubility, CACO-2 permeability, stability in liver microsomes, plasma protein binding, Cyp450 inhibition, dose-percent inhibition and cytotoxicity plots (<a href="/doi/suppl/10.1021/acs.jmedchem.9b02149/suppl_file/jm9b02149_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.9b02149/suppl_file/jm9b02149_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b02149/suppl_file/jm9b02149_si_001.pdf">jm9b02149_si_001.pdf (370.92 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b02149/suppl_file/jm9b02149_si_002.csv">jm9b02149_si_002.csv (3.79 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.9b02149" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_66554" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_66554" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Asim K. Debnath</span> - <span class="hlFld-Affiliation affiliation">Laboratory
of Molecular Modeling & Drug Design, Lindsley F. Kimball Research
Institute, New York Blood Center, 310 E 67th Street, New York 10065, New York, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-2761-0506" title="Orcid link">http://orcid.org/0000-0003-2761-0506</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#5d3c39383f333c29351d33243f3e73322f3a"><span class="__cf_email__" data-cfemail="39585d5c5b57584d517957405b5a17564b5e">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Francesca Curreli</span> - <span class="hlFld-Affiliation affiliation">Laboratory
of Molecular Modeling & Drug Design, Lindsley F. Kimball Research
Institute, New York Blood Center, 310 E 67th Street, New York 10065, New York, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shahad Ahmed</span> - <span class="hlFld-Affiliation affiliation">Laboratory
of Molecular Modeling & Drug Design, Lindsley F. Kimball Research
Institute, New York Blood Center, 310 E 67th Street, New York 10065, New York, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sofia M. Benedict Victor</span> - <span class="hlFld-Affiliation affiliation">Laboratory
of Molecular Modeling & Drug Design, Lindsley F. Kimball Research
Institute, New York Blood Center, 310 E 67th Street, New York 10065, New York, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ildar R. Iusupov</span> - <span class="hlFld-Affiliation affiliation">EDASA
Scientific, Scientific Park, Moscow State
University, Leninskie
Gory Bld. 75, 77-101b,Moscow 119992, Russia</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dmitry S. Belov</span> - <span class="hlFld-Affiliation affiliation">EDASA
Scientific, Scientific Park, Moscow State
University, Leninskie
Gory Bld. 75, 77-101b,Moscow 119992, Russia</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Pavel O. Markov</span> - <span class="hlFld-Affiliation affiliation">EDASA
Scientific, Scientific Park, Moscow State
University, Leninskie
Gory Bld. 75, 77-101b,Moscow 119992, Russia</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Alexander V. Kurkin</span> - <span class="hlFld-Affiliation affiliation">EDASA
Scientific, Scientific Park, Moscow State
University, Leninskie
Gory Bld. 75, 77-101b,Moscow 119992, Russia</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Andrea Altieri</span> - <span class="hlFld-Affiliation affiliation">EDASA
Scientific, Scientific Park, Moscow State
University, Leninskie
Gory Bld. 75, 77-101b,Moscow 119992, Russia</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i356">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_34216" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_34216" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This study was supported by funds from NIH Grant No. R01 AI104416 (A.K.D.) and the New York Blood Center (A.K.D.). The ADME study was conducted by Absorption Systems LLC.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">HIV-1</td><td class="NLM_def"><p class="first last">human immunodeficiency virus type 1</p></td></tr><tr><td class="NLM_term">Env</td><td class="NLM_def"><p class="first last">envelope</p></td></tr><tr><td class="NLM_term">AIDS</td><td class="NLM_def"><p class="first last">acquire immunodeficiency syndrome</p></td></tr><tr><td class="NLM_term">VSV-G</td><td class="NLM_def"><p class="first last">vesicular stomatitis virus-G</p></td></tr><tr><td class="NLM_term">ADMET</td><td class="NLM_def"><p class="first last">absorption, distribution, metabolism, and excretion</p></td></tr><tr><td class="NLM_term">TBDPSCl</td><td class="NLM_def"><p class="first last"><i>tert</i>-butyl(chloro)diphenylsilane</p></td></tr><tr><td class="NLM_term">DCM</td><td class="NLM_def"><p class="first last">dichloromethane</p></td></tr><tr><td class="NLM_term">DIPEA</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-diisopropylethylamine</p></td></tr><tr><td class="NLM_term">HBTU</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>,<i>N</i>′,<i>N</i>′-tetramethyl-<i>O</i>-(1<i>H</i>-benzotriazol-1-yl)-uronium hexafluorophosphate</p></td></tr><tr><td class="NLM_term">NDMBA</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-dimethyl barbituric acid</p></td></tr><tr><td class="NLM_term">TBSCl</td><td class="NLM_def"><p class="first last"><i>tert</i>-butyldimethylsilyl chloride</p></td></tr><tr><td class="NLM_term">Alloc</td><td class="NLM_def"><p class="first last">allyloxycarbonyl</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i358">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_08148" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_08148" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 67 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Berger, E. A.</span></span> <span> </span><span class="NLM_article-title">HIV entry and tropism. When one receptor is not enough</span>. <i>Adv. Exp. Med. Biol.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>452</i></span>,  <span class="NLM_fpage">151</span>– <span class="NLM_lpage">157</span>, <span class="refDoi"> DOI: 10.1007/978-1-4615-5355-7_16</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=10.1007%2F978-1-4615-5355-7_16" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=9889968" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=1%3ACAS%3A528%3ADyaK1cXotVGqsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=452&publication_year=1998&pages=151-157&author=E.+A.+Berger&title=HIV+entry+and+tropism.+When+one+receptor+is+not+enough&doi=10.1007%2F978-1-4615-5355-7_16"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">HIV entry and tropism: when one receptor is not enough</span></div><div class="casAuthors">Berger, Edward A.</div><div class="citationInfo"><span class="NLM_cas:title">Advances in Experimental Medicine and Biology</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">452</span>
        (<span class="NLM_cas:issue">Mechanisms of Lymphocyte Activation and Immune Regulation VII</span>),
    <span class="NLM_cas:pages">151-157</span>CODEN:
                <span class="NLM_cas:coden">AEMBAP</span>;
        ISSN:<span class="NLM_cas:issn">0065-2598</span>.
    
            (<span class="NLM_cas:orgname">Plenum Publishing Corp.</span>)
        </div><div class="casAbstract">A review with 39 refs.  Topics discussed include evidence for the existence of HIV coreceptors; CXCR4; CCR5; and mode of action of coreceptors in the fusion/infection process.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFFgDELx7MJ7Vg90H21EOLACvtfcHk0lgmwhVUhwaQIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXotVGqsLs%253D&md5=088234e35f5fead82bc7262f18dbb2d0</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1007%2F978-1-4615-5355-7_16&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-1-4615-5355-7_16%26sid%3Dliteratum%253Aachs%26aulast%3DBerger%26aufirst%3DE.%2BA.%26atitle%3DHIV%2520entry%2520and%2520tropism.%2520When%2520one%2520receptor%2520is%2520not%2520enough%26jtitle%3DAdv.%2520Exp.%2520Med.%2520Biol.%26date%3D1998%26volume%3D452%26spage%3D151%26epage%3D157%26doi%3D10.1007%2F978-1-4615-5355-7_16" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blair, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meanwell, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallace, O. B.</span></span> <span> </span><span class="NLM_article-title">HIV-1 entry - an expanding portal for drug discovery</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">183</span>– <span class="NLM_lpage">194</span>, <span class="refDoi"> DOI: 10.1016/S1359-6446(00)01484-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=10.1016%2FS1359-6446%2800%2901484-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=10790262" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=1%3ACAS%3A528%3ADC%252BD3cXislehu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2000&pages=183-194&author=W.+S.+Blairauthor=P.+F.+Linauthor=N.+A.+Meanwellauthor=O.+B.+Wallace&title=HIV-1+entry+-+an+expanding+portal+for+drug+discovery&doi=10.1016%2FS1359-6446%2800%2901484-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">HIV-1 entry - an expanding portal for drug discovery</span></div><div class="casAuthors">Blair, W. S.; Lin, P.-F.; Meanwell, N. A.; Wallace, O. B.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">183-194</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review and discussion with 66 refs.  The advent of highly active antiretroviral therapy (HAART)-combinations of protease and reverse transcriptase inhibitors-provided a potent and clin. effective method of suppressing viral load in HIV-1- infected individuals.  However, although initially successful, a broader clin. experience has revealed limitations in this therapeutic regimen, with up to 40% of treated individuals ultimately failing to sustain control over viral replication.  Significant advances in understanding the process by which HIV-1 enters host cells have brought into clear focus a target for drug discovery not represented in the current clin. armamentarium.  In this article, the mechanism of HIV-1 entry is reviewed in the context of representative antiviral agents that interfere with key steps in this process.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRY3TNUX-AuLVg90H21EOLACvtfcHk0lgmwhVUhwaQIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXislehu7c%253D&md5=c9323fe99bf289a476ff06597d97ffac</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2FS1359-6446%2800%2901484-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1359-6446%252800%252901484-7%26sid%3Dliteratum%253Aachs%26aulast%3DBlair%26aufirst%3DW.%2BS.%26aulast%3DLin%26aufirst%3DP.%2BF.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DWallace%26aufirst%3DO.%2BB.%26atitle%3DHIV-1%2520entry%2520-%2520an%2520expanding%2520portal%2520for%2520drug%2520discovery%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2000%26volume%3D5%26spage%3D183%26epage%3D194%26doi%3D10.1016%2FS1359-6446%2800%2901484-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Caffrey, M.</span></span> <span> </span><span class="NLM_article-title">HIV envelope: challenges and opportunities for development of entry inhibitors</span>. <i>Trends Microbiol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">191</span>– <span class="NLM_lpage">197</span>, <span class="refDoi"> DOI: 10.1016/j.tim.2011.02.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=10.1016%2Fj.tim.2011.02.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=21377881" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=1%3ACAS%3A528%3ADC%252BC3MXkt1KhtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2011&pages=191-197&author=M.+Caffrey&title=HIV+envelope%3A+challenges+and+opportunities+for+development+of+entry+inhibitors&doi=10.1016%2Fj.tim.2011.02.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">HIV envelope: challenges and opportunities for development of entry inhibitors</span></div><div class="casAuthors">Caffrey, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Microbiology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">191-197</span>CODEN:
                <span class="NLM_cas:coden">TRMIEA</span>;
        ISSN:<span class="NLM_cas:issn">0966-842X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The HIV envelope proteins glycoprotein 120 (gp120) and glycoprotein 41 (gp41) play crucial roles in HIV entry, therefore they are of extreme interest in the development of novel therapeutics.  Studies using diverse methods, including structural biol. and mutagenesis, have resulted in a detailed model for envelope-mediated entry, which consists of multiple conformations, each a potential target for therapeutic intervention.  In this review, the challenges, strategies and progress to date for developing novel entry inhibitors directed at disrupting HIV gp120 and gp41 function are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhU7id80YXh7Vg90H21EOLACvtfcHk0lgSf_7nPFiIvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXkt1KhtLs%253D&md5=1baeddf2495b214487488d3827095b27</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2Fj.tim.2011.02.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tim.2011.02.001%26sid%3Dliteratum%253Aachs%26aulast%3DCaffrey%26aufirst%3DM.%26atitle%3DHIV%2520envelope%253A%2520challenges%2520and%2520opportunities%2520for%2520development%2520of%2520entry%2520inhibitors%26jtitle%3DTrends%2520Microbiol.%26date%3D2011%26volume%3D19%26spage%3D191%26epage%3D197%26doi%3D10.1016%2Fj.tim.2011.02.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chan, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, P. S.</span></span> <span> </span><span class="NLM_article-title">HIV entry and its inhibition</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>93</i></span>,  <span class="NLM_fpage">681</span>– <span class="NLM_lpage">684</span>, <span class="refDoi"> DOI: 10.1016/S0092-8674(00)81430-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=10.1016%2FS0092-8674%2800%2981430-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=9630213" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=1%3ACAS%3A528%3ADyaK1cXjsl2ksLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=1998&pages=681-684&author=D.+C.+Chanauthor=P.+S.+Kim&title=HIV+entry+and+its+inhibition&doi=10.1016%2FS0092-8674%2800%2981430-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">HIV entry and its inhibition</span></div><div class="casAuthors">Chan, David C.; Kim, Peter S.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, Massachusetts)</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">681-684</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review with 22 refs. on recent insights in HIV envelope protein structure and function and the current understanding of the viral entry process.  The authors also reviewed how these finding lead to new approaches for inhibiting HIV entry and may provide insights into the design of better HIV vaccines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeFZy87GmmlrVg90H21EOLACvtfcHk0lgSf_7nPFiIvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXjsl2ksLs%253D&md5=dc7d38422e8c901b2804d79a3c224f9d</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2800%2981430-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252800%252981430-0%26sid%3Dliteratum%253Aachs%26aulast%3DChan%26aufirst%3DD.%2BC.%26aulast%3DKim%26aufirst%3DP.%2BS.%26atitle%3DHIV%2520entry%2520and%2520its%2520inhibition%26jtitle%3DCell%26date%3D1998%26volume%3D93%26spage%3D681%26epage%3D684%26doi%3D10.1016%2FS0092-8674%2800%2981430-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kadow, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ueda, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meanwell, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connolly, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeung, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bender, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colonno, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathew, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chien, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grasela, D.</span></span> <span> </span><span class="NLM_article-title">Inhibitors of human immunodeficiency virus type 1 (HIV-1) attachment 6. Preclinical and human pharmacokinetic profiling of BMS-663749, a phosphonooxymethyl prodrug of the HIV-1 attachment inhibitor 2-(4-benzoyl-1-piperazinyl)-1-(4,7-dimethoxy-1H-pyrrolo[2,3-c]pyridin-3-yl)-2-oxo ethanone (BMS-488043)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">2048</span>– <span class="NLM_lpage">2056</span>, <span class="refDoi"> DOI: 10.1021/jm201218m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm201218m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=1%3ACAS%3A528%3ADC%252BC38XislSksbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=2048-2056&author=J.+F.+Kadowauthor=Y.+Uedaauthor=N.+A.+Meanwellauthor=T.+P.+Connollyauthor=T.+Wangauthor=C.+P.+Chenauthor=K.+S.+Yeungauthor=J.+Zhuauthor=J.+A.+Benderauthor=Z.+Yangauthor=D.+Parkerauthor=P.+F.+Linauthor=R.+J.+Colonnoauthor=M.+Mathewauthor=D.+Morganauthor=M.+Zhengauthor=C.+Chienauthor=D.+Grasela&title=Inhibitors+of+human+immunodeficiency+virus+type+1+%28HIV-1%29+attachment+6.+Preclinical+and+human+pharmacokinetic+profiling+of+BMS-663749%2C+a+phosphonooxymethyl+prodrug+of+the+HIV-1+attachment+inhibitor+2-%284-benzoyl-1-piperazinyl%29-1-%284%2C7-dimethoxy-1H-pyrrolo%5B2%2C3-c%5Dpyridin-3-yl%29-2-oxo+ethanone+%28BMS-488043%29&doi=10.1021%2Fjm201218m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitors of Human Immunodeficiency Virus Type 1 (HIV-1) Attachment 6. Preclinical and Human Pharmacokinetic Profiling of BMS-663749, a Phosphonooxymethyl Prodrug of the HIV-1 Attachment Inhibitor 2-(4-Benzoyl-1-piperazinyl)-1-(4,7-dimethoxy-1H-pyrrolo[2,3-c]pyridin-3-yl)-2-oxoethanone (BMS-488043)</span></div><div class="casAuthors">Kadow, John F.; Ueda, Yasutsugu; Meanwell, Nicholas A.; Connolly, Timothy P.; Wang, Tao; Chen, Chung-Pin; Yeung, Kap-Sun; Zhu, Juliang; Bender, John A.; Yang, Zhong; Parker, Dawn; Lin, Pin-Fang; Colonno, Richard J.; Mathew, Marina; Morgan, Daniel; Zheng, Ming; Chien, Caly; Grasela, Dennis</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2048-2056</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">BMS-663749, a phosphonooxymethyl prodrug of the HIV-1 attachment inhibitor 2-(4-benzoyl-1-piperazinyl)-1-(4,7-dimethoxy-1H-pyrrolo[2,3-c]pyridin-3-yl)-2-oxoethanone (BMS-488043) was prepd. and profiled in a variety of preclin. in vitro and in vivo models designed to assess its ability to deliver parent drug following oral administration.  The data showed that prodrug BMS-663749 had excellent potential to significantly reduce dissoln. rate-limited absorption following oral dosing in humans.  Clin. studies in normal healthy subjects confirmed the potential of BMS-663749, revealing that the prodrug significantly increased both the AUC and Cmax of BMS-488043 compared to a solid capsule formulation contg. the parent drug upon dose escalation.  These data provided guidance for further efforts to obtain an effective HIV-1 attachment inhibitor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGquRUP4I30EK7Vg90H21EOLACvtfcHk0lgSf_7nPFiIvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XislSksbs%253D&md5=bcc45742e8dcab5fcfd595c94e0951e8</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1021%2Fjm201218m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201218m%26sid%3Dliteratum%253Aachs%26aulast%3DKadow%26aufirst%3DJ.%2BF.%26aulast%3DUeda%26aufirst%3DY.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DConnolly%26aufirst%3DT.%2BP.%26aulast%3DWang%26aufirst%3DT.%26aulast%3DChen%26aufirst%3DC.%2BP.%26aulast%3DYeung%26aufirst%3DK.%2BS.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DBender%26aufirst%3DJ.%2BA.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DParker%26aufirst%3DD.%26aulast%3DLin%26aufirst%3DP.%2BF.%26aulast%3DColonno%26aufirst%3DR.%2BJ.%26aulast%3DMathew%26aufirst%3DM.%26aulast%3DMorgan%26aufirst%3DD.%26aulast%3DZheng%26aufirst%3DM.%26aulast%3DChien%26aufirst%3DC.%26aulast%3DGrasela%26aufirst%3DD.%26atitle%3DInhibitors%2520of%2520human%2520immunodeficiency%2520virus%2520type%25201%2520%2528HIV-1%2529%2520attachment%25206.%2520Preclinical%2520and%2520human%2520pharmacokinetic%2520profiling%2520of%2520BMS-663749%252C%2520a%2520phosphonooxymethyl%2520prodrug%2520of%2520the%2520HIV-1%2520attachment%2520inhibitor%25202-%25284-benzoyl-1-piperazinyl%2529-1-%25284%252C7-dimethoxy-1H-pyrrolo%255B2%252C3-c%255Dpyridin-3-yl%2529-2-oxo%2520ethanone%2520%2528BMS-488043%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D2048%26epage%3D2056%26doi%3D10.1021%2Fjm201218m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nowicka-Sans, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, Y. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McAuliffe, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dicker, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, H. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eggers, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ray, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wind-Rotolo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Majumdar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stock, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lataillade, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanna, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matiskella, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ueda, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kadow, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meanwell, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krystal, M.</span></span> <span> </span><span class="NLM_article-title">In vitro antiviral characteristics of HIV-1 attachment inhibitor BMS-626529, the active component of the prodrug BMS-663068</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">3498</span>– <span class="NLM_lpage">3507</span>, <span class="refDoi"> DOI: 10.1128/AAC.00426-12</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=10.1128%2FAAC.00426-12" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=22547625" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=1%3ACAS%3A528%3ADC%252BC38XpsV2ju74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2012&pages=3498-3507&author=B.+Nowicka-Sansauthor=Y.+F.+Gongauthor=B.+McAuliffeauthor=I.+Dickerauthor=H.+T.+Hoauthor=N.+Zhouauthor=B.+Eggersauthor=P.+F.+Linauthor=N.+Rayauthor=M.+Wind-Rotoloauthor=L.+Zhuauthor=A.+Majumdarauthor=D.+Stockauthor=M.+Latailladeauthor=G.+J.+Hannaauthor=J.+D.+Matiskellaauthor=Y.+Uedaauthor=T.+Wangauthor=J.+F.+Kadowauthor=N.+A.+Meanwellauthor=M.+Krystal&title=In+vitro+antiviral+characteristics+of+HIV-1+attachment+inhibitor+BMS-626529%2C+the+active+component+of+the+prodrug+BMS-663068&doi=10.1128%2FAAC.00426-12"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro antiviral characteristics of HIV-1 attachment inhibitor BMS-626529, the active component of the prodrug BMS-663068</span></div><div class="casAuthors">Nowicka-Sans, Beata; Gong, Yi-Fei; McAuliffe, Brian; Dicker, Ira; Ho, Hsu-Tso; Zhou, Nannan; Eggers, Betsy; Lin, Pin-Fang; Ray, Neelanjana; Wind-Rotolo, Megan; Zhu, Li; Majumdar, Antara; Stock, David; Lataillade, Max; Hanna, George J.; Matiskella, John D.; Ueda, Yasutsugu; Wang, Tao; Kadow, John F.; Meanwell, Nicholas A.; Krystal, Mark</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3498-3507</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">BMS-663068 is the phosphonooxymethyl prodrug of BMS-626529, a novel small-mol. attachment inhibitor that targets HIV-1 gp120 and prevents its binding to CD4+ T cells.  The activity of BMS-626529 is virus dependent, due to heterogeneity within gp120.  In order to better understand the anti-HIV-1 spectrum of BMS-626529 against HIV-1, in vitro activities against a wide variety of lab. strains and clin. isolates were detd.  BMS-626529 had half-maximal effective concn. (EC50) values of <10 nM against the vast majority of viral isolates; however, susceptibility varied by >6 log10, with half-maximal effective concn. values in the low pM range against the most susceptible viruses.  The in vitro antiviral activity of BMS-626529 was generally not assocd. with either tropism or subtype, with few exceptions.  Measurement of the binding affinity of BMS-626529 for purified gp120 suggests that a contributory factor to its inhibitory potency may be a relatively long dissociative half-life.  Finally, in two-drug combination studies, BMS-626529 demonstrated additive or synergistic interactions with antiretroviral drugs of different mechanistic classes.  These results suggest that BMS-626529 should be active against the majority of HIV-1 viruses and support the continued clin. development of the compd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTOoFBxJXxT7Vg90H21EOLACvtfcHk0liM4ACt4xLrVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XpsV2ju74%253D&md5=85a1eb4a32a558f9cfeae31c9968073e</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1128%2FAAC.00426-12&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.00426-12%26sid%3Dliteratum%253Aachs%26aulast%3DNowicka-Sans%26aufirst%3DB.%26aulast%3DGong%26aufirst%3DY.%2BF.%26aulast%3DMcAuliffe%26aufirst%3DB.%26aulast%3DDicker%26aufirst%3DI.%26aulast%3DHo%26aufirst%3DH.%2BT.%26aulast%3DZhou%26aufirst%3DN.%26aulast%3DEggers%26aufirst%3DB.%26aulast%3DLin%26aufirst%3DP.%2BF.%26aulast%3DRay%26aufirst%3DN.%26aulast%3DWind-Rotolo%26aufirst%3DM.%26aulast%3DZhu%26aufirst%3DL.%26aulast%3DMajumdar%26aufirst%3DA.%26aulast%3DStock%26aufirst%3DD.%26aulast%3DLataillade%26aufirst%3DM.%26aulast%3DHanna%26aufirst%3DG.%2BJ.%26aulast%3DMatiskella%26aufirst%3DJ.%2BD.%26aulast%3DUeda%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DT.%26aulast%3DKadow%26aufirst%3DJ.%2BF.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DKrystal%26aufirst%3DM.%26atitle%3DIn%2520vitro%2520antiviral%2520characteristics%2520of%2520HIV-1%2520attachment%2520inhibitor%2520BMS-626529%252C%2520the%2520active%2520component%2520of%2520the%2520prodrug%2520BMS-663068%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2012%26volume%3D56%26spage%3D3498%26epage%3D3507%26doi%3D10.1128%2FAAC.00426-12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallace, O. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deshpande, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zadjura, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tweedie, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ranadive, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, Y. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ricarrdi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spicer, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deminie, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rose, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blair, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, P. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colonno, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meanwell, N. A.</span></span> <span> </span><span class="NLM_article-title">Discovery of 4-benzoyl-1-[(4-methoxy-1H- pyrrolo[2,3-b]pyridin-3-yl)oxoacetyl]-2- (R)-methylpiperazine (BMS-378806): a novel HIV-1 attachment inhibitor that interferes with CD4-gp120 interactions</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">4236</span>– <span class="NLM_lpage">4239</span>, <span class="refDoi"> DOI: 10.1021/jm034082o</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm034082o" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=1%3ACAS%3A528%3ADC%252BD3sXmsl2nt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=4236-4239&author=T.+Wangauthor=Z.+Zhangauthor=O.+B.+Wallaceauthor=M.+Deshpandeauthor=H.+Fangauthor=Z.+Yangauthor=L.+M.+Zadjuraauthor=D.+L.+Tweedieauthor=S.+Huangauthor=F.+Zhaoauthor=S.+Ranadiveauthor=B.+S.+Robinsonauthor=Y.+F.+Gongauthor=K.+Ricarrdiauthor=T.+P.+Spicerauthor=C.+Deminieauthor=R.+Roseauthor=H.+G.+Wangauthor=W.+S.+Blairauthor=P.+Y.+Shiauthor=P.+F.+Linauthor=R.+J.+Colonnoauthor=N.+A.+Meanwell&title=Discovery+of+4-benzoyl-1-%5B%284-methoxy-1H-+pyrrolo%5B2%2C3-b%5Dpyridin-3-yl%29oxoacetyl%5D-2-+%28R%29-methylpiperazine+%28BMS-378806%29%3A+a+novel+HIV-1+attachment+inhibitor+that+interferes+with+CD4-gp120+interactions&doi=10.1021%2Fjm034082o"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 4-benzoyl-1-[(4-methoxy-1H- pyrrolo[2,3-b]pyridin-3-yl)oxoacetyl]-2- (R)-methylpiperazine (BMS-378806): A Novel HIV-1 Attachment Inhibitor That Interferes with CD4-gp120 Interactions</span></div><div class="casAuthors">Wang, Tao; Zhang, Zhongxing; Wallace, Owen B.; Deshpande, Milind; Fang, Haiquan; Yang, Zheng; Zadjura, Lisa M.; Tweedie, Donald L.; Huang, Stella; Zhao, Fang; Ranadive, Sunanda; Robinson, Brett S.; Gong, Yi-Fei; Ricarrdi, Keith; Spicer, Timothy P.; Deminie, Carol; Rose, Ronald; Wang, Hwei-Gene Heidi; Blair, Wade S.; Shi, Pei-Yong; Lin, Pin-fang; Colonno, Richard J.; Meanwell, Nicholas A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">4236-4239</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Indole deriv. 1 interferes with the interaction of the HIV surface protein gp120 with the host cell receptor CD4.  The 4-fluoro deriv. 2 exhibited markedly enhanced potency and was bioavailable in the rat, dog, and cynomolgus monkey when administered orally as a soln. formulation.  However, aq. suspensions of 2 were poorly bioavailable, indicative of dissoln.-limited absorption.  The 7-azaindole deriv. 3, BMS-378806, exhibited improved pharmaceutical properties while retaining the HIV-1 inhibitory profile of 2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdBR3IszWDCbVg90H21EOLACvtfcHk0ljn3aBuKkvxFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXmsl2nt7w%253D&md5=bd3d210677181d1748c8f8ba309c37bb</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1021%2Fjm034082o&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm034082o%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DWallace%26aufirst%3DO.%2BB.%26aulast%3DDeshpande%26aufirst%3DM.%26aulast%3DFang%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DZadjura%26aufirst%3DL.%2BM.%26aulast%3DTweedie%26aufirst%3DD.%2BL.%26aulast%3DHuang%26aufirst%3DS.%26aulast%3DZhao%26aufirst%3DF.%26aulast%3DRanadive%26aufirst%3DS.%26aulast%3DRobinson%26aufirst%3DB.%2BS.%26aulast%3DGong%26aufirst%3DY.%2BF.%26aulast%3DRicarrdi%26aufirst%3DK.%26aulast%3DSpicer%26aufirst%3DT.%2BP.%26aulast%3DDeminie%26aufirst%3DC.%26aulast%3DRose%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DH.%2BG.%26aulast%3DBlair%26aufirst%3DW.%2BS.%26aulast%3DShi%26aufirst%3DP.%2BY.%26aulast%3DLin%26aufirst%3DP.%2BF.%26aulast%3DColonno%26aufirst%3DR.%2BJ.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26atitle%3DDiscovery%2520of%25204-benzoyl-1-%255B%25284-methoxy-1H-%2520pyrrolo%255B2%252C3-b%255Dpyridin-3-yl%2529oxoacetyl%255D-2-%2520%2528R%2529-methylpiperazine%2520%2528BMS-378806%2529%253A%2520a%2520novel%2520HIV-1%2520attachment%2520inhibitor%2520that%2520interferes%2520with%2520CD4-gp120%2520interactions%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26spage%3D4236%26epage%3D4239%26doi%3D10.1021%2Fjm034082o" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Belov, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curreli, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurkin, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altieri, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Debnath, A. K.</span></span> <span> </span><span class="NLM_article-title">Guanidine-containing phenyl-pyrrole compounds as probes for generating HIV nntry inhibitors targeted to gp120</span>. <i>ChemistrySelect</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">6450</span>– <span class="NLM_lpage">6453</span>, <span class="refDoi"> DOI: 10.1002/slct.201801662</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=10.1002%2Fslct.201801662" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtF2ls7fE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2018&pages=6450-6453&author=D.+S.+Belovauthor=F.+Curreliauthor=A.+V.+Kurkinauthor=A.+Altieriauthor=A.+K.+Debnath&title=Guanidine-containing+phenyl-pyrrole+compounds+as+probes+for+generating+HIV+nntry+inhibitors+targeted+to+gp120&doi=10.1002%2Fslct.201801662"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Guanidine-Containing Phenyl-Pyrrole Compounds as Probes for Generating HIV Entry Inhibitors Targeted to gp120</span></div><div class="casAuthors">Belov, Dmitry S.; Curreli, Francesca; Kurkin, Alexander V.; Altieri, Andrea; Debnath, Asim K.</div><div class="citationInfo"><span class="NLM_cas:title">ChemistrySelect</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">6450-6453</span>CODEN:
                <span class="NLM_cas:coden">CHEMUD</span>;
        ISSN:<span class="NLM_cas:issn">2365-6549</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Asp368 in the HIV-1 envelope glycoprotein gp120 plays a crit. role in binding to the Arg59 of the primary cellular receptor CD4 through forming a salt-bridge to initiate HIV-1 entry and infection.  The mols. capable of interfering with the entry of virus to host cells are termed HIV-1 entry/attachment inhibitors.  Earlier, we designed N-(2-amino-1-(5-(hydroxymethyl)-4-methylthiazol-2-yl)ethyl)-5-(4-chloro-3-fluorophenyl)-1H-pyrrole-2-carboxamide series compds. as entry inhibitors targeted to HIV-1 gp120.  Here, we report the incorporation of guanidine moiety to replace free amine in some of those HIV-1 entry inhibitors.  Guanidine group is expected to simulate Arg59 and interact with Asp368 of the gp120 to form salt-bridge and thus blocking the binding of HIV-1 with the cell receptor CD4.  The resulting compds. were tested against Env-pseudotyped HIV-1, and few of them showed low μM inhibition.  The guanidines also showed higher aq. soly. than compds. with a free amine.  One of the guanidines, N-(2-(2-guanidinoacetamido)-1-(4-(hydroxymethyl)thiazol-2-yl)ethyl)-5-(4-(trifluoromethyl)phenyl)-1H-pyrrole-2-carboxamide (10), is expected to be a lead for further optimization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9MMlNN_OZ1rVg90H21EOLACvtfcHk0ljn3aBuKkvxFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtF2ls7fE&md5=80487a6dd17b1e8ee6feb1f85dbbe069</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1002%2Fslct.201801662&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fslct.201801662%26sid%3Dliteratum%253Aachs%26aulast%3DBelov%26aufirst%3DD.%2BS.%26aulast%3DCurreli%26aufirst%3DF.%26aulast%3DKurkin%26aufirst%3DA.%2BV.%26aulast%3DAltieri%26aufirst%3DA.%26aulast%3DDebnath%26aufirst%3DA.%2BK.%26atitle%3DGuanidine-containing%2520phenyl-pyrrole%2520compounds%2520as%2520probes%2520for%2520generating%2520HIV%2520nntry%2520inhibitors%2520targeted%2520to%2520gp120%26jtitle%3DChemistrySelect%26date%3D2018%26volume%3D3%26spage%3D6450%26epage%3D6453%26doi%3D10.1002%2Fslct.201801662" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Curreli, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, Y. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belov, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramesh, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurkin, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altieri, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwong, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Debnath, A. K.</span></span> <span> </span><span class="NLM_article-title">Synthesis, antiviral potency, in vitro ADMET and X-ray structure of potent CD4-mimics as entry inhibitors that target the Phe43 cavity of HIV-1 gp120</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">3124</span>– <span class="NLM_lpage">3153</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00179</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00179" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjvVOnsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=3124-3153&author=F.+Curreliauthor=Y.+D.+Kwonauthor=D.+S.+Belovauthor=R.+R.+Rameshauthor=A.+V.+Kurkinauthor=A.+Altieriauthor=P.+D.+Kwongauthor=A.+K.+Debnath&title=Synthesis%2C+antiviral+potency%2C+in+vitro+ADMET+and+X-ray+structure+of+potent+CD4-mimics+as+entry+inhibitors+that+target+the+Phe43+cavity+of+HIV-1+gp120&doi=10.1021%2Facs.jmedchem.7b00179"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, Antiviral Potency, in Vitro ADMET, and X-ray Structure of Potent CD4 Mimics as Entry Inhibitors That Target the Phe43 Cavity of HIV-1 gp120</span></div><div class="casAuthors">Curreli, Francesca; Kwon, Young Do; Belov, Dmitry S.; Ramesh, Ranjith R.; Kurkin, Alexander V.; Altieri, Andrea; Kwong, Peter D.; Debnath, Asim K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3124-3153</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In our attempt to optimize the lead HIV-1 entry antagonist, NBD-11021, we present in this study the rational design and synthesis of 60 new analogs and detn. of their antiviral activity in a single-cycle and a multicycle infection assay to derive a comprehensive structure-activity relationship (SAR).  Two of these compds., I and II, showed significant improvement in antiviral activity compared to the lead entry antagonist in a single-cycle assay against a large panel of Env-pseudotyped viruses.  The X-ray structure of a similar compd., NBD-14010, confirmed the binding mode of the newly designed compds.  The in vitro ADMET profiles of these compds. are comparable to that of the most potent attachment inhibitor BMS-626529, a prodrug of which is currently undergoing phase III clin. trials.  The systematic study presented here is expected to pave the way for improving the potency, toxicity, and ADMET profile of this series of compds. with the potential to be moved to the early preclin. development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrF4GuoyULRebVg90H21EOLACvtfcHk0ljn3aBuKkvxFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjvVOnsbY%253D&md5=af68fad9120d8dfd31e26f4607b523d9</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00179&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00179%26sid%3Dliteratum%253Aachs%26aulast%3DCurreli%26aufirst%3DF.%26aulast%3DKwon%26aufirst%3DY.%2BD.%26aulast%3DBelov%26aufirst%3DD.%2BS.%26aulast%3DRamesh%26aufirst%3DR.%2BR.%26aulast%3DKurkin%26aufirst%3DA.%2BV.%26aulast%3DAltieri%26aufirst%3DA.%26aulast%3DKwong%26aufirst%3DP.%2BD.%26aulast%3DDebnath%26aufirst%3DA.%2BK.%26atitle%3DSynthesis%252C%2520antiviral%2520potency%252C%2520in%2520vitro%2520ADMET%2520and%2520X-ray%2520structure%2520of%2520potent%2520CD4-mimics%2520as%2520entry%2520inhibitors%2520that%2520target%2520the%2520Phe43%2520cavity%2520of%2520HIV-1%2520gp120%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D3124%26epage%3D3153%26doi%3D10.1021%2Facs.jmedchem.7b00179" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Curreli, F. B. D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, Y. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramesh, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furimsky, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Loughlin, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byrge, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iyer, L. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mirsalis, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurkin, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altieri, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Debnath, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belov, D. S.</span></span> <span> </span><span class="NLM_article-title">Structure-based lead optimization to improve antiviral potency and ADMET properties of phenyl-1H-pyrrole-carboxamide entry inhibitors targeted to HIV-1 gp120</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>154</i></span>,  <span class="NLM_fpage">367</span>– <span class="NLM_lpage">391</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.04.062</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=10.1016%2Fj.ejmech.2018.04.062" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=29860061" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVKrsbbF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=154&publication_year=2018&pages=367-391&author=F.+B.+D.+S.+Curreliauthor=Y.+D.+Kwonauthor=R.+Rameshauthor=A.+M.+Furimskyauthor=K.+O%E2%80%99Loughlinauthor=P.+C.+Byrgeauthor=L.+V.+Iyerauthor=J.+C.+Mirsalisauthor=A.+V.+Kurkinauthor=A.+Altieriauthor=A.+K.+Debnathauthor=D.+S.+Belov&title=Structure-based+lead+optimization+to+improve+antiviral+potency+and+ADMET+properties+of+phenyl-1H-pyrrole-carboxamide+entry+inhibitors+targeted+to+HIV-1+gp120&doi=10.1016%2Fj.ejmech.2018.04.062"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-based lead optimization to improve antiviral potency and ADMET properties of phenyl-1H-pyrrole-carboxamide entry inhibitors targeted to HIV-1 gp120</span></div><div class="casAuthors">Curreli, Francesca; Belov, Dmitry S.; Kwon, Young Do; Ramesh, Ranjith; Furimsky, Anna M.; O'Loughlin, Kathleen; Byrge, Patricia C.; Iyer, Lalitha V.; Mirsalis, Jon C.; Kurkin, Alexander V.; Altieri, Andrea; Debnath, Asim K.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">154</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">367-391</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">The authors are continuing the concerted effort to optimize the first lead entry antagonist, NBD-11021, which targets the Phe 43 cavity of the HIV-1 envelope glycoprotein gp120, to improve antiviral potency and ADMET properties.  The authors present a structure-based approach that helped to generate working hypotheses to modify further a recently reported advanced lead entry antagonist, NBD-14107, which showed significant improvement in antiviral potency when tested in a single-cycle assay against a large panel of Env-pseudotyped viruses.  The authors report the synthesis of twenty-nine new compds. and evaluation of their antiviral activity in a single-cycle and multi-cycle assay to derive a comprehensive structure-activity relationship (SAR).  The authors have selected three inhibitors with the high selectivity index for testing against a large panel of 55 Env-pseudotyped viruses representing a diverse set of clin. isolates of different subtypes.  The antiviral activity of one of these potent inhibitors, 55 (NBD-14189), against some clin. isolates was as low as 63 nM.  The authors detd. the sensitivity of CD4-binding site mutated-pseudoviruses to these inhibitors to confirm that they target HIV-1 gp120.  Furthermore, the authors assessed their ADMET properties and compared them to the clin. candidate attachment inhibitor, BMS-626529.  The ADMET data indicate that some of these new inhibitors have comparable ADMET properties to BMS-626529 and can be optimized further to potential clin. candidates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOsCIZiXSbKrVg90H21EOLACvtfcHk0lh4Ti7a0PGphw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVKrsbbF&md5=f8fff60fbfc867abdee1d6963e3d6593</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.04.062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.04.062%26sid%3Dliteratum%253Aachs%26aulast%3DCurreli%26aufirst%3DF.%2BB.%2BD.%2BS.%26aulast%3DKwon%26aufirst%3DY.%2BD.%26aulast%3DRamesh%26aufirst%3DR.%26aulast%3DFurimsky%26aufirst%3DA.%2BM.%26aulast%3DO%25E2%2580%2599Loughlin%26aufirst%3DK.%26aulast%3DByrge%26aufirst%3DP.%2BC.%26aulast%3DIyer%26aufirst%3DL.%2BV.%26aulast%3DMirsalis%26aufirst%3DJ.%2BC.%26aulast%3DKurkin%26aufirst%3DA.%2BV.%26aulast%3DAltieri%26aufirst%3DA.%26aulast%3DDebnath%26aufirst%3DA.%2BK.%26aulast%3DBelov%26aufirst%3DD.%2BS.%26atitle%3DStructure-based%2520lead%2520optimization%2520to%2520improve%2520antiviral%2520potency%2520and%2520ADMET%2520properties%2520of%2520phenyl-1H-pyrrole-carboxamide%2520entry%2520inhibitors%2520targeted%2520to%2520HIV-1%2520gp120%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D154%26spage%3D367%26epage%3D391%26doi%3D10.1016%2Fj.ejmech.2018.04.062" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, Y. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finzi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dogo-Isonagie, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuckey, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vicic, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Debnath, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bewley, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mascola, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sodroski, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwong, P. D.</span></span> <span> </span><span class="NLM_article-title">Unliganded HIV-1 gp120 core structures assume the CD4-bound conformation with regulation by quaternary interactions and variable loops</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>109</i></span>,  <span class="NLM_fpage">5663</span>– <span class="NLM_lpage">5668</span>, <span class="refDoi"> DOI: 10.1073/pnas.1112391109</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=10.1073%2Fpnas.1112391109" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=22451932" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=1%3ACAS%3A528%3ADC%252BC38XmtVOisLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2012&pages=5663-5668&author=Y.+D.+Kwonauthor=A.+Finziauthor=X.+Wuauthor=C.+Dogo-Isonagieauthor=L.+K.+Leeauthor=L.+R.+Mooreauthor=S.+D.+Schmidtauthor=J.+Stuckeyauthor=Y.+Yangauthor=T.+Zhouauthor=J.+Zhuauthor=D.+A.+Vicicauthor=A.+K.+Debnathauthor=L.+Shapiroauthor=C.+A.+Bewleyauthor=J.+R.+Mascolaauthor=J.+G.+Sodroskiauthor=P.+D.+Kwong&title=Unliganded+HIV-1+gp120+core+structures+assume+the+CD4-bound+conformation+with+regulation+by+quaternary+interactions+and+variable+loops&doi=10.1073%2Fpnas.1112391109"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Unliganded HIV-1 gp120 core structures assume the CD4-bound conformation with regulation by quaternary interactions and variable loops</span></div><div class="casAuthors">Kwon, Young Do; Finzi, Andres; Wu, Xueling; Dogo-Isonagie, Cajetan; Lee, Lawrence K.; Moore, Lucas R.; Schmidt, Stephen D.; Stuckey, Jonathan; Yang, Yongping; Zhou, Tongqing; Zhu, Jiang; Vicic, David A.; Debnath, Asim K.; Shapiro, Lawrence; Bewley, Carole A.; Mascola, John R.; Sodroski, Joseph G.; Kwong, Peter D.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">5663-5668, S5663/1-S5663/33</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The HIV-1 envelope (Env) spike (gp1203/gp413) undergoes considerable structural rearrangements to mediate virus entry into cells and to evade the host immune response.  Engagement of CD4, the primary human receptor, fixes a particular conformation and primes Env for entry.  The CD4-bound state, however, is prone to spontaneous inactivation and susceptible to antibody neutralization.  How does unliganded HIV-1 maintain CD4-binding capacity and regulate transitions to the CD4-bound state.  To define this mechanistically, we detd. crystal structures of unliganded core gp12O from HIV-1 clades B, C, and E.  Notably, all of these unliganded HIV-1 structures resembled the CD4-bound state.  Conformational fixation with ligand selection and thermodn. anal. of full-length and core gp12O interactions revealed that the tendency of HIV-1 gp12O to adopt the CD4-bound conformation was restrained by the V1 N2- and V3-variable loops.  In parallel, we detd. the structure of core gp120 in complex with the small mol., NBD-556, which specifically recognizes the CD4-bound conformation of gp120.  Neutralization by NBD-556 indicated that Env spikes on primary isolates rarely assume the CD4-bound conformation spontaneously, although they could do so when quaternary restraints were loosened.  Together, the results suggest that the CD4-bound conformation represents a "ground state" for the gp12O core, with variable loop and quaternary interactions restraining unliganded gp12O from "snapping" into this conformation.  A mechanism of control involving deformations in unliganded structure from a functionally crit. state (e.g., the CD4-bound state) provides advantages in terms of HIV-1 Env structural diversity and resistance to antibodies and inhibitors, while maintaining elements essential for entry.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoS3b-Y8pziGrVg90H21EOLACvtfcHk0lh4Ti7a0PGphw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmtVOisLc%253D&md5=2ad1a0459b9ede5cd0d3db0116fd7a0b</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1112391109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1112391109%26sid%3Dliteratum%253Aachs%26aulast%3DKwon%26aufirst%3DY.%2BD.%26aulast%3DFinzi%26aufirst%3DA.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DDogo-Isonagie%26aufirst%3DC.%26aulast%3DLee%26aufirst%3DL.%2BK.%26aulast%3DMoore%26aufirst%3DL.%2BR.%26aulast%3DSchmidt%26aufirst%3DS.%2BD.%26aulast%3DStuckey%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DT.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DVicic%26aufirst%3DD.%2BA.%26aulast%3DDebnath%26aufirst%3DA.%2BK.%26aulast%3DShapiro%26aufirst%3DL.%26aulast%3DBewley%26aufirst%3DC.%2BA.%26aulast%3DMascola%26aufirst%3DJ.%2BR.%26aulast%3DSodroski%26aufirst%3DJ.%2BG.%26aulast%3DKwong%26aufirst%3DP.%2BD.%26atitle%3DUnliganded%2520HIV-1%2520gp120%2520core%2520structures%2520assume%2520the%2520CD4-bound%2520conformation%2520with%2520regulation%2520by%2520quaternary%2520interactions%2520and%2520variable%2520loops%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2012%26volume%3D109%26spage%3D5663%26epage%3D5668%26doi%3D10.1073%2Fpnas.1112391109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, Y. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lalonde, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elban, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugawara, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Courter, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A. B.,  III</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Debnath, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwong, P. D.</span></span> <span> </span><span class="NLM_article-title">Crystal structures of HIV-1 gp120 envelope glycoprotein in complex with NBD analogues that target the CD4-binding site</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">12</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0085940</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=10.1371%2Fjournal.pone.0085940" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=1-12&author=Y.+D.+Kwonauthor=J.+M.+Lalondeauthor=Y.+Yangauthor=M.+A.+Elbanauthor=A.+Sugawaraauthor=J.+R.+Courterauthor=D.+M.+Jonesauthor=A.+B.+Smithauthor=A.+K.+Debnathauthor=P.+D.+Kwong&title=Crystal+structures+of+HIV-1+gp120+envelope+glycoprotein+in+complex+with+NBD+analogues+that+target+the+CD4-binding+site&doi=10.1371%2Fjournal.pone.0085940"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0085940&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0085940%26sid%3Dliteratum%253Aachs%26aulast%3DKwon%26aufirst%3DY.%2BD.%26aulast%3DLalonde%26aufirst%3DJ.%2BM.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DElban%26aufirst%3DM.%2BA.%26aulast%3DSugawara%26aufirst%3DA.%26aulast%3DCourter%26aufirst%3DJ.%2BR.%26aulast%3DJones%26aufirst%3DD.%2BM.%26aulast%3DSmith%26aufirst%3DA.%2BB.%26aulast%3DDebnath%26aufirst%3DA.%2BK.%26aulast%3DKwong%26aufirst%3DP.%2BD.%26atitle%3DCrystal%2520structures%2520of%2520HIV-1%2520gp120%2520envelope%2520glycoprotein%2520in%2520complex%2520with%2520NBD%2520analogues%2520that%2520target%2520the%2520CD4-binding%2520site%26jtitle%3DPLoS%2520One%26date%3D2014%26volume%3D9%26spage%3D1%26epage%3D12%26doi%3D10.1371%2Fjournal.pone.0085940" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strick, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neamati, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Debnath, A. K.</span></span> <span> </span><span class="NLM_article-title">Identification of N-phenyl-N’-(2,2,6,6-tetramethyl-piperidin-4-yl)-oxalamides as a new class of HIV-1 entry inhibitors that prevent gp120 binding to CD4</span>. <i>Virology</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>339</i></span>,  <span class="NLM_fpage">213</span>– <span class="NLM_lpage">225</span>, <span class="refDoi"> DOI: 10.1016/j.virol.2005.06.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=10.1016%2Fj.virol.2005.06.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=15996703" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=1%3ACAS%3A528%3ADC%252BD2MXos1Wqs7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=339&publication_year=2005&pages=213-225&author=Q.+Zhaoauthor=L.+Maauthor=S.+Jiangauthor=H.+Luauthor=S.+Liuauthor=Y.+Heauthor=N.+Strickauthor=N.+Neamatiauthor=A.+K.+Debnath&title=Identification+of+N-phenyl-N%E2%80%99-%282%2C2%2C6%2C6-tetramethyl-piperidin-4-yl%29-oxalamides+as+a+new+class+of+HIV-1+entry+inhibitors+that+prevent+gp120+binding+to+CD4&doi=10.1016%2Fj.virol.2005.06.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of N-phenyl-N'-(2,2,6,6-tetramethyl-piperidin-4-yl)-oxalamides as a new class of HIV-1 entry inhibitors that prevent gp120 binding to CD4</span></div><div class="casAuthors">Zhao, Qian; Ma, Liying; Jiang, Shibo; Lu, Hong; Liu, Shuwen; He, Yuxian; Strick, Nathan; Neamati, Nouri; Debnath, Asim Kumar</div><div class="citationInfo"><span class="NLM_cas:title">Virology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">339</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">213-225</span>CODEN:
                <span class="NLM_cas:coden">VIRLAX</span>;
        ISSN:<span class="NLM_cas:issn">0042-6822</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">We have identified two N-phenyl-N'-(2,2,6,6-tetramethyl-piperidin-4-yl)-oxalamide analogs as a novel class of human immunodeficiency virus type 1 (HIV-1) entry inhibitors that block the gp120-CD4 interaction, using database screening techniques.  The lead compds., NBD-556 and NBD-557, are small mol. org. compds. with drug-like properties.  These compds. showed potent cell fusion and virus-cell fusion inhibitory activity at low micromolar levels.  A systematic study showed that these compds. target viral entry by inhibiting the binding of HIV-1 envelope glycoprotein gp120 to the cellular receptor CD4 but did not inhibit reverse transcriptase, integrase, or protease, indicating that they do not target the later stages of the HIV-1 life cycle to inhibit HIV-1 infection.  These compds. were equally potent inhibitors of both X4 and R5 viruses tested in CXCR4 and CCR5 expressing cell lines, resp., indicating that their anti-HIV-1 activity is not dependent on the coreceptor tropism of the virus.  A surface plasmon resonance study, which measures binding affinity, clearly demonstrated that these compds. bind to unliganded HIV-1 gp120 but not to the cellular receptor CD4.  NBD-556 and NBD-557 were active against HIV-1 lab.-adapted strains including an AZT-resistant strain and HIV-1 primary isolates, indicating that these compds. can potentially be further modified to become potent HIV-1 entry inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZSz2irXkLMLVg90H21EOLACvtfcHk0lhjZaatnZTAaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXos1Wqs7w%253D&md5=15c9a147d5a7410d40076690822b3aff</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2Fj.virol.2005.06.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.virol.2005.06.008%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DQ.%26aulast%3DMa%26aufirst%3DL.%26aulast%3DJiang%26aufirst%3DS.%26aulast%3DLu%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DHe%26aufirst%3DY.%26aulast%3DStrick%26aufirst%3DN.%26aulast%3DNeamati%26aufirst%3DN.%26aulast%3DDebnath%26aufirst%3DA.%2BK.%26atitle%3DIdentification%2520of%2520N-phenyl-N%25E2%2580%2599-%25282%252C2%252C6%252C6-tetramethyl-piperidin-4-yl%2529-oxalamides%2520as%2520a%2520new%2520class%2520of%2520HIV-1%2520entry%2520inhibitors%2520that%2520prevent%2520gp120%2520binding%2520to%2520CD4%26jtitle%3DVirology%26date%3D2005%26volume%3D339%26spage%3D213%26epage%3D225%26doi%3D10.1016%2Fj.virol.2005.06.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Courter, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madani, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sodroski, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freire, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwong, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hendrickson, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaiken, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lalonde, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A. B.,  III</span></span> <span> </span><span class="NLM_article-title">Structure-based design, synthesis and validation of CD4-mimetic small molecule inhibitors of HIV-1 entry: conversion of a viral entry agonist to an antagonist</span>. <i>Acc. Chem. Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">1228</span>– <span class="NLM_lpage">1237</span>, <span class="refDoi"> DOI: 10.1021/ar4002735</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ar4002735" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVOqtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2014&pages=1228-1237&author=J.+R.+Courterauthor=N.+Madaniauthor=J.+Sodroskiauthor=A.+Schonauthor=E.+Freireauthor=P.+D.+Kwongauthor=W.+A.+Hendricksonauthor=I.+M.+Chaikenauthor=J.+M.+Lalondeauthor=A.+B.+Smith&title=Structure-based+design%2C+synthesis+and+validation+of+CD4-mimetic+small+molecule+inhibitors+of+HIV-1+entry%3A+conversion+of+a+viral+entry+agonist+to+an+antagonist&doi=10.1021%2Far4002735"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Based Design, Synthesis and Validation of CD4-Mimetic Small Molecule Inhibitors of HIV-1 Entry: Conversion of a Viral Entry Agonist to an Antagonist</span></div><div class="casAuthors">Courter, Joel R.; Madani, Navid; Sodroski, Joseph; Schon, Arne; Freire, Ernesto; Kwong, Peter D.; Hendrickson, Wayne A.; Chaiken, Irwin M.; La Londe, Judith M.; Smith, Amos B., III</div><div class="citationInfo"><span class="NLM_cas:title">Accounts of Chemical Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1228-1237</span>CODEN:
                <span class="NLM_cas:coden">ACHRE4</span>;
        ISSN:<span class="NLM_cas:issn">0001-4842</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">This Account provides an overview of a multidisciplinary consortium focused on structure-based strategies to devise small mol. antagonists of HIV-1 entry into human T-cells, which if successful would hold considerable promise for the development of prophylactic modalities to prevent HIV transmission and thereby alter the course of the AIDS pandemic.  Entry of the human immunodeficiency virus (HIV) into target T-cells entails an interaction between CD4 on the host T-cell and gp120, a component of the trimeric envelope glycoprotein spike on the virion surface.  The resultant interaction initiates a series of conformational changes within the envelope spike that permits binding to a chemokine receptor, formation of the gp41 fusion complex, and cell entry.  A hydrophobic cavity at the CD4-gp120 interface, defined by x-ray crystallog., provided an initial site for small mol. antagonist design.  This site however has evolved to facilitate viral entry.  As such, the binding of prospective small mol. inhibitors within this gp120 cavity can inadvertently trigger an allosteric entry signal.  Structural characterization of the CD4-gp120 interface, which provided the foundation for small mol. structure-based inhibitor design, will be presented first.  An integrated approach combining biochem., virol., structural, computational, and synthetic studies, along with a detailed anal. of ligand binding energetics, revealed that modestly active small mol. inhibitors of HIV entry can also promote viral entry into cells lacking the CD4 receptor protein; these competitive inhibitors were termed small mol. CD4 mimetics.  Related congeners were subsequently identified with both improved binding affinity and more potent viral entry inhibition.  Further assessment of the affinity-enhanced small mol. CD4 mimetics demonstrated that premature initiation of conformational change within the viral envelope spike, prior to cell encounter, can lead to irreversible deactivation of viral entry machinery.  Related congeners, which bind the same gp120 site, possess different propensities to elicit the allosteric response that underlies the undesired enhancement of CD4-independent viral entry.  Subsequently, key hotspots in the CD4-gp120 interface were categorized using mutagenesis and isothermal titrn. calorimetry according to the capacity to increase binding affinity without triggering the allosteric signal.  This anal., combined with cocrystal structures of small mol. viral entry agonists with gp120, led to the development of fully functional antagonists of HIV-1 entry.  Addnl. structure-based design exploiting two hotspots followed by synthesis has now yielded low micromolar inhibitors of viral entry.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplvC-F21zbMLVg90H21EOLACvtfcHk0ljH0yuUjPaAyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVOqtb8%253D&md5=dbe222907f1cf595e79e4fcb12cd9d85</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1021%2Far4002735&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Far4002735%26sid%3Dliteratum%253Aachs%26aulast%3DCourter%26aufirst%3DJ.%2BR.%26aulast%3DMadani%26aufirst%3DN.%26aulast%3DSodroski%26aufirst%3DJ.%26aulast%3DSchon%26aufirst%3DA.%26aulast%3DFreire%26aufirst%3DE.%26aulast%3DKwong%26aufirst%3DP.%2BD.%26aulast%3DHendrickson%26aufirst%3DW.%2BA.%26aulast%3DChaiken%26aufirst%3DI.%2BM.%26aulast%3DLalonde%26aufirst%3DJ.%2BM.%26aulast%3DSmith%26aufirst%3DA.%2BB.%26atitle%3DStructure-based%2520design%252C%2520synthesis%2520and%2520validation%2520of%2520CD4-mimetic%2520small%2520molecule%2520inhibitors%2520of%2520HIV-1%2520entry%253A%2520conversion%2520of%2520a%2520viral%2520entry%2520agonist%2520to%2520an%2520antagonist%26jtitle%3DAcc.%2520Chem.%2520Res.%26date%3D2014%26volume%3D47%26spage%3D1228%26epage%3D1237%26doi%3D10.1021%2Far4002735" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lalonde, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, Y. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Courter, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soeta, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Princiotto, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freire, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwong, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mascola, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sodroski, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madani, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A. B.,  III</span></span> <span> </span><span class="NLM_article-title">Structure-based design, synthesis, and characterization of dual hotspot small-molecule HIV-1 entry inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">4382</span>– <span class="NLM_lpage">4396</span>, <span class="refDoi"> DOI: 10.1021/jm300265j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300265j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=1%3ACAS%3A528%3ADC%252BC38Xltl2gs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=4382-4396&author=J.+M.+Lalondeauthor=Y.+D.+Kwonauthor=D.+M.+Jonesauthor=A.+W.+Sunauthor=J.+R.+Courterauthor=T.+Soetaauthor=T.+Kobayashiauthor=A.+M.+Princiottoauthor=X.+Wuauthor=A.+Schonauthor=E.+Freireauthor=P.+D.+Kwongauthor=J.+R.+Mascolaauthor=J.+Sodroskiauthor=N.+Madaniauthor=A.+B.+Smith&title=Structure-based+design%2C+synthesis%2C+and+characterization+of+dual+hotspot+small-molecule+HIV-1+entry+inhibitors&doi=10.1021%2Fjm300265j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Based Design, Synthesis, and Characterization of Dual Hotspot Small-Molecule HIV-1 Entry Inhibitors</span></div><div class="casAuthors">LaLonde, Judith M.; Kwon, Young Do; Jones, David M.; Sun, Alexander W.; Courter, Joel R.; Soeta, Takahiro; Kobayashi, Toyoharu; Princiotto, Amy M.; Wu, Xueling; Schon, Arne; Freire, Ernesto; Kwong, Peter D.; Mascola, John R.; Sodroski, Joseph; Madani, Navid; Smith, Amos B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4382-4396</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Cellular infection by HIV-1 is initiated with a binding event between the viral envelope glycoprotein gp120 and the cellular receptor protein CD4.  The CD4-gp120 interface is dominated by two hotspots: a hydrophobic gp120 cavity capped by Phe43CD4 and an electrostatic interaction between residues Arg59CD4 and Asp368gp120.  The CD4 mimetic small-mol. NBD-556 (1) binds within the gp120 cavity; however, 1 and related congeners demonstrate limited viral neutralization breadth.  Herein, we report the design, synthesis, characterization, and X-ray structures of gp120 in complex with small mols. that simultaneously engage both binding hotspots.  The compds. specifically inhibit viral infection of 42 tier 2 clades B and C viruses and are shown to be antagonists of entry into CD4-neg. cells.  Dual hotspot design thus provides both a means to enhance neutralization potency of HIV-1 entry inhibitors and a novel structural paradigm for inhibiting the CD4-gp120 protein-protein interaction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNognNQUm1FrVg90H21EOLACvtfcHk0ljH0yuUjPaAyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xltl2gs7g%253D&md5=2b7b963e311bb4aa8e6e5a7798064509</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Fjm300265j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300265j%26sid%3Dliteratum%253Aachs%26aulast%3DLalonde%26aufirst%3DJ.%2BM.%26aulast%3DKwon%26aufirst%3DY.%2BD.%26aulast%3DJones%26aufirst%3DD.%2BM.%26aulast%3DSun%26aufirst%3DA.%2BW.%26aulast%3DCourter%26aufirst%3DJ.%2BR.%26aulast%3DSoeta%26aufirst%3DT.%26aulast%3DKobayashi%26aufirst%3DT.%26aulast%3DPrinciotto%26aufirst%3DA.%2BM.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DSchon%26aufirst%3DA.%26aulast%3DFreire%26aufirst%3DE.%26aulast%3DKwong%26aufirst%3DP.%2BD.%26aulast%3DMascola%26aufirst%3DJ.%2BR.%26aulast%3DSodroski%26aufirst%3DJ.%26aulast%3DMadani%26aufirst%3DN.%26aulast%3DSmith%26aufirst%3DA.%2BB.%26atitle%3DStructure-based%2520design%252C%2520synthesis%252C%2520and%2520characterization%2520of%2520dual%2520hotspot%2520small-molecule%2520HIV-1%2520entry%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D4382%26epage%3D4396%26doi%3D10.1021%2Fjm300265j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lalonde, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le-Khac, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Courter, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Princiotto, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mascola, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freire, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sodroski, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madani, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hendrickson, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A. B.,  III</span></span> <span> </span><span class="NLM_article-title">Structure-based design and synthesis of an HIV-1 entry inhibitor exploiting X-ray and thermodynamic characterization</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">338</span>– <span class="NLM_lpage">343</span>, <span class="refDoi"> DOI: 10.1021/ml300407y</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml300407y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=1%3ACAS%3A528%3ADC%252BC3sXit1Sqs7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=338-343&author=J.+M.+Lalondeauthor=M.+Le-Khacauthor=D.+M.+Jonesauthor=J.+R.+Courterauthor=J.+Parkauthor=A.+Schonauthor=A.+M.+Princiottoauthor=X.+Wuauthor=J.+R.+Mascolaauthor=E.+Freireauthor=J.+Sodroskiauthor=N.+Madaniauthor=W.+A.+Hendricksonauthor=A.+B.+Smith&title=Structure-based+design+and+synthesis+of+an+HIV-1+entry+inhibitor+exploiting+X-ray+and+thermodynamic+characterization&doi=10.1021%2Fml300407y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Based Design and Synthesis of an HIV-1 Entry Inhibitor Exploiting X-ray and Thermodynamic Characterization</span></div><div class="casAuthors">LaLonde, Judith M.; Le-Khac, Matthew; Jones, David M.; Courter, Joel R.; Park, Jongwoo; Schon, Arne; Princiotto, Amy M.; Wu, Xueling; Mascola, John R.; Freire, Ernesto; Sodroski, Joseph; Madani, Navid; Hendrickson, Wayne A.; Smith, Amos B.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">338-343</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The design, synthesis, thermodn. and crystallog. characterization of a potent, broad spectrum, second-generation HIV-1 entry inhibitor that engages conserved carbonyl hydrogen bonds within gp120 has been achieved.  The optimized antagonist exhibits a submicromolar binding affinity (110 nM) and inhibits viral entry of clade B and C viruses (IC50 geometric mean titer of 1.7 and 14.0 μM, resp.), without promoting CD4-independent viral entry.  The thermodn. signatures indicate a binding preference for the (R,R)- over the (S,S)-enantiomer.  The crystal structure of the small-mol./gp120 complex reveals the displacement of crystallog. water and the formation of a hydrogen bond with a backbone carbonyl of the bridging sheet.  Thus, structure-based design and synthesis targeting the highly conserved and structurally characterized CD4-gp120 interface is an effective tactic to enhance the neutralization potency of small-mol. HIV-1 entry inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqh7x2FvVHCWrVg90H21EOLACvtfcHk0liLw81gqIsD9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXit1Sqs7k%253D&md5=5fbf7ba309222bd3b1064524a94e2af3</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Fml300407y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml300407y%26sid%3Dliteratum%253Aachs%26aulast%3DLalonde%26aufirst%3DJ.%2BM.%26aulast%3DLe-Khac%26aufirst%3DM.%26aulast%3DJones%26aufirst%3DD.%2BM.%26aulast%3DCourter%26aufirst%3DJ.%2BR.%26aulast%3DPark%26aufirst%3DJ.%26aulast%3DSchon%26aufirst%3DA.%26aulast%3DPrinciotto%26aufirst%3DA.%2BM.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DMascola%26aufirst%3DJ.%2BR.%26aulast%3DFreire%26aufirst%3DE.%26aulast%3DSodroski%26aufirst%3DJ.%26aulast%3DMadani%26aufirst%3DN.%26aulast%3DHendrickson%26aufirst%3DW.%2BA.%26aulast%3DSmith%26aufirst%3DA.%2BB.%26atitle%3DStructure-based%2520design%2520and%2520synthesis%2520of%2520an%2520HIV-1%2520entry%2520inhibitor%2520exploiting%2520X-ray%2520and%2520thermodynamic%2520characterization%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D4%26spage%3D338%26epage%3D343%26doi%3D10.1021%2Fml300407y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Melillo, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Courter, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lalonde, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wendler, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Princiotto, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seaman, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freire, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sodroski, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madani, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hendrickson, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A. B.,  III</span></span> <span> </span><span class="NLM_article-title">Small-molecule CD4-mimics: structure-based optimization of HIV-1 entry inhibition</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">330</span>– <span class="NLM_lpage">334</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.5b00471</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.5b00471" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVKrs7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=330-334&author=B.+Melilloauthor=S.+Liangauthor=J.+Parkauthor=A.+Schonauthor=J.+R.+Courterauthor=J.+M.+Lalondeauthor=D.+J.+Wendlerauthor=A.+M.+Princiottoauthor=M.+S.+Seamanauthor=E.+Freireauthor=J.+Sodroskiauthor=N.+Madaniauthor=W.+A.+Hendricksonauthor=A.+B.+Smith&title=Small-molecule+CD4-mimics%3A+structure-based+optimization+of+HIV-1+entry+inhibition&doi=10.1021%2Facsmedchemlett.5b00471"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Small-Molecule CD4-Mimics: Structure-Based Optimization of HIV-1 Entry Inhibition</span></div><div class="casAuthors">Melillo, Bruno; Liang, Shuaiyi; Park, Jongwoo; Schon, Arne; Courter, Joel R.; LaLonde, Judith M.; Wendler, Daniel J.; Princiotto, Amy M.; Seaman, Michael S.; Freire, Ernesto; Sodroski, Joseph; Madani, Navid; Hendrickson, Wayne A.; Smith, Amos B.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">330-334</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The optimization, based on computational, thermodn., and crystallog. data, of a series of small-mol. ligands of the Phe 43 cavity of the envelope glycoprotein gp120 of human immunodeficiency virus (HIV) has been achieved.  Importantly, biol. evaluation revealed that the small-mol. CD4 mimics inhibit HIV-1 entry into target cells with both significantly higher potency and neutralization breadth than previous congeners, while maintaining high selectivity for the target virus.  Their binding mode was characterized via thermodn. and crystallog. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobuaf6aAaI_7Vg90H21EOLACvtfcHk0ljusRxKZz9hww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVKrs7w%253D&md5=512ed31929b2a4f5334653e40bcbeb14</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.5b00471&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.5b00471%26sid%3Dliteratum%253Aachs%26aulast%3DMelillo%26aufirst%3DB.%26aulast%3DLiang%26aufirst%3DS.%26aulast%3DPark%26aufirst%3DJ.%26aulast%3DSchon%26aufirst%3DA.%26aulast%3DCourter%26aufirst%3DJ.%2BR.%26aulast%3DLalonde%26aufirst%3DJ.%2BM.%26aulast%3DWendler%26aufirst%3DD.%2BJ.%26aulast%3DPrinciotto%26aufirst%3DA.%2BM.%26aulast%3DSeaman%26aufirst%3DM.%2BS.%26aulast%3DFreire%26aufirst%3DE.%26aulast%3DSodroski%26aufirst%3DJ.%26aulast%3DMadani%26aufirst%3DN.%26aulast%3DHendrickson%26aufirst%3DW.%2BA.%26aulast%3DSmith%26aufirst%3DA.%2BB.%26atitle%3DSmall-molecule%2520CD4-mimics%253A%2520structure-based%2520optimization%2520of%2520HIV-1%2520entry%2520inhibition%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D7%26spage%3D330%26epage%3D334%26doi%3D10.1021%2Facsmedchemlett.5b00471" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Si, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madani, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chruma, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klein, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phan, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biorn, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cocklin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaiken, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freire, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A. B.,  III</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sodroski, J. G.</span></span> <span> </span><span class="NLM_article-title">Small-molecule inhibitors of HIV-1 entry block receptor-induced conformational changes in the viral envelope glycoproteins</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>101</i></span>,  <span class="NLM_fpage">5036</span>– <span class="NLM_lpage">5041</span>, <span class="refDoi"> DOI: 10.1073/pnas.0307953101</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=10.1073%2Fpnas.0307953101" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=15051887" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjsFCisLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2004&pages=5036-5041&author=Z.+Siauthor=N.+Madaniauthor=J.+M.+Coxauthor=J.+J.+Chrumaauthor=J.+C.+Kleinauthor=A.+Schonauthor=N.+Phanauthor=L.+Wangauthor=A.+C.+Biornauthor=S.+Cocklinauthor=I.+Chaikenauthor=E.+Freireauthor=A.+B.+Smithauthor=J.+G.+Sodroski&title=Small-molecule+inhibitors+of+HIV-1+entry+block+receptor-induced+conformational+changes+in+the+viral+envelope+glycoproteins&doi=10.1073%2Fpnas.0307953101"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Small-molecule inhibitors of HIV-1 entry block receptor-induced conformational changes in the viral envelope glycoproteins</span></div><div class="casAuthors">Si, Zhihai; Madani, Navid; Cox, Jason M.; Chruma, Jason J.; Klein, Jeffrey C.; Schoen, Arne; Phan, Ngoc; Wang, Liping; Biorn, Alyssa C.; Cocklin, Simon; Chaiken, Irwin; Freire, Ernesto; Smith, Amos B., III; Sodroski, Joseph G.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">101</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5036-5041</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">When interacting with the CD4 receptor, the HIV gp120 envelope glycoprotein undergoes conformational changes that allow binding to the chemokine receptor.  Receptor binding is proposed to lead to conformational changes in the gp41 transmembrane envelope glycoprotein involving the creation and/or exposure of a coiled coil consisting of three heptad repeat (HR) sequences.  The subsequent interaction of the HR2 region of gp41 with this coiled coil results in the assembly of a six-helix bundle that promotes the fusion of the viral and target cell membranes.  Here we show that CD4 binding to gp120 induces the formation and/or exposure of the gp41 HR1 coiled coil in a process that does not involve gp120 shedding and that depends on the proteolytic maturation of the gp160 envelope glycoprotein precursor.  Importantly, BMS-806 and related HIV-1 entry inhibitors bind gp120 and block the CD4 induction of HR1 exposure without significantly affecting CD4 binding.  Moreover, these compds. do not disrupt gp120-chemokine receptor binding or the HR1-HR2 interaction within gp41.  These studies thus define a receptor-induced conformational rearrangement of gp120-gp41 that is important for both CD4-dependent and CD4-independent HIV-1 entry and is susceptible to inhibition by low-mol.-wt. compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCK84PlI4vMbVg90H21EOLACvtfcHk0ljusRxKZz9hww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjsFCisLs%253D&md5=2509801a7e57d0fc066f0c08f720f80e</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0307953101&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0307953101%26sid%3Dliteratum%253Aachs%26aulast%3DSi%26aufirst%3DZ.%26aulast%3DMadani%26aufirst%3DN.%26aulast%3DCox%26aufirst%3DJ.%2BM.%26aulast%3DChruma%26aufirst%3DJ.%2BJ.%26aulast%3DKlein%26aufirst%3DJ.%2BC.%26aulast%3DSchon%26aufirst%3DA.%26aulast%3DPhan%26aufirst%3DN.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DBiorn%26aufirst%3DA.%2BC.%26aulast%3DCocklin%26aufirst%3DS.%26aulast%3DChaiken%26aufirst%3DI.%26aulast%3DFreire%26aufirst%3DE.%26aulast%3DSmith%26aufirst%3DA.%2BB.%26aulast%3DSodroski%26aufirst%3DJ.%2BG.%26atitle%3DSmall-molecule%2520inhibitors%2520of%2520HIV-1%2520entry%2520block%2520receptor-induced%2520conformational%2520changes%2520in%2520the%2520viral%2520envelope%2520glycoproteins%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2004%26volume%3D101%26spage%3D5036%26epage%3D5041%26doi%3D10.1073%2Fpnas.0307953101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pancera, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, Y. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bylund, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Druz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narpala, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Dell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailer, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chuang, G. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Louder, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rawi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soumana, D. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finzi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herschhorn, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madani, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sodroski, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freire, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langley, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mascola, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDermott, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwong, P. D.</span></span> <span> </span><span class="NLM_article-title">Crystal structures of trimeric HIV envelope with entry inhibitors BMS-378806 and BMS-626529</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">1115</span>– <span class="NLM_lpage">1122</span>, <span class="refDoi"> DOI: 10.1038/nchembio.2460</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=10.1038%2Fnchembio.2460" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=28825711" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlKjtbnP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2017&pages=1115-1122&author=M.+Panceraauthor=Y.+T.+Laiauthor=T.+Bylundauthor=A.+Druzauthor=S.+Narpalaauthor=S.+O%E2%80%99Dellauthor=A.+Schonauthor=R.+T.+Bailerauthor=G.+Y.+Chuangauthor=H.+Gengauthor=M.+K.+Louderauthor=R.+Rawiauthor=D.+I.+Soumanaauthor=A.+Finziauthor=A.+Herschhornauthor=N.+Madaniauthor=J.+Sodroskiauthor=E.+Freireauthor=D.+R.+Langleyauthor=J.+R.+Mascolaauthor=A.+B.+McDermottauthor=P.+D.+Kwong&title=Crystal+structures+of+trimeric+HIV+envelope+with+entry+inhibitors+BMS-378806+and+BMS-626529&doi=10.1038%2Fnchembio.2460"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structures of trimeric HIV envelope with entry inhibitors BMS-378806 and BMS-626529</span></div><div class="casAuthors">Pancera, Marie; Lai, Yen-Ting; Bylund, Tatsiana; Druz, Aliaksandr; Narpala, Sandeep; O'Dell, Sijy; Schon, Arne; Bailer, Robert T.; Chuang, Gwo-Yu; Geng, Hui; Louder, Mark K.; Rawi, Reda; Soumana, Djade I.; Finzi, Andres; Herschhorn, Alon; Madani, Navid; Sodroski, Joseph; Freire, Ernesto; Langley, David R.; Mascola, John R.; McDermott, Adrian B.; Kwong, Peter D.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1115-1122</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">The HIV-1 envelope (Env) spike is a conformational machine that transitions between prefusion (closed, CD4- and CCR5-bound) and postfusion states to facilitate HIV-1 entry into cells.  Although the prefusion closed conformation is a potential target for inhibition, development of small-mol. leads has been stymied by difficulties in obtaining structural information.  Here, the authors report crystal structures at 3.8-Å resoln. of an HIV-1-Env trimer with BMS-378806 and a deriv. BMS-626529 for which a prodrug version is currently in Phase III clin. trials.  Both lead candidates recognized an induced binding pocket that was mostly excluded from solvent and comprised of Env elements from a conserved helix and the β20-21 hairpin.  In both structures, the β20-21 region assumed a conformation distinct from prefusion-closed and CD4-bound states.  Together with biophys. and antigenicity characterizations, the structures illuminate the allosteric and competitive mechanisms by which these small-mol. leads inhibit CD4-induced structural changes in Env.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq08375JqIny7Vg90H21EOLACvtfcHk0lgiBYrcrwkhQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlKjtbnP&md5=4f79455289aed50834a0ad20e21dba9a</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.2460&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.2460%26sid%3Dliteratum%253Aachs%26aulast%3DPancera%26aufirst%3DM.%26aulast%3DLai%26aufirst%3DY.%2BT.%26aulast%3DBylund%26aufirst%3DT.%26aulast%3DDruz%26aufirst%3DA.%26aulast%3DNarpala%26aufirst%3DS.%26aulast%3DO%25E2%2580%2599Dell%26aufirst%3DS.%26aulast%3DSchon%26aufirst%3DA.%26aulast%3DBailer%26aufirst%3DR.%2BT.%26aulast%3DChuang%26aufirst%3DG.%2BY.%26aulast%3DGeng%26aufirst%3DH.%26aulast%3DLouder%26aufirst%3DM.%2BK.%26aulast%3DRawi%26aufirst%3DR.%26aulast%3DSoumana%26aufirst%3DD.%2BI.%26aulast%3DFinzi%26aufirst%3DA.%26aulast%3DHerschhorn%26aufirst%3DA.%26aulast%3DMadani%26aufirst%3DN.%26aulast%3DSodroski%26aufirst%3DJ.%26aulast%3DFreire%26aufirst%3DE.%26aulast%3DLangley%26aufirst%3DD.%2BR.%26aulast%3DMascola%26aufirst%3DJ.%2BR.%26aulast%3DMcDermott%26aufirst%3DA.%2BB.%26aulast%3DKwong%26aufirst%3DP.%2BD.%26atitle%3DCrystal%2520structures%2520of%2520trimeric%2520HIV%2520envelope%2520with%2520entry%2520inhibitors%2520BMS-378806%2520and%2520BMS-626529%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2017%26volume%3D13%26spage%3D1115%26epage%3D1122%26doi%3D10.1038%2Fnchembio.2460" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Madani, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Princiotto, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lalonde, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Courter, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soeta, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brower, E. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Do Kwon, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wyatt, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwong, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freire, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A. B.,  III</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sodroski, J.</span></span> <span> </span><span class="NLM_article-title">Small-molecule CD4 mimics interact with a highly conserved pocket on HIV-1 gp120</span>. <i>Structure</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">1689</span>– <span class="NLM_lpage">1701</span>, <span class="refDoi"> DOI: 10.1016/j.str.2008.09.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=10.1016%2Fj.str.2008.09.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=19000821" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtlGmtb7O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2008&pages=1689-1701&author=N.+Madaniauthor=A.+Schonauthor=A.+M.+Princiottoauthor=J.+M.+Lalondeauthor=J.+R.+Courterauthor=T.+Soetaauthor=D.+Ngauthor=L.+Wangauthor=E.+T.+Browerauthor=S.+H.+Xiangauthor=Y.+Do+Kwonauthor=C.+C.+Huangauthor=R.+Wyattauthor=P.+D.+Kwongauthor=E.+Freireauthor=A.+B.+Smithauthor=J.+Sodroski&title=Small-molecule+CD4+mimics+interact+with+a+highly+conserved+pocket+on+HIV-1+gp120&doi=10.1016%2Fj.str.2008.09.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Small-Molecule CD4 Mimics Interact with a Highly Conserved Pocket on HIV-1 gp120</span></div><div class="casAuthors">Madani, Navid; Schoen, Arne; Princiotto, Amy M.; LaLonde, Judith M.; Courter, Joel R.; Soeta, Takahiro; Ng, Danny; Wang, Liping; Brower, Evan T.; Xiang, Shi-Hua; Kwon, Young Do; Huang, Chih-chin; Wyatt, Richard; Kwong, Peter D.; Freire, Ernesto; Smith, Amos B.; Sodroski, Joseph</div><div class="citationInfo"><span class="NLM_cas:title">Structure (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1689-1701</span>CODEN:
                <span class="NLM_cas:coden">STRUE6</span>;
        ISSN:<span class="NLM_cas:issn">0969-2126</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Human immunodeficiency virus (HIV-1) interaction with the primary receptor, CD4, induces conformational changes in the viral envelope glycoproteins that allow binding to the CCR5 s receptor and virus entry into the host cell.  The small mol. NBD-556 mimics CD4 by binding the gp120 exterior envelope glycoprotein, moderately inhibiting virus entry into CD4-expressing target cells and enhancing CCR5 binding and virus entry into CCR5-expressing cells lacking CD4.  Studies of NBD-556 analogs and gp120 mutants suggest that (1) NBD-556 binds within the Phe 43 cavity, a highly conserved, functionally important pocket formed as gp120 assumes the CD4-bound conformation; (2) the NBD-556 Ph ring projects into the Phe 43 cavity; (3) enhancement of CD4-independent infection by NBD-556 requires the induction of conformational changes in gp120; and (4) increased affinity of NBD-556 analogs for gp120 improves antiviral potency during infection of CD4-expressing cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpR6c6HGLqwjbVg90H21EOLACvtfcHk0lgiBYrcrwkhQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtlGmtb7O&md5=8f146ad8772ee8c04d6f560d644407e1</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.str.2008.09.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.str.2008.09.005%26sid%3Dliteratum%253Aachs%26aulast%3DMadani%26aufirst%3DN.%26aulast%3DSchon%26aufirst%3DA.%26aulast%3DPrinciotto%26aufirst%3DA.%2BM.%26aulast%3DLalonde%26aufirst%3DJ.%2BM.%26aulast%3DCourter%26aufirst%3DJ.%2BR.%26aulast%3DSoeta%26aufirst%3DT.%26aulast%3DNg%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DBrower%26aufirst%3DE.%2BT.%26aulast%3DXiang%26aufirst%3DS.%2BH.%26aulast%3DDo%2BKwon%26aufirst%3DY.%26aulast%3DHuang%26aufirst%3DC.%2BC.%26aulast%3DWyatt%26aufirst%3DR.%26aulast%3DKwong%26aufirst%3DP.%2BD.%26aulast%3DFreire%26aufirst%3DE.%26aulast%3DSmith%26aufirst%3DA.%2BB.%26aulast%3DSodroski%26aufirst%3DJ.%26atitle%3DSmall-molecule%2520CD4%2520mimics%2520interact%2520with%2520a%2520highly%2520conserved%2520pocket%2520on%2520HIV-1%2520gp120%26jtitle%3DStructure%26date%3D2008%26volume%3D16%26spage%3D1689%26epage%3D1701%26doi%3D10.1016%2Fj.str.2008.09.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Curreli, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, Y. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scacalossi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belov, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tikhonov, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andreev, I. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altieri, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurkin, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwong, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Debnath, A. K.</span></span> <span> </span><span class="NLM_article-title">Structure-based design of a small molecule CD4-antagonist with broad spectrum anti-HIV-1 activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">6909</span>– <span class="NLM_lpage">6927</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00709</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00709" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlOqu7jK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=6909-6927&author=F.+Curreliauthor=Y.+D.+Kwonauthor=H.+Zhangauthor=D.+Scacalossiauthor=D.+S.+Belovauthor=A.+A.+Tikhonovauthor=I.+A.+Andreevauthor=A.+Altieriauthor=A.+V.+Kurkinauthor=P.+D.+Kwongauthor=A.+K.+Debnath&title=Structure-based+design+of+a+small+molecule+CD4-antagonist+with+broad+spectrum+anti-HIV-1+activity&doi=10.1021%2Facs.jmedchem.5b00709"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Based Design of a Small Molecule CD4-Antagonist with Broad Spectrum Anti-HIV-1 Activity</span></div><div class="casAuthors">Curreli, Francesca; Kwon, Young Do; Zhang, Hongtao; Scacalossi, Daniel; Belov, Dmitry S.; Tikhonov, Artur A.; Andreev, Ivan A.; Altieri, Andrea; Kurkin, Alexander V.; Kwong, Peter D.; Debnath, Asim K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">6909-6927</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Earlier the authors reported the discovery and design of NBD-556 and their analogs which demonstrated their potential as HIV-1 entry inhibitors.  However, progress in developing these inhibitors has been stymied by their CD4-agonist properties, an unfavorable trait for use as drug.  Here, the authors demonstrate the successful conversion of a full CD4-agonist (NBD-556) through a partial CD4-agonist (NBD-09027), to a full CD4-antagonist I (NBD-11021) by structure-based modification of the crit. oxalamide mid-region, previously thought to be intolerant of modification.  I showed unprecedented neutralization breath for this class of inhibitors, with pan-neutralization against a panel of 56 Env-pseudotyped HIV-1 representing diverse subtypes of clin. isolates (IC50 as low as 270 nM).  The cocrystal structure of NBD-11021 complexed to a monomeric HIV-1 gp120 core revealed its detail binding characteristics.  The study is expected to provide a framework for further development of NBD series as HIV-1 entry inhibitors for clin. application against AIDS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsZjeIlR_smLVg90H21EOLACvtfcHk0lhEdhAvfel__w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlOqu7jK&md5=db75d8df02d72d932b75596bec6fc1fc</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00709&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00709%26sid%3Dliteratum%253Aachs%26aulast%3DCurreli%26aufirst%3DF.%26aulast%3DKwon%26aufirst%3DY.%2BD.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DScacalossi%26aufirst%3DD.%26aulast%3DBelov%26aufirst%3DD.%2BS.%26aulast%3DTikhonov%26aufirst%3DA.%2BA.%26aulast%3DAndreev%26aufirst%3DI.%2BA.%26aulast%3DAltieri%26aufirst%3DA.%26aulast%3DKurkin%26aufirst%3DA.%2BV.%26aulast%3DKwong%26aufirst%3DP.%2BD.%26aulast%3DDebnath%26aufirst%3DA.%2BK.%26atitle%3DStructure-based%2520design%2520of%2520a%2520small%2520molecule%2520CD4-antagonist%2520with%2520broad%2520spectrum%2520anti-HIV-1%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D6909%26epage%3D6927%26doi%3D10.1021%2Facs.jmedchem.5b00709" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Curreli, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, Y. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scacalossi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwong, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Debnath, A. K.</span></span> <span> </span><span class="NLM_article-title">Binding mode characterization of NBD series CD4-mimetic HIV-1 entry inhibitors by X-ray structure and resistance study</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">5478</span>– <span class="NLM_lpage">5491</span>, <span class="refDoi"> DOI: 10.1128/AAC.03339-14</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=10.1128%2FAAC.03339-14" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=25001301" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1eqsLfE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2014&pages=5478-5491&author=F.+Curreliauthor=Y.+D.+Kwonauthor=H.+Zhangauthor=Y.+Yangauthor=D.+Scacalossiauthor=P.+D.+Kwongauthor=A.+K.+Debnath&title=Binding+mode+characterization+of+NBD+series+CD4-mimetic+HIV-1+entry+inhibitors+by+X-ray+structure+and+resistance+study&doi=10.1128%2FAAC.03339-14"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Binding mode characterization of NBD series CD4-mimetic HIV-1 entry inhibitors by X-ray structure and resistance study</span></div><div class="casAuthors">Curreli, Francesca; Kwon, Young Do; Zhang, Hongtao; Yang, Yongping; Scacalossi, Daniel; Kwong, Peter D.; Debnath, Asim K.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">5478-5491, 15 pp.</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">1098-6596</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">We previously identified two small-mol. CD4 mimetics - NBD-556 and NBD-557 - and synthesized a series of NBD compds. that resulted in improved neutralization activity in a single-cycle HIV-1 infectivity assay.  For the current investigation, we selected several of the most active compds. and assessed their antiviral activity on a panel of 53 ref. HIV-1 Env pseudoviruses representing diverse clades of clin. isolates.  The selected compds. inhibited tested clades with low-micromolar potencies.  Mechanism studies indicated that they act as CD4 agonists, a potentially unfavorable therapeutic trait, in that they can bind to the gp120 envelope glycoprotein and initiate a similar physiol. response as CD4.  However, one of the compds., NBD-09027, exhibited reduced agonist properties, in both functional and biophys. studies.  To understand the binding mode of these inhibitors, we first generated HIV-1-resistant mutants, assessed their behavior with NBD compds., and detd. the X-ray structures of two inhibitors, NBD-09027 and NBD-10007, in complex with the HIV-1 gp120 core at ∼2-Å resoln.  Both studies confirmed that the NBD compds. bind similarly to NBD-556 and NBD-557 by inserting their hydrophobic groups into the Phe43 cavity of gp120.  The basic nitrogen of the piperidine ring is located in close proximity to D368 of gp120 but it does not form any H-bond or salt bridge, a likely explanation for their nonoptimal antagonist properties.  The results reveal the structural and biol. character of the NBD series of CD4 mimetics and identify ways to reduce their agonist properties and convert them to antagonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQafZBXLanQbVg90H21EOLACvtfcHk0lhEdhAvfel__w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1eqsLfE&md5=d872c92f7a508790f83359add7bfff1d</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1128%2FAAC.03339-14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.03339-14%26sid%3Dliteratum%253Aachs%26aulast%3DCurreli%26aufirst%3DF.%26aulast%3DKwon%26aufirst%3DY.%2BD.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DScacalossi%26aufirst%3DD.%26aulast%3DKwong%26aufirst%3DP.%2BD.%26aulast%3DDebnath%26aufirst%3DA.%2BK.%26atitle%3DBinding%2520mode%2520characterization%2520of%2520NBD%2520series%2520CD4-mimetic%2520HIV-1%2520entry%2520inhibitors%2520by%2520X-ray%2520structure%2520and%2520resistance%2520study%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2014%26volume%3D58%26spage%3D5478%26epage%3D5491%26doi%3D10.1128%2FAAC.03339-14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hamada, Y.</span></span> In  <i>Role of pyridines in medicinal chemistry and design of BACE1 inhibitors possessing a pyridine scaffold</i><i>;</i> <span class="NLM_contrib-group"><span class="NLM_string-name">Pandey, P. P.</span></span>, Ed.; <span class="NLM_publisher-name">IntechOpen</span>, <span class="NLM_year">2018</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=10.5772%2Fintechopen.74719" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=Y.+Hamadaauthor=P.+P.+Pandey&title=Role+of+pyridines+in+medicinal+chemistry+and+design+of+BACE1+inhibitors+possessing+a+pyridine+scaffold"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.5772%2Fintechopen.74719&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.5772%252Fintechopen.74719%26sid%3Dliteratum%253Aachs%26aulast%3DHamada%26aufirst%3DY.%26btitle%3DRole%2520of%2520pyridines%2520in%2520medicinal%2520chemistry%2520and%2520design%2520of%2520BACE1%2520inhibitors%2520possessing%2520a%2520pyridine%2520scaffold%26aulast%3DPandey%26aufirst%3DP.%2BP.%26pub%3DIntechOpen%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bender, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zadjura, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Arienzo, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiGiugno Parker, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gesenberg, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamanaka, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, Y. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, H. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McAuliffe, B. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eggers, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nowicka-Sans, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dicker, I. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colonno, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meanwell, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kadow, J. F.</span></span> <span> </span><span class="NLM_article-title">Inhibitors of human immunodeficiency virus type 1 (HIV-1) attachment. 5. An evolution from indole to azaindoles leading to the discovery of 1-(4-benzoylpiperazin-1-yl)-2-(4,7-dimethoxy-1H-pyrrolo[2,3-c]pyridin-3-yl)ethane −1,2-dione (BMS-488043), a drug candidate that demonstrates antiviral activity in HIV-1-infected subjects</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">7778</span>– <span class="NLM_lpage">7787</span>, <span class="refDoi"> DOI: 10.1021/jm900843g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm900843g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFKns7zK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=7778-7787&author=T.+Wangauthor=Z.+Yinauthor=Z.+Zhangauthor=J.+A.+Benderauthor=Z.+Yangauthor=G.+Johnsonauthor=Z.+Yangauthor=L.+M.+Zadjuraauthor=C.+J.+D%E2%80%99Arienzoauthor=D.+DiGiugno+Parkerauthor=C.+Gesenbergauthor=G.+A.+Yamanakaauthor=Y.+F.+Gongauthor=H.+T.+Hoauthor=H.+Fangauthor=N.+Zhouauthor=B.+V.+McAuliffeauthor=B.+J.+Eggersauthor=L.+Fanauthor=B.+Nowicka-Sansauthor=I.+B.+Dickerauthor=Q.+Gaoauthor=R.+J.+Colonnoauthor=P.+F.+Linauthor=N.+A.+Meanwellauthor=J.+F.+Kadow&title=Inhibitors+of+human+immunodeficiency+virus+type+1+%28HIV-1%29+attachment.+5.+An+evolution+from+indole+to+azaindoles+leading+to+the+discovery+of+1-%284-benzoylpiperazin-1-yl%29-2-%284%2C7-dimethoxy-1H-pyrrolo%5B2%2C3-c%5Dpyridin-3-yl%29ethane+%E2%88%921%2C2-dione+%28BMS-488043%29%2C+a+drug+candidate+that+demonstrates+antiviral+activity+in+HIV-1-infected+subjects&doi=10.1021%2Fjm900843g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitors of Human Immunodeficiency Virus Type 1 (HIV-1) Attachment. 5. An Evolution from Indole to Azaindoles Leading to the Discovery of 1-(4-Benzoylpiperazin-1-yl)-2-(4,7-dimethoxy-1H-pyrrolo[2,3-c]pyridin-3-yl)ethane-1,2-dione (BMS-488043), a Drug Candidate That Demonstrates Antiviral Activity in HIV-1-Infected Subjects</span></div><div class="casAuthors">Wang, Tao; Yin, Zhiwei; Zhang, Zhongxing; Bender, John A.; Yang, Zhong; Johnson, Graham; Yang, Zheng; Zadjura, Lisa M.; D'Arienzo, Celia J.; DiGiugno Parker, Dawn; Gesenberg, Christophe; Yamanaka, Gregory A.; Gong, Yi-Fei; Ho, Hsu-Tso; Fang, Hua; Zhou, Nannan; McAuliffe, Brian V.; Eggers, Betsy J.; Fan, Li; Nowicka-Sans, Beata; Dicker, Ira B.; Gao, Qi; Colonno, Richard J.; Lin, Pin-Fang; Meanwell, Nicholas A.; Kadow, John F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">7778-7787</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Azaindole derivs. derived from the screening lead 1-(4-benzoylpiperazin-1-yl)-2-(1H-indol-3-yl)ethane-1,2-dione were prepd. and characterized to assess their potential as inhibitors of HIV-1 attachment.  Systematic replacement of each of the unfused carbon atoms in the Ph ring of the indole moiety by a nitrogen atom provided four different azaindole derivs. that displayed a clear SAR for antiviral activity and all of which displayed marked improvements in pharmaceutical properties.  Optimization of these azaindole leads resulted in the identification of two compds. that were advanced to clin. studies: (R)-1-(4-benzoyl-2-methylpiperazin-1-yl)-2-(4-methoxy-1H-pyrrolo[2,3-b]pyridin-3-yl)ethane-1,2-dione I, and 1-(4-benzoylpiperazin-1-yl)-2-(4,7-dimethoxy-1H-pyrrolo[2,3-c]pyridin-3-yl)ethane-1,2-dione, II.  In a preliminary clin. study, II administered as monotherapy for 8 days, reduced viremia in HIV-1-infected subjects, providing proof of concept for this mechanistic class.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr84dI0I-kTkrVg90H21EOLACvtfcHk0ljRoDbgRMVJ8w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFKns7zK&md5=c381dc8129dcc2a36547db53aae3a654</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Fjm900843g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm900843g%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DT.%26aulast%3DYin%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DBender%26aufirst%3DJ.%2BA.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DJohnson%26aufirst%3DG.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DZadjura%26aufirst%3DL.%2BM.%26aulast%3DD%25E2%2580%2599Arienzo%26aufirst%3DC.%2BJ.%26aulast%3DDiGiugno%2BParker%26aufirst%3DD.%26aulast%3DGesenberg%26aufirst%3DC.%26aulast%3DYamanaka%26aufirst%3DG.%2BA.%26aulast%3DGong%26aufirst%3DY.%2BF.%26aulast%3DHo%26aufirst%3DH.%2BT.%26aulast%3DFang%26aufirst%3DH.%26aulast%3DZhou%26aufirst%3DN.%26aulast%3DMcAuliffe%26aufirst%3DB.%2BV.%26aulast%3DEggers%26aufirst%3DB.%2BJ.%26aulast%3DFan%26aufirst%3DL.%26aulast%3DNowicka-Sans%26aufirst%3DB.%26aulast%3DDicker%26aufirst%3DI.%2BB.%26aulast%3DGao%26aufirst%3DQ.%26aulast%3DColonno%26aufirst%3DR.%2BJ.%26aulast%3DLin%26aufirst%3DP.%2BF.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DKadow%26aufirst%3DJ.%2BF.%26atitle%3DInhibitors%2520of%2520human%2520immunodeficiency%2520virus%2520type%25201%2520%2528HIV-1%2529%2520attachment.%25205.%2520An%2520evolution%2520from%2520indole%2520to%2520azaindoles%2520leading%2520to%2520the%2520discovery%2520of%25201-%25284-benzoylpiperazin-1-yl%2529-2-%25284%252C7-dimethoxy-1H-pyrrolo%255B2%252C3-c%255Dpyridin-3-yl%2529ethane%2520%25E2%2588%25921%252C2-dione%2520%2528BMS-488043%2529%252C%2520a%2520drug%2520candidate%2520that%2520demonstrates%2520antiviral%2520activity%2520in%2520HIV-1-infected%2520subjects%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D7778%26epage%3D7787%26doi%3D10.1021%2Fjm900843g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hartz, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahuja, V. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhuo, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mattson, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denhart, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deskus, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vrudhula, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ditta, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shu, Y. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grace, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lentz, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lelas, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molski, T. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krishnananthan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian-Cutrone, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schartman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denton, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lodge, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaczek, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macor, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bronson, J. J.</span></span> <span> </span><span class="NLM_article-title">A strategy to minimize reactive metabolite formation: discovery of (S)-4-(1-cyclopropyl-2-methoxyethyl)-6-[6-(difluoromethoxy)-2,5-dimethylpyridin-3 -ylamino]-5-oxo-4,5-dihydropyrazine-2-carbonitrile as a potent, orally bioavailable corticotropin-releasing factor-1 receptor antagonist</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">7653</span>– <span class="NLM_lpage">7668</span>, <span class="refDoi"> DOI: 10.1021/jm900716v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm900716v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtVOnsrzM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=7653-7668&author=R.+A.+Hartzauthor=V.+T.+Ahujaauthor=X.+Zhuoauthor=R.+J.+Mattsonauthor=D.+J.+Denhartauthor=J.+A.+Deskusauthor=V.+M.+Vrudhulaauthor=S.+Panauthor=J.+L.+Dittaauthor=Y.+Z.+Shuauthor=J.+E.+Graceauthor=K.+A.+Lentzauthor=S.+Lelasauthor=Y.+W.+Liauthor=T.+F.+Molskiauthor=S.+Krishnananthanauthor=H.+Wongauthor=J.+Qian-Cutroneauthor=R.+Schartmanauthor=R.+Dentonauthor=N.+J.+Lodgeauthor=R.+Zaczekauthor=J.+E.+Macorauthor=J.+J.+Bronson&title=A+strategy+to+minimize+reactive+metabolite+formation%3A+discovery+of+%28S%29-4-%281-cyclopropyl-2-methoxyethyl%29-6-%5B6-%28difluoromethoxy%29-2%2C5-dimethylpyridin-3+-ylamino%5D-5-oxo-4%2C5-dihydropyrazine-2-carbonitrile+as+a+potent%2C+orally+bioavailable+corticotropin-releasing+factor-1+receptor+antagonist&doi=10.1021%2Fjm900716v"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">A Strategy to Minimize Reactive Metabolite Formation: Discovery of (S)-4-(1-Cyclopropyl-2-methoxyethyl)-6-[6-(difluoromethoxy)-2,5-dimethylpyridin-3-ylamino]-5-oxo-4,5-dihydropyrazine-2-carbonitrile as a Potent, Orally Bioavailable Corticotropin-Releasing Factor-1 Receptor Antagonist</span></div><div class="casAuthors">Hartz, Richard A.; Ahuja, Vijay T.; Zhuo, Xiaoliang; Mattson, Ronald J.; Denhart, Derek J.; Deskus, Jeffrey A.; Vrudhula, Vivekananda M.; Pan, Senliang; Ditta, Jonathan L.; Shu, Yue-Zhong; Grace, James E.; Lentz, Kimberley A.; Lelas, Snjezana; Li, Yu-Wen; Molski, Thaddeus F.; Krishnananthan, Subramaniam; Wong, Henry; Qian-Cutrone, Jingfang; Schartman, Richard; Denton, Rex; Lodge, Nicholas J.; Zaczek, Robert; Macor, John E.; Bronson, Joanne J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">7653-7668</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Detailed metabolic characterization of 8 (VIII), an earlier lead pyrazinone-based corticotropin-releasing factor-1 (CRF1) receptor antagonist, revealed that this compd. formed significant levels of reactive metabolites, as measured by in vivo and in vitro biotransformation studies.  This was of particular concern due to the body of evidence suggesting that reactive metabolites may be involved in idiosyncratic drug reactions.  Further optimization of the structure-activity relationships and in vivo properties of pyrazinone-based CRF1 receptor antagonists and studies to assess the formation of reactive metabolites led to the discovery of 19e (XIX), a high affinity CRF1 receptor antagonist (IC50 = 0.86 nM) wherein GSH adducts were estd. to be only 0.1% of the total amt. of drug-related material excreted through bile and urine, indicating low levels of reactive metabolite formation in vivo.  A novel 6-(difluoromethoxy)-2,5-dimethylpyridin-3-amine group in XIX contributed to the potency and improved in vivo properties of this compd. and related analogs.  XIX had excellent pharmacokinetic properties in rats and dogs and showed efficacy in the defensive withdrawal model of anxiety in rats.  The lowest efficacious dose was 1.8 mg/kg.  The results of a two-week rat safety study with XIX indicated that this compd. was well-tolerated.  Safety: authors caution safety in conversion of 2-amino-3-methylpyridine to 3-methyl-5-nitropyridin-2-ol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXgjp_vZ9dU7Vg90H21EOLACvtfcHk0liFWZHJB5ubbg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtVOnsrzM&md5=b340d132071b98a2b488952c2bcef4e5</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fjm900716v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm900716v%26sid%3Dliteratum%253Aachs%26aulast%3DHartz%26aufirst%3DR.%2BA.%26aulast%3DAhuja%26aufirst%3DV.%2BT.%26aulast%3DZhuo%26aufirst%3DX.%26aulast%3DMattson%26aufirst%3DR.%2BJ.%26aulast%3DDenhart%26aufirst%3DD.%2BJ.%26aulast%3DDeskus%26aufirst%3DJ.%2BA.%26aulast%3DVrudhula%26aufirst%3DV.%2BM.%26aulast%3DPan%26aufirst%3DS.%26aulast%3DDitta%26aufirst%3DJ.%2BL.%26aulast%3DShu%26aufirst%3DY.%2BZ.%26aulast%3DGrace%26aufirst%3DJ.%2BE.%26aulast%3DLentz%26aufirst%3DK.%2BA.%26aulast%3DLelas%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DY.%2BW.%26aulast%3DMolski%26aufirst%3DT.%2BF.%26aulast%3DKrishnananthan%26aufirst%3DS.%26aulast%3DWong%26aufirst%3DH.%26aulast%3DQian-Cutrone%26aufirst%3DJ.%26aulast%3DSchartman%26aufirst%3DR.%26aulast%3DDenton%26aufirst%3DR.%26aulast%3DLodge%26aufirst%3DN.%2BJ.%26aulast%3DZaczek%26aufirst%3DR.%26aulast%3DMacor%26aufirst%3DJ.%2BE.%26aulast%3DBronson%26aufirst%3DJ.%2BJ.%26atitle%3DA%2520strategy%2520to%2520minimize%2520reactive%2520metabolite%2520formation%253A%2520discovery%2520of%2520%2528S%2529-4-%25281-cyclopropyl-2-methoxyethyl%2529-6-%255B6-%2528difluoromethoxy%2529-2%252C5-dimethylpyridin-3%2520-ylamino%255D-5-oxo-4%252C5-dihydropyrazine-2-carbonitrile%2520as%2520a%2520potent%252C%2520orally%2520bioavailable%2520corticotropin-releasing%2520factor-1%2520receptor%2520antagonist%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D7653%26epage%3D7668%26doi%3D10.1021%2Fjm900716v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Belov, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ivanov, V. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curreli, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurkin, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altieri, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Debnath, A. K.</span></span> <span> </span><span class="NLM_article-title">Synthesis of 5-arylpyrrole-2-carboxylic acids as key intermediates for NBD series HIV-1 entry inhibitors</span>. <i>Synthesis</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">3692</span>– <span class="NLM_lpage">3699</span>, <span class="refDoi"> DOI: 10.1055/s-0036-1588780</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=10.1055%2Fs-0036-1588780" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmtlWltL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2017&pages=3692-3699&author=D.+S.+Belovauthor=V.+N.+Ivanovauthor=F.+Curreliauthor=A.+V.+Kurkinauthor=A.+Altieriauthor=A.+K.+Debnath&title=Synthesis+of+5-arylpyrrole-2-carboxylic+acids+as+key+intermediates+for+NBD+series+HIV-1+entry+inhibitors&doi=10.1055%2Fs-0036-1588780"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of 5-Arylpyrrole-2-carboxylic Acids as Key Intermediates for NBD Series HIV-1 Entry Inhibitors</span></div><div class="casAuthors">Belov, Dmitry S.; Ivanov, Vladimir N.; Curreli, Francesca; Kurkin, Alexander V.; Altieri, Andrea; Debnath, Asim K.</div><div class="citationInfo"><span class="NLM_cas:title">Synthesis</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">3692-3699</span>CODEN:
                <span class="NLM_cas:coden">SYNTBF</span>;
        ISSN:<span class="NLM_cas:issn">1437-210X</span>.
    
            (<span class="NLM_cas:orgname">Georg Thieme Verlag</span>)
        </div><div class="casAbstract">5-Arylpyrrole-2-carboxylic acids are important key intermediates in the synthesis of HIV-1 entry inhibitors (such as NBD-11021 and NBD-14010).  Herein, a general method for the synthesis of some 5-arylpyrrole-2-carboxylic acids, e.g., I, in three steps starting from pyrrole is presented.  By this method, the compds. could be prepd. on gram scale and without chromatog. purifn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZei1QnIu1E7Vg90H21EOLACvtfcHk0lij9ER0DIf1Dg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmtlWltL4%253D&md5=d828eca316d04a7e8649f64889ee11e2</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1055%2Fs-0036-1588780&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-0036-1588780%26sid%3Dliteratum%253Aachs%26aulast%3DBelov%26aufirst%3DD.%2BS.%26aulast%3DIvanov%26aufirst%3DV.%2BN.%26aulast%3DCurreli%26aufirst%3DF.%26aulast%3DKurkin%26aufirst%3DA.%2BV.%26aulast%3DAltieri%26aufirst%3DA.%26aulast%3DDebnath%26aufirst%3DA.%2BK.%26atitle%3DSynthesis%2520of%25205-arylpyrrole-2-carboxylic%2520acids%2520as%2520key%2520intermediates%2520for%2520NBD%2520series%2520HIV-1%2520entry%2520inhibitors%26jtitle%3DSynthesis%26date%3D2017%26volume%3D49%26spage%3D3692%26epage%3D3699%26doi%3D10.1055%2Fs-0036-1588780" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Curreli, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belov, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramesh, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altieri, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurkin, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Debnath, A. K.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis and evaluation of small molecule CD4-mimics as entry inhibitors possessing broad spectrum anti-HIV-1 activity</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">5988</span>– <span class="NLM_lpage">6003</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2016.09.057</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=10.1016%2Fj.bmc.2016.09.057" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=27707628" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1Wqu7%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2016&pages=5988-6003&author=F.+Curreliauthor=D.+S.+Belovauthor=R.+R.+Rameshauthor=N.+Patelauthor=A.+Altieriauthor=A.+V.+Kurkinauthor=A.+K.+Debnath&title=Design%2C+synthesis+and+evaluation+of+small+molecule+CD4-mimics+as+entry+inhibitors+possessing+broad+spectrum+anti-HIV-1+activity&doi=10.1016%2Fj.bmc.2016.09.057"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and evaluation of small molecule CD4-mimics as entry inhibitors possessing broad spectrum anti-HIV-1 activity</span></div><div class="casAuthors">Curreli, Francesca; Belov, Dmitry S.; Ramesh, Ranjith R.; Patel, Naisargi; Altieri, Andrea; Kurkin, Alexander V.; Debnath, Asim K.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">5988-6003</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Since the first discovery of a CD4-mimic, NBD-556, which targets the Phe43 cavity of HIV-1 gp120, the authors and other groups made considerable progress in designing new CD4-mimics with viral entry-antagonist property.  In the continued effort to make further progress the authors have synthesized twenty five new analogs based on the earlier reported viral entry antagonist, NBD-11021.  These compds. were tested first in HIV-1 Env-pseudovirus based single-cycle infection assay as well as in a multicycle infection assay.  Four of these new compds. showed much improved antiviral potency as well as cytotoxicity.  The authors selected two of the best compds. I (NBD-14009) and II (NBD-14010) to test against a panel of 51 Env-pseudotyped HIV-1 representing diverse subtypes of clin. isolates.  These compds. showed noticeable breadth of antiviral potency with IC50 of as low as 150 nM.  These compds. also inhibited cell-to-cell fusion and cell-to-cell HIV-1 transmission.  The study is expected to pave the way of designing more potent and selective HIV-1 entry inhibitors targeted to the Phe43 cavity of HIV-1 gp120.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8tvfa755JPrVg90H21EOLACvtfcHk0lij9ER0DIf1Dg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1Wqu7%252FO&md5=3dfef59f6bbe43266f3520165585b547</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2016.09.057&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2016.09.057%26sid%3Dliteratum%253Aachs%26aulast%3DCurreli%26aufirst%3DF.%26aulast%3DBelov%26aufirst%3DD.%2BS.%26aulast%3DRamesh%26aufirst%3DR.%2BR.%26aulast%3DPatel%26aufirst%3DN.%26aulast%3DAltieri%26aufirst%3DA.%26aulast%3DKurkin%26aufirst%3DA.%2BV.%26aulast%3DDebnath%26aufirst%3DA.%2BK.%26atitle%3DDesign%252C%2520synthesis%2520and%2520evaluation%2520of%2520small%2520molecule%2520CD4-mimics%2520as%2520entry%2520inhibitors%2520possessing%2520broad%2520spectrum%2520anti-HIV-1%2520activity%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2016%26volume%3D24%26spage%3D5988%26epage%3D6003%26doi%3D10.1016%2Fj.bmc.2016.09.057" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Curreli, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belov, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmed, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramesh, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurkin, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altieri, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Debnath, A. K.</span></span> <span> </span><span class="NLM_article-title">Synthesis, antiviral activity, and structure-activity relationship of 1,3-benzodioxolyl pyrrole-based entry inhibitors targeting the Phe43 cavity in HIV-1 gp120</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">2332</span>– <span class="NLM_lpage">2348</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201800534</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=10.1002%2Fcmdc.201800534" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=30257071" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFCgtrzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&pages=2332-2348&author=F.+Curreliauthor=D.+S.+Belovauthor=S.+Ahmedauthor=R.+R.+Rameshauthor=A.+V.+Kurkinauthor=A.+Altieriauthor=A.+K.+Debnath&title=Synthesis%2C+antiviral+activity%2C+and+structure-activity+relationship+of+1%2C3-benzodioxolyl+pyrrole-based+entry+inhibitors+targeting+the+Phe43+cavity+in+HIV-1+gp120&doi=10.1002%2Fcmdc.201800534"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, Antiviral Activity, and Structure-Activity Relationship of 1,3-Benzodioxolyl Pyrrole-Based Entry Inhibitors Targeting the Phe43 Cavity in HIV-1 gp120</span></div><div class="casAuthors">Curreli, Francesca; Belov, Dmitry S.; Ahmed, Shahad; Ramesh, Ranjith R.; Kurkin, Alexander V.; Altieri, Andrea; Debnath, Asim K.</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">2332-2348</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The pathway by which HIV-1 enters host cells is a prime target for novel drug discovery because of its crit. role in the life cycle of HIV-1.  The HIV-1 envelope glycoprotein gp120 plays an important role in initiating virus entry by targeting the primary cell receptor CD4.  We explored the substitution of bulky mol. groups in region I in the NBD class of entry inhibitors.  Previous attempts at bulky substituents in that region abolished antiviral activity, even though the binding site is hydrophobic.  We synthesized a series of entry inhibitors contg. the 1,3-benzodioxolyl moiety or its bioisostere, 2,1,3-benzothiadiazole.  The introduction of the bulkier groups was well tolerated, and despite only minor improvements in antiviral activity, the selectivity index of these compds. improved significantly.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOG5Bxud-tqbVg90H21EOLACvtfcHk0liViQh1dIUHlA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFCgtrzP&md5=64730c9bd543fffc0b1dfdebe3e83763</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201800534&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201800534%26sid%3Dliteratum%253Aachs%26aulast%3DCurreli%26aufirst%3DF.%26aulast%3DBelov%26aufirst%3DD.%2BS.%26aulast%3DAhmed%26aufirst%3DS.%26aulast%3DRamesh%26aufirst%3DR.%2BR.%26aulast%3DKurkin%26aufirst%3DA.%2BV.%26aulast%3DAltieri%26aufirst%3DA.%26aulast%3DDebnath%26aufirst%3DA.%2BK.%26atitle%3DSynthesis%252C%2520antiviral%2520activity%252C%2520and%2520structure-activity%2520relationship%2520of%25201%252C3-benzodioxolyl%2520pyrrole-based%2520entry%2520inhibitors%2520targeting%2520the%2520Phe43%2520cavity%2520in%2520HIV-1%2520gp120%26jtitle%3DChemMedChem%26date%3D2018%26volume%3D13%26spage%3D2332%26epage%3D2348%26doi%3D10.1002%2Fcmdc.201800534" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Queiroz, M. J. ú.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Begouin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pereira, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferreira, P. M. T.</span></span> <span> </span><span class="NLM_article-title">New synthesis of methyl 5-aryl or heteroaryl pyrrole-2-carboxylates by a tandem Sonogashira coupling/5-endo-dig-cyclization from β-iododehydroamino acid methyl esters and terminal alkynes</span>. <i>Tetrahedron</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">10714</span>– <span class="NLM_lpage">10720</span>, <span class="refDoi"> DOI: 10.1016/j.tet.2008.08.105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=10.1016%2Fj.tet.2008.08.105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1Cqsr%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2008&pages=10714-10720&author=M.+J.+%C3%BA.+Queirozauthor=A.+Begouinauthor=G.+Pereiraauthor=P.+M.+T.+Ferreira&title=New+synthesis+of+methyl+5-aryl+or+heteroaryl+pyrrole-2-carboxylates+by+a+tandem+Sonogashira+coupling%2F5-endo-dig-cyclization+from+%CE%B2-iododehydroamino+acid+methyl+esters+and+terminal+alkynes&doi=10.1016%2Fj.tet.2008.08.105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">New synthesis of methyl 5-aryl- or 5-heteroarylpyrrole-2-carboxylates by a tandem Sonogashira coupling/5-endo-dig-cyclization from β-iododehydroamino acid methyl esters and terminal alkynes</span></div><div class="casAuthors">Queiroz, Maria-Joao R. P.; Begouin, Agathe; Pereira, Goreti; Ferreira, Paula M. T.</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">47</span>),
    <span class="NLM_cas:pages">10714-10720</span>CODEN:
                <span class="NLM_cas:coden">TETRAB</span>;
        ISSN:<span class="NLM_cas:issn">0040-4020</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A new and versatile Pd/CuI catalyzed protocol was developed for the synthesis in good to high yields of substituted pyrroles, e.g., I, from N-Boc-β-iododehydroamino acid Me esters and several terminal alkynes.  This one-pot, two-step procedure occurs by a Sonogashira coupling followed by a 5-endo-dig-cyclization, which involves the nitrogen atom of the dehydroamino acid.  After several expts. using different Pd(0) and Pd(II) species, it was possible to establish the more general reaction conditions, which are: the use of a Pd(II) catalyst, CuI and Cs2CO3 as base in dry DMF at 70°.  The best yields were obtained with arylacetylenes bearing electron-donating groups and with electron-rich heteroarylacetylenes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoReF40VuTUq7Vg90H21EOLACvtfcHk0lhI24UuKKtwIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1Cqsr%252FN&md5=ac05f13fef051e9c7496a295fda0a33f</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2Fj.tet.2008.08.105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tet.2008.08.105%26sid%3Dliteratum%253Aachs%26aulast%3DQueiroz%26aufirst%3DM.%2BJ.%2B%25C3%25BA.%26aulast%3DBegouin%26aufirst%3DA.%26aulast%3DPereira%26aufirst%3DG.%26aulast%3DFerreira%26aufirst%3DP.%2BM.%2BT.%26atitle%3DNew%2520synthesis%2520of%2520methyl%25205-aryl%2520or%2520heteroaryl%2520pyrrole-2-carboxylates%2520by%2520a%2520tandem%2520Sonogashira%2520coupling%252F5-endo-dig-cyclization%2520from%2520%25CE%25B2-iododehydroamino%2520acid%2520methyl%2520esters%2520and%2520terminal%2520alkynes%26jtitle%3DTetrahedron%26date%3D2008%26volume%3D64%26spage%3D10714%26epage%3D10720%26doi%3D10.1016%2Fj.tet.2008.08.105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kobayakawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konno, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohashi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masuda, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshimura, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harada, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamamura, H.</span></span> <span> </span><span class="NLM_article-title">Soluble-type small-molecule CD4 mimics as HIV entry inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">719</span>– <span class="NLM_lpage">723</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2019.01.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=10.1016%2Fj.bmcl.2019.01.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=30665681" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsVyjt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2019&pages=719-723&author=T.+Kobayakawaauthor=K.+Konnoauthor=N.+Ohashiauthor=K.+Takahashiauthor=A.+Masudaauthor=K.+Yoshimuraauthor=S.+Haradaauthor=H.+Tamamura&title=Soluble-type+small-molecule+CD4+mimics+as+HIV+entry+inhibitors&doi=10.1016%2Fj.bmcl.2019.01.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Soluble-type small-molecule CD4 mimics as HIV entry inhibitors</span></div><div class="casAuthors">Kobayakawa, Takuya; Konno, Kiju; Ohashi, Nami; Takahashi, Kohei; Masuda, Ami; Yoshimura, Kazuhisa; Harada, Shigeyoshi; Tamamura, Hirokazu</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">719-723</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Several small mol. CD4 mimics have been reported previously as HIV-1 entry inhibitors, which block the interaction between the Phe43 cavity of HIV-1 gp120 and the host CD4.  Known CD4 mimics such as NBD-556 possess significant anti-HIV activity but are less sol. in water, perhaps due to their hydrophobic arom. ring-contg. structures.  Compds. with a pyridinyl group in place of the Ph group in these mols. have been designed and synthesized in an attempt to increase the hydrophilicity.  Some of these new CD4 mimics, contg. a tetramethylpiperidine ring show significantly higher water soly. than NBD-556 and have high anti-HIV activity and synergistic anti-HIV activity with a neutralizing antibody.  The CD4 mimic that has a cyclohexylpiperidine ring and a 6-fluoropyridin-3-yl ring has high anti-HIV activity and no significant cytotoxicity.  The present results will be useful in the future design and development of novel sol.-type mol. CD4 mimics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqN4Aonl-kVDbVg90H21EOLACvtfcHk0lhI24UuKKtwIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsVyjt7w%253D&md5=69a0292b74499b81123afa66bc2e0eb8</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2019.01.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2019.01.011%26sid%3Dliteratum%253Aachs%26aulast%3DKobayakawa%26aufirst%3DT.%26aulast%3DKonno%26aufirst%3DK.%26aulast%3DOhashi%26aufirst%3DN.%26aulast%3DTakahashi%26aufirst%3DK.%26aulast%3DMasuda%26aufirst%3DA.%26aulast%3DYoshimura%26aufirst%3DK.%26aulast%3DHarada%26aufirst%3DS.%26aulast%3DTamamura%26aufirst%3DH.%26atitle%3DSoluble-type%2520small-molecule%2520CD4%2520mimics%2520as%2520HIV%2520entry%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D29%26spage%3D719%26epage%3D723%26doi%3D10.1016%2Fj.bmcl.2019.01.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Curreli, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, Y. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scacalossi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwong, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Debnath, A. K.</span></span> <span> </span><span class="NLM_article-title">Binding mode characterization of NBD series CD4-mimetic HIV-1 entry inhibitors by X-ray structure and resistance study</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">5478</span>– <span class="NLM_lpage">5491</span>, <span class="refDoi"> DOI: 10.1128/AAC.03339-14</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=10.1128%2FAAC.03339-14" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=25001301" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1eqsLfE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2014&pages=5478-5491&author=F.+Curreliauthor=Y.+D.+Kwonauthor=H.+Zhangauthor=Y.+Yangauthor=D.+Scacalossiauthor=P.+D.+Kwongauthor=A.+K.+Debnath&title=Binding+mode+characterization+of+NBD+series+CD4-mimetic+HIV-1+entry+inhibitors+by+X-ray+structure+and+resistance+study&doi=10.1128%2FAAC.03339-14"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Binding mode characterization of NBD series CD4-mimetic HIV-1 entry inhibitors by X-ray structure and resistance study</span></div><div class="casAuthors">Curreli, Francesca; Kwon, Young Do; Zhang, Hongtao; Yang, Yongping; Scacalossi, Daniel; Kwong, Peter D.; Debnath, Asim K.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">5478-5491, 15 pp.</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">1098-6596</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">We previously identified two small-mol. CD4 mimetics - NBD-556 and NBD-557 - and synthesized a series of NBD compds. that resulted in improved neutralization activity in a single-cycle HIV-1 infectivity assay.  For the current investigation, we selected several of the most active compds. and assessed their antiviral activity on a panel of 53 ref. HIV-1 Env pseudoviruses representing diverse clades of clin. isolates.  The selected compds. inhibited tested clades with low-micromolar potencies.  Mechanism studies indicated that they act as CD4 agonists, a potentially unfavorable therapeutic trait, in that they can bind to the gp120 envelope glycoprotein and initiate a similar physiol. response as CD4.  However, one of the compds., NBD-09027, exhibited reduced agonist properties, in both functional and biophys. studies.  To understand the binding mode of these inhibitors, we first generated HIV-1-resistant mutants, assessed their behavior with NBD compds., and detd. the X-ray structures of two inhibitors, NBD-09027 and NBD-10007, in complex with the HIV-1 gp120 core at ∼2-Å resoln.  Both studies confirmed that the NBD compds. bind similarly to NBD-556 and NBD-557 by inserting their hydrophobic groups into the Phe43 cavity of gp120.  The basic nitrogen of the piperidine ring is located in close proximity to D368 of gp120 but it does not form any H-bond or salt bridge, a likely explanation for their nonoptimal antagonist properties.  The results reveal the structural and biol. character of the NBD series of CD4 mimetics and identify ways to reduce their agonist properties and convert them to antagonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQafZBXLanQbVg90H21EOLACvtfcHk0lhy-J4SIQN9MQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1eqsLfE&md5=d872c92f7a508790f83359add7bfff1d</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1128%2FAAC.03339-14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.03339-14%26sid%3Dliteratum%253Aachs%26aulast%3DCurreli%26aufirst%3DF.%26aulast%3DKwon%26aufirst%3DY.%2BD.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DScacalossi%26aufirst%3DD.%26aulast%3DKwong%26aufirst%3DP.%2BD.%26aulast%3DDebnath%26aufirst%3DA.%2BK.%26atitle%3DBinding%2520mode%2520characterization%2520of%2520NBD%2520series%2520CD4-mimetic%2520HIV-1%2520entry%2520inhibitors%2520by%2520X-ray%2520structure%2520and%2520resistance%2520study%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2014%26volume%3D58%26spage%3D5478%26epage%3D5491%26doi%3D10.1128%2FAAC.03339-14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madani, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klein, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hubicki, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A. B.,  III</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sodroski, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freire, E.</span></span> <span> </span><span class="NLM_article-title">Thermodynamics of binding of a low-molecular-weight CD4 mimetic to HIV-1 gp120</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">10973</span>– <span class="NLM_lpage">10980</span>, <span class="refDoi"> DOI: 10.1021/bi061193r</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi061193r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=1%3ACAS%3A280%3ADC%252BD28rivFGrug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2006&pages=10973-10980&author=A.+Schonauthor=N.+Madaniauthor=J.+C.+Kleinauthor=A.+Hubickiauthor=D.+Ngauthor=X.+Yangauthor=A.+B.+Smithauthor=J.+Sodroskiauthor=E.+Freire&title=Thermodynamics+of+binding+of+a+low-molecular-weight+CD4+mimetic+to+HIV-1+gp120&doi=10.1021%2Fbi061193r"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Thermodynamics of binding of a low-molecular-weight CD4 mimetic to HIV-1 gp120</span></div><div class="casAuthors">Schon Arne; Madani Navid; Klein Jeffrey C; Hubicki Amy; Ng Danny; Yang Xinzhen; Smith Amos B 3rd; Sodroski Joseph; Freire Ernesto</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">36</span>),
    <span class="NLM_cas:pages">10973-80</span>
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    </div><div class="casAbstract">NBD-556 and the chemically and structurally similar NBD-557 are two low-molecular weight compounds that reportedly block the interaction between the HIV-1 envelope glycoprotein gp120 and its receptor, CD4.  NBD-556 binds to gp120 with a binding affinity of 2.7 x 10(5) M(-1) (K(d) = 3.7 muM) in a process characterized by a large favorable change in enthalpy partially compensated by a large unfavorable entropy change, a thermodynamic signature similar to that observed for binding of sCD4 to gp120.  NBD-556 binding is associated with a large structuring of the gp120 molecule, as also demonstrated by CD spectroscopy.  NBD-556, like CD4, activates the binding of gp120 to the HIV-1 coreceptor, CCR5, and to the 17b monoclonal antibody, which recognizes the coreceptor binding site of gp120.  NBD-556 stimulates HIV-1 infection of CD4-negative, CCR5-expressing cells.  The thermodynamic signature of the binding of NBD-556 to gp120 is very different from that of another viral entry inhibitor, BMS-378806.  Whereas NBD-556 binds gp120 with a large favorable enthalpy and compensating unfavorable entropy changes, BMS-378806 does so with a small binding enthalpy change in a mostly entropy-driven process.  NBD-556 is a competitive inhibitor of sCD4 and elicits a similar structuring of the coreceptor binding site, whereas BMS-378806 does not compete with sCD4 and does not induce coreceptor binding.  These studies demonstrate that low-molecular-weight compounds can induce conformational changes in the HIV-1 gp120 glycoprotein similar to those observed upon CD4 binding, revealing distinct strategies for inhibiting the function of the HIV-1 gp120 envelope glycoprotein.  Furthermore, competitive and noncompetitive compounds have characteristic thermodynamic signatures that can be used to guide the design of more potent and effective viral entry inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRIz0DwBgcSFxWfpMXQLRstfW6udTcc2eatUwtzSc43urntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD28rivFGrug%253D%253D&md5=52d9c713cf0fea54c071a34f3875ccd8</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Fbi061193r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi061193r%26sid%3Dliteratum%253Aachs%26aulast%3DSchon%26aufirst%3DA.%26aulast%3DMadani%26aufirst%3DN.%26aulast%3DKlein%26aufirst%3DJ.%2BC.%26aulast%3DHubicki%26aufirst%3DA.%26aulast%3DNg%26aufirst%3DD.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DSmith%26aufirst%3DA.%2BB.%26aulast%3DSodroski%26aufirst%3DJ.%26aulast%3DFreire%26aufirst%3DE.%26atitle%3DThermodynamics%2520of%2520binding%2520of%2520a%2520low-molecular-weight%2520CD4%2520mimetic%2520to%2520HIV-1%2520gp120%26jtitle%3DBiochemistry%26date%3D2006%26volume%3D45%26spage%3D10973%26epage%3D10980%26doi%3D10.1021%2Fbi061193r" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blair, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spicer, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, Y. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rose, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamanaka, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fridell, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deminie, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demers, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zadjura, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meanwell, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colonno, R.</span></span> <span> </span><span class="NLM_article-title">A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>100</i></span>,  <span class="NLM_fpage">11013</span>– <span class="NLM_lpage">11018</span>, <span class="refDoi"> DOI: 10.1073/pnas.1832214100</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=10.1073%2Fpnas.1832214100" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=12930892" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=1%3ACAS%3A528%3ADC%252BD3sXnslynurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2003&pages=11013-11018&author=P.+F.+Linauthor=W.+Blairauthor=T.+Wangauthor=T.+Spicerauthor=Q.+Guoauthor=N.+Zhouauthor=Y.+F.+Gongauthor=H.+G.+Wangauthor=R.+Roseauthor=G.+Yamanakaauthor=B.+Robinsonauthor=C.+B.+Liauthor=R.+Fridellauthor=C.+Deminieauthor=G.+Demersauthor=Z.+Yangauthor=L.+Zadjuraauthor=N.+Meanwellauthor=R.+Colonno&title=A+small+molecule+HIV-1+inhibitor+that+targets+the+HIV-1+envelope+and+inhibits+CD4+receptor+binding&doi=10.1073%2Fpnas.1832214100"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding</span></div><div class="casAuthors">Lin, Pin-Fang; Blair, Wade; Wang, Tao; Spicer, Timothy; Guo, Qi; Zhou, Nannan; Gong, Yi-Fei; Wang, H. -G. Heidi; Rose, Ronald; Yamanaka, Gregory; Robinson, Brett; Li, Chang-Ben; Fridell, Robert; Deminie, Carol; Demers, Gwendeline; Yang, Zheng; Zadjura, Lisa; Meanwell, Nicholas; Colonno, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">11013-11018</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">BMS-378806 is a recently discovered small mol. HIV-1 inhibitor that blocks viral entrance to cells.  The compd. exhibits potent inhibitory activity against a panel of R5- (virus using the CCR5 coreceptor), X4- (virus using the CXCR4 coreceptor), and R5/X4 HIV-1 lab. and clin. isolates of the B subtype (median EC50 of 0.04 μM) in culture assays.  BMS-378806 is selective for HIV-1 and inactive against HIV-2, SIV and a panel of other viruses, and exhibits no significant cytotoxicity in the 14 cell types tested (concn. for 50% redn. of cell growth, >225 μM).  Mechanism of action studies demonstrated that BMS-378806 binds to gp120 and inhibits the interactions of the HIV-1 envelope protein to cellular CD4 receptors.  Further confirmation that BMS-378806 targets the envelope in infected cells was obtained through the isolation of resistant variants and the mapping of resistance substitutions to the HIV-1 envelope.  In particular, two substitutions, M426L and M475I, are situated in the CD4 binding pocket of gp120.  Recombinant HIV-1 carrying these two substitutions demonstrated significantly reduced susceptibility to compd. inhibition.  BMS-378806 displays many favorable pharmacol. traits, such as low protein binding, minimal human serum effect on anti-HIV-1 potency, good oral bioavailability in animal species, and a clean safety profile in initial animal toxicol. studies.  Together, the data show that BMS-378806 is a representative of a new class of HIV inhibitors that has the potential to become a valued addn. to our current armamentarium of antiretroviral drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRxcq5wksNmrVg90H21EOLACvtfcHk0lje3MO0RUTuyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXnslynurg%253D&md5=9066843a4e1b65984343fccd70ae4323</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1832214100&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1832214100%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DP.%2BF.%26aulast%3DBlair%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DT.%26aulast%3DSpicer%26aufirst%3DT.%26aulast%3DGuo%26aufirst%3DQ.%26aulast%3DZhou%26aufirst%3DN.%26aulast%3DGong%26aufirst%3DY.%2BF.%26aulast%3DWang%26aufirst%3DH.%2BG.%26aulast%3DRose%26aufirst%3DR.%26aulast%3DYamanaka%26aufirst%3DG.%26aulast%3DRobinson%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DC.%2BB.%26aulast%3DFridell%26aufirst%3DR.%26aulast%3DDeminie%26aufirst%3DC.%26aulast%3DDemers%26aufirst%3DG.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DZadjura%26aufirst%3DL.%26aulast%3DMeanwell%26aufirst%3DN.%26aulast%3DColonno%26aufirst%3DR.%26atitle%3DA%2520small%2520molecule%2520HIV-1%2520inhibitor%2520that%2520targets%2520the%2520HIV-1%2520envelope%2520and%2520inhibits%2520CD4%2520receptor%2520binding%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2003%26volume%3D100%26spage%3D11013%26epage%3D11018%26doi%3D10.1073%2Fpnas.1832214100" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parast, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nduati, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">John-Stewart, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mbori-Ngacha, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rainwater, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Overbaugh, J.</span></span> <span> </span><span class="NLM_article-title">Neutralization escape variants of human immunodeficiency virus type 1 are transmitted from mother to infant</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>80</i></span>,  <span class="NLM_fpage">835</span>– <span class="NLM_lpage">844</span>, <span class="refDoi"> DOI: 10.1128/JVI.80.2.835-844.2006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=10.1128%2FJVI.80.2.835-844.2006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=16378985" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=1%3ACAS%3A528%3ADC%252BD28XivVOrtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2006&pages=835-844&author=X.+Wuauthor=A.+B.+Parastauthor=B.+A.+Richardsonauthor=R.+Nduatiauthor=G.+John-Stewartauthor=D.+Mbori-Ngachaauthor=S.+M.+Rainwaterauthor=J.+Overbaugh&title=Neutralization+escape+variants+of+human+immunodeficiency+virus+type+1+are+transmitted+from+mother+to+infant&doi=10.1128%2FJVI.80.2.835-844.2006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Neutralization escape variants of human immunodeficiency virus type 1 are transmitted from mother to infant</span></div><div class="casAuthors">Wu, Xueling; Parast, Adam B.; Richardson, Barbra A.; Nduati, Ruth; John-Stewart, Grace; Mbori-Ngacha, Dorothy; Rainwater, Stephanie M. J.; Overbaugh, Julie</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">80</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">835-844</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Maternal passive immunity typically plays a crit. role in protecting infants from new infections; however, the specific contribution of neutralizing antibodies in limiting mother-to-child transmission of human immunodeficiency virus type 1 is unclear.  By examg. cloned envelope variants from 12 transmission pairs, we found that vertically transmitted variants were more resistant to neutralization by maternal plasma than were maternal viral variants near the time of transmission.  The vertically transmitted envelope variants were poorly neutralized by monoclonal antibodies biz, 2G12, 2F5, and 4E10 individually or in combination.  Despite the fact that the infant viruses were among the most neutralization resistant in the mother, they had relatively few glycosylation sites.  Moreover, the transmitted variants elicited de novo neutralizing antibodies in the infants, indicating that they were not inherently difficult to neutralize.  The neutralization resistance of vertically transmitted viruses is in contrast to the relative neutralization sensitivity of viruses sexually transmitted within discordant couples, suggesting that the antigenic properties of viruses that are favored for transmission may differ depending upon mode of transmission.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpg1ghxbC6IW7Vg90H21EOLACvtfcHk0lje3MO0RUTuyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XivVOrtQ%253D%253D&md5=3d7befeb4abfc14465b28311dd8292e6</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1128%2FJVI.80.2.835-844.2006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.80.2.835-844.2006%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DX.%26aulast%3DParast%26aufirst%3DA.%2BB.%26aulast%3DRichardson%26aufirst%3DB.%2BA.%26aulast%3DNduati%26aufirst%3DR.%26aulast%3DJohn-Stewart%26aufirst%3DG.%26aulast%3DMbori-Ngacha%26aufirst%3DD.%26aulast%3DRainwater%26aufirst%3DS.%2BM.%26aulast%3DOverbaugh%26aufirst%3DJ.%26atitle%3DNeutralization%2520escape%2520variants%2520of%2520human%2520immunodeficiency%2520virus%2520type%25201%2520are%2520transmitted%2520from%2520mother%2520to%2520infant%26jtitle%3DJ.%2520Virol.%26date%3D2006%26volume%3D80%26spage%3D835%26epage%3D844%26doi%3D10.1128%2FJVI.80.2.835-844.2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Agosto, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uchil, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mothes, W.</span></span> <span> </span><span class="NLM_article-title">HIV cell-to-cell transmission: effects on pathogenesis and antiretroviral therapy</span>. <i>Trends Microbiol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">289</span>– <span class="NLM_lpage">295</span>, <span class="refDoi"> DOI: 10.1016/j.tim.2015.02.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=10.1016%2Fj.tim.2015.02.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=25766144" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjs1Kjt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2015&pages=289-295&author=L.+M.+Agostoauthor=P.+D.+Uchilauthor=W.+Mothes&title=HIV+cell-to-cell+transmission%3A+effects+on+pathogenesis+and+antiretroviral+therapy&doi=10.1016%2Fj.tim.2015.02.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">HIV cell-to-cell transmission: effects on pathogenesis and antiretroviral therapy</span></div><div class="casAuthors">Agosto, Luis M.; Uchil, Pradeep D.; Mothes, Walther</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Microbiology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">289-295</span>CODEN:
                <span class="NLM_cas:coden">TRMIEA</span>;
        ISSN:<span class="NLM_cas:issn">0966-842X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">HIV spreads more efficiently in vitro when infected cells directly contact uninfected cells to form virol. synapses.  A hallmark of virol. synapses is that viruses can be transmitted at a higher multiplicity of infection (MOI) that, in vitro, results in a higher no. of proviruses.  Whether HIV also spreads by cell-cell contact in vivo is a matter of debate.  Here we discuss recent data that suggest that contact-mediated transmission largely manifests itself in vivo as CD4+ T cell depletion.  The assault of a cell by a large no. of incoming particles is likely to be efficiently sensed by the innate cellular surveillance to trigger cell death.  The large no. of particles transferred across virol. synapses has also been implicated in reduced efficacy of antiretroviral therapies.  Thus, antiretroviral therapies must remain effective against the high MOI obsd. during cell-to-cell transmission to inhibit both viral replication and the pathogenesis assocd. with HIV infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmKTY4Az8TlrVg90H21EOLACvtfcHk0lg4xvtoQK2Z7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjs1Kjt7o%253D&md5=00eac88b406a7e52b22c12922f2b5fc9</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1016%2Fj.tim.2015.02.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tim.2015.02.003%26sid%3Dliteratum%253Aachs%26aulast%3DAgosto%26aufirst%3DL.%2BM.%26aulast%3DUchil%26aufirst%3DP.%2BD.%26aulast%3DMothes%26aufirst%3DW.%26atitle%3DHIV%2520cell-to-cell%2520transmission%253A%2520effects%2520on%2520pathogenesis%2520and%2520antiretroviral%2520therapy%26jtitle%3DTrends%2520Microbiol.%26date%3D2015%26volume%3D23%26spage%3D289%26epage%3D295%26doi%3D10.1016%2Fj.tim.2015.02.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abela, I. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berlinger, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schanz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reynell, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunthard, H. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rusert, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trkola, A.</span></span> <span> </span><span class="NLM_article-title">Cell-cell transmission enables HIV-1 to evade inhibition by potent CD4bs directed antibodies</span>. <i>PLoS Pathog.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>8</i></span>, <span class="NLM_elocation-id">e1002634</span> <span class="refDoi"> DOI: 10.1371/journal.ppat.1002634</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=10.1371%2Fjournal.ppat.1002634" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=22496655" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=1%3ACAS%3A528%3ADC%252BC38Xlsl2qs7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2012&author=I.+A.+Abelaauthor=L.+Berlingerauthor=M.+Schanzauthor=L.+Reynellauthor=H.+F.+Gunthardauthor=P.+Rusertauthor=A.+Trkola&title=Cell-cell+transmission+enables+HIV-1+to+evade+inhibition+by+potent+CD4bs+directed+antibodies&doi=10.1371%2Fjournal.ppat.1002634"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Cell-cell transmission enables HIV-1 to evade inhibition by potent CD4bs directed antibodies</span></div><div class="casAuthors">Abela, Irene A.; Berlinger, Livia; Schanz, Merle; Reynell, Lucy; Guenthard, Huldrych F.; Rusert, Peter; Trkola, Alexandra</div><div class="citationInfo"><span class="NLM_cas:title">PLoS Pathogens</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">e1002634</span>CODEN:
                <span class="NLM_cas:coden">PPLACN</span>;
        ISSN:<span class="NLM_cas:issn">1553-7374</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">HIV is known to spread efficiently both in a cell-free state and from cell to cell, however the relative importance of the cell-cell transmission mode in natural infection has not yet been resolved.  Likewise to what extent cell-cell transmission is vulnerable to inhibition by neutralizing antibodies and entry inhibitors remains to be detd.  Here we report on neutralizing antibody activity during cell-cell transmission using specifically tailored exptl. strategies which enable unambiguous discrimination between the two transmission routes.  We demonstrate that the activity of neutralizing monoclonal antibodies (mAbs) and entry inhibitors during cell-cell transmission varies depending on their mode of action.  While gp41 directed agents remain active, CD4 binding site (CD4bs) directed inhibitors, including the potent neutralizing mAb VRC01, dramatically lose potency during cell-cell transmission.  This implies that CD4bs mAbs act preferentially through blocking free virus transmission, while still allowing HIV to spread through cell-cell contacts.  Thus providing a plausible explanation for how HIV maintains infectivity and rapidly escapes potent and broadly active CD4bs directed antibody responses in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqguQxbGgAR8LVg90H21EOLACvtfcHk0lg4xvtoQK2Z7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xlsl2qs7w%253D&md5=ffd09b3f9804da82500d931c946fbc53</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1371%2Fjournal.ppat.1002634&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.ppat.1002634%26sid%3Dliteratum%253Aachs%26aulast%3DAbela%26aufirst%3DI.%2BA.%26aulast%3DBerlinger%26aufirst%3DL.%26aulast%3DSchanz%26aufirst%3DM.%26aulast%3DReynell%26aufirst%3DL.%26aulast%3DGunthard%26aufirst%3DH.%2BF.%26aulast%3DRusert%26aufirst%3DP.%26aulast%3DTrkola%26aufirst%3DA.%26atitle%3DCell-cell%2520transmission%2520enables%2520HIV-1%2520to%2520evade%2520inhibition%2520by%2520potent%2520CD4bs%2520directed%2520antibodies%26jtitle%3DPLoS%2520Pathog.%26date%3D2012%26volume%3D8%26doi%3D10.1371%2Fjournal.ppat.1002634" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Durham, N. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yewdall, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zony, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, B. K.</span></span> <span> </span><span class="NLM_article-title">Neutralization resistance of virological synapse-mediated HIV-1 Infection is regulated by the gp41 cytoplasmic tail</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>86</i></span>,  <span class="NLM_fpage">7484</span>– <span class="NLM_lpage">7495</span>, <span class="refDoi"> DOI: 10.1128/JVI.00230-12</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=10.1128%2FJVI.00230-12" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=22553332" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVegsbbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=86&publication_year=2012&pages=7484-7495&author=N.+D.+Durhamauthor=A.+W.+Yewdallauthor=P.+Chenauthor=R.+Leeauthor=C.+Zonyauthor=J.+E.+Robinsonauthor=B.+K.+Chen&title=Neutralization+resistance+of+virological+synapse-mediated+HIV-1+Infection+is+regulated+by+the+gp41+cytoplasmic+tail&doi=10.1128%2FJVI.00230-12"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Neutralization resistance of virological synapse-mediated HIV-1 infection is regulated by the gp41 cytoplasmic tail</span></div><div class="casAuthors">Durham, Natasha D.; Yewdall, Alice W.; Chen, Ping; Lee, Rebecca; Zony, Chati; Robinson, James E.; Chen, Benjamin K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">86</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">7484-7495</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Human immunodeficiency virus type 1 (HIV-1) infection can spread efficiently from infected to uninfected T cells through adhesive contacts called virol. synapses (VSs).  In this process, cell-surface envelope glycoprotein (Env) initiates adhesion and viral transfer into an uninfected recipient cell.  Previous studies have found some HIV-1-neutralizing patient sera to be less effective at blocking VS-mediated infection than infection with cell-free virus.  Here we employ sensitive flow cytometry-based infection assays to measure the inhibitory potency of HIV-1-neutralizing monoclonal antibodies (MAb) and HIV-1-neutralizing patient sera against cell-free and VS-mediated infection.  To various degrees, anti-Env MAbs exhibited significantly higher 50% inhibitory concn. (IC50s) against VS-mediated infection than cell-free infection.  Notably, the MAb 17b, which binds a CD4-induced (CD4i) epitope on gp120, displayed a 72-fold reduced efficacy against VS-mediated inocula compared to cell-free inocula.  A mutant with truncation mutation in the gp41 cytoplasmic tail (CT) which is unable to modulate Env fusogenicity in response to virus particle maturation but which can still engage in cell-to-cell infection was tested for the ability to resist neutralizing antibodies.  The ΔCT mutation increased cell surface staining by neutralizing antibodies, significantly enhanced neutralization of VS-mediated infection, and had reduced or no effect on cell-free infection, depending upon the antibody.  Our results suggest that the gp41 CT regulates the exposure of key neutralizing epitopes during cell-to-cell infection and plays an important role in immune evasion.  Vaccine strategies should consider immunogens that reflect Env conformations exposed on the infected cell surface to enhance protection against VS-mediated HIV-1 spread.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXu523tMUDKbVg90H21EOLACvtfcHk0ljKWFy1EF5zYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVegsbbP&md5=a07cc2d4d1ddbacbd87f8bbb520ccd3e</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1128%2FJVI.00230-12&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.00230-12%26sid%3Dliteratum%253Aachs%26aulast%3DDurham%26aufirst%3DN.%2BD.%26aulast%3DYewdall%26aufirst%3DA.%2BW.%26aulast%3DChen%26aufirst%3DP.%26aulast%3DLee%26aufirst%3DR.%26aulast%3DZony%26aufirst%3DC.%26aulast%3DRobinson%26aufirst%3DJ.%2BE.%26aulast%3DChen%26aufirst%3DB.%2BK.%26atitle%3DNeutralization%2520resistance%2520of%2520virological%2520synapse-mediated%2520HIV-1%2520Infection%2520is%2520regulated%2520by%2520the%2520gp41%2520cytoplasmic%2520tail%26jtitle%3DJ.%2520Virol.%26date%3D2012%26volume%3D86%26spage%3D7484%26epage%3D7495%26doi%3D10.1128%2FJVI.00230-12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zony, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, B. K.</span></span> <span> </span><span class="NLM_article-title">Reduced potency and incomplete neutralization of broadly neutralizing antibodies against Cell-to-Cell transmission of HIV-1 with transmitted founder Envs</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>91</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">19</span>, <span class="refDoi"> DOI: 10.1128/JVI.02425-16</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=10.1128%2FJVI.02425-16" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFensbrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=2017&pages=1-19&author=H.+Liauthor=C.+Zonyauthor=P.+Chenauthor=B.+K.+Chen&title=Reduced+potency+and+incomplete+neutralization+of+broadly+neutralizing+antibodies+against+Cell-to-Cell+transmission+of+HIV-1+with+transmitted+founder+Envs&doi=10.1128%2FJVI.02425-16"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">CD8+ T cell immune response in immunocompetent mice during zika virus infection</span></div><div class="casAuthors">Huang, Huarong; Li, Shihua; Zhang, Yongli; Han, Xiaojuan; Jia, Baoqian; Liu, Hongtao; Liu, Dandan; Tan, Shuguang; Wang, Qihui; Bi, Yuhai; Liu, William J.; Hou, Baidong; Gao, George Fu; Zhang, Fuping</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">91</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">1-15</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">1098-5514</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Zika virus (ZIKV) infection causees neurol. complications, including Guillain-Barr´e syndrome in adults and central nervous system (CNS) abnormalities in fetuses.  We investigated the immune response, esp. the CD8+ T cell response in C57BL/6 (B6) wild-type (WT) mice, during ZIKV infection.  We found that a robust CD8+ T cell response was elicited, major histocompatibility complex class I-restricted CD8+ T cell epitopes were identified, a tetramer that recognizes ZIKV-specific CD8+ T cells was developed, and virus-specific memory CD8+ T cells were generated in these mice.  The CD8+ T cells from these infected mice were functional, as evidenced by the fact that the adoptive transfer of ZIKV-specific CD8+ T cells could prevent ZIKV infection in the CNS and was cross protective against dengue virus infection.  Our findings provide comprehensive insight into immune responses against ZIKV and further demonstrate that WT mice could be a natural and easy-access model for evaluating immune responses to ZIKV infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZA4dpV1EG-7Vg90H21EOLACvtfcHk0ljKWFy1EF5zYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFensbrI&md5=19a3e320b2a2b9d8ed13a75be9a856cb</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1128%2FJVI.02425-16&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.02425-16%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DH.%26aulast%3DZony%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DP.%26aulast%3DChen%26aufirst%3DB.%2BK.%26atitle%3DReduced%2520potency%2520and%2520incomplete%2520neutralization%2520of%2520broadly%2520neutralizing%2520antibodies%2520against%2520Cell-to-Cell%2520transmission%2520of%2520HIV-1%2520with%2520transmitted%2520founder%2520Envs%26jtitle%3DJ.%2520Virol.%26date%3D2017%26volume%3D91%26spage%3D1%26epage%3D19%26doi%3D10.1128%2FJVI.02425-16" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Agosto, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munro, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mothes, W.</span></span> <span> </span><span class="NLM_article-title">Highly active antiretroviral therapies are effective against HIV-1 cell-to-cell transmission</span>. <i>PLoS Pathog.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>10</i></span>, <span class="NLM_elocation-id">e1003982</span> <span class="refDoi"> DOI: 10.1371/journal.ppat.1003982</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=10.1371%2Fjournal.ppat.1003982" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=24586176" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=1%3ACAS%3A528%3ADC%252BC2cXkvVens7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2014&author=L.+M.+Agostoauthor=P.+Zhongauthor=J.+Munroauthor=W.+Mothes&title=Highly+active+antiretroviral+therapies+are+effective+against+HIV-1+cell-to-cell+transmission&doi=10.1371%2Fjournal.ppat.1003982"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Highly active antiretroviral therapies are effective against HIV-1 cell-to-cell transmission</span></div><div class="casAuthors">Agosto, Luis M.; Zhong, Peng; Munro, James; Mothes, Walther</div><div class="citationInfo"><span class="NLM_cas:title">PLoS Pathogens</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">e1003982/1-e1003982/12, 12 pp.</span>CODEN:
                <span class="NLM_cas:coden">PPLACN</span>;
        ISSN:<span class="NLM_cas:issn">1553-7374</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">HIV-1 cell-to-cell transmission allows for 2-3 orders of magnitude more efficient viral spread than cell-free dissemination.  The high local multiplicity of infection (MOI) obsd. at cell-cell contact sites may lower the efficacy of antiretroviral therapies (ART).  Here we test the efficacy of commonly used antiretroviral inhibitors against cell-to-cell and cell-free HIV-1 transmission.  We demonstrate that, while some nucleoside-analog reverse transcriptase inhibitors (NRTI) are less effective against HIV-1 cell-to-cell transmission, most non-nucleoside-analog reverse transcriptase inhibitors (NNRTI), entry inhibitors and protease inhibitors remain highly effective.  Moreover, poor NRTIs become highly effective when applied in combinations explaining the effectiveness of ART in clin. settings.  Investigating the underlying mechanism, we observe a strict correlation between the ability of individual drugs and combinations of drugs to interfere with HIV-1 cell-to-cell transmission, and their effectiveness against high viral MOIs.  Our results suggest that the ability to suppress high viral MOI is a feature of effective ART regimens and this parameter should be considered when designing novel antiviral therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8R3z_rByrLLVg90H21EOLACvtfcHk0ljKWFy1EF5zYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXkvVens7o%253D&md5=31a44c3e858228af6d49deb4042e5b7c</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1371%2Fjournal.ppat.1003982&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.ppat.1003982%26sid%3Dliteratum%253Aachs%26aulast%3DAgosto%26aufirst%3DL.%2BM.%26aulast%3DZhong%26aufirst%3DP.%26aulast%3DMunro%26aufirst%3DJ.%26aulast%3DMothes%26aufirst%3DW.%26atitle%3DHighly%2520active%2520antiretroviral%2520therapies%2520are%2520effective%2520against%2520HIV-1%2520cell-to-cell%2520transmission%26jtitle%3DPLoS%2520Pathog.%26date%3D2014%26volume%3D10%26doi%3D10.1371%2Fjournal.ppat.1003982" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kennedy, T.</span></span> <span> </span><span class="NLM_article-title">Managing the drug discovery/development interface</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">436</span>– <span class="NLM_lpage">444</span>, <span class="refDoi"> DOI: 10.1016/S1359-6446(97)01099-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=10.1016%2FS1359-6446%2897%2901099-4" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=1997&pages=436-444&author=T.+Kennedy&title=Managing+the+drug+discovery%2Fdevelopment+interface&doi=10.1016%2FS1359-6446%2897%2901099-4"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1016%2FS1359-6446%2897%2901099-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1359-6446%252897%252901099-4%26sid%3Dliteratum%253Aachs%26aulast%3DKennedy%26aufirst%3DT.%26atitle%3DManaging%2520the%2520drug%2520discovery%252Fdevelopment%2520interface%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D1997%26volume%3D2%26spage%3D436%26epage%3D444%26doi%3D10.1016%2FS1359-6446%2897%2901099-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Waring, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arrowsmith, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leach, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leeson, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mandrell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owen, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pairaudeau, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pennie, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pickett, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallace, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weir, A.</span></span> <span> </span><span class="NLM_article-title">An analysis of the attrition of drug candidates from four major pharmaceutical companies</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">475</span>– <span class="NLM_lpage">486</span>, <span class="refDoi"> DOI: 10.1038/nrd4609</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=10.1038%2Fnrd4609" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=26091267" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFeju7jM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=475-486&author=M.+J.+Waringauthor=J.+Arrowsmithauthor=A.+R.+Leachauthor=P.+D.+Leesonauthor=S.+Mandrellauthor=R.+M.+Owenauthor=G.+Pairaudeauauthor=W.+D.+Pennieauthor=S.+D.+Pickettauthor=J.+Wangauthor=O.+Wallaceauthor=A.+Weir&title=An+analysis+of+the+attrition+of+drug+candidates+from+four+major+pharmaceutical+companies&doi=10.1038%2Fnrd4609"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">An analysis of the attrition of drug candidates from four major pharmaceutical companies</span></div><div class="casAuthors">Waring, Michael J.; Arrowsmith, John; Leach, Andrew R.; Leeson, Paul D.; Mandrell, Sam; Owen, Robert M.; Pairaudeau, Garry; Pennie, William D.; Pickett, Stephen D.; Wang, Jibo; Wallace, Owen; Weir, Alex</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">475-486</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The pharmaceutical industry remains under huge pressure to address the high attrition rates in drug development.  Attempts to reduce the no. of efficacy- and safety-related failures by analyzing possible links to the physicochem. properties of small-mol. drug candidates have been inconclusive because of the limited size of data sets from individual companies.  Here, we describe the compilation and anal. of combined data on the attrition of drug candidates from AstraZeneca, Eli Lilly and Company, GlaxoSmithKline and Pfizer.  The anal. reaffirms that control of physicochem. properties during compd. optimization is beneficial in identifying compds. of candidate drug quality and indicates for the first time a link between the physicochem. properties of compds. and clin. failure due to safety issues.  The results also suggest that further control of physicochem. properties is unlikely to have a significant effect on attrition rates and that addnl. work is required to address safety-related failures.  Further cross-company collaborations will be crucial to future progress in this area.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsLfBWrLC3ZLVg90H21EOLACvtfcHk0lgR5s_9SZbzNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFeju7jM&md5=1fdc374d32816b1e91438152299dd1b1</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1038%2Fnrd4609&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4609%26sid%3Dliteratum%253Aachs%26aulast%3DWaring%26aufirst%3DM.%2BJ.%26aulast%3DArrowsmith%26aufirst%3DJ.%26aulast%3DLeach%26aufirst%3DA.%2BR.%26aulast%3DLeeson%26aufirst%3DP.%2BD.%26aulast%3DMandrell%26aufirst%3DS.%26aulast%3DOwen%26aufirst%3DR.%2BM.%26aulast%3DPairaudeau%26aufirst%3DG.%26aulast%3DPennie%26aufirst%3DW.%2BD.%26aulast%3DPickett%26aufirst%3DS.%2BD.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DWallace%26aufirst%3DO.%26aulast%3DWeir%26aufirst%3DA.%26atitle%3DAn%2520analysis%2520of%2520the%2520attrition%2520of%2520drug%2520candidates%2520from%2520four%2520major%2520pharmaceutical%2520companies%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2015%26volume%3D14%26spage%3D475%26epage%3D486%26doi%3D10.1038%2Fnrd4609" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wei, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Decker, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arani, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kilby, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saag, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kappes, J. C.</span></span> <span> </span><span class="NLM_article-title">Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">1896</span>– <span class="NLM_lpage">1905</span>, <span class="refDoi"> DOI: 10.1128/AAC.46.6.1896-1905.2002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=10.1128%2FAAC.46.6.1896-1905.2002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=12019106" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=1%3ACAS%3A528%3ADC%252BD38XktFCmsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2002&pages=1896-1905&author=X.+Weiauthor=J.+M.+Deckerauthor=H.+Liuauthor=Z.+Zhangauthor=R.+B.+Araniauthor=J.+M.+Kilbyauthor=M.+S.+Saagauthor=X.+Wuauthor=G.+M.+Shawauthor=J.+C.+Kappes&title=Emergence+of+resistant+human+immunodeficiency+virus+type+1+in+patients+receiving+fusion+inhibitor+%28T-20%29+monotherapy&doi=10.1128%2FAAC.46.6.1896-1905.2002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy</span></div><div class="casAuthors">Wei, Xiping; Decker, Julie M.; Liu, Hongmei; Zhang, Zee; Arani, Ramin B.; Kilby, J. Michael; Saag, Michael S.; Wu, Xiaoyun; Shaw, George M.; Kappes, John C.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1896-1905</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The synthetic peptide T-20 (enfuvirtide) represents the first of a new class of antiretroviral compds. to demonstrate in vivo potency by targeting a step in viral entry.  T-20 inhibits a conformational change in the human immunodeficiency virus type 1 (HIV-1) transmembrane glycoprotein (gp41) that is required for fusion between HIV-1 and target cell membranes.  The initial phase I clin. trial of T-20 treatment for HIV-infected patients thus provided a unique opportunity to evaluate the emergence of resistant virus in vivo to this novel class of antiretroviral agents.  All four patients who received an intermediate dose of T-20 (30 mg twice daily) had an initial decline in plasma viral load over the first 10 days but a rising trend by day 14, suggestive of selection for resistant virus.  Plasma virus derived from patients enrolled in all dosage groups of the phase I T-20 trial was analyzed by population sequencing before and after treatment.  While no mutations were found within a highly conserved 3-amino-acid sequence (GIV) known to be crit. for fusion at baseline, after 14 days of therapy, virus from one patient in the 30-mg dose group (30-1) developed a mutation in this motif, specifically an aspartic acid (D) substitution for glycine (G) at position 36.  Multiple env clones were derived from the plasma virus of all four patients in the 30-mg dosage group.  Sequence anal. of 49 clones derived from the plasma of patient 30-1 on day 14 revealed that 25 clones contained the G36D mutation, while 8 contained the V38A mutation.  Dual mutations involving G36D and other residues within the HR1 domain were also identified.  In 5 of the 49 env clones, other mutations involving residues 32 (Q32R or Q32H) and 39 (Q39R) were found in combination with G36D.  Cloned env sequences derived from the plasma virus of subject 30-3 also had single mutations in the GIV sequence (V38M and I37V) detectable following therapy with T-20.  The plasma virus from subjects 30-2 and 30-4 did not contain changes within the GIV sequence.  To analyze the biol. resistance properties of these mutations, we developed a novel single-cycle HIV-1 entry assay using JC53BL cells which express β-galactosidase and luciferase under control of the HIV-1 long terminal repeat.  Full-length env clones were derived from the plasma virus of patients 30-1 and 30-3 and used to generate pseudotyped virus stocks.  The mean 50% inhibition concns. (IC50s) for mutants G36D and V38A (patient 30-1) were 2.3 μg/mL and 11.2 μg/mL, resp., statistically significant increases of 9.1- and 45-fold, resp., compared with those of wild-type Env.  The IC50 for the V38 M mutation (patient 30-3) was 7.6 μg/mL, an 8-fold increase compared with that of the wild type.  The I37V mutation resulted in an IC50 3.2-fold greater than that of the wild type.  Envs with double mutations (Q32R plus G36D and Q32H plus G36D) exhibited a level of resistance similar to that of G36D alone.  These findings provide the first evidence for the rapid emergence of clin. resistance to a novel class of HIV-1 entry inhibitors and may be relevant to future treatment strategies involving these agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTmBSTKEK3v7Vg90H21EOLACvtfcHk0lgR5s_9SZbzNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XktFCmsb8%253D&md5=65977bf843ca8ec9411a88b50ef71206</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1128%2FAAC.46.6.1896-1905.2002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.46.6.1896-1905.2002%26sid%3Dliteratum%253Aachs%26aulast%3DWei%26aufirst%3DX.%26aulast%3DDecker%26aufirst%3DJ.%2BM.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DArani%26aufirst%3DR.%2BB.%26aulast%3DKilby%26aufirst%3DJ.%2BM.%26aulast%3DSaag%26aufirst%3DM.%2BS.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DShaw%26aufirst%3DG.%2BM.%26aulast%3DKappes%26aufirst%3DJ.%2BC.%26atitle%3DEmergence%2520of%2520resistant%2520human%2520immunodeficiency%2520virus%2520type%25201%2520in%2520patients%2520receiving%2520fusion%2520inhibitor%2520%2528T-20%2529%2520monotherapy%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2002%26volume%3D46%26spage%3D1896%26epage%3D1905%26doi%3D10.1128%2FAAC.46.6.1896-1905.2002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bjorndal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jansson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiore, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colognesi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlsson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albert, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scarlatti, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Littman, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fenyo, E. M.</span></span> <span> </span><span class="NLM_article-title">Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">7478</span>– <span class="NLM_lpage">7487</span>, <span class="refDoi"> DOI: 10.1128/JVI.71.10.7478-7487.1997</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=10.1128%2FJVI.71.10.7478-7487.1997" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=9311827" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=1%3ACAS%3A528%3ADyaK2sXmt1Omsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=1997&pages=7478-7487&author=A.+Bjorndalauthor=H.+Dengauthor=M.+Janssonauthor=J.+R.+Fioreauthor=C.+Colognesiauthor=A.+Karlssonauthor=J.+Albertauthor=G.+Scarlattiauthor=D.+R.+Littmanauthor=E.+M.+Fenyo&title=Coreceptor+usage+of+primary+human+immunodeficiency+virus+type+1+isolates+varies+according+to+biological+phenotype&doi=10.1128%2FJVI.71.10.7478-7487.1997"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype</span></div><div class="casAuthors">Bjorndal, Asa; Deng, Hongkui; Jansson, Marianne; Fiore, Jose R.; Colognesi, Claudia; Karlsson, Anders; Albert, Jan; Scarlatti, Gabriella; Littman, Dan R.; Fenyo, Eva Maria</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">7478-7487</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The biol. phenotype of primary human immunodeficiency virus type 1 (HIV-1) isolates varies according to the severity of the HIV infection.  Here the authors show that the two previously described groups of rapid/high, syncytium-inducing (SI) and slow/low, non-syncytium-inducing (NSI) isolates are distinguished by their ability to utilize different chemokine receptors for entry into target cells.  Recent studies have identified the C-X-C chemokine receptor CXCR4 (also named fusin or Lestr) and the C-C chemokine receptor CCR5 as the principal entry cofactors for T-cell-line-tropic and non-T-cell-line-tropic HIV-1, resp.  Using U87.CD4 glioma cell lines, stably expressing the chemokine receptor CCR1, CCR2b, CCR3, CCR5, or CXCR4, the authors have tested chemokine receptor specificity for a panel of genetically diverse envelope glycoprotein genes cloned from primary HIV-1 isolates and have found that receptor usage was closely assocd. with the biol. phenotype of the virus isolate but not the genetic subtype.  They have also analyzed a panel of 36 well-characterized primary HIV-1 isolates for syncytium induction and replication in the same series of cell lines.  Infection by slow/low viruses was restricted to cells expressing CCR5, whereas rapid/high viruses could use a variety of chemokine receptors.  In addn. to the regular use of CXCR4, many rapid/high viruses used CCR5 and some also used CCR3 and CCR2b.  Progressive HIV-1 infection is characterized by the emergence of viruses resistant to inhibition by β-chemokines, which corresponded to changes in coreceptor usage.  The broadening of the host range may even enable the use of uncharacterized coreceptors, in that two isolates from immunodeficient patients infected the parental U87.CD4 cell line lacking any engineered coreceptor.  Two primary isolates with multiple coreceptor usage were shown to consist of mixed populations, one with a narrow host range using CCR5 only and the other with a broad host range using CCR3, CCR5, or CXCR4, similar to the original population.  The results show that all 36 primary HIV-1 isolates induce syncytia, provided that target cells carry the particular coreceptor required by the virus.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7xCNHpx6JQrVg90H21EOLACvtfcHk0liv0Xk9KwhcMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXmt1Omsr4%253D&md5=9c509d74aaeb47df187b01a3d874ec48</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1128%2FJVI.71.10.7478-7487.1997&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.71.10.7478-7487.1997%26sid%3Dliteratum%253Aachs%26aulast%3DBjorndal%26aufirst%3DA.%26aulast%3DDeng%26aufirst%3DH.%26aulast%3DJansson%26aufirst%3DM.%26aulast%3DFiore%26aufirst%3DJ.%2BR.%26aulast%3DColognesi%26aufirst%3DC.%26aulast%3DKarlsson%26aufirst%3DA.%26aulast%3DAlbert%26aufirst%3DJ.%26aulast%3DScarlatti%26aufirst%3DG.%26aulast%3DLittman%26aufirst%3DD.%2BR.%26aulast%3DFenyo%26aufirst%3DE.%2BM.%26atitle%3DCoreceptor%2520usage%2520of%2520primary%2520human%2520immunodeficiency%2520virus%2520type%25201%2520isolates%2520varies%2520according%2520to%2520biological%2520phenotype%26jtitle%3DJ.%2520Virol.%26date%3D1997%26volume%3D71%26spage%3D7478%26epage%3D7487%26doi%3D10.1128%2FJVI.71.10.7478-7487.1997" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Popovic, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarngadharan, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Read, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallo, R. C.</span></span> <span> </span><span class="NLM_article-title">Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1984</span>,  <span class="NLM_volume"><i>224</i></span>,  <span class="NLM_fpage">497</span>– <span class="NLM_lpage">500</span>, <span class="refDoi"> DOI: 10.1126/science.6200935</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=10.1126%2Fscience.6200935" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=6200935" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=1%3ACAS%3A280%3ADyaL2c7nt1aisw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=224&publication_year=1984&pages=497-500&author=M.+Popovicauthor=M.+G.+Sarngadharanauthor=E.+Readauthor=R.+C.+Gallo&title=Detection%2C+isolation%2C+and+continuous+production+of+cytopathic+retroviruses+%28HTLV-III%29+from+patients+with+AIDS+and+pre-AIDS&doi=10.1126%2Fscience.6200935"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS</span></div><div class="casAuthors">Popovic M; Sarngadharan M G; Read E; Gallo R C</div><div class="citationInfo"><span class="NLM_cas:title">Science (New York, N.Y.)</span>
        (<span class="NLM_cas:date">1984</span>),
    <span class="NLM_cas:volume">224</span>
        (<span class="NLM_cas:issue">4648</span>),
    <span class="NLM_cas:pages">497-500</span>
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    </div><div class="casAbstract">A cell system was developed for the reproducible detection of human T-lymphotropic retroviruses (HTLV family) from patients with the acquired immunodeficiency syndrome (AIDS) or with signs or symptoms that frequently precede AIDS (pre-AIDS).  The cells are specific clones from a permissive human neoplastic T-cell line.  Some of the clones permanently grow and continuously produce large amounts of virus after infection with cytopathic (HTLV-III) variants of these viruses.  One cytopathic effect of HTLV-III in this system is the arrangement of multiple nuclei in a characteristic ring formation in giant cells of the infected T-cell population.  These structures can be used as an indicator to detect HTLV-III in clinical specimens.  This system opens the way to the routine detection of HTLV-III and related cytopathic variants of HTLV in patients with AIDS or pre-AIDS and in healthy carriers, and it provides large amounts of virus for detailed molecular and immunological analyses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSuh_pMc3WcAUbxh97K6Vt6fW6udTcc2eYczd4Xfcssw7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL2c7nt1aisw%253D%253D&md5=3a239f3c54c182c0f19ee56fa31ab6fb</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1126%2Fscience.6200935&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.6200935%26sid%3Dliteratum%253Aachs%26aulast%3DPopovic%26aufirst%3DM.%26aulast%3DSarngadharan%26aufirst%3DM.%2BG.%26aulast%3DRead%26aufirst%3DE.%26aulast%3DGallo%26aufirst%3DR.%2BC.%26atitle%3DDetection%252C%2520isolation%252C%2520and%2520continuous%2520production%2520of%2520cytopathic%2520retroviruses%2520%2528HTLV-III%2529%2520from%2520patients%2520with%2520AIDS%2520and%2520pre-AIDS%26jtitle%3DScience%26date%3D1984%26volume%3D224%26spage%3D497%26epage%3D500%26doi%3D10.1126%2Fscience.6200935" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baba, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyake, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okamoto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iizawa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okonogi, K.</span></span> <span> </span><span class="NLM_article-title">Establishment of a CCR5-expressing T-lymphoblastoid cell line highly susceptible to R5 HIV type 1</span>. <i>AIDS Res. Hum. Retroviruses</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">935</span>– <span class="NLM_lpage">941</span>, <span class="refDoi"> DOI: 10.1089/08892220050058344</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=10.1089%2F08892220050058344" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=10890354" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=1%3ACAS%3A528%3ADC%252BD3cXlt1yhsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2000&pages=935-941&author=M.+Babaauthor=H.+Miyakeauthor=M.+Okamotoauthor=Y.+Iizawaauthor=K.+Okonogi&title=Establishment+of+a+CCR5-expressing+T-lymphoblastoid+cell+line+highly+susceptible+to+R5+HIV+type+1&doi=10.1089%2F08892220050058344"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Establishment of a CCR5-expressing T-lymphoblastoid cell line highly susceptible to R5 HIV type 1</span></div><div class="casAuthors">Baba, Masanori; Miyake, Hiroshi; Okamoto, Mika; Iizawa, Yuji; Okonogi, Kenji</div><div class="citationInfo"><span class="NLM_cas:title">AIDS Research and Human Retroviruses</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">935-941</span>CODEN:
                <span class="NLM_cas:coden">ARHRE7</span>;
        ISSN:<span class="NLM_cas:issn">0889-2229</span>.
    
            (<span class="NLM_cas:orgname">Mary Ann Liebert, Inc.</span>)
        </div><div class="casAbstract">The β-chemokine receptor CCR5 is considered to be an attractive target for inhibition of CCR5-using (R5 or macrophage-tropic) HIV-1.  However, R5 HIV-1 cannot replicate in CD4+ T cell or monocyte lines because of the lack of CCR5 expression on their surface, which apparently hampers discovery and development of effective CCR5 antagonists against HIV-1 replication.  In this study, we have established the CCR5-expressing T cell line MOLT-4/CCR5, highly permissive to the replication of R5 HIV-1.  The cells express a considerable amt. of CCR5 on their surface.  When the cells were infected with the R5 HIV-1 strains Ba-L and JR-FL, the virus-induced cytopathic effect (syncytium formation) was obsd., and the cells produced large amts. of HIV-1 p24 antigen in the culture supernatants.  The analyses of progeny viruses for their coreceptor use and gp120 V3 nucleotide sequence revealed that they were R5 HIV-1.  The parental cell line MOLT-4 was much less susceptible to Ba-L and totally insusceptible to JR-FL.  Furthermore, MOLT-4/CCR5 cells could support the replication of an R5 clin. isolate, but MOLT-4 cells could not.  When TAK-779, a novel small-mol. nonpeptide CCR5 antagonist, was examd. for its inhibitory effect on R5 HIV-1 replication in MOLT-4/CCR5 cells, the compd. displayed potent antiviral activity, as demonstrated in peripheral blood mononuclear cells.  These results indicate that the established cell line will be an extremely useful tool for expts. with R5 HIV-1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoX1tLnB7wNP7Vg90H21EOLACvtfcHk0liv0Xk9KwhcMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXlt1yhsLo%253D&md5=c4ef29a4b2ee84ec89fc19df56f684a6</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1089%2F08892220050058344&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252F08892220050058344%26sid%3Dliteratum%253Aachs%26aulast%3DBaba%26aufirst%3DM.%26aulast%3DMiyake%26aufirst%3DH.%26aulast%3DOkamoto%26aufirst%3DM.%26aulast%3DIizawa%26aufirst%3DY.%26aulast%3DOkonogi%26aufirst%3DK.%26atitle%3DEstablishment%2520of%2520a%2520CCR5-expressing%2520T-lymphoblastoid%2520cell%2520line%2520highly%2520susceptible%2520to%2520R5%2520HIV%2520type%25201%26jtitle%3DAIDS%2520Res.%2520Hum.%2520Retroviruses%26date%3D2000%26volume%3D16%26spage%3D935%26epage%3D941%26doi%3D10.1089%2F08892220050058344" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kolchinsky, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mirzabekov, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farzan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiprilov, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cayabyab, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mooney, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choe, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sodroski, J.</span></span> <span> </span><span class="NLM_article-title">Adaptation of a CCR5-using, primary human immunodeficiency virus type 1 isolate for CD4-independent replication</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">8120</span>– <span class="NLM_lpage">8126</span>, <span class="refDoi"> DOI: 10.1128/JVI.73.10.8120-8126.1999</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=10.1128%2FJVI.73.10.8120-8126.1999" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=10482561" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=1%3ACAS%3A528%3ADyaK1MXlvFyrtr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=1999&pages=8120-8126&author=P.+Kolchinskyauthor=T.+Mirzabekovauthor=M.+Farzanauthor=E.+Kiprilovauthor=M.+Cayabyabauthor=L.+J.+Mooneyauthor=H.+Choeauthor=J.+Sodroski&title=Adaptation+of+a+CCR5-using%2C+primary+human+immunodeficiency+virus+type+1+isolate+for+CD4-independent+replication&doi=10.1128%2FJVI.73.10.8120-8126.1999"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Adaptation of a CCR5-using, primary human immunodeficiency virus type 1 isolate for CD4-independent replication</span></div><div class="casAuthors">Kolchinsky, Peter; Mirzabekov, Tajib; Farzan, Michael; Kiprilov, Enko; Cayabyab, Mark; Mooney, Larissa J.; Choe, Hyeryun; Sodroski, Joseph</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">8120-8126</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The gp120 envelope glycoprotein of the human immunodeficiency virus type 1 (HIV-1) promotes virus entry by sequentially binding CD4 and chemokine receptors on the target cell.  Primary, clin. HIV-1 isolates require interaction with CD4 to allow gp120 to bind the CCR5 chemokine receptor efficiently.  The authors adapted a primary HIV-1 isolate, ADA, to replicate in CD4-neg. canine cells expressing human CCR5.  The gp120 changes responsible for the adaptation were limited to alteration of glycosylation addn. sites in the V2 loop-V1-V2 stem.  The gp120 glycoproteins of the adapted viruses bound CCR5 directly, without prior interaction with CD4.  Thus, a major function of CD4 binding in the entry of primary HIV-1 isolates can be bypassed by changes in the gp120 V1-V2 elements, which allow the envelope glycoproteins to assume a conformation competent for CCR5 binding.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1fq87S6oMRLVg90H21EOLACvtfcHk0lgo-X8gRQ0NIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXlvFyrtr0%253D&md5=713cd1c7f3105f250ab088d7b613d0ff</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1128%2FJVI.73.10.8120-8126.1999&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.73.10.8120-8126.1999%26sid%3Dliteratum%253Aachs%26aulast%3DKolchinsky%26aufirst%3DP.%26aulast%3DMirzabekov%26aufirst%3DT.%26aulast%3DFarzan%26aufirst%3DM.%26aulast%3DKiprilov%26aufirst%3DE.%26aulast%3DCayabyab%26aufirst%3DM.%26aulast%3DMooney%26aufirst%3DL.%2BJ.%26aulast%3DChoe%26aufirst%3DH.%26aulast%3DSodroski%26aufirst%3DJ.%26atitle%3DAdaptation%2520of%2520a%2520CCR5-using%252C%2520primary%2520human%2520immunodeficiency%2520virus%2520type%25201%2520isolate%2520for%2520CD4-independent%2520replication%26jtitle%3DJ.%2520Virol.%26date%3D1999%26volume%3D73%26spage%3D8120%26epage%3D8126%26doi%3D10.1128%2FJVI.73.10.8120-8126.1999" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Page, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Landau, N. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Littman, D. R.</span></span> <span> </span><span class="NLM_article-title">Construction and use of a human immunodeficiency virus vector for analysis of virus infectivity</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">5270</span>– <span class="NLM_lpage">5276</span>, <span class="refDoi"> DOI: 10.1128/JVI.64.11.5270-5276.1990</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=10.1128%2FJVI.64.11.5270-5276.1990" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=2214018" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=1%3ACAS%3A528%3ADyaK3cXmtVKit7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=1990&pages=5270-5276&author=K.+A.+Pageauthor=N.+R.+Landauauthor=D.+R.+Littman&title=Construction+and+use+of+a+human+immunodeficiency+virus+vector+for+analysis+of+virus+infectivity&doi=10.1128%2FJVI.64.11.5270-5276.1990"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Construction and use of a human immunodeficiency virus vector for analysis of virus infectivity</span></div><div class="casAuthors">Page, Kathleen A.; Landau, Nathaniel R.; Littman, Dan R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">5270-6</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    </div><div class="casAbstract">A recombinant human immunodeficiency virus (HIV) vector was constructed to facilitate studies of virus infectivity.  A drug-resistance gene was inserted into a gp160- HIV proviral genome such that it could be packaged into HIV virions.  The HIV genome was rendered replication defective by deletion of sequences encoding gp160 and insertion of a gpt gene with a simian virus 40 promoter at the deletion site.  Cotransfection of the envelope-deficient genome with a gp160 expression vector resulted in packaging of the defective HIV-gpt genome into infectious virions.  The drug-resistance gene was transmitted and expressed upon infection of susceptible cells, enabling their selection in mycophenolic acid.  In the absence of gp160, noninfectious HIV particles were efficiently produced by cells transfected with the HIV-gpt genome.  This demonstrates that HIV virion formation is not dependent on the presence of a viral envelope glycoprotein.  Expression of a murine leukemia virus amphotropic envelope gene in cells transfected with HIV-gpt resulted in the prodn. of virus capable of infecting both human and murine cells.  These results indicate that HIV can incorporate envelope glycoproteins other than gp160 onto particles and that this can lead to altered host range.  Like HIV type 1 and vesicular stomatitis virus (HIV) pseudotypes, gp-160+ HIV-gpt did not infect murine NIH 3T3 cells that bear human CD4, confirming that these cells are blocked at an early stage of HIV infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjSByFmAfL27Vg90H21EOLACvtfcHk0lgo-X8gRQ0NIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXmtVKit7k%253D&md5=2b766f598da3ec623b169c861d80dd5c</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1128%2FJVI.64.11.5270-5276.1990&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.64.11.5270-5276.1990%26sid%3Dliteratum%253Aachs%26aulast%3DPage%26aufirst%3DK.%2BA.%26aulast%3DLandau%26aufirst%3DN.%2BR.%26aulast%3DLittman%26aufirst%3DD.%2BR.%26atitle%3DConstruction%2520and%2520use%2520of%2520a%2520human%2520immunodeficiency%2520virus%2520vector%2520for%2520analysis%2520of%2520virus%2520infectivity%26jtitle%3DJ.%2520Virol.%26date%3D1990%26volume%3D64%26spage%3D5270%26epage%3D5276%26doi%3D10.1128%2FJVI.64.11.5270-5276.1990" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blish, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jalalian-Lechak, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rainwater, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dogan, O. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Overbaugh, J.</span></span> <span> </span><span class="NLM_article-title">Cross-subtype neutralization sensitivity despite monoclonal antibody resistance among early subtype A, C, and D envelope variants of human immunodeficiency virus type 1</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>83</i></span>,  <span class="NLM_fpage">7783</span>– <span class="NLM_lpage">7788</span>, <span class="refDoi"> DOI: 10.1128/JVI.00673-09</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=10.1128%2FJVI.00673-09" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=19474105" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=1%3ACAS%3A528%3ADC%252BD1MXovFentL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=2009&pages=7783-7788&author=C.+A.+Blishauthor=Z.+Jalalian-Lechakauthor=S.+Rainwaterauthor=M.+A.+Nguyenauthor=O.+C.+Doganauthor=J.+Overbaugh&title=Cross-subtype+neutralization+sensitivity+despite+monoclonal+antibody+resistance+among+early+subtype+A%2C+C%2C+and+D+envelope+variants+of+human+immunodeficiency+virus+type+1&doi=10.1128%2FJVI.00673-09"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Cross-subtype neutralization sensitivity despite monoclonal antibody resistance among early subtype A, C, and D envelope variants of human immunodeficiency virus type 1</span></div><div class="casAuthors">Blish, Catherine A.; Jalalian-Lechak, Zahra; Rainwater, Stephanie; Nguyen, Minh-An; Dogan, Ozge C.; Overbaugh, Julie</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">83</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">7783-7788</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The human immunodeficiency virus type 1 (HIV-1) variants that are transmitted to newly infected individuals are the primary targets of interventions, such as vaccines and microbicides, aimed at preventing new infections.  Newly acquired subtype A, B, and C variants have been the focus of neutralization studies, although many of these viruses, particularly of subtypes A and B, represent viruses circulating more than a decade ago.  In order to better represent the global diversity of transmitted HIV-1 variants, an addnl. 31 sexually transmitted Kenyan HIV-1 env genes, representing several recent infections with subtype A, as well as subtypes A/D, C, and D, were cloned, and their neutralization profiles were characterized.  Most env variants were resistant to neutralization by the monoclonal antibodies (MAbs) b12, 4E10, 2F5, and 2G12, suggesting that targeting the epitopes of these MAbs may not be effective against variants that are spreading in areas of endemicity.  However, significant cross-subtype neutralization by plasma was obsd., indicating that there may be other epitopes, not yet defined by the limited available MAbs, which could be recognized more broadly.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo981ipEMtqbrVg90H21EOLACvtfcHk0lgo-X8gRQ0NIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXovFentL0%253D&md5=24ee4b6f47c1168fc36fb2ef6341d04a</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1128%2FJVI.00673-09&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.00673-09%26sid%3Dliteratum%253Aachs%26aulast%3DBlish%26aufirst%3DC.%2BA.%26aulast%3DJalalian-Lechak%26aufirst%3DZ.%26aulast%3DRainwater%26aufirst%3DS.%26aulast%3DNguyen%26aufirst%3DM.%2BA.%26aulast%3DDogan%26aufirst%3DO.%2BC.%26aulast%3DOverbaugh%26aufirst%3DJ.%26atitle%3DCross-subtype%2520neutralization%2520sensitivity%2520despite%2520monoclonal%2520antibody%2520resistance%2520among%2520early%2520subtype%2520A%252C%2520C%252C%2520and%2520D%2520envelope%2520variants%2520of%2520human%2520immunodeficiency%2520virus%2520type%25201%26jtitle%3DJ.%2520Virol.%26date%3D2009%26volume%3D83%26spage%3D7783%26epage%3D7788%26doi%3D10.1128%2FJVI.00673-09" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Long, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rainwater, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lavreys, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mandaliya, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Overbaugh, J.</span></span> <span> </span><span class="NLM_article-title">HIV type 1 variants transmitted to women in Kenya require the CCR5 coreceptor for entry, regardless of the genetic complexity of the infecting virus</span>. <i>AIDS Res. Hum. Retroviruses</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">567</span>– <span class="NLM_lpage">576</span>, <span class="refDoi"> DOI: 10.1089/088922202753747914</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=10.1089%2F088922202753747914" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=12036486" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=1%3ACAS%3A528%3ADC%252BD38XktlGntb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2002&pages=567-576&author=E.+M.+Longauthor=S.+M.+Rainwaterauthor=L.+Lavreysauthor=K.+Mandaliyaauthor=J.+Overbaugh&title=HIV+type+1+variants+transmitted+to+women+in+Kenya+require+the+CCR5+coreceptor+for+entry%2C+regardless+of+the+genetic+complexity+of+the+infecting+virus&doi=10.1089%2F088922202753747914"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">HIV type 1 variants transmitted to women in Kenya require the CCR5 coreceptor for entry, regardless of the genetic complexity of the infecting virus</span></div><div class="casAuthors">Long, E. Michelle; Rainwater, Stephanie M. J.; Lavreys, Ludo; Mandaliya, Kishorchandra; Overbaugh, Julie</div><div class="citationInfo"><span class="NLM_cas:title">AIDS Research and Human Retroviruses</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">567-576</span>CODEN:
                <span class="NLM_cas:coden">ARHRE7</span>;
        ISSN:<span class="NLM_cas:issn">0889-2229</span>.
    
            (<span class="NLM_cas:orgname">Mary Ann Liebert, Inc.</span>)
        </div><div class="casAbstract">Although nearly half of the HIV-1-infected adults in the world are women, little is known about the virol. determinants of transmission to women.  Studies suggest that women are frequently infected with multiple HIV-1 genotypes, whereas men are infected with a single genotype.  In the current study, we assessed whether the diverse HIV-1 genomes present at the time of infection in women encode viruses that have diverse coreceptor specificities.  For this purpose, we defined the coreceptor requirements of viruses found in recently infected Kenyan women, three of whom had multiple viral genotypes and the remaining two of whom had a single genotype.  Full-length envelope clones were amplified directly from blood and the dominant genotypes were identified.  Envelope clones derived from all five women were able to pseudotype infectious particles competent to infect cells expressing CCR5, but not cells expressing only CXCR4.  Thus, regardless of viral complexity at the time of infection, the viruses present at early stages of HIV-1 infection in women use CCR5, suggesting that cells expressing CCR5 are important targets for heterosexual HIV-1 transmission to women.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUHUUUjpIVdrVg90H21EOLACvtfcHk0liZ41dfH_85qQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XktlGntb8%253D&md5=c07468fa8307e287f733a92def00bf0d</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1089%2F088922202753747914&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252F088922202753747914%26sid%3Dliteratum%253Aachs%26aulast%3DLong%26aufirst%3DE.%2BM.%26aulast%3DRainwater%26aufirst%3DS.%2BM.%26aulast%3DLavreys%26aufirst%3DL.%26aulast%3DMandaliya%26aufirst%3DK.%26aulast%3DOverbaugh%26aufirst%3DJ.%26atitle%3DHIV%2520type%25201%2520variants%2520transmitted%2520to%2520women%2520in%2520Kenya%2520require%2520the%2520CCR5%2520coreceptor%2520for%2520entry%252C%2520regardless%2520of%2520the%2520genetic%2520complexity%2520of%2520the%2520infecting%2520virus%26jtitle%3DAIDS%2520Res.%2520Hum.%2520Retroviruses%26date%3D2002%26volume%3D18%26spage%3D567%26epage%3D576%26doi%3D10.1089%2F088922202753747914" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kulkarni, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lapedes, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gnanakaran, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daniels, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhattacharya, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polonis, V. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCutchan, F. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellenberger, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butera, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bollinger, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korber, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paranjape, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montefiori, D. C.</span></span> <span> </span><span class="NLM_article-title">Highly complex neutralization determinants on a monophyletic lineage of newly transmitted subtype C HIV-1 Env clones from India</span>. <i>Virology</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>385</i></span>,  <span class="NLM_fpage">505</span>– <span class="NLM_lpage">520</span>, <span class="refDoi"> DOI: 10.1016/j.virol.2008.12.032</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=10.1016%2Fj.virol.2008.12.032" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=19167740" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=1%3ACAS%3A528%3ADC%252BD1MXisFOnt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=385&publication_year=2009&pages=505-520&author=S.+S.+Kulkarniauthor=A.+Lapedesauthor=H.+Tangauthor=S.+Gnanakaranauthor=M.+G.+Danielsauthor=M.+Zhangauthor=T.+Bhattacharyaauthor=M.+Liauthor=V.+R.+Polonisauthor=F.+E.+McCutchanauthor=L.+Morrisauthor=D.+Ellenbergerauthor=S.+T.+Buteraauthor=R.+C.+Bollingerauthor=B.+T.+Korberauthor=R.+S.+Paranjapeauthor=D.+C.+Montefiori&title=Highly+complex+neutralization+determinants+on+a+monophyletic+lineage+of+newly+transmitted+subtype+C+HIV-1+Env+clones+from+India&doi=10.1016%2Fj.virol.2008.12.032"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Highly complex neutralization determinants on a monophyletic lineage of newly transmitted subtype C HIV-1 Env clones from India</span></div><div class="casAuthors">Kulkarni, Smita S.; Lapedes, Alan; Tang, Haili; Gnanakaran, S.; Daniels, Marcus G.; Zhang, Ming; Bhattacharya, Tanmoy; Li, Ming; Polonis, Victoria R.; McCutchan, Francine E.; Morris, Lynn; Ellenberger, Dennis; Butera, Salvatore T.; Bollinger, Robert C.; Korber, Bette T.; Paranjape, Ramesh S.; Montefiori, David C.</div><div class="citationInfo"><span class="NLM_cas:title">Virology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">385</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">505-520</span>CODEN:
                <span class="NLM_cas:coden">VIRLAX</span>;
        ISSN:<span class="NLM_cas:issn">0042-6822</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Little is known about the neutralization properties of HIV-1 in India to optimally design and test vaccines.  For this reason, a functional Env clone was obtained from each of ten newly acquired, heterosexually transmitted HIV-1 infections in Pune, Maharashtra.  These clones formed a phylogenetically distinct genetic lineage within subtype C. As Env-pseudotyped viruses the clones were mostly resistant to IgG1b12, 2G12 and 2F5 but all were sensitive to 4E10.  When compared to a large multi-subtype panel of Env-pseudotyped viruses (subtypes B, C and CRF02AG) in neutralization assays with a multi-subtype panel of HIV-1-pos. plasma samples, the Indian Envs were remarkably complex.  With the exception of the Indian Envs, results of a hierarchical clustering anal. showed a strong subtype assocn. with the patterns of neutralization susceptibility.  From these patterns the authors were able to identify 19 neutralization cluster-assocd. amino acid signatures in gp120 and 14 signatures in the ectodomain and cytoplasmic tail of gp41.  The authors conclude that newly transmitted Indian Envs are antigenically complex in spite of close genetic similarity.  Delineation of neutralization-assocd. amino acid signatures provides a deeper understanding of the antigenic structure of HIV-1 Env.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprmIj9kIl2drVg90H21EOLACvtfcHk0liZ41dfH_85qQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXisFOnt7Y%253D&md5=7bed6bd07204db651cef191d57a3e05e</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1016%2Fj.virol.2008.12.032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.virol.2008.12.032%26sid%3Dliteratum%253Aachs%26aulast%3DKulkarni%26aufirst%3DS.%2BS.%26aulast%3DLapedes%26aufirst%3DA.%26aulast%3DTang%26aufirst%3DH.%26aulast%3DGnanakaran%26aufirst%3DS.%26aulast%3DDaniels%26aufirst%3DM.%2BG.%26aulast%3DZhang%26aufirst%3DM.%26aulast%3DBhattacharya%26aufirst%3DT.%26aulast%3DLi%26aufirst%3DM.%26aulast%3DPolonis%26aufirst%3DV.%2BR.%26aulast%3DMcCutchan%26aufirst%3DF.%2BE.%26aulast%3DMorris%26aufirst%3DL.%26aulast%3DEllenberger%26aufirst%3DD.%26aulast%3DButera%26aufirst%3DS.%2BT.%26aulast%3DBollinger%26aufirst%3DR.%2BC.%26aulast%3DKorber%26aufirst%3DB.%2BT.%26aulast%3DParanjape%26aufirst%3DR.%2BS.%26aulast%3DMontefiori%26aufirst%3DD.%2BC.%26atitle%3DHighly%2520complex%2520neutralization%2520determinants%2520on%2520a%2520monophyletic%2520lineage%2520of%2520newly%2520transmitted%2520subtype%2520C%2520HIV-1%2520Env%2520clones%2520from%2520India%26jtitle%3DVirology%26date%3D2009%26volume%3D385%26spage%3D505%26epage%3D520%26doi%3D10.1016%2Fj.virol.2008.12.032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mascola, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stamatatos, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polonis, V. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koutsoukos, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voss, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goepfert, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilbert, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greene, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bilska, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kothe, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salazar-Gonzalez, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Decker, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hahn, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montefiori, D. C.</span></span> <span> </span><span class="NLM_article-title">Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">10108</span>– <span class="NLM_lpage">10125</span>, <span class="refDoi"> DOI: 10.1128/JVI.79.16.10108-10125.2005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=10.1128%2FJVI.79.16.10108-10125.2005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=16051804" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=1%3ACAS%3A528%3ADC%252BD2MXntFCrtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2005&pages=10108-10125&author=M.+Liauthor=F.+Gaoauthor=J.+R.+Mascolaauthor=L.+Stamatatosauthor=V.+R.+Polonisauthor=M.+Koutsoukosauthor=G.+Vossauthor=P.+Goepfertauthor=P.+Gilbertauthor=K.+M.+Greeneauthor=M.+Bilskaauthor=D.+L.+Kotheauthor=J.+F.+Salazar-Gonzalezauthor=X.+Weiauthor=J.+M.+Deckerauthor=B.+H.+Hahnauthor=D.+C.+Montefiori&title=Human+immunodeficiency+virus+type+1+env+clones+from+acute+and+early+subtype+B+infections+for+standardized+assessments+of+vaccine-elicited+neutralizing+antibodies&doi=10.1128%2FJVI.79.16.10108-10125.2005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies</span></div><div class="casAuthors">Li, Ming; Gao, Feng; Mascola, John R.; Stamatatos, Leonidas; Polonis, Victoria R.; Koutsoukos, Marguerite; Voss, Gerald; Goepfert, Paul; Gilbert, Peter; Greene, Kelli M.; Bilska, Miroslawa; Kothe, Denise L.; Salazar-Gonzalez, Jesus F.; Wei, Xiping; Decker, Julie M.; Hahn, Beatrice H.; Montefiori, David C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">10108-10125</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Induction of broadly cross-reactive neutralizing antibodies is a high priority for AIDS vaccine development but one that has proven difficult to be achieved.  While most immunogens generate antibodies that neutralize a subset of T-cell-line-adapted strains of human immunodeficiency virus type 1 (HIV-1), none so far have generated a potent, broadly cross-reactive response against primary isolates of the virus.  Even small increments in immunogen improvement leading to increases in neutralizing antibody titers and cross-neutralizing activity would accelerate vaccine development; however, a lack of uniformity in target strains used by different investigators to assess cross-neutralization has made the comparison of vaccine-induced antibody responses difficult.  Thus, there is an urgent need to establish std. panels of HIV-1 ref. strains for wide distribution.  To facilitate this, full-length gp160 genes were cloned from acute and early subtype B infections and characterized for use as ref. reagents to assess neutralizing antibodies against clade B HIV-1.  Individual gp160 clones were screened for infectivity as Env-pseudotyped viruses in a luciferase reporter gene assay in JC53-BL (TZM-bl) cells.  Functional env clones were sequenced and their neutralization phenotypes characterized by using sol. CD4, monoclonal antibodies, and serum samples from infected individuals and noninfected recipients of a recombinant gp120 vaccine.  Env clones from 12 R5 primary HIV-1 isolates were selected that were not unusually sensitive or resistant to neutralization and comprised a wide spectrum of genetic, antigenic, and geog. diversity.  These ref. reagents will facilitate proficiency testing and other validation efforts aimed at improving assay performance across labs. and can be used for standardized assessments of vaccine-elicited neutralizing antibodies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxX0pqgVl3rLVg90H21EOLACvtfcHk0liXndLbxSSL2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXntFCrtL8%253D&md5=26a5971a0c8043e4e114f57006f1cbb3</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1128%2FJVI.79.16.10108-10125.2005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.79.16.10108-10125.2005%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DM.%26aulast%3DGao%26aufirst%3DF.%26aulast%3DMascola%26aufirst%3DJ.%2BR.%26aulast%3DStamatatos%26aufirst%3DL.%26aulast%3DPolonis%26aufirst%3DV.%2BR.%26aulast%3DKoutsoukos%26aufirst%3DM.%26aulast%3DVoss%26aufirst%3DG.%26aulast%3DGoepfert%26aufirst%3DP.%26aulast%3DGilbert%26aufirst%3DP.%26aulast%3DGreene%26aufirst%3DK.%2BM.%26aulast%3DBilska%26aufirst%3DM.%26aulast%3DKothe%26aufirst%3DD.%2BL.%26aulast%3DSalazar-Gonzalez%26aufirst%3DJ.%2BF.%26aulast%3DWei%26aufirst%3DX.%26aulast%3DDecker%26aufirst%3DJ.%2BM.%26aulast%3DHahn%26aufirst%3DB.%2BH.%26aulast%3DMontefiori%26aufirst%3DD.%2BC.%26atitle%3DHuman%2520immunodeficiency%2520virus%2520type%25201%2520env%2520clones%2520from%2520acute%2520and%2520early%2520subtype%2520B%2520infections%2520for%2520standardized%2520assessments%2520of%2520vaccine-elicited%2520neutralizing%2520antibodies%26jtitle%3DJ.%2520Virol.%26date%3D2005%26volume%3D79%26spage%3D10108%26epage%3D10125%26doi%3D10.1128%2FJVI.79.16.10108-10125.2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wei, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Decker, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hui, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kappes, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salazar-Gonzalez, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salazar, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kilby, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saag, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Komarova, N. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nowak, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hahn, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwong, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, G. M.</span></span> <span> </span><span class="NLM_article-title">Antibody neutralization and escape by HIV-1</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>422</i></span>,  <span class="NLM_fpage">307</span>– <span class="NLM_lpage">312</span>, <span class="refDoi"> DOI: 10.1038/nature01470</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=10.1038%2Fnature01470" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=12646921" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=1%3ACAS%3A528%3ADC%252BD3sXitFKmurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=422&publication_year=2003&pages=307-312&author=X.+Weiauthor=J.+M.+Deckerauthor=S.+Wangauthor=H.+Huiauthor=J.+C.+Kappesauthor=X.+Wuauthor=J.+F.+Salazar-Gonzalezauthor=M.+G.+Salazarauthor=J.+M.+Kilbyauthor=M.+S.+Saagauthor=N.+L.+Komarovaauthor=M.+A.+Nowakauthor=B.+H.+Hahnauthor=P.+D.+Kwongauthor=G.+M.+Shaw&title=Antibody+neutralization+and+escape+by+HIV-1&doi=10.1038%2Fnature01470"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Antibody neutralization and escape by HIV-1</span></div><div class="casAuthors">Wei, Xiping; Decker, Julie M.; Wang, Shuyi; Hui, Huxiong; Kappes, John C.; Wu, Xiaoyun; Salazar-Gonzalez, Jesus F.; Salazar, Maria G.; Kilby, J. Michael; Saag, Michael S.; Komarova, Natalia L.; Nowak, Martin A.; Hahn, Beatrice H.; Kwong, Peter D.; Shaw, George M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">422</span>
        (<span class="NLM_cas:issue">6929</span>),
    <span class="NLM_cas:pages">307-312</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Neutralizing antibodies (Nab) are a principal component of an effective human immune response to many pathogens, yet their role in HIV-1 infection is unclear.  To gain a better understanding of this role, we examd. plasma from patients with acute HIV infection.  Here we report the detection of autologous Nab as early as 52 days after detection of HIV-specific antibodies.  The viral inhibitory activity of Nab resulted in complete replacement of neutralization-sensitive virus by successive populations of resistant virus.  Escape virus contained mutations in the env gene that were unexpectedly sparse, did not map generally to known neutralization epitopes, and involved primarily changes in N-linked glycosylation.  This pattern of escape, and the exceptional d. of HIV-1 envelope glycosylation generally, led us to postulate an evolving glycan shield' mechanism of neutralization escape whereby selected changes in glycan packing prevent Nab binding but not receptor binding.  Direct support for this model was obtained by mutational substitution showing that Nab-selected alterations in glycosylation conferred escape from both autologous antibody and epitope-specific monoclonal antibodies.  The evolving glycan shield thus represents a new mechanism contributing to HIV-1 persistence in the face of an evolving antibody repertoire.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWf_6H0ez_frVg90H21EOLACvtfcHk0liXndLbxSSL2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXitFKmurY%253D&md5=f2b0675ba66493cd8952d7f9fe93faf3</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1038%2Fnature01470&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature01470%26sid%3Dliteratum%253Aachs%26aulast%3DWei%26aufirst%3DX.%26aulast%3DDecker%26aufirst%3DJ.%2BM.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DHui%26aufirst%3DH.%26aulast%3DKappes%26aufirst%3DJ.%2BC.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DSalazar-Gonzalez%26aufirst%3DJ.%2BF.%26aulast%3DSalazar%26aufirst%3DM.%2BG.%26aulast%3DKilby%26aufirst%3DJ.%2BM.%26aulast%3DSaag%26aufirst%3DM.%2BS.%26aulast%3DKomarova%26aufirst%3DN.%2BL.%26aulast%3DNowak%26aufirst%3DM.%2BA.%26aulast%3DHahn%26aufirst%3DB.%2BH.%26aulast%3DKwong%26aufirst%3DP.%2BD.%26aulast%3DShaw%26aufirst%3DG.%2BM.%26atitle%3DAntibody%2520neutralization%2520and%2520escape%2520by%2520HIV-1%26jtitle%3DNature%26date%3D2003%26volume%3D422%26spage%3D307%26epage%3D312%26doi%3D10.1038%2Fnature01470" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Keele, B. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giorgi, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salazar-Gonzalez, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Decker, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pham, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salazar, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grayson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirchherr, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ping, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swanstrom, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomaras, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blattner, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goepfert, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kilby, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saag, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delwart, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Busch, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montefiori, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haynes, B. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaschen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Athreya, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seoighe, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perelson, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhattacharya, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korber, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hahn, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, G. M.</span></span> <span> </span><span class="NLM_article-title">Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>105</i></span>,  <span class="NLM_fpage">7552</span>– <span class="NLM_lpage">7557</span>, <span class="refDoi"> DOI: 10.1073/pnas.0802203105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=10.1073%2Fpnas.0802203105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=18490657" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmvFKksrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=7552-7557&author=B.+F.+Keeleauthor=E.+E.+Giorgiauthor=J.+F.+Salazar-Gonzalezauthor=J.+M.+Deckerauthor=K.+T.+Phamauthor=M.+G.+Salazarauthor=C.+Sunauthor=T.+Graysonauthor=S.+Wangauthor=H.+Liauthor=X.+Weiauthor=C.+Jiangauthor=J.+L.+Kirchherrauthor=F.+Gaoauthor=J.+A.+Andersonauthor=L.+H.+Pingauthor=R.+Swanstromauthor=G.+D.+Tomarasauthor=W.+A.+Blattnerauthor=P.+A.+Goepfertauthor=J.+M.+Kilbyauthor=M.+S.+Saagauthor=E.+L.+Delwartauthor=M.+P.+Buschauthor=M.+S.+Cohenauthor=D.+C.+Montefioriauthor=B.+F.+Haynesauthor=B.+Gaschenauthor=G.+S.+Athreyaauthor=H.+Y.+Leeauthor=N.+Woodauthor=C.+Seoigheauthor=A.+S.+Perelsonauthor=T.+Bhattacharyaauthor=B.+T.+Korberauthor=B.+H.+Hahnauthor=G.+M.+Shaw&title=Identification+and+characterization+of+transmitted+and+early+founder+virus+envelopes+in+primary+HIV-1+infection&doi=10.1073%2Fpnas.0802203105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection</span></div><div class="casAuthors">Keele, Brandon F.; Giorgi, Elena E.; Salazar-Gonzalez, Jesus F.; Decker, Julie M.; Pham, Kimmy T.; Salazar, Maria G.; Sun, Chuanxi; Grayson, Truman; Wang, Shuyi; Li, Hui; Wei, Xiping; Jiang, Chunlai; Kirchherr, Jennifer L.; Gao, Feng; Anderson, Jeffery A.; Ping, Li-Hua; Swanstrom, Ronald; Tomaras, Georgia D.; Blattner, William A.; Goepfert, Paul A.; Kilby, J. Michael; Saag, Michael S.; Delwart, Eric L.; Busch, Michael P.; Cohen, Myron S.; Montefiori, David C.; Haynes, Barton F.; Gaschen, Brian; Athreya, Gayathri S.; Lee, Ha Y.; Wood, Natasha; Seoighe, Cathal; Perelson, Alan S.; Bhattacharya, Tanmoy; Korber, Bette T.; Hahn, Beatrice H.; Shaw, George M.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">7552-7557</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The precise identification of the HIV-1 envelope glycoprotein (Env) responsible for productive clin. infection could be instrumental in elucidating the mol. basis of HIV-1 transmission and in designing effective vaccines.  Here, a math. model of random viral evolution was developed and, together with phylogenetic tree construction, was used to analyze 3449 complete env sequences derived by single genome amplification from 102 subjects with acute HIV-1 (clade B) infection.  Viral env genes evolving from individual transmitted or founder viruses generally exhibited a Poisson distribution of mutations and star-like phylogeny, which coalesced to an inferred consensus sequence at or near the estd. time of virus transmission.  Overall, 78 of 102 subjects had evidence of productive clin. infection by a single virus, and 24 others had evidence of productive clin. infection by a min. of 2-5 viruses.  Phenotypic anal. of transmitted or early founder Envs revealed a consistent pattern of CCR5 dependence, masking of coreceptor binding regions, and equiv. or modestly enhanced resistance to the fusion inhibitor T1249 and broadly neutralizing antibodies compared with Envs from chronically infected subjects.  Low multiplicity infection and limited viral evolution preceding peak viremia suggest a finite window of potential vulnerability of HIV-1 to vaccine-elicited immune responses, although phenotypic properties of transmitted Envs pose a formidable defense.  Sequence data were deposited in GenBank/EMBL/DDBJ under accession nos. EU574937-EU579293.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpi2zkTgwHOJbVg90H21EOLACvtfcHk0lj4ix3RQDkDbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmvFKksrg%253D&md5=5f32b92d162ed3c7f1f6c37d5cc970d0</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0802203105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0802203105%26sid%3Dliteratum%253Aachs%26aulast%3DKeele%26aufirst%3DB.%2BF.%26aulast%3DGiorgi%26aufirst%3DE.%2BE.%26aulast%3DSalazar-Gonzalez%26aufirst%3DJ.%2BF.%26aulast%3DDecker%26aufirst%3DJ.%2BM.%26aulast%3DPham%26aufirst%3DK.%2BT.%26aulast%3DSalazar%26aufirst%3DM.%2BG.%26aulast%3DSun%26aufirst%3DC.%26aulast%3DGrayson%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DWei%26aufirst%3DX.%26aulast%3DJiang%26aufirst%3DC.%26aulast%3DKirchherr%26aufirst%3DJ.%2BL.%26aulast%3DGao%26aufirst%3DF.%26aulast%3DAnderson%26aufirst%3DJ.%2BA.%26aulast%3DPing%26aufirst%3DL.%2BH.%26aulast%3DSwanstrom%26aufirst%3DR.%26aulast%3DTomaras%26aufirst%3DG.%2BD.%26aulast%3DBlattner%26aufirst%3DW.%2BA.%26aulast%3DGoepfert%26aufirst%3DP.%2BA.%26aulast%3DKilby%26aufirst%3DJ.%2BM.%26aulast%3DSaag%26aufirst%3DM.%2BS.%26aulast%3DDelwart%26aufirst%3DE.%2BL.%26aulast%3DBusch%26aufirst%3DM.%2BP.%26aulast%3DCohen%26aufirst%3DM.%2BS.%26aulast%3DMontefiori%26aufirst%3DD.%2BC.%26aulast%3DHaynes%26aufirst%3DB.%2BF.%26aulast%3DGaschen%26aufirst%3DB.%26aulast%3DAthreya%26aufirst%3DG.%2BS.%26aulast%3DLee%26aufirst%3DH.%2BY.%26aulast%3DWood%26aufirst%3DN.%26aulast%3DSeoighe%26aufirst%3DC.%26aulast%3DPerelson%26aufirst%3DA.%2BS.%26aulast%3DBhattacharya%26aufirst%3DT.%26aulast%3DKorber%26aufirst%3DB.%2BT.%26aulast%3DHahn%26aufirst%3DB.%2BH.%26aulast%3DShaw%26aufirst%3DG.%2BM.%26atitle%3DIdentification%2520and%2520characterization%2520of%2520transmitted%2520and%2520early%2520founder%2520virus%2520envelopes%2520in%2520primary%2520HIV-1%2520infection%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2008%26volume%3D105%26spage%3D7552%26epage%3D7557%26doi%3D10.1073%2Fpnas.0802203105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Derdeyn, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Decker, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bibollet-Ruche, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mokili, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muldoon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denham, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heil, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kasolo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Musonda, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hahn, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korber, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunter, E.</span></span> <span> </span><span class="NLM_article-title">Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>303</i></span>,  <span class="NLM_fpage">2019</span>– <span class="NLM_lpage">2022</span>, <span class="refDoi"> DOI: 10.1126/science.1093137</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=10.1126%2Fscience.1093137" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=15044802" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=1%3ACAS%3A528%3ADC%252BD2cXisVGlt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=303&publication_year=2004&pages=2019-2022&author=C.+A.+Derdeynauthor=J.+M.+Deckerauthor=F.+Bibollet-Rucheauthor=J.+L.+Mokiliauthor=M.+Muldoonauthor=S.+A.+Denhamauthor=M.+L.+Heilauthor=F.+Kasoloauthor=R.+Musondaauthor=B.+H.+Hahnauthor=G.+M.+Shawauthor=B.+T.+Korberauthor=S.+Allenauthor=E.+Hunter&title=Envelope-constrained+neutralization-sensitive+HIV-1+after+heterosexual+transmission&doi=10.1126%2Fscience.1093137"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Envelope-Constrained Neutralization-Sensitive HIV-1 After Heterosexual Transmission</span></div><div class="casAuthors">Derdeyn, Cynthia A.; Decker, Julie M.; Bibollet-Ruche, Frederic; Mokili, John L.; Muldoon, Mark; Denham, Scott A.; Heil, Marintha L.; Kasolo, Francis; Musonda, Rosemary; Hahn, Beatrice H.; Shaw, George M.; Korber, Bette T.; Allen, Susan; Hunter, Eric</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">303</span>
        (<span class="NLM_cas:issue">5666</span>),
    <span class="NLM_cas:pages">2019-2022</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Heterosexual transmission accounts for the majority of human immunodeficiency virus-1 (HIV-1) infections worldwide, yet the viral properties that det. transmission fitness or outgrowth have not been elucidated.  Here we show, for eight heterosexual transmission pairs, that recipient viruses were monophyletic, encoding compact, glycan-restricted envelope glycoproteins.  These viruses were also uniquely sensitive to neutralization by antibody from the transmitting partner.  Thus, the exposure of neutralizing epitopes, which are lost in chronic infection because of immune escape, appears to be favored in the newly infected host.  This reveals characteristics of the envelope glycoprotein that influence HIV-1 transmission and may have implications for vaccine design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo04BvbhoVSV7Vg90H21EOLACvtfcHk0lj4ix3RQDkDbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXisVGlt7s%253D&md5=8da57ef2bf9fe854836b59769f5b0951</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1126%2Fscience.1093137&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1093137%26sid%3Dliteratum%253Aachs%26aulast%3DDerdeyn%26aufirst%3DC.%2BA.%26aulast%3DDecker%26aufirst%3DJ.%2BM.%26aulast%3DBibollet-Ruche%26aufirst%3DF.%26aulast%3DMokili%26aufirst%3DJ.%2BL.%26aulast%3DMuldoon%26aufirst%3DM.%26aulast%3DDenham%26aufirst%3DS.%2BA.%26aulast%3DHeil%26aufirst%3DM.%2BL.%26aulast%3DKasolo%26aufirst%3DF.%26aulast%3DMusonda%26aufirst%3DR.%26aulast%3DHahn%26aufirst%3DB.%2BH.%26aulast%3DShaw%26aufirst%3DG.%2BM.%26aulast%3DKorber%26aufirst%3DB.%2BT.%26aulast%3DAllen%26aufirst%3DS.%26aulast%3DHunter%26aufirst%3DE.%26atitle%3DEnvelope-constrained%2520neutralization-sensitive%2520HIV-1%2520after%2520heterosexual%2520transmission%26jtitle%3DScience%26date%3D2004%26volume%3D303%26spage%3D2019%26epage%3D2022%26doi%3D10.1126%2Fscience.1093137" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salazar-Gonzalez, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Derdeyn, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williamson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Decker, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salazar, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polonis, V. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mlisana, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karim, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greene, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bilska, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chomba, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulenga, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vwalika, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korber, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunter, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hahn, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montefiori, D. C.</span></span> <span> </span><span class="NLM_article-title">Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>80</i></span>,  <span class="NLM_fpage">11776</span>– <span class="NLM_lpage">11790</span>, <span class="refDoi"> DOI: 10.1128/JVI.01730-06</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=10.1128%2FJVI.01730-06" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=16971434" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht12hu7bO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2006&pages=11776-11790&author=M.+Liauthor=J.+F.+Salazar-Gonzalezauthor=C.+A.+Derdeynauthor=L.+Morrisauthor=C.+Williamsonauthor=J.+E.+Robinsonauthor=J.+M.+Deckerauthor=Y.+Liauthor=M.+G.+Salazarauthor=V.+R.+Polonisauthor=K.+Mlisanaauthor=S.+A.+Karimauthor=K.+Hongauthor=K.+M.+Greeneauthor=M.+Bilskaauthor=J.+Zhouauthor=S.+Allenauthor=E.+Chombaauthor=J.+Mulengaauthor=C.+Vwalikaauthor=F.+Gaoauthor=M.+Zhangauthor=B.+T.+Korberauthor=E.+Hunterauthor=B.+H.+Hahnauthor=D.+C.+Montefiori&title=Genetic+and+neutralization+properties+of+subtype+C+human+immunodeficiency+virus+type+1+molecular+env+clones+from+acute+and+early+heterosexually+acquired+infections+in+Southern+Africa&doi=10.1128%2FJVI.01730-06"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in southern Africa</span></div><div class="casAuthors">Li, Ming; Salazar-Gonzalez, Jesus F.; Derdeyn, Cynthia A.; Morris, Lynn; Williamson, Carolyn; Robinson, James E.; Decker, Julie M.; Li, Yingying; Salazar, Maria G.; Polonis, Victoria R.; Mlisana, Koleka; Karim, Salim Abdool; Hong, Kunxue; Greene, Kelli M.; Bilska, Miroslawa; Zhou, Jintao; Allen, Susan; Chomba, Elwyn; Mulenga, Joseph; Vwalika, Cheswa; Gao, Feng; Zhang, Ming; Korber, Bette T. M.; Hunter, Eric; Hahn, Beatrice H.; Montefiori, David C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">80</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">11776-11790</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">A std. panel of subtype C human immunodeficiency virus type 1 (HIV-1) Env-pseudotyped viruses was created by cloning, sequencing, and characterizing functional gp160 genes from 18 acute and early heterosexually acquired infections in South Africa and Zambia.  In general, the gp120 region of these clones was shorter (most evident in V1 and V4) and less glycosylated compared to newly transmitted subtype B viruses, and it was underglycosylated but no different in length compared to chronic subtype C viruses.  The gp120s also exhibited low amino acid sequence variability (12%) in V3 and high variability (39%) immediately downstream of V3, a feature shared with newly transmitted subtype B viruses and chronic viruses of both subtypes.  When tested as Env-pseudotyped viruses in a luciferase reporter gene assay, all clones possessed an R5 phenotype and resembled primary isolates in their sensitivity to neutralization by HIV-1-pos. plasmas.  Results obtained with a multisubtype plasma panel suggested partial subtype preference in the neutralizing antibody response to infection.  The clones were typical of subtype C in that all were resistant to 2G12 (assocd. with loss of N-glycosylation at position 295) and most were resistant to 2F5, but all were sensitive to 4E10 and many were sensitive to IgG1b12.  Finally, conserved neutralization epitopes in the CD4-induced coreceptor binding domain of gp120 were poorly accessible and were difficult to induce and stabilize with sol. CD4 on Env-pseudotyped viruses.  These results illustrate key genetic and antigenic properties of subtype C HIV-1 that might impact the design and testing of candidate vaccines.  A subset of these gp160 clones are suitable for use as ref. reagents to facilitate standardized assessments of vaccine-elicited neutralizing antibody responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotHCKTjmLyaLVg90H21EOLACvtfcHk0lji1dACkwgkkQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht12hu7bO&md5=ad1d3cad132002306d58759c87dd2d9e</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1128%2FJVI.01730-06&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.01730-06%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DM.%26aulast%3DSalazar-Gonzalez%26aufirst%3DJ.%2BF.%26aulast%3DDerdeyn%26aufirst%3DC.%2BA.%26aulast%3DMorris%26aufirst%3DL.%26aulast%3DWilliamson%26aufirst%3DC.%26aulast%3DRobinson%26aufirst%3DJ.%2BE.%26aulast%3DDecker%26aufirst%3DJ.%2BM.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DSalazar%26aufirst%3DM.%2BG.%26aulast%3DPolonis%26aufirst%3DV.%2BR.%26aulast%3DMlisana%26aufirst%3DK.%26aulast%3DKarim%26aufirst%3DS.%2BA.%26aulast%3DHong%26aufirst%3DK.%26aulast%3DGreene%26aufirst%3DK.%2BM.%26aulast%3DBilska%26aufirst%3DM.%26aulast%3DZhou%26aufirst%3DJ.%26aulast%3DAllen%26aufirst%3DS.%26aulast%3DChomba%26aufirst%3DE.%26aulast%3DMulenga%26aufirst%3DJ.%26aulast%3DVwalika%26aufirst%3DC.%26aulast%3DGao%26aufirst%3DF.%26aulast%3DZhang%26aufirst%3DM.%26aulast%3DKorber%26aufirst%3DB.%2BT.%26aulast%3DHunter%26aufirst%3DE.%26aulast%3DHahn%26aufirst%3DB.%2BH.%26aulast%3DMontefiori%26aufirst%3DD.%2BC.%26atitle%3DGenetic%2520and%2520neutralization%2520properties%2520of%2520subtype%2520C%2520human%2520immunodeficiency%2520virus%2520type%25201%2520molecular%2520env%2520clones%2520from%2520acute%2520and%2520early%2520heterosexually%2520acquired%2520infections%2520in%2520Southern%2520Africa%26jtitle%3DJ.%2520Virol.%26date%3D2006%26volume%3D80%26spage%3D11776%26epage%3D11790%26doi%3D10.1128%2FJVI.01730-06" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Williamson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maughan, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ping, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dryga, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reap, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cilliers, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Harmelen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pascual, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramjee, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnston, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karim, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swanstrom, R.</span></span> <span> </span><span class="NLM_article-title">Characterization and selection of HIV-1 subtype C isolates for use in vaccine development</span>. <i>AIDS Res. Hum. Retroviruses</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">133</span>– <span class="NLM_lpage">144</span>, <span class="refDoi"> DOI: 10.1089/088922203762688649</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=10.1089%2F088922203762688649" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=12639249" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=1%3ACAS%3A528%3ADC%252BD3sXht1Gkurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2003&pages=133-144&author=C.+Williamsonauthor=L.+Morrisauthor=M.+F.+Maughanauthor=L.+H.+Pingauthor=S.+A.+Drygaauthor=R.+Thomasauthor=E.+A.+Reapauthor=T.+Cilliersauthor=J.+van+Harmelenauthor=A.+Pascualauthor=G.+Ramjeeauthor=G.+Grayauthor=R.+Johnstonauthor=S.+A.+Karimauthor=R.+Swanstrom&title=Characterization+and+selection+of+HIV-1+subtype+C+isolates+for+use+in+vaccine+development&doi=10.1089%2F088922203762688649"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization and Selection of HIV-1 Subtype C Isolates for Use in Vaccine Development</span></div><div class="casAuthors">Williamson, Carolyn; Morris, Lynn; Maughan, Maureen F.; Ping, Li-Hua; Dryga, Sergey A.; Thomas, Robin; Reap, Elizabeth A.; Cilliers, Tonie; van Harmelen, Joanne; Pascual, Alvaro; Ramjee, Gita; Gray, Glenda; Johnston, Robert; Karim, Salim Abdool; Swanstrom, Ronald</div><div class="citationInfo"><span class="NLM_cas:title">AIDS Research and Human Retroviruses</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">133-144</span>CODEN:
                <span class="NLM_cas:coden">ARHRE7</span>;
        ISSN:<span class="NLM_cas:issn">0889-2229</span>.
    
            (<span class="NLM_cas:orgname">Mary Ann Liebert, Inc.</span>)
        </div><div class="casAbstract">HIV-1 genetic diversity among circulating strains presents a major challenge for HIV-1 vaccine development, particularly for developing countries where less sequence information is available.  To identify representative viruses for inclusion in candidate vaccines targeted for South Africa, the authors applied an efficient sequence survey strategy to samples from recently and chronically infected persons residing in potential vaccine trial sites.  All 111 sequences were subtype C, including 30 partial gag, 26 partial pol, 27 V2-V3 env, and 28 V5-partial gp41 sequences.  Of the 10 viruses cultured from recently infected individuals, 9 were R5 and 1 was R5X4.  Two isolates, Du151 and Du422, collected within 2 mo of infection, were selected as vaccine strains on the basis of their amino acid similarity to a derived South African consensus sequence.  The selection of recently transmitted R5 isolates for vaccine design may provide an advantage in a subtype C R5-dominant epidemic.  The full-length Du422 gag and Du151 pol and env genes were cloned into the Venezuelan equine encephalitis (VEE) replicon particle (VRP) expression system.  Du422 Gag protein expressed from the VRP accumulated to a high level and was immunogenic as demonstrated by cytotoxic T lymphocyte responses in mice vaccinated with gag-VRPs.  Optimization of codon use for VRP expression in human cells did not enhance expression of the gag gene.  The cloned Du151 env gene encoded a functional protein as demonstrated by fusion of VRP-infected cells with cells expressing CD4 and CCR5.  Genes identified in this study have been incorporated into the VEE VRP candidate vaccines targeted for clin. trial in South Africa.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeHHsVF06RSLVg90H21EOLACvtfcHk0lji1dACkwgkkQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXht1Gkurs%253D&md5=0622e5b95c153c5bfe5f404ca571b3e6</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1089%2F088922203762688649&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252F088922203762688649%26sid%3Dliteratum%253Aachs%26aulast%3DWilliamson%26aufirst%3DC.%26aulast%3DMorris%26aufirst%3DL.%26aulast%3DMaughan%26aufirst%3DM.%2BF.%26aulast%3DPing%26aufirst%3DL.%2BH.%26aulast%3DDryga%26aufirst%3DS.%2BA.%26aulast%3DThomas%26aufirst%3DR.%26aulast%3DReap%26aufirst%3DE.%2BA.%26aulast%3DCilliers%26aufirst%3DT.%26aulast%3Dvan%2BHarmelen%26aufirst%3DJ.%26aulast%3DPascual%26aufirst%3DA.%26aulast%3DRamjee%26aufirst%3DG.%26aulast%3DGray%26aufirst%3DG.%26aulast%3DJohnston%26aufirst%3DR.%26aulast%3DKarim%26aufirst%3DS.%2BA.%26aulast%3DSwanstrom%26aufirst%3DR.%26atitle%3DCharacterization%2520and%2520selection%2520of%2520HIV-1%2520subtype%2520C%2520isolates%2520for%2520use%2520in%2520vaccine%2520development%26jtitle%3DAIDS%2520Res.%2520Hum.%2520Retroviruses%26date%3D2003%26volume%3D19%26spage%3D133%26epage%3D144%26doi%3D10.1089%2F088922203762688649" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parast, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nduati, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">John-Stewart, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mbori-Ngacha, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rainwater, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Overbaugh, J.</span></span> <span> </span><span class="NLM_article-title">Neutralization escape variants of human immunodeficiency virus type 1 are transmitted from mother to infant</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>80</i></span>,  <span class="NLM_fpage">835</span>– <span class="NLM_lpage">844</span>, <span class="refDoi"> DOI: 10.1128/JVI.80.2.835-844.2006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=10.1128%2FJVI.80.2.835-844.2006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=16378985" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=1%3ACAS%3A528%3ADC%252BD28XivVOrtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2006&pages=835-844&author=X.+Wuauthor=A.+B.+Parastauthor=B.+A.+Richardsonauthor=R.+Nduatiauthor=G.+John-Stewartauthor=D.+Mbori-Ngachaauthor=S.+M.+Rainwaterauthor=J.+Overbaugh&title=Neutralization+escape+variants+of+human+immunodeficiency+virus+type+1+are+transmitted+from+mother+to+infant&doi=10.1128%2FJVI.80.2.835-844.2006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Neutralization escape variants of human immunodeficiency virus type 1 are transmitted from mother to infant</span></div><div class="casAuthors">Wu, Xueling; Parast, Adam B.; Richardson, Barbra A.; Nduati, Ruth; John-Stewart, Grace; Mbori-Ngacha, Dorothy; Rainwater, Stephanie M. J.; Overbaugh, Julie</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">80</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">835-844</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Maternal passive immunity typically plays a crit. role in protecting infants from new infections; however, the specific contribution of neutralizing antibodies in limiting mother-to-child transmission of human immunodeficiency virus type 1 is unclear.  By examg. cloned envelope variants from 12 transmission pairs, we found that vertically transmitted variants were more resistant to neutralization by maternal plasma than were maternal viral variants near the time of transmission.  The vertically transmitted envelope variants were poorly neutralized by monoclonal antibodies biz, 2G12, 2F5, and 4E10 individually or in combination.  Despite the fact that the infant viruses were among the most neutralization resistant in the mother, they had relatively few glycosylation sites.  Moreover, the transmitted variants elicited de novo neutralizing antibodies in the infants, indicating that they were not inherently difficult to neutralize.  The neutralization resistance of vertically transmitted viruses is in contrast to the relative neutralization sensitivity of viruses sexually transmitted within discordant couples, suggesting that the antigenic properties of viruses that are favored for transmission may differ depending upon mode of transmission.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpg1ghxbC6IW7Vg90H21EOLACvtfcHk0lisvAHPxbfEFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XivVOrtQ%253D%253D&md5=3d7befeb4abfc14465b28311dd8292e6</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1128%2FJVI.80.2.835-844.2006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.80.2.835-844.2006%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DX.%26aulast%3DParast%26aufirst%3DA.%2BB.%26aulast%3DRichardson%26aufirst%3DB.%2BA.%26aulast%3DNduati%26aufirst%3DR.%26aulast%3DJohn-Stewart%26aufirst%3DG.%26aulast%3DMbori-Ngacha%26aufirst%3DD.%26aulast%3DRainwater%26aufirst%3DS.%2BM.%26aulast%3DOverbaugh%26aufirst%3DJ.%26atitle%3DNeutralization%2520escape%2520variants%2520of%2520human%2520immunodeficiency%2520virus%2520type%25201%2520are%2520transmitted%2520from%2520mother%2520to%2520infant%26jtitle%3DJ.%2520Virol.%26date%3D2006%26volume%3D80%26spage%3D835%26epage%3D844%26doi%3D10.1128%2FJVI.80.2.835-844.2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Connor, R. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choe, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Landau, N. R.</span></span> <span> </span><span class="NLM_article-title">Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes</span>. <i>Virology</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>206</i></span>,  <span class="NLM_fpage">935</span>– <span class="NLM_lpage">944</span>, <span class="refDoi"> DOI: 10.1006/viro.1995.1016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=10.1006%2Fviro.1995.1016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=7531918" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=1%3ACAS%3A528%3ADyaK2MXjs1WkurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=206&publication_year=1995&pages=935-944&author=R.+I.+Connorauthor=B.+K.+Chenauthor=S.+Choeauthor=N.+R.+Landau&title=Vpr+is+required+for+efficient+replication+of+human+immunodeficiency+virus+type-1+in+mononuclear+phagocytes&doi=10.1006%2Fviro.1995.1016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes</span></div><div class="casAuthors">Connor, Ruth I.; Chen, Benjamin Kuan; Choe, Sunny; Landau, Nathaniel R.</div><div class="citationInfo"><span class="NLM_cas:title">Virology</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">206</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">935-44</span>CODEN:
                <span class="NLM_cas:coden">VIRLAX</span>;
        ISSN:<span class="NLM_cas:issn">0042-6822</span>.
    
            (<span class="NLM_cas:orgname">Academic</span>)
        </div><div class="casAbstract">HIV-1 vpr encodes a 96-amino acid, nuclear protein whose function is not well understood.  Unlike the other lentivirus regulatory proteins, Vpr is present in virions at relatively high copy no.  In cells, Vpr is localized to the nucleus.  Possible functions for vpr consistent with these findings include the nuclear import of preintegration complexes, transactivation of cellular genes, or induction of cellular differentiation.  The authors show here, using both replication competent, macrophage-tropic virus and a sensitive, single-cycle luciferase HIV-1 reporter vector, that vpr is important for efficient viral replication in primary monocyte/macrophages, but appears to play no role in activated or resting T cell infection.  The block to infection in monocytes was localized by PCR anal. of newly synthesized viral DNA and with the luciferase reporter vector to a stage in the viral life cycle after entry and reverse transcription, yet prior to, or at the time of, proviral transcription.  In addn., infection of mononuclear phagocyte with virions that had been loaded with Vpr mols. in the producer cells by trans-complementation still showed a vpr-phenotype.  These data suggest a role for vpr mols. produced in newly infected cells, in addn. to its presumed function in the virion.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgyuTZ6ZIJ-7Vg90H21EOLACvtfcHk0lisvAHPxbfEFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXjs1WkurY%253D&md5=09620dfc7aaf57ec9c46ffaef438630f</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1006%2Fviro.1995.1016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fviro.1995.1016%26sid%3Dliteratum%253Aachs%26aulast%3DConnor%26aufirst%3DR.%2BI.%26aulast%3DChen%26aufirst%3DB.%2BK.%26aulast%3DChoe%26aufirst%3DS.%26aulast%3DLandau%26aufirst%3DN.%2BR.%26atitle%3DVpr%2520is%2520required%2520for%2520efficient%2520replication%2520of%2520human%2520immunodeficiency%2520virus%2520type-1%2520in%2520mononuclear%2520phagocytes%26jtitle%3DVirology%26date%3D1995%26volume%3D206%26spage%3D935%26epage%3D944%26doi%3D10.1006%2Fviro.1995.1016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">He, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choe, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">di Marzio, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, D. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Landau, N. R.</span></span> <span> </span><span class="NLM_article-title">Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34cdc2 activity</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">6705</span>– <span class="NLM_lpage">6711</span>, <span class="refDoi"> DOI: 10.1128/JVI.69.11.6705-6711.1995</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=10.1128%2FJVI.69.11.6705-6711.1995" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=7474080" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=1%3ACAS%3A528%3ADyaK2MXoslWkt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=1995&pages=6705-6711&author=J.+Heauthor=S.+Choeauthor=R.+Walkerauthor=P.+di+Marzioauthor=D.+O.+Morganauthor=N.+R.+Landau&title=Human+immunodeficiency+virus+type+1+viral+protein+R+%28Vpr%29+arrests+cells+in+the+G2+phase+of+the+cell+cycle+by+inhibiting+p34cdc2+activity&doi=10.1128%2FJVI.69.11.6705-6711.1995"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34cdc2 activity</span></div><div class="casAuthors">He, Jianglin; Choe, Sunny; Walker, Robert; Di Marzio, Paola; Morgan, David O.; Landau, Nathaniel R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">6705-11</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The Vpr accessory gene product of human immunodeficiency virus types 1 and 2 and simian immunodeficiency virus is believed to play a role in permitting entry of the viral core into the nucleus of nondividing cells.  A second role for Vpr was recently suggested by (M. E. Rogel, et al., 1995) who showed that Vpr prevents the establishment in vitro of chronically infected HIV producer cell lines, apparently by causing infected cells to arrest in the G2/M phase of the cell cycle.  In cycling cells, progression from G2 to M phase is driven by activation of the p34cdc2/cyclin B complex, an event caused, in part, by dephosphorylation of two regulatory amino acids of p34cdc2 (Thr-14 and Tyr-15).  We show here that Vpr arrests the cell cycle in G2 by preventing the activation of the p34cdc2/cyclin B complex.  Vpr expression in cells caused p34cdc2 to remain in the phosphorylated, inactive state.  The p34cdc2/cyclin B complexes immunopptn. from cells expressing Vpr were almost completely inactive in a histone H1 kinase assay.  Coexpression of a constitutively active mutant p34cdc2 mol. with Vpr relieved the G2 arrest.  These findings strongly suggest that Vpr arrests cells in G2 by preventing the activation of the p34cdc2/cyclin B complex that is required for entry into M phase.  In vivo, Vpr might, by preventing p34cdc2 activation, delay or prevent apoptosis of infected cells.  This would increase the amt. of virus each infected cell produced.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfPunHH8sjFbVg90H21EOLACvtfcHk0lhr0CeNSe-h0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXoslWkt74%253D&md5=cf13092726ac54f93a13fb9439e971c2</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1128%2FJVI.69.11.6705-6711.1995&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.69.11.6705-6711.1995%26sid%3Dliteratum%253Aachs%26aulast%3DHe%26aufirst%3DJ.%26aulast%3DChoe%26aufirst%3DS.%26aulast%3DWalker%26aufirst%3DR.%26aulast%3Ddi%2BMarzio%26aufirst%3DP.%26aulast%3DMorgan%26aufirst%3DD.%2BO.%26aulast%3DLandau%26aufirst%3DN.%2BR.%26atitle%3DHuman%2520immunodeficiency%2520virus%2520type%25201%2520viral%2520protein%2520R%2520%2528Vpr%2529%2520arrests%2520cells%2520in%2520the%2520G2%2520phase%2520of%2520the%2520cell%2520cycle%2520by%2520inhibiting%2520p34cdc2%2520activity%26jtitle%3DJ.%2520Virol.%26date%3D1995%26volume%3D69%26spage%3D6705%26epage%3D6711%26doi%3D10.1128%2FJVI.69.11.6705-6711.1995" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Adachi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gendelman, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koenig, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Folks, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willey, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, M. A.</span></span> <span> </span><span class="NLM_article-title">Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">1986</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">284</span>– <span class="NLM_lpage">291</span>, <span class="refDoi"> DOI: 10.1128/JVI.59.2.284-291.1986</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=10.1128%2FJVI.59.2.284-291.1986" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=3016298" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=1%3ACAS%3A280%3ADyaL283otFyhtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=1986&pages=284-291&author=A.+Adachiauthor=H.+E.+Gendelmanauthor=S.+Koenigauthor=T.+Folksauthor=R.+Willeyauthor=A.+Rabsonauthor=M.+A.+Martin&title=Production+of+acquired+immunodeficiency+syndrome-associated+retrovirus+in+human+and+nonhuman+cells+transfected+with+an+infectious+molecular+clone&doi=10.1128%2FJVI.59.2.284-291.1986"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone</span></div><div class="casAuthors">Adachi A; Gendelman H E; Koenig S; Folks T; Willey R; Rabson A; Martin M A</div><div class="citationInfo"><span class="NLM_cas:title">Journal of virology</span>
        (<span class="NLM_cas:date">1986</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">284-91</span>
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    </div><div class="casAbstract">We constructed an infectious molecular clone of acquired immunodeficiency syndrome-associated retrovirus.  Upon transfection, this clone directed the production of infectious virus particles in a wide variety of cells in addition to human T4 cells.  The progeny, infectious virions, were synthesized in mouse, mink, monkey, and several human non-T cell lines, indicating the absence of any intracellular obstacle to viral RNA or protein production or assembly.  During the course of these studies, a human colon carcinoma cell line, exquisitely sensitive to DNA transfection, was identified.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTnWWZt8wKSPuIHSmpohpd0fW6udTcc2eZcZq6UWScg1Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL283otFyhtQ%253D%253D&md5=295ec341d4d4a282e4d10c9fea3d647e</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1128%2FJVI.59.2.284-291.1986&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.59.2.284-291.1986%26sid%3Dliteratum%253Aachs%26aulast%3DAdachi%26aufirst%3DA.%26aulast%3DGendelman%26aufirst%3DH.%2BE.%26aulast%3DKoenig%26aufirst%3DS.%26aulast%3DFolks%26aufirst%3DT.%26aulast%3DWilley%26aufirst%3DR.%26aulast%3DRabson%26aufirst%3DA.%26aulast%3DMartin%26aufirst%3DM.%2BA.%26atitle%3DProduction%2520of%2520acquired%2520immunodeficiency%2520syndrome-associated%2520retrovirus%2520in%2520human%2520and%2520nonhuman%2520cells%2520transfected%2520with%2520an%2520infectious%2520molecular%2520clone%26jtitle%3DJ.%2520Virol.%26date%3D1986%26volume%3D59%26spage%3D284%26epage%3D291%26doi%3D10.1128%2FJVI.59.2.284-291.1986" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rimsky, L. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shugars, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matthews, T. J.</span></span> <span> </span><span class="NLM_article-title">Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>72</i></span>,  <span class="NLM_fpage">986</span>– <span class="NLM_lpage">93</span>, <span class="refDoi"> DOI: 10.1128/JVI.72.2.986-993.1998</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=10.1128%2FJVI.72.2.986-993.1998" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=9444991" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=1%3ACAS%3A528%3ADyaK1cXlt1GgsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=1998&pages=986-93&author=L.+T.+Rimskyauthor=D.+C.+Shugarsauthor=T.+J.+Matthews&title=Determinants+of+human+immunodeficiency+virus+type+1+resistance+to+gp41-derived+inhibitory+peptides&doi=10.1128%2FJVI.72.2.986-993.1998"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides</span></div><div class="casAuthors">Rimsky, Laurence T.; Shugars, Diane C.; Matthews, Thomas J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">986-993</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">A synthetic peptide, DP178, contg. amino acids 127-162 of the human immunodeficiency virus type 1 (HIV-1) gp41 Env glycoprotein, is a potent inhibitor of virus infection and virus mediated cell-to-cell fusion (C. Wild, et al., 1993).  In an effort to understand the mechanism of action of this peptide, the authors derived resistant variants of HIV-1IIIB and NL4-3 by serial virus passage in the presence of increasing doses of the peptide.  Sequence anal. of the resistant isolates suggested that a contiguous 3-amino-acid sequence within the N-terminal heptad repeat motif of gp41 was assocd. with resistance.  Site-directed mutagenesis studies confirmed this observation and indicated that changes in 2 of these 3 residues were necessary for development of the resistant phenotype.  Direct binding of DP178 to recombinant protein and synthetic peptide analogs contg. the wild-type and mutant heptad repeat sequences revealed a strong correlation between DP178 binding and the biol. sensitivity of the corresponding virus isolates to DP178.  The results are discussed from the standpoints of the mechanism of action of DP178 and recent crystallog. information for a core structure of the gp41 ectodomain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozLL8yJTuHq7Vg90H21EOLACvtfcHk0lhr0CeNSe-h0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXlt1GgsQ%253D%253D&md5=885536c0373f2270edcfcd558f1111c3</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1128%2FJVI.72.2.986-993.1998&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.72.2.986-993.1998%26sid%3Dliteratum%253Aachs%26aulast%3DRimsky%26aufirst%3DL.%2BT.%26aulast%3DShugars%26aufirst%3DD.%2BC.%26aulast%3DMatthews%26aufirst%3DT.%2BJ.%26atitle%3DDeterminants%2520of%2520human%2520immunodeficiency%2520virus%2520type%25201%2520resistance%2520to%2520gp41-derived%2520inhibitory%2520peptides%26jtitle%3DJ.%2520Virol.%26date%3D1998%26volume%3D72%26spage%3D986%26epage%3D93%26doi%3D10.1128%2FJVI.72.2.986-993.1998" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Balamane, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varghese, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melikian, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fessel, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katzenstein, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shafer, R. W.</span></span> <span> </span><span class="NLM_article-title">Panel of prototypical recombinant infectious molecular clones resistant to nevirapine, efavirenz, etravirine, and rilpivirine</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">4522</span>– <span class="NLM_lpage">4524</span>, <span class="refDoi"> DOI: 10.1128/AAC.00648-12</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=10.1128%2FAAC.00648-12" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=22664973" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFajsLzO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2012&pages=4522-4524&author=M.+Balamaneauthor=V.+Vargheseauthor=G.+L.+Melikianauthor=W.+J.+Fesselauthor=D.+A.+Katzensteinauthor=R.+W.+Shafer&title=Panel+of+prototypical+recombinant+infectious+molecular+clones+resistant+to+nevirapine%2C+efavirenz%2C+etravirine%2C+and+rilpivirine&doi=10.1128%2FAAC.00648-12"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Panel of prototypical recombinant infectious molecular clones resistant to nevirapine, efavirenz, etravirine, and rilpivirine</span></div><div class="casAuthors">Balamane, Maya; Varghese, Vici; Melikian, George L.; Fessel, W. Jeffrey; Katzenstein, David A.; Shafer, Robert W.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">4522-4524</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">We created a panel of 10 representative multi-nonnucleoside reverse transcriptase inhibitor (NNRTI)-resistant recombinant infectious mol. HIV-1 clones to assist researchers studying NNRTI resistance or developing novel NNRTIs.  The cloned viruses contain most of the major NNRTI resistance mutations and most of the significantly assocd. mutation pairs that we identified in two network analyses.  Each virus in the panel has intermediate- or high-level resistance to all or three of the four most commonly used NNRTIs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtl3gk5s6CGrVg90H21EOLACvtfcHk0lgsizg7ddms9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFajsLzO&md5=5d724094bab15760dcd65662e8ea1b71</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1128%2FAAC.00648-12&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.00648-12%26sid%3Dliteratum%253Aachs%26aulast%3DBalamane%26aufirst%3DM.%26aulast%3DVarghese%26aufirst%3DV.%26aulast%3DMelikian%26aufirst%3DG.%2BL.%26aulast%3DFessel%26aufirst%3DW.%2BJ.%26aulast%3DKatzenstein%26aufirst%3DD.%2BA.%26aulast%3DShafer%26aufirst%3DR.%2BW.%26atitle%3DPanel%2520of%2520prototypical%2520recombinant%2520infectious%2520molecular%2520clones%2520resistant%2520to%2520nevirapine%252C%2520efavirenz%252C%2520etravirine%252C%2520and%2520rilpivirine%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2012%26volume%3D56%26spage%3D4522%26epage%3D4524%26doi%3D10.1128%2FAAC.00648-12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reuman, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bachmann, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varghese, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fessel, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shafer, R. W.</span></span> <span> </span><span class="NLM_article-title">Panel of prototypical raltegravir-resistant infectious molecular clones in a novel integrase-deleted cloning vector</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">934</span>– <span class="NLM_lpage">936</span>, <span class="refDoi"> DOI: 10.1128/AAC.01345-09</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=10.1128%2FAAC.01345-09" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=19917747" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhvFShs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2010&pages=934-936&author=E.+C.+Reumanauthor=M.+H.+Bachmannauthor=V.+Vargheseauthor=W.+J.+Fesselauthor=R.+W.+Shafer&title=Panel+of+prototypical+raltegravir-resistant+infectious+molecular+clones+in+a+novel+integrase-deleted+cloning+vector&doi=10.1128%2FAAC.01345-09"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Panel of prototypical raltegravir-resistant infectious molecular clones in a novel integrase-deleted cloning vector</span></div><div class="casAuthors">Reuman, Elizabeth C.; Bachmann, Michael H.; Varghese, Vici; Fessel, W. Jeffrey; Shafer, Robert W.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">934-936</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">We created an HIV-1 cloning vector, pNL4.3ΔIN, to generate recombinant infectious mol. clones for anal. of patient-derived HIV-1 integrase coding regions.  Using this vector, we constructed a panel of clin. derived viruses with the canonical patterns of raltegravir resistance mutations and submitted the panel to the NIH AIDS Research and Ref. Reagent Program.  Investigational integrase inhibitors with activity against these clones are likely to retain activity against the most clin. relevant raltegravir-resistant variants.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobyvfHkutEHLVg90H21EOLACvtfcHk0lgsizg7ddms9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhvFShs7s%253D&md5=72b064cf2ef84283ec852a378f01e467</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1128%2FAAC.01345-09&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.01345-09%26sid%3Dliteratum%253Aachs%26aulast%3DReuman%26aufirst%3DE.%2BC.%26aulast%3DBachmann%26aufirst%3DM.%2BH.%26aulast%3DVarghese%26aufirst%3DV.%26aulast%3DFessel%26aufirst%3DW.%2BJ.%26aulast%3DShafer%26aufirst%3DR.%2BW.%26atitle%3DPanel%2520of%2520prototypical%2520raltegravir-resistant%2520infectious%2520molecular%2520clones%2520in%2520a%2520novel%2520integrase-deleted%2520cloning%2520vector%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2010%26volume%3D54%26spage%3D934%26epage%3D936%26doi%3D10.1128%2FAAC.01345-09" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Varghese, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitsuya, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fessel, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, T. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melikian, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katzenstein, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiffer, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holmes, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shafer, R. W.</span></span> <span> </span><span class="NLM_article-title">Prototypical recombinant multi-protease-inhibitor-resistant infectious molecular clones of human immunodeficiency virus type 1</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">4290</span>– <span class="NLM_lpage">4299</span>, <span class="refDoi"> DOI: 10.1128/AAC.00614-13</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=10.1128%2FAAC.00614-13" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=23796938" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtlSns7bM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2013&pages=4290-4299&author=V.+Vargheseauthor=Y.+Mitsuyaauthor=W.+J.+Fesselauthor=T.+F.+Liuauthor=G.+L.+Melikianauthor=D.+A.+Katzensteinauthor=C.+A.+Schifferauthor=S.+P.+Holmesauthor=R.+W.+Shafer&title=Prototypical+recombinant+multi-protease-inhibitor-resistant+infectious+molecular+clones+of+human+immunodeficiency+virus+type+1&doi=10.1128%2FAAC.00614-13"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Prototypical recombinant multi-protease-inhibitor-resistant infectious molecular clones of human immunodeficiency virus type 1</span></div><div class="casAuthors">Varghese, Vici; Mitsuya, Yumi; Fessel, W. Jeffrey; Liu, Tommy F.; Melikian, George L.; Katzenstein, David A.; Schiffer, Celia A.; Holmes, Susan P.; Shafer, Robert W.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4290-4299</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">1098-6596</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The many genetic manifestations of HIV-1 protease inhibitor (PI) resistance present challenges to research into the mechanisms of PI resistance and the assessment of new PIs.  To address these challenges, we created a panel of recombinant multi-PI-resistant infectious mol. clones designed to represent the spectrum of clin. relevant multi-PI-resistant viruses.  To assess the representativeness of this panel, we examd. the sequences of the panel's viruses in the context of a correlation network of PI resistance amino acid substitutions in sequences from more than 10,000 patients.  The panel of recombinant infectious mol. clones comprised 29 of 41 study-defined PI resistance amino acid substitutions and 23 of the 27 tightest amino acid substitution clusters.  Based on their phenotypic properties, the clones were classified into four groups with increasing cross-resistance to the PIs most commonly used for salvage therapy: lopinavir (LPV), tipranavir (TPV), and darunavir (DRV).  The panel of recombinant infectious mol. clones has been made available without restriction through the NIH AIDS Research and Ref. Reagent Program.  The public availability of the panel makes it possible to compare the inhibitory activities of different PIs with one another.  The diversity of the panel and the high-level PI resistance of its clones suggest that investigational PIs active against the clones in this panel will retain antiviral activity against most if not all clin. relevant PI-resistant viruses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtlR3mT_rhVbVg90H21EOLACvtfcHk0lgsizg7ddms9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtlSns7bM&md5=d28211fe6a88a631b568ff9861bee481</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1128%2FAAC.00614-13&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.00614-13%26sid%3Dliteratum%253Aachs%26aulast%3DVarghese%26aufirst%3DV.%26aulast%3DMitsuya%26aufirst%3DY.%26aulast%3DFessel%26aufirst%3DW.%2BJ.%26aulast%3DLiu%26aufirst%3DT.%2BF.%26aulast%3DMelikian%26aufirst%3DG.%2BL.%26aulast%3DKatzenstein%26aufirst%3DD.%2BA.%26aulast%3DSchiffer%26aufirst%3DC.%2BA.%26aulast%3DHolmes%26aufirst%3DS.%2BP.%26aulast%3DShafer%26aufirst%3DR.%2BW.%26atitle%3DPrototypical%2520recombinant%2520multi-protease-inhibitor-resistant%2520infectious%2520molecular%2520clones%2520of%2520human%2520immunodeficiency%2520virus%2520type%25201%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2013%26volume%3D57%26spage%3D4290%26epage%3D4299%26doi%3D10.1128%2FAAC.00614-13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lackman-Smith, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snyder, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ratner, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rohan, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patton, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramratnam, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cole, A. M.</span></span> <span> </span><span class="NLM_article-title">Antiviral activity of retrocyclin RC-101, a candidate microbicide against cell-associated HIV-1</span>. <i>AIDS Res. Hum. Retroviruses</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">391</span>– <span class="NLM_lpage">396</span>, <span class="refDoi"> DOI: 10.1089/aid.2012.0135</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=10.1089%2Faid.2012.0135" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=22924614" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVOjurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2013&pages=391-396&author=P.+Guptaauthor=C.+Lackman-Smithauthor=B.+Snyderauthor=D.+Ratnerauthor=L.+C.+Rohanauthor=D.+Pattonauthor=B.+Ramratnamauthor=A.+M.+Cole&title=Antiviral+activity+of+retrocyclin+RC-101%2C+a+candidate+microbicide+against+cell-associated+HIV-1&doi=10.1089%2Faid.2012.0135"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Antiviral Activity of Retrocyclin RC-101, a Candidate Microbicide Against Cell-Associated HIV-1</span></div><div class="casAuthors">Gupta, Phalguni; Lackman-Smith, Carol; Snyder, Beth; Ratner, Deena; Rohan, Lisa C.; Patton, Dorothy; Ramratnam, Bharat; Cole, Alexander M.</div><div class="citationInfo"><span class="NLM_cas:title">AIDS Research and Human Retroviruses</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">391-396</span>CODEN:
                <span class="NLM_cas:coden">ARHRE7</span>;
        ISSN:<span class="NLM_cas:issn">0889-2229</span>.
    
            (<span class="NLM_cas:orgname">Mary Ann Liebert, Inc.</span>)
        </div><div class="casAbstract">Microbicides have been evaluated mostly against cell-free HIV-1.  Because semen contains both cell-free and cell-assocd. HIV-1, HIV-1 transmission could occur via either or both sources.  Therefore, it is important to examine the antiviral activity of microbicides against cell-assocd. HIV-1.  The cyclic antimicrobial peptide retrocyclin RC-101 has been shown previously to have antiviral activity against cell-free HIV-1, with no assocd. cellular toxicity.  In this article we have examd. the antiviral activity of RC-101 against cell-assocd. HIV-1.  The results demonstrate potent antiviral activity of RC-101 against cell-cell HIV-1 transmission in both CD4-dependent and CD4-independent assays against CCR5- and CXCR4-tropic HIV-1, with no cellular toxicity.  Furthermore, this antiviral activity was retained in the presence of human seminal plasma.  The potent antiviral activity of RC-101 against cell-assocd. HIV-1 reported here, and the previously reported antiviral activity in cervical tissues, suggest that RC-101 is an excellent and promising microbicide candidate against HIV-1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAyS93vgYB5LVg90H21EOLACvtfcHk0liCW1pH3gdTCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVOjurc%253D&md5=dc03a192fbe8805225208b1a5136ff29</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1089%2Faid.2012.0135&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252Faid.2012.0135%26sid%3Dliteratum%253Aachs%26aulast%3DGupta%26aufirst%3DP.%26aulast%3DLackman-Smith%26aufirst%3DC.%26aulast%3DSnyder%26aufirst%3DB.%26aulast%3DRatner%26aufirst%3DD.%26aulast%3DRohan%26aufirst%3DL.%2BC.%26aulast%3DPatton%26aufirst%3DD.%26aulast%3DRamratnam%26aufirst%3DB.%26aulast%3DCole%26aufirst%3DA.%2BM.%26atitle%3DAntiviral%2520activity%2520of%2520retrocyclin%2520RC-101%252C%2520a%2520candidate%2520microbicide%2520against%2520cell-associated%2520HIV-1%26jtitle%3DAIDS%2520Res.%2520Hum.%2520Retroviruses%26date%3D2013%26volume%3D29%26spage%3D391%26epage%3D396%26doi%3D10.1089%2Faid.2012.0135" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lackman-Smith, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osterling, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luckenbaugh, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mankowski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snyder, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paull, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Profy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ptak, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buckheit, R. W.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watson, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cummins, J. E.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanders-Beer, B. E.</span></span> <span> </span><span class="NLM_article-title">Development of a comprehensive human immunodeficiency virus type 1 screening algorithm for discovery and preclinical testing of topical microbicides</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">1768</span>– <span class="NLM_lpage">1781</span>, <span class="refDoi"> DOI: 10.1128/AAC.01328-07</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=10.1128%2FAAC.01328-07" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=18316528" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=1%3ACAS%3A528%3ADC%252BD1cXls1aju74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2008&pages=1768-1781&author=C.+Lackman-Smithauthor=C.+Osterlingauthor=K.+Luckenbaughauthor=M.+Mankowskiauthor=B.+Snyderauthor=G.+Lewisauthor=J.+Paullauthor=A.+Profyauthor=R.+G.+Ptakauthor=R.+W.+Buckheitauthor=K.+M.+Watsonauthor=J.+E.+Cumminsauthor=B.+E.+Sanders-Beer&title=Development+of+a+comprehensive+human+immunodeficiency+virus+type+1+screening+algorithm+for+discovery+and+preclinical+testing+of+topical+microbicides&doi=10.1128%2FAAC.01328-07"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Development of a comprehensive human immunodeficiency virus type 1 screening algorithm for discovery and preclinical testing of topical microbicides</span></div><div class="casAuthors">Lackman-Smith, Carol; Osterling, Clay; Luckenbaugh, Katherine; Mankowski, Marie; Snyder, Beth; Lewis, Gareth; Paull, Jeremy; Profy, Albert; Ptak, Roger G.; Buckheit, Robert W., Jr.; Watson, Karen M.; Cummins, James E., Jr.; Sanders-Beer, Brigitte E.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1768-1781</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Topical microbicides are self-administered, prophylactic products for protection against sexually transmitted pathogens.  A large no. of compds. with known anti-human immunodeficiency virus type 1 (HIV-1) inhibitory activity have been proposed as candidate topical microbicides.  To identify potential leads, an in vitro screening algorithm was developed to evaluate candidate microbicides in assays that assess inhibition of cell-assocd. and cell-free HIV-1 transmission, entry, and fusion.  The algorithm advances compds. by evaluation in a series of defined assays that generate measurements of relative antiviral potency to det. advancement or failure.  Initial testing consists of a dual detn. of inhibitory activity in the CD4-dependent CCR5-tropic cell-assocd. transmission inhibition assay and in the CD4/CCR5-mediated HIV-1 entry assay.  The activity is confirmed by repeat testing, and identified actives are advanced to secondary screens to det. their effect on transmission of CXCR4-tropic viruses in the presence or absence of CD4 and their ability to inhibit CXCR4- and CCR5-tropic envelope-mediated cell-to-cell fusion.  In addn., confirmed active compds. are also evaluated in the presence of human seminal plasma, in assays incorporating a pH 4 to 7 transition, and for growth inhibition of relevant strains of lactobacilli.  Leads may then be advanced for specialized testing, including detns. in human cervical explants and in peripheral blood mononuclear cells against primary HIV subtypes, combination testing with other inhibitors, and addnl. cytotoxicity assays.  PRO2000 and SPL7013 (the active component of VivaGel), two microbicide products currently being evaluated in human clin. trials, were tested in this in vitro algorithm and were shown to be highly active against CCR5- and CXCR4-tropic HIV-1 infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp03Yb1WRdB_LVg90H21EOLACvtfcHk0liCW1pH3gdTCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXls1aju74%253D&md5=2080bcd8421ea686cb18e7f626cd0420</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1128%2FAAC.01328-07&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.01328-07%26sid%3Dliteratum%253Aachs%26aulast%3DLackman-Smith%26aufirst%3DC.%26aulast%3DOsterling%26aufirst%3DC.%26aulast%3DLuckenbaugh%26aufirst%3DK.%26aulast%3DMankowski%26aufirst%3DM.%26aulast%3DSnyder%26aufirst%3DB.%26aulast%3DLewis%26aufirst%3DG.%26aulast%3DPaull%26aufirst%3DJ.%26aulast%3DProfy%26aufirst%3DA.%26aulast%3DPtak%26aufirst%3DR.%2BG.%26aulast%3DBuckheit%26aufirst%3DR.%2BW.%26aulast%3DWatson%26aufirst%3DK.%2BM.%26aulast%3DCummins%26aufirst%3DJ.%2BE.%26aulast%3DSanders-Beer%26aufirst%3DB.%2BE.%26atitle%3DDevelopment%2520of%2520a%2520comprehensive%2520human%2520immunodeficiency%2520virus%2520type%25201%2520screening%2520algorithm%2520for%2520discovery%2520and%2520preclinical%2520testing%2520of%2520topical%2520microbicides%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2008%26volume%3D52%26spage%3D1768%26epage%3D1781%26doi%3D10.1128%2FAAC.01328-07" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Praveen, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yathirajan, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narayana, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarojini, B. K.</span></span> <span> </span><span class="NLM_article-title">Synthesis, characterization and antimicrobial studies of a few novel thiazole derivatives</span>. <i>Med. Chem. Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">259</span>– <span class="NLM_lpage">268</span>, <span class="refDoi"> DOI: 10.1007/s00044-013-0629-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=10.1007%2Fs00044-013-0629-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=1%3ACAS%3A528%3ADC%252BC3sXotlGhs7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2014&pages=259-268&author=A.+S.+Praveenauthor=H.+S.+Yathirajanauthor=B.+Narayanaauthor=B.+K.+Sarojini&title=Synthesis%2C+characterization+and+antimicrobial+studies+of+a+few+novel+thiazole+derivatives&doi=10.1007%2Fs00044-013-0629-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, characterization and antimicrobial studies of a few novel thiazole derivatives</span></div><div class="casAuthors">Praveen, Aletti S.; Yathirajan, Hemmige S.; Narayana, Badiadka; Sarojini, Balladka K.</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Chemistry Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">259-268</span>CODEN:
                <span class="NLM_cas:coden">MCREEB</span>;
        ISSN:<span class="NLM_cas:issn">1054-2523</span>.
    
            (<span class="NLM_cas:orgname">Birkhaeuser Boston</span>)
        </div><div class="casAbstract">A series of novel N-[4-(substituted)-1,3-thiazol-2-yl]-2-(substituted)acetamides and Me 2-(2-(2-(substituted)acetamido)thiazol-4-yl)acetates were synthesized.  All compds. were screened for their in vitro antibacterial activity against S. aureus, E. coli, P. aeruginosa, and K. pneumonia by disk diffusion and for antifungal activity against P. marneffei, T. mentagrophytes, A. flavus, and A. fumigatus by serial plate diln.  Some of the compds. exhibited growth inhibition against all the tested bacterial strains, with MIC of 12.5-6.25 μg/mL.  Among the compds. tested for antifungal activity, several of them showed a wide range of activity against all the tested strains.  Most of the newly synthesized compds. were effective against fungal strains rather than bacterial strains.  However, some of the compds. showed selective sensitivity against some of the bacterial strains, whereas they were unable to sustain the growth of other strains.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTRcarsuGjkrVg90H21EOLACvtfcHk0lizmaFoXwCaVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXotlGhs7Y%253D&md5=54236fbcccbd308cdd0a85c29f4a417e</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1007%2Fs00044-013-0629-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00044-013-0629-x%26sid%3Dliteratum%253Aachs%26aulast%3DPraveen%26aufirst%3DA.%2BS.%26aulast%3DYathirajan%26aufirst%3DH.%2BS.%26aulast%3DNarayana%26aufirst%3DB.%26aulast%3DSarojini%26aufirst%3DB.%2BK.%26atitle%3DSynthesis%252C%2520characterization%2520and%2520antimicrobial%2520studies%2520of%2520a%2520few%2520novel%2520thiazole%2520derivatives%26jtitle%3DMed.%2520Chem.%2520Res.%26date%3D2014%26volume%3D23%26spage%3D259%26epage%3D268%26doi%3D10.1007%2Fs00044-013-0629-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 5 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Takuya Kobayakawa, Kohei Tsuji, Kiju Konno, Ai Himeno, Ami Masuda, Tingting Yang, Kohei Takahashi, Yusuke Ishida, Nami Ohashi, Takeo Kuwata, Kaho Matsumoto, Kazuhisa Yoshimura, Hiromi Sakawaki, Tomoyuki Miura, Shigeyoshi Harada, Shuzo Matsushita, <span class="NLM_string-name hlFld-ContribAuthor">Hirokazu Tamamura</span>. </span><span class="cited-content_cbyCitation_article-title">Hybrids of Small-Molecule CD4 Mimics with Polyethylene Glycol Units as HIV Entry Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (3)
                                     , 1481-1496. <a href="https://doi.org/10.1021/acs.jmedchem.0c01153" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01153</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01153&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01153%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DHybrids%252Bof%252BSmall-Molecule%252BCD4%252BMimics%252Bwith%252BPolyethylene%252BGlycol%252BUnits%252Bas%252BHIV%252BEntry%252BInhibitors%26aulast%3DKobayakawa%26aufirst%3DTakuya%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D04072020%26date%3D26012021%26volume%3D64%26issue%3D3%26spage%3D1481%26epage%3D1496" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ildar R.  Iusupov</span>, <span class="hlFld-ContribAuthor ">Francesca  Curreli</span>, <span class="hlFld-ContribAuthor ">Evgeniy A.  Spiridonov</span>, <span class="hlFld-ContribAuthor ">Pavel O.  Markov</span>, <span class="hlFld-ContribAuthor ">Shahad  Ahmed</span>, <span class="hlFld-ContribAuthor ">Dmitry S.  Belov</span>, <span class="hlFld-ContribAuthor ">Ekaterina V.  Manasova</span>, <span class="hlFld-ContribAuthor ">Andrea  Altieri</span>, <span class="hlFld-ContribAuthor ">Alexander V.  Kurkin</span>, <span class="hlFld-ContribAuthor ">Asim K.  Debnath</span>. </span><span class="cited-content_cbyCitation_article-title">Design of gp120 HIV-1 entry inhibitors by scaffold hopping via isosteric replacements. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>2 </em>, 113681. <a href="https://doi.org/10.1016/j.ejmech.2021.113681" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113681</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113681&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113681%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%252Bof%252Bgp120%252BHIV-1%252Bentry%252Binhibitors%252Bby%252Bscaffold%252Bhopping%252Bvia%252Bisosteric%252Breplacements%26aulast%3DIusupov%26aufirst%3DIldar%2BR.%26date%3D2021%26volume%3D2%26spage%3D113681" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hossein  Mousavi</span>. </span><span class="cited-content_cbyCitation_article-title">A comprehensive survey upon diverse and prolific applications of chitosan-based catalytic systems in one-pot multi-component synthesis of heterocyclic rings. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Biological Macromolecules</span><span> <strong>2021,</strong> <em>57 </em><a href="https://doi.org/10.1016/j.ijbiomac.2021.06.123" title="DOI URL">https://doi.org/10.1016/j.ijbiomac.2021.06.123</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ijbiomac.2021.06.123&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ijbiomac.2021.06.123%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Biological%2520Macromolecules%26atitle%3DA%252Bcomprehensive%252Bsurvey%252Bupon%252Bdiverse%252Band%252Bprolific%252Bapplications%252Bof%252Bchitosan-based%252Bcatalytic%252Bsystems%252Bin%252Bone-pot%252Bmulti-component%252Bsynthesis%252Bof%252Bheterocyclic%252Brings%26aulast%3DMousavi%26aufirst%3DHossein%26date%3D2021%26volume%3D57" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lu  Lu</span>, <span class="hlFld-ContribAuthor ">Shan  Su</span>, <span class="hlFld-ContribAuthor ">Haitao  Yang</span>, <span class="hlFld-ContribAuthor ">Shibo  Jiang</span>. </span><span class="cited-content_cbyCitation_article-title">Antivirals with common targets against highly pathogenic viruses. </span><span class="cited-content_cbyCitation_journal-name">Cell</span><span> <strong>2021,</strong> <em>184 </em>
                                    (6)
                                     , 1604-1620. <a href="https://doi.org/10.1016/j.cell.2021.02.013" title="DOI URL">https://doi.org/10.1016/j.cell.2021.02.013</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.cell.2021.02.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.cell.2021.02.013%26sid%3Dliteratum%253Aachs%26jtitle%3DCell%26atitle%3DAntivirals%252Bwith%252Bcommon%252Btargets%252Bagainst%252Bhighly%252Bpathogenic%252Bviruses%26aulast%3DLu%26aufirst%3DLu%26date%3D2021%26volume%3D184%26issue%3D6%26spage%3D1604%26epage%3D1620" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Francesca  Curreli</span>, <span class="hlFld-ContribAuthor ">Shahad  Ahmed</span>, <span class="hlFld-ContribAuthor ">Sofia M.  Benedict Victor</span>, <span class="hlFld-ContribAuthor ">Ildar R.  Iusupov</span>, <span class="hlFld-ContribAuthor ">Evgeny A.  Spiridonov</span>, <span class="hlFld-ContribAuthor ">Dmitry S.  Belov</span>, <span class="hlFld-ContribAuthor ">Andrea  Altieri</span>, <span class="hlFld-ContribAuthor ">Alexander V.  Kurkin</span>, <span class="hlFld-ContribAuthor ">Asim K.  Debnath</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis, and antiviral activity of a series of CD4-mimetic small-molecule HIV-1 entry inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2021,</strong> <em>32 </em>, 116000. <a href="https://doi.org/10.1016/j.bmc.2021.116000" title="DOI URL">https://doi.org/10.1016/j.bmc.2021.116000</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2021.116000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2021.116000%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%25252C%252Band%252Bantiviral%252Bactivity%252Bof%252Ba%252Bseries%252Bof%252BCD4-mimetic%252Bsmall-molecule%252BHIV-1%252Bentry%252Binhibitors%26aulast%3DCurreli%26aufirst%3DFrancesca%26date%3D2021%26volume%3D32%26spage%3D116000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b02149/20200221/images/medium/jm9b02149_0012.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b02149/20200221/images/large/jm9b02149_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02149&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b02149/20200221/images/medium/jm9b02149_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b02149/20200221/images/large/jm9b02149_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Chronology of improvement of anti-HIV-1 activity (IC<sub>50</sub> against HIV-1HXB2) and SI.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b02149/20200221/images/large/jm9b02149_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02149&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b02149/20200221/images/medium/jm9b02149_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b02149/20200221/images/large/jm9b02149_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Intermediate Acids</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b02149/20200221/images/large/jm9b02149_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02149&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b02149/20200221/images/medium/jm9b02149_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b02149/20200221/images/large/jm9b02149_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of 5-(2-Methoxypyridin-4-yl)-1<i>H</i>-pyrrole-2-carboxylic Acid</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b02149/20200221/images/large/jm9b02149_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02149&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b02149/20200221/images/medium/jm9b02149_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b02149/20200221/images/large/jm9b02149_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of 5-(5-Substituted-2-yl)-3-methyl-1<i>H</i>-pyrrole-2-carboxylic Acid and Na Salt<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b02149/20200221/images/large/jm9b02149_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02149&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Asterisk (*) indicates acidification step performed only for <b>S16</b>.</p></p></figure><figure data-id="sch4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b02149/20200221/images/medium/jm9b02149_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b02149/20200221/images/large/jm9b02149_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of Allyl Allyl(2-amino-2-(4-(2-((<i>tert</i>-Butyldiphenylsilyl)oxy)-1-hydroxyethyl)thiazol-2-yl)ethyl)carbamate (<b>S23 fS</b> and <b>S23 fR</b>)<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b02149/20200221/images/large/jm9b02149_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02149&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Note all enantiomer compounds derived from the stereo-controlled addition of the allyl <i>N</i>-allyl-<i>N</i>-[(2<i>E</i>)-2-<i>tert</i>-butylsulfinyliminoethyl]carbamate with absolute configuration <i>S</i>, were specified with the <b>fS</b> descriptor, and all enantiomer compounds derived from the stereo-controlled addition of the allyl <i>N</i>-allyl-<i>N</i>-[(2<i>E</i>)-2-<i>tert</i>-butylsulfinyliminoethyl]carbamate with the absolute configuration <i>R</i> have been specified with the <b>fR</b> descriptor as per previous works.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a></p></p></figure><figure data-id="sch5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b02149/20200221/images/medium/jm9b02149_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b02149/20200221/images/large/jm9b02149_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of Allyl <i>N</i>-Allyl-<i>N</i>-[2-amino-2-[4-[2-[<i>tert</i>-butyl(diphenyl)silyl]oxy-1-hydroxy-ethyl]thiazol-2-yl]ethyl]carbamate (<b>S32 fR</b> and <b>S32 fS</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b02149/20200221/images/large/jm9b02149_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02149&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b02149/20200221/images/medium/jm9b02149_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b02149/20200221/images/large/jm9b02149_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Synthesis of <i>tert</i>-Butyl (2-amino-2-(4-(((<i>tert</i>-butyldimethylsilyl)oxy)methyl)thiazol-2-yl)propyl)carbamate (<b>S37</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b02149/20200221/images/large/jm9b02149_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02149&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch7" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b02149/20200221/images/medium/jm9b02149_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b02149/20200221/images/large/jm9b02149_0009.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 7. Synthesis of HIV-1 Inhibitors 1-48 in Table 1</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b02149/20200221/images/large/jm9b02149_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02149&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b02149/20200221/images/medium/jm9b02149_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b02149/20200221/images/large/jm9b02149_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Infectivity of Cf2Th–CCR5 cells by CD4-dependent HIV-1<sub>ADA</sub>. Cf2Th–CCR5 cells were infected with CD4-dependent HIV-1<sub>ADA</sub> in the presence of <b>8</b> and <b>33</b>. NBD-556 was used as a control. The relative virus infectivity designates the ratio of the amount of infection detected in the presence of the compounds and the amount of infection detected in the absence of the compounds. Three independent experiments were performed in triplicate, and the graph is representative of one experiment. The toxicity of the compounds against these cells was evaluated to calculate the CC<sub>50</sub> values: for NBD-556 the CC<sub>50</sub> was greater than 60; for <b>8</b> and <b>33</b> it was greater than 47. All the values represent the mean ± standard deviation.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b02149/20200221/images/large/jm9b02149_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02149&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i358">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_01756" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_01756" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 67 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Berger, E. A.</span></span> <span> </span><span class="NLM_article-title">HIV entry and tropism. When one receptor is not enough</span>. <i>Adv. Exp. Med. Biol.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>452</i></span>,  <span class="NLM_fpage">151</span>– <span class="NLM_lpage">157</span>, <span class="refDoi"> DOI: 10.1007/978-1-4615-5355-7_16</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=10.1007%2F978-1-4615-5355-7_16" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=9889968" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=1%3ACAS%3A528%3ADyaK1cXotVGqsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=452&publication_year=1998&pages=151-157&author=E.+A.+Berger&title=HIV+entry+and+tropism.+When+one+receptor+is+not+enough&doi=10.1007%2F978-1-4615-5355-7_16"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">HIV entry and tropism: when one receptor is not enough</span></div><div class="casAuthors">Berger, Edward A.</div><div class="citationInfo"><span class="NLM_cas:title">Advances in Experimental Medicine and Biology</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">452</span>
        (<span class="NLM_cas:issue">Mechanisms of Lymphocyte Activation and Immune Regulation VII</span>),
    <span class="NLM_cas:pages">151-157</span>CODEN:
                <span class="NLM_cas:coden">AEMBAP</span>;
        ISSN:<span class="NLM_cas:issn">0065-2598</span>.
    
            (<span class="NLM_cas:orgname">Plenum Publishing Corp.</span>)
        </div><div class="casAbstract">A review with 39 refs.  Topics discussed include evidence for the existence of HIV coreceptors; CXCR4; CCR5; and mode of action of coreceptors in the fusion/infection process.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFFgDELx7MJ7Vg90H21EOLACvtfcHk0lhV9r9B6RPADg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXotVGqsLs%253D&md5=088234e35f5fead82bc7262f18dbb2d0</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1007%2F978-1-4615-5355-7_16&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-1-4615-5355-7_16%26sid%3Dliteratum%253Aachs%26aulast%3DBerger%26aufirst%3DE.%2BA.%26atitle%3DHIV%2520entry%2520and%2520tropism.%2520When%2520one%2520receptor%2520is%2520not%2520enough%26jtitle%3DAdv.%2520Exp.%2520Med.%2520Biol.%26date%3D1998%26volume%3D452%26spage%3D151%26epage%3D157%26doi%3D10.1007%2F978-1-4615-5355-7_16" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blair, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meanwell, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallace, O. B.</span></span> <span> </span><span class="NLM_article-title">HIV-1 entry - an expanding portal for drug discovery</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">183</span>– <span class="NLM_lpage">194</span>, <span class="refDoi"> DOI: 10.1016/S1359-6446(00)01484-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=10.1016%2FS1359-6446%2800%2901484-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=10790262" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=1%3ACAS%3A528%3ADC%252BD3cXislehu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2000&pages=183-194&author=W.+S.+Blairauthor=P.+F.+Linauthor=N.+A.+Meanwellauthor=O.+B.+Wallace&title=HIV-1+entry+-+an+expanding+portal+for+drug+discovery&doi=10.1016%2FS1359-6446%2800%2901484-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">HIV-1 entry - an expanding portal for drug discovery</span></div><div class="casAuthors">Blair, W. S.; Lin, P.-F.; Meanwell, N. A.; Wallace, O. B.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">183-194</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review and discussion with 66 refs.  The advent of highly active antiretroviral therapy (HAART)-combinations of protease and reverse transcriptase inhibitors-provided a potent and clin. effective method of suppressing viral load in HIV-1- infected individuals.  However, although initially successful, a broader clin. experience has revealed limitations in this therapeutic regimen, with up to 40% of treated individuals ultimately failing to sustain control over viral replication.  Significant advances in understanding the process by which HIV-1 enters host cells have brought into clear focus a target for drug discovery not represented in the current clin. armamentarium.  In this article, the mechanism of HIV-1 entry is reviewed in the context of representative antiviral agents that interfere with key steps in this process.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRY3TNUX-AuLVg90H21EOLACvtfcHk0lhV9r9B6RPADg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXislehu7c%253D&md5=c9323fe99bf289a476ff06597d97ffac</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2FS1359-6446%2800%2901484-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1359-6446%252800%252901484-7%26sid%3Dliteratum%253Aachs%26aulast%3DBlair%26aufirst%3DW.%2BS.%26aulast%3DLin%26aufirst%3DP.%2BF.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DWallace%26aufirst%3DO.%2BB.%26atitle%3DHIV-1%2520entry%2520-%2520an%2520expanding%2520portal%2520for%2520drug%2520discovery%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2000%26volume%3D5%26spage%3D183%26epage%3D194%26doi%3D10.1016%2FS1359-6446%2800%2901484-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Caffrey, M.</span></span> <span> </span><span class="NLM_article-title">HIV envelope: challenges and opportunities for development of entry inhibitors</span>. <i>Trends Microbiol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">191</span>– <span class="NLM_lpage">197</span>, <span class="refDoi"> DOI: 10.1016/j.tim.2011.02.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=10.1016%2Fj.tim.2011.02.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=21377881" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=1%3ACAS%3A528%3ADC%252BC3MXkt1KhtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2011&pages=191-197&author=M.+Caffrey&title=HIV+envelope%3A+challenges+and+opportunities+for+development+of+entry+inhibitors&doi=10.1016%2Fj.tim.2011.02.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">HIV envelope: challenges and opportunities for development of entry inhibitors</span></div><div class="casAuthors">Caffrey, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Microbiology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">191-197</span>CODEN:
                <span class="NLM_cas:coden">TRMIEA</span>;
        ISSN:<span class="NLM_cas:issn">0966-842X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The HIV envelope proteins glycoprotein 120 (gp120) and glycoprotein 41 (gp41) play crucial roles in HIV entry, therefore they are of extreme interest in the development of novel therapeutics.  Studies using diverse methods, including structural biol. and mutagenesis, have resulted in a detailed model for envelope-mediated entry, which consists of multiple conformations, each a potential target for therapeutic intervention.  In this review, the challenges, strategies and progress to date for developing novel entry inhibitors directed at disrupting HIV gp120 and gp41 function are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhU7id80YXh7Vg90H21EOLACvtfcHk0lhV36JTrIcpIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXkt1KhtLs%253D&md5=1baeddf2495b214487488d3827095b27</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2Fj.tim.2011.02.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tim.2011.02.001%26sid%3Dliteratum%253Aachs%26aulast%3DCaffrey%26aufirst%3DM.%26atitle%3DHIV%2520envelope%253A%2520challenges%2520and%2520opportunities%2520for%2520development%2520of%2520entry%2520inhibitors%26jtitle%3DTrends%2520Microbiol.%26date%3D2011%26volume%3D19%26spage%3D191%26epage%3D197%26doi%3D10.1016%2Fj.tim.2011.02.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chan, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, P. S.</span></span> <span> </span><span class="NLM_article-title">HIV entry and its inhibition</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>93</i></span>,  <span class="NLM_fpage">681</span>– <span class="NLM_lpage">684</span>, <span class="refDoi"> DOI: 10.1016/S0092-8674(00)81430-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=10.1016%2FS0092-8674%2800%2981430-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=9630213" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=1%3ACAS%3A528%3ADyaK1cXjsl2ksLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=1998&pages=681-684&author=D.+C.+Chanauthor=P.+S.+Kim&title=HIV+entry+and+its+inhibition&doi=10.1016%2FS0092-8674%2800%2981430-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">HIV entry and its inhibition</span></div><div class="casAuthors">Chan, David C.; Kim, Peter S.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, Massachusetts)</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">681-684</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review with 22 refs. on recent insights in HIV envelope protein structure and function and the current understanding of the viral entry process.  The authors also reviewed how these finding lead to new approaches for inhibiting HIV entry and may provide insights into the design of better HIV vaccines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeFZy87GmmlrVg90H21EOLACvtfcHk0lhV36JTrIcpIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXjsl2ksLs%253D&md5=dc7d38422e8c901b2804d79a3c224f9d</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2800%2981430-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252800%252981430-0%26sid%3Dliteratum%253Aachs%26aulast%3DChan%26aufirst%3DD.%2BC.%26aulast%3DKim%26aufirst%3DP.%2BS.%26atitle%3DHIV%2520entry%2520and%2520its%2520inhibition%26jtitle%3DCell%26date%3D1998%26volume%3D93%26spage%3D681%26epage%3D684%26doi%3D10.1016%2FS0092-8674%2800%2981430-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kadow, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ueda, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meanwell, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connolly, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeung, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bender, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colonno, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathew, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chien, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grasela, D.</span></span> <span> </span><span class="NLM_article-title">Inhibitors of human immunodeficiency virus type 1 (HIV-1) attachment 6. Preclinical and human pharmacokinetic profiling of BMS-663749, a phosphonooxymethyl prodrug of the HIV-1 attachment inhibitor 2-(4-benzoyl-1-piperazinyl)-1-(4,7-dimethoxy-1H-pyrrolo[2,3-c]pyridin-3-yl)-2-oxo ethanone (BMS-488043)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">2048</span>– <span class="NLM_lpage">2056</span>, <span class="refDoi"> DOI: 10.1021/jm201218m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm201218m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=1%3ACAS%3A528%3ADC%252BC38XislSksbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=2048-2056&author=J.+F.+Kadowauthor=Y.+Uedaauthor=N.+A.+Meanwellauthor=T.+P.+Connollyauthor=T.+Wangauthor=C.+P.+Chenauthor=K.+S.+Yeungauthor=J.+Zhuauthor=J.+A.+Benderauthor=Z.+Yangauthor=D.+Parkerauthor=P.+F.+Linauthor=R.+J.+Colonnoauthor=M.+Mathewauthor=D.+Morganauthor=M.+Zhengauthor=C.+Chienauthor=D.+Grasela&title=Inhibitors+of+human+immunodeficiency+virus+type+1+%28HIV-1%29+attachment+6.+Preclinical+and+human+pharmacokinetic+profiling+of+BMS-663749%2C+a+phosphonooxymethyl+prodrug+of+the+HIV-1+attachment+inhibitor+2-%284-benzoyl-1-piperazinyl%29-1-%284%2C7-dimethoxy-1H-pyrrolo%5B2%2C3-c%5Dpyridin-3-yl%29-2-oxo+ethanone+%28BMS-488043%29&doi=10.1021%2Fjm201218m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitors of Human Immunodeficiency Virus Type 1 (HIV-1) Attachment 6. Preclinical and Human Pharmacokinetic Profiling of BMS-663749, a Phosphonooxymethyl Prodrug of the HIV-1 Attachment Inhibitor 2-(4-Benzoyl-1-piperazinyl)-1-(4,7-dimethoxy-1H-pyrrolo[2,3-c]pyridin-3-yl)-2-oxoethanone (BMS-488043)</span></div><div class="casAuthors">Kadow, John F.; Ueda, Yasutsugu; Meanwell, Nicholas A.; Connolly, Timothy P.; Wang, Tao; Chen, Chung-Pin; Yeung, Kap-Sun; Zhu, Juliang; Bender, John A.; Yang, Zhong; Parker, Dawn; Lin, Pin-Fang; Colonno, Richard J.; Mathew, Marina; Morgan, Daniel; Zheng, Ming; Chien, Caly; Grasela, Dennis</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2048-2056</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">BMS-663749, a phosphonooxymethyl prodrug of the HIV-1 attachment inhibitor 2-(4-benzoyl-1-piperazinyl)-1-(4,7-dimethoxy-1H-pyrrolo[2,3-c]pyridin-3-yl)-2-oxoethanone (BMS-488043) was prepd. and profiled in a variety of preclin. in vitro and in vivo models designed to assess its ability to deliver parent drug following oral administration.  The data showed that prodrug BMS-663749 had excellent potential to significantly reduce dissoln. rate-limited absorption following oral dosing in humans.  Clin. studies in normal healthy subjects confirmed the potential of BMS-663749, revealing that the prodrug significantly increased both the AUC and Cmax of BMS-488043 compared to a solid capsule formulation contg. the parent drug upon dose escalation.  These data provided guidance for further efforts to obtain an effective HIV-1 attachment inhibitor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGquRUP4I30EK7Vg90H21EOLACvtfcHk0lhV36JTrIcpIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XislSksbs%253D&md5=bcc45742e8dcab5fcfd595c94e0951e8</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1021%2Fjm201218m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201218m%26sid%3Dliteratum%253Aachs%26aulast%3DKadow%26aufirst%3DJ.%2BF.%26aulast%3DUeda%26aufirst%3DY.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DConnolly%26aufirst%3DT.%2BP.%26aulast%3DWang%26aufirst%3DT.%26aulast%3DChen%26aufirst%3DC.%2BP.%26aulast%3DYeung%26aufirst%3DK.%2BS.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DBender%26aufirst%3DJ.%2BA.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DParker%26aufirst%3DD.%26aulast%3DLin%26aufirst%3DP.%2BF.%26aulast%3DColonno%26aufirst%3DR.%2BJ.%26aulast%3DMathew%26aufirst%3DM.%26aulast%3DMorgan%26aufirst%3DD.%26aulast%3DZheng%26aufirst%3DM.%26aulast%3DChien%26aufirst%3DC.%26aulast%3DGrasela%26aufirst%3DD.%26atitle%3DInhibitors%2520of%2520human%2520immunodeficiency%2520virus%2520type%25201%2520%2528HIV-1%2529%2520attachment%25206.%2520Preclinical%2520and%2520human%2520pharmacokinetic%2520profiling%2520of%2520BMS-663749%252C%2520a%2520phosphonooxymethyl%2520prodrug%2520of%2520the%2520HIV-1%2520attachment%2520inhibitor%25202-%25284-benzoyl-1-piperazinyl%2529-1-%25284%252C7-dimethoxy-1H-pyrrolo%255B2%252C3-c%255Dpyridin-3-yl%2529-2-oxo%2520ethanone%2520%2528BMS-488043%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D2048%26epage%3D2056%26doi%3D10.1021%2Fjm201218m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nowicka-Sans, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, Y. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McAuliffe, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dicker, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, H. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eggers, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ray, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wind-Rotolo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Majumdar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stock, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lataillade, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanna, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matiskella, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ueda, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kadow, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meanwell, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krystal, M.</span></span> <span> </span><span class="NLM_article-title">In vitro antiviral characteristics of HIV-1 attachment inhibitor BMS-626529, the active component of the prodrug BMS-663068</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">3498</span>– <span class="NLM_lpage">3507</span>, <span class="refDoi"> DOI: 10.1128/AAC.00426-12</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=10.1128%2FAAC.00426-12" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=22547625" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=1%3ACAS%3A528%3ADC%252BC38XpsV2ju74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2012&pages=3498-3507&author=B.+Nowicka-Sansauthor=Y.+F.+Gongauthor=B.+McAuliffeauthor=I.+Dickerauthor=H.+T.+Hoauthor=N.+Zhouauthor=B.+Eggersauthor=P.+F.+Linauthor=N.+Rayauthor=M.+Wind-Rotoloauthor=L.+Zhuauthor=A.+Majumdarauthor=D.+Stockauthor=M.+Latailladeauthor=G.+J.+Hannaauthor=J.+D.+Matiskellaauthor=Y.+Uedaauthor=T.+Wangauthor=J.+F.+Kadowauthor=N.+A.+Meanwellauthor=M.+Krystal&title=In+vitro+antiviral+characteristics+of+HIV-1+attachment+inhibitor+BMS-626529%2C+the+active+component+of+the+prodrug+BMS-663068&doi=10.1128%2FAAC.00426-12"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro antiviral characteristics of HIV-1 attachment inhibitor BMS-626529, the active component of the prodrug BMS-663068</span></div><div class="casAuthors">Nowicka-Sans, Beata; Gong, Yi-Fei; McAuliffe, Brian; Dicker, Ira; Ho, Hsu-Tso; Zhou, Nannan; Eggers, Betsy; Lin, Pin-Fang; Ray, Neelanjana; Wind-Rotolo, Megan; Zhu, Li; Majumdar, Antara; Stock, David; Lataillade, Max; Hanna, George J.; Matiskella, John D.; Ueda, Yasutsugu; Wang, Tao; Kadow, John F.; Meanwell, Nicholas A.; Krystal, Mark</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3498-3507</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">BMS-663068 is the phosphonooxymethyl prodrug of BMS-626529, a novel small-mol. attachment inhibitor that targets HIV-1 gp120 and prevents its binding to CD4+ T cells.  The activity of BMS-626529 is virus dependent, due to heterogeneity within gp120.  In order to better understand the anti-HIV-1 spectrum of BMS-626529 against HIV-1, in vitro activities against a wide variety of lab. strains and clin. isolates were detd.  BMS-626529 had half-maximal effective concn. (EC50) values of <10 nM against the vast majority of viral isolates; however, susceptibility varied by >6 log10, with half-maximal effective concn. values in the low pM range against the most susceptible viruses.  The in vitro antiviral activity of BMS-626529 was generally not assocd. with either tropism or subtype, with few exceptions.  Measurement of the binding affinity of BMS-626529 for purified gp120 suggests that a contributory factor to its inhibitory potency may be a relatively long dissociative half-life.  Finally, in two-drug combination studies, BMS-626529 demonstrated additive or synergistic interactions with antiretroviral drugs of different mechanistic classes.  These results suggest that BMS-626529 should be active against the majority of HIV-1 viruses and support the continued clin. development of the compd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTOoFBxJXxT7Vg90H21EOLACvtfcHk0ljg1GQUat82Bw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XpsV2ju74%253D&md5=85a1eb4a32a558f9cfeae31c9968073e</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1128%2FAAC.00426-12&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.00426-12%26sid%3Dliteratum%253Aachs%26aulast%3DNowicka-Sans%26aufirst%3DB.%26aulast%3DGong%26aufirst%3DY.%2BF.%26aulast%3DMcAuliffe%26aufirst%3DB.%26aulast%3DDicker%26aufirst%3DI.%26aulast%3DHo%26aufirst%3DH.%2BT.%26aulast%3DZhou%26aufirst%3DN.%26aulast%3DEggers%26aufirst%3DB.%26aulast%3DLin%26aufirst%3DP.%2BF.%26aulast%3DRay%26aufirst%3DN.%26aulast%3DWind-Rotolo%26aufirst%3DM.%26aulast%3DZhu%26aufirst%3DL.%26aulast%3DMajumdar%26aufirst%3DA.%26aulast%3DStock%26aufirst%3DD.%26aulast%3DLataillade%26aufirst%3DM.%26aulast%3DHanna%26aufirst%3DG.%2BJ.%26aulast%3DMatiskella%26aufirst%3DJ.%2BD.%26aulast%3DUeda%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DT.%26aulast%3DKadow%26aufirst%3DJ.%2BF.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DKrystal%26aufirst%3DM.%26atitle%3DIn%2520vitro%2520antiviral%2520characteristics%2520of%2520HIV-1%2520attachment%2520inhibitor%2520BMS-626529%252C%2520the%2520active%2520component%2520of%2520the%2520prodrug%2520BMS-663068%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2012%26volume%3D56%26spage%3D3498%26epage%3D3507%26doi%3D10.1128%2FAAC.00426-12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallace, O. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deshpande, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zadjura, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tweedie, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ranadive, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, Y. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ricarrdi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spicer, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deminie, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rose, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blair, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, P. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colonno, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meanwell, N. A.</span></span> <span> </span><span class="NLM_article-title">Discovery of 4-benzoyl-1-[(4-methoxy-1H- pyrrolo[2,3-b]pyridin-3-yl)oxoacetyl]-2- (R)-methylpiperazine (BMS-378806): a novel HIV-1 attachment inhibitor that interferes with CD4-gp120 interactions</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">4236</span>– <span class="NLM_lpage">4239</span>, <span class="refDoi"> DOI: 10.1021/jm034082o</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm034082o" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=1%3ACAS%3A528%3ADC%252BD3sXmsl2nt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=4236-4239&author=T.+Wangauthor=Z.+Zhangauthor=O.+B.+Wallaceauthor=M.+Deshpandeauthor=H.+Fangauthor=Z.+Yangauthor=L.+M.+Zadjuraauthor=D.+L.+Tweedieauthor=S.+Huangauthor=F.+Zhaoauthor=S.+Ranadiveauthor=B.+S.+Robinsonauthor=Y.+F.+Gongauthor=K.+Ricarrdiauthor=T.+P.+Spicerauthor=C.+Deminieauthor=R.+Roseauthor=H.+G.+Wangauthor=W.+S.+Blairauthor=P.+Y.+Shiauthor=P.+F.+Linauthor=R.+J.+Colonnoauthor=N.+A.+Meanwell&title=Discovery+of+4-benzoyl-1-%5B%284-methoxy-1H-+pyrrolo%5B2%2C3-b%5Dpyridin-3-yl%29oxoacetyl%5D-2-+%28R%29-methylpiperazine+%28BMS-378806%29%3A+a+novel+HIV-1+attachment+inhibitor+that+interferes+with+CD4-gp120+interactions&doi=10.1021%2Fjm034082o"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 4-benzoyl-1-[(4-methoxy-1H- pyrrolo[2,3-b]pyridin-3-yl)oxoacetyl]-2- (R)-methylpiperazine (BMS-378806): A Novel HIV-1 Attachment Inhibitor That Interferes with CD4-gp120 Interactions</span></div><div class="casAuthors">Wang, Tao; Zhang, Zhongxing; Wallace, Owen B.; Deshpande, Milind; Fang, Haiquan; Yang, Zheng; Zadjura, Lisa M.; Tweedie, Donald L.; Huang, Stella; Zhao, Fang; Ranadive, Sunanda; Robinson, Brett S.; Gong, Yi-Fei; Ricarrdi, Keith; Spicer, Timothy P.; Deminie, Carol; Rose, Ronald; Wang, Hwei-Gene Heidi; Blair, Wade S.; Shi, Pei-Yong; Lin, Pin-fang; Colonno, Richard J.; Meanwell, Nicholas A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">4236-4239</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Indole deriv. 1 interferes with the interaction of the HIV surface protein gp120 with the host cell receptor CD4.  The 4-fluoro deriv. 2 exhibited markedly enhanced potency and was bioavailable in the rat, dog, and cynomolgus monkey when administered orally as a soln. formulation.  However, aq. suspensions of 2 were poorly bioavailable, indicative of dissoln.-limited absorption.  The 7-azaindole deriv. 3, BMS-378806, exhibited improved pharmaceutical properties while retaining the HIV-1 inhibitory profile of 2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdBR3IszWDCbVg90H21EOLACvtfcHk0ljg1GQUat82Bw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXmsl2nt7w%253D&md5=bd3d210677181d1748c8f8ba309c37bb</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1021%2Fjm034082o&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm034082o%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DWallace%26aufirst%3DO.%2BB.%26aulast%3DDeshpande%26aufirst%3DM.%26aulast%3DFang%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DZadjura%26aufirst%3DL.%2BM.%26aulast%3DTweedie%26aufirst%3DD.%2BL.%26aulast%3DHuang%26aufirst%3DS.%26aulast%3DZhao%26aufirst%3DF.%26aulast%3DRanadive%26aufirst%3DS.%26aulast%3DRobinson%26aufirst%3DB.%2BS.%26aulast%3DGong%26aufirst%3DY.%2BF.%26aulast%3DRicarrdi%26aufirst%3DK.%26aulast%3DSpicer%26aufirst%3DT.%2BP.%26aulast%3DDeminie%26aufirst%3DC.%26aulast%3DRose%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DH.%2BG.%26aulast%3DBlair%26aufirst%3DW.%2BS.%26aulast%3DShi%26aufirst%3DP.%2BY.%26aulast%3DLin%26aufirst%3DP.%2BF.%26aulast%3DColonno%26aufirst%3DR.%2BJ.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26atitle%3DDiscovery%2520of%25204-benzoyl-1-%255B%25284-methoxy-1H-%2520pyrrolo%255B2%252C3-b%255Dpyridin-3-yl%2529oxoacetyl%255D-2-%2520%2528R%2529-methylpiperazine%2520%2528BMS-378806%2529%253A%2520a%2520novel%2520HIV-1%2520attachment%2520inhibitor%2520that%2520interferes%2520with%2520CD4-gp120%2520interactions%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26spage%3D4236%26epage%3D4239%26doi%3D10.1021%2Fjm034082o" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Belov, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curreli, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurkin, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altieri, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Debnath, A. K.</span></span> <span> </span><span class="NLM_article-title">Guanidine-containing phenyl-pyrrole compounds as probes for generating HIV nntry inhibitors targeted to gp120</span>. <i>ChemistrySelect</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">6450</span>– <span class="NLM_lpage">6453</span>, <span class="refDoi"> DOI: 10.1002/slct.201801662</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=10.1002%2Fslct.201801662" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtF2ls7fE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2018&pages=6450-6453&author=D.+S.+Belovauthor=F.+Curreliauthor=A.+V.+Kurkinauthor=A.+Altieriauthor=A.+K.+Debnath&title=Guanidine-containing+phenyl-pyrrole+compounds+as+probes+for+generating+HIV+nntry+inhibitors+targeted+to+gp120&doi=10.1002%2Fslct.201801662"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Guanidine-Containing Phenyl-Pyrrole Compounds as Probes for Generating HIV Entry Inhibitors Targeted to gp120</span></div><div class="casAuthors">Belov, Dmitry S.; Curreli, Francesca; Kurkin, Alexander V.; Altieri, Andrea; Debnath, Asim K.</div><div class="citationInfo"><span class="NLM_cas:title">ChemistrySelect</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">6450-6453</span>CODEN:
                <span class="NLM_cas:coden">CHEMUD</span>;
        ISSN:<span class="NLM_cas:issn">2365-6549</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Asp368 in the HIV-1 envelope glycoprotein gp120 plays a crit. role in binding to the Arg59 of the primary cellular receptor CD4 through forming a salt-bridge to initiate HIV-1 entry and infection.  The mols. capable of interfering with the entry of virus to host cells are termed HIV-1 entry/attachment inhibitors.  Earlier, we designed N-(2-amino-1-(5-(hydroxymethyl)-4-methylthiazol-2-yl)ethyl)-5-(4-chloro-3-fluorophenyl)-1H-pyrrole-2-carboxamide series compds. as entry inhibitors targeted to HIV-1 gp120.  Here, we report the incorporation of guanidine moiety to replace free amine in some of those HIV-1 entry inhibitors.  Guanidine group is expected to simulate Arg59 and interact with Asp368 of the gp120 to form salt-bridge and thus blocking the binding of HIV-1 with the cell receptor CD4.  The resulting compds. were tested against Env-pseudotyped HIV-1, and few of them showed low μM inhibition.  The guanidines also showed higher aq. soly. than compds. with a free amine.  One of the guanidines, N-(2-(2-guanidinoacetamido)-1-(4-(hydroxymethyl)thiazol-2-yl)ethyl)-5-(4-(trifluoromethyl)phenyl)-1H-pyrrole-2-carboxamide (10), is expected to be a lead for further optimization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9MMlNN_OZ1rVg90H21EOLACvtfcHk0lih0Iu1ZGMJRA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtF2ls7fE&md5=80487a6dd17b1e8ee6feb1f85dbbe069</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1002%2Fslct.201801662&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fslct.201801662%26sid%3Dliteratum%253Aachs%26aulast%3DBelov%26aufirst%3DD.%2BS.%26aulast%3DCurreli%26aufirst%3DF.%26aulast%3DKurkin%26aufirst%3DA.%2BV.%26aulast%3DAltieri%26aufirst%3DA.%26aulast%3DDebnath%26aufirst%3DA.%2BK.%26atitle%3DGuanidine-containing%2520phenyl-pyrrole%2520compounds%2520as%2520probes%2520for%2520generating%2520HIV%2520nntry%2520inhibitors%2520targeted%2520to%2520gp120%26jtitle%3DChemistrySelect%26date%3D2018%26volume%3D3%26spage%3D6450%26epage%3D6453%26doi%3D10.1002%2Fslct.201801662" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Curreli, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, Y. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belov, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramesh, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurkin, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altieri, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwong, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Debnath, A. K.</span></span> <span> </span><span class="NLM_article-title">Synthesis, antiviral potency, in vitro ADMET and X-ray structure of potent CD4-mimics as entry inhibitors that target the Phe43 cavity of HIV-1 gp120</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">3124</span>– <span class="NLM_lpage">3153</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00179</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00179" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjvVOnsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=3124-3153&author=F.+Curreliauthor=Y.+D.+Kwonauthor=D.+S.+Belovauthor=R.+R.+Rameshauthor=A.+V.+Kurkinauthor=A.+Altieriauthor=P.+D.+Kwongauthor=A.+K.+Debnath&title=Synthesis%2C+antiviral+potency%2C+in+vitro+ADMET+and+X-ray+structure+of+potent+CD4-mimics+as+entry+inhibitors+that+target+the+Phe43+cavity+of+HIV-1+gp120&doi=10.1021%2Facs.jmedchem.7b00179"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, Antiviral Potency, in Vitro ADMET, and X-ray Structure of Potent CD4 Mimics as Entry Inhibitors That Target the Phe43 Cavity of HIV-1 gp120</span></div><div class="casAuthors">Curreli, Francesca; Kwon, Young Do; Belov, Dmitry S.; Ramesh, Ranjith R.; Kurkin, Alexander V.; Altieri, Andrea; Kwong, Peter D.; Debnath, Asim K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3124-3153</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In our attempt to optimize the lead HIV-1 entry antagonist, NBD-11021, we present in this study the rational design and synthesis of 60 new analogs and detn. of their antiviral activity in a single-cycle and a multicycle infection assay to derive a comprehensive structure-activity relationship (SAR).  Two of these compds., I and II, showed significant improvement in antiviral activity compared to the lead entry antagonist in a single-cycle assay against a large panel of Env-pseudotyped viruses.  The X-ray structure of a similar compd., NBD-14010, confirmed the binding mode of the newly designed compds.  The in vitro ADMET profiles of these compds. are comparable to that of the most potent attachment inhibitor BMS-626529, a prodrug of which is currently undergoing phase III clin. trials.  The systematic study presented here is expected to pave the way for improving the potency, toxicity, and ADMET profile of this series of compds. with the potential to be moved to the early preclin. development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrF4GuoyULRebVg90H21EOLACvtfcHk0lih0Iu1ZGMJRA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjvVOnsbY%253D&md5=af68fad9120d8dfd31e26f4607b523d9</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00179&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00179%26sid%3Dliteratum%253Aachs%26aulast%3DCurreli%26aufirst%3DF.%26aulast%3DKwon%26aufirst%3DY.%2BD.%26aulast%3DBelov%26aufirst%3DD.%2BS.%26aulast%3DRamesh%26aufirst%3DR.%2BR.%26aulast%3DKurkin%26aufirst%3DA.%2BV.%26aulast%3DAltieri%26aufirst%3DA.%26aulast%3DKwong%26aufirst%3DP.%2BD.%26aulast%3DDebnath%26aufirst%3DA.%2BK.%26atitle%3DSynthesis%252C%2520antiviral%2520potency%252C%2520in%2520vitro%2520ADMET%2520and%2520X-ray%2520structure%2520of%2520potent%2520CD4-mimics%2520as%2520entry%2520inhibitors%2520that%2520target%2520the%2520Phe43%2520cavity%2520of%2520HIV-1%2520gp120%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D3124%26epage%3D3153%26doi%3D10.1021%2Facs.jmedchem.7b00179" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Curreli, F. B. D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, Y. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramesh, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furimsky, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Loughlin, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byrge, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iyer, L. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mirsalis, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurkin, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altieri, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Debnath, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belov, D. S.</span></span> <span> </span><span class="NLM_article-title">Structure-based lead optimization to improve antiviral potency and ADMET properties of phenyl-1H-pyrrole-carboxamide entry inhibitors targeted to HIV-1 gp120</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>154</i></span>,  <span class="NLM_fpage">367</span>– <span class="NLM_lpage">391</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.04.062</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=10.1016%2Fj.ejmech.2018.04.062" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=29860061" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVKrsbbF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=154&publication_year=2018&pages=367-391&author=F.+B.+D.+S.+Curreliauthor=Y.+D.+Kwonauthor=R.+Rameshauthor=A.+M.+Furimskyauthor=K.+O%E2%80%99Loughlinauthor=P.+C.+Byrgeauthor=L.+V.+Iyerauthor=J.+C.+Mirsalisauthor=A.+V.+Kurkinauthor=A.+Altieriauthor=A.+K.+Debnathauthor=D.+S.+Belov&title=Structure-based+lead+optimization+to+improve+antiviral+potency+and+ADMET+properties+of+phenyl-1H-pyrrole-carboxamide+entry+inhibitors+targeted+to+HIV-1+gp120&doi=10.1016%2Fj.ejmech.2018.04.062"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-based lead optimization to improve antiviral potency and ADMET properties of phenyl-1H-pyrrole-carboxamide entry inhibitors targeted to HIV-1 gp120</span></div><div class="casAuthors">Curreli, Francesca; Belov, Dmitry S.; Kwon, Young Do; Ramesh, Ranjith; Furimsky, Anna M.; O'Loughlin, Kathleen; Byrge, Patricia C.; Iyer, Lalitha V.; Mirsalis, Jon C.; Kurkin, Alexander V.; Altieri, Andrea; Debnath, Asim K.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">154</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">367-391</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">The authors are continuing the concerted effort to optimize the first lead entry antagonist, NBD-11021, which targets the Phe 43 cavity of the HIV-1 envelope glycoprotein gp120, to improve antiviral potency and ADMET properties.  The authors present a structure-based approach that helped to generate working hypotheses to modify further a recently reported advanced lead entry antagonist, NBD-14107, which showed significant improvement in antiviral potency when tested in a single-cycle assay against a large panel of Env-pseudotyped viruses.  The authors report the synthesis of twenty-nine new compds. and evaluation of their antiviral activity in a single-cycle and multi-cycle assay to derive a comprehensive structure-activity relationship (SAR).  The authors have selected three inhibitors with the high selectivity index for testing against a large panel of 55 Env-pseudotyped viruses representing a diverse set of clin. isolates of different subtypes.  The antiviral activity of one of these potent inhibitors, 55 (NBD-14189), against some clin. isolates was as low as 63 nM.  The authors detd. the sensitivity of CD4-binding site mutated-pseudoviruses to these inhibitors to confirm that they target HIV-1 gp120.  Furthermore, the authors assessed their ADMET properties and compared them to the clin. candidate attachment inhibitor, BMS-626529.  The ADMET data indicate that some of these new inhibitors have comparable ADMET properties to BMS-626529 and can be optimized further to potential clin. candidates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOsCIZiXSbKrVg90H21EOLACvtfcHk0lg4Crc4HPUFwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVKrsbbF&md5=f8fff60fbfc867abdee1d6963e3d6593</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.04.062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.04.062%26sid%3Dliteratum%253Aachs%26aulast%3DCurreli%26aufirst%3DF.%2BB.%2BD.%2BS.%26aulast%3DKwon%26aufirst%3DY.%2BD.%26aulast%3DRamesh%26aufirst%3DR.%26aulast%3DFurimsky%26aufirst%3DA.%2BM.%26aulast%3DO%25E2%2580%2599Loughlin%26aufirst%3DK.%26aulast%3DByrge%26aufirst%3DP.%2BC.%26aulast%3DIyer%26aufirst%3DL.%2BV.%26aulast%3DMirsalis%26aufirst%3DJ.%2BC.%26aulast%3DKurkin%26aufirst%3DA.%2BV.%26aulast%3DAltieri%26aufirst%3DA.%26aulast%3DDebnath%26aufirst%3DA.%2BK.%26aulast%3DBelov%26aufirst%3DD.%2BS.%26atitle%3DStructure-based%2520lead%2520optimization%2520to%2520improve%2520antiviral%2520potency%2520and%2520ADMET%2520properties%2520of%2520phenyl-1H-pyrrole-carboxamide%2520entry%2520inhibitors%2520targeted%2520to%2520HIV-1%2520gp120%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D154%26spage%3D367%26epage%3D391%26doi%3D10.1016%2Fj.ejmech.2018.04.062" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, Y. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finzi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dogo-Isonagie, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuckey, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vicic, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Debnath, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bewley, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mascola, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sodroski, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwong, P. D.</span></span> <span> </span><span class="NLM_article-title">Unliganded HIV-1 gp120 core structures assume the CD4-bound conformation with regulation by quaternary interactions and variable loops</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>109</i></span>,  <span class="NLM_fpage">5663</span>– <span class="NLM_lpage">5668</span>, <span class="refDoi"> DOI: 10.1073/pnas.1112391109</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=10.1073%2Fpnas.1112391109" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=22451932" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=1%3ACAS%3A528%3ADC%252BC38XmtVOisLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2012&pages=5663-5668&author=Y.+D.+Kwonauthor=A.+Finziauthor=X.+Wuauthor=C.+Dogo-Isonagieauthor=L.+K.+Leeauthor=L.+R.+Mooreauthor=S.+D.+Schmidtauthor=J.+Stuckeyauthor=Y.+Yangauthor=T.+Zhouauthor=J.+Zhuauthor=D.+A.+Vicicauthor=A.+K.+Debnathauthor=L.+Shapiroauthor=C.+A.+Bewleyauthor=J.+R.+Mascolaauthor=J.+G.+Sodroskiauthor=P.+D.+Kwong&title=Unliganded+HIV-1+gp120+core+structures+assume+the+CD4-bound+conformation+with+regulation+by+quaternary+interactions+and+variable+loops&doi=10.1073%2Fpnas.1112391109"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Unliganded HIV-1 gp120 core structures assume the CD4-bound conformation with regulation by quaternary interactions and variable loops</span></div><div class="casAuthors">Kwon, Young Do; Finzi, Andres; Wu, Xueling; Dogo-Isonagie, Cajetan; Lee, Lawrence K.; Moore, Lucas R.; Schmidt, Stephen D.; Stuckey, Jonathan; Yang, Yongping; Zhou, Tongqing; Zhu, Jiang; Vicic, David A.; Debnath, Asim K.; Shapiro, Lawrence; Bewley, Carole A.; Mascola, John R.; Sodroski, Joseph G.; Kwong, Peter D.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">5663-5668, S5663/1-S5663/33</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The HIV-1 envelope (Env) spike (gp1203/gp413) undergoes considerable structural rearrangements to mediate virus entry into cells and to evade the host immune response.  Engagement of CD4, the primary human receptor, fixes a particular conformation and primes Env for entry.  The CD4-bound state, however, is prone to spontaneous inactivation and susceptible to antibody neutralization.  How does unliganded HIV-1 maintain CD4-binding capacity and regulate transitions to the CD4-bound state.  To define this mechanistically, we detd. crystal structures of unliganded core gp12O from HIV-1 clades B, C, and E.  Notably, all of these unliganded HIV-1 structures resembled the CD4-bound state.  Conformational fixation with ligand selection and thermodn. anal. of full-length and core gp12O interactions revealed that the tendency of HIV-1 gp12O to adopt the CD4-bound conformation was restrained by the V1 N2- and V3-variable loops.  In parallel, we detd. the structure of core gp120 in complex with the small mol., NBD-556, which specifically recognizes the CD4-bound conformation of gp120.  Neutralization by NBD-556 indicated that Env spikes on primary isolates rarely assume the CD4-bound conformation spontaneously, although they could do so when quaternary restraints were loosened.  Together, the results suggest that the CD4-bound conformation represents a "ground state" for the gp12O core, with variable loop and quaternary interactions restraining unliganded gp12O from "snapping" into this conformation.  A mechanism of control involving deformations in unliganded structure from a functionally crit. state (e.g., the CD4-bound state) provides advantages in terms of HIV-1 Env structural diversity and resistance to antibodies and inhibitors, while maintaining elements essential for entry.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoS3b-Y8pziGrVg90H21EOLACvtfcHk0lg4Crc4HPUFwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmtVOisLc%253D&md5=2ad1a0459b9ede5cd0d3db0116fd7a0b</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1112391109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1112391109%26sid%3Dliteratum%253Aachs%26aulast%3DKwon%26aufirst%3DY.%2BD.%26aulast%3DFinzi%26aufirst%3DA.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DDogo-Isonagie%26aufirst%3DC.%26aulast%3DLee%26aufirst%3DL.%2BK.%26aulast%3DMoore%26aufirst%3DL.%2BR.%26aulast%3DSchmidt%26aufirst%3DS.%2BD.%26aulast%3DStuckey%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DT.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DVicic%26aufirst%3DD.%2BA.%26aulast%3DDebnath%26aufirst%3DA.%2BK.%26aulast%3DShapiro%26aufirst%3DL.%26aulast%3DBewley%26aufirst%3DC.%2BA.%26aulast%3DMascola%26aufirst%3DJ.%2BR.%26aulast%3DSodroski%26aufirst%3DJ.%2BG.%26aulast%3DKwong%26aufirst%3DP.%2BD.%26atitle%3DUnliganded%2520HIV-1%2520gp120%2520core%2520structures%2520assume%2520the%2520CD4-bound%2520conformation%2520with%2520regulation%2520by%2520quaternary%2520interactions%2520and%2520variable%2520loops%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2012%26volume%3D109%26spage%3D5663%26epage%3D5668%26doi%3D10.1073%2Fpnas.1112391109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, Y. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lalonde, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elban, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugawara, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Courter, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A. B.,  III</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Debnath, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwong, P. D.</span></span> <span> </span><span class="NLM_article-title">Crystal structures of HIV-1 gp120 envelope glycoprotein in complex with NBD analogues that target the CD4-binding site</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">12</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0085940</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=10.1371%2Fjournal.pone.0085940" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=1-12&author=Y.+D.+Kwonauthor=J.+M.+Lalondeauthor=Y.+Yangauthor=M.+A.+Elbanauthor=A.+Sugawaraauthor=J.+R.+Courterauthor=D.+M.+Jonesauthor=A.+B.+Smithauthor=A.+K.+Debnathauthor=P.+D.+Kwong&title=Crystal+structures+of+HIV-1+gp120+envelope+glycoprotein+in+complex+with+NBD+analogues+that+target+the+CD4-binding+site&doi=10.1371%2Fjournal.pone.0085940"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0085940&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0085940%26sid%3Dliteratum%253Aachs%26aulast%3DKwon%26aufirst%3DY.%2BD.%26aulast%3DLalonde%26aufirst%3DJ.%2BM.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DElban%26aufirst%3DM.%2BA.%26aulast%3DSugawara%26aufirst%3DA.%26aulast%3DCourter%26aufirst%3DJ.%2BR.%26aulast%3DJones%26aufirst%3DD.%2BM.%26aulast%3DSmith%26aufirst%3DA.%2BB.%26aulast%3DDebnath%26aufirst%3DA.%2BK.%26aulast%3DKwong%26aufirst%3DP.%2BD.%26atitle%3DCrystal%2520structures%2520of%2520HIV-1%2520gp120%2520envelope%2520glycoprotein%2520in%2520complex%2520with%2520NBD%2520analogues%2520that%2520target%2520the%2520CD4-binding%2520site%26jtitle%3DPLoS%2520One%26date%3D2014%26volume%3D9%26spage%3D1%26epage%3D12%26doi%3D10.1371%2Fjournal.pone.0085940" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strick, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neamati, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Debnath, A. K.</span></span> <span> </span><span class="NLM_article-title">Identification of N-phenyl-N’-(2,2,6,6-tetramethyl-piperidin-4-yl)-oxalamides as a new class of HIV-1 entry inhibitors that prevent gp120 binding to CD4</span>. <i>Virology</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>339</i></span>,  <span class="NLM_fpage">213</span>– <span class="NLM_lpage">225</span>, <span class="refDoi"> DOI: 10.1016/j.virol.2005.06.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=10.1016%2Fj.virol.2005.06.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=15996703" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=1%3ACAS%3A528%3ADC%252BD2MXos1Wqs7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=339&publication_year=2005&pages=213-225&author=Q.+Zhaoauthor=L.+Maauthor=S.+Jiangauthor=H.+Luauthor=S.+Liuauthor=Y.+Heauthor=N.+Strickauthor=N.+Neamatiauthor=A.+K.+Debnath&title=Identification+of+N-phenyl-N%E2%80%99-%282%2C2%2C6%2C6-tetramethyl-piperidin-4-yl%29-oxalamides+as+a+new+class+of+HIV-1+entry+inhibitors+that+prevent+gp120+binding+to+CD4&doi=10.1016%2Fj.virol.2005.06.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of N-phenyl-N'-(2,2,6,6-tetramethyl-piperidin-4-yl)-oxalamides as a new class of HIV-1 entry inhibitors that prevent gp120 binding to CD4</span></div><div class="casAuthors">Zhao, Qian; Ma, Liying; Jiang, Shibo; Lu, Hong; Liu, Shuwen; He, Yuxian; Strick, Nathan; Neamati, Nouri; Debnath, Asim Kumar</div><div class="citationInfo"><span class="NLM_cas:title">Virology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">339</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">213-225</span>CODEN:
                <span class="NLM_cas:coden">VIRLAX</span>;
        ISSN:<span class="NLM_cas:issn">0042-6822</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">We have identified two N-phenyl-N'-(2,2,6,6-tetramethyl-piperidin-4-yl)-oxalamide analogs as a novel class of human immunodeficiency virus type 1 (HIV-1) entry inhibitors that block the gp120-CD4 interaction, using database screening techniques.  The lead compds., NBD-556 and NBD-557, are small mol. org. compds. with drug-like properties.  These compds. showed potent cell fusion and virus-cell fusion inhibitory activity at low micromolar levels.  A systematic study showed that these compds. target viral entry by inhibiting the binding of HIV-1 envelope glycoprotein gp120 to the cellular receptor CD4 but did not inhibit reverse transcriptase, integrase, or protease, indicating that they do not target the later stages of the HIV-1 life cycle to inhibit HIV-1 infection.  These compds. were equally potent inhibitors of both X4 and R5 viruses tested in CXCR4 and CCR5 expressing cell lines, resp., indicating that their anti-HIV-1 activity is not dependent on the coreceptor tropism of the virus.  A surface plasmon resonance study, which measures binding affinity, clearly demonstrated that these compds. bind to unliganded HIV-1 gp120 but not to the cellular receptor CD4.  NBD-556 and NBD-557 were active against HIV-1 lab.-adapted strains including an AZT-resistant strain and HIV-1 primary isolates, indicating that these compds. can potentially be further modified to become potent HIV-1 entry inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZSz2irXkLMLVg90H21EOLACvtfcHk0ljfuTVumm0fTQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXos1Wqs7w%253D&md5=15c9a147d5a7410d40076690822b3aff</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2Fj.virol.2005.06.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.virol.2005.06.008%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DQ.%26aulast%3DMa%26aufirst%3DL.%26aulast%3DJiang%26aufirst%3DS.%26aulast%3DLu%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DHe%26aufirst%3DY.%26aulast%3DStrick%26aufirst%3DN.%26aulast%3DNeamati%26aufirst%3DN.%26aulast%3DDebnath%26aufirst%3DA.%2BK.%26atitle%3DIdentification%2520of%2520N-phenyl-N%25E2%2580%2599-%25282%252C2%252C6%252C6-tetramethyl-piperidin-4-yl%2529-oxalamides%2520as%2520a%2520new%2520class%2520of%2520HIV-1%2520entry%2520inhibitors%2520that%2520prevent%2520gp120%2520binding%2520to%2520CD4%26jtitle%3DVirology%26date%3D2005%26volume%3D339%26spage%3D213%26epage%3D225%26doi%3D10.1016%2Fj.virol.2005.06.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Courter, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madani, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sodroski, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freire, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwong, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hendrickson, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaiken, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lalonde, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A. B.,  III</span></span> <span> </span><span class="NLM_article-title">Structure-based design, synthesis and validation of CD4-mimetic small molecule inhibitors of HIV-1 entry: conversion of a viral entry agonist to an antagonist</span>. <i>Acc. Chem. Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">1228</span>– <span class="NLM_lpage">1237</span>, <span class="refDoi"> DOI: 10.1021/ar4002735</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ar4002735" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVOqtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2014&pages=1228-1237&author=J.+R.+Courterauthor=N.+Madaniauthor=J.+Sodroskiauthor=A.+Schonauthor=E.+Freireauthor=P.+D.+Kwongauthor=W.+A.+Hendricksonauthor=I.+M.+Chaikenauthor=J.+M.+Lalondeauthor=A.+B.+Smith&title=Structure-based+design%2C+synthesis+and+validation+of+CD4-mimetic+small+molecule+inhibitors+of+HIV-1+entry%3A+conversion+of+a+viral+entry+agonist+to+an+antagonist&doi=10.1021%2Far4002735"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Based Design, Synthesis and Validation of CD4-Mimetic Small Molecule Inhibitors of HIV-1 Entry: Conversion of a Viral Entry Agonist to an Antagonist</span></div><div class="casAuthors">Courter, Joel R.; Madani, Navid; Sodroski, Joseph; Schon, Arne; Freire, Ernesto; Kwong, Peter D.; Hendrickson, Wayne A.; Chaiken, Irwin M.; La Londe, Judith M.; Smith, Amos B., III</div><div class="citationInfo"><span class="NLM_cas:title">Accounts of Chemical Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1228-1237</span>CODEN:
                <span class="NLM_cas:coden">ACHRE4</span>;
        ISSN:<span class="NLM_cas:issn">0001-4842</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">This Account provides an overview of a multidisciplinary consortium focused on structure-based strategies to devise small mol. antagonists of HIV-1 entry into human T-cells, which if successful would hold considerable promise for the development of prophylactic modalities to prevent HIV transmission and thereby alter the course of the AIDS pandemic.  Entry of the human immunodeficiency virus (HIV) into target T-cells entails an interaction between CD4 on the host T-cell and gp120, a component of the trimeric envelope glycoprotein spike on the virion surface.  The resultant interaction initiates a series of conformational changes within the envelope spike that permits binding to a chemokine receptor, formation of the gp41 fusion complex, and cell entry.  A hydrophobic cavity at the CD4-gp120 interface, defined by x-ray crystallog., provided an initial site for small mol. antagonist design.  This site however has evolved to facilitate viral entry.  As such, the binding of prospective small mol. inhibitors within this gp120 cavity can inadvertently trigger an allosteric entry signal.  Structural characterization of the CD4-gp120 interface, which provided the foundation for small mol. structure-based inhibitor design, will be presented first.  An integrated approach combining biochem., virol., structural, computational, and synthetic studies, along with a detailed anal. of ligand binding energetics, revealed that modestly active small mol. inhibitors of HIV entry can also promote viral entry into cells lacking the CD4 receptor protein; these competitive inhibitors were termed small mol. CD4 mimetics.  Related congeners were subsequently identified with both improved binding affinity and more potent viral entry inhibition.  Further assessment of the affinity-enhanced small mol. CD4 mimetics demonstrated that premature initiation of conformational change within the viral envelope spike, prior to cell encounter, can lead to irreversible deactivation of viral entry machinery.  Related congeners, which bind the same gp120 site, possess different propensities to elicit the allosteric response that underlies the undesired enhancement of CD4-independent viral entry.  Subsequently, key hotspots in the CD4-gp120 interface were categorized using mutagenesis and isothermal titrn. calorimetry according to the capacity to increase binding affinity without triggering the allosteric signal.  This anal., combined with cocrystal structures of small mol. viral entry agonists with gp120, led to the development of fully functional antagonists of HIV-1 entry.  Addnl. structure-based design exploiting two hotspots followed by synthesis has now yielded low micromolar inhibitors of viral entry.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplvC-F21zbMLVg90H21EOLACvtfcHk0ljfuTVumm0fTQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVOqtb8%253D&md5=dbe222907f1cf595e79e4fcb12cd9d85</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1021%2Far4002735&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Far4002735%26sid%3Dliteratum%253Aachs%26aulast%3DCourter%26aufirst%3DJ.%2BR.%26aulast%3DMadani%26aufirst%3DN.%26aulast%3DSodroski%26aufirst%3DJ.%26aulast%3DSchon%26aufirst%3DA.%26aulast%3DFreire%26aufirst%3DE.%26aulast%3DKwong%26aufirst%3DP.%2BD.%26aulast%3DHendrickson%26aufirst%3DW.%2BA.%26aulast%3DChaiken%26aufirst%3DI.%2BM.%26aulast%3DLalonde%26aufirst%3DJ.%2BM.%26aulast%3DSmith%26aufirst%3DA.%2BB.%26atitle%3DStructure-based%2520design%252C%2520synthesis%2520and%2520validation%2520of%2520CD4-mimetic%2520small%2520molecule%2520inhibitors%2520of%2520HIV-1%2520entry%253A%2520conversion%2520of%2520a%2520viral%2520entry%2520agonist%2520to%2520an%2520antagonist%26jtitle%3DAcc.%2520Chem.%2520Res.%26date%3D2014%26volume%3D47%26spage%3D1228%26epage%3D1237%26doi%3D10.1021%2Far4002735" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lalonde, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, Y. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Courter, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soeta, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Princiotto, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freire, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwong, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mascola, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sodroski, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madani, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A. B.,  III</span></span> <span> </span><span class="NLM_article-title">Structure-based design, synthesis, and characterization of dual hotspot small-molecule HIV-1 entry inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">4382</span>– <span class="NLM_lpage">4396</span>, <span class="refDoi"> DOI: 10.1021/jm300265j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300265j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=1%3ACAS%3A528%3ADC%252BC38Xltl2gs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=4382-4396&author=J.+M.+Lalondeauthor=Y.+D.+Kwonauthor=D.+M.+Jonesauthor=A.+W.+Sunauthor=J.+R.+Courterauthor=T.+Soetaauthor=T.+Kobayashiauthor=A.+M.+Princiottoauthor=X.+Wuauthor=A.+Schonauthor=E.+Freireauthor=P.+D.+Kwongauthor=J.+R.+Mascolaauthor=J.+Sodroskiauthor=N.+Madaniauthor=A.+B.+Smith&title=Structure-based+design%2C+synthesis%2C+and+characterization+of+dual+hotspot+small-molecule+HIV-1+entry+inhibitors&doi=10.1021%2Fjm300265j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Based Design, Synthesis, and Characterization of Dual Hotspot Small-Molecule HIV-1 Entry Inhibitors</span></div><div class="casAuthors">LaLonde, Judith M.; Kwon, Young Do; Jones, David M.; Sun, Alexander W.; Courter, Joel R.; Soeta, Takahiro; Kobayashi, Toyoharu; Princiotto, Amy M.; Wu, Xueling; Schon, Arne; Freire, Ernesto; Kwong, Peter D.; Mascola, John R.; Sodroski, Joseph; Madani, Navid; Smith, Amos B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4382-4396</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Cellular infection by HIV-1 is initiated with a binding event between the viral envelope glycoprotein gp120 and the cellular receptor protein CD4.  The CD4-gp120 interface is dominated by two hotspots: a hydrophobic gp120 cavity capped by Phe43CD4 and an electrostatic interaction between residues Arg59CD4 and Asp368gp120.  The CD4 mimetic small-mol. NBD-556 (1) binds within the gp120 cavity; however, 1 and related congeners demonstrate limited viral neutralization breadth.  Herein, we report the design, synthesis, characterization, and X-ray structures of gp120 in complex with small mols. that simultaneously engage both binding hotspots.  The compds. specifically inhibit viral infection of 42 tier 2 clades B and C viruses and are shown to be antagonists of entry into CD4-neg. cells.  Dual hotspot design thus provides both a means to enhance neutralization potency of HIV-1 entry inhibitors and a novel structural paradigm for inhibiting the CD4-gp120 protein-protein interaction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNognNQUm1FrVg90H21EOLACvtfcHk0lgLzxWLnmXy_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xltl2gs7g%253D&md5=2b7b963e311bb4aa8e6e5a7798064509</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Fjm300265j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300265j%26sid%3Dliteratum%253Aachs%26aulast%3DLalonde%26aufirst%3DJ.%2BM.%26aulast%3DKwon%26aufirst%3DY.%2BD.%26aulast%3DJones%26aufirst%3DD.%2BM.%26aulast%3DSun%26aufirst%3DA.%2BW.%26aulast%3DCourter%26aufirst%3DJ.%2BR.%26aulast%3DSoeta%26aufirst%3DT.%26aulast%3DKobayashi%26aufirst%3DT.%26aulast%3DPrinciotto%26aufirst%3DA.%2BM.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DSchon%26aufirst%3DA.%26aulast%3DFreire%26aufirst%3DE.%26aulast%3DKwong%26aufirst%3DP.%2BD.%26aulast%3DMascola%26aufirst%3DJ.%2BR.%26aulast%3DSodroski%26aufirst%3DJ.%26aulast%3DMadani%26aufirst%3DN.%26aulast%3DSmith%26aufirst%3DA.%2BB.%26atitle%3DStructure-based%2520design%252C%2520synthesis%252C%2520and%2520characterization%2520of%2520dual%2520hotspot%2520small-molecule%2520HIV-1%2520entry%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D4382%26epage%3D4396%26doi%3D10.1021%2Fjm300265j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lalonde, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le-Khac, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Courter, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Princiotto, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mascola, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freire, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sodroski, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madani, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hendrickson, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A. B.,  III</span></span> <span> </span><span class="NLM_article-title">Structure-based design and synthesis of an HIV-1 entry inhibitor exploiting X-ray and thermodynamic characterization</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">338</span>– <span class="NLM_lpage">343</span>, <span class="refDoi"> DOI: 10.1021/ml300407y</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml300407y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=1%3ACAS%3A528%3ADC%252BC3sXit1Sqs7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=338-343&author=J.+M.+Lalondeauthor=M.+Le-Khacauthor=D.+M.+Jonesauthor=J.+R.+Courterauthor=J.+Parkauthor=A.+Schonauthor=A.+M.+Princiottoauthor=X.+Wuauthor=J.+R.+Mascolaauthor=E.+Freireauthor=J.+Sodroskiauthor=N.+Madaniauthor=W.+A.+Hendricksonauthor=A.+B.+Smith&title=Structure-based+design+and+synthesis+of+an+HIV-1+entry+inhibitor+exploiting+X-ray+and+thermodynamic+characterization&doi=10.1021%2Fml300407y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Based Design and Synthesis of an HIV-1 Entry Inhibitor Exploiting X-ray and Thermodynamic Characterization</span></div><div class="casAuthors">LaLonde, Judith M.; Le-Khac, Matthew; Jones, David M.; Courter, Joel R.; Park, Jongwoo; Schon, Arne; Princiotto, Amy M.; Wu, Xueling; Mascola, John R.; Freire, Ernesto; Sodroski, Joseph; Madani, Navid; Hendrickson, Wayne A.; Smith, Amos B.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">338-343</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The design, synthesis, thermodn. and crystallog. characterization of a potent, broad spectrum, second-generation HIV-1 entry inhibitor that engages conserved carbonyl hydrogen bonds within gp120 has been achieved.  The optimized antagonist exhibits a submicromolar binding affinity (110 nM) and inhibits viral entry of clade B and C viruses (IC50 geometric mean titer of 1.7 and 14.0 μM, resp.), without promoting CD4-independent viral entry.  The thermodn. signatures indicate a binding preference for the (R,R)- over the (S,S)-enantiomer.  The crystal structure of the small-mol./gp120 complex reveals the displacement of crystallog. water and the formation of a hydrogen bond with a backbone carbonyl of the bridging sheet.  Thus, structure-based design and synthesis targeting the highly conserved and structurally characterized CD4-gp120 interface is an effective tactic to enhance the neutralization potency of small-mol. HIV-1 entry inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqh7x2FvVHCWrVg90H21EOLACvtfcHk0lgLzxWLnmXy_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXit1Sqs7k%253D&md5=5fbf7ba309222bd3b1064524a94e2af3</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Fml300407y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml300407y%26sid%3Dliteratum%253Aachs%26aulast%3DLalonde%26aufirst%3DJ.%2BM.%26aulast%3DLe-Khac%26aufirst%3DM.%26aulast%3DJones%26aufirst%3DD.%2BM.%26aulast%3DCourter%26aufirst%3DJ.%2BR.%26aulast%3DPark%26aufirst%3DJ.%26aulast%3DSchon%26aufirst%3DA.%26aulast%3DPrinciotto%26aufirst%3DA.%2BM.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DMascola%26aufirst%3DJ.%2BR.%26aulast%3DFreire%26aufirst%3DE.%26aulast%3DSodroski%26aufirst%3DJ.%26aulast%3DMadani%26aufirst%3DN.%26aulast%3DHendrickson%26aufirst%3DW.%2BA.%26aulast%3DSmith%26aufirst%3DA.%2BB.%26atitle%3DStructure-based%2520design%2520and%2520synthesis%2520of%2520an%2520HIV-1%2520entry%2520inhibitor%2520exploiting%2520X-ray%2520and%2520thermodynamic%2520characterization%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D4%26spage%3D338%26epage%3D343%26doi%3D10.1021%2Fml300407y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Melillo, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Courter, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lalonde, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wendler, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Princiotto, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seaman, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freire, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sodroski, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madani, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hendrickson, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A. B.,  III</span></span> <span> </span><span class="NLM_article-title">Small-molecule CD4-mimics: structure-based optimization of HIV-1 entry inhibition</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">330</span>– <span class="NLM_lpage">334</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.5b00471</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.5b00471" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVKrs7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=330-334&author=B.+Melilloauthor=S.+Liangauthor=J.+Parkauthor=A.+Schonauthor=J.+R.+Courterauthor=J.+M.+Lalondeauthor=D.+J.+Wendlerauthor=A.+M.+Princiottoauthor=M.+S.+Seamanauthor=E.+Freireauthor=J.+Sodroskiauthor=N.+Madaniauthor=W.+A.+Hendricksonauthor=A.+B.+Smith&title=Small-molecule+CD4-mimics%3A+structure-based+optimization+of+HIV-1+entry+inhibition&doi=10.1021%2Facsmedchemlett.5b00471"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Small-Molecule CD4-Mimics: Structure-Based Optimization of HIV-1 Entry Inhibition</span></div><div class="casAuthors">Melillo, Bruno; Liang, Shuaiyi; Park, Jongwoo; Schon, Arne; Courter, Joel R.; LaLonde, Judith M.; Wendler, Daniel J.; Princiotto, Amy M.; Seaman, Michael S.; Freire, Ernesto; Sodroski, Joseph; Madani, Navid; Hendrickson, Wayne A.; Smith, Amos B.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">330-334</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The optimization, based on computational, thermodn., and crystallog. data, of a series of small-mol. ligands of the Phe 43 cavity of the envelope glycoprotein gp120 of human immunodeficiency virus (HIV) has been achieved.  Importantly, biol. evaluation revealed that the small-mol. CD4 mimics inhibit HIV-1 entry into target cells with both significantly higher potency and neutralization breadth than previous congeners, while maintaining high selectivity for the target virus.  Their binding mode was characterized via thermodn. and crystallog. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobuaf6aAaI_7Vg90H21EOLACvtfcHk0ljYIs3VKmcj2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVKrs7w%253D&md5=512ed31929b2a4f5334653e40bcbeb14</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.5b00471&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.5b00471%26sid%3Dliteratum%253Aachs%26aulast%3DMelillo%26aufirst%3DB.%26aulast%3DLiang%26aufirst%3DS.%26aulast%3DPark%26aufirst%3DJ.%26aulast%3DSchon%26aufirst%3DA.%26aulast%3DCourter%26aufirst%3DJ.%2BR.%26aulast%3DLalonde%26aufirst%3DJ.%2BM.%26aulast%3DWendler%26aufirst%3DD.%2BJ.%26aulast%3DPrinciotto%26aufirst%3DA.%2BM.%26aulast%3DSeaman%26aufirst%3DM.%2BS.%26aulast%3DFreire%26aufirst%3DE.%26aulast%3DSodroski%26aufirst%3DJ.%26aulast%3DMadani%26aufirst%3DN.%26aulast%3DHendrickson%26aufirst%3DW.%2BA.%26aulast%3DSmith%26aufirst%3DA.%2BB.%26atitle%3DSmall-molecule%2520CD4-mimics%253A%2520structure-based%2520optimization%2520of%2520HIV-1%2520entry%2520inhibition%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D7%26spage%3D330%26epage%3D334%26doi%3D10.1021%2Facsmedchemlett.5b00471" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Si, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madani, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chruma, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klein, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phan, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biorn, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cocklin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaiken, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freire, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A. B.,  III</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sodroski, J. G.</span></span> <span> </span><span class="NLM_article-title">Small-molecule inhibitors of HIV-1 entry block receptor-induced conformational changes in the viral envelope glycoproteins</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>101</i></span>,  <span class="NLM_fpage">5036</span>– <span class="NLM_lpage">5041</span>, <span class="refDoi"> DOI: 10.1073/pnas.0307953101</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=10.1073%2Fpnas.0307953101" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=15051887" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjsFCisLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2004&pages=5036-5041&author=Z.+Siauthor=N.+Madaniauthor=J.+M.+Coxauthor=J.+J.+Chrumaauthor=J.+C.+Kleinauthor=A.+Schonauthor=N.+Phanauthor=L.+Wangauthor=A.+C.+Biornauthor=S.+Cocklinauthor=I.+Chaikenauthor=E.+Freireauthor=A.+B.+Smithauthor=J.+G.+Sodroski&title=Small-molecule+inhibitors+of+HIV-1+entry+block+receptor-induced+conformational+changes+in+the+viral+envelope+glycoproteins&doi=10.1073%2Fpnas.0307953101"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Small-molecule inhibitors of HIV-1 entry block receptor-induced conformational changes in the viral envelope glycoproteins</span></div><div class="casAuthors">Si, Zhihai; Madani, Navid; Cox, Jason M.; Chruma, Jason J.; Klein, Jeffrey C.; Schoen, Arne; Phan, Ngoc; Wang, Liping; Biorn, Alyssa C.; Cocklin, Simon; Chaiken, Irwin; Freire, Ernesto; Smith, Amos B., III; Sodroski, Joseph G.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">101</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5036-5041</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">When interacting with the CD4 receptor, the HIV gp120 envelope glycoprotein undergoes conformational changes that allow binding to the chemokine receptor.  Receptor binding is proposed to lead to conformational changes in the gp41 transmembrane envelope glycoprotein involving the creation and/or exposure of a coiled coil consisting of three heptad repeat (HR) sequences.  The subsequent interaction of the HR2 region of gp41 with this coiled coil results in the assembly of a six-helix bundle that promotes the fusion of the viral and target cell membranes.  Here we show that CD4 binding to gp120 induces the formation and/or exposure of the gp41 HR1 coiled coil in a process that does not involve gp120 shedding and that depends on the proteolytic maturation of the gp160 envelope glycoprotein precursor.  Importantly, BMS-806 and related HIV-1 entry inhibitors bind gp120 and block the CD4 induction of HR1 exposure without significantly affecting CD4 binding.  Moreover, these compds. do not disrupt gp120-chemokine receptor binding or the HR1-HR2 interaction within gp41.  These studies thus define a receptor-induced conformational rearrangement of gp120-gp41 that is important for both CD4-dependent and CD4-independent HIV-1 entry and is susceptible to inhibition by low-mol.-wt. compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCK84PlI4vMbVg90H21EOLACvtfcHk0ljYIs3VKmcj2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjsFCisLs%253D&md5=2509801a7e57d0fc066f0c08f720f80e</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0307953101&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0307953101%26sid%3Dliteratum%253Aachs%26aulast%3DSi%26aufirst%3DZ.%26aulast%3DMadani%26aufirst%3DN.%26aulast%3DCox%26aufirst%3DJ.%2BM.%26aulast%3DChruma%26aufirst%3DJ.%2BJ.%26aulast%3DKlein%26aufirst%3DJ.%2BC.%26aulast%3DSchon%26aufirst%3DA.%26aulast%3DPhan%26aufirst%3DN.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DBiorn%26aufirst%3DA.%2BC.%26aulast%3DCocklin%26aufirst%3DS.%26aulast%3DChaiken%26aufirst%3DI.%26aulast%3DFreire%26aufirst%3DE.%26aulast%3DSmith%26aufirst%3DA.%2BB.%26aulast%3DSodroski%26aufirst%3DJ.%2BG.%26atitle%3DSmall-molecule%2520inhibitors%2520of%2520HIV-1%2520entry%2520block%2520receptor-induced%2520conformational%2520changes%2520in%2520the%2520viral%2520envelope%2520glycoproteins%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2004%26volume%3D101%26spage%3D5036%26epage%3D5041%26doi%3D10.1073%2Fpnas.0307953101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pancera, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, Y. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bylund, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Druz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narpala, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Dell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailer, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chuang, G. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Louder, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rawi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soumana, D. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finzi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herschhorn, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madani, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sodroski, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freire, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langley, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mascola, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDermott, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwong, P. D.</span></span> <span> </span><span class="NLM_article-title">Crystal structures of trimeric HIV envelope with entry inhibitors BMS-378806 and BMS-626529</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">1115</span>– <span class="NLM_lpage">1122</span>, <span class="refDoi"> DOI: 10.1038/nchembio.2460</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=10.1038%2Fnchembio.2460" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=28825711" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlKjtbnP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2017&pages=1115-1122&author=M.+Panceraauthor=Y.+T.+Laiauthor=T.+Bylundauthor=A.+Druzauthor=S.+Narpalaauthor=S.+O%E2%80%99Dellauthor=A.+Schonauthor=R.+T.+Bailerauthor=G.+Y.+Chuangauthor=H.+Gengauthor=M.+K.+Louderauthor=R.+Rawiauthor=D.+I.+Soumanaauthor=A.+Finziauthor=A.+Herschhornauthor=N.+Madaniauthor=J.+Sodroskiauthor=E.+Freireauthor=D.+R.+Langleyauthor=J.+R.+Mascolaauthor=A.+B.+McDermottauthor=P.+D.+Kwong&title=Crystal+structures+of+trimeric+HIV+envelope+with+entry+inhibitors+BMS-378806+and+BMS-626529&doi=10.1038%2Fnchembio.2460"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structures of trimeric HIV envelope with entry inhibitors BMS-378806 and BMS-626529</span></div><div class="casAuthors">Pancera, Marie; Lai, Yen-Ting; Bylund, Tatsiana; Druz, Aliaksandr; Narpala, Sandeep; O'Dell, Sijy; Schon, Arne; Bailer, Robert T.; Chuang, Gwo-Yu; Geng, Hui; Louder, Mark K.; Rawi, Reda; Soumana, Djade I.; Finzi, Andres; Herschhorn, Alon; Madani, Navid; Sodroski, Joseph; Freire, Ernesto; Langley, David R.; Mascola, John R.; McDermott, Adrian B.; Kwong, Peter D.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1115-1122</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">The HIV-1 envelope (Env) spike is a conformational machine that transitions between prefusion (closed, CD4- and CCR5-bound) and postfusion states to facilitate HIV-1 entry into cells.  Although the prefusion closed conformation is a potential target for inhibition, development of small-mol. leads has been stymied by difficulties in obtaining structural information.  Here, the authors report crystal structures at 3.8-Å resoln. of an HIV-1-Env trimer with BMS-378806 and a deriv. BMS-626529 for which a prodrug version is currently in Phase III clin. trials.  Both lead candidates recognized an induced binding pocket that was mostly excluded from solvent and comprised of Env elements from a conserved helix and the β20-21 hairpin.  In both structures, the β20-21 region assumed a conformation distinct from prefusion-closed and CD4-bound states.  Together with biophys. and antigenicity characterizations, the structures illuminate the allosteric and competitive mechanisms by which these small-mol. leads inhibit CD4-induced structural changes in Env.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq08375JqIny7Vg90H21EOLACvtfcHk0ljYIs3VKmcj2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlKjtbnP&md5=4f79455289aed50834a0ad20e21dba9a</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.2460&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.2460%26sid%3Dliteratum%253Aachs%26aulast%3DPancera%26aufirst%3DM.%26aulast%3DLai%26aufirst%3DY.%2BT.%26aulast%3DBylund%26aufirst%3DT.%26aulast%3DDruz%26aufirst%3DA.%26aulast%3DNarpala%26aufirst%3DS.%26aulast%3DO%25E2%2580%2599Dell%26aufirst%3DS.%26aulast%3DSchon%26aufirst%3DA.%26aulast%3DBailer%26aufirst%3DR.%2BT.%26aulast%3DChuang%26aufirst%3DG.%2BY.%26aulast%3DGeng%26aufirst%3DH.%26aulast%3DLouder%26aufirst%3DM.%2BK.%26aulast%3DRawi%26aufirst%3DR.%26aulast%3DSoumana%26aufirst%3DD.%2BI.%26aulast%3DFinzi%26aufirst%3DA.%26aulast%3DHerschhorn%26aufirst%3DA.%26aulast%3DMadani%26aufirst%3DN.%26aulast%3DSodroski%26aufirst%3DJ.%26aulast%3DFreire%26aufirst%3DE.%26aulast%3DLangley%26aufirst%3DD.%2BR.%26aulast%3DMascola%26aufirst%3DJ.%2BR.%26aulast%3DMcDermott%26aufirst%3DA.%2BB.%26aulast%3DKwong%26aufirst%3DP.%2BD.%26atitle%3DCrystal%2520structures%2520of%2520trimeric%2520HIV%2520envelope%2520with%2520entry%2520inhibitors%2520BMS-378806%2520and%2520BMS-626529%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2017%26volume%3D13%26spage%3D1115%26epage%3D1122%26doi%3D10.1038%2Fnchembio.2460" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Madani, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Princiotto, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lalonde, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Courter, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soeta, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brower, E. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Do Kwon, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wyatt, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwong, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freire, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A. B.,  III</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sodroski, J.</span></span> <span> </span><span class="NLM_article-title">Small-molecule CD4 mimics interact with a highly conserved pocket on HIV-1 gp120</span>. <i>Structure</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">1689</span>– <span class="NLM_lpage">1701</span>, <span class="refDoi"> DOI: 10.1016/j.str.2008.09.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=10.1016%2Fj.str.2008.09.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=19000821" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtlGmtb7O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2008&pages=1689-1701&author=N.+Madaniauthor=A.+Schonauthor=A.+M.+Princiottoauthor=J.+M.+Lalondeauthor=J.+R.+Courterauthor=T.+Soetaauthor=D.+Ngauthor=L.+Wangauthor=E.+T.+Browerauthor=S.+H.+Xiangauthor=Y.+Do+Kwonauthor=C.+C.+Huangauthor=R.+Wyattauthor=P.+D.+Kwongauthor=E.+Freireauthor=A.+B.+Smithauthor=J.+Sodroski&title=Small-molecule+CD4+mimics+interact+with+a+highly+conserved+pocket+on+HIV-1+gp120&doi=10.1016%2Fj.str.2008.09.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Small-Molecule CD4 Mimics Interact with a Highly Conserved Pocket on HIV-1 gp120</span></div><div class="casAuthors">Madani, Navid; Schoen, Arne; Princiotto, Amy M.; LaLonde, Judith M.; Courter, Joel R.; Soeta, Takahiro; Ng, Danny; Wang, Liping; Brower, Evan T.; Xiang, Shi-Hua; Kwon, Young Do; Huang, Chih-chin; Wyatt, Richard; Kwong, Peter D.; Freire, Ernesto; Smith, Amos B.; Sodroski, Joseph</div><div class="citationInfo"><span class="NLM_cas:title">Structure (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1689-1701</span>CODEN:
                <span class="NLM_cas:coden">STRUE6</span>;
        ISSN:<span class="NLM_cas:issn">0969-2126</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Human immunodeficiency virus (HIV-1) interaction with the primary receptor, CD4, induces conformational changes in the viral envelope glycoproteins that allow binding to the CCR5 s receptor and virus entry into the host cell.  The small mol. NBD-556 mimics CD4 by binding the gp120 exterior envelope glycoprotein, moderately inhibiting virus entry into CD4-expressing target cells and enhancing CCR5 binding and virus entry into CCR5-expressing cells lacking CD4.  Studies of NBD-556 analogs and gp120 mutants suggest that (1) NBD-556 binds within the Phe 43 cavity, a highly conserved, functionally important pocket formed as gp120 assumes the CD4-bound conformation; (2) the NBD-556 Ph ring projects into the Phe 43 cavity; (3) enhancement of CD4-independent infection by NBD-556 requires the induction of conformational changes in gp120; and (4) increased affinity of NBD-556 analogs for gp120 improves antiviral potency during infection of CD4-expressing cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpR6c6HGLqwjbVg90H21EOLACvtfcHk0lgPWtOIB8xzmg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtlGmtb7O&md5=8f146ad8772ee8c04d6f560d644407e1</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.str.2008.09.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.str.2008.09.005%26sid%3Dliteratum%253Aachs%26aulast%3DMadani%26aufirst%3DN.%26aulast%3DSchon%26aufirst%3DA.%26aulast%3DPrinciotto%26aufirst%3DA.%2BM.%26aulast%3DLalonde%26aufirst%3DJ.%2BM.%26aulast%3DCourter%26aufirst%3DJ.%2BR.%26aulast%3DSoeta%26aufirst%3DT.%26aulast%3DNg%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DBrower%26aufirst%3DE.%2BT.%26aulast%3DXiang%26aufirst%3DS.%2BH.%26aulast%3DDo%2BKwon%26aufirst%3DY.%26aulast%3DHuang%26aufirst%3DC.%2BC.%26aulast%3DWyatt%26aufirst%3DR.%26aulast%3DKwong%26aufirst%3DP.%2BD.%26aulast%3DFreire%26aufirst%3DE.%26aulast%3DSmith%26aufirst%3DA.%2BB.%26aulast%3DSodroski%26aufirst%3DJ.%26atitle%3DSmall-molecule%2520CD4%2520mimics%2520interact%2520with%2520a%2520highly%2520conserved%2520pocket%2520on%2520HIV-1%2520gp120%26jtitle%3DStructure%26date%3D2008%26volume%3D16%26spage%3D1689%26epage%3D1701%26doi%3D10.1016%2Fj.str.2008.09.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Curreli, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, Y. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scacalossi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belov, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tikhonov, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andreev, I. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altieri, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurkin, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwong, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Debnath, A. K.</span></span> <span> </span><span class="NLM_article-title">Structure-based design of a small molecule CD4-antagonist with broad spectrum anti-HIV-1 activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">6909</span>– <span class="NLM_lpage">6927</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00709</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00709" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlOqu7jK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=6909-6927&author=F.+Curreliauthor=Y.+D.+Kwonauthor=H.+Zhangauthor=D.+Scacalossiauthor=D.+S.+Belovauthor=A.+A.+Tikhonovauthor=I.+A.+Andreevauthor=A.+Altieriauthor=A.+V.+Kurkinauthor=P.+D.+Kwongauthor=A.+K.+Debnath&title=Structure-based+design+of+a+small+molecule+CD4-antagonist+with+broad+spectrum+anti-HIV-1+activity&doi=10.1021%2Facs.jmedchem.5b00709"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Based Design of a Small Molecule CD4-Antagonist with Broad Spectrum Anti-HIV-1 Activity</span></div><div class="casAuthors">Curreli, Francesca; Kwon, Young Do; Zhang, Hongtao; Scacalossi, Daniel; Belov, Dmitry S.; Tikhonov, Artur A.; Andreev, Ivan A.; Altieri, Andrea; Kurkin, Alexander V.; Kwong, Peter D.; Debnath, Asim K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">6909-6927</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Earlier the authors reported the discovery and design of NBD-556 and their analogs which demonstrated their potential as HIV-1 entry inhibitors.  However, progress in developing these inhibitors has been stymied by their CD4-agonist properties, an unfavorable trait for use as drug.  Here, the authors demonstrate the successful conversion of a full CD4-agonist (NBD-556) through a partial CD4-agonist (NBD-09027), to a full CD4-antagonist I (NBD-11021) by structure-based modification of the crit. oxalamide mid-region, previously thought to be intolerant of modification.  I showed unprecedented neutralization breath for this class of inhibitors, with pan-neutralization against a panel of 56 Env-pseudotyped HIV-1 representing diverse subtypes of clin. isolates (IC50 as low as 270 nM).  The cocrystal structure of NBD-11021 complexed to a monomeric HIV-1 gp120 core revealed its detail binding characteristics.  The study is expected to provide a framework for further development of NBD series as HIV-1 entry inhibitors for clin. application against AIDS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsZjeIlR_smLVg90H21EOLACvtfcHk0lgPWtOIB8xzmg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlOqu7jK&md5=db75d8df02d72d932b75596bec6fc1fc</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00709&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00709%26sid%3Dliteratum%253Aachs%26aulast%3DCurreli%26aufirst%3DF.%26aulast%3DKwon%26aufirst%3DY.%2BD.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DScacalossi%26aufirst%3DD.%26aulast%3DBelov%26aufirst%3DD.%2BS.%26aulast%3DTikhonov%26aufirst%3DA.%2BA.%26aulast%3DAndreev%26aufirst%3DI.%2BA.%26aulast%3DAltieri%26aufirst%3DA.%26aulast%3DKurkin%26aufirst%3DA.%2BV.%26aulast%3DKwong%26aufirst%3DP.%2BD.%26aulast%3DDebnath%26aufirst%3DA.%2BK.%26atitle%3DStructure-based%2520design%2520of%2520a%2520small%2520molecule%2520CD4-antagonist%2520with%2520broad%2520spectrum%2520anti-HIV-1%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D6909%26epage%3D6927%26doi%3D10.1021%2Facs.jmedchem.5b00709" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Curreli, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, Y. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scacalossi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwong, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Debnath, A. K.</span></span> <span> </span><span class="NLM_article-title">Binding mode characterization of NBD series CD4-mimetic HIV-1 entry inhibitors by X-ray structure and resistance study</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">5478</span>– <span class="NLM_lpage">5491</span>, <span class="refDoi"> DOI: 10.1128/AAC.03339-14</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=10.1128%2FAAC.03339-14" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=25001301" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1eqsLfE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2014&pages=5478-5491&author=F.+Curreliauthor=Y.+D.+Kwonauthor=H.+Zhangauthor=Y.+Yangauthor=D.+Scacalossiauthor=P.+D.+Kwongauthor=A.+K.+Debnath&title=Binding+mode+characterization+of+NBD+series+CD4-mimetic+HIV-1+entry+inhibitors+by+X-ray+structure+and+resistance+study&doi=10.1128%2FAAC.03339-14"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Binding mode characterization of NBD series CD4-mimetic HIV-1 entry inhibitors by X-ray structure and resistance study</span></div><div class="casAuthors">Curreli, Francesca; Kwon, Young Do; Zhang, Hongtao; Yang, Yongping; Scacalossi, Daniel; Kwong, Peter D.; Debnath, Asim K.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">5478-5491, 15 pp.</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">1098-6596</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">We previously identified two small-mol. CD4 mimetics - NBD-556 and NBD-557 - and synthesized a series of NBD compds. that resulted in improved neutralization activity in a single-cycle HIV-1 infectivity assay.  For the current investigation, we selected several of the most active compds. and assessed their antiviral activity on a panel of 53 ref. HIV-1 Env pseudoviruses representing diverse clades of clin. isolates.  The selected compds. inhibited tested clades with low-micromolar potencies.  Mechanism studies indicated that they act as CD4 agonists, a potentially unfavorable therapeutic trait, in that they can bind to the gp120 envelope glycoprotein and initiate a similar physiol. response as CD4.  However, one of the compds., NBD-09027, exhibited reduced agonist properties, in both functional and biophys. studies.  To understand the binding mode of these inhibitors, we first generated HIV-1-resistant mutants, assessed their behavior with NBD compds., and detd. the X-ray structures of two inhibitors, NBD-09027 and NBD-10007, in complex with the HIV-1 gp120 core at ∼2-Å resoln.  Both studies confirmed that the NBD compds. bind similarly to NBD-556 and NBD-557 by inserting their hydrophobic groups into the Phe43 cavity of gp120.  The basic nitrogen of the piperidine ring is located in close proximity to D368 of gp120 but it does not form any H-bond or salt bridge, a likely explanation for their nonoptimal antagonist properties.  The results reveal the structural and biol. character of the NBD series of CD4 mimetics and identify ways to reduce their agonist properties and convert them to antagonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQafZBXLanQbVg90H21EOLACvtfcHk0ljfzcPMBfo-Xw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1eqsLfE&md5=d872c92f7a508790f83359add7bfff1d</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1128%2FAAC.03339-14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.03339-14%26sid%3Dliteratum%253Aachs%26aulast%3DCurreli%26aufirst%3DF.%26aulast%3DKwon%26aufirst%3DY.%2BD.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DScacalossi%26aufirst%3DD.%26aulast%3DKwong%26aufirst%3DP.%2BD.%26aulast%3DDebnath%26aufirst%3DA.%2BK.%26atitle%3DBinding%2520mode%2520characterization%2520of%2520NBD%2520series%2520CD4-mimetic%2520HIV-1%2520entry%2520inhibitors%2520by%2520X-ray%2520structure%2520and%2520resistance%2520study%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2014%26volume%3D58%26spage%3D5478%26epage%3D5491%26doi%3D10.1128%2FAAC.03339-14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hamada, Y.</span></span> In  <i>Role of pyridines in medicinal chemistry and design of BACE1 inhibitors possessing a pyridine scaffold</i><i>;</i> <span class="NLM_contrib-group"><span class="NLM_string-name">Pandey, P. P.</span></span>, Ed.; <span class="NLM_publisher-name">IntechOpen</span>, <span class="NLM_year">2018</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=10.5772%2Fintechopen.74719" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=Y.+Hamadaauthor=P.+P.+Pandey&title=Role+of+pyridines+in+medicinal+chemistry+and+design+of+BACE1+inhibitors+possessing+a+pyridine+scaffold"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.5772%2Fintechopen.74719&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.5772%252Fintechopen.74719%26sid%3Dliteratum%253Aachs%26aulast%3DHamada%26aufirst%3DY.%26btitle%3DRole%2520of%2520pyridines%2520in%2520medicinal%2520chemistry%2520and%2520design%2520of%2520BACE1%2520inhibitors%2520possessing%2520a%2520pyridine%2520scaffold%26aulast%3DPandey%26aufirst%3DP.%2BP.%26pub%3DIntechOpen%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bender, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zadjura, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Arienzo, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiGiugno Parker, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gesenberg, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamanaka, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, Y. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, H. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McAuliffe, B. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eggers, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nowicka-Sans, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dicker, I. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colonno, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meanwell, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kadow, J. F.</span></span> <span> </span><span class="NLM_article-title">Inhibitors of human immunodeficiency virus type 1 (HIV-1) attachment. 5. An evolution from indole to azaindoles leading to the discovery of 1-(4-benzoylpiperazin-1-yl)-2-(4,7-dimethoxy-1H-pyrrolo[2,3-c]pyridin-3-yl)ethane −1,2-dione (BMS-488043), a drug candidate that demonstrates antiviral activity in HIV-1-infected subjects</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">7778</span>– <span class="NLM_lpage">7787</span>, <span class="refDoi"> DOI: 10.1021/jm900843g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm900843g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFKns7zK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=7778-7787&author=T.+Wangauthor=Z.+Yinauthor=Z.+Zhangauthor=J.+A.+Benderauthor=Z.+Yangauthor=G.+Johnsonauthor=Z.+Yangauthor=L.+M.+Zadjuraauthor=C.+J.+D%E2%80%99Arienzoauthor=D.+DiGiugno+Parkerauthor=C.+Gesenbergauthor=G.+A.+Yamanakaauthor=Y.+F.+Gongauthor=H.+T.+Hoauthor=H.+Fangauthor=N.+Zhouauthor=B.+V.+McAuliffeauthor=B.+J.+Eggersauthor=L.+Fanauthor=B.+Nowicka-Sansauthor=I.+B.+Dickerauthor=Q.+Gaoauthor=R.+J.+Colonnoauthor=P.+F.+Linauthor=N.+A.+Meanwellauthor=J.+F.+Kadow&title=Inhibitors+of+human+immunodeficiency+virus+type+1+%28HIV-1%29+attachment.+5.+An+evolution+from+indole+to+azaindoles+leading+to+the+discovery+of+1-%284-benzoylpiperazin-1-yl%29-2-%284%2C7-dimethoxy-1H-pyrrolo%5B2%2C3-c%5Dpyridin-3-yl%29ethane+%E2%88%921%2C2-dione+%28BMS-488043%29%2C+a+drug+candidate+that+demonstrates+antiviral+activity+in+HIV-1-infected+subjects&doi=10.1021%2Fjm900843g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitors of Human Immunodeficiency Virus Type 1 (HIV-1) Attachment. 5. An Evolution from Indole to Azaindoles Leading to the Discovery of 1-(4-Benzoylpiperazin-1-yl)-2-(4,7-dimethoxy-1H-pyrrolo[2,3-c]pyridin-3-yl)ethane-1,2-dione (BMS-488043), a Drug Candidate That Demonstrates Antiviral Activity in HIV-1-Infected Subjects</span></div><div class="casAuthors">Wang, Tao; Yin, Zhiwei; Zhang, Zhongxing; Bender, John A.; Yang, Zhong; Johnson, Graham; Yang, Zheng; Zadjura, Lisa M.; D'Arienzo, Celia J.; DiGiugno Parker, Dawn; Gesenberg, Christophe; Yamanaka, Gregory A.; Gong, Yi-Fei; Ho, Hsu-Tso; Fang, Hua; Zhou, Nannan; McAuliffe, Brian V.; Eggers, Betsy J.; Fan, Li; Nowicka-Sans, Beata; Dicker, Ira B.; Gao, Qi; Colonno, Richard J.; Lin, Pin-Fang; Meanwell, Nicholas A.; Kadow, John F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">7778-7787</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Azaindole derivs. derived from the screening lead 1-(4-benzoylpiperazin-1-yl)-2-(1H-indol-3-yl)ethane-1,2-dione were prepd. and characterized to assess their potential as inhibitors of HIV-1 attachment.  Systematic replacement of each of the unfused carbon atoms in the Ph ring of the indole moiety by a nitrogen atom provided four different azaindole derivs. that displayed a clear SAR for antiviral activity and all of which displayed marked improvements in pharmaceutical properties.  Optimization of these azaindole leads resulted in the identification of two compds. that were advanced to clin. studies: (R)-1-(4-benzoyl-2-methylpiperazin-1-yl)-2-(4-methoxy-1H-pyrrolo[2,3-b]pyridin-3-yl)ethane-1,2-dione I, and 1-(4-benzoylpiperazin-1-yl)-2-(4,7-dimethoxy-1H-pyrrolo[2,3-c]pyridin-3-yl)ethane-1,2-dione, II.  In a preliminary clin. study, II administered as monotherapy for 8 days, reduced viremia in HIV-1-infected subjects, providing proof of concept for this mechanistic class.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr84dI0I-kTkrVg90H21EOLACvtfcHk0ljfzcPMBfo-Xw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFKns7zK&md5=c381dc8129dcc2a36547db53aae3a654</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Fjm900843g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm900843g%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DT.%26aulast%3DYin%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DBender%26aufirst%3DJ.%2BA.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DJohnson%26aufirst%3DG.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DZadjura%26aufirst%3DL.%2BM.%26aulast%3DD%25E2%2580%2599Arienzo%26aufirst%3DC.%2BJ.%26aulast%3DDiGiugno%2BParker%26aufirst%3DD.%26aulast%3DGesenberg%26aufirst%3DC.%26aulast%3DYamanaka%26aufirst%3DG.%2BA.%26aulast%3DGong%26aufirst%3DY.%2BF.%26aulast%3DHo%26aufirst%3DH.%2BT.%26aulast%3DFang%26aufirst%3DH.%26aulast%3DZhou%26aufirst%3DN.%26aulast%3DMcAuliffe%26aufirst%3DB.%2BV.%26aulast%3DEggers%26aufirst%3DB.%2BJ.%26aulast%3DFan%26aufirst%3DL.%26aulast%3DNowicka-Sans%26aufirst%3DB.%26aulast%3DDicker%26aufirst%3DI.%2BB.%26aulast%3DGao%26aufirst%3DQ.%26aulast%3DColonno%26aufirst%3DR.%2BJ.%26aulast%3DLin%26aufirst%3DP.%2BF.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DKadow%26aufirst%3DJ.%2BF.%26atitle%3DInhibitors%2520of%2520human%2520immunodeficiency%2520virus%2520type%25201%2520%2528HIV-1%2529%2520attachment.%25205.%2520An%2520evolution%2520from%2520indole%2520to%2520azaindoles%2520leading%2520to%2520the%2520discovery%2520of%25201-%25284-benzoylpiperazin-1-yl%2529-2-%25284%252C7-dimethoxy-1H-pyrrolo%255B2%252C3-c%255Dpyridin-3-yl%2529ethane%2520%25E2%2588%25921%252C2-dione%2520%2528BMS-488043%2529%252C%2520a%2520drug%2520candidate%2520that%2520demonstrates%2520antiviral%2520activity%2520in%2520HIV-1-infected%2520subjects%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D7778%26epage%3D7787%26doi%3D10.1021%2Fjm900843g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hartz, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahuja, V. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhuo, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mattson, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denhart, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deskus, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vrudhula, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ditta, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shu, Y. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grace, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lentz, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lelas, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molski, T. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krishnananthan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian-Cutrone, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schartman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denton, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lodge, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaczek, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macor, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bronson, J. J.</span></span> <span> </span><span class="NLM_article-title">A strategy to minimize reactive metabolite formation: discovery of (S)-4-(1-cyclopropyl-2-methoxyethyl)-6-[6-(difluoromethoxy)-2,5-dimethylpyridin-3 -ylamino]-5-oxo-4,5-dihydropyrazine-2-carbonitrile as a potent, orally bioavailable corticotropin-releasing factor-1 receptor antagonist</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">7653</span>– <span class="NLM_lpage">7668</span>, <span class="refDoi"> DOI: 10.1021/jm900716v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm900716v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtVOnsrzM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=7653-7668&author=R.+A.+Hartzauthor=V.+T.+Ahujaauthor=X.+Zhuoauthor=R.+J.+Mattsonauthor=D.+J.+Denhartauthor=J.+A.+Deskusauthor=V.+M.+Vrudhulaauthor=S.+Panauthor=J.+L.+Dittaauthor=Y.+Z.+Shuauthor=J.+E.+Graceauthor=K.+A.+Lentzauthor=S.+Lelasauthor=Y.+W.+Liauthor=T.+F.+Molskiauthor=S.+Krishnananthanauthor=H.+Wongauthor=J.+Qian-Cutroneauthor=R.+Schartmanauthor=R.+Dentonauthor=N.+J.+Lodgeauthor=R.+Zaczekauthor=J.+E.+Macorauthor=J.+J.+Bronson&title=A+strategy+to+minimize+reactive+metabolite+formation%3A+discovery+of+%28S%29-4-%281-cyclopropyl-2-methoxyethyl%29-6-%5B6-%28difluoromethoxy%29-2%2C5-dimethylpyridin-3+-ylamino%5D-5-oxo-4%2C5-dihydropyrazine-2-carbonitrile+as+a+potent%2C+orally+bioavailable+corticotropin-releasing+factor-1+receptor+antagonist&doi=10.1021%2Fjm900716v"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">A Strategy to Minimize Reactive Metabolite Formation: Discovery of (S)-4-(1-Cyclopropyl-2-methoxyethyl)-6-[6-(difluoromethoxy)-2,5-dimethylpyridin-3-ylamino]-5-oxo-4,5-dihydropyrazine-2-carbonitrile as a Potent, Orally Bioavailable Corticotropin-Releasing Factor-1 Receptor Antagonist</span></div><div class="casAuthors">Hartz, Richard A.; Ahuja, Vijay T.; Zhuo, Xiaoliang; Mattson, Ronald J.; Denhart, Derek J.; Deskus, Jeffrey A.; Vrudhula, Vivekananda M.; Pan, Senliang; Ditta, Jonathan L.; Shu, Yue-Zhong; Grace, James E.; Lentz, Kimberley A.; Lelas, Snjezana; Li, Yu-Wen; Molski, Thaddeus F.; Krishnananthan, Subramaniam; Wong, Henry; Qian-Cutrone, Jingfang; Schartman, Richard; Denton, Rex; Lodge, Nicholas J.; Zaczek, Robert; Macor, John E.; Bronson, Joanne J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">7653-7668</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Detailed metabolic characterization of 8 (VIII), an earlier lead pyrazinone-based corticotropin-releasing factor-1 (CRF1) receptor antagonist, revealed that this compd. formed significant levels of reactive metabolites, as measured by in vivo and in vitro biotransformation studies.  This was of particular concern due to the body of evidence suggesting that reactive metabolites may be involved in idiosyncratic drug reactions.  Further optimization of the structure-activity relationships and in vivo properties of pyrazinone-based CRF1 receptor antagonists and studies to assess the formation of reactive metabolites led to the discovery of 19e (XIX), a high affinity CRF1 receptor antagonist (IC50 = 0.86 nM) wherein GSH adducts were estd. to be only 0.1% of the total amt. of drug-related material excreted through bile and urine, indicating low levels of reactive metabolite formation in vivo.  A novel 6-(difluoromethoxy)-2,5-dimethylpyridin-3-amine group in XIX contributed to the potency and improved in vivo properties of this compd. and related analogs.  XIX had excellent pharmacokinetic properties in rats and dogs and showed efficacy in the defensive withdrawal model of anxiety in rats.  The lowest efficacious dose was 1.8 mg/kg.  The results of a two-week rat safety study with XIX indicated that this compd. was well-tolerated.  Safety: authors caution safety in conversion of 2-amino-3-methylpyridine to 3-methyl-5-nitropyridin-2-ol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXgjp_vZ9dU7Vg90H21EOLACvtfcHk0lhu1Fl_Lw14Xw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtVOnsrzM&md5=b340d132071b98a2b488952c2bcef4e5</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fjm900716v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm900716v%26sid%3Dliteratum%253Aachs%26aulast%3DHartz%26aufirst%3DR.%2BA.%26aulast%3DAhuja%26aufirst%3DV.%2BT.%26aulast%3DZhuo%26aufirst%3DX.%26aulast%3DMattson%26aufirst%3DR.%2BJ.%26aulast%3DDenhart%26aufirst%3DD.%2BJ.%26aulast%3DDeskus%26aufirst%3DJ.%2BA.%26aulast%3DVrudhula%26aufirst%3DV.%2BM.%26aulast%3DPan%26aufirst%3DS.%26aulast%3DDitta%26aufirst%3DJ.%2BL.%26aulast%3DShu%26aufirst%3DY.%2BZ.%26aulast%3DGrace%26aufirst%3DJ.%2BE.%26aulast%3DLentz%26aufirst%3DK.%2BA.%26aulast%3DLelas%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DY.%2BW.%26aulast%3DMolski%26aufirst%3DT.%2BF.%26aulast%3DKrishnananthan%26aufirst%3DS.%26aulast%3DWong%26aufirst%3DH.%26aulast%3DQian-Cutrone%26aufirst%3DJ.%26aulast%3DSchartman%26aufirst%3DR.%26aulast%3DDenton%26aufirst%3DR.%26aulast%3DLodge%26aufirst%3DN.%2BJ.%26aulast%3DZaczek%26aufirst%3DR.%26aulast%3DMacor%26aufirst%3DJ.%2BE.%26aulast%3DBronson%26aufirst%3DJ.%2BJ.%26atitle%3DA%2520strategy%2520to%2520minimize%2520reactive%2520metabolite%2520formation%253A%2520discovery%2520of%2520%2528S%2529-4-%25281-cyclopropyl-2-methoxyethyl%2529-6-%255B6-%2528difluoromethoxy%2529-2%252C5-dimethylpyridin-3%2520-ylamino%255D-5-oxo-4%252C5-dihydropyrazine-2-carbonitrile%2520as%2520a%2520potent%252C%2520orally%2520bioavailable%2520corticotropin-releasing%2520factor-1%2520receptor%2520antagonist%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D7653%26epage%3D7668%26doi%3D10.1021%2Fjm900716v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Belov, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ivanov, V. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curreli, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurkin, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altieri, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Debnath, A. K.</span></span> <span> </span><span class="NLM_article-title">Synthesis of 5-arylpyrrole-2-carboxylic acids as key intermediates for NBD series HIV-1 entry inhibitors</span>. <i>Synthesis</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">3692</span>– <span class="NLM_lpage">3699</span>, <span class="refDoi"> DOI: 10.1055/s-0036-1588780</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=10.1055%2Fs-0036-1588780" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmtlWltL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2017&pages=3692-3699&author=D.+S.+Belovauthor=V.+N.+Ivanovauthor=F.+Curreliauthor=A.+V.+Kurkinauthor=A.+Altieriauthor=A.+K.+Debnath&title=Synthesis+of+5-arylpyrrole-2-carboxylic+acids+as+key+intermediates+for+NBD+series+HIV-1+entry+inhibitors&doi=10.1055%2Fs-0036-1588780"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of 5-Arylpyrrole-2-carboxylic Acids as Key Intermediates for NBD Series HIV-1 Entry Inhibitors</span></div><div class="casAuthors">Belov, Dmitry S.; Ivanov, Vladimir N.; Curreli, Francesca; Kurkin, Alexander V.; Altieri, Andrea; Debnath, Asim K.</div><div class="citationInfo"><span class="NLM_cas:title">Synthesis</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">3692-3699</span>CODEN:
                <span class="NLM_cas:coden">SYNTBF</span>;
        ISSN:<span class="NLM_cas:issn">1437-210X</span>.
    
            (<span class="NLM_cas:orgname">Georg Thieme Verlag</span>)
        </div><div class="casAbstract">5-Arylpyrrole-2-carboxylic acids are important key intermediates in the synthesis of HIV-1 entry inhibitors (such as NBD-11021 and NBD-14010).  Herein, a general method for the synthesis of some 5-arylpyrrole-2-carboxylic acids, e.g., I, in three steps starting from pyrrole is presented.  By this method, the compds. could be prepd. on gram scale and without chromatog. purifn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZei1QnIu1E7Vg90H21EOLACvtfcHk0lhu1Fl_Lw14Xw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmtlWltL4%253D&md5=d828eca316d04a7e8649f64889ee11e2</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1055%2Fs-0036-1588780&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-0036-1588780%26sid%3Dliteratum%253Aachs%26aulast%3DBelov%26aufirst%3DD.%2BS.%26aulast%3DIvanov%26aufirst%3DV.%2BN.%26aulast%3DCurreli%26aufirst%3DF.%26aulast%3DKurkin%26aufirst%3DA.%2BV.%26aulast%3DAltieri%26aufirst%3DA.%26aulast%3DDebnath%26aufirst%3DA.%2BK.%26atitle%3DSynthesis%2520of%25205-arylpyrrole-2-carboxylic%2520acids%2520as%2520key%2520intermediates%2520for%2520NBD%2520series%2520HIV-1%2520entry%2520inhibitors%26jtitle%3DSynthesis%26date%3D2017%26volume%3D49%26spage%3D3692%26epage%3D3699%26doi%3D10.1055%2Fs-0036-1588780" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Curreli, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belov, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramesh, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altieri, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurkin, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Debnath, A. K.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis and evaluation of small molecule CD4-mimics as entry inhibitors possessing broad spectrum anti-HIV-1 activity</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">5988</span>– <span class="NLM_lpage">6003</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2016.09.057</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=10.1016%2Fj.bmc.2016.09.057" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=27707628" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1Wqu7%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2016&pages=5988-6003&author=F.+Curreliauthor=D.+S.+Belovauthor=R.+R.+Rameshauthor=N.+Patelauthor=A.+Altieriauthor=A.+V.+Kurkinauthor=A.+K.+Debnath&title=Design%2C+synthesis+and+evaluation+of+small+molecule+CD4-mimics+as+entry+inhibitors+possessing+broad+spectrum+anti-HIV-1+activity&doi=10.1016%2Fj.bmc.2016.09.057"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and evaluation of small molecule CD4-mimics as entry inhibitors possessing broad spectrum anti-HIV-1 activity</span></div><div class="casAuthors">Curreli, Francesca; Belov, Dmitry S.; Ramesh, Ranjith R.; Patel, Naisargi; Altieri, Andrea; Kurkin, Alexander V.; Debnath, Asim K.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">5988-6003</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Since the first discovery of a CD4-mimic, NBD-556, which targets the Phe43 cavity of HIV-1 gp120, the authors and other groups made considerable progress in designing new CD4-mimics with viral entry-antagonist property.  In the continued effort to make further progress the authors have synthesized twenty five new analogs based on the earlier reported viral entry antagonist, NBD-11021.  These compds. were tested first in HIV-1 Env-pseudovirus based single-cycle infection assay as well as in a multicycle infection assay.  Four of these new compds. showed much improved antiviral potency as well as cytotoxicity.  The authors selected two of the best compds. I (NBD-14009) and II (NBD-14010) to test against a panel of 51 Env-pseudotyped HIV-1 representing diverse subtypes of clin. isolates.  These compds. showed noticeable breadth of antiviral potency with IC50 of as low as 150 nM.  These compds. also inhibited cell-to-cell fusion and cell-to-cell HIV-1 transmission.  The study is expected to pave the way of designing more potent and selective HIV-1 entry inhibitors targeted to the Phe43 cavity of HIV-1 gp120.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8tvfa755JPrVg90H21EOLACvtfcHk0lg6Mq92NM5sWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1Wqu7%252FO&md5=3dfef59f6bbe43266f3520165585b547</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2016.09.057&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2016.09.057%26sid%3Dliteratum%253Aachs%26aulast%3DCurreli%26aufirst%3DF.%26aulast%3DBelov%26aufirst%3DD.%2BS.%26aulast%3DRamesh%26aufirst%3DR.%2BR.%26aulast%3DPatel%26aufirst%3DN.%26aulast%3DAltieri%26aufirst%3DA.%26aulast%3DKurkin%26aufirst%3DA.%2BV.%26aulast%3DDebnath%26aufirst%3DA.%2BK.%26atitle%3DDesign%252C%2520synthesis%2520and%2520evaluation%2520of%2520small%2520molecule%2520CD4-mimics%2520as%2520entry%2520inhibitors%2520possessing%2520broad%2520spectrum%2520anti-HIV-1%2520activity%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2016%26volume%3D24%26spage%3D5988%26epage%3D6003%26doi%3D10.1016%2Fj.bmc.2016.09.057" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Curreli, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belov, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmed, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramesh, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurkin, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altieri, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Debnath, A. K.</span></span> <span> </span><span class="NLM_article-title">Synthesis, antiviral activity, and structure-activity relationship of 1,3-benzodioxolyl pyrrole-based entry inhibitors targeting the Phe43 cavity in HIV-1 gp120</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">2332</span>– <span class="NLM_lpage">2348</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201800534</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=10.1002%2Fcmdc.201800534" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=30257071" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFCgtrzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&pages=2332-2348&author=F.+Curreliauthor=D.+S.+Belovauthor=S.+Ahmedauthor=R.+R.+Rameshauthor=A.+V.+Kurkinauthor=A.+Altieriauthor=A.+K.+Debnath&title=Synthesis%2C+antiviral+activity%2C+and+structure-activity+relationship+of+1%2C3-benzodioxolyl+pyrrole-based+entry+inhibitors+targeting+the+Phe43+cavity+in+HIV-1+gp120&doi=10.1002%2Fcmdc.201800534"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, Antiviral Activity, and Structure-Activity Relationship of 1,3-Benzodioxolyl Pyrrole-Based Entry Inhibitors Targeting the Phe43 Cavity in HIV-1 gp120</span></div><div class="casAuthors">Curreli, Francesca; Belov, Dmitry S.; Ahmed, Shahad; Ramesh, Ranjith R.; Kurkin, Alexander V.; Altieri, Andrea; Debnath, Asim K.</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">2332-2348</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The pathway by which HIV-1 enters host cells is a prime target for novel drug discovery because of its crit. role in the life cycle of HIV-1.  The HIV-1 envelope glycoprotein gp120 plays an important role in initiating virus entry by targeting the primary cell receptor CD4.  We explored the substitution of bulky mol. groups in region I in the NBD class of entry inhibitors.  Previous attempts at bulky substituents in that region abolished antiviral activity, even though the binding site is hydrophobic.  We synthesized a series of entry inhibitors contg. the 1,3-benzodioxolyl moiety or its bioisostere, 2,1,3-benzothiadiazole.  The introduction of the bulkier groups was well tolerated, and despite only minor improvements in antiviral activity, the selectivity index of these compds. improved significantly.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOG5Bxud-tqbVg90H21EOLACvtfcHk0lg6Mq92NM5sWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFCgtrzP&md5=64730c9bd543fffc0b1dfdebe3e83763</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201800534&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201800534%26sid%3Dliteratum%253Aachs%26aulast%3DCurreli%26aufirst%3DF.%26aulast%3DBelov%26aufirst%3DD.%2BS.%26aulast%3DAhmed%26aufirst%3DS.%26aulast%3DRamesh%26aufirst%3DR.%2BR.%26aulast%3DKurkin%26aufirst%3DA.%2BV.%26aulast%3DAltieri%26aufirst%3DA.%26aulast%3DDebnath%26aufirst%3DA.%2BK.%26atitle%3DSynthesis%252C%2520antiviral%2520activity%252C%2520and%2520structure-activity%2520relationship%2520of%25201%252C3-benzodioxolyl%2520pyrrole-based%2520entry%2520inhibitors%2520targeting%2520the%2520Phe43%2520cavity%2520in%2520HIV-1%2520gp120%26jtitle%3DChemMedChem%26date%3D2018%26volume%3D13%26spage%3D2332%26epage%3D2348%26doi%3D10.1002%2Fcmdc.201800534" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Queiroz, M. J. ú.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Begouin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pereira, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferreira, P. M. T.</span></span> <span> </span><span class="NLM_article-title">New synthesis of methyl 5-aryl or heteroaryl pyrrole-2-carboxylates by a tandem Sonogashira coupling/5-endo-dig-cyclization from β-iododehydroamino acid methyl esters and terminal alkynes</span>. <i>Tetrahedron</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">10714</span>– <span class="NLM_lpage">10720</span>, <span class="refDoi"> DOI: 10.1016/j.tet.2008.08.105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=10.1016%2Fj.tet.2008.08.105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1Cqsr%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2008&pages=10714-10720&author=M.+J.+%C3%BA.+Queirozauthor=A.+Begouinauthor=G.+Pereiraauthor=P.+M.+T.+Ferreira&title=New+synthesis+of+methyl+5-aryl+or+heteroaryl+pyrrole-2-carboxylates+by+a+tandem+Sonogashira+coupling%2F5-endo-dig-cyclization+from+%CE%B2-iododehydroamino+acid+methyl+esters+and+terminal+alkynes&doi=10.1016%2Fj.tet.2008.08.105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">New synthesis of methyl 5-aryl- or 5-heteroarylpyrrole-2-carboxylates by a tandem Sonogashira coupling/5-endo-dig-cyclization from β-iododehydroamino acid methyl esters and terminal alkynes</span></div><div class="casAuthors">Queiroz, Maria-Joao R. P.; Begouin, Agathe; Pereira, Goreti; Ferreira, Paula M. T.</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">47</span>),
    <span class="NLM_cas:pages">10714-10720</span>CODEN:
                <span class="NLM_cas:coden">TETRAB</span>;
        ISSN:<span class="NLM_cas:issn">0040-4020</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A new and versatile Pd/CuI catalyzed protocol was developed for the synthesis in good to high yields of substituted pyrroles, e.g., I, from N-Boc-β-iododehydroamino acid Me esters and several terminal alkynes.  This one-pot, two-step procedure occurs by a Sonogashira coupling followed by a 5-endo-dig-cyclization, which involves the nitrogen atom of the dehydroamino acid.  After several expts. using different Pd(0) and Pd(II) species, it was possible to establish the more general reaction conditions, which are: the use of a Pd(II) catalyst, CuI and Cs2CO3 as base in dry DMF at 70°.  The best yields were obtained with arylacetylenes bearing electron-donating groups and with electron-rich heteroarylacetylenes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoReF40VuTUq7Vg90H21EOLACvtfcHk0lg6Mq92NM5sWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1Cqsr%252FN&md5=ac05f13fef051e9c7496a295fda0a33f</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2Fj.tet.2008.08.105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tet.2008.08.105%26sid%3Dliteratum%253Aachs%26aulast%3DQueiroz%26aufirst%3DM.%2BJ.%2B%25C3%25BA.%26aulast%3DBegouin%26aufirst%3DA.%26aulast%3DPereira%26aufirst%3DG.%26aulast%3DFerreira%26aufirst%3DP.%2BM.%2BT.%26atitle%3DNew%2520synthesis%2520of%2520methyl%25205-aryl%2520or%2520heteroaryl%2520pyrrole-2-carboxylates%2520by%2520a%2520tandem%2520Sonogashira%2520coupling%252F5-endo-dig-cyclization%2520from%2520%25CE%25B2-iododehydroamino%2520acid%2520methyl%2520esters%2520and%2520terminal%2520alkynes%26jtitle%3DTetrahedron%26date%3D2008%26volume%3D64%26spage%3D10714%26epage%3D10720%26doi%3D10.1016%2Fj.tet.2008.08.105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kobayakawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konno, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohashi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masuda, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshimura, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harada, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamamura, H.</span></span> <span> </span><span class="NLM_article-title">Soluble-type small-molecule CD4 mimics as HIV entry inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">719</span>– <span class="NLM_lpage">723</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2019.01.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=10.1016%2Fj.bmcl.2019.01.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=30665681" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsVyjt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2019&pages=719-723&author=T.+Kobayakawaauthor=K.+Konnoauthor=N.+Ohashiauthor=K.+Takahashiauthor=A.+Masudaauthor=K.+Yoshimuraauthor=S.+Haradaauthor=H.+Tamamura&title=Soluble-type+small-molecule+CD4+mimics+as+HIV+entry+inhibitors&doi=10.1016%2Fj.bmcl.2019.01.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Soluble-type small-molecule CD4 mimics as HIV entry inhibitors</span></div><div class="casAuthors">Kobayakawa, Takuya; Konno, Kiju; Ohashi, Nami; Takahashi, Kohei; Masuda, Ami; Yoshimura, Kazuhisa; Harada, Shigeyoshi; Tamamura, Hirokazu</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">719-723</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Several small mol. CD4 mimics have been reported previously as HIV-1 entry inhibitors, which block the interaction between the Phe43 cavity of HIV-1 gp120 and the host CD4.  Known CD4 mimics such as NBD-556 possess significant anti-HIV activity but are less sol. in water, perhaps due to their hydrophobic arom. ring-contg. structures.  Compds. with a pyridinyl group in place of the Ph group in these mols. have been designed and synthesized in an attempt to increase the hydrophilicity.  Some of these new CD4 mimics, contg. a tetramethylpiperidine ring show significantly higher water soly. than NBD-556 and have high anti-HIV activity and synergistic anti-HIV activity with a neutralizing antibody.  The CD4 mimic that has a cyclohexylpiperidine ring and a 6-fluoropyridin-3-yl ring has high anti-HIV activity and no significant cytotoxicity.  The present results will be useful in the future design and development of novel sol.-type mol. CD4 mimics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqN4Aonl-kVDbVg90H21EOLACvtfcHk0lgeA_hHIm2RJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsVyjt7w%253D&md5=69a0292b74499b81123afa66bc2e0eb8</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2019.01.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2019.01.011%26sid%3Dliteratum%253Aachs%26aulast%3DKobayakawa%26aufirst%3DT.%26aulast%3DKonno%26aufirst%3DK.%26aulast%3DOhashi%26aufirst%3DN.%26aulast%3DTakahashi%26aufirst%3DK.%26aulast%3DMasuda%26aufirst%3DA.%26aulast%3DYoshimura%26aufirst%3DK.%26aulast%3DHarada%26aufirst%3DS.%26aulast%3DTamamura%26aufirst%3DH.%26atitle%3DSoluble-type%2520small-molecule%2520CD4%2520mimics%2520as%2520HIV%2520entry%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D29%26spage%3D719%26epage%3D723%26doi%3D10.1016%2Fj.bmcl.2019.01.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Curreli, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, Y. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scacalossi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwong, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Debnath, A. K.</span></span> <span> </span><span class="NLM_article-title">Binding mode characterization of NBD series CD4-mimetic HIV-1 entry inhibitors by X-ray structure and resistance study</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">5478</span>– <span class="NLM_lpage">5491</span>, <span class="refDoi"> DOI: 10.1128/AAC.03339-14</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=10.1128%2FAAC.03339-14" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=25001301" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1eqsLfE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2014&pages=5478-5491&author=F.+Curreliauthor=Y.+D.+Kwonauthor=H.+Zhangauthor=Y.+Yangauthor=D.+Scacalossiauthor=P.+D.+Kwongauthor=A.+K.+Debnath&title=Binding+mode+characterization+of+NBD+series+CD4-mimetic+HIV-1+entry+inhibitors+by+X-ray+structure+and+resistance+study&doi=10.1128%2FAAC.03339-14"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Binding mode characterization of NBD series CD4-mimetic HIV-1 entry inhibitors by X-ray structure and resistance study</span></div><div class="casAuthors">Curreli, Francesca; Kwon, Young Do; Zhang, Hongtao; Yang, Yongping; Scacalossi, Daniel; Kwong, Peter D.; Debnath, Asim K.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">5478-5491, 15 pp.</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">1098-6596</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">We previously identified two small-mol. CD4 mimetics - NBD-556 and NBD-557 - and synthesized a series of NBD compds. that resulted in improved neutralization activity in a single-cycle HIV-1 infectivity assay.  For the current investigation, we selected several of the most active compds. and assessed their antiviral activity on a panel of 53 ref. HIV-1 Env pseudoviruses representing diverse clades of clin. isolates.  The selected compds. inhibited tested clades with low-micromolar potencies.  Mechanism studies indicated that they act as CD4 agonists, a potentially unfavorable therapeutic trait, in that they can bind to the gp120 envelope glycoprotein and initiate a similar physiol. response as CD4.  However, one of the compds., NBD-09027, exhibited reduced agonist properties, in both functional and biophys. studies.  To understand the binding mode of these inhibitors, we first generated HIV-1-resistant mutants, assessed their behavior with NBD compds., and detd. the X-ray structures of two inhibitors, NBD-09027 and NBD-10007, in complex with the HIV-1 gp120 core at ∼2-Å resoln.  Both studies confirmed that the NBD compds. bind similarly to NBD-556 and NBD-557 by inserting their hydrophobic groups into the Phe43 cavity of gp120.  The basic nitrogen of the piperidine ring is located in close proximity to D368 of gp120 but it does not form any H-bond or salt bridge, a likely explanation for their nonoptimal antagonist properties.  The results reveal the structural and biol. character of the NBD series of CD4 mimetics and identify ways to reduce their agonist properties and convert them to antagonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQafZBXLanQbVg90H21EOLACvtfcHk0lgeA_hHIm2RJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1eqsLfE&md5=d872c92f7a508790f83359add7bfff1d</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1128%2FAAC.03339-14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.03339-14%26sid%3Dliteratum%253Aachs%26aulast%3DCurreli%26aufirst%3DF.%26aulast%3DKwon%26aufirst%3DY.%2BD.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DScacalossi%26aufirst%3DD.%26aulast%3DKwong%26aufirst%3DP.%2BD.%26aulast%3DDebnath%26aufirst%3DA.%2BK.%26atitle%3DBinding%2520mode%2520characterization%2520of%2520NBD%2520series%2520CD4-mimetic%2520HIV-1%2520entry%2520inhibitors%2520by%2520X-ray%2520structure%2520and%2520resistance%2520study%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2014%26volume%3D58%26spage%3D5478%26epage%3D5491%26doi%3D10.1128%2FAAC.03339-14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madani, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klein, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hubicki, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A. B.,  III</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sodroski, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freire, E.</span></span> <span> </span><span class="NLM_article-title">Thermodynamics of binding of a low-molecular-weight CD4 mimetic to HIV-1 gp120</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">10973</span>– <span class="NLM_lpage">10980</span>, <span class="refDoi"> DOI: 10.1021/bi061193r</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi061193r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=1%3ACAS%3A280%3ADC%252BD28rivFGrug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2006&pages=10973-10980&author=A.+Schonauthor=N.+Madaniauthor=J.+C.+Kleinauthor=A.+Hubickiauthor=D.+Ngauthor=X.+Yangauthor=A.+B.+Smithauthor=J.+Sodroskiauthor=E.+Freire&title=Thermodynamics+of+binding+of+a+low-molecular-weight+CD4+mimetic+to+HIV-1+gp120&doi=10.1021%2Fbi061193r"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Thermodynamics of binding of a low-molecular-weight CD4 mimetic to HIV-1 gp120</span></div><div class="casAuthors">Schon Arne; Madani Navid; Klein Jeffrey C; Hubicki Amy; Ng Danny; Yang Xinzhen; Smith Amos B 3rd; Sodroski Joseph; Freire Ernesto</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">36</span>),
    <span class="NLM_cas:pages">10973-80</span>
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    </div><div class="casAbstract">NBD-556 and the chemically and structurally similar NBD-557 are two low-molecular weight compounds that reportedly block the interaction between the HIV-1 envelope glycoprotein gp120 and its receptor, CD4.  NBD-556 binds to gp120 with a binding affinity of 2.7 x 10(5) M(-1) (K(d) = 3.7 muM) in a process characterized by a large favorable change in enthalpy partially compensated by a large unfavorable entropy change, a thermodynamic signature similar to that observed for binding of sCD4 to gp120.  NBD-556 binding is associated with a large structuring of the gp120 molecule, as also demonstrated by CD spectroscopy.  NBD-556, like CD4, activates the binding of gp120 to the HIV-1 coreceptor, CCR5, and to the 17b monoclonal antibody, which recognizes the coreceptor binding site of gp120.  NBD-556 stimulates HIV-1 infection of CD4-negative, CCR5-expressing cells.  The thermodynamic signature of the binding of NBD-556 to gp120 is very different from that of another viral entry inhibitor, BMS-378806.  Whereas NBD-556 binds gp120 with a large favorable enthalpy and compensating unfavorable entropy changes, BMS-378806 does so with a small binding enthalpy change in a mostly entropy-driven process.  NBD-556 is a competitive inhibitor of sCD4 and elicits a similar structuring of the coreceptor binding site, whereas BMS-378806 does not compete with sCD4 and does not induce coreceptor binding.  These studies demonstrate that low-molecular-weight compounds can induce conformational changes in the HIV-1 gp120 glycoprotein similar to those observed upon CD4 binding, revealing distinct strategies for inhibiting the function of the HIV-1 gp120 envelope glycoprotein.  Furthermore, competitive and noncompetitive compounds have characteristic thermodynamic signatures that can be used to guide the design of more potent and effective viral entry inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRIz0DwBgcSFxWfpMXQLRstfW6udTcc2eb_Xk1cB3fVRLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD28rivFGrug%253D%253D&md5=52d9c713cf0fea54c071a34f3875ccd8</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Fbi061193r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi061193r%26sid%3Dliteratum%253Aachs%26aulast%3DSchon%26aufirst%3DA.%26aulast%3DMadani%26aufirst%3DN.%26aulast%3DKlein%26aufirst%3DJ.%2BC.%26aulast%3DHubicki%26aufirst%3DA.%26aulast%3DNg%26aufirst%3DD.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DSmith%26aufirst%3DA.%2BB.%26aulast%3DSodroski%26aufirst%3DJ.%26aulast%3DFreire%26aufirst%3DE.%26atitle%3DThermodynamics%2520of%2520binding%2520of%2520a%2520low-molecular-weight%2520CD4%2520mimetic%2520to%2520HIV-1%2520gp120%26jtitle%3DBiochemistry%26date%3D2006%26volume%3D45%26spage%3D10973%26epage%3D10980%26doi%3D10.1021%2Fbi061193r" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blair, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spicer, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, Y. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rose, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamanaka, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fridell, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deminie, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demers, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zadjura, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meanwell, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colonno, R.</span></span> <span> </span><span class="NLM_article-title">A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>100</i></span>,  <span class="NLM_fpage">11013</span>– <span class="NLM_lpage">11018</span>, <span class="refDoi"> DOI: 10.1073/pnas.1832214100</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=10.1073%2Fpnas.1832214100" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=12930892" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=1%3ACAS%3A528%3ADC%252BD3sXnslynurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2003&pages=11013-11018&author=P.+F.+Linauthor=W.+Blairauthor=T.+Wangauthor=T.+Spicerauthor=Q.+Guoauthor=N.+Zhouauthor=Y.+F.+Gongauthor=H.+G.+Wangauthor=R.+Roseauthor=G.+Yamanakaauthor=B.+Robinsonauthor=C.+B.+Liauthor=R.+Fridellauthor=C.+Deminieauthor=G.+Demersauthor=Z.+Yangauthor=L.+Zadjuraauthor=N.+Meanwellauthor=R.+Colonno&title=A+small+molecule+HIV-1+inhibitor+that+targets+the+HIV-1+envelope+and+inhibits+CD4+receptor+binding&doi=10.1073%2Fpnas.1832214100"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding</span></div><div class="casAuthors">Lin, Pin-Fang; Blair, Wade; Wang, Tao; Spicer, Timothy; Guo, Qi; Zhou, Nannan; Gong, Yi-Fei; Wang, H. -G. Heidi; Rose, Ronald; Yamanaka, Gregory; Robinson, Brett; Li, Chang-Ben; Fridell, Robert; Deminie, Carol; Demers, Gwendeline; Yang, Zheng; Zadjura, Lisa; Meanwell, Nicholas; Colonno, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">11013-11018</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">BMS-378806 is a recently discovered small mol. HIV-1 inhibitor that blocks viral entrance to cells.  The compd. exhibits potent inhibitory activity against a panel of R5- (virus using the CCR5 coreceptor), X4- (virus using the CXCR4 coreceptor), and R5/X4 HIV-1 lab. and clin. isolates of the B subtype (median EC50 of 0.04 μM) in culture assays.  BMS-378806 is selective for HIV-1 and inactive against HIV-2, SIV and a panel of other viruses, and exhibits no significant cytotoxicity in the 14 cell types tested (concn. for 50% redn. of cell growth, >225 μM).  Mechanism of action studies demonstrated that BMS-378806 binds to gp120 and inhibits the interactions of the HIV-1 envelope protein to cellular CD4 receptors.  Further confirmation that BMS-378806 targets the envelope in infected cells was obtained through the isolation of resistant variants and the mapping of resistance substitutions to the HIV-1 envelope.  In particular, two substitutions, M426L and M475I, are situated in the CD4 binding pocket of gp120.  Recombinant HIV-1 carrying these two substitutions demonstrated significantly reduced susceptibility to compd. inhibition.  BMS-378806 displays many favorable pharmacol. traits, such as low protein binding, minimal human serum effect on anti-HIV-1 potency, good oral bioavailability in animal species, and a clean safety profile in initial animal toxicol. studies.  Together, the data show that BMS-378806 is a representative of a new class of HIV inhibitors that has the potential to become a valued addn. to our current armamentarium of antiretroviral drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRxcq5wksNmrVg90H21EOLACvtfcHk0lj4GglKQPhA9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXnslynurg%253D&md5=9066843a4e1b65984343fccd70ae4323</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1832214100&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1832214100%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DP.%2BF.%26aulast%3DBlair%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DT.%26aulast%3DSpicer%26aufirst%3DT.%26aulast%3DGuo%26aufirst%3DQ.%26aulast%3DZhou%26aufirst%3DN.%26aulast%3DGong%26aufirst%3DY.%2BF.%26aulast%3DWang%26aufirst%3DH.%2BG.%26aulast%3DRose%26aufirst%3DR.%26aulast%3DYamanaka%26aufirst%3DG.%26aulast%3DRobinson%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DC.%2BB.%26aulast%3DFridell%26aufirst%3DR.%26aulast%3DDeminie%26aufirst%3DC.%26aulast%3DDemers%26aufirst%3DG.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DZadjura%26aufirst%3DL.%26aulast%3DMeanwell%26aufirst%3DN.%26aulast%3DColonno%26aufirst%3DR.%26atitle%3DA%2520small%2520molecule%2520HIV-1%2520inhibitor%2520that%2520targets%2520the%2520HIV-1%2520envelope%2520and%2520inhibits%2520CD4%2520receptor%2520binding%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2003%26volume%3D100%26spage%3D11013%26epage%3D11018%26doi%3D10.1073%2Fpnas.1832214100" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parast, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nduati, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">John-Stewart, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mbori-Ngacha, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rainwater, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Overbaugh, J.</span></span> <span> </span><span class="NLM_article-title">Neutralization escape variants of human immunodeficiency virus type 1 are transmitted from mother to infant</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>80</i></span>,  <span class="NLM_fpage">835</span>– <span class="NLM_lpage">844</span>, <span class="refDoi"> DOI: 10.1128/JVI.80.2.835-844.2006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=10.1128%2FJVI.80.2.835-844.2006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=16378985" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=1%3ACAS%3A528%3ADC%252BD28XivVOrtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2006&pages=835-844&author=X.+Wuauthor=A.+B.+Parastauthor=B.+A.+Richardsonauthor=R.+Nduatiauthor=G.+John-Stewartauthor=D.+Mbori-Ngachaauthor=S.+M.+Rainwaterauthor=J.+Overbaugh&title=Neutralization+escape+variants+of+human+immunodeficiency+virus+type+1+are+transmitted+from+mother+to+infant&doi=10.1128%2FJVI.80.2.835-844.2006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Neutralization escape variants of human immunodeficiency virus type 1 are transmitted from mother to infant</span></div><div class="casAuthors">Wu, Xueling; Parast, Adam B.; Richardson, Barbra A.; Nduati, Ruth; John-Stewart, Grace; Mbori-Ngacha, Dorothy; Rainwater, Stephanie M. J.; Overbaugh, Julie</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">80</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">835-844</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Maternal passive immunity typically plays a crit. role in protecting infants from new infections; however, the specific contribution of neutralizing antibodies in limiting mother-to-child transmission of human immunodeficiency virus type 1 is unclear.  By examg. cloned envelope variants from 12 transmission pairs, we found that vertically transmitted variants were more resistant to neutralization by maternal plasma than were maternal viral variants near the time of transmission.  The vertically transmitted envelope variants were poorly neutralized by monoclonal antibodies biz, 2G12, 2F5, and 4E10 individually or in combination.  Despite the fact that the infant viruses were among the most neutralization resistant in the mother, they had relatively few glycosylation sites.  Moreover, the transmitted variants elicited de novo neutralizing antibodies in the infants, indicating that they were not inherently difficult to neutralize.  The neutralization resistance of vertically transmitted viruses is in contrast to the relative neutralization sensitivity of viruses sexually transmitted within discordant couples, suggesting that the antigenic properties of viruses that are favored for transmission may differ depending upon mode of transmission.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpg1ghxbC6IW7Vg90H21EOLACvtfcHk0lj4GglKQPhA9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XivVOrtQ%253D%253D&md5=3d7befeb4abfc14465b28311dd8292e6</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1128%2FJVI.80.2.835-844.2006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.80.2.835-844.2006%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DX.%26aulast%3DParast%26aufirst%3DA.%2BB.%26aulast%3DRichardson%26aufirst%3DB.%2BA.%26aulast%3DNduati%26aufirst%3DR.%26aulast%3DJohn-Stewart%26aufirst%3DG.%26aulast%3DMbori-Ngacha%26aufirst%3DD.%26aulast%3DRainwater%26aufirst%3DS.%2BM.%26aulast%3DOverbaugh%26aufirst%3DJ.%26atitle%3DNeutralization%2520escape%2520variants%2520of%2520human%2520immunodeficiency%2520virus%2520type%25201%2520are%2520transmitted%2520from%2520mother%2520to%2520infant%26jtitle%3DJ.%2520Virol.%26date%3D2006%26volume%3D80%26spage%3D835%26epage%3D844%26doi%3D10.1128%2FJVI.80.2.835-844.2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Agosto, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uchil, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mothes, W.</span></span> <span> </span><span class="NLM_article-title">HIV cell-to-cell transmission: effects on pathogenesis and antiretroviral therapy</span>. <i>Trends Microbiol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">289</span>– <span class="NLM_lpage">295</span>, <span class="refDoi"> DOI: 10.1016/j.tim.2015.02.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=10.1016%2Fj.tim.2015.02.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=25766144" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjs1Kjt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2015&pages=289-295&author=L.+M.+Agostoauthor=P.+D.+Uchilauthor=W.+Mothes&title=HIV+cell-to-cell+transmission%3A+effects+on+pathogenesis+and+antiretroviral+therapy&doi=10.1016%2Fj.tim.2015.02.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">HIV cell-to-cell transmission: effects on pathogenesis and antiretroviral therapy</span></div><div class="casAuthors">Agosto, Luis M.; Uchil, Pradeep D.; Mothes, Walther</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Microbiology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">289-295</span>CODEN:
                <span class="NLM_cas:coden">TRMIEA</span>;
        ISSN:<span class="NLM_cas:issn">0966-842X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">HIV spreads more efficiently in vitro when infected cells directly contact uninfected cells to form virol. synapses.  A hallmark of virol. synapses is that viruses can be transmitted at a higher multiplicity of infection (MOI) that, in vitro, results in a higher no. of proviruses.  Whether HIV also spreads by cell-cell contact in vivo is a matter of debate.  Here we discuss recent data that suggest that contact-mediated transmission largely manifests itself in vivo as CD4+ T cell depletion.  The assault of a cell by a large no. of incoming particles is likely to be efficiently sensed by the innate cellular surveillance to trigger cell death.  The large no. of particles transferred across virol. synapses has also been implicated in reduced efficacy of antiretroviral therapies.  Thus, antiretroviral therapies must remain effective against the high MOI obsd. during cell-to-cell transmission to inhibit both viral replication and the pathogenesis assocd. with HIV infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmKTY4Az8TlrVg90H21EOLACvtfcHk0lh9niB2esZuUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjs1Kjt7o%253D&md5=00eac88b406a7e52b22c12922f2b5fc9</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1016%2Fj.tim.2015.02.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tim.2015.02.003%26sid%3Dliteratum%253Aachs%26aulast%3DAgosto%26aufirst%3DL.%2BM.%26aulast%3DUchil%26aufirst%3DP.%2BD.%26aulast%3DMothes%26aufirst%3DW.%26atitle%3DHIV%2520cell-to-cell%2520transmission%253A%2520effects%2520on%2520pathogenesis%2520and%2520antiretroviral%2520therapy%26jtitle%3DTrends%2520Microbiol.%26date%3D2015%26volume%3D23%26spage%3D289%26epage%3D295%26doi%3D10.1016%2Fj.tim.2015.02.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abela, I. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berlinger, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schanz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reynell, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunthard, H. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rusert, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trkola, A.</span></span> <span> </span><span class="NLM_article-title">Cell-cell transmission enables HIV-1 to evade inhibition by potent CD4bs directed antibodies</span>. <i>PLoS Pathog.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>8</i></span>, <span class="NLM_elocation-id">e1002634</span> <span class="refDoi"> DOI: 10.1371/journal.ppat.1002634</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=10.1371%2Fjournal.ppat.1002634" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=22496655" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=1%3ACAS%3A528%3ADC%252BC38Xlsl2qs7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2012&author=I.+A.+Abelaauthor=L.+Berlingerauthor=M.+Schanzauthor=L.+Reynellauthor=H.+F.+Gunthardauthor=P.+Rusertauthor=A.+Trkola&title=Cell-cell+transmission+enables+HIV-1+to+evade+inhibition+by+potent+CD4bs+directed+antibodies&doi=10.1371%2Fjournal.ppat.1002634"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Cell-cell transmission enables HIV-1 to evade inhibition by potent CD4bs directed antibodies</span></div><div class="casAuthors">Abela, Irene A.; Berlinger, Livia; Schanz, Merle; Reynell, Lucy; Guenthard, Huldrych F.; Rusert, Peter; Trkola, Alexandra</div><div class="citationInfo"><span class="NLM_cas:title">PLoS Pathogens</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">e1002634</span>CODEN:
                <span class="NLM_cas:coden">PPLACN</span>;
        ISSN:<span class="NLM_cas:issn">1553-7374</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">HIV is known to spread efficiently both in a cell-free state and from cell to cell, however the relative importance of the cell-cell transmission mode in natural infection has not yet been resolved.  Likewise to what extent cell-cell transmission is vulnerable to inhibition by neutralizing antibodies and entry inhibitors remains to be detd.  Here we report on neutralizing antibody activity during cell-cell transmission using specifically tailored exptl. strategies which enable unambiguous discrimination between the two transmission routes.  We demonstrate that the activity of neutralizing monoclonal antibodies (mAbs) and entry inhibitors during cell-cell transmission varies depending on their mode of action.  While gp41 directed agents remain active, CD4 binding site (CD4bs) directed inhibitors, including the potent neutralizing mAb VRC01, dramatically lose potency during cell-cell transmission.  This implies that CD4bs mAbs act preferentially through blocking free virus transmission, while still allowing HIV to spread through cell-cell contacts.  Thus providing a plausible explanation for how HIV maintains infectivity and rapidly escapes potent and broadly active CD4bs directed antibody responses in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqguQxbGgAR8LVg90H21EOLACvtfcHk0lh9niB2esZuUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xlsl2qs7w%253D&md5=ffd09b3f9804da82500d931c946fbc53</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1371%2Fjournal.ppat.1002634&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.ppat.1002634%26sid%3Dliteratum%253Aachs%26aulast%3DAbela%26aufirst%3DI.%2BA.%26aulast%3DBerlinger%26aufirst%3DL.%26aulast%3DSchanz%26aufirst%3DM.%26aulast%3DReynell%26aufirst%3DL.%26aulast%3DGunthard%26aufirst%3DH.%2BF.%26aulast%3DRusert%26aufirst%3DP.%26aulast%3DTrkola%26aufirst%3DA.%26atitle%3DCell-cell%2520transmission%2520enables%2520HIV-1%2520to%2520evade%2520inhibition%2520by%2520potent%2520CD4bs%2520directed%2520antibodies%26jtitle%3DPLoS%2520Pathog.%26date%3D2012%26volume%3D8%26doi%3D10.1371%2Fjournal.ppat.1002634" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Durham, N. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yewdall, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zony, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, B. K.</span></span> <span> </span><span class="NLM_article-title">Neutralization resistance of virological synapse-mediated HIV-1 Infection is regulated by the gp41 cytoplasmic tail</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>86</i></span>,  <span class="NLM_fpage">7484</span>– <span class="NLM_lpage">7495</span>, <span class="refDoi"> DOI: 10.1128/JVI.00230-12</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=10.1128%2FJVI.00230-12" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=22553332" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVegsbbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=86&publication_year=2012&pages=7484-7495&author=N.+D.+Durhamauthor=A.+W.+Yewdallauthor=P.+Chenauthor=R.+Leeauthor=C.+Zonyauthor=J.+E.+Robinsonauthor=B.+K.+Chen&title=Neutralization+resistance+of+virological+synapse-mediated+HIV-1+Infection+is+regulated+by+the+gp41+cytoplasmic+tail&doi=10.1128%2FJVI.00230-12"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Neutralization resistance of virological synapse-mediated HIV-1 infection is regulated by the gp41 cytoplasmic tail</span></div><div class="casAuthors">Durham, Natasha D.; Yewdall, Alice W.; Chen, Ping; Lee, Rebecca; Zony, Chati; Robinson, James E.; Chen, Benjamin K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">86</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">7484-7495</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Human immunodeficiency virus type 1 (HIV-1) infection can spread efficiently from infected to uninfected T cells through adhesive contacts called virol. synapses (VSs).  In this process, cell-surface envelope glycoprotein (Env) initiates adhesion and viral transfer into an uninfected recipient cell.  Previous studies have found some HIV-1-neutralizing patient sera to be less effective at blocking VS-mediated infection than infection with cell-free virus.  Here we employ sensitive flow cytometry-based infection assays to measure the inhibitory potency of HIV-1-neutralizing monoclonal antibodies (MAb) and HIV-1-neutralizing patient sera against cell-free and VS-mediated infection.  To various degrees, anti-Env MAbs exhibited significantly higher 50% inhibitory concn. (IC50s) against VS-mediated infection than cell-free infection.  Notably, the MAb 17b, which binds a CD4-induced (CD4i) epitope on gp120, displayed a 72-fold reduced efficacy against VS-mediated inocula compared to cell-free inocula.  A mutant with truncation mutation in the gp41 cytoplasmic tail (CT) which is unable to modulate Env fusogenicity in response to virus particle maturation but which can still engage in cell-to-cell infection was tested for the ability to resist neutralizing antibodies.  The ΔCT mutation increased cell surface staining by neutralizing antibodies, significantly enhanced neutralization of VS-mediated infection, and had reduced or no effect on cell-free infection, depending upon the antibody.  Our results suggest that the gp41 CT regulates the exposure of key neutralizing epitopes during cell-to-cell infection and plays an important role in immune evasion.  Vaccine strategies should consider immunogens that reflect Env conformations exposed on the infected cell surface to enhance protection against VS-mediated HIV-1 spread.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXu523tMUDKbVg90H21EOLACvtfcHk0lh9niB2esZuUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVegsbbP&md5=a07cc2d4d1ddbacbd87f8bbb520ccd3e</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1128%2FJVI.00230-12&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.00230-12%26sid%3Dliteratum%253Aachs%26aulast%3DDurham%26aufirst%3DN.%2BD.%26aulast%3DYewdall%26aufirst%3DA.%2BW.%26aulast%3DChen%26aufirst%3DP.%26aulast%3DLee%26aufirst%3DR.%26aulast%3DZony%26aufirst%3DC.%26aulast%3DRobinson%26aufirst%3DJ.%2BE.%26aulast%3DChen%26aufirst%3DB.%2BK.%26atitle%3DNeutralization%2520resistance%2520of%2520virological%2520synapse-mediated%2520HIV-1%2520Infection%2520is%2520regulated%2520by%2520the%2520gp41%2520cytoplasmic%2520tail%26jtitle%3DJ.%2520Virol.%26date%3D2012%26volume%3D86%26spage%3D7484%26epage%3D7495%26doi%3D10.1128%2FJVI.00230-12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zony, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, B. K.</span></span> <span> </span><span class="NLM_article-title">Reduced potency and incomplete neutralization of broadly neutralizing antibodies against Cell-to-Cell transmission of HIV-1 with transmitted founder Envs</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>91</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">19</span>, <span class="refDoi"> DOI: 10.1128/JVI.02425-16</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=10.1128%2FJVI.02425-16" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFensbrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=2017&pages=1-19&author=H.+Liauthor=C.+Zonyauthor=P.+Chenauthor=B.+K.+Chen&title=Reduced+potency+and+incomplete+neutralization+of+broadly+neutralizing+antibodies+against+Cell-to-Cell+transmission+of+HIV-1+with+transmitted+founder+Envs&doi=10.1128%2FJVI.02425-16"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">CD8+ T cell immune response in immunocompetent mice during zika virus infection</span></div><div class="casAuthors">Huang, Huarong; Li, Shihua; Zhang, Yongli; Han, Xiaojuan; Jia, Baoqian; Liu, Hongtao; Liu, Dandan; Tan, Shuguang; Wang, Qihui; Bi, Yuhai; Liu, William J.; Hou, Baidong; Gao, George Fu; Zhang, Fuping</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">91</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">1-15</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">1098-5514</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Zika virus (ZIKV) infection causees neurol. complications, including Guillain-Barr´e syndrome in adults and central nervous system (CNS) abnormalities in fetuses.  We investigated the immune response, esp. the CD8+ T cell response in C57BL/6 (B6) wild-type (WT) mice, during ZIKV infection.  We found that a robust CD8+ T cell response was elicited, major histocompatibility complex class I-restricted CD8+ T cell epitopes were identified, a tetramer that recognizes ZIKV-specific CD8+ T cells was developed, and virus-specific memory CD8+ T cells were generated in these mice.  The CD8+ T cells from these infected mice were functional, as evidenced by the fact that the adoptive transfer of ZIKV-specific CD8+ T cells could prevent ZIKV infection in the CNS and was cross protective against dengue virus infection.  Our findings provide comprehensive insight into immune responses against ZIKV and further demonstrate that WT mice could be a natural and easy-access model for evaluating immune responses to ZIKV infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZA4dpV1EG-7Vg90H21EOLACvtfcHk0ljFuaPFenb7hg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFensbrI&md5=19a3e320b2a2b9d8ed13a75be9a856cb</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1128%2FJVI.02425-16&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.02425-16%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DH.%26aulast%3DZony%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DP.%26aulast%3DChen%26aufirst%3DB.%2BK.%26atitle%3DReduced%2520potency%2520and%2520incomplete%2520neutralization%2520of%2520broadly%2520neutralizing%2520antibodies%2520against%2520Cell-to-Cell%2520transmission%2520of%2520HIV-1%2520with%2520transmitted%2520founder%2520Envs%26jtitle%3DJ.%2520Virol.%26date%3D2017%26volume%3D91%26spage%3D1%26epage%3D19%26doi%3D10.1128%2FJVI.02425-16" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Agosto, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munro, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mothes, W.</span></span> <span> </span><span class="NLM_article-title">Highly active antiretroviral therapies are effective against HIV-1 cell-to-cell transmission</span>. <i>PLoS Pathog.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>10</i></span>, <span class="NLM_elocation-id">e1003982</span> <span class="refDoi"> DOI: 10.1371/journal.ppat.1003982</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=10.1371%2Fjournal.ppat.1003982" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=24586176" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=1%3ACAS%3A528%3ADC%252BC2cXkvVens7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2014&author=L.+M.+Agostoauthor=P.+Zhongauthor=J.+Munroauthor=W.+Mothes&title=Highly+active+antiretroviral+therapies+are+effective+against+HIV-1+cell-to-cell+transmission&doi=10.1371%2Fjournal.ppat.1003982"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Highly active antiretroviral therapies are effective against HIV-1 cell-to-cell transmission</span></div><div class="casAuthors">Agosto, Luis M.; Zhong, Peng; Munro, James; Mothes, Walther</div><div class="citationInfo"><span class="NLM_cas:title">PLoS Pathogens</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">e1003982/1-e1003982/12, 12 pp.</span>CODEN:
                <span class="NLM_cas:coden">PPLACN</span>;
        ISSN:<span class="NLM_cas:issn">1553-7374</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">HIV-1 cell-to-cell transmission allows for 2-3 orders of magnitude more efficient viral spread than cell-free dissemination.  The high local multiplicity of infection (MOI) obsd. at cell-cell contact sites may lower the efficacy of antiretroviral therapies (ART).  Here we test the efficacy of commonly used antiretroviral inhibitors against cell-to-cell and cell-free HIV-1 transmission.  We demonstrate that, while some nucleoside-analog reverse transcriptase inhibitors (NRTI) are less effective against HIV-1 cell-to-cell transmission, most non-nucleoside-analog reverse transcriptase inhibitors (NNRTI), entry inhibitors and protease inhibitors remain highly effective.  Moreover, poor NRTIs become highly effective when applied in combinations explaining the effectiveness of ART in clin. settings.  Investigating the underlying mechanism, we observe a strict correlation between the ability of individual drugs and combinations of drugs to interfere with HIV-1 cell-to-cell transmission, and their effectiveness against high viral MOIs.  Our results suggest that the ability to suppress high viral MOI is a feature of effective ART regimens and this parameter should be considered when designing novel antiviral therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8R3z_rByrLLVg90H21EOLACvtfcHk0ljFuaPFenb7hg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXkvVens7o%253D&md5=31a44c3e858228af6d49deb4042e5b7c</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1371%2Fjournal.ppat.1003982&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.ppat.1003982%26sid%3Dliteratum%253Aachs%26aulast%3DAgosto%26aufirst%3DL.%2BM.%26aulast%3DZhong%26aufirst%3DP.%26aulast%3DMunro%26aufirst%3DJ.%26aulast%3DMothes%26aufirst%3DW.%26atitle%3DHighly%2520active%2520antiretroviral%2520therapies%2520are%2520effective%2520against%2520HIV-1%2520cell-to-cell%2520transmission%26jtitle%3DPLoS%2520Pathog.%26date%3D2014%26volume%3D10%26doi%3D10.1371%2Fjournal.ppat.1003982" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kennedy, T.</span></span> <span> </span><span class="NLM_article-title">Managing the drug discovery/development interface</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">436</span>– <span class="NLM_lpage">444</span>, <span class="refDoi"> DOI: 10.1016/S1359-6446(97)01099-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=10.1016%2FS1359-6446%2897%2901099-4" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=1997&pages=436-444&author=T.+Kennedy&title=Managing+the+drug+discovery%2Fdevelopment+interface&doi=10.1016%2FS1359-6446%2897%2901099-4"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1016%2FS1359-6446%2897%2901099-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1359-6446%252897%252901099-4%26sid%3Dliteratum%253Aachs%26aulast%3DKennedy%26aufirst%3DT.%26atitle%3DManaging%2520the%2520drug%2520discovery%252Fdevelopment%2520interface%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D1997%26volume%3D2%26spage%3D436%26epage%3D444%26doi%3D10.1016%2FS1359-6446%2897%2901099-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Waring, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arrowsmith, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leach, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leeson, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mandrell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owen, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pairaudeau, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pennie, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pickett, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallace, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weir, A.</span></span> <span> </span><span class="NLM_article-title">An analysis of the attrition of drug candidates from four major pharmaceutical companies</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">475</span>– <span class="NLM_lpage">486</span>, <span class="refDoi"> DOI: 10.1038/nrd4609</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=10.1038%2Fnrd4609" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=26091267" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFeju7jM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=475-486&author=M.+J.+Waringauthor=J.+Arrowsmithauthor=A.+R.+Leachauthor=P.+D.+Leesonauthor=S.+Mandrellauthor=R.+M.+Owenauthor=G.+Pairaudeauauthor=W.+D.+Pennieauthor=S.+D.+Pickettauthor=J.+Wangauthor=O.+Wallaceauthor=A.+Weir&title=An+analysis+of+the+attrition+of+drug+candidates+from+four+major+pharmaceutical+companies&doi=10.1038%2Fnrd4609"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">An analysis of the attrition of drug candidates from four major pharmaceutical companies</span></div><div class="casAuthors">Waring, Michael J.; Arrowsmith, John; Leach, Andrew R.; Leeson, Paul D.; Mandrell, Sam; Owen, Robert M.; Pairaudeau, Garry; Pennie, William D.; Pickett, Stephen D.; Wang, Jibo; Wallace, Owen; Weir, Alex</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">475-486</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The pharmaceutical industry remains under huge pressure to address the high attrition rates in drug development.  Attempts to reduce the no. of efficacy- and safety-related failures by analyzing possible links to the physicochem. properties of small-mol. drug candidates have been inconclusive because of the limited size of data sets from individual companies.  Here, we describe the compilation and anal. of combined data on the attrition of drug candidates from AstraZeneca, Eli Lilly and Company, GlaxoSmithKline and Pfizer.  The anal. reaffirms that control of physicochem. properties during compd. optimization is beneficial in identifying compds. of candidate drug quality and indicates for the first time a link between the physicochem. properties of compds. and clin. failure due to safety issues.  The results also suggest that further control of physicochem. properties is unlikely to have a significant effect on attrition rates and that addnl. work is required to address safety-related failures.  Further cross-company collaborations will be crucial to future progress in this area.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsLfBWrLC3ZLVg90H21EOLACvtfcHk0li7oP3ydnoOBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFeju7jM&md5=1fdc374d32816b1e91438152299dd1b1</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1038%2Fnrd4609&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4609%26sid%3Dliteratum%253Aachs%26aulast%3DWaring%26aufirst%3DM.%2BJ.%26aulast%3DArrowsmith%26aufirst%3DJ.%26aulast%3DLeach%26aufirst%3DA.%2BR.%26aulast%3DLeeson%26aufirst%3DP.%2BD.%26aulast%3DMandrell%26aufirst%3DS.%26aulast%3DOwen%26aufirst%3DR.%2BM.%26aulast%3DPairaudeau%26aufirst%3DG.%26aulast%3DPennie%26aufirst%3DW.%2BD.%26aulast%3DPickett%26aufirst%3DS.%2BD.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DWallace%26aufirst%3DO.%26aulast%3DWeir%26aufirst%3DA.%26atitle%3DAn%2520analysis%2520of%2520the%2520attrition%2520of%2520drug%2520candidates%2520from%2520four%2520major%2520pharmaceutical%2520companies%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2015%26volume%3D14%26spage%3D475%26epage%3D486%26doi%3D10.1038%2Fnrd4609" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wei, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Decker, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arani, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kilby, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saag, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kappes, J. C.</span></span> <span> </span><span class="NLM_article-title">Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">1896</span>– <span class="NLM_lpage">1905</span>, <span class="refDoi"> DOI: 10.1128/AAC.46.6.1896-1905.2002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=10.1128%2FAAC.46.6.1896-1905.2002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=12019106" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=1%3ACAS%3A528%3ADC%252BD38XktFCmsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2002&pages=1896-1905&author=X.+Weiauthor=J.+M.+Deckerauthor=H.+Liuauthor=Z.+Zhangauthor=R.+B.+Araniauthor=J.+M.+Kilbyauthor=M.+S.+Saagauthor=X.+Wuauthor=G.+M.+Shawauthor=J.+C.+Kappes&title=Emergence+of+resistant+human+immunodeficiency+virus+type+1+in+patients+receiving+fusion+inhibitor+%28T-20%29+monotherapy&doi=10.1128%2FAAC.46.6.1896-1905.2002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy</span></div><div class="casAuthors">Wei, Xiping; Decker, Julie M.; Liu, Hongmei; Zhang, Zee; Arani, Ramin B.; Kilby, J. Michael; Saag, Michael S.; Wu, Xiaoyun; Shaw, George M.; Kappes, John C.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1896-1905</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The synthetic peptide T-20 (enfuvirtide) represents the first of a new class of antiretroviral compds. to demonstrate in vivo potency by targeting a step in viral entry.  T-20 inhibits a conformational change in the human immunodeficiency virus type 1 (HIV-1) transmembrane glycoprotein (gp41) that is required for fusion between HIV-1 and target cell membranes.  The initial phase I clin. trial of T-20 treatment for HIV-infected patients thus provided a unique opportunity to evaluate the emergence of resistant virus in vivo to this novel class of antiretroviral agents.  All four patients who received an intermediate dose of T-20 (30 mg twice daily) had an initial decline in plasma viral load over the first 10 days but a rising trend by day 14, suggestive of selection for resistant virus.  Plasma virus derived from patients enrolled in all dosage groups of the phase I T-20 trial was analyzed by population sequencing before and after treatment.  While no mutations were found within a highly conserved 3-amino-acid sequence (GIV) known to be crit. for fusion at baseline, after 14 days of therapy, virus from one patient in the 30-mg dose group (30-1) developed a mutation in this motif, specifically an aspartic acid (D) substitution for glycine (G) at position 36.  Multiple env clones were derived from the plasma virus of all four patients in the 30-mg dosage group.  Sequence anal. of 49 clones derived from the plasma of patient 30-1 on day 14 revealed that 25 clones contained the G36D mutation, while 8 contained the V38A mutation.  Dual mutations involving G36D and other residues within the HR1 domain were also identified.  In 5 of the 49 env clones, other mutations involving residues 32 (Q32R or Q32H) and 39 (Q39R) were found in combination with G36D.  Cloned env sequences derived from the plasma virus of subject 30-3 also had single mutations in the GIV sequence (V38M and I37V) detectable following therapy with T-20.  The plasma virus from subjects 30-2 and 30-4 did not contain changes within the GIV sequence.  To analyze the biol. resistance properties of these mutations, we developed a novel single-cycle HIV-1 entry assay using JC53BL cells which express β-galactosidase and luciferase under control of the HIV-1 long terminal repeat.  Full-length env clones were derived from the plasma virus of patients 30-1 and 30-3 and used to generate pseudotyped virus stocks.  The mean 50% inhibition concns. (IC50s) for mutants G36D and V38A (patient 30-1) were 2.3 μg/mL and 11.2 μg/mL, resp., statistically significant increases of 9.1- and 45-fold, resp., compared with those of wild-type Env.  The IC50 for the V38 M mutation (patient 30-3) was 7.6 μg/mL, an 8-fold increase compared with that of the wild type.  The I37V mutation resulted in an IC50 3.2-fold greater than that of the wild type.  Envs with double mutations (Q32R plus G36D and Q32H plus G36D) exhibited a level of resistance similar to that of G36D alone.  These findings provide the first evidence for the rapid emergence of clin. resistance to a novel class of HIV-1 entry inhibitors and may be relevant to future treatment strategies involving these agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTmBSTKEK3v7Vg90H21EOLACvtfcHk0li7oP3ydnoOBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XktFCmsb8%253D&md5=65977bf843ca8ec9411a88b50ef71206</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1128%2FAAC.46.6.1896-1905.2002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.46.6.1896-1905.2002%26sid%3Dliteratum%253Aachs%26aulast%3DWei%26aufirst%3DX.%26aulast%3DDecker%26aufirst%3DJ.%2BM.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DArani%26aufirst%3DR.%2BB.%26aulast%3DKilby%26aufirst%3DJ.%2BM.%26aulast%3DSaag%26aufirst%3DM.%2BS.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DShaw%26aufirst%3DG.%2BM.%26aulast%3DKappes%26aufirst%3DJ.%2BC.%26atitle%3DEmergence%2520of%2520resistant%2520human%2520immunodeficiency%2520virus%2520type%25201%2520in%2520patients%2520receiving%2520fusion%2520inhibitor%2520%2528T-20%2529%2520monotherapy%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2002%26volume%3D46%26spage%3D1896%26epage%3D1905%26doi%3D10.1128%2FAAC.46.6.1896-1905.2002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bjorndal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jansson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiore, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colognesi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlsson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albert, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scarlatti, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Littman, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fenyo, E. M.</span></span> <span> </span><span class="NLM_article-title">Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">7478</span>– <span class="NLM_lpage">7487</span>, <span class="refDoi"> DOI: 10.1128/JVI.71.10.7478-7487.1997</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=10.1128%2FJVI.71.10.7478-7487.1997" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=9311827" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=1%3ACAS%3A528%3ADyaK2sXmt1Omsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=1997&pages=7478-7487&author=A.+Bjorndalauthor=H.+Dengauthor=M.+Janssonauthor=J.+R.+Fioreauthor=C.+Colognesiauthor=A.+Karlssonauthor=J.+Albertauthor=G.+Scarlattiauthor=D.+R.+Littmanauthor=E.+M.+Fenyo&title=Coreceptor+usage+of+primary+human+immunodeficiency+virus+type+1+isolates+varies+according+to+biological+phenotype&doi=10.1128%2FJVI.71.10.7478-7487.1997"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype</span></div><div class="casAuthors">Bjorndal, Asa; Deng, Hongkui; Jansson, Marianne; Fiore, Jose R.; Colognesi, Claudia; Karlsson, Anders; Albert, Jan; Scarlatti, Gabriella; Littman, Dan R.; Fenyo, Eva Maria</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">7478-7487</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The biol. phenotype of primary human immunodeficiency virus type 1 (HIV-1) isolates varies according to the severity of the HIV infection.  Here the authors show that the two previously described groups of rapid/high, syncytium-inducing (SI) and slow/low, non-syncytium-inducing (NSI) isolates are distinguished by their ability to utilize different chemokine receptors for entry into target cells.  Recent studies have identified the C-X-C chemokine receptor CXCR4 (also named fusin or Lestr) and the C-C chemokine receptor CCR5 as the principal entry cofactors for T-cell-line-tropic and non-T-cell-line-tropic HIV-1, resp.  Using U87.CD4 glioma cell lines, stably expressing the chemokine receptor CCR1, CCR2b, CCR3, CCR5, or CXCR4, the authors have tested chemokine receptor specificity for a panel of genetically diverse envelope glycoprotein genes cloned from primary HIV-1 isolates and have found that receptor usage was closely assocd. with the biol. phenotype of the virus isolate but not the genetic subtype.  They have also analyzed a panel of 36 well-characterized primary HIV-1 isolates for syncytium induction and replication in the same series of cell lines.  Infection by slow/low viruses was restricted to cells expressing CCR5, whereas rapid/high viruses could use a variety of chemokine receptors.  In addn. to the regular use of CXCR4, many rapid/high viruses used CCR5 and some also used CCR3 and CCR2b.  Progressive HIV-1 infection is characterized by the emergence of viruses resistant to inhibition by β-chemokines, which corresponded to changes in coreceptor usage.  The broadening of the host range may even enable the use of uncharacterized coreceptors, in that two isolates from immunodeficient patients infected the parental U87.CD4 cell line lacking any engineered coreceptor.  Two primary isolates with multiple coreceptor usage were shown to consist of mixed populations, one with a narrow host range using CCR5 only and the other with a broad host range using CCR3, CCR5, or CXCR4, similar to the original population.  The results show that all 36 primary HIV-1 isolates induce syncytia, provided that target cells carry the particular coreceptor required by the virus.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7xCNHpx6JQrVg90H21EOLACvtfcHk0li7oP3ydnoOBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXmt1Omsr4%253D&md5=9c509d74aaeb47df187b01a3d874ec48</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1128%2FJVI.71.10.7478-7487.1997&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.71.10.7478-7487.1997%26sid%3Dliteratum%253Aachs%26aulast%3DBjorndal%26aufirst%3DA.%26aulast%3DDeng%26aufirst%3DH.%26aulast%3DJansson%26aufirst%3DM.%26aulast%3DFiore%26aufirst%3DJ.%2BR.%26aulast%3DColognesi%26aufirst%3DC.%26aulast%3DKarlsson%26aufirst%3DA.%26aulast%3DAlbert%26aufirst%3DJ.%26aulast%3DScarlatti%26aufirst%3DG.%26aulast%3DLittman%26aufirst%3DD.%2BR.%26aulast%3DFenyo%26aufirst%3DE.%2BM.%26atitle%3DCoreceptor%2520usage%2520of%2520primary%2520human%2520immunodeficiency%2520virus%2520type%25201%2520isolates%2520varies%2520according%2520to%2520biological%2520phenotype%26jtitle%3DJ.%2520Virol.%26date%3D1997%26volume%3D71%26spage%3D7478%26epage%3D7487%26doi%3D10.1128%2FJVI.71.10.7478-7487.1997" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Popovic, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarngadharan, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Read, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallo, R. C.</span></span> <span> </span><span class="NLM_article-title">Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1984</span>,  <span class="NLM_volume"><i>224</i></span>,  <span class="NLM_fpage">497</span>– <span class="NLM_lpage">500</span>, <span class="refDoi"> DOI: 10.1126/science.6200935</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=10.1126%2Fscience.6200935" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=6200935" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=1%3ACAS%3A280%3ADyaL2c7nt1aisw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=224&publication_year=1984&pages=497-500&author=M.+Popovicauthor=M.+G.+Sarngadharanauthor=E.+Readauthor=R.+C.+Gallo&title=Detection%2C+isolation%2C+and+continuous+production+of+cytopathic+retroviruses+%28HTLV-III%29+from+patients+with+AIDS+and+pre-AIDS&doi=10.1126%2Fscience.6200935"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS</span></div><div class="casAuthors">Popovic M; Sarngadharan M G; Read E; Gallo R C</div><div class="citationInfo"><span class="NLM_cas:title">Science (New York, N.Y.)</span>
        (<span class="NLM_cas:date">1984</span>),
    <span class="NLM_cas:volume">224</span>
        (<span class="NLM_cas:issue">4648</span>),
    <span class="NLM_cas:pages">497-500</span>
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    </div><div class="casAbstract">A cell system was developed for the reproducible detection of human T-lymphotropic retroviruses (HTLV family) from patients with the acquired immunodeficiency syndrome (AIDS) or with signs or symptoms that frequently precede AIDS (pre-AIDS).  The cells are specific clones from a permissive human neoplastic T-cell line.  Some of the clones permanently grow and continuously produce large amounts of virus after infection with cytopathic (HTLV-III) variants of these viruses.  One cytopathic effect of HTLV-III in this system is the arrangement of multiple nuclei in a characteristic ring formation in giant cells of the infected T-cell population.  These structures can be used as an indicator to detect HTLV-III in clinical specimens.  This system opens the way to the routine detection of HTLV-III and related cytopathic variants of HTLV in patients with AIDS or pre-AIDS and in healthy carriers, and it provides large amounts of virus for detailed molecular and immunological analyses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSuh_pMc3WcAUbxh97K6Vt6fW6udTcc2eb4g6RXL-CKHLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL2c7nt1aisw%253D%253D&md5=3a239f3c54c182c0f19ee56fa31ab6fb</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1126%2Fscience.6200935&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.6200935%26sid%3Dliteratum%253Aachs%26aulast%3DPopovic%26aufirst%3DM.%26aulast%3DSarngadharan%26aufirst%3DM.%2BG.%26aulast%3DRead%26aufirst%3DE.%26aulast%3DGallo%26aufirst%3DR.%2BC.%26atitle%3DDetection%252C%2520isolation%252C%2520and%2520continuous%2520production%2520of%2520cytopathic%2520retroviruses%2520%2528HTLV-III%2529%2520from%2520patients%2520with%2520AIDS%2520and%2520pre-AIDS%26jtitle%3DScience%26date%3D1984%26volume%3D224%26spage%3D497%26epage%3D500%26doi%3D10.1126%2Fscience.6200935" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baba, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyake, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okamoto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iizawa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okonogi, K.</span></span> <span> </span><span class="NLM_article-title">Establishment of a CCR5-expressing T-lymphoblastoid cell line highly susceptible to R5 HIV type 1</span>. <i>AIDS Res. Hum. Retroviruses</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">935</span>– <span class="NLM_lpage">941</span>, <span class="refDoi"> DOI: 10.1089/08892220050058344</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=10.1089%2F08892220050058344" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=10890354" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=1%3ACAS%3A528%3ADC%252BD3cXlt1yhsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2000&pages=935-941&author=M.+Babaauthor=H.+Miyakeauthor=M.+Okamotoauthor=Y.+Iizawaauthor=K.+Okonogi&title=Establishment+of+a+CCR5-expressing+T-lymphoblastoid+cell+line+highly+susceptible+to+R5+HIV+type+1&doi=10.1089%2F08892220050058344"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Establishment of a CCR5-expressing T-lymphoblastoid cell line highly susceptible to R5 HIV type 1</span></div><div class="casAuthors">Baba, Masanori; Miyake, Hiroshi; Okamoto, Mika; Iizawa, Yuji; Okonogi, Kenji</div><div class="citationInfo"><span class="NLM_cas:title">AIDS Research and Human Retroviruses</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">935-941</span>CODEN:
                <span class="NLM_cas:coden">ARHRE7</span>;
        ISSN:<span class="NLM_cas:issn">0889-2229</span>.
    
            (<span class="NLM_cas:orgname">Mary Ann Liebert, Inc.</span>)
        </div><div class="casAbstract">The β-chemokine receptor CCR5 is considered to be an attractive target for inhibition of CCR5-using (R5 or macrophage-tropic) HIV-1.  However, R5 HIV-1 cannot replicate in CD4+ T cell or monocyte lines because of the lack of CCR5 expression on their surface, which apparently hampers discovery and development of effective CCR5 antagonists against HIV-1 replication.  In this study, we have established the CCR5-expressing T cell line MOLT-4/CCR5, highly permissive to the replication of R5 HIV-1.  The cells express a considerable amt. of CCR5 on their surface.  When the cells were infected with the R5 HIV-1 strains Ba-L and JR-FL, the virus-induced cytopathic effect (syncytium formation) was obsd., and the cells produced large amts. of HIV-1 p24 antigen in the culture supernatants.  The analyses of progeny viruses for their coreceptor use and gp120 V3 nucleotide sequence revealed that they were R5 HIV-1.  The parental cell line MOLT-4 was much less susceptible to Ba-L and totally insusceptible to JR-FL.  Furthermore, MOLT-4/CCR5 cells could support the replication of an R5 clin. isolate, but MOLT-4 cells could not.  When TAK-779, a novel small-mol. nonpeptide CCR5 antagonist, was examd. for its inhibitory effect on R5 HIV-1 replication in MOLT-4/CCR5 cells, the compd. displayed potent antiviral activity, as demonstrated in peripheral blood mononuclear cells.  These results indicate that the established cell line will be an extremely useful tool for expts. with R5 HIV-1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoX1tLnB7wNP7Vg90H21EOLACvtfcHk0ljrETUIZJacJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXlt1yhsLo%253D&md5=c4ef29a4b2ee84ec89fc19df56f684a6</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1089%2F08892220050058344&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252F08892220050058344%26sid%3Dliteratum%253Aachs%26aulast%3DBaba%26aufirst%3DM.%26aulast%3DMiyake%26aufirst%3DH.%26aulast%3DOkamoto%26aufirst%3DM.%26aulast%3DIizawa%26aufirst%3DY.%26aulast%3DOkonogi%26aufirst%3DK.%26atitle%3DEstablishment%2520of%2520a%2520CCR5-expressing%2520T-lymphoblastoid%2520cell%2520line%2520highly%2520susceptible%2520to%2520R5%2520HIV%2520type%25201%26jtitle%3DAIDS%2520Res.%2520Hum.%2520Retroviruses%26date%3D2000%26volume%3D16%26spage%3D935%26epage%3D941%26doi%3D10.1089%2F08892220050058344" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kolchinsky, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mirzabekov, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farzan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiprilov, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cayabyab, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mooney, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choe, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sodroski, J.</span></span> <span> </span><span class="NLM_article-title">Adaptation of a CCR5-using, primary human immunodeficiency virus type 1 isolate for CD4-independent replication</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">8120</span>– <span class="NLM_lpage">8126</span>, <span class="refDoi"> DOI: 10.1128/JVI.73.10.8120-8126.1999</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=10.1128%2FJVI.73.10.8120-8126.1999" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=10482561" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=1%3ACAS%3A528%3ADyaK1MXlvFyrtr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=1999&pages=8120-8126&author=P.+Kolchinskyauthor=T.+Mirzabekovauthor=M.+Farzanauthor=E.+Kiprilovauthor=M.+Cayabyabauthor=L.+J.+Mooneyauthor=H.+Choeauthor=J.+Sodroski&title=Adaptation+of+a+CCR5-using%2C+primary+human+immunodeficiency+virus+type+1+isolate+for+CD4-independent+replication&doi=10.1128%2FJVI.73.10.8120-8126.1999"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Adaptation of a CCR5-using, primary human immunodeficiency virus type 1 isolate for CD4-independent replication</span></div><div class="casAuthors">Kolchinsky, Peter; Mirzabekov, Tajib; Farzan, Michael; Kiprilov, Enko; Cayabyab, Mark; Mooney, Larissa J.; Choe, Hyeryun; Sodroski, Joseph</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">8120-8126</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The gp120 envelope glycoprotein of the human immunodeficiency virus type 1 (HIV-1) promotes virus entry by sequentially binding CD4 and chemokine receptors on the target cell.  Primary, clin. HIV-1 isolates require interaction with CD4 to allow gp120 to bind the CCR5 chemokine receptor efficiently.  The authors adapted a primary HIV-1 isolate, ADA, to replicate in CD4-neg. canine cells expressing human CCR5.  The gp120 changes responsible for the adaptation were limited to alteration of glycosylation addn. sites in the V2 loop-V1-V2 stem.  The gp120 glycoproteins of the adapted viruses bound CCR5 directly, without prior interaction with CD4.  Thus, a major function of CD4 binding in the entry of primary HIV-1 isolates can be bypassed by changes in the gp120 V1-V2 elements, which allow the envelope glycoproteins to assume a conformation competent for CCR5 binding.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1fq87S6oMRLVg90H21EOLACvtfcHk0lj3Ts6b0VeoHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXlvFyrtr0%253D&md5=713cd1c7f3105f250ab088d7b613d0ff</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1128%2FJVI.73.10.8120-8126.1999&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.73.10.8120-8126.1999%26sid%3Dliteratum%253Aachs%26aulast%3DKolchinsky%26aufirst%3DP.%26aulast%3DMirzabekov%26aufirst%3DT.%26aulast%3DFarzan%26aufirst%3DM.%26aulast%3DKiprilov%26aufirst%3DE.%26aulast%3DCayabyab%26aufirst%3DM.%26aulast%3DMooney%26aufirst%3DL.%2BJ.%26aulast%3DChoe%26aufirst%3DH.%26aulast%3DSodroski%26aufirst%3DJ.%26atitle%3DAdaptation%2520of%2520a%2520CCR5-using%252C%2520primary%2520human%2520immunodeficiency%2520virus%2520type%25201%2520isolate%2520for%2520CD4-independent%2520replication%26jtitle%3DJ.%2520Virol.%26date%3D1999%26volume%3D73%26spage%3D8120%26epage%3D8126%26doi%3D10.1128%2FJVI.73.10.8120-8126.1999" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Page, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Landau, N. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Littman, D. R.</span></span> <span> </span><span class="NLM_article-title">Construction and use of a human immunodeficiency virus vector for analysis of virus infectivity</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">5270</span>– <span class="NLM_lpage">5276</span>, <span class="refDoi"> DOI: 10.1128/JVI.64.11.5270-5276.1990</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=10.1128%2FJVI.64.11.5270-5276.1990" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=2214018" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=1%3ACAS%3A528%3ADyaK3cXmtVKit7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=1990&pages=5270-5276&author=K.+A.+Pageauthor=N.+R.+Landauauthor=D.+R.+Littman&title=Construction+and+use+of+a+human+immunodeficiency+virus+vector+for+analysis+of+virus+infectivity&doi=10.1128%2FJVI.64.11.5270-5276.1990"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Construction and use of a human immunodeficiency virus vector for analysis of virus infectivity</span></div><div class="casAuthors">Page, Kathleen A.; Landau, Nathaniel R.; Littman, Dan R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">5270-6</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    </div><div class="casAbstract">A recombinant human immunodeficiency virus (HIV) vector was constructed to facilitate studies of virus infectivity.  A drug-resistance gene was inserted into a gp160- HIV proviral genome such that it could be packaged into HIV virions.  The HIV genome was rendered replication defective by deletion of sequences encoding gp160 and insertion of a gpt gene with a simian virus 40 promoter at the deletion site.  Cotransfection of the envelope-deficient genome with a gp160 expression vector resulted in packaging of the defective HIV-gpt genome into infectious virions.  The drug-resistance gene was transmitted and expressed upon infection of susceptible cells, enabling their selection in mycophenolic acid.  In the absence of gp160, noninfectious HIV particles were efficiently produced by cells transfected with the HIV-gpt genome.  This demonstrates that HIV virion formation is not dependent on the presence of a viral envelope glycoprotein.  Expression of a murine leukemia virus amphotropic envelope gene in cells transfected with HIV-gpt resulted in the prodn. of virus capable of infecting both human and murine cells.  These results indicate that HIV can incorporate envelope glycoproteins other than gp160 onto particles and that this can lead to altered host range.  Like HIV type 1 and vesicular stomatitis virus (HIV) pseudotypes, gp-160+ HIV-gpt did not infect murine NIH 3T3 cells that bear human CD4, confirming that these cells are blocked at an early stage of HIV infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjSByFmAfL27Vg90H21EOLACvtfcHk0lj3Ts6b0VeoHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXmtVKit7k%253D&md5=2b766f598da3ec623b169c861d80dd5c</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1128%2FJVI.64.11.5270-5276.1990&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.64.11.5270-5276.1990%26sid%3Dliteratum%253Aachs%26aulast%3DPage%26aufirst%3DK.%2BA.%26aulast%3DLandau%26aufirst%3DN.%2BR.%26aulast%3DLittman%26aufirst%3DD.%2BR.%26atitle%3DConstruction%2520and%2520use%2520of%2520a%2520human%2520immunodeficiency%2520virus%2520vector%2520for%2520analysis%2520of%2520virus%2520infectivity%26jtitle%3DJ.%2520Virol.%26date%3D1990%26volume%3D64%26spage%3D5270%26epage%3D5276%26doi%3D10.1128%2FJVI.64.11.5270-5276.1990" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blish, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jalalian-Lechak, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rainwater, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dogan, O. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Overbaugh, J.</span></span> <span> </span><span class="NLM_article-title">Cross-subtype neutralization sensitivity despite monoclonal antibody resistance among early subtype A, C, and D envelope variants of human immunodeficiency virus type 1</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>83</i></span>,  <span class="NLM_fpage">7783</span>– <span class="NLM_lpage">7788</span>, <span class="refDoi"> DOI: 10.1128/JVI.00673-09</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=10.1128%2FJVI.00673-09" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=19474105" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=1%3ACAS%3A528%3ADC%252BD1MXovFentL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=2009&pages=7783-7788&author=C.+A.+Blishauthor=Z.+Jalalian-Lechakauthor=S.+Rainwaterauthor=M.+A.+Nguyenauthor=O.+C.+Doganauthor=J.+Overbaugh&title=Cross-subtype+neutralization+sensitivity+despite+monoclonal+antibody+resistance+among+early+subtype+A%2C+C%2C+and+D+envelope+variants+of+human+immunodeficiency+virus+type+1&doi=10.1128%2FJVI.00673-09"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Cross-subtype neutralization sensitivity despite monoclonal antibody resistance among early subtype A, C, and D envelope variants of human immunodeficiency virus type 1</span></div><div class="casAuthors">Blish, Catherine A.; Jalalian-Lechak, Zahra; Rainwater, Stephanie; Nguyen, Minh-An; Dogan, Ozge C.; Overbaugh, Julie</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">83</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">7783-7788</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The human immunodeficiency virus type 1 (HIV-1) variants that are transmitted to newly infected individuals are the primary targets of interventions, such as vaccines and microbicides, aimed at preventing new infections.  Newly acquired subtype A, B, and C variants have been the focus of neutralization studies, although many of these viruses, particularly of subtypes A and B, represent viruses circulating more than a decade ago.  In order to better represent the global diversity of transmitted HIV-1 variants, an addnl. 31 sexually transmitted Kenyan HIV-1 env genes, representing several recent infections with subtype A, as well as subtypes A/D, C, and D, were cloned, and their neutralization profiles were characterized.  Most env variants were resistant to neutralization by the monoclonal antibodies (MAbs) b12, 4E10, 2F5, and 2G12, suggesting that targeting the epitopes of these MAbs may not be effective against variants that are spreading in areas of endemicity.  However, significant cross-subtype neutralization by plasma was obsd., indicating that there may be other epitopes, not yet defined by the limited available MAbs, which could be recognized more broadly.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo981ipEMtqbrVg90H21EOLACvtfcHk0lj3Ts6b0VeoHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXovFentL0%253D&md5=24ee4b6f47c1168fc36fb2ef6341d04a</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1128%2FJVI.00673-09&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.00673-09%26sid%3Dliteratum%253Aachs%26aulast%3DBlish%26aufirst%3DC.%2BA.%26aulast%3DJalalian-Lechak%26aufirst%3DZ.%26aulast%3DRainwater%26aufirst%3DS.%26aulast%3DNguyen%26aufirst%3DM.%2BA.%26aulast%3DDogan%26aufirst%3DO.%2BC.%26aulast%3DOverbaugh%26aufirst%3DJ.%26atitle%3DCross-subtype%2520neutralization%2520sensitivity%2520despite%2520monoclonal%2520antibody%2520resistance%2520among%2520early%2520subtype%2520A%252C%2520C%252C%2520and%2520D%2520envelope%2520variants%2520of%2520human%2520immunodeficiency%2520virus%2520type%25201%26jtitle%3DJ.%2520Virol.%26date%3D2009%26volume%3D83%26spage%3D7783%26epage%3D7788%26doi%3D10.1128%2FJVI.00673-09" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Long, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rainwater, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lavreys, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mandaliya, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Overbaugh, J.</span></span> <span> </span><span class="NLM_article-title">HIV type 1 variants transmitted to women in Kenya require the CCR5 coreceptor for entry, regardless of the genetic complexity of the infecting virus</span>. <i>AIDS Res. Hum. Retroviruses</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">567</span>– <span class="NLM_lpage">576</span>, <span class="refDoi"> DOI: 10.1089/088922202753747914</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=10.1089%2F088922202753747914" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=12036486" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=1%3ACAS%3A528%3ADC%252BD38XktlGntb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2002&pages=567-576&author=E.+M.+Longauthor=S.+M.+Rainwaterauthor=L.+Lavreysauthor=K.+Mandaliyaauthor=J.+Overbaugh&title=HIV+type+1+variants+transmitted+to+women+in+Kenya+require+the+CCR5+coreceptor+for+entry%2C+regardless+of+the+genetic+complexity+of+the+infecting+virus&doi=10.1089%2F088922202753747914"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">HIV type 1 variants transmitted to women in Kenya require the CCR5 coreceptor for entry, regardless of the genetic complexity of the infecting virus</span></div><div class="casAuthors">Long, E. Michelle; Rainwater, Stephanie M. J.; Lavreys, Ludo; Mandaliya, Kishorchandra; Overbaugh, Julie</div><div class="citationInfo"><span class="NLM_cas:title">AIDS Research and Human Retroviruses</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">567-576</span>CODEN:
                <span class="NLM_cas:coden">ARHRE7</span>;
        ISSN:<span class="NLM_cas:issn">0889-2229</span>.
    
            (<span class="NLM_cas:orgname">Mary Ann Liebert, Inc.</span>)
        </div><div class="casAbstract">Although nearly half of the HIV-1-infected adults in the world are women, little is known about the virol. determinants of transmission to women.  Studies suggest that women are frequently infected with multiple HIV-1 genotypes, whereas men are infected with a single genotype.  In the current study, we assessed whether the diverse HIV-1 genomes present at the time of infection in women encode viruses that have diverse coreceptor specificities.  For this purpose, we defined the coreceptor requirements of viruses found in recently infected Kenyan women, three of whom had multiple viral genotypes and the remaining two of whom had a single genotype.  Full-length envelope clones were amplified directly from blood and the dominant genotypes were identified.  Envelope clones derived from all five women were able to pseudotype infectious particles competent to infect cells expressing CCR5, but not cells expressing only CXCR4.  Thus, regardless of viral complexity at the time of infection, the viruses present at early stages of HIV-1 infection in women use CCR5, suggesting that cells expressing CCR5 are important targets for heterosexual HIV-1 transmission to women.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUHUUUjpIVdrVg90H21EOLACvtfcHk0ljPYSY21ZniAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XktlGntb8%253D&md5=c07468fa8307e287f733a92def00bf0d</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1089%2F088922202753747914&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252F088922202753747914%26sid%3Dliteratum%253Aachs%26aulast%3DLong%26aufirst%3DE.%2BM.%26aulast%3DRainwater%26aufirst%3DS.%2BM.%26aulast%3DLavreys%26aufirst%3DL.%26aulast%3DMandaliya%26aufirst%3DK.%26aulast%3DOverbaugh%26aufirst%3DJ.%26atitle%3DHIV%2520type%25201%2520variants%2520transmitted%2520to%2520women%2520in%2520Kenya%2520require%2520the%2520CCR5%2520coreceptor%2520for%2520entry%252C%2520regardless%2520of%2520the%2520genetic%2520complexity%2520of%2520the%2520infecting%2520virus%26jtitle%3DAIDS%2520Res.%2520Hum.%2520Retroviruses%26date%3D2002%26volume%3D18%26spage%3D567%26epage%3D576%26doi%3D10.1089%2F088922202753747914" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kulkarni, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lapedes, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gnanakaran, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daniels, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhattacharya, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polonis, V. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCutchan, F. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellenberger, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butera, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bollinger, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korber, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paranjape, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montefiori, D. C.</span></span> <span> </span><span class="NLM_article-title">Highly complex neutralization determinants on a monophyletic lineage of newly transmitted subtype C HIV-1 Env clones from India</span>. <i>Virology</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>385</i></span>,  <span class="NLM_fpage">505</span>– <span class="NLM_lpage">520</span>, <span class="refDoi"> DOI: 10.1016/j.virol.2008.12.032</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=10.1016%2Fj.virol.2008.12.032" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=19167740" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=1%3ACAS%3A528%3ADC%252BD1MXisFOnt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=385&publication_year=2009&pages=505-520&author=S.+S.+Kulkarniauthor=A.+Lapedesauthor=H.+Tangauthor=S.+Gnanakaranauthor=M.+G.+Danielsauthor=M.+Zhangauthor=T.+Bhattacharyaauthor=M.+Liauthor=V.+R.+Polonisauthor=F.+E.+McCutchanauthor=L.+Morrisauthor=D.+Ellenbergerauthor=S.+T.+Buteraauthor=R.+C.+Bollingerauthor=B.+T.+Korberauthor=R.+S.+Paranjapeauthor=D.+C.+Montefiori&title=Highly+complex+neutralization+determinants+on+a+monophyletic+lineage+of+newly+transmitted+subtype+C+HIV-1+Env+clones+from+India&doi=10.1016%2Fj.virol.2008.12.032"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Highly complex neutralization determinants on a monophyletic lineage of newly transmitted subtype C HIV-1 Env clones from India</span></div><div class="casAuthors">Kulkarni, Smita S.; Lapedes, Alan; Tang, Haili; Gnanakaran, S.; Daniels, Marcus G.; Zhang, Ming; Bhattacharya, Tanmoy; Li, Ming; Polonis, Victoria R.; McCutchan, Francine E.; Morris, Lynn; Ellenberger, Dennis; Butera, Salvatore T.; Bollinger, Robert C.; Korber, Bette T.; Paranjape, Ramesh S.; Montefiori, David C.</div><div class="citationInfo"><span class="NLM_cas:title">Virology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">385</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">505-520</span>CODEN:
                <span class="NLM_cas:coden">VIRLAX</span>;
        ISSN:<span class="NLM_cas:issn">0042-6822</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Little is known about the neutralization properties of HIV-1 in India to optimally design and test vaccines.  For this reason, a functional Env clone was obtained from each of ten newly acquired, heterosexually transmitted HIV-1 infections in Pune, Maharashtra.  These clones formed a phylogenetically distinct genetic lineage within subtype C. As Env-pseudotyped viruses the clones were mostly resistant to IgG1b12, 2G12 and 2F5 but all were sensitive to 4E10.  When compared to a large multi-subtype panel of Env-pseudotyped viruses (subtypes B, C and CRF02AG) in neutralization assays with a multi-subtype panel of HIV-1-pos. plasma samples, the Indian Envs were remarkably complex.  With the exception of the Indian Envs, results of a hierarchical clustering anal. showed a strong subtype assocn. with the patterns of neutralization susceptibility.  From these patterns the authors were able to identify 19 neutralization cluster-assocd. amino acid signatures in gp120 and 14 signatures in the ectodomain and cytoplasmic tail of gp41.  The authors conclude that newly transmitted Indian Envs are antigenically complex in spite of close genetic similarity.  Delineation of neutralization-assocd. amino acid signatures provides a deeper understanding of the antigenic structure of HIV-1 Env.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprmIj9kIl2drVg90H21EOLACvtfcHk0ljPYSY21ZniAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXisFOnt7Y%253D&md5=7bed6bd07204db651cef191d57a3e05e</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1016%2Fj.virol.2008.12.032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.virol.2008.12.032%26sid%3Dliteratum%253Aachs%26aulast%3DKulkarni%26aufirst%3DS.%2BS.%26aulast%3DLapedes%26aufirst%3DA.%26aulast%3DTang%26aufirst%3DH.%26aulast%3DGnanakaran%26aufirst%3DS.%26aulast%3DDaniels%26aufirst%3DM.%2BG.%26aulast%3DZhang%26aufirst%3DM.%26aulast%3DBhattacharya%26aufirst%3DT.%26aulast%3DLi%26aufirst%3DM.%26aulast%3DPolonis%26aufirst%3DV.%2BR.%26aulast%3DMcCutchan%26aufirst%3DF.%2BE.%26aulast%3DMorris%26aufirst%3DL.%26aulast%3DEllenberger%26aufirst%3DD.%26aulast%3DButera%26aufirst%3DS.%2BT.%26aulast%3DBollinger%26aufirst%3DR.%2BC.%26aulast%3DKorber%26aufirst%3DB.%2BT.%26aulast%3DParanjape%26aufirst%3DR.%2BS.%26aulast%3DMontefiori%26aufirst%3DD.%2BC.%26atitle%3DHighly%2520complex%2520neutralization%2520determinants%2520on%2520a%2520monophyletic%2520lineage%2520of%2520newly%2520transmitted%2520subtype%2520C%2520HIV-1%2520Env%2520clones%2520from%2520India%26jtitle%3DVirology%26date%3D2009%26volume%3D385%26spage%3D505%26epage%3D520%26doi%3D10.1016%2Fj.virol.2008.12.032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mascola, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stamatatos, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polonis, V. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koutsoukos, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voss, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goepfert, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilbert, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greene, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bilska, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kothe, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salazar-Gonzalez, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Decker, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hahn, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montefiori, D. C.</span></span> <span> </span><span class="NLM_article-title">Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">10108</span>– <span class="NLM_lpage">10125</span>, <span class="refDoi"> DOI: 10.1128/JVI.79.16.10108-10125.2005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=10.1128%2FJVI.79.16.10108-10125.2005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=16051804" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=1%3ACAS%3A528%3ADC%252BD2MXntFCrtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2005&pages=10108-10125&author=M.+Liauthor=F.+Gaoauthor=J.+R.+Mascolaauthor=L.+Stamatatosauthor=V.+R.+Polonisauthor=M.+Koutsoukosauthor=G.+Vossauthor=P.+Goepfertauthor=P.+Gilbertauthor=K.+M.+Greeneauthor=M.+Bilskaauthor=D.+L.+Kotheauthor=J.+F.+Salazar-Gonzalezauthor=X.+Weiauthor=J.+M.+Deckerauthor=B.+H.+Hahnauthor=D.+C.+Montefiori&title=Human+immunodeficiency+virus+type+1+env+clones+from+acute+and+early+subtype+B+infections+for+standardized+assessments+of+vaccine-elicited+neutralizing+antibodies&doi=10.1128%2FJVI.79.16.10108-10125.2005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies</span></div><div class="casAuthors">Li, Ming; Gao, Feng; Mascola, John R.; Stamatatos, Leonidas; Polonis, Victoria R.; Koutsoukos, Marguerite; Voss, Gerald; Goepfert, Paul; Gilbert, Peter; Greene, Kelli M.; Bilska, Miroslawa; Kothe, Denise L.; Salazar-Gonzalez, Jesus F.; Wei, Xiping; Decker, Julie M.; Hahn, Beatrice H.; Montefiori, David C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">10108-10125</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Induction of broadly cross-reactive neutralizing antibodies is a high priority for AIDS vaccine development but one that has proven difficult to be achieved.  While most immunogens generate antibodies that neutralize a subset of T-cell-line-adapted strains of human immunodeficiency virus type 1 (HIV-1), none so far have generated a potent, broadly cross-reactive response against primary isolates of the virus.  Even small increments in immunogen improvement leading to increases in neutralizing antibody titers and cross-neutralizing activity would accelerate vaccine development; however, a lack of uniformity in target strains used by different investigators to assess cross-neutralization has made the comparison of vaccine-induced antibody responses difficult.  Thus, there is an urgent need to establish std. panels of HIV-1 ref. strains for wide distribution.  To facilitate this, full-length gp160 genes were cloned from acute and early subtype B infections and characterized for use as ref. reagents to assess neutralizing antibodies against clade B HIV-1.  Individual gp160 clones were screened for infectivity as Env-pseudotyped viruses in a luciferase reporter gene assay in JC53-BL (TZM-bl) cells.  Functional env clones were sequenced and their neutralization phenotypes characterized by using sol. CD4, monoclonal antibodies, and serum samples from infected individuals and noninfected recipients of a recombinant gp120 vaccine.  Env clones from 12 R5 primary HIV-1 isolates were selected that were not unusually sensitive or resistant to neutralization and comprised a wide spectrum of genetic, antigenic, and geog. diversity.  These ref. reagents will facilitate proficiency testing and other validation efforts aimed at improving assay performance across labs. and can be used for standardized assessments of vaccine-elicited neutralizing antibodies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxX0pqgVl3rLVg90H21EOLACvtfcHk0lj-UCLZIPDI1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXntFCrtL8%253D&md5=26a5971a0c8043e4e114f57006f1cbb3</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1128%2FJVI.79.16.10108-10125.2005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.79.16.10108-10125.2005%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DM.%26aulast%3DGao%26aufirst%3DF.%26aulast%3DMascola%26aufirst%3DJ.%2BR.%26aulast%3DStamatatos%26aufirst%3DL.%26aulast%3DPolonis%26aufirst%3DV.%2BR.%26aulast%3DKoutsoukos%26aufirst%3DM.%26aulast%3DVoss%26aufirst%3DG.%26aulast%3DGoepfert%26aufirst%3DP.%26aulast%3DGilbert%26aufirst%3DP.%26aulast%3DGreene%26aufirst%3DK.%2BM.%26aulast%3DBilska%26aufirst%3DM.%26aulast%3DKothe%26aufirst%3DD.%2BL.%26aulast%3DSalazar-Gonzalez%26aufirst%3DJ.%2BF.%26aulast%3DWei%26aufirst%3DX.%26aulast%3DDecker%26aufirst%3DJ.%2BM.%26aulast%3DHahn%26aufirst%3DB.%2BH.%26aulast%3DMontefiori%26aufirst%3DD.%2BC.%26atitle%3DHuman%2520immunodeficiency%2520virus%2520type%25201%2520env%2520clones%2520from%2520acute%2520and%2520early%2520subtype%2520B%2520infections%2520for%2520standardized%2520assessments%2520of%2520vaccine-elicited%2520neutralizing%2520antibodies%26jtitle%3DJ.%2520Virol.%26date%3D2005%26volume%3D79%26spage%3D10108%26epage%3D10125%26doi%3D10.1128%2FJVI.79.16.10108-10125.2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wei, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Decker, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hui, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kappes, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salazar-Gonzalez, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salazar, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kilby, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saag, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Komarova, N. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nowak, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hahn, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwong, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, G. M.</span></span> <span> </span><span class="NLM_article-title">Antibody neutralization and escape by HIV-1</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>422</i></span>,  <span class="NLM_fpage">307</span>– <span class="NLM_lpage">312</span>, <span class="refDoi"> DOI: 10.1038/nature01470</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=10.1038%2Fnature01470" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=12646921" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=1%3ACAS%3A528%3ADC%252BD3sXitFKmurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=422&publication_year=2003&pages=307-312&author=X.+Weiauthor=J.+M.+Deckerauthor=S.+Wangauthor=H.+Huiauthor=J.+C.+Kappesauthor=X.+Wuauthor=J.+F.+Salazar-Gonzalezauthor=M.+G.+Salazarauthor=J.+M.+Kilbyauthor=M.+S.+Saagauthor=N.+L.+Komarovaauthor=M.+A.+Nowakauthor=B.+H.+Hahnauthor=P.+D.+Kwongauthor=G.+M.+Shaw&title=Antibody+neutralization+and+escape+by+HIV-1&doi=10.1038%2Fnature01470"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Antibody neutralization and escape by HIV-1</span></div><div class="casAuthors">Wei, Xiping; Decker, Julie M.; Wang, Shuyi; Hui, Huxiong; Kappes, John C.; Wu, Xiaoyun; Salazar-Gonzalez, Jesus F.; Salazar, Maria G.; Kilby, J. Michael; Saag, Michael S.; Komarova, Natalia L.; Nowak, Martin A.; Hahn, Beatrice H.; Kwong, Peter D.; Shaw, George M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">422</span>
        (<span class="NLM_cas:issue">6929</span>),
    <span class="NLM_cas:pages">307-312</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Neutralizing antibodies (Nab) are a principal component of an effective human immune response to many pathogens, yet their role in HIV-1 infection is unclear.  To gain a better understanding of this role, we examd. plasma from patients with acute HIV infection.  Here we report the detection of autologous Nab as early as 52 days after detection of HIV-specific antibodies.  The viral inhibitory activity of Nab resulted in complete replacement of neutralization-sensitive virus by successive populations of resistant virus.  Escape virus contained mutations in the env gene that were unexpectedly sparse, did not map generally to known neutralization epitopes, and involved primarily changes in N-linked glycosylation.  This pattern of escape, and the exceptional d. of HIV-1 envelope glycosylation generally, led us to postulate an evolving glycan shield' mechanism of neutralization escape whereby selected changes in glycan packing prevent Nab binding but not receptor binding.  Direct support for this model was obtained by mutational substitution showing that Nab-selected alterations in glycosylation conferred escape from both autologous antibody and epitope-specific monoclonal antibodies.  The evolving glycan shield thus represents a new mechanism contributing to HIV-1 persistence in the face of an evolving antibody repertoire.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWf_6H0ez_frVg90H21EOLACvtfcHk0lj-UCLZIPDI1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXitFKmurY%253D&md5=f2b0675ba66493cd8952d7f9fe93faf3</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1038%2Fnature01470&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature01470%26sid%3Dliteratum%253Aachs%26aulast%3DWei%26aufirst%3DX.%26aulast%3DDecker%26aufirst%3DJ.%2BM.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DHui%26aufirst%3DH.%26aulast%3DKappes%26aufirst%3DJ.%2BC.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DSalazar-Gonzalez%26aufirst%3DJ.%2BF.%26aulast%3DSalazar%26aufirst%3DM.%2BG.%26aulast%3DKilby%26aufirst%3DJ.%2BM.%26aulast%3DSaag%26aufirst%3DM.%2BS.%26aulast%3DKomarova%26aufirst%3DN.%2BL.%26aulast%3DNowak%26aufirst%3DM.%2BA.%26aulast%3DHahn%26aufirst%3DB.%2BH.%26aulast%3DKwong%26aufirst%3DP.%2BD.%26aulast%3DShaw%26aufirst%3DG.%2BM.%26atitle%3DAntibody%2520neutralization%2520and%2520escape%2520by%2520HIV-1%26jtitle%3DNature%26date%3D2003%26volume%3D422%26spage%3D307%26epage%3D312%26doi%3D10.1038%2Fnature01470" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Keele, B. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giorgi, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salazar-Gonzalez, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Decker, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pham, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salazar, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grayson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirchherr, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ping, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swanstrom, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomaras, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blattner, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goepfert, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kilby, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saag, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delwart, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Busch, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montefiori, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haynes, B. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaschen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Athreya, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seoighe, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perelson, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhattacharya, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korber, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hahn, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, G. M.</span></span> <span> </span><span class="NLM_article-title">Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>105</i></span>,  <span class="NLM_fpage">7552</span>– <span class="NLM_lpage">7557</span>, <span class="refDoi"> DOI: 10.1073/pnas.0802203105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=10.1073%2Fpnas.0802203105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=18490657" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmvFKksrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=7552-7557&author=B.+F.+Keeleauthor=E.+E.+Giorgiauthor=J.+F.+Salazar-Gonzalezauthor=J.+M.+Deckerauthor=K.+T.+Phamauthor=M.+G.+Salazarauthor=C.+Sunauthor=T.+Graysonauthor=S.+Wangauthor=H.+Liauthor=X.+Weiauthor=C.+Jiangauthor=J.+L.+Kirchherrauthor=F.+Gaoauthor=J.+A.+Andersonauthor=L.+H.+Pingauthor=R.+Swanstromauthor=G.+D.+Tomarasauthor=W.+A.+Blattnerauthor=P.+A.+Goepfertauthor=J.+M.+Kilbyauthor=M.+S.+Saagauthor=E.+L.+Delwartauthor=M.+P.+Buschauthor=M.+S.+Cohenauthor=D.+C.+Montefioriauthor=B.+F.+Haynesauthor=B.+Gaschenauthor=G.+S.+Athreyaauthor=H.+Y.+Leeauthor=N.+Woodauthor=C.+Seoigheauthor=A.+S.+Perelsonauthor=T.+Bhattacharyaauthor=B.+T.+Korberauthor=B.+H.+Hahnauthor=G.+M.+Shaw&title=Identification+and+characterization+of+transmitted+and+early+founder+virus+envelopes+in+primary+HIV-1+infection&doi=10.1073%2Fpnas.0802203105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection</span></div><div class="casAuthors">Keele, Brandon F.; Giorgi, Elena E.; Salazar-Gonzalez, Jesus F.; Decker, Julie M.; Pham, Kimmy T.; Salazar, Maria G.; Sun, Chuanxi; Grayson, Truman; Wang, Shuyi; Li, Hui; Wei, Xiping; Jiang, Chunlai; Kirchherr, Jennifer L.; Gao, Feng; Anderson, Jeffery A.; Ping, Li-Hua; Swanstrom, Ronald; Tomaras, Georgia D.; Blattner, William A.; Goepfert, Paul A.; Kilby, J. Michael; Saag, Michael S.; Delwart, Eric L.; Busch, Michael P.; Cohen, Myron S.; Montefiori, David C.; Haynes, Barton F.; Gaschen, Brian; Athreya, Gayathri S.; Lee, Ha Y.; Wood, Natasha; Seoighe, Cathal; Perelson, Alan S.; Bhattacharya, Tanmoy; Korber, Bette T.; Hahn, Beatrice H.; Shaw, George M.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">7552-7557</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The precise identification of the HIV-1 envelope glycoprotein (Env) responsible for productive clin. infection could be instrumental in elucidating the mol. basis of HIV-1 transmission and in designing effective vaccines.  Here, a math. model of random viral evolution was developed and, together with phylogenetic tree construction, was used to analyze 3449 complete env sequences derived by single genome amplification from 102 subjects with acute HIV-1 (clade B) infection.  Viral env genes evolving from individual transmitted or founder viruses generally exhibited a Poisson distribution of mutations and star-like phylogeny, which coalesced to an inferred consensus sequence at or near the estd. time of virus transmission.  Overall, 78 of 102 subjects had evidence of productive clin. infection by a single virus, and 24 others had evidence of productive clin. infection by a min. of 2-5 viruses.  Phenotypic anal. of transmitted or early founder Envs revealed a consistent pattern of CCR5 dependence, masking of coreceptor binding regions, and equiv. or modestly enhanced resistance to the fusion inhibitor T1249 and broadly neutralizing antibodies compared with Envs from chronically infected subjects.  Low multiplicity infection and limited viral evolution preceding peak viremia suggest a finite window of potential vulnerability of HIV-1 to vaccine-elicited immune responses, although phenotypic properties of transmitted Envs pose a formidable defense.  Sequence data were deposited in GenBank/EMBL/DDBJ under accession nos. EU574937-EU579293.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpi2zkTgwHOJbVg90H21EOLACvtfcHk0ljWjC67FEWOPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmvFKksrg%253D&md5=5f32b92d162ed3c7f1f6c37d5cc970d0</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0802203105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0802203105%26sid%3Dliteratum%253Aachs%26aulast%3DKeele%26aufirst%3DB.%2BF.%26aulast%3DGiorgi%26aufirst%3DE.%2BE.%26aulast%3DSalazar-Gonzalez%26aufirst%3DJ.%2BF.%26aulast%3DDecker%26aufirst%3DJ.%2BM.%26aulast%3DPham%26aufirst%3DK.%2BT.%26aulast%3DSalazar%26aufirst%3DM.%2BG.%26aulast%3DSun%26aufirst%3DC.%26aulast%3DGrayson%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DWei%26aufirst%3DX.%26aulast%3DJiang%26aufirst%3DC.%26aulast%3DKirchherr%26aufirst%3DJ.%2BL.%26aulast%3DGao%26aufirst%3DF.%26aulast%3DAnderson%26aufirst%3DJ.%2BA.%26aulast%3DPing%26aufirst%3DL.%2BH.%26aulast%3DSwanstrom%26aufirst%3DR.%26aulast%3DTomaras%26aufirst%3DG.%2BD.%26aulast%3DBlattner%26aufirst%3DW.%2BA.%26aulast%3DGoepfert%26aufirst%3DP.%2BA.%26aulast%3DKilby%26aufirst%3DJ.%2BM.%26aulast%3DSaag%26aufirst%3DM.%2BS.%26aulast%3DDelwart%26aufirst%3DE.%2BL.%26aulast%3DBusch%26aufirst%3DM.%2BP.%26aulast%3DCohen%26aufirst%3DM.%2BS.%26aulast%3DMontefiori%26aufirst%3DD.%2BC.%26aulast%3DHaynes%26aufirst%3DB.%2BF.%26aulast%3DGaschen%26aufirst%3DB.%26aulast%3DAthreya%26aufirst%3DG.%2BS.%26aulast%3DLee%26aufirst%3DH.%2BY.%26aulast%3DWood%26aufirst%3DN.%26aulast%3DSeoighe%26aufirst%3DC.%26aulast%3DPerelson%26aufirst%3DA.%2BS.%26aulast%3DBhattacharya%26aufirst%3DT.%26aulast%3DKorber%26aufirst%3DB.%2BT.%26aulast%3DHahn%26aufirst%3DB.%2BH.%26aulast%3DShaw%26aufirst%3DG.%2BM.%26atitle%3DIdentification%2520and%2520characterization%2520of%2520transmitted%2520and%2520early%2520founder%2520virus%2520envelopes%2520in%2520primary%2520HIV-1%2520infection%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2008%26volume%3D105%26spage%3D7552%26epage%3D7557%26doi%3D10.1073%2Fpnas.0802203105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Derdeyn, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Decker, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bibollet-Ruche, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mokili, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muldoon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denham, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heil, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kasolo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Musonda, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hahn, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korber, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunter, E.</span></span> <span> </span><span class="NLM_article-title">Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>303</i></span>,  <span class="NLM_fpage">2019</span>– <span class="NLM_lpage">2022</span>, <span class="refDoi"> DOI: 10.1126/science.1093137</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=10.1126%2Fscience.1093137" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=15044802" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=1%3ACAS%3A528%3ADC%252BD2cXisVGlt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=303&publication_year=2004&pages=2019-2022&author=C.+A.+Derdeynauthor=J.+M.+Deckerauthor=F.+Bibollet-Rucheauthor=J.+L.+Mokiliauthor=M.+Muldoonauthor=S.+A.+Denhamauthor=M.+L.+Heilauthor=F.+Kasoloauthor=R.+Musondaauthor=B.+H.+Hahnauthor=G.+M.+Shawauthor=B.+T.+Korberauthor=S.+Allenauthor=E.+Hunter&title=Envelope-constrained+neutralization-sensitive+HIV-1+after+heterosexual+transmission&doi=10.1126%2Fscience.1093137"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Envelope-Constrained Neutralization-Sensitive HIV-1 After Heterosexual Transmission</span></div><div class="casAuthors">Derdeyn, Cynthia A.; Decker, Julie M.; Bibollet-Ruche, Frederic; Mokili, John L.; Muldoon, Mark; Denham, Scott A.; Heil, Marintha L.; Kasolo, Francis; Musonda, Rosemary; Hahn, Beatrice H.; Shaw, George M.; Korber, Bette T.; Allen, Susan; Hunter, Eric</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">303</span>
        (<span class="NLM_cas:issue">5666</span>),
    <span class="NLM_cas:pages">2019-2022</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Heterosexual transmission accounts for the majority of human immunodeficiency virus-1 (HIV-1) infections worldwide, yet the viral properties that det. transmission fitness or outgrowth have not been elucidated.  Here we show, for eight heterosexual transmission pairs, that recipient viruses were monophyletic, encoding compact, glycan-restricted envelope glycoproteins.  These viruses were also uniquely sensitive to neutralization by antibody from the transmitting partner.  Thus, the exposure of neutralizing epitopes, which are lost in chronic infection because of immune escape, appears to be favored in the newly infected host.  This reveals characteristics of the envelope glycoprotein that influence HIV-1 transmission and may have implications for vaccine design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo04BvbhoVSV7Vg90H21EOLACvtfcHk0ljWjC67FEWOPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXisVGlt7s%253D&md5=8da57ef2bf9fe854836b59769f5b0951</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1126%2Fscience.1093137&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1093137%26sid%3Dliteratum%253Aachs%26aulast%3DDerdeyn%26aufirst%3DC.%2BA.%26aulast%3DDecker%26aufirst%3DJ.%2BM.%26aulast%3DBibollet-Ruche%26aufirst%3DF.%26aulast%3DMokili%26aufirst%3DJ.%2BL.%26aulast%3DMuldoon%26aufirst%3DM.%26aulast%3DDenham%26aufirst%3DS.%2BA.%26aulast%3DHeil%26aufirst%3DM.%2BL.%26aulast%3DKasolo%26aufirst%3DF.%26aulast%3DMusonda%26aufirst%3DR.%26aulast%3DHahn%26aufirst%3DB.%2BH.%26aulast%3DShaw%26aufirst%3DG.%2BM.%26aulast%3DKorber%26aufirst%3DB.%2BT.%26aulast%3DAllen%26aufirst%3DS.%26aulast%3DHunter%26aufirst%3DE.%26atitle%3DEnvelope-constrained%2520neutralization-sensitive%2520HIV-1%2520after%2520heterosexual%2520transmission%26jtitle%3DScience%26date%3D2004%26volume%3D303%26spage%3D2019%26epage%3D2022%26doi%3D10.1126%2Fscience.1093137" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salazar-Gonzalez, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Derdeyn, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williamson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Decker, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salazar, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polonis, V. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mlisana, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karim, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greene, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bilska, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chomba, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulenga, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vwalika, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korber, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunter, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hahn, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montefiori, D. C.</span></span> <span> </span><span class="NLM_article-title">Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>80</i></span>,  <span class="NLM_fpage">11776</span>– <span class="NLM_lpage">11790</span>, <span class="refDoi"> DOI: 10.1128/JVI.01730-06</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=10.1128%2FJVI.01730-06" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=16971434" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht12hu7bO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2006&pages=11776-11790&author=M.+Liauthor=J.+F.+Salazar-Gonzalezauthor=C.+A.+Derdeynauthor=L.+Morrisauthor=C.+Williamsonauthor=J.+E.+Robinsonauthor=J.+M.+Deckerauthor=Y.+Liauthor=M.+G.+Salazarauthor=V.+R.+Polonisauthor=K.+Mlisanaauthor=S.+A.+Karimauthor=K.+Hongauthor=K.+M.+Greeneauthor=M.+Bilskaauthor=J.+Zhouauthor=S.+Allenauthor=E.+Chombaauthor=J.+Mulengaauthor=C.+Vwalikaauthor=F.+Gaoauthor=M.+Zhangauthor=B.+T.+Korberauthor=E.+Hunterauthor=B.+H.+Hahnauthor=D.+C.+Montefiori&title=Genetic+and+neutralization+properties+of+subtype+C+human+immunodeficiency+virus+type+1+molecular+env+clones+from+acute+and+early+heterosexually+acquired+infections+in+Southern+Africa&doi=10.1128%2FJVI.01730-06"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in southern Africa</span></div><div class="casAuthors">Li, Ming; Salazar-Gonzalez, Jesus F.; Derdeyn, Cynthia A.; Morris, Lynn; Williamson, Carolyn; Robinson, James E.; Decker, Julie M.; Li, Yingying; Salazar, Maria G.; Polonis, Victoria R.; Mlisana, Koleka; Karim, Salim Abdool; Hong, Kunxue; Greene, Kelli M.; Bilska, Miroslawa; Zhou, Jintao; Allen, Susan; Chomba, Elwyn; Mulenga, Joseph; Vwalika, Cheswa; Gao, Feng; Zhang, Ming; Korber, Bette T. M.; Hunter, Eric; Hahn, Beatrice H.; Montefiori, David C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">80</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">11776-11790</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">A std. panel of subtype C human immunodeficiency virus type 1 (HIV-1) Env-pseudotyped viruses was created by cloning, sequencing, and characterizing functional gp160 genes from 18 acute and early heterosexually acquired infections in South Africa and Zambia.  In general, the gp120 region of these clones was shorter (most evident in V1 and V4) and less glycosylated compared to newly transmitted subtype B viruses, and it was underglycosylated but no different in length compared to chronic subtype C viruses.  The gp120s also exhibited low amino acid sequence variability (12%) in V3 and high variability (39%) immediately downstream of V3, a feature shared with newly transmitted subtype B viruses and chronic viruses of both subtypes.  When tested as Env-pseudotyped viruses in a luciferase reporter gene assay, all clones possessed an R5 phenotype and resembled primary isolates in their sensitivity to neutralization by HIV-1-pos. plasmas.  Results obtained with a multisubtype plasma panel suggested partial subtype preference in the neutralizing antibody response to infection.  The clones were typical of subtype C in that all were resistant to 2G12 (assocd. with loss of N-glycosylation at position 295) and most were resistant to 2F5, but all were sensitive to 4E10 and many were sensitive to IgG1b12.  Finally, conserved neutralization epitopes in the CD4-induced coreceptor binding domain of gp120 were poorly accessible and were difficult to induce and stabilize with sol. CD4 on Env-pseudotyped viruses.  These results illustrate key genetic and antigenic properties of subtype C HIV-1 that might impact the design and testing of candidate vaccines.  A subset of these gp160 clones are suitable for use as ref. reagents to facilitate standardized assessments of vaccine-elicited neutralizing antibody responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotHCKTjmLyaLVg90H21EOLACvtfcHk0lgNyDB0SXYUbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht12hu7bO&md5=ad1d3cad132002306d58759c87dd2d9e</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1128%2FJVI.01730-06&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.01730-06%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DM.%26aulast%3DSalazar-Gonzalez%26aufirst%3DJ.%2BF.%26aulast%3DDerdeyn%26aufirst%3DC.%2BA.%26aulast%3DMorris%26aufirst%3DL.%26aulast%3DWilliamson%26aufirst%3DC.%26aulast%3DRobinson%26aufirst%3DJ.%2BE.%26aulast%3DDecker%26aufirst%3DJ.%2BM.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DSalazar%26aufirst%3DM.%2BG.%26aulast%3DPolonis%26aufirst%3DV.%2BR.%26aulast%3DMlisana%26aufirst%3DK.%26aulast%3DKarim%26aufirst%3DS.%2BA.%26aulast%3DHong%26aufirst%3DK.%26aulast%3DGreene%26aufirst%3DK.%2BM.%26aulast%3DBilska%26aufirst%3DM.%26aulast%3DZhou%26aufirst%3DJ.%26aulast%3DAllen%26aufirst%3DS.%26aulast%3DChomba%26aufirst%3DE.%26aulast%3DMulenga%26aufirst%3DJ.%26aulast%3DVwalika%26aufirst%3DC.%26aulast%3DGao%26aufirst%3DF.%26aulast%3DZhang%26aufirst%3DM.%26aulast%3DKorber%26aufirst%3DB.%2BT.%26aulast%3DHunter%26aufirst%3DE.%26aulast%3DHahn%26aufirst%3DB.%2BH.%26aulast%3DMontefiori%26aufirst%3DD.%2BC.%26atitle%3DGenetic%2520and%2520neutralization%2520properties%2520of%2520subtype%2520C%2520human%2520immunodeficiency%2520virus%2520type%25201%2520molecular%2520env%2520clones%2520from%2520acute%2520and%2520early%2520heterosexually%2520acquired%2520infections%2520in%2520Southern%2520Africa%26jtitle%3DJ.%2520Virol.%26date%3D2006%26volume%3D80%26spage%3D11776%26epage%3D11790%26doi%3D10.1128%2FJVI.01730-06" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Williamson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maughan, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ping, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dryga, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reap, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cilliers, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Harmelen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pascual, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramjee, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnston, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karim, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swanstrom, R.</span></span> <span> </span><span class="NLM_article-title">Characterization and selection of HIV-1 subtype C isolates for use in vaccine development</span>. <i>AIDS Res. Hum. Retroviruses</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">133</span>– <span class="NLM_lpage">144</span>, <span class="refDoi"> DOI: 10.1089/088922203762688649</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=10.1089%2F088922203762688649" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=12639249" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=1%3ACAS%3A528%3ADC%252BD3sXht1Gkurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2003&pages=133-144&author=C.+Williamsonauthor=L.+Morrisauthor=M.+F.+Maughanauthor=L.+H.+Pingauthor=S.+A.+Drygaauthor=R.+Thomasauthor=E.+A.+Reapauthor=T.+Cilliersauthor=J.+van+Harmelenauthor=A.+Pascualauthor=G.+Ramjeeauthor=G.+Grayauthor=R.+Johnstonauthor=S.+A.+Karimauthor=R.+Swanstrom&title=Characterization+and+selection+of+HIV-1+subtype+C+isolates+for+use+in+vaccine+development&doi=10.1089%2F088922203762688649"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization and Selection of HIV-1 Subtype C Isolates for Use in Vaccine Development</span></div><div class="casAuthors">Williamson, Carolyn; Morris, Lynn; Maughan, Maureen F.; Ping, Li-Hua; Dryga, Sergey A.; Thomas, Robin; Reap, Elizabeth A.; Cilliers, Tonie; van Harmelen, Joanne; Pascual, Alvaro; Ramjee, Gita; Gray, Glenda; Johnston, Robert; Karim, Salim Abdool; Swanstrom, Ronald</div><div class="citationInfo"><span class="NLM_cas:title">AIDS Research and Human Retroviruses</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">133-144</span>CODEN:
                <span class="NLM_cas:coden">ARHRE7</span>;
        ISSN:<span class="NLM_cas:issn">0889-2229</span>.
    
            (<span class="NLM_cas:orgname">Mary Ann Liebert, Inc.</span>)
        </div><div class="casAbstract">HIV-1 genetic diversity among circulating strains presents a major challenge for HIV-1 vaccine development, particularly for developing countries where less sequence information is available.  To identify representative viruses for inclusion in candidate vaccines targeted for South Africa, the authors applied an efficient sequence survey strategy to samples from recently and chronically infected persons residing in potential vaccine trial sites.  All 111 sequences were subtype C, including 30 partial gag, 26 partial pol, 27 V2-V3 env, and 28 V5-partial gp41 sequences.  Of the 10 viruses cultured from recently infected individuals, 9 were R5 and 1 was R5X4.  Two isolates, Du151 and Du422, collected within 2 mo of infection, were selected as vaccine strains on the basis of their amino acid similarity to a derived South African consensus sequence.  The selection of recently transmitted R5 isolates for vaccine design may provide an advantage in a subtype C R5-dominant epidemic.  The full-length Du422 gag and Du151 pol and env genes were cloned into the Venezuelan equine encephalitis (VEE) replicon particle (VRP) expression system.  Du422 Gag protein expressed from the VRP accumulated to a high level and was immunogenic as demonstrated by cytotoxic T lymphocyte responses in mice vaccinated with gag-VRPs.  Optimization of codon use for VRP expression in human cells did not enhance expression of the gag gene.  The cloned Du151 env gene encoded a functional protein as demonstrated by fusion of VRP-infected cells with cells expressing CD4 and CCR5.  Genes identified in this study have been incorporated into the VEE VRP candidate vaccines targeted for clin. trial in South Africa.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeHHsVF06RSLVg90H21EOLACvtfcHk0lgNyDB0SXYUbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXht1Gkurs%253D&md5=0622e5b95c153c5bfe5f404ca571b3e6</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1089%2F088922203762688649&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252F088922203762688649%26sid%3Dliteratum%253Aachs%26aulast%3DWilliamson%26aufirst%3DC.%26aulast%3DMorris%26aufirst%3DL.%26aulast%3DMaughan%26aufirst%3DM.%2BF.%26aulast%3DPing%26aufirst%3DL.%2BH.%26aulast%3DDryga%26aufirst%3DS.%2BA.%26aulast%3DThomas%26aufirst%3DR.%26aulast%3DReap%26aufirst%3DE.%2BA.%26aulast%3DCilliers%26aufirst%3DT.%26aulast%3Dvan%2BHarmelen%26aufirst%3DJ.%26aulast%3DPascual%26aufirst%3DA.%26aulast%3DRamjee%26aufirst%3DG.%26aulast%3DGray%26aufirst%3DG.%26aulast%3DJohnston%26aufirst%3DR.%26aulast%3DKarim%26aufirst%3DS.%2BA.%26aulast%3DSwanstrom%26aufirst%3DR.%26atitle%3DCharacterization%2520and%2520selection%2520of%2520HIV-1%2520subtype%2520C%2520isolates%2520for%2520use%2520in%2520vaccine%2520development%26jtitle%3DAIDS%2520Res.%2520Hum.%2520Retroviruses%26date%3D2003%26volume%3D19%26spage%3D133%26epage%3D144%26doi%3D10.1089%2F088922203762688649" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parast, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nduati, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">John-Stewart, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mbori-Ngacha, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rainwater, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Overbaugh, J.</span></span> <span> </span><span class="NLM_article-title">Neutralization escape variants of human immunodeficiency virus type 1 are transmitted from mother to infant</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>80</i></span>,  <span class="NLM_fpage">835</span>– <span class="NLM_lpage">844</span>, <span class="refDoi"> DOI: 10.1128/JVI.80.2.835-844.2006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=10.1128%2FJVI.80.2.835-844.2006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=16378985" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=1%3ACAS%3A528%3ADC%252BD28XivVOrtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2006&pages=835-844&author=X.+Wuauthor=A.+B.+Parastauthor=B.+A.+Richardsonauthor=R.+Nduatiauthor=G.+John-Stewartauthor=D.+Mbori-Ngachaauthor=S.+M.+Rainwaterauthor=J.+Overbaugh&title=Neutralization+escape+variants+of+human+immunodeficiency+virus+type+1+are+transmitted+from+mother+to+infant&doi=10.1128%2FJVI.80.2.835-844.2006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Neutralization escape variants of human immunodeficiency virus type 1 are transmitted from mother to infant</span></div><div class="casAuthors">Wu, Xueling; Parast, Adam B.; Richardson, Barbra A.; Nduati, Ruth; John-Stewart, Grace; Mbori-Ngacha, Dorothy; Rainwater, Stephanie M. J.; Overbaugh, Julie</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">80</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">835-844</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Maternal passive immunity typically plays a crit. role in protecting infants from new infections; however, the specific contribution of neutralizing antibodies in limiting mother-to-child transmission of human immunodeficiency virus type 1 is unclear.  By examg. cloned envelope variants from 12 transmission pairs, we found that vertically transmitted variants were more resistant to neutralization by maternal plasma than were maternal viral variants near the time of transmission.  The vertically transmitted envelope variants were poorly neutralized by monoclonal antibodies biz, 2G12, 2F5, and 4E10 individually or in combination.  Despite the fact that the infant viruses were among the most neutralization resistant in the mother, they had relatively few glycosylation sites.  Moreover, the transmitted variants elicited de novo neutralizing antibodies in the infants, indicating that they were not inherently difficult to neutralize.  The neutralization resistance of vertically transmitted viruses is in contrast to the relative neutralization sensitivity of viruses sexually transmitted within discordant couples, suggesting that the antigenic properties of viruses that are favored for transmission may differ depending upon mode of transmission.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpg1ghxbC6IW7Vg90H21EOLACvtfcHk0lgNyDB0SXYUbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XivVOrtQ%253D%253D&md5=3d7befeb4abfc14465b28311dd8292e6</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1128%2FJVI.80.2.835-844.2006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.80.2.835-844.2006%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DX.%26aulast%3DParast%26aufirst%3DA.%2BB.%26aulast%3DRichardson%26aufirst%3DB.%2BA.%26aulast%3DNduati%26aufirst%3DR.%26aulast%3DJohn-Stewart%26aufirst%3DG.%26aulast%3DMbori-Ngacha%26aufirst%3DD.%26aulast%3DRainwater%26aufirst%3DS.%2BM.%26aulast%3DOverbaugh%26aufirst%3DJ.%26atitle%3DNeutralization%2520escape%2520variants%2520of%2520human%2520immunodeficiency%2520virus%2520type%25201%2520are%2520transmitted%2520from%2520mother%2520to%2520infant%26jtitle%3DJ.%2520Virol.%26date%3D2006%26volume%3D80%26spage%3D835%26epage%3D844%26doi%3D10.1128%2FJVI.80.2.835-844.2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Connor, R. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choe, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Landau, N. R.</span></span> <span> </span><span class="NLM_article-title">Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes</span>. <i>Virology</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>206</i></span>,  <span class="NLM_fpage">935</span>– <span class="NLM_lpage">944</span>, <span class="refDoi"> DOI: 10.1006/viro.1995.1016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=10.1006%2Fviro.1995.1016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=7531918" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=1%3ACAS%3A528%3ADyaK2MXjs1WkurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=206&publication_year=1995&pages=935-944&author=R.+I.+Connorauthor=B.+K.+Chenauthor=S.+Choeauthor=N.+R.+Landau&title=Vpr+is+required+for+efficient+replication+of+human+immunodeficiency+virus+type-1+in+mononuclear+phagocytes&doi=10.1006%2Fviro.1995.1016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes</span></div><div class="casAuthors">Connor, Ruth I.; Chen, Benjamin Kuan; Choe, Sunny; Landau, Nathaniel R.</div><div class="citationInfo"><span class="NLM_cas:title">Virology</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">206</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">935-44</span>CODEN:
                <span class="NLM_cas:coden">VIRLAX</span>;
        ISSN:<span class="NLM_cas:issn">0042-6822</span>.
    
            (<span class="NLM_cas:orgname">Academic</span>)
        </div><div class="casAbstract">HIV-1 vpr encodes a 96-amino acid, nuclear protein whose function is not well understood.  Unlike the other lentivirus regulatory proteins, Vpr is present in virions at relatively high copy no.  In cells, Vpr is localized to the nucleus.  Possible functions for vpr consistent with these findings include the nuclear import of preintegration complexes, transactivation of cellular genes, or induction of cellular differentiation.  The authors show here, using both replication competent, macrophage-tropic virus and a sensitive, single-cycle luciferase HIV-1 reporter vector, that vpr is important for efficient viral replication in primary monocyte/macrophages, but appears to play no role in activated or resting T cell infection.  The block to infection in monocytes was localized by PCR anal. of newly synthesized viral DNA and with the luciferase reporter vector to a stage in the viral life cycle after entry and reverse transcription, yet prior to, or at the time of, proviral transcription.  In addn., infection of mononuclear phagocyte with virions that had been loaded with Vpr mols. in the producer cells by trans-complementation still showed a vpr-phenotype.  These data suggest a role for vpr mols. produced in newly infected cells, in addn. to its presumed function in the virion.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgyuTZ6ZIJ-7Vg90H21EOLACvtfcHk0lhtjg8Uzy4Rrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXjs1WkurY%253D&md5=09620dfc7aaf57ec9c46ffaef438630f</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1006%2Fviro.1995.1016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fviro.1995.1016%26sid%3Dliteratum%253Aachs%26aulast%3DConnor%26aufirst%3DR.%2BI.%26aulast%3DChen%26aufirst%3DB.%2BK.%26aulast%3DChoe%26aufirst%3DS.%26aulast%3DLandau%26aufirst%3DN.%2BR.%26atitle%3DVpr%2520is%2520required%2520for%2520efficient%2520replication%2520of%2520human%2520immunodeficiency%2520virus%2520type-1%2520in%2520mononuclear%2520phagocytes%26jtitle%3DVirology%26date%3D1995%26volume%3D206%26spage%3D935%26epage%3D944%26doi%3D10.1006%2Fviro.1995.1016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">He, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choe, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">di Marzio, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, D. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Landau, N. R.</span></span> <span> </span><span class="NLM_article-title">Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34cdc2 activity</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">6705</span>– <span class="NLM_lpage">6711</span>, <span class="refDoi"> DOI: 10.1128/JVI.69.11.6705-6711.1995</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=10.1128%2FJVI.69.11.6705-6711.1995" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=7474080" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=1%3ACAS%3A528%3ADyaK2MXoslWkt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=1995&pages=6705-6711&author=J.+Heauthor=S.+Choeauthor=R.+Walkerauthor=P.+di+Marzioauthor=D.+O.+Morganauthor=N.+R.+Landau&title=Human+immunodeficiency+virus+type+1+viral+protein+R+%28Vpr%29+arrests+cells+in+the+G2+phase+of+the+cell+cycle+by+inhibiting+p34cdc2+activity&doi=10.1128%2FJVI.69.11.6705-6711.1995"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34cdc2 activity</span></div><div class="casAuthors">He, Jianglin; Choe, Sunny; Walker, Robert; Di Marzio, Paola; Morgan, David O.; Landau, Nathaniel R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">6705-11</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The Vpr accessory gene product of human immunodeficiency virus types 1 and 2 and simian immunodeficiency virus is believed to play a role in permitting entry of the viral core into the nucleus of nondividing cells.  A second role for Vpr was recently suggested by (M. E. Rogel, et al., 1995) who showed that Vpr prevents the establishment in vitro of chronically infected HIV producer cell lines, apparently by causing infected cells to arrest in the G2/M phase of the cell cycle.  In cycling cells, progression from G2 to M phase is driven by activation of the p34cdc2/cyclin B complex, an event caused, in part, by dephosphorylation of two regulatory amino acids of p34cdc2 (Thr-14 and Tyr-15).  We show here that Vpr arrests the cell cycle in G2 by preventing the activation of the p34cdc2/cyclin B complex.  Vpr expression in cells caused p34cdc2 to remain in the phosphorylated, inactive state.  The p34cdc2/cyclin B complexes immunopptn. from cells expressing Vpr were almost completely inactive in a histone H1 kinase assay.  Coexpression of a constitutively active mutant p34cdc2 mol. with Vpr relieved the G2 arrest.  These findings strongly suggest that Vpr arrests cells in G2 by preventing the activation of the p34cdc2/cyclin B complex that is required for entry into M phase.  In vivo, Vpr might, by preventing p34cdc2 activation, delay or prevent apoptosis of infected cells.  This would increase the amt. of virus each infected cell produced.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfPunHH8sjFbVg90H21EOLACvtfcHk0lhtjg8Uzy4Rrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXoslWkt74%253D&md5=cf13092726ac54f93a13fb9439e971c2</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1128%2FJVI.69.11.6705-6711.1995&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.69.11.6705-6711.1995%26sid%3Dliteratum%253Aachs%26aulast%3DHe%26aufirst%3DJ.%26aulast%3DChoe%26aufirst%3DS.%26aulast%3DWalker%26aufirst%3DR.%26aulast%3Ddi%2BMarzio%26aufirst%3DP.%26aulast%3DMorgan%26aufirst%3DD.%2BO.%26aulast%3DLandau%26aufirst%3DN.%2BR.%26atitle%3DHuman%2520immunodeficiency%2520virus%2520type%25201%2520viral%2520protein%2520R%2520%2528Vpr%2529%2520arrests%2520cells%2520in%2520the%2520G2%2520phase%2520of%2520the%2520cell%2520cycle%2520by%2520inhibiting%2520p34cdc2%2520activity%26jtitle%3DJ.%2520Virol.%26date%3D1995%26volume%3D69%26spage%3D6705%26epage%3D6711%26doi%3D10.1128%2FJVI.69.11.6705-6711.1995" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Adachi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gendelman, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koenig, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Folks, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willey, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, M. A.</span></span> <span> </span><span class="NLM_article-title">Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">1986</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">284</span>– <span class="NLM_lpage">291</span>, <span class="refDoi"> DOI: 10.1128/JVI.59.2.284-291.1986</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=10.1128%2FJVI.59.2.284-291.1986" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=3016298" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=1%3ACAS%3A280%3ADyaL283otFyhtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=1986&pages=284-291&author=A.+Adachiauthor=H.+E.+Gendelmanauthor=S.+Koenigauthor=T.+Folksauthor=R.+Willeyauthor=A.+Rabsonauthor=M.+A.+Martin&title=Production+of+acquired+immunodeficiency+syndrome-associated+retrovirus+in+human+and+nonhuman+cells+transfected+with+an+infectious+molecular+clone&doi=10.1128%2FJVI.59.2.284-291.1986"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone</span></div><div class="casAuthors">Adachi A; Gendelman H E; Koenig S; Folks T; Willey R; Rabson A; Martin M A</div><div class="citationInfo"><span class="NLM_cas:title">Journal of virology</span>
        (<span class="NLM_cas:date">1986</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">284-91</span>
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    </div><div class="casAbstract">We constructed an infectious molecular clone of acquired immunodeficiency syndrome-associated retrovirus.  Upon transfection, this clone directed the production of infectious virus particles in a wide variety of cells in addition to human T4 cells.  The progeny, infectious virions, were synthesized in mouse, mink, monkey, and several human non-T cell lines, indicating the absence of any intracellular obstacle to viral RNA or protein production or assembly.  During the course of these studies, a human colon carcinoma cell line, exquisitely sensitive to DNA transfection, was identified.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTnWWZt8wKSPuIHSmpohpd0fW6udTcc2ebqrpAKu5jTaLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL283otFyhtQ%253D%253D&md5=295ec341d4d4a282e4d10c9fea3d647e</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1128%2FJVI.59.2.284-291.1986&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.59.2.284-291.1986%26sid%3Dliteratum%253Aachs%26aulast%3DAdachi%26aufirst%3DA.%26aulast%3DGendelman%26aufirst%3DH.%2BE.%26aulast%3DKoenig%26aufirst%3DS.%26aulast%3DFolks%26aufirst%3DT.%26aulast%3DWilley%26aufirst%3DR.%26aulast%3DRabson%26aufirst%3DA.%26aulast%3DMartin%26aufirst%3DM.%2BA.%26atitle%3DProduction%2520of%2520acquired%2520immunodeficiency%2520syndrome-associated%2520retrovirus%2520in%2520human%2520and%2520nonhuman%2520cells%2520transfected%2520with%2520an%2520infectious%2520molecular%2520clone%26jtitle%3DJ.%2520Virol.%26date%3D1986%26volume%3D59%26spage%3D284%26epage%3D291%26doi%3D10.1128%2FJVI.59.2.284-291.1986" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rimsky, L. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shugars, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matthews, T. J.</span></span> <span> </span><span class="NLM_article-title">Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>72</i></span>,  <span class="NLM_fpage">986</span>– <span class="NLM_lpage">93</span>, <span class="refDoi"> DOI: 10.1128/JVI.72.2.986-993.1998</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=10.1128%2FJVI.72.2.986-993.1998" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=9444991" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=1%3ACAS%3A528%3ADyaK1cXlt1GgsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=1998&pages=986-93&author=L.+T.+Rimskyauthor=D.+C.+Shugarsauthor=T.+J.+Matthews&title=Determinants+of+human+immunodeficiency+virus+type+1+resistance+to+gp41-derived+inhibitory+peptides&doi=10.1128%2FJVI.72.2.986-993.1998"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides</span></div><div class="casAuthors">Rimsky, Laurence T.; Shugars, Diane C.; Matthews, Thomas J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">986-993</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">A synthetic peptide, DP178, contg. amino acids 127-162 of the human immunodeficiency virus type 1 (HIV-1) gp41 Env glycoprotein, is a potent inhibitor of virus infection and virus mediated cell-to-cell fusion (C. Wild, et al., 1993).  In an effort to understand the mechanism of action of this peptide, the authors derived resistant variants of HIV-1IIIB and NL4-3 by serial virus passage in the presence of increasing doses of the peptide.  Sequence anal. of the resistant isolates suggested that a contiguous 3-amino-acid sequence within the N-terminal heptad repeat motif of gp41 was assocd. with resistance.  Site-directed mutagenesis studies confirmed this observation and indicated that changes in 2 of these 3 residues were necessary for development of the resistant phenotype.  Direct binding of DP178 to recombinant protein and synthetic peptide analogs contg. the wild-type and mutant heptad repeat sequences revealed a strong correlation between DP178 binding and the biol. sensitivity of the corresponding virus isolates to DP178.  The results are discussed from the standpoints of the mechanism of action of DP178 and recent crystallog. information for a core structure of the gp41 ectodomain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozLL8yJTuHq7Vg90H21EOLACvtfcHk0lgmC5E2BQerAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXlt1GgsQ%253D%253D&md5=885536c0373f2270edcfcd558f1111c3</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1128%2FJVI.72.2.986-993.1998&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.72.2.986-993.1998%26sid%3Dliteratum%253Aachs%26aulast%3DRimsky%26aufirst%3DL.%2BT.%26aulast%3DShugars%26aufirst%3DD.%2BC.%26aulast%3DMatthews%26aufirst%3DT.%2BJ.%26atitle%3DDeterminants%2520of%2520human%2520immunodeficiency%2520virus%2520type%25201%2520resistance%2520to%2520gp41-derived%2520inhibitory%2520peptides%26jtitle%3DJ.%2520Virol.%26date%3D1998%26volume%3D72%26spage%3D986%26epage%3D93%26doi%3D10.1128%2FJVI.72.2.986-993.1998" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Balamane, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varghese, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melikian, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fessel, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katzenstein, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shafer, R. W.</span></span> <span> </span><span class="NLM_article-title">Panel of prototypical recombinant infectious molecular clones resistant to nevirapine, efavirenz, etravirine, and rilpivirine</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">4522</span>– <span class="NLM_lpage">4524</span>, <span class="refDoi"> DOI: 10.1128/AAC.00648-12</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=10.1128%2FAAC.00648-12" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=22664973" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFajsLzO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2012&pages=4522-4524&author=M.+Balamaneauthor=V.+Vargheseauthor=G.+L.+Melikianauthor=W.+J.+Fesselauthor=D.+A.+Katzensteinauthor=R.+W.+Shafer&title=Panel+of+prototypical+recombinant+infectious+molecular+clones+resistant+to+nevirapine%2C+efavirenz%2C+etravirine%2C+and+rilpivirine&doi=10.1128%2FAAC.00648-12"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Panel of prototypical recombinant infectious molecular clones resistant to nevirapine, efavirenz, etravirine, and rilpivirine</span></div><div class="casAuthors">Balamane, Maya; Varghese, Vici; Melikian, George L.; Fessel, W. Jeffrey; Katzenstein, David A.; Shafer, Robert W.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">4522-4524</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">We created a panel of 10 representative multi-nonnucleoside reverse transcriptase inhibitor (NNRTI)-resistant recombinant infectious mol. HIV-1 clones to assist researchers studying NNRTI resistance or developing novel NNRTIs.  The cloned viruses contain most of the major NNRTI resistance mutations and most of the significantly assocd. mutation pairs that we identified in two network analyses.  Each virus in the panel has intermediate- or high-level resistance to all or three of the four most commonly used NNRTIs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtl3gk5s6CGrVg90H21EOLACvtfcHk0lgmC5E2BQerAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFajsLzO&md5=5d724094bab15760dcd65662e8ea1b71</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1128%2FAAC.00648-12&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.00648-12%26sid%3Dliteratum%253Aachs%26aulast%3DBalamane%26aufirst%3DM.%26aulast%3DVarghese%26aufirst%3DV.%26aulast%3DMelikian%26aufirst%3DG.%2BL.%26aulast%3DFessel%26aufirst%3DW.%2BJ.%26aulast%3DKatzenstein%26aufirst%3DD.%2BA.%26aulast%3DShafer%26aufirst%3DR.%2BW.%26atitle%3DPanel%2520of%2520prototypical%2520recombinant%2520infectious%2520molecular%2520clones%2520resistant%2520to%2520nevirapine%252C%2520efavirenz%252C%2520etravirine%252C%2520and%2520rilpivirine%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2012%26volume%3D56%26spage%3D4522%26epage%3D4524%26doi%3D10.1128%2FAAC.00648-12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reuman, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bachmann, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varghese, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fessel, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shafer, R. W.</span></span> <span> </span><span class="NLM_article-title">Panel of prototypical raltegravir-resistant infectious molecular clones in a novel integrase-deleted cloning vector</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">934</span>– <span class="NLM_lpage">936</span>, <span class="refDoi"> DOI: 10.1128/AAC.01345-09</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=10.1128%2FAAC.01345-09" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=19917747" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhvFShs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2010&pages=934-936&author=E.+C.+Reumanauthor=M.+H.+Bachmannauthor=V.+Vargheseauthor=W.+J.+Fesselauthor=R.+W.+Shafer&title=Panel+of+prototypical+raltegravir-resistant+infectious+molecular+clones+in+a+novel+integrase-deleted+cloning+vector&doi=10.1128%2FAAC.01345-09"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Panel of prototypical raltegravir-resistant infectious molecular clones in a novel integrase-deleted cloning vector</span></div><div class="casAuthors">Reuman, Elizabeth C.; Bachmann, Michael H.; Varghese, Vici; Fessel, W. Jeffrey; Shafer, Robert W.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">934-936</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">We created an HIV-1 cloning vector, pNL4.3ΔIN, to generate recombinant infectious mol. clones for anal. of patient-derived HIV-1 integrase coding regions.  Using this vector, we constructed a panel of clin. derived viruses with the canonical patterns of raltegravir resistance mutations and submitted the panel to the NIH AIDS Research and Ref. Reagent Program.  Investigational integrase inhibitors with activity against these clones are likely to retain activity against the most clin. relevant raltegravir-resistant variants.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobyvfHkutEHLVg90H21EOLACvtfcHk0lhpfkbGbCJe1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhvFShs7s%253D&md5=72b064cf2ef84283ec852a378f01e467</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1128%2FAAC.01345-09&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.01345-09%26sid%3Dliteratum%253Aachs%26aulast%3DReuman%26aufirst%3DE.%2BC.%26aulast%3DBachmann%26aufirst%3DM.%2BH.%26aulast%3DVarghese%26aufirst%3DV.%26aulast%3DFessel%26aufirst%3DW.%2BJ.%26aulast%3DShafer%26aufirst%3DR.%2BW.%26atitle%3DPanel%2520of%2520prototypical%2520raltegravir-resistant%2520infectious%2520molecular%2520clones%2520in%2520a%2520novel%2520integrase-deleted%2520cloning%2520vector%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2010%26volume%3D54%26spage%3D934%26epage%3D936%26doi%3D10.1128%2FAAC.01345-09" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Varghese, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitsuya, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fessel, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, T. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melikian, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katzenstein, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiffer, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holmes, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shafer, R. W.</span></span> <span> </span><span class="NLM_article-title">Prototypical recombinant multi-protease-inhibitor-resistant infectious molecular clones of human immunodeficiency virus type 1</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">4290</span>– <span class="NLM_lpage">4299</span>, <span class="refDoi"> DOI: 10.1128/AAC.00614-13</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=10.1128%2FAAC.00614-13" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=23796938" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtlSns7bM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2013&pages=4290-4299&author=V.+Vargheseauthor=Y.+Mitsuyaauthor=W.+J.+Fesselauthor=T.+F.+Liuauthor=G.+L.+Melikianauthor=D.+A.+Katzensteinauthor=C.+A.+Schifferauthor=S.+P.+Holmesauthor=R.+W.+Shafer&title=Prototypical+recombinant+multi-protease-inhibitor-resistant+infectious+molecular+clones+of+human+immunodeficiency+virus+type+1&doi=10.1128%2FAAC.00614-13"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Prototypical recombinant multi-protease-inhibitor-resistant infectious molecular clones of human immunodeficiency virus type 1</span></div><div class="casAuthors">Varghese, Vici; Mitsuya, Yumi; Fessel, W. Jeffrey; Liu, Tommy F.; Melikian, George L.; Katzenstein, David A.; Schiffer, Celia A.; Holmes, Susan P.; Shafer, Robert W.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4290-4299</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">1098-6596</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The many genetic manifestations of HIV-1 protease inhibitor (PI) resistance present challenges to research into the mechanisms of PI resistance and the assessment of new PIs.  To address these challenges, we created a panel of recombinant multi-PI-resistant infectious mol. clones designed to represent the spectrum of clin. relevant multi-PI-resistant viruses.  To assess the representativeness of this panel, we examd. the sequences of the panel's viruses in the context of a correlation network of PI resistance amino acid substitutions in sequences from more than 10,000 patients.  The panel of recombinant infectious mol. clones comprised 29 of 41 study-defined PI resistance amino acid substitutions and 23 of the 27 tightest amino acid substitution clusters.  Based on their phenotypic properties, the clones were classified into four groups with increasing cross-resistance to the PIs most commonly used for salvage therapy: lopinavir (LPV), tipranavir (TPV), and darunavir (DRV).  The panel of recombinant infectious mol. clones has been made available without restriction through the NIH AIDS Research and Ref. Reagent Program.  The public availability of the panel makes it possible to compare the inhibitory activities of different PIs with one another.  The diversity of the panel and the high-level PI resistance of its clones suggest that investigational PIs active against the clones in this panel will retain antiviral activity against most if not all clin. relevant PI-resistant viruses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtlR3mT_rhVbVg90H21EOLACvtfcHk0lhpfkbGbCJe1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtlSns7bM&md5=d28211fe6a88a631b568ff9861bee481</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1128%2FAAC.00614-13&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.00614-13%26sid%3Dliteratum%253Aachs%26aulast%3DVarghese%26aufirst%3DV.%26aulast%3DMitsuya%26aufirst%3DY.%26aulast%3DFessel%26aufirst%3DW.%2BJ.%26aulast%3DLiu%26aufirst%3DT.%2BF.%26aulast%3DMelikian%26aufirst%3DG.%2BL.%26aulast%3DKatzenstein%26aufirst%3DD.%2BA.%26aulast%3DSchiffer%26aufirst%3DC.%2BA.%26aulast%3DHolmes%26aufirst%3DS.%2BP.%26aulast%3DShafer%26aufirst%3DR.%2BW.%26atitle%3DPrototypical%2520recombinant%2520multi-protease-inhibitor-resistant%2520infectious%2520molecular%2520clones%2520of%2520human%2520immunodeficiency%2520virus%2520type%25201%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2013%26volume%3D57%26spage%3D4290%26epage%3D4299%26doi%3D10.1128%2FAAC.00614-13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lackman-Smith, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snyder, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ratner, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rohan, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patton, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramratnam, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cole, A. M.</span></span> <span> </span><span class="NLM_article-title">Antiviral activity of retrocyclin RC-101, a candidate microbicide against cell-associated HIV-1</span>. <i>AIDS Res. Hum. Retroviruses</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">391</span>– <span class="NLM_lpage">396</span>, <span class="refDoi"> DOI: 10.1089/aid.2012.0135</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=10.1089%2Faid.2012.0135" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=22924614" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVOjurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2013&pages=391-396&author=P.+Guptaauthor=C.+Lackman-Smithauthor=B.+Snyderauthor=D.+Ratnerauthor=L.+C.+Rohanauthor=D.+Pattonauthor=B.+Ramratnamauthor=A.+M.+Cole&title=Antiviral+activity+of+retrocyclin+RC-101%2C+a+candidate+microbicide+against+cell-associated+HIV-1&doi=10.1089%2Faid.2012.0135"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Antiviral Activity of Retrocyclin RC-101, a Candidate Microbicide Against Cell-Associated HIV-1</span></div><div class="casAuthors">Gupta, Phalguni; Lackman-Smith, Carol; Snyder, Beth; Ratner, Deena; Rohan, Lisa C.; Patton, Dorothy; Ramratnam, Bharat; Cole, Alexander M.</div><div class="citationInfo"><span class="NLM_cas:title">AIDS Research and Human Retroviruses</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">391-396</span>CODEN:
                <span class="NLM_cas:coden">ARHRE7</span>;
        ISSN:<span class="NLM_cas:issn">0889-2229</span>.
    
            (<span class="NLM_cas:orgname">Mary Ann Liebert, Inc.</span>)
        </div><div class="casAbstract">Microbicides have been evaluated mostly against cell-free HIV-1.  Because semen contains both cell-free and cell-assocd. HIV-1, HIV-1 transmission could occur via either or both sources.  Therefore, it is important to examine the antiviral activity of microbicides against cell-assocd. HIV-1.  The cyclic antimicrobial peptide retrocyclin RC-101 has been shown previously to have antiviral activity against cell-free HIV-1, with no assocd. cellular toxicity.  In this article we have examd. the antiviral activity of RC-101 against cell-assocd. HIV-1.  The results demonstrate potent antiviral activity of RC-101 against cell-cell HIV-1 transmission in both CD4-dependent and CD4-independent assays against CCR5- and CXCR4-tropic HIV-1, with no cellular toxicity.  Furthermore, this antiviral activity was retained in the presence of human seminal plasma.  The potent antiviral activity of RC-101 against cell-assocd. HIV-1 reported here, and the previously reported antiviral activity in cervical tissues, suggest that RC-101 is an excellent and promising microbicide candidate against HIV-1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAyS93vgYB5LVg90H21EOLACvtfcHk0lhvN__xlQYJOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVOjurc%253D&md5=dc03a192fbe8805225208b1a5136ff29</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1089%2Faid.2012.0135&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252Faid.2012.0135%26sid%3Dliteratum%253Aachs%26aulast%3DGupta%26aufirst%3DP.%26aulast%3DLackman-Smith%26aufirst%3DC.%26aulast%3DSnyder%26aufirst%3DB.%26aulast%3DRatner%26aufirst%3DD.%26aulast%3DRohan%26aufirst%3DL.%2BC.%26aulast%3DPatton%26aufirst%3DD.%26aulast%3DRamratnam%26aufirst%3DB.%26aulast%3DCole%26aufirst%3DA.%2BM.%26atitle%3DAntiviral%2520activity%2520of%2520retrocyclin%2520RC-101%252C%2520a%2520candidate%2520microbicide%2520against%2520cell-associated%2520HIV-1%26jtitle%3DAIDS%2520Res.%2520Hum.%2520Retroviruses%26date%3D2013%26volume%3D29%26spage%3D391%26epage%3D396%26doi%3D10.1089%2Faid.2012.0135" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lackman-Smith, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osterling, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luckenbaugh, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mankowski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snyder, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paull, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Profy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ptak, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buckheit, R. W.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watson, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cummins, J. E.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanders-Beer, B. E.</span></span> <span> </span><span class="NLM_article-title">Development of a comprehensive human immunodeficiency virus type 1 screening algorithm for discovery and preclinical testing of topical microbicides</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">1768</span>– <span class="NLM_lpage">1781</span>, <span class="refDoi"> DOI: 10.1128/AAC.01328-07</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=10.1128%2FAAC.01328-07" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=18316528" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=1%3ACAS%3A528%3ADC%252BD1cXls1aju74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2008&pages=1768-1781&author=C.+Lackman-Smithauthor=C.+Osterlingauthor=K.+Luckenbaughauthor=M.+Mankowskiauthor=B.+Snyderauthor=G.+Lewisauthor=J.+Paullauthor=A.+Profyauthor=R.+G.+Ptakauthor=R.+W.+Buckheitauthor=K.+M.+Watsonauthor=J.+E.+Cumminsauthor=B.+E.+Sanders-Beer&title=Development+of+a+comprehensive+human+immunodeficiency+virus+type+1+screening+algorithm+for+discovery+and+preclinical+testing+of+topical+microbicides&doi=10.1128%2FAAC.01328-07"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Development of a comprehensive human immunodeficiency virus type 1 screening algorithm for discovery and preclinical testing of topical microbicides</span></div><div class="casAuthors">Lackman-Smith, Carol; Osterling, Clay; Luckenbaugh, Katherine; Mankowski, Marie; Snyder, Beth; Lewis, Gareth; Paull, Jeremy; Profy, Albert; Ptak, Roger G.; Buckheit, Robert W., Jr.; Watson, Karen M.; Cummins, James E., Jr.; Sanders-Beer, Brigitte E.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1768-1781</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Topical microbicides are self-administered, prophylactic products for protection against sexually transmitted pathogens.  A large no. of compds. with known anti-human immunodeficiency virus type 1 (HIV-1) inhibitory activity have been proposed as candidate topical microbicides.  To identify potential leads, an in vitro screening algorithm was developed to evaluate candidate microbicides in assays that assess inhibition of cell-assocd. and cell-free HIV-1 transmission, entry, and fusion.  The algorithm advances compds. by evaluation in a series of defined assays that generate measurements of relative antiviral potency to det. advancement or failure.  Initial testing consists of a dual detn. of inhibitory activity in the CD4-dependent CCR5-tropic cell-assocd. transmission inhibition assay and in the CD4/CCR5-mediated HIV-1 entry assay.  The activity is confirmed by repeat testing, and identified actives are advanced to secondary screens to det. their effect on transmission of CXCR4-tropic viruses in the presence or absence of CD4 and their ability to inhibit CXCR4- and CCR5-tropic envelope-mediated cell-to-cell fusion.  In addn., confirmed active compds. are also evaluated in the presence of human seminal plasma, in assays incorporating a pH 4 to 7 transition, and for growth inhibition of relevant strains of lactobacilli.  Leads may then be advanced for specialized testing, including detns. in human cervical explants and in peripheral blood mononuclear cells against primary HIV subtypes, combination testing with other inhibitors, and addnl. cytotoxicity assays.  PRO2000 and SPL7013 (the active component of VivaGel), two microbicide products currently being evaluated in human clin. trials, were tested in this in vitro algorithm and were shown to be highly active against CCR5- and CXCR4-tropic HIV-1 infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp03Yb1WRdB_LVg90H21EOLACvtfcHk0lhvN__xlQYJOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXls1aju74%253D&md5=2080bcd8421ea686cb18e7f626cd0420</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1128%2FAAC.01328-07&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.01328-07%26sid%3Dliteratum%253Aachs%26aulast%3DLackman-Smith%26aufirst%3DC.%26aulast%3DOsterling%26aufirst%3DC.%26aulast%3DLuckenbaugh%26aufirst%3DK.%26aulast%3DMankowski%26aufirst%3DM.%26aulast%3DSnyder%26aufirst%3DB.%26aulast%3DLewis%26aufirst%3DG.%26aulast%3DPaull%26aufirst%3DJ.%26aulast%3DProfy%26aufirst%3DA.%26aulast%3DPtak%26aufirst%3DR.%2BG.%26aulast%3DBuckheit%26aufirst%3DR.%2BW.%26aulast%3DWatson%26aufirst%3DK.%2BM.%26aulast%3DCummins%26aufirst%3DJ.%2BE.%26aulast%3DSanders-Beer%26aufirst%3DB.%2BE.%26atitle%3DDevelopment%2520of%2520a%2520comprehensive%2520human%2520immunodeficiency%2520virus%2520type%25201%2520screening%2520algorithm%2520for%2520discovery%2520and%2520preclinical%2520testing%2520of%2520topical%2520microbicides%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2008%26volume%3D52%26spage%3D1768%26epage%3D1781%26doi%3D10.1128%2FAAC.01328-07" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Praveen, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yathirajan, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narayana, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarojini, B. K.</span></span> <span> </span><span class="NLM_article-title">Synthesis, characterization and antimicrobial studies of a few novel thiazole derivatives</span>. <i>Med. Chem. Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">259</span>– <span class="NLM_lpage">268</span>, <span class="refDoi"> DOI: 10.1007/s00044-013-0629-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=10.1007%2Fs00044-013-0629-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;key=1%3ACAS%3A528%3ADC%252BC3sXotlGhs7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2014&pages=259-268&author=A.+S.+Praveenauthor=H.+S.+Yathirajanauthor=B.+Narayanaauthor=B.+K.+Sarojini&title=Synthesis%2C+characterization+and+antimicrobial+studies+of+a+few+novel+thiazole+derivatives&doi=10.1007%2Fs00044-013-0629-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, characterization and antimicrobial studies of a few novel thiazole derivatives</span></div><div class="casAuthors">Praveen, Aletti S.; Yathirajan, Hemmige S.; Narayana, Badiadka; Sarojini, Balladka K.</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Chemistry Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">259-268</span>CODEN:
                <span class="NLM_cas:coden">MCREEB</span>;
        ISSN:<span class="NLM_cas:issn">1054-2523</span>.
    
            (<span class="NLM_cas:orgname">Birkhaeuser Boston</span>)
        </div><div class="casAbstract">A series of novel N-[4-(substituted)-1,3-thiazol-2-yl]-2-(substituted)acetamides and Me 2-(2-(2-(substituted)acetamido)thiazol-4-yl)acetates were synthesized.  All compds. were screened for their in vitro antibacterial activity against S. aureus, E. coli, P. aeruginosa, and K. pneumonia by disk diffusion and for antifungal activity against P. marneffei, T. mentagrophytes, A. flavus, and A. fumigatus by serial plate diln.  Some of the compds. exhibited growth inhibition against all the tested bacterial strains, with MIC of 12.5-6.25 μg/mL.  Among the compds. tested for antifungal activity, several of them showed a wide range of activity against all the tested strains.  Most of the newly synthesized compds. were effective against fungal strains rather than bacterial strains.  However, some of the compds. showed selective sensitivity against some of the bacterial strains, whereas they were unable to sustain the growth of other strains.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTRcarsuGjkrVg90H21EOLACvtfcHk0lhvN__xlQYJOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXotlGhs7Y%253D&md5=54236fbcccbd308cdd0a85c29f4a417e</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1007%2Fs00044-013-0629-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00044-013-0629-x%26sid%3Dliteratum%253Aachs%26aulast%3DPraveen%26aufirst%3DA.%2BS.%26aulast%3DYathirajan%26aufirst%3DH.%2BS.%26aulast%3DNarayana%26aufirst%3DB.%26aulast%3DSarojini%26aufirst%3DB.%2BK.%26atitle%3DSynthesis%252C%2520characterization%2520and%2520antimicrobial%2520studies%2520of%2520a%2520few%2520novel%2520thiazole%2520derivatives%26jtitle%3DMed.%2520Chem.%2520Res.%26date%3D2014%26volume%3D23%26spage%3D259%26epage%3D268%26doi%3D10.1007%2Fs00044-013-0629-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i355"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b02149">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_83523"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.9b02149?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b02149</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">ADME solubility, CACO-2 permeability, stability in liver microsomes, plasma protein binding, Cyp450 inhibition, dose-percent inhibition and cytotoxicity plots (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b02149/suppl_file/jm9b02149_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b02149/suppl_file/jm9b02149_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b02149/suppl_file/jm9b02149_si_001.pdf">jm9b02149_si_001.pdf (370.92 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b02149/suppl_file/jm9b02149_si_002.csv">jm9b02149_si_002.csv (3.79 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.9b02149&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.9b02149%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2020.63.issue-4%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.9b02149" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                3MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6799c9cb7dd324c3","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
